Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Annual Meeting Program
Document related concepts
no text concepts found
Transcript
Annual Meeting Program May 29-June 2, 2015 McCormick Place | Chicago, Illinois am.asco.org For the most up-to-date program information, download the iPlanner mobile app at am.asco.org/arc. 51st Annual Meeting May 29–June 2, 2015 Chicago, Illinois ANNUAL MEETING PROGRAM Copyright 2015 by the American Society of Clinical Oncology. All programs presented at the 2015 Annual Meeting constitute copyrighted presentations owned by the American Society of Clinical Oncology. Copyright of the 2015 ASCO Annual Meeting Program is owned by the American Society of Clinical Oncology. ASCO reserves the rights to all recordings or reproductions or presentations at this Annual Meeting and all ASCO educational and scientific meetings. Attendees are encouraged to check the Annual Meeting program materials for information about Annual Meeting-related publications for purchase and additional ASCO online resources at am.asco.org, including the ASCO Virtual Meeting. FOLLOW #ASCO15 ON TWITTER 1 CONTENTS Scientific Sessions ............................................................................ Program Information ......................................................................... Continuing Medical Education and Program Evaluation ......................... Planning Committees ........................................................................ Onsite Details ................................................................................... Featured Voices on Twitter and Tweetup .............................................. Policies ........................................................................................... Awards ............................................................................................ Supporters ....................................................................................... Ancillary Educational Events Directory ................................................ Program by Day ................................................................................ FOLLOW #ASCO15 ON TWITTER 4 7 9 10 14 16 17 18 25 28 33 3 SCIENTIFIC SESSIONS Breast Cancer HER2/ER Oral Abstract Session .............................................................. Triple-Negative/Cytotoxics/Local Therapy Oral Abstract Session ......................... Clinical Science Symposium: Predicting Response in Triple-Negative and HER2Positive Breast Cancer: Unlocking Pieces to Solve the Puzzles ........................ HER2/ER Poster Discussion Session ........................................................ Triple-Negative/Cytotoxics/Local Therapy Poster Discussion Session ................... HER2/ER Poster Session ...................................................................... Triple-Negative/Cytotoxics/Local Therapy Poster Session ................................. 202 294 191 88 128 51 62 Cancer Prevention, Genetics, and Epidemiology Oral Abstract Session .......................................................................... 92 Clinical Science Symposium: A Tale of Two Genomes: Interpreting Somatic and Germ-Line Sequencing Results Together ................................................. Poster Discussion Session .................................................................... Poster Session .................................................................................. 247 298 260 Central Nervous System Tumors Oral Abstract Session .......................................................................... 304 Clinical Science Symposium: Immunotherapy for Central Nervous System Tumors: Biomarkers and Novel Data ................................................................ Poster Discussion Session .................................................................... Poster Session .................................................................................. 143 298 265 Developmental Therapeutics and Translational Research Clinical Pharmacology and Experimental Therapeutics Oral Abstract Session .......... Immunotherapy Oral Abstract Session ....................................................... Clinical Pharmacology and Experimental Therapeutics Poster Discussion Session .... Immunotherapy Poster Discussion Session ................................................. Clinical Pharmacology and Experimental Therapeutics Poster Session .................. Immunotherapy Poster Session ............................................................... 305 258 89 128 70 79 Gastrointestinal Cancer Colorectal Cancer Oral Abstract Session .................................................... Noncolorectal Cancer Oral Abstract Session ................................................ Clinical Science Symposium: To Lump or To Split: Molecular, Anatomic, and Etiologic Subtyping of Noncolorectal Gastrointestinal Malignancies and Potential Therapeutic Implications ................................................................................... Colorectal Cancer Poster Discussion Session ............................................... Noncolorectal Cancer Poster Discussion Session .......................................... Colorectal Cancer Poster Session ............................................................ Noncolorectal Cancer Poster Session ........................................................ 130 145 197 254 291 208 219 Genitourinary Cancer Prostate Cancer Oral Abstract Session ...................................................... Nonprostate Cancer Oral Abstract Session .................................................. Clinical Science Symposium: Molecular Drivers and Genomic Biomarkers in Genitourinary Cancers ...................................................................... Prostate Cancer Poster Discussion Session ................................................. Nonprostate Cancer Poster Discussion Session ............................................ Prostate Poster Session ....................................................................... Nonprostate Poster Session ................................................................... 185 248 308 134 299 97 271 Gynecologic Cancer Oral Abstract Session .......................................................................... Clinical Science Symposium: Intersection of the Mutanome and the Immunome ....... Poster Discussion Session .................................................................... Poster Session .................................................................................. 204 293 135 103 Head and Neck Cancer Oral Abstract Session .......................................................................... 259 4 FOLLOW #ASCO15 ON TWITTER Clinical Science Symposium: New Evidence on the Role of Surgery and PET Scans after Primary Chemoradiotherapy .......................................................... Poster Discussion Session .................................................................... Poster Session .................................................................................. 202 135 112 Health Services Research and Quality of Care Oral Abstract Session .......................................................................... 93 Clinical Science Symposium: Navigating Racial and Economic Disparities in Cancer Care Delivery ................................................................................. Poster Discussion Session .................................................................... Poster Session .................................................................................. 143 299 277 Leukemia, Myelodysplasia, and Transplantation Oral Abstract Session .......................................................................... 94 Poster Discussion Session .................................................................... 186 Poster Session .................................................................................. 147 Lung Cancer Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers Oral Abstract Session ....................................................................................... Non-Small Cell Metastatic Oral Abstract Session ........................................... Clinical Science Symposium: Immunotherapy in Lung Cancer: A Paradigm Shift ....... Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers Poster Discussion Session ....................................................................................... Non-Small Cell Metastatic Poster Discussion Session ..................................... Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers Poster Session .... Non-Small Cell Metastatic Poster Session ................................................... 131 146 196 255 291 231 237 Lymphoma and Plasma Cell Disorders Lymphoma Oral Abstract Session ............................................................ 249 Myeloma Oral Abstract Session ............................................................... 309 Clinical Science Symposium: Chimeric Antigen Receptor T-Cell Therapy for B-Cell Malignancies ................................................................................. Poster Discussion Session .................................................................... Poster Session .................................................................................. 292 193 155 Melanoma/Skin Cancers Oral Abstract Session .......................................................................... 95 Poster Discussion Session .................................................................... 300 Poster Session .................................................................................. 284 Patient and Survivor Care Oral Abstract Session .......................................................................... 205 Clinical Science Symposium: Predicting and Improving Adverse Outcomes in Older Patients with Cancer ......................................................................... Poster Discussion Session .................................................................... Poster Session .................................................................................. 144 136 118 Pediatric Oncology Pediatric Oncology I Oral Abstract Session .................................................. Pediatric Oncology II Oral Abstract Session ................................................. Poster Discussion Session .................................................................... Poster Session .................................................................................. 133 207 187 163 Sarcoma Oral Abstract Session .......................................................................... Poster Discussion Session .................................................................... Poster Session .................................................................................. 295 194 168 Tumor Biology Oral Abstract Session .......................................................................... Poster Discussion Session .................................................................... Poster Session .................................................................................. FOLLOW #ASCO15 ON TWITTER 296 187 174 5 SCIENTIFIC SESSIONS continued Multidisciplinary Sessions Clinical Science Symposium: Immunotherapy for Every Patient: Check Your Enthusiasm ................................................................................... Clinical Science Symposium: Targeted Therapies: Does the Disease Still Matter? ..... Clinical Science Symposium: New Diagnostics: When Actionable Is Objectionable .... Global Oncology Symposium .................................................................. Highlights of the Day Session I Including Clinical Trials Participation Awards ........... Highlights of the Day Session II Including Partners in Progress Award ................... Highlights of the Day Session III .............................................................. Molecular Biology Tumor Board ............................................................... Plenary Session Including the Science of Oncology Award and Lecture ................. 6 50 184 247 38 140 199 302 35 191 FOLLOW #ASCO15 ON TWITTER PROGRAM INFORMATION The Annual Meeting Program features the program organized by day. Dates and times are subject to change. For the most up-to-date version of the program, consult the iPlanner, available via the Attendee Resource Center (am.asco.org/arc). Cross-Cutting Tracks The topics of clinical trials, ethics, geriatric oncology, international, and value are important for all oncology professionals and cut across disease- and topic-based tracks. These cross-cutting themes have been incorporated into sessions of every track throughout the meeting. For sessions that feature a cross-cutting track, visit am.asco.org or search by track in the iPlanner. eQ&A Most Education and Scientific Sessions will offer multiple formats for question and answer (Q&A) participation. In addition to asking a question via floor microphones, you can also submit questions to session faculty using the following electronic (eQ&A) methods. Questions will be answered as time permits during the scheduled session time. Website (domestic/international attendees) 䡲 Go to pollev.com/roomname (insert the name of the room after the backslash; e.g., pollev.com/s101) 䡲 Type the speaker’s name, your question, and click submit Text message (domestic attendees only) 䡲 Text the Room Name to 22333. You will receive a confirmation that you have joined the room. To ask a question, type the speaker’s name, your question, and send. Text questions are limited to 130 characters. 䡲 If you go to a different room, follow the instructions to join a new room; the system will remove you from the previous room. iPlanner App 䡲 Submit a question via the iPlanner mobile app by navigating to the session information page and selecting “eQ&A: Ask a Question” at the bottom of the page. Room Names Arie E354b E450 EHallD2 EHallD1 S100bc S100a S102 NHallB1 S103 S404 S406 S504 Scientific Sessions Plenary Session The Plenary Session includes abstracts selected by the Scientific Program Committee as having practice-changing findings of the highest scientific merit. Highlights of the Day Sessions Highlights of the Day Sessions invite expert discussants to present key findings, put abstracts into clinical context, and provide an overview of the previous day’s Oral Abstract Sessions. Oral Abstract Sessions Oral Abstract Sessions include didactic presentations of abstracts of the highest scientific merit, as determined by the Scientific Program Committee. Experts in the field serve as discussants and provide comprehensive themed discussions of the findings from the abstracts. Clinical Science Symposia Clinical Science Symposia provide a forum for science in oncology, combining didactic lectures on a specific topic with the presentation of abstracts. Experts in the field serve as discussants to place studies in the appropriate context and critically discuss the conclusions in terms of their applicability to clinical practice. New this year, three special Clinical Science Symposia will be designated around specific pathways that cut across cancer types. FOLLOW #ASCO15 ON TWITTER 7 PROGRAM INFORMATION continued Poster Discussion Sessions Select posters from the Poster Sessions will be discussed by expert discussants, with the abstract authors participating as panel members. These sessions will be followed by networking with the discussants and authors. Poster Sessions Poster Sessions include selected abstracts of clinical research in poster format. Trials in Progress (TPS) abstracts are presented within a track’s Poster Session. Educational Sessions Special Sessions Special Sessions are focused educational sessions that include award presentations and award lectures by recipients of ASCO’s Special Awards; joint sessions planned collaboratively with other societies; and sessions identified as being of particular interest, importance, and relevance to oncology professionals. Education Sessions Education Sessions offer multidisciplinary explorations of focused topics in clinical oncology. Extended Education Sessions Extended Education Sessions are part of ASCO’s continuing effort to provide in-depth learning experiences on topics that address educational needs in oncology. Meet the Professor Sessions (Ticketed) Meet the Professor Sessions provide open discussion between recognized experts and session attendees, with an opportunity for attendees to obtain answers to specific questions. Clinical Problems in Oncology Sessions (Ticketed) Clinical Problems in Oncology Sessions combine the use of case-based panel discussion with interactive audience-response technology. 8 FOLLOW #ASCO15 ON TWITTER Program Evaluation Every participant is encouraged to submit feedback, provide session ratings, and access certificates for the 2015 ASCO Annual Meeting through the iPlanner, the electronic meeting companion. You can access the web version or download the mobile app via the Attendee Resource Center (am.asco.org/arc). Your feedback is utilized by leadership to enhance programs, develop new initiatives, gauge educational impact, and plan for future meetings. Credit requests and evaluations are due by Tuesday, July 7, 2015. Access the following via the iPlanner mobile app or website: ● To provide feedback on a specific session 1. Select a session by searching by time or track 2. Select “Rate This Session” to submit feedback on each session you attend ● To access certificates and claim CME credit 1. Select a session by searching by time or track 2. Select “Claim CME Credit” to obtain a CME Certificate or Certificate of Participation ● To provide feedback on your overall Meeting experience 1. Choose “Give Feedback” from the iPlanner mobile app home screen to submit a Feedback Form These tools can also be accessed through the “Evaluation, CME, and Certificates” block in the Attendee Resource Center. CME and Certificates This live activity has been approved for 39.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. All nonphysician attendees are welcome to submit a request for a Certificate of Participation, which may enable nonphysicians to apply their participation toward re-licensure. Please note that all final decisions regarding the awarding of credits will be made by the licensing organization to which the credits were submitted. For questions or assistance, contact [email protected]. Proof of Attendance Certificates of Attendance are available for attendees who need a record of their attendance at the Meeting but who do not require documentation for continuing education purposes. Please note that this certificate does not award any AMA PRA Category 1 Credit™. Certificates of Attendance are available for download through the “Evaluation, CME, and Certificates” block in the Attendee Resource Center at am.asco.org/arc. FOLLOW #ASCO15 ON TWITTER 9 PLANNING COMMITTEES 2014 –2015 ASCO Board of Directors ASCO Officers President Peter Paul Yu, MD, FACP, FASCO President-Elect Julie M. Vose, MD, MBA, FASCO Immediate Past President Clifford A. Hudis, MD, FACP Treasurer Susan L. Cohn, MD Chief Executive Officer Allen S. Lichter, MD, FASCO Directors Smita Bhatia, MD, MPH Charles David Blanke, MD, FACP, FASCO Linda D. Bosserman, MD, FACP Walter J. Curran Jr., MD Stephen S. Grubbs, MD Paulo M. G. Hoff, MD, PhD, FACP Hagop M. Kantarjian, MD David Khayat, MD, PhD, FASCO Gary H. Lyman, MD, MPH, FACP, FRCP (Edin), FASCO Neal J. Meropol, MD, FASCO Therese M. Mulvey, MD, FASCO W. Charles Penley, MD, FASCO Carolyn D. Runowicz, MD, FASCO Lillian L. Siu, MD, FRCPC, FASCO Eric P. Winer, MD, FASCO 2015 Conquer Cancer Foundation Board of Directors Conquer Cancer Foundation Officers Chair W. Charles Penley, MD, FASCO Treasurer Gabriel N. Hortobagyi, MD, FASCO Secretary Thomas G. Roberts Jr., MD, MSocSc Chief Executive Officer Allen S. Lichter, MD, FASCO Directors Nancy R. Daly, MS, MPH Lawrence H. Einhorn, MD, FASCO John H. Glick, MD, FASCO Michael L. Gordon, JD Beth Y. Karlan, MD Raj Mantena, RPh Thomas A. Marsland, MD, FASCO Robert J. Mayer, MD, FASCO Martin J. Murphy, DMedSc, PhD, FASCO, Chair Emeritus Steven T. Rosen, MD, FACP Aaron A. Sasson Sandra M. Swain, MD, FACP, FASCO Cancer Communications Committee News Planning Subcommittee Chair Gregory A. Masters, MD, FACP, FASCO Chair-Elect Don S. Dizon, MD Immediate Past Chair Jyoti D. Patel, MD Subcommittee Liaisons Hagop Kantarjian, MD, Board Liaison Maria Teresa Bourlon, MD, Career Development Subcommittee Liaison Brian Michael Alexander, MD Harold J. Burstein, MD, PhD, FASCO Patricia A. Ganz, MD, FASCO Stephen Hunger, MD Smitha S. Krishnamurthi, MD Merry Jennifer Markham, MD Erica L. Mayer, MD, MPH Sumanta Kumar Pal, MD Joe B. Putnam, MD, FACS Charles J. Ryan, MD Lynn Mara Schuchter, MD, FASCO Gary K. Schwartz, MD 10 FOLLOW #ASCO15 ON TWITTER Cancer Education Committee John V. Cox, DO, MBA, FASCO, Chair Apar Kishor Ganti, MD, MBBS, Chair-Elect Gini F. Fleming, MD, Immediate Past Chair Lillian L. Siu, MD, Board Liaison Breast Cancer Track Maxine S. Jochelson, MD, Track Leader Jennifer A. Brown, MD Angela DeMichele, MD Charles E. Geyer Jr., MD, FACP Raquel Nunes, MD Debra A. Patt, MD, MPH, MBA Hope S. Rugo, MD Julia R. White, MD Cancer Prevention, Genetics, and Epidemiology Track Joshua David Schiffman, MD, Track Leader Monique A. De Bruin, MD Jeri Kim, MD P. Kelly Marcom, MD Howard L. McLeod, PharmD Electra D. Paskett, PhD Ming Tai-Seale, PhD Donald Lawrence Wickerham, MD Care Delivery and Practice Management Track David G. Pfister, MD, Track Leader Aditya Bardia, MBBS, MPH Kelly Bugos, RN John Emmett Hennessy, MBA, CMPE Thomas H. Openshaw, MD Jeffery C. Ward, MD Central Nervous System Tumors Track Manmeet Singh Ahluwalia, MD, Track Leader Jaishri O’Neill Blakeley, MD Roger Stupp, MD Clinical Trials Track Janet Dancey, MD Sumithra J. Mandrekar, PhD Bhupinder Singh Mann, MBBS Apostolia Maria Tsimberidou, MD, PhD Developmental Therapeutics and Translational Research Track Roisin M. Connolly, MBBS, Track Leader Howard A. Burris, MD Francisco J. Esteva, MD, PhD John Charles Morris, MD Ethics Track Jon C. Tilburt, MD Beverly Moy, MD Gastrointestinal (Colorectal) Cancer Track Martin R.Weiser, MD, Track Leader Chris R. Garrett, MD Donald A. Richards, MD, PhD Henry Q. Xiong, MD Gastrointestinal (Noncolorectal) Cancer Track Matthew H. G. Katz, MD, FACS, Track Leader Tanios S. Bekaii-Saab, MD Jimmy J. Hwang, MD Se Hoon Park, MD Vincent J. Picozzi, MD Manish A. Shah, MD FOLLOW #ASCO15 ON TWITTER Genitourinary Cancer Track Andrea Borghese Apolo, MD, Track Leader Thomas E. Hutson, DO, PharmD, FACP Jose A. Karam, MD John Ward McClean, MD Stephen Boyd Riggs, MD Nicholas J. Vogelzang, MD, FASCO Geriatric Oncology Track Andrew S. Artz, MD, MS William P. Tew, MD William W. Tse, MD Gynecologic Cancer Track Linda R. Duska, MD, Track Leader Helen Mackay, MD Matthew A. Powell, MD Head and Neck Cancer Track Anthony Cmelak, MD, Track Leader Matthew G. Fury, MD John Truelson, MD Apar Kishor Ganti, MD, MBBS Health Services Research and Quality of Care Track Jennifer W. Mack, MD, Track Leader Daniel J. Becker, MD Nina A. Bickell, MD, MPH Nicole Kuderer, MD Dawn L. Hershman, MD Bruce Lee Jacobs, MD Leukemia, Myelodysplasia, and Transplantation Track David Leibowitz, MD, Track Leader Jonathan Michael Gerber, MD Jeffrey E. Lancet, MD Lung Cancer Track Laura Quan Man Chow, MD, Track Leader Martin J. Edelman, MD Craig H. Reynolds, MD David R. Spigel, MD Glen J. Weiss, MD Mauro Zukin, MD Lymphoma and Plasma Cell Disorders Track Grzegorz S. Nowakowski, MD, Track Leader Jeffrey Matous, MD John M. Pagel, MD, PhD Donna Ellen Reece, MD Michael A. Thompson, MD, PhD Melanoma/Skin Cancers Track Suraj S. Venna, MD, Track Leader Sanjiv S. Agarwala, MD Jason John Luke, MD, FACP Janice M. Mehnert, MD Ahmad A. Tarhini, MD, PhD Patient and Survivor Care Track Karen L. Smith, MD, Track Leader Deborah Mayer, PhD, AOCN, ANP-BC Barbara J. Miller, MS, PA-C 11 PLANNING COMMITTEES continued Maria Alma Rodriguez, MD Nagendra Tirumali, MD Pediatric Oncology Track Gregory T. Armstrong, MD, MSCE, Track Leader Najat C. Daw, MD Stewart Goldman, MD Joel A. Weinthal, MD Professional Development Track Anne S. Tsao, MD, Track Leader Kristin Anderson, MD, MPH Kelly J. Cooke, DO Laura Williams Goff, MD Lee M. Krug, MD Jason Michael Samuelian, MD Sarcoma Track Gary K. Schwartz, MD, Track Leader L. Johnetta Blakely, MD Robert Mikael Henshaw, MD Min S. Park, MD, MS Tumor Biology Track Elizabeth A. Maher, MD, PhD, Track Leader Elise C. Kohn, MD Kimryn Rathmell, MD, PhD Eliezer Mendel Van Allen, MD CEC Continuing Medical Education Subcommittee Antoinette J. Wozniak, MD, Chair Michael P. Kosty, MD, FACP, FASCO, Immediate Past Chair Catherine H. Van Poznak, MD, Chair-Elect Marlo A. Blazer, PharmD Mary E. Cianfrocca, DO Thomas W. Flaig, MD Celestia S. Higano, MD, FACP Wells A. Messersmith, MD Michael O. Meyers, MD R. Steven Paulson, MD Maura Polansky, MS, PA-C Bridgett Rossi, RN, MSN, CCRN, OCN Jennifer E. Schwartz, MD, FRCPC Thomas J. Semrad, MD Eric D. Tetzlaff, PA-C Ulka N. Vaishampayan, MD Marie Wood, MD Scientific Program Committee Alan P. Venook, MD, Chair Lynn Mara Schuchter, Chair-Elect Jedd D. Wolchok, MD, PhD, Immediate Past Chair Biostatistics Track Katherine Panageas, PhD, Track Leader Urania Dafni, ScD Susan G. Hilsenbeck, PhD Wendy B. London, PhD Ying Lu, PhD Sumithra J. Mandrekar, PhD Donna Niedzwiecki, PhD Breast Cancer—HER2/ER Track Priya Rastogi, MD, Track Leader Carey K. Anders, MD Tufia C. Haddad, MD Cornelia Liedtke, MD Shanu Modi, MD Patrick Glyn Morris, MD Alexandra Thomas, MD Breast Cancer—Triple-Negative/Cytotoxics/Local Therapy Track Steven J. Isakoff, MD, PhD, Track Leader Eleanor Elizabeth Harris, MD Tari A. King, MD Pamela N. Munster, MD Deborah Toppmeyer, MD Tiffany A. Traina, MD Janice Maria Walshe, MD Cancer Prevention, Genetics, and Epidemiology Track James M. Foran MD, FRCPC, Track Leader Habibul Ahsan, MBBS, MSc Eric Andrew Collisson, MD Adam J. Olszewski, MD Brian M. Wolpin, MD Central Nervous System Tumors Track Andrew B. Lassman, MD, Track Leader Eric L. Chang, MD Howard Alan Fine, MD Daphne A. Haas-Kogan, MD Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics Track Miguel Angel Villalona-Calero, MD, Track Leader Emiliano Calvo, MD, PhD Ryan Bruce Corcoran, MD, PhD Gerald Steven Falchook, MD Herbert Hurwitz, MD Robin Kate Kelley, MD Scott Kopetz, MD Timothy Anthony Yap, PhD, MBBS, BSc, MRCP Developmental Therapeutics—Immunotherapy Track Neil Howard Segal, MD, PhD, Track Leader Charlotte Eielson Ariyan, MD, PhD Gregory Lawrence Beatty, MD, PhD Jonathan S. Cebon, MD, PhD Lawrence Fong, MD Zihai Li, MD, PhD Andrew Parsa, MD, PhD 12 FOLLOW #ASCO15 ON TWITTER Gastrointestinal (Colorectal) Cancer Track Edward Chu, MD, Track Leader Chloe Evelyn Atreya, MD, PhD Nancy N. Baxter, MD Gong Chen, MD, PhD Steven J. Cohen, MD Gunnar Folprecht, MD Kimmie Ng, MD, MPH Bert H. O’Neil, MD Thomas John Semrad, MD, FACP Richard H. Wilson, MD Zhen Zhang, MD, PhD Gastrointestinal (Noncolorectal) Cancer Track Andrew H. Ko, MD, Track Leader Ghassan K. Abou-Alfa, MD Waddah B. Al-Refaie, MD Karyn A. Goodman, MD Syma Iqbal, MD Milind M. Javle, MD Lisa A. Kachnic, MD Geoffrey Yuyat Ku, MD, MBA Emil Lou, MD, PhD Nipun B. Merchant, MD James Posey, MD Genitourinary Cancer Track Michael J. Morris, MD, Track Leader Peter Albers, MD Kathleen A. Cooney, MD Robert Dreicer, MD Terence W. Friedlander, MD Noah M. Hahn, MD Jonathan E. Rosenberg, MD Mark N. Stein, MD Cora N. Sternberg, MD Scott T. Tagawa, MD, MS Neha Vapiwala, MD Gynecologic Cancer Track David R. Spriggs, MD, Track Leader John K. Chan, MD Levi S. Downs Jr., MD Paul Haluska, MD, PhD Rebecca Sophie Kristeleit, MD, PhD Kunle Odunsi, MD Head and Neck Cancer Track Quynh-Thu Le, MD, Track Leader John F. Deeken, MD Robert L. Ferris, MD, PhD, FACS Robert I. Haddad, MD Vassiliki Papadimitrakopoulou, MD Health Services Research and Quality of Care Track Helen M. Parsons, PhD, Track Leader George J. Chang, MD, MS Shawn Dana Glisson, MD, FACP Monika K. Krzyzanowska, MD, MPH Rebecca A. Miksad, MD Arden M. Morris, MD Craig Evan Pollack, MD Leukemia, Myelodysplasia, and Transplantation Track Michael Russell Bishop MD, FACP, Track Leader FOLLOW #ASCO15 ON TWITTER Charalambos Andreadis, MD, MSCE Ravi Bhatia, MD Joseph G. Jurcic, MD Celalettin Ustun, MD Lung Cancer—Non–Small Cell Local-Regional/Small Cell/Other Thoracic Cancers Track Gregory J. Riely, MD, PhD, Track Leader Edward B. Garon, MD Scott N. Gettinger, MD Thomas A. Hensing, MD Chuong D. Hoang, MD Tom John, PhD, FRACP, MBBS Feng Ming Kong, MD Lung Cancer—Non–Small Cell Metastatic Track Grace K. Dy, MD, Track Leader Matthew A. Gubens, MD Mark G. Kris, MD Geoffrey R. Oxnard, MD Luis Paz-Ares MD, PhD Nathan A. Pennell, MD, PhD Jonathan Riess, MD Lecia V. Sequist, MD, MPH Lymphoma and Plasma Cell Disorders Track Saad Zafar Usmani, MD, FACP, Track Leader Ranjana H. Advani, MD Alexander M. Lesokhin, MD Sagar Lonial, MD Thomas G. Martin III, MD Owen A. O’Connor, MD, PhD Melanoma/Skin Cancers Track Svetomir Markovic, MD, PhD, Track Leader Paul B. Chapman, MD Adil Daud, MD Georgina V. Long, PhD, BSc, FRACP, MBBS Patient and Survivor Care Track Shari Beth Goldfarb, MD, Track Leader Tessa Cigler, MD, MPH Tara O. Henderson, MD, MPH Monica Alexandra Iriso, MD Arif Kamal, MD Kavitha Ramchandran, MD Charles L. Shapiro, MD Katherine Van Loon, MD, MPH Pediatric Oncology Track Lisa Diller, MD, Track Leader Steven G. DuBois, MD Jeffrey Toretsky, MD Sarcoma Track Jonathan C. Trent II, MD, PhD, Track Leader Venkata Ramesh Bulusu, MD, FRCR Eric K. Nakakura, MD, PhD Dennis A. Priebat, MD Tumor Biology Track Victoria Louise Seewaldt, MD, Track Leader Michael J. Birrer, MD, PhD Wolfgang Michael Korn, MD Mark M. Moasser, MD Andrew B. Nixon, PhD David Potter, MD, PhD Lawrence H. Schwartz, MD 13 ONSITE DETAILS ASCO Annual Business Meeting ASCO Members are encouraged to attend the 2015 ASCO Annual Business Meeting on Monday, June 1, from 12:00 PM to 1:00 PM in the South Building, Room S100a. The Annual Business Meeting includes the following: ● a report by the ASCO Treasurer on the financial state of the Society; ● a report by the Chief Executive Officer; ● the introduction of newly elected ASCO officers; ● passing of the presidential gavel; and ● an open forum for discussion of new initiatives and other Society matters of interest. ASCO Headquarters Office Need Assistance? Lost your badge? Head to ASCO Headquarters, located in the North Building, Room N427a. Emergency Response for Visitors If an alarm sounds in McCormick Place: ● Visitors will be directed over the public announcement system to exit through the closest “Emergency Exit.” ● Doors marked as “Stairs” also serve as emergency exits. ● In the event of a power failure, all emergency systems will run on emergency power. ● Temporary safe areas are available in open parking lots, roadways, and grass areas adjacent to McCormick Place. Faculty Registration and Presenter Ready Room During registration hours, all faculty will check in at the Faculty Registration and Presenter Ready Room, located in the North Building, Room N426, to receive their badges and Meeting materials. Additionally, faculty and oral abstract presenters should report to this room to review and submit their presentations with assistance from ASCO’s audiovisual personnel. Oncology Professionals Hall Located in the South Building, Level 3, Hall A, the Oncology Professionals Hall comprises Exhibits, Posters, the Industry Expert Theater, a Food Court, and ASCO Bistro. Exhibits will highlight the most advanced treatments, products, and services in oncology and provide attendees the opportunity to meet with representatives from pharmaceutical companies, scientific publishers, and advocacy groups. Exhibits are open during the following hours: Saturday, May 30 .............................9:00 AM–5:00 PM Sunday, May 31 ...............................9:00 AM–5:00 PM Monday, June 1 ................................9:00 AM–5:00 PM The Exhibitor Directory, which includes a list of all exhibitors, is available in multiple locations: Hall C Registration, Materials Pickup, and the Grand Concourse entrance to the Oncology Professionals Hall. Electronic versions of the Exhibitor Directory can be accessed through the iPlanner app and at kiosks outside of the Grand Concourse entrance to the Hall. General Posters are located on the far right side of the Oncology Professionals Hall and can be accessed from the Grand Concourse entrance to the Oncology Professionals Hall. Industry Expert Theater The Industry Expert Theater is located in the back of the Oncology Professionals Hall by the Food Court and will host hour-long presentations from industry leaders sharing the latest in oncology practices, products, services, and technologies. Presentations are not certified for Continuing Medical Education credit. The schedule will be available in the back of the Exhibitor Directory and online at am.asco.org. Clinical Information Sharing That Works—REALLY! (An Interoperability Demonstration) Make room in your schedule to attend interactive interoperability demonstrations. Presenters will highlight seamless data sharing and electronic information exchange between clinical systems and applications. Beginning at 9:00 AM on Monday, June 1, visit S405 at the top of each hour to see demonstrations of improvements to the coordination and quality of care through real-time presentations in multiple electronic health records and modular applications that use internationally recognized standards for electronic information exchange between physicians and patients. Services Available at McCormick Place ● Air Travel Assistance Desk: North Building, Level 3, Grand Concourse Lobby ● Annual Meeting Information Desks: Located throughout McCormick Place ● ASCO University Bookstore: North Building, Level 3, Grand Concourse Lobby; South Building, Level 3, ASCO Central (Booth #7004) ● Charging Stations for Electronic Devices: Located on round tables throughout McCormick Place ● Chicago Information Desk: North Building, Level 3, Grand Concourse Lobby ● CME Help Desk: North Building 3, Level Grand Concourse Lobby ● ePoster /Virtual Meeting Station: Oncology Professionals Hall; South Building Level 3 ● First Aid Stations: South Building, Level 2.5 near Business Center; East Building, Level 1 near Arie Crown Theater ● Hotel Assistance Desk: North Building, Level 3, Grand Concourse Lobby ● International Assistance Desk: North Building, Level 3, Grand Concourse Lobby ● Internet Stations with Printers: South Building, S101 Lobby; North Building, Level 2, by McDonalds; North Building, Level 2.5; East Building, Hall D2 Lobby 14 FOLLOW #ASCO15 ON TWITTER ● Laptop Station with Power Strips and Ethernet: North Building, Level 3, Grand Concourse Lobby ● Member Services Desk: North Building, Level 3, Grand Concourse Lobby; Oncology Professionals Hall, South Building, ASCO Central (Booth #7004); North Building, Level 2, Hall C, Registration ● Networking Cafes with Power Outlets (featuring ASCO Live): North Building, Level 3, Grand Concourse Lobby; South Building, S103 Lobby; East Building, Level 2, Arie Crown Lobby; East Building, Level 3, D2 Lobby ● Nursing Lounge: North Building, Level 2, Room N227a ● Restaurant Reservations and ASCO Bistro Tickets Desk: North Building, Level 3, Grand Concourse Lobby ● Share Your Meeting Feedback Desk: North Building 3, Level Grand Concourse Lobby; South Building, Level 3, Oncology Professional Hall Entrance. ● Technology Assistance Desk: North Building, Level 3, Grand Concourse Lobby Shuttle Bus Service Complimentary shuttle service is provided between McCormick Place and all official ASCO hotels. The most up-to-date shuttle schedule is available at am.asco.org/arc. Please be sure to check the ASCO Shuttle sign in your hotel for any changes, additional information, frequency of service, and specific departure times for the designated route. Hours of Operation Friday, May 29 Shuttle between hotels and McCormick Place 6:45 AM–7:00 PM* Saturday, May 30 Shuttle between hotels and McCormick Place 6:45 AM–7:00 PM* Sunday, May 31 Shuttle between hotels and McCormick Place 6:45 AM–7:00 PM* Monday, June 1 Shuttle between hotels and McCormick Place 6:45 AM–7:00 PM* Tuesday, June 2 Shuttle between hotels and McCormick Place 6:45 AM–1:30 PM* * Last shuttle departs McCormick Place at this time. Service will be approximately every 20 minutes. McCormick Place is the transfer point for all routes. If you have any questions regarding the shuttle, or would like to make a reservation for a wheelchair accessible ASCO Shuttle, please see the ASCO Shuttle supervisor at McCormick Place during shuttle hours or call Kushner & Associates at 312-808-2000 during shuttle hours. FOLLOW #ASCO15 ON TWITTER 15 ONSITE DETAILS continued Featured Voices on Twitter If you use Twitter, we invite you to use and follow the official meeting hashtag #ASCO15 and to follow ASCO’s Featured Voices for observations and insight. We thank our members who have agreed to lead this social media conversation throughout the 2015 Annual Meeting. We invite all to join the conversation, too. This year’s voices are as follows Deanna Attai, MD @DrAttai Anees B. Chagpar, MD @AneesChagpar Matthew Katz, MD @subatomicdoc Gilberto Lopes, MD @GlopesMd Don S. Dizon, MD, FACP @drdonsdizon Michael J. Fisch, MD, MPH @fischmd Thomas George, MD @TGeorgeMD Merry J. Markham, MD @DrMarkham Robert S. Miller, MD @rsm2800 Ryan Nipp, MD @RyanNipp David Graham, MD @davidgrahammd Arif Kamal, MD @arifkamalmd Naoto T. Ueno, MD, PhD @teamoncology Sumanta Pal, MD @montypal Nathan A. Pennell, MD, PhD @n8pennell Richard L. Schilsky, MD, FASCO @rschilsky Michael Thompson, MD, PhD @mtmdphd Eric D. Whitman, MD @Melanoma_doctor Peter Paul Yu, MD, FACP, FASCO @YupOnc Yousuf Zafar, MD, MHS @yzafar Please join us for the official #ASCO15 tweetup on Saturday, May 30 at 5:45 PM in McCormick Place, Plate Room (South Building, Level 2.5 Food Court). Signs will be posted and staff will be guiding attendees to the exact location. 16 FOLLOW #ASCO15 ON TWITTER POLICIES For questions regarding these policies or attendee conduct, contact the ASCO Meetings Department at [email protected] or visit ASCO Headquarters (Room N427a). Special Assistance ASCO, all official ASCO hotels, and McCormick Place comply with the Americans with Disabilities Act. If you require special assistance, please contact the 2015 ASCO Annual Customer Service Center at [email protected] or visit the Hotel Assistance Desk in the Grand Concourse Lobby onsite. Age Requirement for Attendees Because of the detailed nature of the programs and forums, no one under the age of 18 will be admitted to any official Meeting function. This includes, but is not limited to, all Meeting sessions, the Oncology Professionals Hall, and all ASCO-sponsored evening events. Important Security and Attendee Conduct Information For security reasons, the 2015 ASCO Annual Meeting badge will be required for admittance to all events. Please wear your badge so that it can be easily seen at all times. Lost badges should be reported to the Registration staff immediately. The following badge policies will be in effect throughout the Meeting: ● The 2015 ASCO Annual Meeting badge is the sole property of ASCO. ● The badge is nontransferable. ● False certification of individuals as paid Meeting attendees, misuse of badges, any method of assisting unauthorized persons to gain access to any Meeting event, or any inappropriate or unauthorized conduct will be just cause for repossessing badges of any individuals involved and expelling all parties involved from the Meeting without obligation on the part of ASCO for refund of any fees. In addition, individuals who are part of the 2015 ASCO Annual Meeting may not engage in any demonstrations or other behavior that ASCO deems to be potentially disruptive to the conduct of the Meeting. Violation of this rule is grounds for immediate dismissal from the Meeting and/or ineligibility for attendance at future ASCO meetings or symposia. Any person who is dismissed from the Meeting may request that ASCO review the matter, provided, however, that such dismissal will be effective immediately and will continue until and unless ASCO issues a contrary decision. Cancellation Statement ASCO reserves the right to cancel the 2015 ASCO Annual Meeting because of unforeseen circumstances. In the event of such cancellation, the full registration fee will be returned to each registrant. Equal Opportunity Statement The 2015 ASCO Annual Meeting is available without regard to race, color, sex, national origin, disability, age, or veteran status as provided by law and in accordance with ASCO’s respect for personal dignity. Authorization for Use of Image, Name, and Other Likeness By attending the 2015 ASCO Annual Meeting or entering in the facility in which the 2015 ASCO Annual Meeting takes place, you agree that ASCO or authorized third parties may photograph or record your likeness, image, name, voice, and/or words, and may publish, display, reproduce, copy, and distribute your likeness, image, name, voice, and/or words for promotional, educational, or membership activities worldwide in all forms of media now known or later developed, including but not limited to advertising, training, websites, presentations, and marketing materials. You further acknowledge that ASCO or authorized third parties shall have the right, but not the obligation, to identify you in connection with such media by name and/or affiliation. Recording (Audio, Video, and Still Photography) Copyright of the 2015 ASCO Annual Meeting program is owned by ASCO. ASCO reserves the rights to all recordings or reproductions of presentations at this Meeting and all ASCO meetings and symposia. Any photography, filming, taping, recording, or reproduction in any medium, including via the use of tripodbased equipment, of any of the programs and/or posters presented at the 2015 ASCO Annual Meeting without the express written consent of ASCO is strictly forbidden. Exception: Non-flash photography and audio or video recording using hand-held equipment, for strictly personal and noncommercial use, are permitted if not disruptive, as determined by ASCO. No Soliciting in the Oncology Professionals Hall The Oncology Professionals Hall gives 2015 ASCO Annual Meeting attendees the opportunity to meet with representatives from the health care industry about their products and services in a professional atmosphere that is consistent with the educational mission of ASCO. Meeting attendees are prohibited from soliciting business from other attendees or exhibitors in the Oncology Professionals Hall, unless the solicitation occurs within the specific exhibit space of the attendee. No Smoking Smoking is prohibited in all 2015 ASCO Annual Meeting facilities, including public areas and the Oncology Professionals Hall. This policy will be enforced. FOLLOW #ASCO15 ON TWITTER 17 AWARDS ASCO 2015 SPECIAL AWARDS David A. Karnofsky Memorial Award and Lecture Presented during the Annual Meeting Opening Session, Saturday, May 30, 9:30 AM, N Hall B1 Suzanne L. Topalian, MD, The Sidney Kimmel Comprehensive Cancer Center Science of Oncology Award and Lecture Presented during the Plenary Session, Sunday, May 31, 1:00 PM, N Hall B1 James P. Allison, PhD, The University of Texas MD Anderson Cancer Center ASCO–American Cancer Society Award and Lecture Presented on Monday, June 1, 11:30 AM, S102 Ernest Hawk, MD, MPH, The University of Texas MD Anderson Cancer Center B. J. Kennedy Award and Lecture for Scientific Excellence in Geriatric Oncology Presented on Sunday, May 31, 9:45 AM, S102 Silvio Monfardini, MD, Istituto Palazzolo, Fondazione Don Gnocchi Gianni Bonadonna Breast Cancer Award and Lecture Presented at the 2015 Breast Cancer Symposium, September 25–27, San Francisco, California Matthew Ellis, MD, PhD, Baylor College of Medicine Pediatric Oncology Award and Lecture Presented on Saturday, May 30, 1:15 PM, S504 Stephen E. Sallan, MD, Harvard Medical School/Dana-Farber Cancer Institute Distinguished Achievement Award Presented during the President’s Dinner, Friday, May 29 George Bosl, MD, FASCO, Memorial Sloan Kettering Cancer Center Excellence in Teaching Award Presented during the Special Session for Program Directors and Key Clinical Faculty, Friday, May 29, E350 Dean F. Bajorin, MD, FACP, FASCO, Memorial Sloan Kettering Cancer Center Humanitarian Award Presented during the President’s Dinner, Friday, May 29 Jose Angel Sanchez, MD, Hospital Escuela, University of Honduras Partners in Progress Award Presented during the Highlights of the Day II Session, Monday, June 1, 7:30 AM, E Hall D1 Mary Lou Smith, JD, MBA, Research Advocacy Network Special Recognition Award Presented during the President’s Dinner, Friday, May 29 Archie Bleyer, MD, Knight Cancer Institute of the Oregon Health & Science University Fellow of the American Society of Clinical Oncology (FASCO) Presented during the President’s Dinner, Friday, May 29 Kathy S. Albain, MD Craig Earle, MD Roscoe F. Morton, MD, FACP Lori J. Pierce, MD Lillian L. Siu, MD, FRCPC Eric J. Small, MD Sandra M. Swain, MD, FACP 18 FOLLOW #ASCO15 ON TWITTER Conquer Cancer Foundation Grants and Awards 2015 Merit Awards Bradley Stuart Beller Special Merit Award This special recognition is given to the fellow who submitted the overall highest-ranking abstract as determined by the Scientific Program Committee. María José de Miguel-Luken, MD, The Institute of Cancer Research and The Royal Marsden Hospital Brigid Leventhal Special Merit Award In honor of Brigid Leventhal, a physician-pioneer in pediatric research, the Brigid Leventhal Merit Award is presented to the fellow who submitted the highest-ranking abstract in pediatrics as determined by the Scientific Program Committee. Mark A. Applebaum, MD, The University of Chicago Pain and Symptom Management Special Merit Award This special recognition is given to the fellow who submitted the highest-ranking abstract in pain and symptom management research as determined by the Scientific Program Committee. Ryan David Nipp, MD, Dana-Farber Cancer Institute/Harvard Cancer Center James B. Nachman ASCO Junior Faculty Award in Pediatric Oncology Established in memory of James B. Nachman, MD, Professor of Pediatrics at the University of Chicago and an internationally renowned pediatric cancer expert, this award is given to the junior faculty member who submitted the highest-ranking abstract in pediatric oncology as determined by the Scientific Program Committee. Sébastien Héritier, MD, Versailles University & APHP, Trousseau Hospital Merit Award Recipients* Merit Awards are given annually in recognition of outstanding abstracts submitted to the Annual Meeting. The Merit Award program was established to encourage more fellows and residents to attend the Annual Meeting and to further promote clinical research in young scientists. Tarek M. A. Abdel-Fatah, MBChB, PhD, MSc, Nottingham University City Hospital NHS Foundation Trust Wassim Abida, MD, PhD, Memorial Sloan Kettering Cancer Center Melissa Kate Accordino, MD, New York Presbyterian Columbia Anosheh Afghahi, MD, MPH, Stanford University Medical Center Arun Azad, MBBS, PhD, FRACP, BC Cancer Agency Hatem Abdel Azim, MD, PhD, Institut Jules Bordet Myron Best, BMed, VU University Medical Center Pierre Camateros, MD, PhD, University of British Columbia Wen Yee Chay, MBBS, MRCP, BC Cancer Agency Yin Ting Cheung, PhD, BSc (Pharm), St. Jude Children’s Research Hospital Dai Chihara, MD, PhD, The University of Texas MD Anderson Cancer Center Victoria L. Chiou, MD, National Cancer Institute at the National Institutes of Health Erin Frances Cobain, MD, University of Michigan Health System Natalie Cook, MD, PhD, Princess Margaret Cancer Centre Francesco Crea, MD, PhD, BC Cancer Agency Jennifer A. Crozier, MD, Mayo Clinic May Daher, MD, The University of Texas MD Anderson Cancer Center Yasir Elamin, MD, Education Centre Beaumont Hospital Lawson Eng, MD, Princess Margaret Cancer Centre Zeynep Eroglu, MD, City of Hope Bishoy Faltas, MD, Weill Cornell Medical College Andre Poisl Fay, MD, Dana-Farber Cancer Institute Pauline Funchain, MD, Cleveland Clinic Daniel A. Goldstein, MD, Winship Cancer Institute of Emory University Wilson I. Gonsalves, MD, Mayo Clinic Emily Jean Guerard, MD, The University of North Carolina at Chapel Hill Anasuya Gunturi, MD, PhD, Beth Israel Deaconess Medical Center Jason W.D. Hearn, MD, Cleveland Clinic Yanfeng Hu, MD, Nanfang Hospital, Southern Medical University Kathryn Elizabeth Hudson, MD, Duke University Medical Center Scott F. Huntington, MD, MPH, Abramson Cancer Center of the University of Pennsylvania Haruka Itakura, MD, Stanford University Medical Center Kevin Jao, MD, FRCPC, Princess Margaret Cancer Centre John M. Kaczmar, MD, Temple University/Fox Chase Cancer Center Reva Kakkar Basho, MD, The University of Texas MD Anderson Cancer Center Shumei Kato, MD, The University of Texas MD Anderson Cancer Center Yuki Katsuya, MD, National Cancer Center Hospital FOLLOW #ASCO15 ON TWITTER 19 AWARDS continued Sharon Kim, BA, Mayo Clinic Vadim S. Koshkin, MD, University of Michigan Jeremy Howard Lewin, MBBS, FRACP, Peter MacCallum Cancer Centre Stephanie Lheureux, MD, PhD, Princess Margaret Cancer Centre Bob T. Li, MBBS, MPH, FRACP, Memorial Sloan Kettering Cancer Center Xuewen Liu, MD, PhD, Columbia University Medical Center & Sun Yat-sen University Cancer Center Kah Poh Loh, MBBCh, Baystate Medical Center David Lorente, MD, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust Arin L. Madenci, MD, MPH, Brigham and Women’s Hospital Parag Mahale, MBBS, MPH, The University of Texas MD Anderson Cancer Center Steven Brad Maron, MD, The University of Chicago Jonathan Michael Marron, MD, Dana-Farber Cancer Institute, Boston Children’s Hospital Deborah Catherine Marshall, MD, University of California, San Diego Kara Noelle Maxwell, MD, PhD, University of Pennsylvania Perelman School of Medicine Maria May, MD, IBYME-CONICET Alvaro G. Menendez, MD, Roger Williams Medical Center/Boston University School of Medicine Vasiliki Michalarea, MBBS, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust Demytra Krista Lee Mitsis, MD, Roswell Park Cancer Institute Amr Mohamed, MD, Morehouse School of Medicine Jarushka Naidoo, MBBCh BAO, MRCPI, Memorial Sloan Kettering Cancer Center Hiten Naik, BHSc (Hon), University of Toronto Terence Ng, BSc (Pharm) Hons, National University of Singapore David B. Page, MD, Memorial Sloan Kettering Cancer Center Shalu Pahuja, MD, University of Pittsburgh Medical Center Haeseong Park, MD, MPH, The University of Texas MD Anderson Cancer Center YaoYao Guan Pollock, MD, Johns Hopkins University School of Medicine Erqi L. Pollom, MD, Stanford University Medical Center Sangeetha Prabhakaran, MD, Moffitt Cancer Center Amanda J. Redig, MD, PhD, Dana-Farber Cancer Institute Eleni Marie Rettig, MD, Johns Hopkins University School of Medicine Adrian G. Sacher, MD, Dana-Farber Cancer Institute Setareh Samimi, MD, Vancouver Centre: BC Cancer Agency Koji Sasaki, MD, The University of Texas MD Anderson Cancer Center Peter Stephen Savas, MBBS, Peter MacCallum Cancer Centre Maria Clemence Schwaederle, PharmD, UC San Diego Moores Cancer Center Nirav Niranjan Shah, MD, Abramson Cancer Center of the University of Pennsylvania Payal Deepak Shah, MD, Memorial Sloan Kettering Cancer Center Brandon S. Sheffield, MD, University of British Columbia Julia Chia-Ying Shih, MD, Albert Einstein College of Medicine, Jacobi Medical Center Shivani S. Shinde, MD, MPH, Mayo Clinic Catherine A. Shu, MD, Memorial Sloan Kettering Cancer Center Elizabeth Catherine Smyth, MB BCh, MSc, Royal Marsden Hospital Lillian Mary Smyth, MD, Memorial Sloan Kettering Cancer Center Anna Spreafico, MD, PhD, Princess Margaret Cancer Centre Amirrtha Srikanthan, MD, Princess Margaret Hospital Conor Ernst Steuer, MD, Emory University Daniel G. Stover, MD, Dana-Farber Cancer Institute Jaszianne A. Tolbert, MD, The Children’s Mercy Hospital Meghna S. Trivedi, MD, Columbia University Medical Center Neelima Vidula, MD, University of California, San Francisco Judy Sing-Zan Wang, MD, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Ying Wang, MD, University of British Columbia Stephanie B. Wheeler, PhD, The University of North Carolina at Chapel Hill Michelle K. Wilson, MBChB, FRACP, Princess Margaret Cancer Centre Dimitrios Zardavas, MD, Breast International Group Nicholas Zdenkowski, BMed, ANZ Breast Cancer Trials Group Tian Zhang, MD, Duke University Medical Center Maria Zlobinsky Rubinstein, MD, Montefiore Medical Center Merit Awards were generously supported by Amgen; AstraZeneca; the Bradley Stuart Beller Endowment Fund; the Conquer Cancer Foundation Mission Endowment; Gilead Sciences, Inc.; Incyte Corporation; the Kidney Cancer Association; Lilly; Novartis Oncology; Onyx Pharmaceuticals; Jackson G. Simpson; Takeda Oncology; and TESARO. (This list reflects commitments as of April 22, 2015.) *As of April 22, 2015. 20 FOLLOW #ASCO15 ON TWITTER 2015 Comparative Effectiveness Research Professorship in Breast Cancer Dawn Hershman, MD, MS, Columbia University Medical Center This grant was generously supported by Breast Cancer Research Foundation®. 2015 Advanced Clinical Research Award in Breast Cancer Priyanka Sharma, MD, University of Kansas Medical Center This grant was generously supported by Breast Cancer Research Foundation®. 2015 Career Development Awards* Sandra Pierina D’Angelo, MD, Memorial Sloan Kettering Cancer Center Ayca Gucalp, MD, Memorial Sloan Kettering Cancer Center Siwen Hu-Lieskovan, MD, PhD, David Geffen School of Medicine at UCLA Douglas Buckner Johnson, MD, Vanderbilt University Medical Center David Margel, MD, PhD, Rabin Medical Center Sean Matthew McBride, MD, MPH, Memorial Sloan Kettering Cancer Center Katherine Elizabeth Reeder-Hayes, MD, MBA, The University of North Carolina at Chapel Hill Rizwan Romee, MD, Washington University Florian Rudolf Schroeck, MD, MS, Dartmouth College Vamsidhar Velcheti, MD, The Cleveland Clinic Jason R. Westin, MD, The University of Texas MD Anderson Cancer Center These grants were generously supported by Astellas; AstraZeneca; Breast Cancer Research Foundation®; the Conquer Cancer Foundation Mission Endowment; Genentech BioOncology™; Lilly; and Takeda Oncology. (This list reflects commitments as of April 22, 2015.) *As of March 27, 2015. 2015 Clinical Trials Participation Awards The purpose of the Clinical Trials Participation Awards is to increase the awareness of and participation in clinical trials among physicians through the recognition of quality, community-based clinical research sites. This award is generously supported by the Coalition of Cancer Cooperative Groups. Cancer Care Specialists of Central Illinois, Decatur, IL Oncology and Hematology Associates of Southwest Virginia/Blue Ridge Cancer Care, Roanoke, VA Oncology Hematology Care, Inc., Cincinnati, OH Scottsdale Healthcare, Scottsdale, AZ St. Joseph’s Hospital and Medical Center, Phoenix, AZ The Moses H. Cone Memorial Hospital/Cone Health Cancer Center, Greensboro, NC 2015 International Development and Education Awards* The Conquer Cancer Foundation’s International Development and Education Award (IDEA) provides support for early-career oncologists in developing countries to attend the ASCO Annual Meeting and spend additional time at a cancer center in the United States or Canada. Eligible recipients also receive three years of complimentary ASCO membership, which includes a subscription to the Journal of Clinical Oncology. The awards are designed to provide continuing medical education, assist in career development, and help establish strong relationships between recipients and leading ASCO Members who serve as scientific mentors. Shayan Kaka Salh Al-askary, MBBS (MBChB), Hiwa Cancer Center (Iraq) Hamoud Hodeish Al-Hussaini, MD, MSc, National Oncology Center (Yemen) Nisreen Yousef Amayiri, MBBS, MD, King Hussein Cancer Center (Jordan) Nicoleta Zenovia Antone, MD, Ion Chiricuta Oncology Institute Cluj-Napoca (Romania) Marjorie Rose Ferriols Bravo, MD, St. Luke’s Medical Center (Philippines) Christianne Bourlon, MD, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran (Mexico) Claudia Maria Calderon, MD, Hospital General San Felipe (Honduras) Jarin Chindaprasirt, MD, Chulalongkorn University (Thailand) Rajeeb Kumar Shree Deo, MBBS, MD, Birendra Hospital (Nepal) Nilufer Jasmine Selimah Fauzee, MBBS, MD, Central Health Laboratory, Victoria Hospital (Mauritius) FOLLOW #ASCO15 ON TWITTER 21 AWARDS continued Alvaro Henrique Ingles Garces, MD, Brazilian National Cancer Institute (INCA) (Brazil) Khaoula Mazouzi, MD, CHU Constantine - Ibn Badis Hospital (Algeria) Vivian Paintsil, MBBS (MBChB), Komfo Anokye Teaching Hospital (Ghana) Herman Perroud, MD, PhD, Andres Hospital Italiano de Rosario (Argentina) Chepsy Cherian Philip, MBBS, MD, DM, Christian Medical College & Hospital (India) George Pupwe, MBBS (MBChB), Stellenbosh University-Medical School (South Africa) Arathi Srinivasan, MBBS, MD, Kanchi Kamakoti Childs Trust Hospital (India) Sule Unal, MD, Hacettepe University (Turkey) Jule Franve Vasquez, MD, Instituto Nacional de Enfermedades Neoplasicas (Peru) Qiongwen Zhang, MD, PhD, West China Hospital of Sichuan University (China) These awards were generously supported by AstraZeneca; Roche; and Takeda Oncology. 2015 Long-term International Fellowships Malek Baassiri, MD “Late Outcomes of Adult Survivors of Childhood Acute Myeloblastic Leukemia (AML) Diagnosed Between 1962-2002” Home Institution: American University of Beirut Medical Center (Lebanon) U.S. Sponsoring Institution: St. Jude Children’s Research Hospital Mentor: Melissa Hudson, MD Kimrom Hagos, MD “Radiation and Chemoradiation side effect in patients with cervical cancer” Home Institution: Black Lion Hospital, Addis Ababa University (Ethiopia) U.S. Sponsoring Institution: Oregon Health & Science University Mentor: Charles Thomas, MD These awards were generously supported by the Conquer Cancer Foundation; Gilead Sciences, Inc.; and Roche. (This list reflects commitments as of April 22, 2015.) 2015 Medical Student Rotation for Underrepresented Populations Oladapo Adeniran, University of Illinois at Chicago Cecil Benitez, Stanford University Mario Martinez, University of Illinois at Chicago Angel Moran, University of California, Davis Dionisia Quiroga, Michigan State University Elisa Quiroz, Ponce Health Sciences University Jasmine Smith, University of South Carolina School of Medicine Greenville These awards were generously supported by the Conquer Cancer Foundation Mission Endowment; Eisai Inc.; Genentech BioOncology™; and Lilly. (This list reflects commitments as of April 22, 2015.) 2015 Resident Travel Award for Underrepresented Populations Olufunke Akinbobuyi, MD, Morehouse School of Medicine Idoroenyi Amanam, MD, St. Mary Medical Center Ebenezer Appah, MD, Meharry Medical College Frederick Doamekpor, MD, Morehouse School of Medicine Nancy Osuji-Oduh, MD, Morehouse School of Medicine Linnea Perkins, MD, Ochsner Clinic Sonya Reid-Lawrence, MD, Meharry Medical College Oluchi Ukaegbu, MD, Vanderbilt University Medical Center These awards were generously supported by Janssen Biotech, Inc. and Novartis Oncology. (This list reflects commitments as of April 22, 2015.) 2015 Young Investigator Awards* Daniel H. Ahn, DO, The Ohio State University Ali Imran Amjad, MBBS, MD, University of Pittsburgh Mark M. Awad, MD, PhD, Dana-Farber Cancer Institute Pavan Bachireddy, MD, Dana-Farber Cancer Institute Adam Richard Belanger, MD, The University of North Carolina at Chapel Hill Melissa A. Burns, MD, Dana-Farber Cancer Institute 22 FOLLOW #ASCO15 ON TWITTER Matthew T. Campbell, MD, The University of Texas MD Anderson Cancer Center Lan Gardner Coffman, MD, PhD, The University of Michigan Natalie Bucheimer Collins, MD, PhD, Dana-Farber Cancer Institute Cristina Cruz, MD, PhD, Vall d’Hebron Institute of Oncology William Brian Dalton, MD, PhD, Johns Hopkins University Helen Dinkelspiel, MD, Columbia University Medical Center Lara Ann Dunn, MD, Memorial Sloan Kettering Cancer Center Daniel Nathan Egan, MD, Fred Hutchinson Cancer Research Center Yasir Y. Elamin, MBBS, The Royal College of Surgeons in Ireland Bishoy Morris Faltas, MD, Joan & Sanford I. Weill Medical College of Cornell University Christian Gocke, MD, PhD, Johns Hopkins University Jennifer Brooke Goldstein, MD, The University of Texas MD Anderson Cancer Center John Gordan, MD, PhD, University of California, San Francisco Scott M. Haake, MD, H. Lee Moffitt Cancer Center and Research Institute at the University of South Florida Jonathan Matthew Hernandez, MD, Memorial Sloan Kettering Cancer Center Valerie Malyvanh Jansen, MD, PhD, Vanderbilt University Medical Center Matko Kalac, MD, PhD, Columbia University Medical Center Michael Khodadoust, MD, PhD, Stanford University Michael Sangmin Lee, MD, The University of Texas MD Anderson Cancer Center Jonathan Merle Lehman, MD, PhD, Vanderbilt University Medical Center Bob Li, MBBS, MPH, Memorial Sloan Kettering Cancer Center Loretta Sze-Mun Li, MD, Dana-Farber Cancer Institute Jyoti Malhotra, MD, MPH, Mount Sinai School of Medicine Gulam Abbas Manji, MD, PhD, Columbia University Medical Center Mark C. Markowski, MD, PhD, Johns Hopkins University Benjamin Louis Maughan, MD, Johns Hopkins University Kara N. Maxwell, MD, PhD, University of Pennsylvania Shannon Rose McCurdy, MD, Johns Hopkins University Jennifer Leigh McQuade, MD, The University of Texas MD Anderson Cancer Center David Jesse Mulvihill, MD, Rutgers, The State University of New Jersey Prabhjot S. Mundi, MD, Columbia University Medical Center Mark Alan Murakami, MD, Dana-Farber Cancer Institute David B. Page, MD, Memorial Sloan Kettering Cancer Center Anthony Joseph Paravati, MD, MBA, University of California, San Diego Robin Parihar, MD, PhD, Baylor College of Medicine Eirini Pectasides, MD, Beth Israel Deaconess Medical Center Jonathan Peled, MD, PhD, Memorial Sloan Kettering Cancer Center Nitya Prabhakar Raj, MD, Memorial Sloan Kettering Cancer Center David Ronan Raleigh, MD, PhD, University of California, San Francisco Jorge Daniel Ramos, DO, University of Washington Saleha Sajid, MBBS, MD, The University of Chicago Eric L. Smith, MD, PhD, Memorial Sloan Kettering Cancer Center Alexandra Snyder Charen, MD, Memorial Sloan Kettering Cancer Center Enrique Soto Perez de Celis, MD, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran Elizabeth Harmon Stover, MD, PhD, Dana-Farber Cancer Institute Benjamin Addison Teply, MD, MS, Johns Hopkins University Zuzana Tothova, MD, PhD, Dana-Farber Cancer Institute Michelle Treasure, MD, Case Western Reserve University Kristina Marie Vander Wall, MD, University of California, Los Angeles Aaron David Viny, MD, MS, Memorial Sloan Kettering Cancer Center Kristina Hoot Young, MD, PhD, Providence Portland Medical Center Jianjun Zhang, MD, PhD, The University of Texas MD Anderson Cancer Center These grants were generously supported by AbbVie, Inc.; the American Association for Cancer Research; Amgen; Anonymous; ASCO and Conquer Cancer Foundation Boards of Directors; ASCO State Affiliate Council and ASCO Clinical Practice Committee; AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; Breast Cancer Research Foundation®; Celgene Corporation; The Cholangiocarcinoma Foundation; Conquer Cancer Foundation; Conquer Cancer Foundation Women Who Conquer Cancer; Eisai Inc.; Ethicon; Florida Society of Clinical Oncology; Genentech BioOncology™; Gilead Sciences, Inc.; Incyte Corporation; Janssen FOLLOW #ASCO15 ON TWITTER 23 AWARDS continued Biotech, Inc.; the John and Elizabeth Leonard Family Foundation; Journal of Clinical Oncology; Kidney Cancer Association; Lilly; Merck Oncology; Novartis Oncology; Onyx Pharmaceuticals; Susan K. Parsons, MD, and Walter Armstrong; Pfizer Oncology; The Reid R. Sacco Adolescent and Young Adult Alliance; Roche; The Scopus Foundation; Young A. Sohn and Mark Armenante; the Strike 3 Foundation; Takeda Oncology; and The WWWW Foundation Inc. (QuadW) and The Sarcoma Fund of the QuadW Foundation of Communities Foundation of Texas. (This list reflects commitments as of April 22, 2015.) *As of April 23, 2015. Past Grant Recipients The Conquer Cancer Foundation congratulates the following grant recipients whose abstracts were selected for the 2015 Annual Meeting. Their abstracts include the results of the research funded by the Conquer Cancer Foundation. Visit conquercancerfoundation.org for more information about the Conquer Cancer Foundation Grants and Awards Program. Rahul Aggarwal, MD, 2012 Young Investigator Award (YIA) Daniel Fontes Argolo, MD, 2014 Long-term International Fellowship (LIFe) Karen Effinger, MD, MS, 2014 Young Investigator Award (YIA) Alan Ho, MD, PhD, 2012 Career Development Award (CDA) Neil Iyengar, MD, 2013 Young Investigator Award (YIA) Meghan Karuturi, MD, 2014 Young Investigator Award (YIA) Geoffrey Oxnard, MD, 2012 Career Development Award (CDA) Ann Partridge, MD, MPH, 2010 Improving Cancer Care Grant (ICCG) Melinda Telli, MD, 2010 Young Investigator Award (YIA) Eliezer Van Allen, MD, 2013 Young Investigator Award (YIA) 24 FOLLOW #ASCO15 ON TWITTER 2015 ANNUAL MEETING SUPPORTERS* MISSION ENDOWMENT FOUNDING DONORS Bayer HealthCare Pharmaceuticals Inc. Gastrointestinal (Noncolorectal) Cancer Track Genentech BioOncology™ GlaxoSmithKline Oncology Novartis Oncology Sanofi Oncology Boehringer Ingelheim Pharmaceuticals, Inc. Lung Cancer Track MISSION ENDOWMENT SUSTAINING DONORS AbbVie, Inc. Amgen Celgene Corporation Eisai Inc. HELSINN Incyte Corporation Lilly Onyx Pharmaceuticals Sanofi Oncology Takeda Oncology ENDOWED FUND DONORS Bradley Stuart Beller Endowment Fund Bradley Stuart Beller Special Merit Award Evelyn H. Lauder YIA Endowment Fund Breast Cancer Research Foundation® James B. Nachman Pediatric Oncology Fund James B. Nachman ASCO Junior Faculty Award in Pediatric Oncology John R. Durant, MD, YIA Endowment Fund Celgene Corporation The Sally Gordon YIA Endowment Fund Anonymous CANCERLINQ™ MAJOR SUPPORTERS Amgen Astellas Bayer HealthCare Pharmaceuticals Inc. Cancer Treatment Centers of America® Chan Soon-Shiong Family Foundation Genentech BioOncology™ HELSINN Lilly Raj Mantena, RPh Novartis Oncology Pfizer Oncology Thomas G. Roberts, Jr., MD, and Susan M. DaSilva Susan G. Komen® Celgene Corporation Breast Cancer Track Gastrointestinal (Noncolorectal) Cancer Track Leukemia, Myelodysplasia, and Transplantation Track Lung Cancer Track Lymphoma and Plasma Cell Disorders Track Genentech BioOncology™ Annual Meeting Proceedings and Educational Book Bundle Breast Cancer Track Gynecologic Cancer Track Melanoma/Skin Cancers Track Genomic Health, Inc. Breast Cancer Track HELSINN Health Services Research and Quality of Care Track Patient and Survivor Care Track Incyte Corporation Gastrointestinal (Noncolorectal) Cancer Track Kidney Cancer Association Genitourinary Cancer Track Lilly Breast Cancer Track Gastrointestinal (Colorectal) Cancer Track Lung Cancer Track Pre-Annual Meeting Seminar: New Drugs in Oncology Ludwig Cancer Research Cancer Prevention, Genetics, and Epidemiology Track Merck Oncology Annual Meeting Proceedings and Educational Book Bundle Breast Cancer Track Clinical Trials Track Gastrointestinal (Noncolorectal) Cancer Track Genitourinary Cancer Track Lung Cancer Track Myriad Genetics Laboratories, Inc. Cancer Prevention, Genetics, and Epidemiology Track EDUCATIONAL SUPPORT Novartis Oncology Best of ASCO Meetings Breast Cancer Track Gastrointestinal (Noncolorectal) Cancer Track Amgen Clinical Trials Track Gastrointestinal (Colorectal) Cancer Track Onyx Pharmaceuticals Leukemia, Myelodysplasia, and Transplantation Track Lymphoma and Plasma Cell Disorders Track Astellas Medivation Genitourinary Cancer Track Pfizer Oncology Gastrointestinal (Noncolorectal) Cancer Track Genitourinary Cancer Track Leukemia, Myelodysplasia, and Transplantation Track Lymphoma and Plasma Cell Disorders Track AstraZeneca Breast Cancer Track Gynecologic Cancer Track Lung Cancer Track FOLLOW #ASCO15 ON TWITTER Pharmacyclics Leukemia, Myelodysplasia, and Transplantation Track 25 2015 ANNUAL MEETING SUPPORTERS* continued Society for Neuro-Oncology in honor of its 20th Anniversary Central Nervous System Tumors Track Teva Oncology Pre-Annual Meeting Seminar: Hematology for the Oncologist GENERAL SUPPORT AbbVie, Inc. Young Investigator Award Alliance for Academic Internal Medicine and The John A. Hartford Foundation B.J. Kennedy Award and Lecture Breast Cancer Research Foundation® Advanced Clinical Research Award in Breast Cancer Career Development Award in Breast Cancer Comparative Effectiveness Research Professorship in Breast Cancer Young Investigator Award in Breast Cancer (3) Young Investigator Award in Breast Cancer, in honor of Susan Hirschhorn and in memory of her mother Bristol-Myers Squibb Annual Meeting Program Publications Bundle ASCO iMeeting Mobile Application Onsite Connectivity Resources Bundle Brooks Brothers Corporate Allies Conquering Cancer American Association for Cancer Research Conquer Cancer Foundation of ASCO/AACR Young Investigator Translational Cancer Research Award Celgene Corporation ASCO Virtual Meeting American Cancer Society ASCO-American Cancer Society Award and Lecture The Cholangiocarcinoma Foundation Young Investigator Award in Cholangiocarcinoma Amgen Career Development Award Merit Awards Young Investigator Award Coalition of Cancer Cooperative Groups Clinical Trials Participation Award Anonymous Young Investigator Award (2) ASCO and Conquer Cancer Foundation Boards of Directors Jane C. Wright, MD, Young Investigator Award ASCO International International Innovation Grant ASCO State Affiliate Council and ASCO Clinical Practice Committee Young Investigator Award Astellas Career Development Award AstraZeneca Career Development Award International Development and Education Award International Innovation Grant Merit Awards Young Investigator Award BABETTE Corporate Allies Conquering Cancer Bayer HealthCare Pharmaceuticals Inc. ASCO Live International Development and Education Award Special Attendees Lounge Bundle Bloomingdale’s Corporate Allies Conquering Cancer Boehringer Ingelheim Pharmaceuticals, Inc. Onsite Connectivity Resources Bundle Young Investigator Award 26 Conquer Cancer Foundation International Development and Education Award Long-term International Fellowship Young Investigator Award Conquer Cancer Foundation Mission Endowment Career Development Award Medical Student Rotation for Underrepresented Populations Merit Awards Conquer Cancer Foundation Women Who Conquer Cancer Young Investigator Award David Yurman Corporate Allies Conquering Cancer Eisai Inc. Medical Student Rotation for Underrepresented Populations Onsite Connectivity Resources Bundle Young Investigator Award Ethicon Young Investigator Award Fashion Outlets of Chicago Corporate Allies Conquering Cancer Florida Society of Clinical Oncology Young Investigator Award Genentech BioOncology™ Career Development Award (3) Medical Student Rotation for Underrepresented Populations Young Investigator Award (6) Gilead Sciences, Inc. Long-Term International Fellowship FOLLOW #ASCO15 ON TWITTER Merit Awards Young Investigator Award Palo Alto Medical Foundation Leaders in Practice-Silver Supporter GlaxoSmithKline Oncology Career Development Award Gianni Bonadonna Breast Cancer Award and Lecture Susan K. Parsons, MD, and Walter Armstrong Young Investigator Award GO Airport Express Corporate Allies Conquering Cancer HELSINN General Mission Support iPlanner Mobile Application and Website Bundle Incyte Corporation Merit Awards Young Investigator Award Infinity Pharmaceuticals Inc. Onsite Connectivity Resources Bundle Ipsen Biopharmaceuticals Inc. Onsite Connectivity Resources Bundle Janssen Biotech, Inc. Resident Travel Award for Underrepresented Populations Young Investigator Award (2) John and Elizabeth Leonard Family Foundation Young Investigator Award Patient Access Network Foundation Patient Advocate Scholarship Program Pfizer Oncology Young Investigator Award The Reid R. Sacco Adolescent and Young Adult Alliance Young Investigator Award Roche Career Development Award International Development and Education Award International Innovation Grant Long-Term International Fellowship Young Investigator Award The Scopus Foundation Young Investigator Award Seattle Genetics General Mission Support iPlanner Mobile Application and Website Bundle Special Attendees Lounge Bundle Jackson G. Simpson Merit Awards Journal of Clinical Oncology Young Investigator Award Young A. Sohn and Mark Armenante Young Investigator Award Kidney Cancer Association Merit Award in Kidney Cancer Young Investigator Award in Kidney Cancer Strike 3 Foundation Young Investigator Award in Pediatric Oncology (2) Lilly Career Development Award Medical Student Rotation for Underrepresented Populations Merit Awards Patient Advocate Scholarship Program Bundle Special Attendees Lounge Bundle Young Investigator Award Merck Oncology Annual Meeting Program Publications Bundle Young Investigator Award (4) Michael’s Mission Michael’s Mission/Conquer Cancer Foundation of ASCO Career Development Award Novartis Oncology Merit Awards Resident Travel Award for Underrepresented Populations Young Investigator Award Onyx Pharmaceuticals Merit Awards Patient Advocate Scholarship Program Bundle Young Investigator Award TAIHO Oncology, Inc. iPlanner Mobile Application and Website Bundle Takeda Oncology Abstracts on ASCO.org ASCO Virtual Meeting Career Development Award International Development and Education Award Merit Awards Oncology Trainee Travel Awards Patient Advocate Scholarship Program Bundle Young Investigator Award (2) TESARO Merit Awards Teva Oncology iPlanner Mobile Application and Website Bundle Onsite Connectivity Resources Bundle Patient Advocate Scholarship Program Bundle Tourneau, LLC Corporate Allies Conquering Cancer WWWW Foundation Inc. (QuadW) and The Sarcoma Fund of the QuadW Foundation of Communities Foundation of Texas Young Investigator Award in Sarcoma, in Memory of Willie Tichenor *This list reflects commitments as of April 22, 2015. FOLLOW #ASCO15 ON TWITTER 27 ANCILLARY EDUCATIONAL EVENTS DIRECTORY Below is a list of educational events hosted by other CME-accredited providers taking place in Chicago during the 2015 ASCO Annual Meeting. For more information regarding these events, consult the contact information in the listings below. The events listed in this directory are independent, accredited educational activities held adjunct to the ASCO Annual Meeting. These presentations are not sponsored or endorsed by ASCO. Title: Questions from the Community: Investigators Provide Perspectives on Challenging Clinical Issues in the Management of Non–Small Cell Lung Cancer Date and Time: Friday, May 29 from 7:00 PM–9:00 PM Location: Hilton Chicago, Grand Ballroom CME Provider and Supporter(s): This event is sponsored by Research To Practice and supported by an educational grant from Lilly. Registration and Contact Information: Registration is encouraged as seating is limited. Register online at researchtopractice.com/Meetings/NSCLC2015. For more information, please contact [email protected] or call (800) 233– 6153. Event Summary This CME symposium will focus on the discussion of actual cases and other challenging clinical situations identified by a number of community-based oncologists to create a dynamic learning format designed to both improve clinicians’ knowledge and assist them in becoming better and more effective caregivers. In the months leading up to the event, Research To Practice, in collaboration with the invited faculty, will consult with a small group of practicing medical oncologists who care for patients with non–small cell lung cancer to identify clinical situations and/or ambiguous data sets for which they would like to receive expert perspective and feedback. During each of the 5 modules at the live activity, one invited faculty member will deliver a brief presentation reviewing recent data sets and ongoing clinical trials that inform decision making related to the clinical scenarios identified during the premeeting planning sessions. Following each didactic presentation, an extended panel discussion will be introduced to obtain the perspectives of the other faculty members on these topics. To maintain audience interest and relevance, clinician attendees will have the opportunity to participate in a premeeting survey utilizing networked iPads that will include general and case-based questions related to the topics that will be discussed. The results will be displayed throughout the event to foster additional conversation. Faculty Moderator Neil Love, MD Research To Practice Speakers Corey J. Langer, MD Director of Thoracic Oncology, Abramson Cancer Center Professor of Medicine, Perelman School of Medicine, University of Pennsylvania Vice Chair, Radiation Therapy Oncology Group Tony S. K. Mok, MD Professor, Department of Clinical Oncology, The Chinese University of Hong Kong Lecia V. Sequist, MD, MPH Associate Professor of Medicine, Harvard Medical School, Center for Thoracic Cancers, Massachusetts General Hospital Cancer Center David R. Spigel, MD Program Director, Lung Cancer Research, Sarah Cannon Research Institute Heather Wakelee, MD Associate Professor of Medicine Division of Oncology, Stanford Cancer Institute, Stanford University School of Medicine Title: Transforming Immuno-Oncology Across Solid Tumors: Targeting Pathways, Efficacy, and Combinations Date and Time: Friday, May 29 from 7:00 PM–9:00 PM (Registration and dinner begin at 6:00 PM.) Location: Hilton Chicago, International South Ballroom CME Provider and Supporter(s): This event is sponsored by Physicians’ Education Resource and supported by an educational grant from AstraZeneca. Registration and Contact Information: Registration is encouraged as seating is limited. Register online at gotoper.com/go/ASC15Immuno. For more information, please contact [email protected] or (609) 378-3701. Event Summary Immuno-Oncology is without a doubt one of the most exciting areas of cancer treatment development in recent years. Novel immuno-oncology strategies are being evaluated in a number of solid tumors for which there remains great unmet clinical needs, including lung cancer, squamous cell carcinoma of the head and 28 FOLLOW #ASCO15 ON TWITTER neck, and mesothelioma. These novel approaches to care for these tumors have the potential to redefine how cancer is treated and managed. This symposium is structured in an interactive format that chronicles the advances in medicine through a historical perspective, while employing an evidence-based roadmap to forecast future therapeutic options with the potential to dramatically improve patient care. It includes multimedia technology and interactive presentations from expert faculty that allow medical professionals to enhance their understanding of the advances in immuno-oncology in order to translate and impact treatment practices in the future. There is no registration fee to participate in this live educational symposium. However, preregistration is recommended, as seating is limited. Faculty Moderator Roy S. Herbst, MD, PhD—Chair Ensign Professor of Medicine (Medical Oncology), Professor of Pharmacology, Chief of Medical Oncology, Associate Director for Translational Research, Yale Cancer Center, Yale School of Medicine Speakers Julie Brahmer, MD Interim Director, The Sidney Kimmel Comprehensive Cancer Center (Johns Hopkins Bayview campus) Interim Co-Director, Upper Aerodigestive Program, Associate Professor, Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Barbara Burtness, MD Clinical Research Program Leader, Head and Neck Cancers Program, Co-Director, Developmental Therapeutics Research Program, Professor of Medicine, Medical Oncology, Yale Cancer Center Naiyer Rizvi, MD Director, Thoracic Oncology, Director, Immunotherapeutics, Price Chair, Clinical Translational Research, Columbia University Medical Center Title: The Clinical Potential of Novel Poly ADP-Ribose Polymerase (PARP) Inhibitors for Improved Management of Epithelial Ovarian Cancer Date and Time: Saturday, May 30 from 6:30 PM– 8:45 PM Location: Hilton Chicago, International North Ballroom CME Provider and Supporter(s): This event is sponsored by Imedex and supported by an educational grant from AstraZeneca. Registration and Contact Information: Registration is encouraged as seating is limited. Register online at imedex.com/ovarian-cancer-parp-inhibitors/index.asp. For more information, please contact [email protected] or call (800) 233 0957 (domestic) or ⫹1 (678) 242 0906 (outside the U.S.). Event Summary Care for patients with gynecologic cancers is becoming increasingly complex. PARP inhibitors (PARPis) have been investigated in the maintenance and second-line setting in ovarian cancers with encouraging response rates and improvement in progression-free survival, especially in patients with high-grade serous carcinoma. Eight PARPis are currently being evaluated in more than 35 clinical trials. Increasingly, clinical trial design and treatment of ovarian cancer are being based on histologic and molecular characteristics of the tumor, and PARPis have the potential to be the first targeted agents that allow for patient selection to improve clinical outcomes. Join us for this interactive symposium during which world-renowned experts engage in case and panel discussions to evaluate the benefits and risks of emerging PARPis, identify ways to safely and effectively incorporate these agents into practice, and provide tips for referring patient to appropriate trials. Faculty Bradley J. Monk, MD, FACOG, FACS—Chair Creighton University School of Medicine, St. Joseph’s Hospital and Medical Center Thomas J. Herzog, MD University of Cincinnati Ursula A. Matulonis, MD Dana-Farber Cancer Institute/Harvard University School of Medicine Title: Identification and Innovation of Novel EGFR TKIs for NSCLC Date and Time: Saturday, May 30 from 7:00 PM–9:00 PM (Registration and dinner seating begins at 6:30 PM.) Location: Hilton Chicago, International South Ballroom CME Provider and Supporter(s): This event is sponsored by Letters & Sciences in joint providership with the Postgraduate Institute for Medicine and supported by an educational grant from AstraZeneca. Registration and Contact Information: Registration is encouraged as seating is limited. Register online at NSCLCNovelTKIs.com. For more information, please email Jamie Miller at [email protected]. FOLLOW #ASCO15 ON TWITTER 29 ANCILLARY EDUCATIONAL EVENTS DIRECTORY continued Event Summary With paradigm shifts in the approach to non–small cell lung cancer (NSCLC) treatment, customization of treatment based on histology and molecular typing has become the standard of care. The identification of treatment-resistant subsets and continuous development of targeted therapies in the NSCLC treatment paradigm require education and expert guidance to support oncologists and other health-care providers in their clinical decision making. To bridge clinical practice and knowledge gaps, leading experts, including a distinguished faculty of principal investigators, clinicians, and researchers will identify the major mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors (TKIs), and discuss the development of rationally designed molecular targeted drugs used to help overcome treatment resistance. The faculty will also address late-breaking evidence, discuss the role and sequencing of next-generation EGFR TKIs, as well as highlight efforts to answer ongoing clinical challenges. Faculty Corey J. Langer, MD—Chair Director of Thoracic Oncology, Abramson Cancer Center of the University of Pennsylvania David S. Ettinger, MD, FACP, FCCP Alex Grass Professor of Oncology, The Johns Hopkins University School of Medicine Pasi A. Janne, MD, PhD Professor of Medicine, Dana-Farber Cancer Institute Heather Wakelee, MD Associate Professor of Medicine (Oncology), Stanford University Title: Best Practices and Emerging Treatment Strategies in the Management of Chemotherapy-Induced Nausea and Vomiting Date and Time: Sunday, May 31 from 6:30 PM–9:00 PM Location: Hilton Chicago, International North Ballroom CME Provider and Supporter(s): This event is sponsored by Imedex and supported by an educational grant from TESARO, Inc. Registration and Contact Information: Registration is encouraged as seating is limited. Register online at imedex.com/cinv-management/index.asp. For more information, please contact [email protected] or call (800) 233 0957 (domestic) or ⫹1 (678) 242 0906 (outside the U.S.). Event Summary Chemotherapy-induced nausea and vomiting (CINV) is regarded by patients as one of the most distressing and feared adverse effects of chemotherapy. Although it is estimated to afflict more than 70% of patients with cancer undergoing both highly and moderately emetogenic treatment, the incidence and effects of CINV on quality of life are often underestimated. Inadequate control of nausea and vomiting may necessitate reduced treatment intensity and result in poor adherence to therapy. Delayed nausea and emesis, which may present even in the absence of acute effects, remain targets for improved therapeutic intervention. Novel antiemetic agents and strategies are being developed to improve CINV control, particularly of delayed nausea. Join us for an interactive symposium during which world-renowned experts engage in case and panel discussions, relating the pathophysiology of CINV to targets for therapeutic intervention and evaluating the implications of recent guidelines and emerging safety and efficacy data for novel therapies and clinical approaches. Faculty Paul J. Hesketh, MD–Chair Lahey Hospital and Medical Center Matti S. Aapro, MD Cinique de Genolier Richard J. Gralla, MD Albert Einstein College of Medicine Title: The Biosimilar Matrix: The Impact of Biosimilars in Managing Neutropenia Date and Time: Sunday, May 31 from 7:00 PM– 8:30 PM (Registration and dinner begin at 6:30 PM.) Location: Sheraton Chicago Hotel & Towers, Chicago Ballroom 8 - Level 4 CME Provider and Supporter(s): This event is sponsored by Medscape Education and supported by an independent educational grant from Sandoz, A Novartis Company. Registration and Contact Information: Register online at medscape.org/sites/townhall/public/biosimilarmatrix. Registration is encouraged as seating is limited. Event Summary The recent introduction of biosimilars to the U.S. health-care scene has resulted in confusion among clinicians regarding what they are, how they are made, how they differ from brand-name products, how they are approved, and how they should be used in practice. A distinguished international team of multidisciplinary 30 FOLLOW #ASCO15 ON TWITTER experts will try to answer these questions by focusing on the efficacy, safety, and pharmacoeconomics of granulocyte colony-stimulating factor (G-CSF) biosimilars in the context of managing neutropenia. Topics to be covered include the development and regulatory pathway of these products, their clinical efficacy and safety, and guidance on the role of G-CSF biosimilars as they may be applied in clinical practice. By the conclusion of this session, attendees can expect to have achieved a greater sense of clarity around these increasingly important biological products and their role in the care of patients with cancer. Faculty Moderator Andrew D. Zelenetz, MD, PhD Memorial Sloan Kettering Cancer Center Speakers Pere Gascón, MD, PhD University of Barcelona Edward Li, PharmD, MPH University of New England College of Pharmacy James G. Stevenson, PharmD University of Michigan College of Pharmacy Title: Novel Perspectives in Personalizing EGFR-Targeted Therapy in NSCLC: Frontline and Overcoming Resistance Date and Time: Sunday, May 31, from 7:00 PM–9:00 PM (Registration and dinner will begin at 6:00 PM.) Location: Sheraton Chicago, Chicago Ballroom VI CME Provider and Supporter(s): This event is sponsored by Physicians’ Education Resource and supported by an educational grant from AstraZeneca. Registration and Contact Information: Registration is encouraged as seating is limited. Register online gotoper.com/go/ASC15Lung. For more information, please contact [email protected] or call 609-378-3701. Event Summary “Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options. . . More Decisions. . . Better Outcomes.” Lung cancer is the leading cause of cancer death in the United States. Despite progress in early detection, lung cancer is often diagnosed at an advanced stage and patient prognosis in advanced disease is poor. Non–small cell lung cancer (NSCLC) is the most common form of lung cancer, and accounts for the vast majority of cases. EGFR-mutations have been established for quite some time as predictive markers of response to certain EGFR-TKI therapies in the front-line setting. However, despite good initial responses observed with front-line approaches in EGFR-mutated tumors, disease progression subsequent to front-line EGFR-TKI treatment is inevitable. Second-generation irreversible EGFR-TKIs have been unable to overcome T790M-mediated resistance as monotherapy, and there is a significant current unmet clinical need for patients with acquired resistance in relapsed advanced NSCLC. This symposium will address these needs in treating EGFR-mutant NSCLC through multiple lines of therapy. There is no registration fee to participate in this live educational symposium. However, preregistration is recommended, as seating is limited. Faculty Moderator Mark G. Kris, MD Attending, Thoracic Oncology Service, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center Speakers David Gandara, MD Professor of Medicine, Division of Hematology/Oncology, Director, Thoracic Oncology Program, Senior Advisor to the Director, UC Davis Comprehensive Cancer Center Geoffrey R. Oxnard, MD Assistant Professor of Medicine, Dana Farber Cancer Institute Helena A. Yu, MD Assistant Attending, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center Title: The Potential Therapeutic Benefits of Emerging Arginine Deprivation Agents Date and Time: Sunday, May 31 from 7:00 PM–9:00 PM (Registration and dinner begins at 6:30 PM.) Location: Hilton Chicago, International South Ballroom CME Provider and Supporter(s): This event is sponsored by Med Learning Group and co-provided by Ultimate Medical Academy/Complete Conference Management with support from an educational grant from FOLLOW #ASCO15 ON TWITTER 31 ANCILLARY EDUCATIONAL EVENTS DIRECTORY continued Polaris Group. Registration and Contact Information: Registration is encouraged as seating is limited. Register online at medlearninggroup.com/cme-programming/asco-symposium. For more information, please contact Joe Guerriero at (908) 358 – 6466. Event Summary This CME symposium is designed to meet the educational needs of oncology physicians and nurses as well as other health-care providers involved in the treatment of patients with various cancers, including but not limited to hepatocellular carcinoma, mesothelioma, acute myelogenous leukemia, acute lymphoblastic leukemia, and non–small cell lung cancer. The faculty will explain the rationale for arginine deprivation therapies, review the clinical experience with emerging ADI-PEG-20 compounds and their potential therapeutic uses, and finally describe strategies to implement these new agents into multimodality drug regimens. Faculty Ghassan Abou-Alfa, MD—Chair Associate Professor, Memorial Sloan Kettering Cancer Center Richard J. Bold, MD Chief of Surgical Oncology, Professor, UC Davis Comprehensive Cancer Center Eileen M. O’Reilly, MD Associate Director, Clinical Research, David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center Peter W. Szlosarek, MD, PhD Physician Scientist, Barts Cancer Institute and St Bartholomew’s Hospital Brian A. Van Tine, MD, PhD Hematology/Oncology, Assistant Professor of Medicine, Sarcoma Program Director, Barnes-Jewish Hospital, Washington University in St. Louis 32 FOLLOW #ASCO15 ON TWITTER American Society of Clinical Oncology 51st Annual Meeting Meeting Program Abstract Key LBA: Late-Breaking Abstract TPS: Trials in Progress Abstract Friday, May 29, 2015 FRIDAY 1:00 PM - 2:15 PM Education Session Acute Lymphoblastic Leukemia: A New Era of Targeted and Immunologic Therapies Location: E450 David I. Marks, MD, PhD University Hospitals Bristol NHS Foundation Trust Treatment of the Older Patient with Acute Lymphoblastic Leukemia: Balancing Risk and Benefit Michel Sadelain, MD—Chair Memorial Sloan Kettering Cancer Center Novel and Effective Immunotherapeutic Approaches in Acute Lymphoblastic Leukemia Adele K. Fielding, MBBS, PhD University College London Management of Ph-Positive Acute Lymphoblastic Leukemia Panel Question and Answer 1:00 PM - 2:15 PM Education Session Controversies in the Management of Germ Cell Tumors Location: E354b Alan Horwich, MD, PhD The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust The Role for Observation in Stage I Germ Cell Tumors, Outcomes, and Challenges Lawrence H. Einhorn, MD Indiana University School of Medicine Salvage Approaches in Refractory Germ Cell Tumors George J. Bosl, MD—Chair Memorial Sloan Kettering Cancer Center Future Directions in Germ Cell Tumors Panel Question and Answer 1:00 PM - 2:15 PM Education Session Early Detection of Cancer: Past, Present, and Future Location: S404 Paul Graham Fisher, MD Stanford University Biomarkers for Early Cancer Detection Joshua David Schiffman, MD—Chair University of Utah Imaging for Early Tumor Surveillance in High-Risk and General Populations Peter Gibbs, MBBS, MD, FRACP Royal Melbourne Hospital Detection of Circulating Tumor Cells and Circulating Tumor DNA Panel Question and Answer 34 Friday, May 29, 2015 FRIDAY 1:00 PM - 2:15 PM Education Session Molecular Oncology Tumor Board Location: S100bc S. Gail Eckhardt, MD—Chair University of Colorado School of Medicine, Anschutz Medical Campus Lillian L. Siu, MD, FRCPC Princess Margaret Cancer Centre Medical Oncology Stanley R. Hamilton, MD The University of Texas MD Anderson Cancer Center Pathology Nikolaus Schultz, PhD Memorial Sloan Kettering Cancer Center Bioinformatics Molly S. Daniels, MS, CGC The University of Texas MD Anderson Cancer Center Genetic Counseling Panel Question and Answer 1:00 PM - 2:15 PM Meet the Professor Session Career Development in Pediatric Clinical Trials: Direction for Young Investigators from NCI and Cooperative Group Leadership—Ticketed Session Location: E451a Nita Seibel, MD National Cancer Institute Lia Gore, MD University of Colorado Cancer Center 1:00 PM - 3:15 PM Extended Education Session Administrative Burdens in Oncology Location: S504 1:00 PM Robin Zon, MD, FACP, FASCO—Chair Michiana Hematology Oncology PC Growing Concern of Administrative Burdens in Practice 1:15 PM Barbara L. McAneny, MD New Mexico Oncology Hematology Consultants, LTD Recognizing and Identifying Administrative Burdens in Practice 1:40 PM Kimberly Woofter, RN Michiana Hematology Oncology PC Practice Administrator’s Perspective 2:05 PM John Emmett Hennessy, CMPE Sarah Cannon Cancer Services Payers, Preauthorizations, and Payments: Transactional Burdens 35 Friday, May 29, 2015 2:30 PM Panel Question and Answer FRIDAY 1:00 PM - 3:15 PM Extended Education Session Controversies in the Management of Premenopausal Breast Cancer: The Role for Ovarian Suppression, Fertility Preservation, Bisphosphonates, and Local Therapy Location: E Hall D1 1:00 PM Hope S. Rugo, MD—Chair University of California, San Francisco Hormonal Therapy for Early-Stage Breast Cancer in Premenopausal Women 1:24 PM Halle C. F. Moore, MD Cleveland Clinic Should We Use GnRH Agonists for Fertility Preservation? 1:48 PM Kutluk Oktay, MD Institute for Fertility Preservation and New York Medical College Fertility Options for Young Women with Breast Cancer 2:12 PM Robert E. Coleman, MBBS, MD, FRCP University of Sheffield, Weston Park Hospital Use of Bisphosphonates in Premenopausal Women 2:36 PM Barbara L. Smith, MD, PhD Massachusetts General Hospital Surgical Options for Young Women with Breast Cancer 3:00 PM Panel Question and Answer 1:00 PM - 3:15 PM Extended Education Session On the Shoulders of Giants: Chronic Lymphocytic Leukemia—Evolution of Targeted and Immunotherapy Location: S406 1:00 PM Marcia S. Brose, MD, PhD—Chair Abramson Cancer Center of the University of Pennsylvania Welcome and Introductions 1:15 PM Jesse A. Soodalter, MD University of Chicago Medicine Case Study Presentation and Discussion 1:45 PM John C. Byrd, MD Ohio State University Medical Center History of Chronic Lymphocytic Leukemia and Molecular Targeted Therapy 2:15 PM Michael Andrew Postow, MD Memorial Sloan Kettering Cancer Center Case Study Presentation and Discussion 2:45 PM Stephen J. Schuster, MD Abramson Cancer Center of the University of Pennsylvania Immunotherapy and Chronic Lymphocytic Leukemia 1:00 PM - 3:15 PM Extended Education Session Personalizing Lung Cancer Therapy in the Adjuvant or Advanced Setting Location: E Arie Crown Theater 36 1:00 PM Thierry Le Chevalier, MD Institut Gustave Roussy Adjuvant Therapy for Elderly and Nonfit Patients in the Pan-Wildtype Setting 1:20 PM Martin J. Edelman, MD—Chair University of Maryland School of Medicine Systemic Therapy of Pan-WT in Metastatic Setting 1:40 PM Marc Ladanyi, MD Memorial Sloan Kettering Cancer Center Next-Generation Sequencing and Other Platforms for Molecular Profiling 2:00 PM Tony Mok, MD Chinese University of Hong Kong Molecularly Targeted Therapies: Their Trials and Roles in the Adjuvant and Postchemoradiation Setting 2:20 PM Grace K. Dy, MD Roswell Park Cancer Institute Clinical Trials and Treatment for Mutations Other Than EGFR/ALK/ROS1 2:40 PM Laura Quan Man Chow University of Washington Considering Immunotherapy in the Adjuvant and Metastatic Setting 3:00 PM Panel Question and Answer FRIDAY Friday, May 29, 2015 1:00 PM - 3:15 PM Extended Education Session The ASCO Obesity Initiative: The Weight of the Evidence Location: S102 1:00 PM Pamela Jean Goodwin, MD, MSc, FRCPC Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto Obesity: Observational Evidence and Mechanisms 1:22 PM Wendy Demark-Wahnefried, PhD, RD University of Alabama at Birmingham Comprehensive Cancer Center Weight Management and Nutrition: Interventions and Practical Considerations 1:44 PM Lee Jones, PhD Memorial Sloan Kettering Cancer Center Physical Activity: Observational Evidence and Mechanisms 2:06 PM Kerry S. Courneya, PhD University of Alberta Physical Activity: Interventions and Practical Considerations 2:28 PM Jennifer A. Ligibel, MD—Chair Dana-Farber Cancer Institute The ASCO Obesity Initiative: Current Status and Next Steps 2:50 PM Panel Question and Answer 1:00 PM - 4:15 PM Extended Education Session MOC and Lifelong Learning Workshop: ABIM Module 2014 —Ticketed Session Location: E451b Antoinette R. Tan, MD Levine Cancer Institute, Carolinas HealthCare System Bhoomi Mehrotra, MD St. Francis Hospital 37 Friday, May 29, 2015 FRIDAY Benjamin Philip Levy, MD Mount Sinai Health Systems 1:00 PM - 5:00 PM Extended Education Session Grant Writing Workshop Location: S103 1:00 PM Dean Frohlich Conquer Cancer Foundation of the American Society of Clinical Oncology Conquer Cancer Foundation Grants Program 1:15 PM Ming Lei, PhD National Cancer Institute at the National Institutes of Health National Cancer Institute Training and Career Development Grants 1:30 PM Susan Blaney, MD Texas Children’s Cancer Center, Baylor College of Medicine Choosing a Mentor and Obtaining Letters of Support 1:45 PM Heather L. McArthur, MD Memorial Sloan Kettering Cancer Center What to Do When Your First Grant Application Gets Rejected 2:00 PM Karla V. Ballman, PhD Mayo Clinic Working with a Biostatistician 2:15 PM Mary L. Disis, MD—Chair University of Washington Grant Writing Pearls Kathleen A. Cooney, MD University of Michigan Comprehensive Cancer Center Small Group Discussion Table Leader Suzanne Eleanor Dahlberg, PhD Dana-Farber Cancer Institute Small Group Discussion Table Leader Norah Lynn Henry, MD, PhD University of Michigan Comprehensive Cancer Center Small Group Discussion Table Leader Dawn L. Hershman, MD, MS Columbia University Medical Center Small Group Discussion Table Leader Bruno C. Medeiros, MD Stanford University School of Medicine Small Group Discussion Table Leader Wells A. Messersmith, MD University of Colorado Cancer Center Small Group Discussion Table Leader 1:00 PM - 5:45 PM Special Session Global Oncology Symposium Location: S100a Gabriel N. Hortobagyi, MD, FACP—Co-Chair The University of Texas MD Anderson Cancer Center 38 Friday, May 29, 2015 FRIDAY Yun Yen, MD, PhD—Co-Chair Taipai Medical University 1:00 PM David J. Kerr, MD, PhD University of Oxford Global Health Policy and the Accidental Tourist 1:30 PM Sun Young Rha, MD, PhD Yonsei University College of Medicine Gastric Cancer: East versus West 1:45 PM Adam Joel Bass, MD Dana-Farber Cancer Institute Gastric Cancer Genetics and Implications of TCGA 2:05 PM Kazuhiro Yoshida, MD, PhD Gifu University School of Medicine Genetic and Biological Characteristics of Gastric Cancer and Its Multidisciplinary Treatment 2:25 PM Randomized controlled trial of comaring gastrectomy (Gx) plus chemotherapy (CTX) with CTX alone in advanced gastric cancer (AGC) with a single non-curable factor: JCOG 0705/KGCA01 study (REGATTA) (Abstract 200) H. K. Yang, T. Tsujinaka, K. Nakamura, Y. W. Kim, M. Terashima, S. U. Han, Y. Iwasaki, W. J. Hyung, A. Takagane, B. J. Park, K. Fujitani, S. Hahn, M. Sasako, Y. J. Bang 2:35 PM Manish A. Shah, MD Weill Cornell Medical College Gastric Cancer Discussion and Wrap-up 3:00 PM Panel Question and Answer 3:15 PM Break 3:30 PM Anil D’Cruz, MBBS, MS, FRCS Tata Memorial Hospital Cancer Disparities and Access to Care 4:00 PM Gilberto Lopes, MD, MBA, FAMS Centro Paulista de Oncologia and HCor Onco Minimal Essential Formularies 4:30 PM Daniel F. Hayes, MD University of Michigan Comprehensive Cancer Center Pathology Introduction 4:35 PM Antonio C. Wolff, MD, FACP, FASCO Johns Hopkins Kimmel Cancer Center ASCO/College of American Pathologists Collaborations 4:50 PM Matthew Zarka, MD Mayo Clinic Arizona Pathology Challenges in Limited Resource Settings 5:10 PM Lawrence N. Shulman, MD Dana-Farber Cancer Institute Improving Pathology in Limited Resource Settings: A Model from Rwanda 5:30 PM Panel Question and Answer 2:45 PM - 4:00 PM Education Session Beyond Tyrosine Kinase Inhibitor Therapy: Incorporating Immunotherapy and Metastasectomy into Renal Cell Carcinoma Management Location: E354b 39 Friday, May 29, 2015 FRIDAY James M. G. Larkin, MD, PhD—Chair The Royal Marsden NHS Foundation Trust New Pathways and Targets: Exploring New Agents for Advanced Renal Cell Carcinoma Martin Henner Voss, MD Memorial Sloan Kettering Cancer Center Integrating Immunotherapy and Other New Agents into the Current Treatment Paradigm in Advanced Renal Cell Carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital The Role of Metastasectomy in Patients with Renal Cell Carcinoma Panel Question and Answer 2:45 PM - 4:00 PM Education Session Management of Hematologic Malignancies in Older Adults Location: E450 H. Joachim Deeg, MD—Chair Fred Hutchinson Cancer Research Center Scientific Basis and Clinical Management of Myelodysplastic Syndrome for Older Adults Maxwell Masters Krem, MD University of Washington Novel Targeted Therapy for Low-grade Lymphoid Malignancies in Older Adults Paul A. Hamlin, MD Memorial Sloan Kettering Cancer Center Management of Diffuse Large B-Cell Lymphoma in Older Adults Panel Question and Answer 2:45 PM - 4:00 PM Meet the Professor Session Achieving Precision Medicine through Therapeutic Drug Monitoring and Pharmacogenomics—Ticketed Session Location: E451a Jan Hendrik Beumer, PharmD, PhD University of Pittsburgh Cancer Institute Federico Innocenti, MD, PhD The University of North Carolina at Chapel Hill 3:45 PM - 6:00 PM Extended Education Session Expediting the Learning Curve for Applied Cancer Genomics Location: S100bc 3:45 PM 40 Howard L. McLeod, PharmD—Chair Moffitt Cancer Center Using Germ-Line and Somatic Genomic Data for Management of Patients with Cancer Friday, May 29, 2015 David N. Hayes, MD, MPH Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill Clinical-Grade Deep Sequencing for Cancer 4:25 PM James M. Ford, MD Stanford University School of Medicine Incidental Germ-Line Findings and What to Do about Them 4:45 PM Eliezer Mendel Van Allen, MD Dana-Farber Cancer Institute Informatic Strategies to Turn Sequence Data into Cancer Patient Management 5:05 PM Christine Marie Walko, PharmD, BCOP Moffitt Cancer Center Using Multidisciplinary Tumor Board to Augment the Value of Cancer Sequencing 5:25 PM Robert R. McWilliams, MD Mayo Clinic Using the Multidisciplinary Tumor Board to Augment the Value of Cancer Sequencing 5:45 PM Panel Question and Answer FRIDAY 4:05 PM 3:45 PM - 6:00 PM Extended Education Session Practical Tips for Academic, Private, and Industry Career Tracks: Negotiating Contracts and Education Debt Management Location: S404 Ezra E. W. Cohen, MD—Chair UC San Diego Moores Cancer Center 3:45 PM David H. Johnson, MD The University of Texas Southwestern Medical Center Academia: Critical Items to Negotiate in Your Contract—Clinical Investigator and Clinician Tracks 4:15 PM Daniel F. Hoth, MD Semafore What I Wish I Knew Before Starting an Industry Career: The Good and the Bad 4:45 PM Linda D. Bosserman, MD, FACP City of Hope Private Practice: Critical Factors to Negotiate in Contracts 5:15 PM Jill Mattia, PhD National Institutes of Health Education Debt: National Institutes of Health Loan Repayment Program 5:45 PM Panel Question and Answer 4:00 PM - 6:00 PM Education Session Special Session for Program Directors and Key Clinical Faculty: Milestones 201—Reviewing the Challenges and Addressing the Obstacles Including the ASCO Excellence in Teaching Award Presentation Location: E350 4:00 PM Clifford A. Hudis, MD, FACP Memorial Sloan Kettering Cancer Center Presentation of the 2015 Excellence in Teaching Award 41 Friday, May 29, 2015 FRIDAY 4:05 PM Dean F. Bajorin, MD—Award Recipient Memorial Sloan Kettering Cancer Center Excellence in Teaching Award 4:10 PM Jill Gilbert, MD—Chair Vanderbilt University Welcome and Introductions 4:30 PM Frances A. Collichio, MD The University of North Carolina at Chapel Hill School of Medicine Tricky Milestones and Tools for Addressing Them 4:50 PM John C. Barrett, MD VCU Massey Cancer Center Tricky Milestones and Tools for Addressing Them 5:10 PM Sandra Moutsios, MD Vanderbilt University Tricky Milestones and Tools for Addressing Them 5:30 PM Helen K. Chew, MD UC Davis Medical Center Tricky Milestones and Tools for Addressing Them 4:30 PM - 5:45 PM Education Session Debate on Chemotherapy and Radium 223 for the Optimal Treatment of Advanced Prostate Cancer Location: E Arie Crown Theater Howard I. Scher, MD Memorial Sloan Kettering Cancer Center Chemotherapy Should Be Given Late for Men with Metastatic Disease Maha Hussain, MD, FACP, FASCO University of Michigan Comprehensive Cancer Center Chemotherapy Should Be Given Early for Men with Metastatic Disease Tanya B. Dorff, MD—Chair USC Norris Comprehensive Cancer Center Radium 223: Defining Timing, Patients, and Duration with Limited Data Panel Question and Answer 4:30 PM - 5:45 PM Education Session Depression, Anxiety, Neuropathy, and Fatigue: An Update on the 2014 ASCO Survivorship Guidelines and How to Incorporate Them into Practice Location: S102 Ann H. Partridge, MD, MPH—Chair Dana-Farber Cancer Institute ASCO Survivorship Guidelines: Challenges to Standardizing the Care for Adult Cancer Survivors Barbara L. Andersen, PhD The Ohio State University ASCO Guidelines: Anxiety and Depression in Cancer Survivors 42 Friday, May 29, 2015 FRIDAY Guido Cavaletti, MD University of Milan-Bicocca ASCO Guidelines: Neuropathy in Cancer Survivors Paul B. Jacobsen, PhD Moffitt Cancer Center ASCO Guidelines: Fatigue in Cancer Survivors Panel Question and Answer 4:30 PM - 5:45 PM Education Session Hepatocellular Carcinoma Tumor Board: Making Sense of the Technologies Location: E354b Riccardo Lencioni, MD Pisa University Hospital and School of Medicine Interventional Radiologist Perspective John Renz, MD, PhD The University of Chicago Medicine Hepatobiliary Surgeon and Transplant Perspective Jorge A. Marrero, MS, MD The University of Texas Southwestern Medical Center Hepatologist Perspective Ghassan K. Abou-Alfa, MD—Chair Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College Medical Oncologist Perspective Panel Question and Answer 4:30 PM - 5:45 PM Education Session Incorporating Novel Agents into Lymphoma Therapy: Value in Everyday Practice Location: E450 Gilles A. Salles, MD PhD Hospices Civils de Lyon, Université Claude Bernard Novel Agents in the Treatment of Follicular Lymphoma Stephen Maxted Ansell, MD Mayo Clinic Novel Agents in Therapy of Hodgkin Lymphoma Michelle A. Fanale, MD—Chair The University of Texas MD Anderson Cancer Center Novel Agents in Therapy of T-Cell Lymphoma Panel Question and Answer 43 Friday, May 29, 2015 FRIDAY 4:30 PM - 5:45 PM Education Session Individualizing the Approach to the Older Woman with Breast Cancer Location: S406 Rinaa S. Punglia, MD, MPH Dana-Farber Cancer Institute Can Radiation Be Avoided or Streamlined in Older Women with Breast Cancer? Hyman B. Muss, MD—Chair The University of North Carolina at Chapel Hill Chemotherapy for Older Patients with Breast Cancer: Should We Use More or Less? Kevin S. Hughes, MD, FACS Massachusetts General Hospital Can We Do Less Surgery in the Breast and Axilla in Older Women with Breast Cancer? Panel Question and Answer 4:30 PM - 5:45 PM Education Session Promises and Pitfalls of Lung Cancer Screening and Surveillance Location: E Hall D1 Claudia I. Henschke, MD, PhD Icahn School of Medicine at Mount Sinai General Overview and Recommendations for Screening and Surveillance Bernardo Haddock Lobo Goulart, MD, MS—Chair Fred Hutchinson Cancer Research Center Implementation Challenges in Lung Cancer Screening Panel Question and Answer 4:30 PM - 5:45 PM Meet the Professor Session ASCO Community Research Forum: Bringing Community-Based Researchers Together to Advance Cancer Research—Ticketed Session Location: E451a Michael A. Thompson, MD, PhD Aurora Research Institute, Aurora Health Care Howard A. Burris, MD Sarah Cannon Research Institute, Tennessee Oncology 4:30 PM - 5:45 PM Clinical Problems in Oncology Session Treating Newly Diagnosed Metastatic Colorectal Cancer: The Role of Chemotherapy, Ablation, and Surgery—Ticketed Session Location: E451b 44 Friday, May 29, 2015 FRIDAY Stephen Barnett Solomon, MD Memorial Sloan Kettering Cancer Center What Is the Role of Ablation/Embolization of Metastases? Thomas Bachleitner-Hofmann, MD Medical University of Vienna Does the Primary Lesion Need Resection? Cathy Eng, MD—Chair The University of Texas MD Anderson Cancer Center What Is the Optimal Chemotherapy Sequence? 45 Saturday, May 30, 2015 7:30 AM - 8:00 AM Education Session How to Navigate the Annual Meeting (Trainees and Early Career Oncologists Only) Location: S501 Jyoti D. Patel, MD—Chair Feinberg School of Medicine, Northwestern University Optimize Your Annual Meeting Experience SATURDAY Don S. Dizon, MD Massachusetts General Hospital Technology Tools and Resources to Help You Navigate the Meeting 8:00 AM - 9:15 AM Education Session Alternatives to ASP-Plus-Six: What Are the Options? Location: S404 Jeffery C. Ward, MD—Chair Swedish Cancer Institute Edmonds The Realpolitik Perspective Blase N. Polite, MD, MPP The University of Chicago The Oncologist’s Perspective Rena M. Conti, PhD The University of Chicago The Economist’s Perspective Panel Question and Answer 8:00 AM - 9:15 AM Education Session Brain Metastases: From Clinical Trials to Clinical Practice Location: E354b Frank Winkler, Dr. Med University of Heidelberg Molecular Biology of Brain Metastases: Implications for Therapy Minesh P. Mehta, MD University of Maryland Medical Systems Whole-Brain Radiation and Stereotactic Radiosurgery in Brain Metastases: What Is the Evidence? Manmeet Singh Ahluwalia, MD—Chair Cleveland Clinic Immunotherapy and Targeted Therapy in Brain Metastases: A Tailor-Made Approach Panel Question and Answer 46 Saturday, May 30, 2015 8:00 AM - 9:15 AM Education Session Breast Cancer Chemoprevention: Proven but Publicly Ignored—An Update of Benefit and Risk Data Location: S100bc Katherine D. Crew, MD, MS Columbia University Medical Center Update on Risks and Benefits of Breast Cancer Chemoprevention Treatments When Applied as Primary Prevention of Breast Cancer SATURDAY Powel Brown, MD, PhD—Chair The University of Texas MD Anderson Cancer Center Provider Perceptions of Breast Cancer Chemoprevention Agents Christine Holmberg, DPhil, MPH Charité Universitätsmedizin Berlin, Berlin School of Public Health Patient Perceptions of Breast Cancer Chemoprevention Agents Panel Question and Answer 8:00 AM - 9:15 AM Education Session Challenges in Melanoma Clinical Trials: Will Our Success Hold Us Back? Location: S406 Lynn Mara Schuchter, MD—Chair Abramson Cancer Center of the University of Pennsylvania A Good Problem to Have: Clinical Trials in the Era of Multiple Effective Agents Marc Robert Theoret, MD National Cancer Institute at the National Institutes of Health A Regulatory Perspective to Novel Therapeutics in Melanoma in 2015 Janice M. Mehnert, MD Rutgers Cancer Institute of New Jersey Should Comorbidities Be an Automatic Exclusion for Clinical Trials? Panel Question and Answer 8:00 AM - 9:15 AM Education Session Diffuse Large B-Cell Lymphoma: Are We Ready for Molecular Subtype-Specific Therapy? Location: E450 David W. Scott, MBCHB, PhD British Columbia Cancer Agency Molecular Subtypes of Diffuse Large B-Cell Lymphoma: Ready for the Clinic? Grzegorz S. Nowakowski, MD—Chair Mayo Clinic Molecular-Subtype-Specific Therapy of Diffuse Large B-Cell Lymphoma: Are We Ready to Change Our Practice? 47 Saturday, May 30, 2015 Myron Stefan Czuczman, MD Roswell Park Cancer Institute C-Myc Positive and Double Hit Diffuse Large B-Cell Lymphoma: Aggressive Subtype, Aggressive Treatment? Panel Question and Answer 8:00 AM - 9:15 AM Education Session Introduction to Methods in Comparative Effectiveness Research Location: S102 SATURDAY Sharon Hermes Giordano, MD, MPH—Chair The University of Texas MD Anderson Cancer Center Overview of Comparative Effectiveness Research and Observational Study Design Caprice Christian Greenberg, MD, MPH University of Wisconsin School of Medicine and Public Health Pragmatic Clinical Trials Including the Use of Patient-Centered Outcomes Natasha K. Stout, MS, PhD Harvard Medical School and Harvard Pilgrim Health Care Institute Methods in Decision Analysis Panel Question and Answer 8:00 AM - 9:15 AM Education Session Real-Time Molecular Genetic Profiling: The Future Is Now (Or Is It?) Location: S504 Donald Williams Parsons, MD, PhD Texas Children’s Cancer Center, Baylor College of Medicine Clinical Tumor and Germ-Line Sequencing of Pediatric Malignancies William L. Carroll, MD NYU Langone Medical Center State-of-the-Art Discovery with Tumor Profiling in Pediatric Oncology Stephen J. Chanock, MD—Chair National Cancer Institute at the National Institutes of Health Risks and Benefits of Real-Time Molecular Profiling Panel Question and Answer 8:00 AM - 9:15 AM Education Session Sequence, Duration, and Cost of Treating Metastatic Unresectable Colorectal Cancer Location: E Hall D2 Marwan Fakih, MD City of Hope Comprehensive Cancer Center When to Add Biologics? 48 Saturday, May 30, 2015 Cornelis J. A. Punt, MD, PhD Academic Medical Center, University of Amsterdam Systemic Treatment: Maintenance versus Holiday? John Marshall, MD—Chair Lombardi Comprehensive Cancer Center, Georgetown University Is the Cost Justified? Panel Question and Answer SATURDAY 8:00 AM - 9:15 AM Education Session Treatment of the BRCA Mutation Carrier: Screening, Surveillance, and Management Location: E Arie Crown Theater Judy Ellen Garber, MD, MPH Dana-Farber Cancer Institute Update on Screening and Surveillance for BRCA Carriers: It’s Not Just Ovarian Cancer Stanley B. Kaye, MBBS, MRCP, MD, FRCP, FRCPS, FRSE, FMedSci The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust Chemotherapy for BRCA Mutation Carriers: Same but Different? Elise C. Kohn, MD—Chair National Cancer Institute at the National Institutes of Health PARP Inhibitors: The Holy Grail for BRCA Carriers? Panel Question and Answer 8:00 AM - 9:15 AM Education Session When More Is Not Better: How to Integrate Goals of Care in Conversations about Stopping Chemotherapy Location: S100a Jennifer S. Temel, MD—Chair Massachusetts General Hospital Cancer Center Challenges in Discussions about Stopping Chemotherapy in the Modern Era: What Do We Know? Lauris Kaldjian, MD University of Iowa An Ethical and Practical Framework Approach for Exploring Goals of Care Thomas LeBlanc, MD, MA Duke University School of Medicine Evidence-Based Communication Strategies for Discussions at End of Life Panel Question and Answer 8:00 AM - 9:15 AM Meet the Professor Session Treatment of Multiple Myeloma in Elderly Patients—Ticketed Session Location: E451a 49 Saturday, May 30, 2015 Donna Ellen Reece, MD Princess Margaret Hospital 8:00 AM - 9:15 AM Clinical Problems in Oncology Session Optimal Lung Cancer Therapy for the Patient with Central Nervous System Metastases and Leptomeningeal Disease—Ticketed Session Location: E451b SATURDAY Mark G. Kris, MD—Chair Memorial Sloan Kettering Cancer Center Systemic Chemotherapy, Immunotherapy, and Relevant Clinical Trials for Brain Metastases and Leptomeningeal Disease in Lung Cancer Christina S. Baik, MD, MPH Fred Hutchinson Cancer Research Center Molecularly Targeted Therapy for Brain Metastases and Leptomeningeal Disease Michael Brada, DSc, FRCP, FRCR University of Liverpool Radiation and Localized Management of Brain Metastases and Leptomeningeal Disease 8:00 AM - 9:30 AM Clinical Science Symposium Immunotherapy for Every Patient: Check Your Enthusiasm Location: E Hall D1 Neil Howard Segal, MD, PhD—Chair Memorial Sloan Kettering Cancer Center 8:00 AM Neil Howard Segal, MD, PhD Memorial Sloan Kettering Cancer Center Introduction 8:05 AM PD-1 blockade in tumors with mismatch repair deficiency. (Abstract LBA100) D. T. Le, J. N. Uram, H. Wang, B. Bartlett, H. Kemberling, A. Eyring, A. Skora, N. S. Azad, D. A. Laheru, R. C. Donehower, B. Luber, T. S. Crocenzi, G. A. Fisher, S. M. Duffy, J. J. Lee, M. Koshiji, J. R. Eshleman, R. A. Anders, B. Vogelstein, L. A. Diaz Jr. 8:17 AM Neil Howard Segal, MD, PhD (Discussion Abstract(s) LBA100) Memorial Sloan Kettering Cancer Center Discussion 8:27 AM Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209 – 040. (Abstract LBA101) A. B. El-Khoueiry, I. Melero, T. S. Crocenzi, T. H. Welling III, T. C. Yau, W. Yeo, A. Chopra, J. Grosso, L. Lang, J. Anderson, C. M. Dela Cruz, B. Sangro 8:39 AM Lawrence Fong, MD (Discussion of Abstract(s) LBA101) UCSF Helen Diller Family Comprehensive Cancer Center Discussion 8:51 AM Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC). (Abstract LBA109) L. Paz-Ares, L. Horn, H. Borghaei, D. R. Spigel, M. Steins, N. Ready, L. Q. M. Chow, E. E. Vokes, E. Felip, E. Holgado, F. Barlesi, M. Kohlhaeufl, O. Rodriguez, O. Arrieta, M. A. Burgio, J. Fayette, S. N. Gettinger, C. Harbison, C. Dorange, F. G. Finckenstein, J. R. Brahmer 9:03 AM Roy S. Herbst, MD, PhD (Discussion of Abstract(s) LBA109) Yale School of Medicine Discussion 9:15 AM Panel Question and Answer 50 Saturday, May 30, 2015 8:00 AM - 11:00 AM Extended Education Session Geriatric Oncology: Research and Practice Updates for the Busy Clinician 8:00 AM Siri Rostoft—Co-Chair Oslo University Hospital Best of Geriatric Conferences and Journals 8:20 AM Andrew E. Chapman, DO Thomas Jefferson University Best of Oncology Conferences and Journals 8:40 AM Panel Question and Answer 8:50 AM Martine Extermann, MD, PhD—Co-Chair Moffitt Cancer Center Case 1: Using Risk-Assessment Tools for Chemotherapy Selection in Elderly Patients 9:20 AM Supriya Gupta Mohile, MD, MS University of Rochester Medical Center Case 2: Incorporating the New International Society of Geriatric Oncology Guidelines into Prostate Cancer Management 9:50 AM Nicole Doser Joz-Roland, MD CUTR Sylvana Case 3: Geriatrician Call-in—Getting Less Confused SATURDAY Location: S103 10:20 AM Hyman B. Muss, MD The University of North Carolina at Chapel Hill Panel Moderator: Digital Geriatric Oncology in Research and Practice—How to Get the Right Data in and Out 10:45 AM Panel Question and Answer 8:00 AM - 11:30 AM Poster Session Breast Cancer—HER2/ER Location: S Hall A Abstracts 513–524 will be discussed during the Breast Cancer—HER2/ER Poster Discussion Session. See page 88 for session information. Board 1 Validation of prediction of distant recurrence (DR) by Prosigna (PAM50) in subgroups of a Danish Breast Cancer Cooperative Group (DBCG) cohort of node-positive (N1), hormone receptor–positive (HRⴙ), postmenopausal early breast cancer (EBC) patients allocated 5yr of endocrine therapy (ET). (Abstract 513) B. Ejlertsen, M. Jensen, J. Eriksen, T. Kibøll, B. Bruun Rasmussen, A. S. Knoop, S. Ferree, T. Haffner, C. Schaper, A. Lænkholm, Danish Breast Cancer Cooperative Group (DBCG) Board 2 Final analysis of a randomized comparison of letrozole (Let) vs observation (Obs) as late reintroduction of adjuvant endocrine therapy (AET) for postmenopausal women with hormone receptor positive (HRⴙ) breast cancer (BC) after completion of prior AET: ANZBCTG 0501 (LATER). (Abstract 514) N. Zdenkowski, M. Green, F. M. Boyle, G. Kannourakis, P. G. Gill, E. Bayliss, C. Saunders, S. Della-Fiorentina, N. Kling, I. Campbell, V. Gebski, A. Veillard, L. C. Davies, R. Thornton, A. Fong, L. L. Reaby, J. F. Forbes, Australia and New Zealand Breast Cancer Trials Group Board 3 Ovarian function suppression, symptom burden, and quality of life in young women with breast cancer: A prospective study. (Abstract 515) S. M. Rosenberg, K. J. Ruddy, R. M. Tamimi, S. I. Gelber, L. Schapira, V. F. Borges, S. E. Come, M. E. Meyer, E. P. Winer, A. H. Partridge 51 Saturday, May 30, 2015 SATURDAY Board 4 Tumor PIK3CA genotype and prognosis: A pooled analysis of 4,241 patients (pts) with early-stage breast cancer (BC). (Abstract 516) D. Zardavas, L. Te Marvelde, R. Milne, H. Joensuu, M. Moynahan, B. Hennessy, I. Bieche, L. H. Saal, O. Stal, B. Iacopetta, J. Dupont Jensen, S. O’Toole, M. Barbareschi, S. Noguchi, E. Lerma, Q. Wang, M. J. Piccart-Gebhart, C. Sotiriou, S. Michiels Sr., S. Loi Board 5 HER3 and paxillin signaling in ERⴙ HER2- metastatic breast cancer (MBC) patients receiving letrozole (L) vs letrozole plus dasatinib (LⴙD) in a randomized phase II trial. (Abstract 517) J. O’Shaughnessy, D. Paul, M. K. Levin, Y. Wang, N. N. Hoke, C. Ramos Board 6 DNA methylation in serum as an independent marker of outcome and treatment response in TBCRC 005: A prospective study in metastatic breast cancer (MBC) patients. (Abstract 518) K. Visvanathan, M. Fackler, Z. Zhang, Z. Lopez-Bujanda, S. Jeter, L. J. Sokoll, L. Cope, C. Umbricht, D. Euhus, J. T. Carpenter, A. M. Storniolo, R. Nanda, N. U. Lin, L. A. Carey, J. N. Ingle, S. Sukumar, A. C. Wolff Board 7 Oncotype DX in BRCA-associated vs. sporadic breast cancers: Differences based on germline mutation status and potential implications for adjuvant systemic therapy (AST). (Abstract 519) P. D. Shah, S. Patil, M. N. Dickler, K. Offit, C. A. Hudis, M. E. Robson Board 8 Efficacy of the PARP inhibitor (PI) ABT-888 (veliparib [vel]) either with carboplatin (carb) or as a single agent followed by post-progression therapy in combination with carb in patients (pts) with BRCA1- or BRCA2- (BRCA)associated metastatic breast cancer (MBC). (Abstract 520) G. Somlo, P. H. Frankel, T. H. Luu, C. X. Ma, B. Arun, A. A. Garcia, T. Cigler, L. Cream, H. A. Harvey, J. A. Sparano, R. Nanda, H. K. Chew, T. J. Moynihan, L. T. Vahdat, M. P. Goetz, A. Hurria, J. E. Mortimer, D. R. Gandara, A. P. Chen, J. N. Weitzel Board 9 DNA repair deficiency biomarkers and identification of ER-positive breast cancer patients who may benefit from veliparib/carboplatin: Results from the I-SPY 2 trial. (Abstract 521) L. van’t Veer, L. Esserman, A. Sanil, A. Glas, T. Severson, S. C. Linn, L. Brown Swigart, G. Hirst, I. Investigators, O. I. Olopade, H. S. Rugo, D. Berry, D. M. Wolf, C. Yau Board 10 A phase Ib study of abemaciclib with therapies for metastatic breast cancer. (Abstract 522) S. M. Tolaney, M. Beeram, J. T. Beck, A. K. Conlin, E. C. Dees, M. N. Dickler, T. L. Helsten, P. R. Conkling, W. J. Edenfield, D. A. Richards, P. Turner, N. Cai, E. M. Chan, S. Pant, C. Becerra, K. Kalinsky, S. Puhalla, B. N. Rexer, H. A. Burris III, M. P. Goetz Board 11 Updated findings of a first-in-human, phase I study of margetuximab (M), an Fc-optimized chimeric monoclonal antibody (MAb), in patients (pts) with HER2-positive advanced solid tumors. (Abstract 523) H. A. Burris, G. Giaccone, S. Im, T. M. Bauer, D. Oh, S. F. Jones, J. L. Nordstrom, H. Li, D. A. Carlin, J. E. Baughman, R. J. Lechleider, Y. Bang Board 12 Adaptively randomized trial of neoadjuvant chemotherapy with or without the Akt inhibitor MK-2206: Graduation results from the I-SPY 2 Trial. (Abstract 524) D. Tripathy, A. J. Chien, N. Hylton, M. B. Buxton, C. A. Ewing, A. M. Wallace, A. Forero, H. G. Kaplan, R. Nanda, K. S. Albain, S. L. Moulder, B. B. Haley, A. DeMichele, W. F. Symmans, L. van ’t Veer, M. Paoloni, L. Esserman, D. A. Berry, D. Yee, I-SPY 2 TRIAL Consortium Board 13 Molecular profiling of ER weakly-positive breast cancer. (Abstract 525) B. S. Sheffield, Z. Kos, X. Wang, C. Chow, S. Lau, R. Wolber, C. B. Gilks, N. Myles, T. A. Thomson, M. M. Hayes, R. Rachamadugu, I. J. Stijleman, P. B. Bernard, T. O. Nielsen, S. K. Chia Board 14 Correlation of Breast Cancer Index HOXB13/IL17BR (H/I), ER, PR and HER2 and prediction of relative endocrine benefit from tamoxifen and anastrozole in HRⴙ breast cancer: A TransATAC study. (Abstract 526) Y. Zhang, I. Sestak, J. M. Cuzick, M. Dowsett, C. A. Schnabel, D. Sgroi Board 15 FES PET/CT analysis to evaluate the impact of localization of breast cancer metastases on ER expression. (Abstract 527) H. H. Nienhuis, M. van Kruchten, 52 Saturday, May 30, 2015 A. W. Glaudemans, A. H. Bongaerts, E. F. De Vries, C. P. Schroder, E. G. de Vries, G. Hospers Breast cancer recurrence in older patients with clinically node-negative T1-T2 tumors managed without sentinel node biopsy (SNB) and without adjuvant radiation therapy. (Abstract 528) M. N. Saleh, B. J. Sakr, S. M. Witherby, A. J. Olszewski, W. M. Sikov Board 17 Role of pazopanib (PZ) in modulating hormone resistance in advanced breast cancer (ABC). (Abstract 529) M. C. Majure, M. E. Melisko, A. R. Karwat, A. J. Chien, A. Goga, M. M. Moasser, J. W. Park, A. N. DeLuca, H. S. Rugo Board 18 Evaluation of possible linkage between everolimus benefit in estrogen receptor (ER)-positive breast cancer and genomic alterations of the PI3K/AKT/mTOR pathway. (Abstract 530) E. P. Black, E. H. Romond, J. Chmielecki, J. Sun, V. Kadamyan, M. D. Chambers, R. L. Stewart, E. V. Dressler, M. Mehdi, C. Horbinski, S. A. Massarweh Board 19 Efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab [TCH-P] in non-metastatic HER2ⴙ breast cancer: The Cleveland Clinic experience. (Abstract 531) S. R. Tiwari, B. Calhoun, J. Abraham, G. T. Budd, H. C. Moore, A. Fanning, S. Valente, R. Stewart, S. W. Andresen, S. B. LeGrand, J. P. Crowe, A. Dawson, J. Rowe, C. Booth, S. R. Grobmyer, A. J. Montero Board 20 Effect of mutations in distinct components of the PI3K/AKT/mTOR pathway on sensitivity to endocrine therapy in estrogen receptor (ER)-positive breast cancer. (Abstract 532) S. A. Massarweh, J. Chmielecki, J. Sun, R. L. Stewart, E. V. Dressler, V. Kadamyan, M. D. Chambers, C. Horbinski, M. Mehdi, E. P. Black, E. H. Romond Board 21 Recurrence score and clinicopathologic characteristics of TAILORx participants by race and ethnicity. (Abstract 533) M. M. Zlobinsky Rubinstein, R. J. Gray, J. A. Sparano, J. Zujewski, T. J. Whelan, K. S. Albain, D. F. Hayes, C. E. Geyer Jr., E. C. Dees, E. A. Perez, M. M. Keane, C. Vallejos, T. F. Goggins, I. A. Mayer, A. Brufsky, D. Toppmeyer, V. G. Kaklamani, J. N. Atkins, J. L. Berenberg, G. W. Sledge Board 22 The vitamin D receptor: A therapeutic target for the treatment of breast cancer? (Abstract 534) A. M. Murray, N. C. Synnott, J. Crown, N. O’Donovan, M. J. Duffy Board 23 Significance of prospective multicenter decision impact WSG-BCIST Study in postmenopausal ERⴙ HER2- N0 early breast cancer (EBC) for molecular testing for intrinsic subtype definition. (Abstract 535) R. Wuerstlein, K. Sotlar, O. Gluz, D. Hofmann, B. Otremba, R. Von Schumann, I. Witzel, C. Schindlbeck, W. Janni, C. Schem, I. Bauerfeind, S. Hasmueller, H. Tesch, A. Paulenz, P. Morel, W. Cowens, J. Hornberger, R. E. Kates, E. Pelz, N. Harbeck, West German Study Group Board 24 Incidence and survival for young women with operable breast cancer: SEER 1992–2011. (Abstract 536) M. C. Schroeder, S. Slycord, C. Lynch, A. Thomas Board 25 An indirect evaluation of bone saturation with zoledronic acid after long-term Q4 week dosing using plasma and urine pharmacokinetics. (Abstract 537) G. N. Hortobagyi, W. Sallas, M. Zheng, R. W. Mohanlal Board 26 Prospective study of the decision-making impact of the Breast Cancer Index in the selection of patients with ERⴙ breast cancer for extended endocrine therapy. (Abstract 538) T. B. Sanft, B. Aktas, B. Schroeder, V. Bossuyt, M. DiGiovanna, M. M. Abu-Khalaf, G. G. Chung, A. Silber, E. W. Hofstatter, S. S. Mougalian, L. Epstein, C. Hatzis, C. A. Schnabel, L. Pusztai Board 27 Case-control study of hormone receptor expression in benign breast and cancer risk. (Abstract 539) C. F. Healy, V. Parimi, S. A. Khan, J. Wang Board 28 Relationship of germline polymorphisms to docetaxel toxicity in the ROSE/TRIO-012 trial. (Abstract 540) S. Damaraju, V. Gorbunova, K. A. Gelmon, J. Garcia Saenz, S. Morales, D. Y. Abigerges, J. Canon, I. Lifirenko, G. L. Cohen, SATURDAY Board 16 53 Saturday, May 30, 2015 G. H. Jerusalem, F. Thireau, R. Fresco, V. Houé, M. F. Press, A. Narasimhan, J. R. Mackey SATURDAY Board 29 Oncotype DX scores in BRCA1 and BRCA2 associated breast cancer. (Abstract 541) N. P. McAndrew, K. N. Maxwell, J. Stopfer, J. Powers, A. C. Brandt, J. M. Long, K. L. Nathanson, S. M. Domchek Board 30 There is more to the picture than meets the eye: Population-based study on biopsy verification of suspected breast cancer recurrences. (Abstract 542) U. Wilking, T. Hatschek, J. C. Bergh, L. S. Lindström Board 31 21-gene recurrence score assay (RS) and impact on adjuvant chemotherapy (CTx) use among lobular (L) and ductal (D) histology hormone receptor positive (HRⴙ) early breast cancers (EBC). (Abstract 543) S. D. Baxter, L. Gondara, C. Speers, A. Davidson, S. K. Chia, V. Bernstein, S. Ellard, S. Tyldesley, C. A. Lohrisch Board 32 Prediction of late distant recurrence (DR) using the Prosigna (PAM50) test in a Danish Breast Cancer Cooperative Group (DBCG) cohort of postmenopausal women diagnosed with hormone receptor-positive (HRⴙ) early breast cancer (EBC) allocated to 5yr of endocrine therapy (ET). (Abstract 544) A. Lænkholm, M. Jensen, J. Eriksen, T. Kibøll, B. Bruun Rasmussen, A. S. Knoop, S. Ferree, T. Haffner, C. Schaper, B. Ejlertsen, Danish Breast Cancer Cooperative Group (DBCG) Board 33 Predictive testing for selection of patients for extended endocrine therapy: Clinical utilization of Breast Cancer Index (BCI) in early-stage, ERⴙ, LNbreast cancer. (Abstract 545) S. C. Malamud, B. Schroeder, T. N. Operana, C. A. Schnabel Board 34 Prediction of 10yr distant recurrence (DR) using the Prosigna (PAM50) assay in a Danish Breast Cancer Cooperative Group (DBCG) cohort of postmenopausal Danish women with hormone receptor-positive (HRⴙ) early breast cancer (EBC) allocated to 5yr of endocrine therapy (ET) alone. (Abstract 546) A. Lænkholm, M. Jensen, J. Eriksen, T. Kibøll, B. Bruun Rasmussen, A. S. Knoop, S. Ferree, T. Haffner, C. Schaper, B. Ejlertsen, Danish Breast Cancer Cooperative Group (DBCG) Board 35 Genetics of ramucirumab-associated hypertension in the ROSE/TRIO-012 breast cancer trial. (Abstract 547) J. R. Mackey, O. N. Lipatov, M. Martin, M. Webster, R. Hegg, S. Verma, M. Ramos Vazquez, R. Fresco, F. Thireau, V. Houé, M. F. Press, A. Narasimhan, S. Damaraju Board 36 Impact of combining PgR score and original preoperative endocrine prognostic index (PEPI) score as a prognostic factor of neoadjuvant endocrine therapy using exemestane in postmenopausal ER-positive/HER2negative breast cancer. (Abstract 548) S. Kurozumi, H. Matsumoto, K. Tozuka, Y. Hayashi, K. Inoue, S. E. Nagai, H. Oba, J. Horiguchi, I. Takeyoshi, M. Kurosumi Board 37 Bevacizumab maintenance (BM) in first line treatment for metastatic breast cancer (MBC): A multicenter retrospective observational study. (Abstract 549) L. Mentuccia, A. Fabi, A. Cassano, P. Vici, A. Michelotti, I. Sperduti, M. G. Sarobba, P. Marchetti, E. Rossi, V. Sini, M. Scognamiglio, D. Pellegrini, J. Giampietro, A. Vaccaro, A. Pellegrino, L. Pizzuti, M. Palleschi, L. I. Moscetti, D. Nicoletta, T. Gamucci Board 38 Could any pT1a,bN0M0 hormone-responsive, invasive breast carcinomas be safely treated without endocrine therapy? (Abstract 550) C. Perrin, J. Frenel, J. Edeline, M. Robert, P. Tas, C. Lefeuvre-Plesse, C. Gourmelon, F. Le Du, M. Campone, P. Kerbrat Board 39 Influence of immunohistological detection of intratumoral urokinase-type plasminogen activator (uPA) on disease outcome in endocrine-treated postmenopausal patients with hormone receptor-positive early breast cancer. (Abstract 551) C. F. Singer, M. Filipits, S. Jahn, L. Abete, R. Jakesz, R. Greil, T. Bauernhofer, W. Kwasny, M. Seifert, F. Fitzal, M. Schmitt, F. Moinfar, M. Gnant 54 Board 40 Prognostic significance of Focal Adhesion Kinase (FAK) in node-negative breast cancer. (Abstract 552) M. Schmidt, L. van de Sandt, K. Almstedt, M. J. Battista, A. Heimes, A. Lebrecht, G. Hoffmann, J. Rahnenfuehrer, J. G. Hengstler Board 41 Medication use trajectories of postmenopausal breast cancer survivors and matched cancer-free controls. (Abstract 553) K. Pan, R. T. Chlebowski, M. S. Simon, R. Ray, J. Livaudais-Toman, S. D. Sullivan, M. L. Stefanick, R. B. Wallace, M. LeBoff, E. C. Bluhm, E. D. Paskett Board 42 Detection and functional analysis of estrogen receptor mutations (ESR1-mut) in patients with metastatic breast cancer (MBC). (Abstract 554) S. Puhalla, P. Wang, A. Bahreini, R. Gyanchandani, T. F. Ambros, R. J. Hartmaier, B. F. Kurland, P. C. Lucas, H. E. Trejo Bittar, R. L. Hamilton, A. Mathew, J. P. Leone, N. E. Davidson, K. R. Weiss, R. J. Watters, M. Nikiforova, A. M. Stern, A. Brufsky, A. V. Lee, S. Oesterreich Board 43 Adjuvant aromatase inhibitor adherence based on the Morisky Medication Adherence Scale and identification of predictors to adherence. (Abstract 555) P. Rosenblatt, O. G. Goloubeva, S. Kesmodel, E. C. Bellavance, S. Chumsri, T. Bao, B. Heiss, E. M. Nichols, S. J. Feigenberg, N. Tait, K. H. Tkaczuk Board 44 Effect of tumor infiltrating lymphocytes (TILs) and stromal CD68 on trastuzumab (T) benefit in early stage HER2 positive breast cancer (BC). (Abstract 556) J. Raphael, I. Y. Gong, S. Nofech-Mozes, J. M. Bartlett, H. Nafisi, S. Verma Board 45 Tamoxifen (TAM)-induced severe hot flashes (HF): Is dose reduction (DR) a safe and effective strategy? (Abstract 557) C. I. Lee, P. Fox, B. Balakrishnar, R. L. Balleine, B. Gao, P. Provan, S. Coulter, M. Tomlins, C. Liddle, R. Hui, M. Wong, H. Gurney, N. Wilcken Board 46 Molecular profiling to identify genetic heterogeneity in synchronous and asynchronous breast cancers. (Abstract 558) W. M. Dean-Colomb, C. Yates, S. K. Reddy, J. O’Shaughnessy, S. Z. Millis Board 47 P95HER2 as a predictive marker in the phase III randomized HERNATA trial of trastuzumab and chemotherapy as first-line therapy to metastatic or locally advanced HER2-positive breast cancer. (Abstract 559) A. S. Knoop, M. Andersson, K. D. Bjerre, Y. Zang, C. A. Schnabel, A. Laenkholm Board 48 Long-term rates of ipsilateral breast tumor recurrence (IBTR) for women with ductal carcinoma in situ (DCIS) meeting LORIS trial eligibility criteria undergoing standard therapy. (Abstract 560) M. L. Pilewskie, C. Olcese, S. Patil, K. J. Van Zee Board 49 Variation in the use of granulocyte-colony stimulating factor (G-CSF) for dose dense paclitaxel: A single institution retrospective study. (Abstract 561) F. R. Paes, I. V. Luis, R. B. Costa, O. Metzger Filho, M. E. Hughes, K. Losk, K. Camuso, C. A. Bunnell, M. Golshan, E. P. Winer, N. U. Lin Board 50 Tumor infiltrating lymphocytes (TIL) and Ki67 suppression after neoadjuvant therapy for HRⴙ/HER2- breast cancer (BC): Results from two prospective trials. (Abstract 562) M. Dieci, G. Ficarra, P. F. Conte, V. Guarneri Board 51 Hormonal treatment (HT) and late recurrence in early-stage breast cancer (BC) patients. (Abstract 563) C. H. Barcenas, A. K. Sinha, G. N. Hortobagyi, V. Valero, N. T. Ueno, S. H. Giordano, M. Chavez-Mac Gregor, A. M. Brewster, A. Lucci Jr., D. Tripathy Board 52 Oncotype-DX recurrence score distribution among breast cancer patients harboring a germline mutation in the BRCA1/2 genes. (Abstract 564) R. Lewin, S. Rizel, D. Hendler, V. Neiman, I. Ben-Aharon, N. Liebermann, D. Margel, D. Zoref, A. Sulkes, R. Yerushalmi Board 54 Steps in developing Watson for Oncology, a decision support system to assist physicians choosing first-line metastatic breast cancer (MBC) therapies: Improved performance with machine learning. (Abstract 566) J. Fu, A. Gucalp, M. G. Zauderer, A. S. Epstein, M. G. Kris, J. Keesing, A. Caroline, M. Megerian, T. Eggebraaten, R. DeLima, M. Setnes, P. Wildt, A. D. Seidman 55 SATURDAY Saturday, May 30, 2015 Saturday, May 30, 2015 SATURDAY Board 55 Variations in measured ER, PR, and HER2 status in synchronous and asynchronous paired breast cancer (BC) tumors. (Abstract 567) C. Yates, S. Z. Millis, S. K. Reddy, Z. Gatalica, J. O’Shaughnessy, W. M. Dean-Colomb Board 56 Meta-analysis of clinical outcomes to second-line endocrine therapy for visceral and non-visceral metastases. (Abstract 568) J. F. Robertson, C. Campbell, A. Di Leo, S. R. Johnston, J. Bliss, I. Bradbury Board 57 Blinded independent validation of the PAM50-based Chemo-Endocrine Sensitivity Predictor (CESP) in hormone receptor (HR)-positive/HER2negative (HRⴙ/HER2-) breast cancer following neoadjuvant chemotherapy (NAC). (Abstract 569) A. Prat, B. Jimenez Rodriguez, P. Sánchez Rovira, M. Alvarez, L. Vicioso, V. de Luque, C. Fernandez-Sousa, M. C. Parrado, A. Santonja, C. Ramirez Tortosa, A. Lavado Fernandez, E. Perez Ruiz, C. Gonzalez-Hermoso, W. Buckingham, N. Dowidar, S. Ferree, A. Jeiranian, C. Schaper, N. Ribelles, E. Alba Board 58 Long-term safety profile of palbociclib (P) in combination with letrozole (L) as first-line treatment for postmenopausal patients with ERⴙ and HER2advanced breast cancer (ABC) (PALOMA-1/TRIO-18). (Abstract 570) D. J. Slamon, J. Crown, I. Lang, S. O. Kulyk, M. Schmidt, R. Patel, A. Thummala, N. L. Voytko, S. Randolph, S. Kim, X. Huang, C. H. Bartlett, P. Schnell, R. S. Finn Board 59 Efficacy and safety of first-line palbociclib plus letrozole compared with letrozole alone in patients aged > 65 years with estrogen receptor-positive, HER2-negative advanced breast cancer: A subgroup analysis by age of the PALOMA-1/TRIO-18 trial. (Abstract 571) J. Crown, R. S. Finn, J. Ettl, K. Boer, R. Patel, A. Thummala, S. Randolph, S. Kim, X. Huang, S. Nadanaciva, P. Schnell, C. H. Bartlett, D. J. Slamon Board 60 The effect of palbociclib (P) in combination with letrozole (L) on bone metastases in women with ERⴙ/ HER2- metastatic breast cancer (MBC): Subanalysis from a randomized phase II study. (Abstract 572) R. S. Finn, J. Crown, I. Lang, S. O. Kulyk, M. Schmidt, R. Patel, A. Thummala, I. Bondarenko, S. Randolph, S. Kim, X. Huang, E. Donnelly, C. H. Bartlett, D. J. Slamon Board 61 Impact of locoregional therapy among women 70 years or older with early stage hormone receptor positive breast cancer: A population based study. (Abstract 573) S. S. Dawood, X. Lei, P. N. Mainwaring, S. Gupta, B. Sirohi, J. Cortes, R. A. Dent Board 62 A combined screening approach of Fracture (Fx) Risk Algorithm (FRAX) and Trabecular Bone Score (TBS) to identify osteoporotic-range fracture risk (ORFR) in breast cancer (BC) patients treated with adjuvant aromatase inhibitor (AI). (Abstract 574) D. B. Page, V. Mariotti, O. Davydov, S. Patil, D. Hans, C. A. Hudis, A. Farooki, M. N. Fornier Board 63 Clinical efficacy and safety profile of palbociclib (P) in combination with letrozole (L) as first-line treatment in patients (pts) with ERⴙ and HER2advanced breast cancer (ABC) who have not received any systemic treatment (ST): A subgroup analysis of PALOMA-1/TRIO-18. (Abstract 575) R. S. Finn, J. Crown, J. Ettl, T. Pinter, A. Thummala, Y. V. Shparyk, R. Patel, S. Randolph, S. Kim, X. Huang, Y. Jiang, C. H. Bartlett, D. J. Slamon Board 64 GHRH-receptor as a new targetable biomarker in breast cancer and its correlation with ER/PR/HER2 status. (Abstract 576) M. Nadji, N. L. Block, A. V. Schally, J. F. Lara, R. A. Michaelson, R. Pulinthanathu, M. Tortora, S. M. Ali, K. Leitzel, S. M. Rizvi, M. Y. Al-Marrawi, A. Lipton Board 65 Activation of PI3K/AKT/mTOR pathway in ERⴙ breast cancer: Analysis of paired primary and metastatic tumor samples. (Abstract 577) T. R. Pacheco, A. C. Fernandes, S. M. Ali, M. Maia-Matos, A. L. Gaspar Gomes da Costa, C. Abreu, A. T. Alves, L. Correia, J. F. Lara, R. A. Michaelson, A. R. Ferreira, M. Matias, K. Leitzel, A. Lipton, L. Costa Board 66 A prospective comparison of ER, PR, Ki67 and gene expression in paired sequential core biopsies of primary, untreated breast cancer. (Abstract 578) A. M. Thompson, S. M. Hadad, L. Jordan, P. Roy, C. Purdie, T. Iwamoto, L. Pusztai, S. L. Moulder 56 Board 67 The pattern of somatic mutations and chromosomal copy number variations (CNV) in young breast cancer (BC) patients (pts). (Abstract 579) H. A. Azim, B. Nguyen, S. Brohee, M. J. Piccart-Gebhart, C. Sotiriou Board 69 Impact on relapse free survival (RFS) of time to hormone therapy (HTx) after diagnosis (Dx) of low risk hormone receptor positive (HRⴙ) early breast cancer (BC). (Abstract 580) W. Chay, C. Speers, L. Gondara, S. Tyldesley, K. A. Gelmon, C. A. Lohrisch Board 70 Correlation between the DCIS Score and traditional clinicopathologic features in the prospectively-designed Ontario population-based validation study. (Abstract 581) E. Rakovitch, S. Nofech-Mozes, W. Hanna, F. L. Baehner, R. Saskin, S. M. Butler, A. Tuck, S. Sengupta, L. Elavathil, P. A. Jani, M. Bonin, M. Chang, S. Robertson, E. Slodkowska, C. H. Fong, J. M. Anderson, F. Jamshidian, D. B. Cherbavaz, S. Shak, L. F. Paszat Board 71 Cyclin D1 as a biomarker of response to fulvestrant (F) in hormone receptorpositive (HRⴙ) breast cancer (BC). (Abstract 582) K. P. Cascetta, D. Germain, A. Tiersten Board 72 Docetaxel, cyclophosphamide and trastuzumab as neoadjuvant chemotherapy in HER2-positive primary breast cancer. (Abstract 583) K. Nakatsukasa, T. Taguchi, R. Sugimoto, K. Sakaguchi, T. Kotani, K. Hukuda, S. Kawakami, I. Hujiwara Board 73 Phase I study of HER3 targeted antibody patritumab in combination with trastuzumab and paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC). (Abstract 584) T. Saeki, H. Mukai, K. Aogi, T. Shigekawa, S. Ueda, Y. Naito, N. Matsubara, S. Takashima, F. Hara, T. Yamashita, S. Ohwada, Y. Sasaki Board 74 Total pathologic complete response (tpCR) and event-free survival (EFS) with subcutaneous (SC) or intravenous (IV) trastuzumab in HER2-positive early breast cancer (EBC). (Abstract 585) C. Jackisch, R. Hegg, D. Stroyakovskiy, J. Ahn, B. Melichar, S. Chen, A. Crepelle-Flechais, D. Heinzmann, M. Shing, X. B. Pivot Board 75 The co-administration of pertuzumab (P) and trastuzumab (T) as a single infusion, followed by vinorelbine (V), in first-line (1L) treatment of HER2positive locally advanced or metastatic breast cancer (MBC) patients (pts): VELVET study interim analysis. (Abstract 586) M. Andersson, J. López-Vega, T. Petit, C. Zamagni, M. Donica, J. Kamber, E. A. Perez Board 76 Associations of HER2-specific immunity with survival during treatment with trastuzumab and chemotherapy in breast cancer. (Abstract 587) K. L. Knutson, R. A. Clynes, P. Yeramian, K. P. Kemp, B. Shreeder, K. V. Ballman, K. S. Tenner, C. L. Erskine, N. Norton, D. W. Northfelt, W. Tan, M. D. Pegram, C. J. Calfa, E. A. Mittendorf, E. A. Perez Board 77 Neoadjuvant chemotherapy in the real world: A study of 22,819 patients from the Japanese National Clinical Database-Breast Cancer Registry. (Abstract 588) N. Niikura, A. Tomotaki, H. Miyata, T. Iwamoto, M. S. Kawai, K. Anan, T. Kinoshita, S. Masuda, K. Tsugawa, Y. Tokuda Board 78 Graded prognostic assessment (GPA) of HER2 positive breast cancer patients with brain metastases. (Abstract 589) M. Chi, V. Alva Venur, A. M. Mohammadi, S. T. Chao, G. T. Budd, A. J. Montero, H. C. Moore, P. Elson, J. H. Suh, L. Angelov, G. H. Barnett, J. Abraham, M. S. Ahluwalia Board 79 Phase I study of LJM716, BYL719, and trastuzumab in patients (pts) with HER2-amplified (HER2ⴙ) metastatic breast cancer (MBC). (Abstract 590) P. D. Shah, S. Chandarlapaty, M. N. Dickler, G. Ulaner, S. J. Zamora, V. Sterlin, A. Iasonos, C. M. Coughlin, A. Morozov, J. Ero, N. Rosen, T. Gilewski, M. N. Fornier, N. T. Sklarin, M. F. Berger, M. Moynahan, C. A. Hudis, J. Baselga, S. Modi Board 80 Effectiveness of targeting HER2 in heavily pretreated patients with occult HER2-positive (tissue-negative, serum-positive and/or HER2-positive circulating tumor cells) metastatic breast cancer in the clinical routine. 57 SATURDAY Saturday, May 30, 2015 Saturday, May 30, 2015 (Abstract 591) C. M. Kurbacher, A. Quade, G. Kunstmann, S. Herz, J. A. Kurbacher, M. A. Warm SATURDAY Board 81 Implications of high tumor infiltrating lymphocytes (TIL) in HER2-positive and triple-negative breast cancer (TNBC). (Abstract 592) V. Kotoula, K. Chatzopoulos, S. Lakis, Z. Alexopoulou, E. Timotheadou, F. Zagouri, G. E. Pentheroudakis, H. Gogas, E. P. Galani, E. Tsolaki, S. Chrisafi, A. Koutras, G. Aravantinos, P. Papakostas, P. A. Kosmidis, D. G. Pectasides, G. Fountzilas Board 82 Correlation of trastuzumab treatment benefit with quantitative HER2 expression levels in HER2 positive metastatic breast cancer. (Abstract 593) B. Bachmeier, J. Sperinde, J. M. Weidler, Y. Lie, A. Chenna, J. Winslow, J. Engel, G. Schubert-Fritschle, C. Sommerhoff, C. J. Petropoulos, M. P. Bates, W. Huang, A. Nerlich Board 83 Prognostic impact of HER2 overexpression/amplification in women with pT1a N0 M0 breast cancer with known screening status: First results from a multicenter population-based cancer registry study. (Abstract 594) A. Musolino, M. Michiara, D. Boggiani, A. Sikokis, A. Rimanti, B. Pellegrino, E. Martella, F. Bozzani, P. Sgargi, M. Panebianco, G. Bisagni, F. Falcini, C. Pinto Board 84 Evaluation of the Breast Cancer Index in patients with HER2ⴙ/HRⴙ breast cancer for risk of late recurrence and potential extended endocrine benefit. (Abstract 595) R. O’Regan, B. Schroeder, N. R. Blatner, C. A. Schnabel Board 85 Determining whether functional subtyping with BluePrint 80-gene profile could potentially identify two distinct triple positive subtypes with and without trastuzumab/chemo-sensitivity. (Abstract 596) P. W. Whitworth, P. D. Beitsch, M. C. Rotkis, J. V. Pellicane, M. Murray, P. Baron, C. L. Dul, A. M. Mislowsky, C. H. Nash, P. D. Richards, L. A. Lee, L. Stork, F. De Snoo, S. Untch, M. Gittleman, S. Akbari, J. Beatty Board 86 Effect of ranolazine administered after trastuzumab treatment on cardiotoxicity in mice. (Abstract 597) N. Maurea, C. Coppola, G. Piscopo, F. Galletta, D. Rea, G. Riccio, G. Lombardi, A. Ottaiano, C. Arra, C. De Lorenzo, R. V. Iaffaioli Board 87 Skin and subcutaneous tissue disorders (SSTDs) in patients (pts) with HER2-positive metastatic breast cancer (MBC) in the phase III trial CLEOPATRA of pertuzumab or placebo with trastuzumab and docetaxel. (Abstract 598) D. Miles, A. Lacasia, L. Lee, K. Dana, S. Heeson, A. Knott, C. C. Portera, S. M. Swain Board 88 Biologic characteristics of breast cancer in male compared to female: SEER analysis. (Abstract 599) M. Shaik, D. Tamkus, A. Al-Janadi Board 89 Effect of high MMP2 and low MMP9 baseline serum levels on outcome in patients with HER2-positive inflammatory breast cancer (IBC) treated with bevacizumab (BEV)- and trastuzumab (TRA)-based neoadjuvant chemotherapy (NAC) in the BEVERLY 2 study. (Abstract 600) E. Tabouret, A. Goncalves, F. Bertucci, J. Pierga, T. Petit, C. Levy, J. Ferrero, M. Campone, J. Gligorov, F. Lerebours, H. H. Roche, T. D. Bachelot, Y. Toiron, J. Borg, O. L. Chinot, P. Viens Board 90 Expression levels of PARP1 and phospho-p65 protein in human HER2positive breast cancers. (Abstract 601) J. A. Stanley, L. C. Klepczyk, K. S. Keene, S. Wei, Y. Li, A. Forero-Torres, W. E. Grizzle, M. Wielgos, J. D. Brazelton, A. F. LoBuglio, E. S. Yang Board 91 Phase 1b study of ONTⴚ380, an oral HER2-specific inhibitor, in combination with capecitabine (C) and trastuzumab (T) in third line ⴙ treatment of HER2ⴙ metastatic breast cancer (MBC). (Abstract 602) E. P. Hamilton, D. A. Yardley, G. N. Hortobagyi, L. N. Walker, V. F. Borges, S. L. Moulder Board 92 Safety of trastuzumab emtansine (T-DM1) in 373 patients 65 years or older with HER2-positive advanced breast cancer: A subgroup analysis of the Kamilla study. (Abstract 603) C. H. Barrios, A. Anton, S. Delaloge, F. Montemurro, R. Wuerstlein, S. Robb, P. Button, P. A. Ellis 58 Board 93 The clinical utility of ERBB2 amplification detection in breast carcinoma using a 341 gene hybrid capture-based next generation sequencing (NGS) assay: Comparison with standard immunohistochemistry (IHC) and Fluorescence In Situ Hybridization (FISH) assays. (Abstract 604) D. S. Ross, A. Zehir, D. T. Cheng, K. Nafa, G. Jour, P. Razavi, D. M. Hyman, J. Baselga, M. F. Berger, M. Ladanyi, M. E. Arcila Board 94 HER2 quantification by mass spectrometry compared to IHC or ISH in predicting clinical benefit from anti-HER2 therapy in HER2-positive breast cancer (BC). (Abstract 605) P. Nuciforo, C. Aura, S. P. Thyparambil, M. Vilaro, A. C. Garrido-Castro, V. Peg, J. Jimenez, W. A. Hoos, J. Burrows, T. A. Hembrough, J. M. Perez-Garcia, J. Cortes, M. Scaltriti Board 95 Crosstalk between PARP-1 and NF-B signaling pathways as a potential determinant of PARPi sensitivity in trastuzumab resistant HER2ⴙ breast cancer cell lines. (Abstract 606) M. Wielgos, T. Cooper, A. Forero-Torres, F. J. Esteva, R. Schiff, C. K. Osborne, A. F. LoBuglio, E. S. Yang Board 96 Phase II study of weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer (MBC): Updated progression-free survival with overall survival result. (Abstract 607) L. M. Smyth, N. M. Iyengar, S. Chandarlapaty, S. Sugarman, E. A. Comen, P. Drullinsky, N. T. Sklarin, T. A. Traina, T. A. Troso-Sandoval, S. Patil, C. Wasserheit-Lieblich, D. S. Argolo, J. Baselga, L. Norton, C. A. Hudis, C. T. Dang Board 97 A phase 1b trial of blood-brain barrier (BBB)-penetrant tyrosine kinase inhibitor (TKI) tesevatinib in combination with trastuzumab for patients with HER2ⴙ metastatic breast cancer (MBC). (Abstract 608) K. L. Jhaveri, E. P. Hamilton, K. Miller, M. Roche, M. S. Berger, E. P. Winer, N. U. Lin Board 98 Characterization of dominant T-cell clones by T-cell receptor (TCR) deep sequencing as a potential predictive biomarker to neoadjuvant trastuzumab (tras) in HER2-positive (HER2ⴙ) breast cancer. (Abstract 609) D. B. Page, Y. H. Wen, E. Brogi, J. Yuan, R. O. Emerson, S. Patil, C. T. Dang, L. Norton, C. A. Hudis, H. L. McArthur Board 99 Efficacy and CNS progression analysis from the randomized phase 2 trial of neratinib ⴙ paclitaxel vs trastuzumab ⴙ paclitaxel as first-line treatment for HER2ⴙ metastatic breast cancer (NEfERTT). (Abstract 610) A. Awada, R. Colomer, I. Bondarenko, K. Inoue, R. A. Badwe, G. Demetriou, X. Wang, V. Smirnov, S. Lee, A. O. Mehta, S. Kim, Z. Shen, T. D. Bachelot, C. Goswami, S. Deo, R. Bose, A. Wong, F. Xu, R. Bryce, L. A. Carey Board 100 Whole exome sequencing (WES) in HER2ⴙ metastatic breast cancer (MBC) patients (pts) with extraordinary responses to trastuzumab (T). (Abstract 611) I. V. Luis, C. Oh, Z. Wang, P. Dipiro, E. M. Macrae, C. Painter, G. Kryukov, I. E. Krop, E. P. Winer, N. U. Lin, N. Wagle Board 101 ONT-380 in the treatment of HER2ⴙ breast cancer central nervous system (CNS) metastases (mets). (Abstract 612) C. Ferrario, S. Welch, J. M. Chaves, L. N. Walker, I. E. Krop, E. P. Hamilton, V. F. Borges, S. L. Moulder Board 102 Lack of correlation of neoantigens arising from tumor somatic mutations with tumor infiltrating lymphocytes (TILs) or survival in HER2-positive breast cancer (HER2ⴙ BC). (Abstract 613) P. S. Savas, R. Salgado, F. Caramia, C. Denkert, S. Loibl, C. Sotiriou, F. Andre, T. P. Speed, S. Loi Board 104 Neuromedin U to increase IL-6 levels and to expand cancer stem cells in HER2-positive breast cancer cells. (Abstract 614) V. G. Martinez, S. Rani, C. Corcoran, J. Crown, L. O’Driscoll Board 105 Effect of somatic mutations in the four genes of the HER family on occurrence in HER2-positive breast cancer, cell proliferation rates, and resistance to HER2-targeted therapies in vitro. (Abstract 615) N. Elster, A. J. Eustace, Y. Fan, J. Naidoo, J. Fay, E. Kay, A. Carr, O. S. Breathnach, P. G. Morris, W. Grogan, A. D. Hill, C. Power, M. J. Allen, S. Kennedy, J. Crown, W. M. Gallagher, S. Toomey, B. Hennessy 59 SATURDAY Saturday, May 30, 2015 Saturday, May 30, 2015 SATURDAY Board 106 Trastuzumab and pertuzumab-based versus other therapy as second-line therapy in HER2-positive metastatic breast cancer: A retrospective study from single center. (Abstract 616) D. S. Argolo, L. M. Smyth, N. M. Iyengar, S. Patil, L. Norton, J. Baselga, C. A. Hudis, C. T. Dang Board 107 HLA-DRB1*07:01 biomarker characterization of hepatotoxicity during lapatinib combination therapies in ALTTO. (Abstract 617) C. F. Spraggs, L. R. Parham, L. Warren, L. S. Williams, L. P. Briley, D. Fraser, Z. Jiang, Z. Aziz, Z. Tong, S. D. Moodley, A. O. Mehta, N. Jackson, J. Byrne, M. Andersson, M. Toi, L. Harris, J. Gralow, R. Crescenzo, A. A. Armour Board 108 Development of PF-05280014, a potential biosimilar to trastuzumab. (Abstract 618) I. A. Jacobs, R. Ewesuedo, D. Yin, R. Li, S. Hurst, A. M. Ryan, C. Ng, M. W. Leach, G. Finch, C. M. Zacharchuk Board 109 Association of tumor infiltrating lymphocytes (TILs) with pathologic response in baseline and post-brief exposure HER2ⴙ breast cancer biopsies from BrUOG-211B. (Abstract 619) S. Avril, V. Varadan, K. Miskimen, J. Gollamudi, M. M. Abu-Khalaf, G. Somlo, W. M. Sikov, L. Harris, S. Vinayak Board 110 Mechanisms of acquired afatinib resistance in HER2-positive breast cancer cells. (Abstract 620) A. Canonici, N. Conlon, C. Morgan, M. Cremona, A. J. Eustace, B. Hennessy, J. Crown, N. O’Donovan Board 111 HER3, PI3K, and JAK2 pathway activation on reverse phase protein microarray (RPMA) in HER2-amplified residual disease (RD) refractory to preoperative chemotherapy plus trastuzumab (H), lapatinib (L), or both (HL). (Abstract 621) F. A. Holmes, C. Ramos, N. N. Hoke, M. K. Levin, V. A. Espina, L. A. Liotta, K. Wang, N. A. Palma, J. O’Shaughnessy Board 112 Final pre-specified analysis of the phase II trial of the AE37ⴙGM-CSF vaccine in high risk breast cancer patients to prevent recurrence. (Abstract 622) J. M. Greene, E. J. Schneble, J. Martin, M. Flores, J. S. Berry IV, A. F. Trappey III, T. J. Vreeland, D. F. Hale, A. K. Sears, G. T. Clifton, E. von Hofe, J. T. Symanowski, A. Ardavanis, N. M. Shumway, S. Ponniah, M. Papamichail, S. A. Perez, G. E. Peoples, E. A. Mittendorf Board 113a MIRACLE study (CBCSG016): A randomized phase II study of letrozole versus letrozole plus everolimus for hormone receptor positive premenopausal women with recurrent or metastatic breast cancer on goserelin treatment after progession on tamoxifen. (Abstract TPS623) B. Xu, D. Liu, J. Lu, T. Ouyang, X. Li, Y. Fan Board 113b MONARCH 3: A randomized phase III study of anastrozole or letrozole plus abemaciclib, a CDK4/6 inhibitor, or placebo in first-line treatment of women with HRⴙ, HER2-locoregionally recurrent or metastatic breast cancer (MBC). (Abstract TPS624) M. P. Goetz, M. Toi, S. Klise, M. Frenzel, N. Bourayou, A. Di Leo Board 114a Phase III, randomized, double-blind, placebo-controlled study of ribociclib (LEE011) in combination with either tamoxifen and goserelin or a nonsteroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with HRⴙ, HER2– advanced breast cancer (aBC): MONALEESA-7. (Abstract TPS625) D. Tripathy, A. Bardia, S. A. Hurvitz, N. Harbeck, M. Colleoni, F. A. Franke, L. W. Chow, S. Im, Z. Shao, J. R. Keyserlingk, L. Mongay Soler, M. Horan, S. V. Dhuria, G. Hughes, Y. Lu Board 114b BELLE-3: A Phase III study of the pan-phosphatidylinositol 3-kinase (PI3K) inhibitor buparlisib (BKM120) with fulvestrant in postmenopausal women with HRⴙ/HER2– locally advanced/metastatic breast cancer (BC) pretreated with aromatase inhibitors (AIs) and refractory to mTOR inhibitor (mTORi)based treatment. (Abstract TPS626) A. Di Leo, E. Ciruelos, W. Janni, P. E. Lonning, R. O’Regan, M. Hubalek, T. Csõszi, T. Decker, V. C. Tjan-Heijnen, D. Weber, M. El-Hashimy, S. Goteti, C. Massacesi, T. D. Bachelot Board 115a LORELEI: A phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib (GDC-0032) versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative, early-stage breast cancer. (Abstract TPS627) E. De Azambuja, C. Saura, M. Oliveira, P. C. Dubsky, 60 Saturday, May 30, 2015 Board 115b A phase 2, randomized, open-label study of lucitanib in patients with FGF aberrant metastatic breast cancer. (Abstract TPS628) M. M. Abu-Khalaf, I. A. Mayer, C. Tankersley, J. Moy, A. R. Allen, C. L. Vogel, F. A. Holmes, R. Nanda, K. Miller, R. Patel, L. Pusztai, C. L. Arteaga Board 116a SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with estrogen receptor (ER)positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA mutant tumors. (Abstract TPS629) J. Baselga, J. Cortes, M. De Laurentiis, V. Diéras, N. Harbeck, Y. Im, W. Jacot, I. E. Krop, S. Verma, T. R. Wilson, R. Lin, F. Schimmoller, J. Y. Hsu Board 116b A phase II trial of neoadjuvant aromatase inhibitor therapy and the mTOR inhibitor everolimus in postmenopausal women with hormone receptor positive/HER2 negative breast cancer and a low/intermediate risk Oncotype Dx Recurrence Score (’ 25). (Abstract TPS630) M. M. Abu-Khalaf, S. S. Mougalian, T. B. Sanft, E. W. Hofstatter, G. G. Chung, K. B. Adelson, A. Silber, D. S. Brandt, K. E. Bober-Sorcinelli, N. Fishbach, W. Zaheer Kidwai, K. D. Sabbath, M. DiGiovanna, W. M. Sikov, L. Pusztai Board 117a Phase III study of Palbociclib in combination with Exemestane vs. Capecitabine, in Hormonal Receptor (HR) positive/HER2 negative Metastatic Breast Cancer (MBC) patients with Resistance to non-steroidal Aromatase inhibitors (NSAI): PEARL study (GEICAM/2013– 02 CECOG/BC.1.3.006) (Abstract TPS631) M. Martin, M. J. Inbar, E. M. Carrasco, I. Lang, M. Escudero, Z. Kahan, C. H. Bartlett, B. Bermejo, E. Gal Yam, J. Chacon, Z. Zvirbule, J. Garcia Saenz, J. de la Haba-Rodriguez, M. Koehler, M. J. Gil Gil, E. Ciruelos Gil, M. Munoz-Mateu, S. Morales Murillo, J. Alonso, C. Zielinski, GEICAM Spanish Breast Cancer Group and CECOG Central European Cooperative Oncology Group Board 117b A phase I trial assessing the maximum tolerated dose (MTD) and pharmacokinetics of intrapleural bevacizumab after pleural puncture in breast cancer patients with symptomatic recurrent metastatic pleural effusion: The BEVAP trial. (Abstract TPS632) B. Rousseau, A. Hulin, X. Paoletti, F. Coussy, F. Mefti, C. Dubot, A. Savignoni, C. Jayr, I. Turbiez, P. Mordant, E. Brain, M. Gutierrez Board 118a A Phase II study of the safety and efficacy of alpelisib or buparlisib plus letrozole in neoadjuvant treatment of postmenopausal women with HRⴙ/HER2–, PIK3CA mutant or wild-type breast cancer. (Abstract TPS633) I. A. Mayer, C. F. Singer, P. A. Fasching, F. A. Holmes, M. Gnant, L. G. Estevez, M. Campone, M. Hubalek, A. C. Wolff, J. A. Perez-Fidalgo, E. P. Winer, G. Atalla-Vidam, C. Kanwal, L. Blumenstein, N. Fretault, I. Diaz-Padilla, C. L. Arteaga Board 118b TARGIT-U.S.: A registry trial of targeted intraoperative radiation therapy following breast-conserving surgery. (Abstract TPS634) M. Alvarado, E. Gallant, J. S. Rice, S. R. Grobmyer, E. E. Harris, D. Holmes, D. Pavord, W. Small Jr. Board 119a I-SPY 2 low risk registry: An I-SPY 2 trial sub-study for women with clinically advanced, ERⴙ, HER2- breast cancer and molecular good-prognosis gene signature. (Abstract TPS635) T. C. Haddad, M. D. Shah, W. F. Symmans, N. Hylton, C. Yau, J. Lyandres, M. E. Melisko, A. Forero, K. S. Albain, H. G. Kaplan, R. K. Viscusi, I. Investigators, D. A. Berry, L. Esserman, A. J. Chien Board 119b E2112: Randomized phase III trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer. (Abstract TPS636) R. M. Connolly, F. Zhao, K. Miller, A. Tevaarwerk, L. I. Wagner, M. Lee, J. Murray, R. J. Gray, R. Piekarz, J. Zujewski, J. A. Sparano Board 120a Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy ⴙ/- one year of everolimus in patients with high-risk, hormone receptor (HR) positive and HER2-negative breast cancer (BC): SWOG/NRG/Alliance S1207 (NCT01674140). (Abstract TPS637) M. 61 SATURDAY D. Zardavas, C. Fesl, A. Bardia, R. Lin, J. O. Fredrickson, H. Parmar, S. M. Singel, J. Y. Hsu, M. J. Piccart-Gebhart, M. Gnant, J. Baselga Saturday, May 30, 2015 Chavez-Mac Gregor, W. E. Barlow, L. Pusztai, M. P. Goetz, P. Rastogi, P. A. Ganz, E. P. Mamounas, S. Paik, H. Bandos, J. Gralow, D. L. Lew, G. N. Hortobagyi SATURDAY Board 120b A phase I study of RAD1901, an oral selective estrogen receptor degrader, in ER–positive, HER2–negative, postmenopausal advanced breast cancer patients. (Abstract TPS638) W. A. Harb, F. Garner, M. Clarkin, K. A. Roberge, A. G. Harris, G. Williams, G. Hattersley Board 121a Brain Metastases in Breast Cancer Network Germany (BMBC; GBG 79): Multicentric, retro- and prospective collection of patient data and biomaterial from patients with brain metastases. (Abstract TPS639) V. Mueller, E. Laakmann, T. N. Fehm, V. Moebus, G. Von Minckwitz, S. Loibl, I. Witzel Board 121b A phase 2 single-arm study to assess clinical activity, efficacy and safety of enzalutamide (ENZA) with trastuzumab in HER2ⴙ ARⴙ metastatic or locally advanced breast cancer. (Abstract TPS640) M. E. Trudeau, E. P. Winer, J. L. Steinberg, M. Liosatos, S. Poondru, M. N. Dydo, A. C. Peterson, W. J. Gradishar Board 122a HERMIONE: A Phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician’s choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and ado-trastuzumab emtansine (T-DM1). (Abstract TPS641) K. Miller, J. Cortes, S. A. Hurvitz, I. E. Krop, D. Tripathy, S. Verma, K. Riahi, J. G. Reynolds, T. J. Wickham, I. Molnar, D. A. Yardley Board 122b PATRICIA: A phase II study of palbociclib and trastuzumab with or without letrozole in previously treated, postmenopausal patients with HER2-positive metastatic breast cancer. (Abstract TPS642) P. Villagrasa, X. Gonzalez, M. Oliveira, J. Vazquez, L. De La Pena, M. Llobet-Canela, A. Prat, E. Ciruelos 8:00 AM - 11:30 AM Poster Session Breast Cancer—Triple-Negative/Cytotoxics/Local Therapy Location: S Hall A Abstracts 1009 –1020 will be discussed during the Breast Cancer—Triple-Negative/Cytotoxics/ Local Therapy Poster Discussion Session. See page 128 for session information. Board 123 Outcomes of adjuvant ACT vs. TC chemotherapy in older women with breast cancer. (Abstract 1009) S. S. Mougalian, J. B. Long, J. Hall, K. B. Adelson, M. M. Abu-Khalaf, L. Pusztai, C. P. Gross Board 124 Absence of disease-specific survival improvement over time among breast cancer patients age 70 and older: 1990 –2007. (Abstract 1010) H. G. Kaplan, J. A. Malmgren, M. K. Atwood Board 125 Contralateral prophylactic mastectomy decision-making in the populationbased iCanCare study of early-stage breast cancer patients: Knowledge and physician influence. (Abstract 1011) R. Jagsi, S. T. Hawley, K. A. Griffith, N. K. Janz, A. W. Kurian, K. C. Ward, A. S. Hamilton, S. J. Katz, M. Morrow Board 126 Can routine cavity shave margins (CSM) improve local control in breast cancer? Initial results of the SHAVE trial, a prospective randomized controlled trial of routine CSM vs. standard partial mastectomy (SPM). (Abstract 1012) A. B. Chagpar, B. K. Killelea, T. N. Tsangaris, M. Butler, K. Stavris, X. Yao, F. Li, V. Bossuyt, L. Pusztai, N. R. Horowitz Board 127 Risk after local excision alone for DCIS patients. (Abstract 1013) E. Rakovitch, S. Nofech-Mozes, W. Hanna, F. L. Baehner, R. Saskin, S. M. Butler, A. Tuck, S. Sengupta, L. Elavathil, P. A. Jani, M. Bonin, M. Chang, S. Robertson, E. Slodkowska, C. H. Fong, J. M. Anderson, F. Jamshidian, D. B. Cherbavaz, S. Shak, L. F. Paszat Board 128 A phase II, open-label, neoadjuvant, randomized study of LCL161 with paclitaxel in patients with triple-negative breast cancer (TNBC). (Abstract 62 Saturday, May 30, 2015 Board 129 A phase I study of veliparib (ABT-888) in combination with weekly carboplatin and paclitaxel in advanced solid malignancies and enriched for triple-negative breast cancer (TNBC). (Abstract 1015) S. Pahuja, J. H. Beumer, L. J. Appleman, H. A. Tawbi, R. G. Stoller, J. J. Lee, Y. Lin, F. Ding, J. Yu, C. P. Belani, A. P. Chen, V. L. Giranda, S. P. Shepherd, E. Chu, S. Puhalla Board 130 Therapy of refractory/relapsed metastatic triple-negative breast cancer (TNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase I/II clinical experience. (Abstract 1016) A. Bardia, L. T. Vahdat, J. R. Diamond, A. Starodub, R. L. Moroose, S. J. Isakoff, A. J. Ocean, J. Berlin, W. A. Messersmith, S. S. Thomas, F. Wilhelm, W. A. Wegener, P. P. Maliakal, R. M. Sharkey, D. M. Goldenberg, I. A. Mayer Board 131 Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early stage breast cancer (NCT01372579). (Abstract 1017) V. G. Kaklamani, E. Hughes, K. P. Siziopikou, K. Timms, V. Abkevich, C. Solimeno, A. Hartman, J. Jeruss, C. Meservey, B. Jovanovic, I. B. Helenowski, S. Kahn, K. P. Bethke, N. Hansen, R. Uthe, S. Rosen, K. Hoskins, J. Von Roenn, S. Jain, W. J. Gradishar Board 132 Combined Homologous Recombination Deficiency (HRD) scores and response to neoadjuvant platinum-based chemotherapy in triple-negative and/or BRCA1/2 mutation-associated breast cancer. (Abstract 1018) M. L. Telli, K. Timms, J. E. Reid, C. Neff, V. Abkevich, A. Gutin, Z. Sangale, D. Illiev, J. T. Jones, B. Hennessy, J. S. Lanchbury, G. B. Mills, A. Hartman, J. M. Ford Board 133 Concordance of intrinsic subtyping and risk of recurrence (ROR) scores between matched primary and metastatic tissue from Triple Negative Breast Cancer Trial (TNT). (Abstract 1019) M. C. Cheang, J. Bliss, M. Dowsett, L. Kilburn, A. Grigoriadis, C. Gillett, S. Pinder, P. Gazinska, B. Haynes, S. Kernaghan, H. Tovey, J. Owen, M. Harries, P. A. Ellis, A. N. Tutt, TNT Trial Management Group and Investigators Board 134 RespondR: A genomic score to predict the responsiveness of triple-negative breast cancer patients to chemotherapy. (Abstract 1020) S. Buechler, Y. Gokmen-Polar, S. S. Badve Board 135 Role of  blocker and angiotensin antagonist for the prophylaxis of early onset anthracycline-induced ventricular dysfunction: A meta-analysis of five randomized controlled trials. (Abstract 1021) N. Vincelette, S. Yun Board 136 Standard chemotherapy versus capcitabine for older women with early stage breast cancer: An update of CALGB/CTSU/Alliance 49907. (Abstract 1022) H. B. Muss, D. A. Berry, C. T. Cirrincione, M. Theodoulou, A. Hurria, H. J. Cohen, A. Partridge, L. Norton, C. A. Hudis, E. P. Winer Board 137 Association of disregulated neuronal and peripheral BDNF with vulnerability to paclitaxel-induced peripheral neuropathy. (Abstract 1023) D. Azoulay, A. Leibovici, R. Sharoni, E. Shaoul, B. Gross, C. Suriu, L. Akria, A. Braester, H. Goldberg Board 138 Hippocampal memory impairment in breast cancer survivors after chemotherapy measurement using covert testing. (Abstract 1024) A. J. Ryals, A. C. Apple, J. X. Wang, D. Cella, F. J. Penedo, L. Wang, J. L. Voss Board 139 Randomized study of tailored neoadjuvant chemotherapy according to the expression of tau, topo II ␣, and ERCC1 versus standard chemotherapy in HER2-negative breast cancer. (Abstract 1025) Y. Lu, D. Yeh, L. Tseng, S. Chen, H. Lien, H. Chang, Y. Chang, S. Huang, C. Lin, A. Cheng, C. Huang Board 140 The utility of bi-weekly eribulin therapy for metastatic breast cancer: A Japanese multicenter phase II study (JUST-STUDY). (Abstract 1026) T. Yoshinami, N. Masuda, T. Nakayama, F. Hara, Y. Sagara, H. Kawaguchi, K. Watanabe, M. Sato, K. Aogi, K. Higaki, T. Morimoto, Y. Shigeoka, S. Tokunaga, H. Morishima, Y. Yanagita, J. Tsurutani, S. Baba, K. Katayama, S. Morita, S. Ohtani 63 SATURDAY 1014) M. Parton, A. Bardia, S. Kummel, L. G. Estevez, C. Huang, J. C. Castan, M. Ruiz Borrego, M. L. Telli, A. Lluch, R. Lopez, J. T. Beck, R. Ismail-Khan, S. Chen, S. A. Hurvitz, I. A. Mayer, R. S. Atienza, S. Cameron, M. Krygowski, S. Kim Saturday, May 30, 2015 SATURDAY Board 141 Utilization of neoadjuvant systemic therapy (NST) for breast cancer. (Abstract 1027) J. J. Mohiuddin, A. M. Deal, L. A. Carey, J. L. Lund, B. R. Baker, T. M. Zagar, E. Jones, L. B. Marks, R. C. Chen Board 142 A comparison of toxicity profiles between standard and lower dose capecitabine (CAP) in breast cancer (BC): a meta-analysis. (Abstract 1028) T. Funakoshi, M. Suzuki, H. B. Muss Board 143 Phase II randomized study of nab-paclitaxel versus conventional paclitaxel as first-line therapy of metastatic HER2-negative breast cancer for neurotoxicity characterization: An Oncosur Study Group study. (Abstract 1029) E. Ciruelos, N. Martinez, B. Cantos, M. Echarri, S. Enrech, C. Bueno, J. A. Guerra, L. Manso, T. Pascual, C. Mendiola, C. Dominguez, J. F. Gonzalo, C. Rodriguez de Antona, M. Apellaniz-Ruiz, J. L. Sanz, J. M. Sepúlveda Board 145 A randomized phase III study of vinflunine versus an alkylating agent of physician’s choice in metastatic breast cancer (MBC) previously treated with or resistant to an anthracycline, a taxane, an antimetabolite and a vincaalkaloid. (Abstract 1031) J. Cortes, C. Levy, Y. Demidchik, L. Roman, H. P. Bourgeois, C. Veyret, S. Spazzapan, J. Ferrero, T. Chao, Y. Karchmit, M. Espie, J. A. Nabholtz, X. Gonzalez, V. Beliakouski, M. Campone Board 146 Efficacy of 12 weeks neoadjuvant nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple-negative breast cancer: WSG-ADAPT TN randomized phase II trial. (Abstract 1032) O. Gluz, U. Nitz, M. Christgen, E. Grischke, H. Forstbauer, M. W. Braun, M. Warm, C. Uleer, B. Aktas, C. Schumacher, J. Hackmann, N. Bangemann, P. Staib, C. Lindner, S. Kummel, C. Liedtke, R. E. Kates, R. Wuerstlein, H. H. Kreipe, N. Harbeck, West German Study Group ADAPT TN Investigators Board 147 Clinical predictors of failure of granulocyte colony stimulating factor (G-CSF) prophylaxis in patients with breast cancer treated with dose dense epirubicin (E), cyclophosphomide (C) ⴙ paclitaxel (T) Adjuvant chemotherapy: Subgroup analysis of the NCIC CTG MA.21 study (NCT00014222). (Abstract 1033) R. Ramjeesingh, J. Kankesan, B. E. Chen, J. L. Pater, L. Han, P. O’Brien, M. J. Burnell, L. E. Shepherd, W. R. Parulekar Board 148 A nomogram to predict axillary response to neoadjuvant chemotherapy in clinically node positive breast patients. (Abstract 1034) J. Vila, R. L. Bassett Jr., E. A. Mittendorf, I. Bedrosian, S. F. Shaitelman, M. C. Stauder, M. Chavez-Mac Gregor, J. K. Litton, W. T. Yang, L. Huo, H. M. Kuerer, K. Hunt, A. S. Caudle Board 149 Direct effects on bone metabolism induced by perioperative anthracyclineand/or taxane-based chemotherapy depend on the menopausal status of patients with primary breast cancer. (Abstract 1035) N. Rauschenbach, A. T. Kurbacher, S. Herz, J. A. Kurbacher, K. Monreal, S. Sperling, C. M. Kurbacher Board 150 Death during study treatment: An evaluation of events in 31 German clinical trials. (Abstract 1036) J. Furlanetto, G. Von Minckwitz, B. Lederer, V. Möbus, H. Lueck, C. Hanusch, C. Thomssen, M. Untch, S. Loibl Board 151 Tumor infiltrating lymphocytes (TILs) in HER2 positive breast cancer: Evaluation according to the new recommendations by the international TILs working group 2014. (Abstract 1037) H. Nafisi, J. Raphael, I. Y. Gong, J. M. Bartlett, S. Verma, S. Nofech-Mozes Board 152 A phase I/II trial of olaparib in combination with eribulin in patients with advanced or metastatic triple negative breast cancer (TNBC) previously treated with anthracyclines and taxanes: First results from phase I. (Abstract 1038) H. Yasojima, H. Yamamoto, N. Masuda, K. Aogi, M. Takahashi, K. Yonemori, M. Takeuchi, A. Hamada, K. Tamura, T. Sukigara, R. Nagasaka, R. Nakano, Y. Tsujimoto, Y. Morioka, K. Higuchi, Y. Fujiwara Board 153 Neoadjuvant chemotherapy plus trastuzumab in stage II/III breast cancer with low HER2 expression. (Abstract 1039) Q. J. Khan, A. O’Dea, C. J. Fabian, C. S. Connor, M. McGinness, J. M. Mammen, J. L. Wagner, S. Baccaray, M. Springer, H. Yeh, P. Sharma 64 Board 154 Mechanistic and clinical analysis of Sperm associated antigen 5 (SPAG5) as a novel prognostic, predictive, actionable gene in Breast Cancer (BC). (Abstract 1040) T. M. Abdel-Fatah, D. Liu, D. Agarwal, R. Russell, O. M. Rueda, P. M. Moseley, A. R. Green, A. Mukherjee, J. Reis-Filho, C. Caldas, I. O. Ellis, G. Ball, S. Y. Chan Board 155 A model-based approach to dose optimization of neurotoxic chemotherapy for metastatic breast cancer (MBC). (Abstract 1041) M. Sharma, E. Gray, S. Mehrotra, K. Wu, W. T. Barry, C. A. Hudis, E. P. Winer, A. P. Lyss, D. Toppmeyer, A. Moreno-Aspitia, H. S. Rugo, M. J. Ratain, J. Gobburu Board 156 Association of non-disruptive P53 mutations with poor progression-free survival (PFS) in resected breast cancer treated with neoadjuvant chemotherapy. (Abstract 1042) A. Martinez-Bueno, S. Baulies, M. A. Molina-Vila, J. Bertran-Alamillo, M. Gonzalez Cao, X. Gonzalez, S. Viteri Ramirez, N. Karachaliou, C. Teixido, M. Sanchez-Ronco, F. Tresserra, M. Cusido, R. Fabregas, R. Rosell Board 157 A single institution experience of salvage therapy for locally advanced breast cancer: Treatments and trends. (Abstract 1043) J. Raphael, T. Paramsothy, J. Lee, S. Gandhi Board 158 Gene expression of metastatic biopsies for prediction of response to palliative chemotherapy in breast cancer. (Abstract 1044) T. Foukakis, J. Lorent, N. Tobin, L. S. Lindström, J. C. Bergh, T. Hatschek Board 159 Proteomic analysis of primary and metastatic breast cancers and expression of the folate receptor as a potential drug target. (Abstract 1045) T. A. Hembrough, F. Cecchi, A. Blackler, S. P. Thyparambil, J. Burrows, J. O’Shaughnessy Board 160 Impact of systemic therapy on the outcomes of patients with metastatic breast cancer to brain: MD Anderson Cancer Center (MDACC) experience 1999 –2012. (Abstract 1046) D. Bugano Diniz Gomes, R. E. Deeba, D. Suki, V. Valero, S. L. Moulder, B. Arun, K. H. Koenig, E. A. Strom, L. Hsu, R. Sawaya, D. Tripathy, N. K. Ibrahim Board 161 Pre-treatment Near-Infrared Spectral Tomography (NIRST) to predict pathologic complete response to neoadjuvant chemotherapy (NAC) in women with locally advanced breast cancer (LABC). (Abstract 1047) P. Kaufman, S. Jiang, R. diFlorio-Alexander, J. Gui, B. W. Pogue, K. D. Paulsen Board 162 Impact of sequencing weekly paclitaxel (T) and dose-dense doxorubicin/cyclophosphamide (DDAC) on tolerability and relative dose intensity (RDI) in breast cancer (BC) patients (pts) receiving neoadjuvant chemotherapy (NAC). (Abstract 1048) N. M. LeCroy, I. Borrero, D. B. Dumercy, E. Velis, A. T. Perez, M. Velez, A. Mani, A. B. Castrellon, C. Hawkins Locke, C. Frankel, C. Sareli, C. J. Calfa Board 163 Clinical evaluation of germline polymorphisms (SNPs) associated with capecitabine (C) toxicity (tox) in metastatic breast cancer (MBC). (Abstract 1049) P. H. O’Donnell, V. Trubetskoy, A. Nurhussein-Patterson, J. P. Hall, D. Huo, G. F. Fleming, J. N. Ingle, I. A. Mayer, P. H. Morrow, A. M. Storniolo, A. ForeroTorres, C. H. Van Poznak, D. E. Merkel, G. L. Rosner, O. I. Olopade, M. J. Ratain, N. Cox, M. Dolan, R. Nanda, Translational Breast Cancer Research Consortium (TBCRC) Board 164 The role of LHRH agonists in ovarian function preservation in premenopausal women undergoing chemotherapy for early stage breast cancer: A systematic review and meta-analysis. (Abstract 1050) R. R. Munhoz, A. A. Pereira, A. D. Sasse, P. M. Hoff, T. A. Traina, C. A. Hudis, R. J. Marques Board 165 FDG-PET/CT versus contrast enhanced CT for prediction of progression-free and disease-specific survival in stage IV breast cancer patients. (Abstract 1051) C. Riedl, K. Pinker, L. Ong, M. S. Jochelson, G. Ulaner, H. L. McArthur, M. N. Dickler, W. Weber 65 SATURDAY Saturday, May 30, 2015 Saturday, May 30, 2015 SATURDAY Board 166 The early effect of breast density legislation on mammogram reporting. (Abstract 1052) E. J. Lee, K. Kam, S. S. Pairawan, K. Anderson, C. Cora, W. Bae, K. Kazanjian, G. Nagaraj, S. S. Lum Board 167 Breast cancer with extensive regional lymph node involvement: Toward optimizing local management. (Abstract 1053) L. Z. Braunstein, S. Galland, S. Goldberg, B. T. Sadek, M. Shenouda, R. Abi-Raad, S. M. MacDonald, A. G. Taghian Board 168 Risk of axillary node metastasis in Paget disease with invasive ductal carcinoma. (Abstract 1054) S. M. Wong, R. A. Freedman, E. Stamell, Y. Sagara, J. E. Brock, S. DeSantis, M. Golshan Board 169 The efficacy and efficiency of half frozen section assessment of breast cancer sentinel lymph nodes: A retrospective analysis of 1116 cases. (Abstract 1055) H. Yang, S. Wang, J. Guo, Y. Cao Board 170 Cosmetic outcome after breast conserving surgery and either external beam or intraoperative radiotherapy for early breast cancer: Objective assessment of patients from a randomized controlled trial in Lublin, Poland. (Abstract 1056) N. R. Williams, A. Kurylcio, M. Jankiewicz, J. Romanek, W. Polkowski, N. Michalopoulos, M. R. Keshtgar Board 171 Phase I dose escalation trial using stereotactic body radiation therapy (SBRT) for partial breast irradiation (PBI). (Abstract 1057) A. S. Rahimi, A. Spangler, D. P. Garwood, A. M. Leitch, R. Rao, S. Seiler, R. D. Wooldridge, A. Rivers, S. Stevenson, S. Goudreau, B. B. Haley, Y. Dong, D. Euhus, K. V. Albuquerque, M. Folkert, J. H. Heinzerling, C. Ding, C. Ahn, H. Choy, R. D. Timmerman Board 172 Evaluation of the new Commission on Cancer Quality measure for postmastectomy radiation treatment for breast cancer. (Abstract 1058) C. A. Minami, N. Hansen, J. B. Strauss, J. Feinglass, J. P. Hayes, N. Rydzewski, D. J. Bentrem, K. Y. Bilimoria Board 173 Breast cancer brain metastases: Comprehensive review of tumor extent, histology and treatment on survival. (Abstract 1059) J. A. Crozier, L. F. Cornell, B. Rawal, E. A. Perez Board 174 Effect of the use of immediate reconstruction on the rates of bilateral mastectomy and adjuvant radiation therapy use in women with node-positive breast cancer treated with neoadjuvant chemotherapy on ACOSOG Z1071 (Alliance). (Abstract 1060) J. C. Boughey, L. M. McCall, B. G. Haffty, T. A. Buchholz, E. A. Mittendorf, K. V. Ballman, K. Hunt Board 175 Residual breast tissue after mastectomy in non high risk and BRCA mutated patients. (Abstract 1061) G. Pfeiler, A. Farr, R. Woitek, T. Helbich, D. Gschwantler-Kaulich, C. F. Singer, M. Bernathova Board 176 Detrimental effect of blood-product transfusion on survival for patients with breast cancer in Florida (1996 –2007). (Abstract 1062) H. Alghamdi, D. Franceschi, F. Miao, M. M. Byrne, T. Koru-Sengul Board 177 Impact of neoadjuvant chemotherapy to surgery interval on survival outcomes in breast cancer patients. (Abstract 1063) R. A. Sanford, X. Lei, C. H. Barcenas, E. A. Mittendorf, A. S. Caudle, V. Valero, D. Tripathy, S. H. Giordano, M. Chavez-Mac Gregor Board 178 Influence of marital status on tumor characteristics and survival in male breast cancer. (Abstract 1064) S. Tadisina, U. Koduru, C. Chacko, O. Adekolujo, R. Ehwarieme, J. Ramzy, M. L. Arora, J. Gernand, R. Kakarala, O. S. Adekolujo, S. Smith Board 179 Phase II study of panitumumab, nab-paclitaxel, and carboplatin followed by FEC neoadjuvant chemotherapy for patients with primary HER-2 negative inflammatory breast cancer. (Abstract 1065) N. Matsuda, R. H. Alvarez, S. Krishnamurthy, J. S. Willey, X. Wang, B. Lim, C. A. Parker, A. Marx, G. Babiera, D. J. Booser, J. L. Murray, B. Arun, A. M. Brewster, J. M. Reuben, W. A. Woodward, A. Lucci Jr., S. M. Gainer, D. Tripathy, V. Valero, N. T. Ueno 66 Board 180 MHC II antigen presentation pathway expression in triple-negative breast cancer. (Abstract 1066) A. Forero-Torres, K. E. Varley, Y. Li, D. Chen, W. E. Grizzle, E. Downs-Kelly, T. C. Burwell, D. J. Buchsbaum, R. M. Myers, A. F. LoBuglio Board 181 A study of triple-negative breast cancer patients tested with a 25-gene panel of hereditary cancer genes. (Abstract 1067) J. F. Sandbach, G. Patel, E. King, B. Evans, J. Kidd, L. R. Langer, K. Brown, R. J. Wenstrup, J. Saam Board 182 Phase I dose-finding study of the gamma secretase inhibitor PF-03084014 (PF-4014) in combination with docetaxel in patients (pts) with advanced triple-negative breast cancer (TNBC). (Abstract 1068) G. Curigliano, P. G. Aftimos, E. C. Dees, P. LoRusso, M. D. Pegram, A. Awada, B. Huang, R. Cesari, Y. Jiang, M. N. Shaik, K. A. Kern, M. A. Locatelli Board 183 Lymphopenia after adjuvant radiotherapy (RT) to predict poor survival in triple-negative breast cancer (TNBC). (Abstract 1069) A. Afghahi, M. Mathur, T. Seto, M. Desai, P. Kenkare, K. C. Horst, A. K. Das, C. A. Thompson, H. S. Luft, P. P. Yu, S. L. Gomez, Y. Low, N. H. Shah, A. W. Kurian, G. W. Sledge Board 184 Masitinib plus carboplatin and gemcitabine for treatment of patients with advanced triple negative breast cancer: An open label phase Ib/II trial. (Abstract 1070) M. Campone, J. Ferrero, K. Gunzer, F. Priou, P. Dubreuil, C. Mansfield, A. Moussy, O. Hermine Board 185 Enzalutamide: A new hormonal treatment for triple-negative breast cancer? (Abstract 1071) F. Caiazza, A. Murray, S. F. Madden, N. C. Synnott, N. O’Donovan, J. Crown, M. J. Duffy Board 186 Prognostic significance of tumor subtypes in male breast cancer: A population-based study. (Abstract 1072) J. P. Leone, J. Leone, A. O. Zwenger, J. Iturbe, C. T. Vallejo, B. A. Leone Board 188 Neoadjuvant chemotherapy with dose-dense doxorubicin, cisplatin, and paclitaxel in patients with early triple-negative breast cancer (TNBC). (Abstract 1074) M. Frolova, E. Ignatova, E. Glazkova, A. Petrovsky, S. Tjulandin Board 189 Rampant centrosome amplification and aggressive disease course of triple-negative breast cancers. (Abstract 1075) V. Pannu, K. Mittal, G. H. Cantuaria, M. D. Reid, X. Li, S. Donthamsetty, M. McBride, R. Osan, P. C. Rida, R. Aneja Board 190 Prognostic role of androgen receptor expression in triple-negative breast cancer. (Abstract 1076) Y. Wang, F. Yang, F. Zhong, X. Guan Board 191 Measurement of nucleotide excision repair activity and correlation with cisplatin sensitivity. (Abstract 1077) A. Calkins, R. Szalat, M. Dreze, M. Schnorenberg, R. Ceccaldi, J. D. Iglehart, J. Lazaro Board 192 Nuclear HSET as a negative prognostic indicator and racial disparity biomarker in breast cancer patients. (Abstract 1078) A. Ogden, P. C. Rida, S. Klimov, V. Pannu, Y. Liu, M. D. Reid, X. Li, G. H. Cantuaria, R. Aneja Board 193 DNA methylation signature to identify treatment response in triple negative breast cancer. (Abstract 1079) B. Pineda, A. Diaz-Lagares, J. A. Perez-Fidalgo, E. Alonso, J. Sandoval, I. Gonzalez, A. Crujeiras, O. Burgues, M. Esteller, A. Lluch, P. Eroles Board 194 A Phase II study of cabozantinib for metastatic triple-negative breast cancer (TNBC). (Abstract 1080) S. M. Tolaney, D. R. Ziehr, H. Guo, W. T. Barry, M. J. Higgins, S. J. Isakoff, J. E. Brock, E. Ivanova, C. Paweletz, M. Demeo, N. H. Ramaiya, B. Overmoyer, R. K. Jain, D. G. Duda, E. P. Winer Board 195 Contribution of immune system and tumor-related interferon signaling to epirubicin response in triple-negative (TN) breast cancers. (Abstract 1081) G. Bianchini, M. Callari, T. Iwamoto, M. Riba, L. Vigano’, A. Locatelli, M. Zambetti, T. Karn, L. Pusztai, L. Gianni Board 196 Cisplatin with or without rucaparib after preoperative chemotherapy in patients with triple negative breast cancer: Final efficacy results of Hoosier 67 SATURDAY Saturday, May 30, 2015 Saturday, May 30, 2015 Oncology Group BRE09 –146. (Abstract 1082) K. Miller, Y. Tong, D. R. Jones, T. Walsh, M. A. Danso, C. X. Ma, P. Silverman, M. King, S. S. Badve, S. M. Perkins SATURDAY Board 197 A novel biomarker to predict sensitivity to enzalutamide (ENZA) in TNBC. (Abstract 1083) J. S. Parker, A. C. Peterson, I. C. Tudor, J. Hoffman, H. Uppal Board 198 Rac1 inhibition to sensitize triple negative breast cancer to EGFR inhibition. (Abstract 1084) G. Azzi, E. Goka, D. Senderoff, M. E. Lippman Board 199 Protein activation mapping and exploratory predictive markers for pCR in triple-negative breast cancer patients treated with neratinib in the I-SPY 2 TRIAL. (Abstract 1085) J. D. Wulfkuhle, C. Yau, D. M. Wolf, R. I. Gallagher, J. Deng, L. Brown Swigart, G. Hirst, M. C. Liu, J. W. Park, L. Esserman, D. A. Berry, L. van’t Veer, E. Petricoin III, I-SPY 2 TRIAL Investigators Board 200 Characterization of KCNK9 in The Cancer Genome Atlas breast cancer dataset. (Abstract 1086) K. A. Dookeran, M. Argos, J. K. Kresovich, G. H. Rauscher Board 201 Expression and significance of the co-regulatory ligands B7-H4 and PD-L1 in triple negative breast cancer. (Abstract 1087) M. Altan, K. A. Schalper, M. Silver, D. L. Rimm Board 202 Clinical utility of in depth RNA sequencing for non-metastatic triple negative breast cancers. (Abstract 1088) B. Thouvenot, S. Verdun, J. Tomasina, B. Hilselberger, M. Brulliard, L. Bonnard, M. Trarbach, V. Ogier, B. E. Bihain Board 203 Prognostic markers in triple-negative breast cancer (TNBC): The role of androgen receptor, e-cadherin, and Ki67. (Abstract 1089) G. R. Ricciardi, B. Adamo, V. Barresi, A. Ieni, T. Franchina, M. Caruso, A. Zacchia, C. Fazzari, G. Tuccari, V. Adamo Board 204 Programmed cell death 1 (PD-1) receptor and programmed death ligand 1 (PD-L1) expression in primary breast cancer (BC); correlations with clinical characteristics and patient outcomes. (Abstract 1090) N. Vidula, C. Yau, A. Goga, H. S. Rugo Board 205 Reproducibility of homologous recombination deficiency (HRD) scores in biopsies of triple negative breast cancer (TNBC) tumors. (Abstract 1091) K. Timms, A. B. Chagpar, V. Wali, V. Bossuyt, J. E. Reid, A. Gutin, C. Neff, E. W. Hofstatter, J. S. Lanchbury, L. Pusztai Board 206 Outcomes with neoadjuvant versus adjuvant chemotherapy for T1–2 node negative triple negative breast cancer. (Abstract 1092) P. Sharma, B. F. Kimler, J. R. Klemp, C. Ward, C. S. Connor, M. McGinness, J. M. Mammen, J. L. Wagner, A. L. Amin, C. J. Fabian, R. A. Jensen, A. K. Godwin, Q. J. Khan Board 207 Transcriptomic and protein expression analysis of helicase antigen (HAGE) in triple negative breast cancer (TNBC) as a novel prognostic and predictive biomarker. (Abstract 1093) T. M. Abdel-Fatah, S. McArdle, D. Agarwal, P. M. Moseley, A. R. Green, G. Ball, A. Pockley, I. O. Ellis, R. Rees, S. Y. Chan Board 208 Association of tumor BRCA1 reversion mutation arising during neoadjuvant platinum-based therapy in breast cancer (BC) with therapy resistance. (Abstract 1094) A. Afghahi, K. Timms, S. Vinayak, K. C. Jensen, P. Chang, A. Hartman, J. M. Ford, M. L. Telli Board 209 Evaluation of local and distant recurrences pattern in patients with triple negative breast cancer according to age. (Abstract 1095) J. C. Radosa, A. Eaton, M. Stempel, A. Khander, C. Liedtke, E. Solomayer, M. Gunthner-Biller, M. Morrow, T. A. King Board 210 Effect of the anti-Warburg agent BPM 31510 on TAC therapy synergy and survival in a xenograft model of triple-negative breast cancer (TNBC). (Abstract 1096) N. R. Narain, A. R. Diers, A. Lee, R. Ouro-Djobo, M. Kiebish, V. Vishnudas, J. J. Jimenez, R. Sarangarajan Board 211 A 3-gene expression score as prognostic factor in triple negative and basal breast tumors with residual disease. (Abstract 1097) J. A. Pinto, J. Araujo, N. K. Cardenas, J. M. Balko, C. L. Arteaga, H. Gomez 68 Board 212 TOP2A-based prognostication in triple negative breast cancer and correlation with basal phenotype. (Abstract 1098) B. C. Calhoun, C. Lanigan, B. Rubin, K. C. Mrazeck, G. Rosa, M. Barnes, S. Dean, B. LaFleur Board 213 Neratinib to inhibit the growth of triple-negative breast cancer cells. (Abstract 1099) M. Mullooly, D. Conklin, P. M. McGowan, N. A. O’Brien, N. O’Donovan, D. J. Slamon, J. Crown, R. S. Finn, M. J. Duffy Board 214a Cardiac toxicity prevention in non-metastatic breast cancer patients treated with anthracycline-based chemotherapy: A randomized, placebo controlled, phase III trial—SAFE trial. (Abstract TPS1100) I. Meattini, R. Tarquini, C. Saieva, A. Valoriani, P. Bonomo, I. Desideri, M. Loi, V. Scotti, C. De Luca Cardillo, S. M. Magrini, G. Gensini, L. Livi Board 214b A randomized phase III trial comparing two dose-dense, dose-intensified approaches (EPC and PM(Cb)) for neoadjuvant treatment of patients with high-risk early breast cancer (GeparOcto). (Abstract TPS1101) A. Schneeweiss, V. Moebus, J. Blohmer, S. D. Costa, C. Denkert, H. Eidtmann, C. Hanusch, J. Hilfrich, J. B. Huober, C. Jackisch, S. Paepke, S. Kümmel, H. Tesch, M. Untch, S. Loibl, G. Von Minckwitz Board 215a Phase 3 randomized, placebo-controlled trial of carboplatin (C) and paclitaxel (P) with/without veliparib (ABT-888) in HER2–BRCA-associated locally advanced or metastatic breast cancer (BC). (Abstract TPS1102) S. Puhalla, H. S. Han, V. Diéras, M. Friedlander, G. Somlo, B. Arun, H. Wildiers, B. Kaufman, J. M. Ayoub, M. Shan, D. Burmedi, Q. Qin, J. Qian, V. L. Giranda, S. P. Shepherd Board 215b POSNOC: Positive sentinel node—Adjuvant therapy alone versus adjuvant therapy plus clearance or axillary radiotherapy: A randomised trial looking at axillary treatment in early breast cancer (ISRCTN54765244). (Abstract TPS1103) A. Goyal, R. E. Coleman, D. J. Dodwell, L. Fallowfield, V. A. Jenkins, B. Mann, M. W. Reed, POSNOC Trialists Group Board 216a A phase 2 randomized, double-blind, placebo-controlled trial of hormone therapy (HT) ⴞ radium-223 dichloride (Ra-223) in HER2- hormone receptorⴙ breast cancer patients (pts) with bone metastases (mets). (Abstract TPS1104) R. E. Coleman, L. Huang, O. Petrenciuc, P. Zaccarini Board 216b NRG BR002: A phase IIR/III trial of standard of care therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical ablation for newly oligometastatic breast cancer. (Abstract TPS1105) S. J. Chmura, K. A. Winter, J. K. Salama, W. A. Woodward, V. F. Borges, H. A. Al-Hallaq, M. Matuszak, N. T. Jaskowiak, M. T. Milano, H. Bandos, J. R. White Board 217a Weekly nab-paclitaxel (nab-P) plus gemcitabine (gem) or carboplatin (carbo) vs gem/carbo as first-line treatment for metastatic triple-negative breast cancer (mTNBC) in a phase 2/3 trial (tnAcity). (Abstract TPS1106) D. A. Yardley, J. Cortes, R. E. Coleman, P. F. Conte, A. Brufsky, J. O’Shaughnessy, G. L. Wright, J. F. Eakle, S. Wilks, M. Shtivelband, R. R. Young, C. Bengala, H. Li, J. Miller, D. Barton, N. Harbeck Board 217b A phase 3, open-label, randomized, parallel, 2-arm international study of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA). (Abstract TPS1107) J. K. Litton, J. L. Blum, Y. Im, M. Martin, L. A. Mina, H. H. Roche, H. S. Rugo, F. Visco, C. Zhang, N. A. Lokker, D. L. Lounsbury, W. Eiermann Board 218a A phase 2 study (2-stage, 2-cohort) of the oral PARP inhibitor talazoparib (BMN 673) in patients with germline BRCA mutation and locally advanced and/or metastatic breast cancer (ABRAZO). (Abstract TPS1108) N. C. Turner, J. Balmaña, P. A. Fasching, S. A. Hurvitz, M. L. Telli, F. Visco, A. M. Wardley, C. Zhang, N. A. Lokker, D. L. Lounsbury, M. E. Robson Board 218b OlympiA: A randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm). (Abstract TPS1109) A. N. Tutt, B. Kaufman, R. D. Gelber, E. Mc Fadden, C. D. Goessl, G. Viale, A. Arahmani, D. Fumagalli, 69 SATURDAY Saturday, May 30, 2015 Saturday, May 30, 2015 H. A. Azim Jr., W. Wu, A. Grocholewicz, J. P. Costantino, P. Rastogi, J. E. Garber, C. E. Geyer Jr. SATURDAY Board 219a METRIC: A randomized international study of the antibody-drug conjugate glembatumumab vedotin (GV or CDX-011) in patients (pts) with metastatic gpNMB-overexpressing triple-negative breast cancer (TNBC). (Abstract TPS1110) D. A. Yardley, M. E. Melisko, A. Forero, B. R. Daniel, A. J. Montero, T. H. Guthrie, V. A. Canfield, C. A. Oakman, H. K. Chew, C. Ferrario, G. H. Volas-Redd, R. R. Young, N. L. Henry, L. Aneiro, Y. He, C. D. Turner, T. A. Davis, L. T. Vahdat, The METRIC Study Group Board 219b LOTUS: A randomized, phase II, multicenter, placebo-controlled study of ipatasertib (Ipat, GDC-0068), an inhibitor of Akt, in combination with paclitaxel (Pac) as front-line treatment for patients (pts) with metastatic triple-negative breast cancer (TNBC). (Abstract TPS1111) S. Kim, A. R. Tan, S. Im, R. Villanueva, V. Valero, C. Saura, M. Oliveira, S. J. Isakoff, S. M. Singel, R. A. Dent Board 220a FAIRLANE: A phase II randomized, double-blind, study of the Akt inhibitor ipatasertib (Ipat, GDC-0068) in combination with paclitaxel (Pac) as neoadjuvant treatment for early stage triple-negative breast cancer (TNBC). (Abstract TPS1112) M. Oliveira, C. Saura, A. Gonzalez-Martin, J. C. Andersen, J. G. Fisher, I. Calvo, E. Ciruelos, M. Gil, L. De La Pena, M. Llobet-Canela, Y. Choi, S. Jia, S. Yalamanchili, S. M. Singel, P. H. Patel, J. Baselga, S. J. Isakoff Board 220b Women’s triple-negative, first-line treatment: Improving outcomes in triplenegative breast cancer (TNBC) using molecular triaging and diagnostic imaging to guide neoadjuvant therapy (NACT). (Abstract TPS1113) S. L. Moulder, N. T. Ueno, W. T. Yang, J. Ensor Jr., V. Valero, J. K. Litton, R. K. Murthy, N. K. Ibrahim, B. Arun, E. A. Mittendorf, K. Hunt, F. Meric-Bernstam, A. M. Thompson, H. Piwnica-Worms, D. Tripathy, W. F. Symmans 8:00 AM - 11:30 AM Poster Session Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics Location: S Hall A Abstracts 2509 –2520 will be discussed during the Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics Poster Discussion Session. See page 89 for session information. Board 225 Preliminary results of TATTON, a multi-arm phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 or selumetinib in EGFR-mutant lung cancer. (Abstract 2509) G. R. Oxnard, S. S. Ramalingam, M. Ahn, S. Kim, H. A. Yu, H. Saka, L. Horn, K. Goto, Y. Ohe, M. Cantarini, P. Frewer, M. Lahn, J. C. Yang Board 226 ABT-414 in patients with advanced solid tumors likely to overexpress the epidermal growth factor receptor (EGFR). (Abstract 2510) G. D. Goss, E. E. Vokes, M. S. Gordon, L. Gandhi, K. P. Papadopoulos, D. W. Rasco, M. Pedersen, J. S. Fischer, K. Chu, W. Ames, H. Xiong, H. Lee, J. Zeng, L. Roberts-Rapp, P. Ansell, E. Reilly, K. D. Holen, A. W. Tolcher Board 227 Phase I expansion of S-222611, a reversible inhibitor of EGFR and HER2, in advanced solid tumors, including patients with brain metastases. (Abstract 2511) S. Deva, R. D. Baird, N. Cresti, J. Garcia-Corbacho, L. Hogarth, E. P. Frenkel, K. Kawaguchi, A. Arimura, K. Donaldson, J. Posner, D. Sarker, D. I. Jodrell, R. Plummer, J. F. Spicer Board 228 Safety and tolerability of increasing doses of CB-839, a first-in-class, orally administered small molecule inhibitor of glutaminase, in solid tumors. (Abstract 2512) J. J. Harding, M. L. Telli, P. N. Munster, M. H. Le, C. Molineaux, 70 Saturday, May 30, 2015 Board 229 A first-in-human dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of oral 2-hydroxyoleic acid (2-OHOA) in adult patients (pt) with advanced solid tumors including grade III/IV glioblastoma multiforme (GBM). (Abstract 2513) D. Roda, Y. Drew, A. Azaro, A. D. Smith, A. Greystoke, E. Sicart, P. V. Escriba, X. Busquets, V. LLado, V. Tur, E. Klumper, J. Rodon Ahnert, L. R. Molife, R. Plummer Board 230 Final results of ProGem1, the first in-human phase I/II study of NUC-1031 in patients with solid malignancies. (Abstract 2514) S. P. Blagden, I. Rizzuto, C. Stavraka, D. O’Shea, P. Suppiah, M. Patel, A. Sukumaran, N. Loyse, N. Bharwani, A. Rockall, H. Gabra, M. El-Bahrawy, H. Wasan, R. C. Leonard, N. A. Habib, J. G. Gribben, E. A. Ghazaly, C. McGuigan Board 231 TP53 mutations emerge in circulating cell-free DNA obtained from patients undergoing treatment with the HDM2 antagonist SAR405838. (Abstract 2515) J. W. Watters, M. A. Dickson, G. K. Schwartz, A. Le Cesne, R. Bahleda, A. J. Wagner, E. Choy, M. J. De Jonge, M. Light, J. Jung, J. Lee, S. Mace Board 232 Genomic mutation profiling (GMP) and clinical outcome of patients treated with buparlisib (PI3K inhibitor) in the “Signature” program. (Abstract 2516) S. A. Piha-Paul, J. A. Knost, F. S. Braiteh, J. T. Beck, D. L. Spitz, S. W. Papish, B. A. Hellerstedt, P. Nikolinakos, M. H. Taylor, S. P. Chawla, L. S. Schwartzberg, D. A. Smith, S. Szpakowski, L. Zhang, T. White, C. Lebedinsky Board 233 Alka-372– 001: First-in-human, phase I study of entrectinib – an oral pan-trk, ROS1, and ALK inhibitor – in patients with advanced solid tumors with relevant molecular alterations. (Abstract 2517) F. G. De Braud, M. Niger, S. Damian, B. Bardazza, A. Martinetti, G. Pelosi, G. Marrapese, L. Palmeri, G. Cerea, E. Valtorta, S. Veronese, A. Sartore-Bianchi, E. Ardini, A. Isachi, M. Martignoni, A. Galvani, D. Luo, L. Yeh, A. M. Senderowicz, S. Siena Board 234 First-in-human, phase I study assessing imalumab (Bax69), a first-in-class anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody in advanced solid tumors. (Abstract 2518) D. Mahalingam, M. R. Patel, J. C. Sachdev, L. L. Hart, N. Halama, R. K. Ramanathan, J. Sarantopoulos, X. Liu, S. Yazji, D. Jaeger, D. R. Adib, R. Kerschbaumer, A. M. Tsimberidou Board 235 First-in-human phase I administration of YS110, a monoclonal antibody directed against the CD26 immunostimulatory molecule in advanced cancer patients. (Abstract 2519) E. Angevin, N. Isambert, V. N. Trillet-Lenoir, B. You, J. Alexandre, G. Zalcman, P. Viehl, F. Farace, F. Valleix, T. Podoll, Y. Kuramochi, I. Miyashita, O. Hosono, N. H. Dang, K. Ohnuma, T. Yamada, Y. Kaneko, C. Morimoto Board 236 First-in-human dose escalation, safety, and PK study of a novel EFNA4-ADC in patients with advanced solid tumors. (Abstract 2520) D. S. Hong, I. GarridoLaguna, I. E. Krop, V. Subbiah, T. L. Werner, C. M. Cotter, E. P. Hamilton, K. Velastegui, D. Xuan, R. Bugarini, A. Gollerkeri, H. A. Burris III Board 237 Phase I study of ontuxizumab, a humanized monoclonal antibody (mAb) recognizing endosialin in Japanese patients (pts) with hepatocellular carcinoma (HCC). (Abstract 2521) M. Ikeda, T. Aramaki, Y. Inaba, K. Nakai, T. Doi, T. Okusaka Board 238 Phase I trial and pharmacokinetic study of Tanibirumab, a fully human monoclonal antibody to the vascular endothelial growth factor receptor 2 in patients with refractory solid tumors. (Abstract 2522) S. Lee, J. Ham, H. Kim, S. Byeon, W. Lee, J. Yoo, J. M. Sun, J. Lee, S. Park, J. Park, M. Ahn, H. Lim, W. Kang, Y. Park Board 239 Molecular characteristics in breast cancer tumors treated with neoadjuvant chemotherapy with and without bevacizumab: Results from NeoAva— Randomized phase II study. (Abstract 2523) O. Engebraaten, L. Silwal-Pandit, E. K. Moller, S. Nord, M. Krohn, H. M. Vollan, H. v. Gythfeldt, E. Borgen, O. Garred, 71 SATURDAY M. K. Bennett, E. Mittra, H. A. Burris III, A. S. Clark, M. Dunphy, F. Meric-Bernstam, M. R. Patel, A. DeMichele, J. R. Infante Saturday, May 30, 2015 A. Fangberget, M. M. Holmen, S. Lundgren, E. A. Wist, O. C. Lingjaerde, B. Naume, A. Borresen-Dale SATURDAY Board 240 Bevacizumab plus Letrozol (LEA clinical trial phase III). Using hypertension for finding biomarkers of efficacy. (Abstract 2524) J. de la Haba-Rodriguez, S. Morales, A. Guerrero, N. Martinez, A. Martinez Peinado, A. Anton, M. MunozMateu, J. Garcia Saenz, M. Ramos Vazquez, M. J. Gil Gil, M. Margeli, S. Servitja, B. Bermejo, J. C. Jurado, E. Aranda, M. Casas, C. Rodrı́guez-Martı́n, E. M. Carrasco, R. Caballero, M. Martin, GEICAM Spanish Breast Cancer Group Board 241 A phase 1 trial of a potent and selective VEGF receptor inhibitor, apatinib, in patients with advanced solid tumors. (Abstract 2525) S. Sharma, Y. Kang, J. R. Weis, G. W. Gilcrease, C. Davidson, R. Kingsford, J. Collett, N. Orgain, M. Ryu, B. Ryoo, S. Park, H. Yoo, S. Kim Board 242 Phase I study of the combination of alisertib (MLN8237) and gemcitabine in advanced solid tumors. (Abstract 2526) E. J. Kim, T. J. Semrad, D. R. Gandara, J. Riess, T. Li, A. Yu, K. Matsukuma, P. C. Mack, K. Kelly Board 243 First-in-human Phase 1 safety, PK, and PD study of the CDK4/6 inhibitor G1T28. (Abstract 2527) R. G. Tiessen, P. J. Roberts, J. A. Sorrentino, H. S. White, K. M. Makhuli, J. E. Bisi, J. C. Strum, E. Hoogdalem, R. K. Malik Board 244 Overcoming the proliferation rate paradox: Clinical evaluation of a continuous dosing scheme of the novel oral Eg5 inhibitor 4SC-205. (Abstract 2528) K. B. Mross, D. Scharr, H. Richly, S. Bauer, B. Krauss, R. Krauss, B. Hauns, T. Prenzel, H. Kohlhof, R. Baumgartner, M. E. Scheulen Board 245 Evaluation of targeted bone marrow arrest by G1T28, a CDK4/6 inhibitor in clinical development to reduce chemotherapy-induced myelosuppression. (Abstract 2529) P. J. Roberts, H. S. White, J. A. Sorrentino, H. Tadema, M. Sale, R. G. Tiessen, J. E. Bisi, K. M. Makhuli, E. Hoogdalem, R. K. Malik, J. C. Strum Board 246 SLC1A5 to predict outcome with chemotherapy in early triple-negative breast cancer. (Abstract 2530) A. Affan, V. Varadan, H. L. Gilmore, K. Miskimen, Y. Jeon, S. Parsai, Z. Ronai, L. Harris Board 247 Phase I dose-escalation study with extended daily administration of Debio1143, an oral inhibitor of apoptosis protein inhibitor, in patients with solid tumors. (Abstract 2531) H. C. Pitot, H. Hurwitz, C. Zanna, J. M. Brill, G. Vuagniaux, E. Rouits, J. M. Sorensen, D. C. Smith Board 248 First-in-human study of TAS-115, a novel oral MET/VEGFR inhibitor, in patients with advanced solid tumors. (Abstract 2532) N. Matsubara, K. Shitara, Y. Naito, Y. Kuboki, I. Ohno, H. Takahashi, H. Bando, T. Kojima, N. Fuse, T. Yamazaki, N. Hirayama, H. Fujita, T. Nishida, T. Doi Board 249 First-in-human study of LY3039478, a Notch signaling inhibitor in advanced or metastatic cancer. (Abstract 2533) C. Massard, A. Azaro, C. Le Tourneau, J. Soria, M. Alt, C. Smith, U. Ohnmacht, G. Oakeley III, B. Patel, E. Yuen, K. A. Benhadji, J. Rodon Ahnert Board 250 Trends in the characteristics, dose-limiting toxicities and efficacy of phase I oncology trials: The Cancer Research UK experience. (Abstract 2534) H. H. Wong, C. Barton, G. Acton, R. McLeod, R. Darby-Dowman, J. McQuillan, H. Turner, S. Wan, Z. Backholer, J. Peters, S. E. Halford Board 251 A phase I study of intravenous artesunate (IV AS) in patients with solid tumors. (Abstract 2535) J. F. Deeken, H. Wang, B. G. Smaglo, J. J. Hwang, A. R. He, L. M. Weiner, J. Marshall, G. Giaccone, S. V. Liu, J. Luecht, C. Urso, J. Y. Spiegel, A. Cheema, M. J. Pishvaian Board 252 Phase Ib study of afatinib plus standard-dose cetuximab in patients (pts) with advanced solid tumors. (Abstract 2536) A. Gazzah, V. Boni, J. Soria, E. Holgado, C. Even, M. Ould Kaci, S. Nazabadioko, W. Xue, E. Calvo Board 253 Phase I trial of the HSP-90 inhibitor PU-H71. (Abstract 2537) J. F. Gerecitano, S. Modi, R. Rampal, A. E. Drilon, M. G. Fury, M. M. Gounder, J. J. Harding, D. M. Hyman, A. M. Varghese, M. H. Voss, F. O. France, T. Taldone, E. Gomes 72 Saturday, May 30, 2015 Board 254 Safety and pharmacokinetics (PK) of cabazitaxel (C) in patients (pts) with hepatic impairment (HI). (Abstract 2538) J. Sarantopoulos, A. C. Mita, A. R. He, J. L. Wade III, C. Hsueh, J. C. Morris, A. C. Lockhart, D. Quinn, J. J. Hwang, J. W. Mier, W. Zhang, C. Wack, J. Yin, P. Clot, O. Rixe Board 255 Phase 1 study of BPM 31510 (Ubidecarenone) in patients with advanced solid tumors (ST): Use of multiomics platform to evaluate reversal of Warburg effect. (Abstract 2539) R. Zinner, P. P. Yu, N. R. Narain, R. Sarangarajan, M. Kiebish, V. Vishnudas, Y. Sun, L. Rodrigues, V. R. Akmaev, S. Brouwer, J. Stevens, E. Benaim, M. A. Shah Board 256 Preliminary clinical pharmacokinetics and pharmacodynamics of Debio 1347 (CH5183284), a novel FGFR inhibitor. (Abstract 2540) C. Zanna, A. Vaslin, M. H. Voss, R. S. Heist, C. Hierro, J. G. Supko, K. Nakai, N. Ishii, A. Menetrey, M. Roubaudi-Fraschini, J. Cordier, J. Douchain, V. Nicolas-Metral Board 257 A phase I study of BI 853520, an inhibitor of focal adhesion kinase (FAK), in patients with advanced or metastatic solid tumors. (Abstract 2541) A. Zer, R. Verheijen, F. Y. De Vos, S. Hotte, F. Eskens, L. Pronk, L. L. Siu, D. Schnell, N. Steeghs, M. H. Langenberg, H. Hirte, M. J. De Jonge Board 258 Phase I study of the safety and tolerability of the Exportin 1 (XPO1) inhibitor Selinexor (SXR) in Asian patients (pts) with advanced solid cancers. (Abstract 2542) D. S. Tan, M. Pang, W. Yong, R. A. Soo, C. E. Chee, Y. Thian, A. Gopinathan, A. L. Wong, P. Koe, R. Sundar, J. Ho, S. Friedlander, Y. Landesman, T. Rashal, D. McCauley, S. Shacham, S. Lee, B. C. Goh Board 259 Predicting outcomes in patients with advanced malignancies treated on Phase 1 clinical trials. (Abstract 2543) K. Wong, D. Gao, H. McCoy, A. Brock, R. W. Powell, C. L. O’Bryant, D. R. Camidge, L. Gore, A. Jimeno, J. R. Diamond, W. A. Messersmith, S. G. Eckhardt, S. Leong Board 260 First-in-man combination phase I study of TAS-114 and S-1 in patients (pts) with advanced solid tumors. (Abstract 2544) T. Doi, K. Yoh, K. Shitara, H. Takahashi, M. Ueno, S. Kobayashi, M. Morimoto, S. Ohkawa, T. Okusaka, H. Ueno, C. Morizane, S. Shiba, N. Okano, D. Naruge, F. Nagashima, J. Furuse, K. Koba, K. Noguchi Board 261 Phase 1, first-in-human study of ARQ 087, an oral pan-Fibroblast Growth Factor Receptor (FGFR) inhibitor, in patients (pts) with advanced solid tumors. (Abstract 2545) K. P. Papadopoulos, A. W. Tolcher, A. Patnaik, D. W. Rasco, G. Chambers, M. Beeram, R. Savage, T. Hall, B. E. Schwartz, J. Kazakin, P. LoRusso Board 262 Dermatologic toxicities of 3,517 solid tumor patients on phase I clinical trials of the National Institutes of Health Cancer Therapy Evaluation Program (CTEP). (Abstract 2546) A. E. Drilon, A. Eaton, K. Schindler, M. M. Gounder, G. L. Smith, D. Vulih, P. J. Harris, D. R. Spriggs, P. Ivy, A. Iasonos, M. E. Lacouture, D. M. Hyman Board 263 A first in human Phase I/II study of NUC-1031 in patients with advanced gynecological cancers. (Abstract 2547) S. P. Blagden, I. Rizzuto, C. Stavraka, D. O’Shea, P. Suppiah, M. Patel, N. Loyse, A. Sukumaran, N. Bharwani, A. Rockall, H. Gabra, M. El-Bahrawy, H. S. Wasan, R. C. Leonard, N. A. Habib, C. McGuigan, J. G. Gribben, E. A. Ghazaly Board 264 Biomarker analysis from a Phase I study of copanlisib with expansion cohorts in solid tumors with and without PIK3CA mutations and NHL. (Abstract 2548) C. E. Pena, M. Jeffers, I. Genvresse, L. J. Appleman, R. K. Ramanathan, A. Patnaik Board 265 Phase I trial of tivantinib in combination with carboplatin and pemetrexed as first-line treatment in patients with advanced nonsquamous non small cell lung cancer or malignant pleural mesothelioma. (Abstract 2549) P. A. Zucali, M. Simonelli, F. De Vincenzo, G. Fatuzzo, M. Bertossi, M. Perrino, C. Miggiano, L. Giordano, C. Bonifacio, F. Mrakic Sposta, A. Santoro 73 SATURDAY DaGama, M. Uddin, G. Chiosis, J. S. Lewis, S. K. Lyashchenko, S. M. Larson, C. Pressl, M. Dunphy Saturday, May 30, 2015 SATURDAY Board 266 SORAVE: A phase I trial to evaluate safety and efficacy of combination therapy with everolimus and sorafenib. (Abstract 2550) C. Mattonet, L. Nogova, M. Scheffler, S. Y. Michels, D. Kahraman, C. Kobe, U. Fuhr, A. A. Suleiman, Y. Tian, F. Soergel, K. Toepelt, R. Schnell, M. Schlaak, K. Rhiem, R. Buettner, J. Wolf Board 267 Phase 1 study of the folic acid (FA) and tubulysin B hydrazide (TubBH) small molecule drug conjugate (SMDC) EC1456 in patients (pts) with advanced cancers (CA). (Abstract 2551) D. Matei, M. J. Edelman, J. C. Sachdev, P. Klein, S. Rao, S. Burgess, R. Clark, R. K. Ramanathan, E. A. Morris, W. A. Harb Board 268 ANG1005 for brain metastases from breast cancer: 18F-FLT-PET and MRI as complementary approaches to response assessment. (Abstract 2552) S. E. Bates, M. L. Lindenberg, C. Bryla, M. E. Burotto Pichun, N. Patronas, L. AmiriKordestani, E. M. Gonzalez, T. Fojo, S. Balasubramaniam, P. L. Choyke Board 269 Pharmacologic advantage (PA) of intraperitoneal (IP) nab-paclitaxel in patients with advanced malignancies primarily confined to the peritoneal cavity. (Abstract 2553) M. C. Cristea, T. W. Synold, P. H. Frankel, S. E. Rivkin, D. Lim, V. M. Chung, J. Chao, M. T. Wakabayashi, I. B. Paz, E. S. Han, P. Lin, L. A. Leong, A. Hakim, M. I. Carroll, H. Openshaw, N. Prakash, T. H. Dellinger, M. S. Park, R. Morgan Board 270 A phase I study of ARQ 197 in combination with temsirolimus in advanced solid tumors. (Abstract 2554) C. Kyriakopoulos, J. Kolesar, J. C. Eickhoff, J. Heideman, G. Liu, K. B. Wisinski Board 271 First-in-human phase I study of the DNA repair inhibitor DT01 in combination with radiotherapy in patients with in transit melanoma. (Abstract 2555) C. Le Tourneau, B. Dreno, Y. Kirova, J. Grob, T. Jouary, C. Dutriaux, L. Thomas, C. Lebbe, L. Mortier, P. Saiag, M. Avril, E. Maubec, P. Bey, J. Cosset, J. Sun, B. Asselain, F. Devun, M. E. Marty, M. Dutreix Board 272 Rationale for the combination of veliparib with platinum-based chemotherapy. (Abstract 2556) D. Maag, L. Solomon, T. Hopkins, G. Bukhofzer, Y. Shi, C. Donawho, G. Zhu, L. E. Rodriguez, T. Penning, E. DiGiammarino, S. C. Panchal, E. F. Johnson Board 273 Genomic landscape of DNA repair genes in cancer: Mutation and copy number variation (CNV) frequencies. (Abstract 2557) J. Anker, Y. Chae Board 274 Phase I clinical trial of temozolomide and methoxyamine (TRC-102) in patients with advanced solid tumors. (Abstract 2558) J. R. Eads, S. S. Krishnamurthi, J. N. Saltzman, N. J. Meropol, J. A. Bokar, J. Gibbons, H. B. Koon, N. Sharma, P. Savvides, J. Pink, Y. Xu, J. H. Beumer, P. Fu, K. Beatty, D. Kane, M. Rodal, J. Czalkiewicz, J. Riendeau, S. L. Gerson, A. Dowlati Board 275 Using gamma-H2AX and H2AX quantitative ELISA for monitoring DNA damage induced by chemotherapeutic agents and irradiation exposure. (Abstract 2559) J. J. Ji, Y. Zhang, C. E. Redon, A. Chen, S. Holbeck, M. G. Hollingshead, R. E. Parchment, Y. Pommier, J. E. Tomaszewski, J. H. Doroshow, W. Bonner Board 276 A phase I study of pazopanib (PAZ) in combination with abexinostat (ABX) in patients (pts) with metastatic solid tumors. (Abstract 2560) R. R. Aggarwal, J. A. Grabowsky, A. Reinert, S. Thomas, T. Truong, C. Chun, P. N. Munster Board 277 Pharmacokinetics/pharmacodynamics (PKPD) of blinatumomab in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL). (Abstract 2561) M. Zhu, A. Kratzer, J. Johnson, C. Holland, C. Brandl, I. Singh, A. Wolf, S. Doshi Board 278 Pharmacogenetic variants associated with differential sirolimus clearance in pediatric patients. (Abstract 2562) J. Wright, R. Karns, T. Mizuno, M. Basu, B. D. Weiss, D. Adams, A. Vinks, B. Aronow, J. P. Perentesis Board 279 Mass balance study of TAS-102 using 14C labeling analyzed by accelerator mass spectrometry. (Abstract 2563) J. J. Lee, J. Seraj, K. Yoshida, M. Narurkar, 74 Saturday, May 30, 2015 Board 280 First-in-human phase I trial of the PI3Kb-selective inhibitor SAR260301 in patients with advanced solid tumors (NCT01673737). (Abstract 2564) P. L. Bedard, M. A. Davies, S. Kopetz, K. T. Flaherty, G. Shapiro, J. J. Luke, A. Spreafico, B. Wu, C. Gomez, S. Cartot-Cotton, F. Mazuir, S. Micallef, B. Demers, D. Juric Board 281 Effect of itraconazole and rifampin on the pharmacokinetics of olaparib tablet formulation in patients with advanced solid tumours: Phase I open-label studies. (Abstract 2565) E. R. Plummer, H. M. Verheul, S. Rottey, K. Leunen, G. H. Jerusalem, C. D. Rolfo, D. L. Nielsen, L. R. Molife, R. Kristeleit, J. d. VosGeelen, M. Mau-Sørensen, P. M. Soetekouw, C. van Herpen, H. Swaisland, A. Fielding, K. So, W. Bannister, L. Dirix Board 282 A first-in-human study of the dual ROCK I/II inhibitor, AT13148, in patients with advanced cancers. (Abstract 2566) D. Papadatos-Pastos, R. Kumar, T. A. Yap, R. Ruddle, S. Decordova, P. Jones, G. Halbert, M. D. Garrett, R. McLeod, Z. Backholer, K. E. Swales, F. I. Raynaud, J. S. De Bono, U. Banerji Board 283 Patterns of hepatic impairment in phase I clinical trials. (Abstract 2567) A. S. Mansfield, D. Vulih, G. L. Smith, P. J. Harris, S. P. Ivy Board 284 Predictive PK/PD models for hematological toxicities to inform MTD determination and regimen selection for ADCs. (Abstract 2568) S. Palani, J. C. Masters, X. Meng, D. Xuan Board 285 Regulatory considerations for clinical pharmacology during development of antibody-drug conjugates. (Abstract 2569) S. S. Shord, S. J. Schrieber, H. Zhao, B. Booth, N. A. Rahman Board 286 A phase I, first-in-human study to evaluate the tolerability, pharmacokinetics and preliminary efficacy of HuMax-tissue factor-ADC (TF-ADC) in patients with solid tumors. (Abstract 2570) U. N. Lassen, D. S. Hong, N. Diamantis, V. Subbiah, R. Kumar, M. Sorensen, S. Lisby, R. L. Coleman, J. S. De Bono Board 287 Exhaustive single nucleotide polymorphism (SNP) analysis of DPYD exome in breast cancer patients (pts) receiving capecitabine. (Abstract 2571) M. Etienne-Grimaldi, J. Boyer, L. Llorca, G. Romieu, T. D. Bachelot, V. Dieras, J. Merlin, F. Pinguet, F. Thomas, C. Ferrand, C. Bobin-Dubigeon, X. B. Pivot, R. Largillier, M. Mousseau, A. Goncalves, H. H. Roche, J. Ciccolini, J. Ferrero, G. A. Milano, GPCO-Unicancer group Board 288 Identification of candidates for sorafenib dose-escalation using sorafenib plasmatic concentration monitoring: Proof of concept. (Abstract 2572) J. Arrondeau, B. Blanchet, A. Thomas-Schoemann, O. Huillard, P. Boudou-Rouquette, J. Giroux, A. Cessot, C. Tlemsani, R. Coriat, J. Alexandre, M. Vidal, F. Goldwasser Board 289 Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors. (Abstract 2573) K. Han, J. Jin, M. Marchand, S. Eppler, N. W. Choong, S. P. Hack, M. A. Sovak, N. Tikoo, R. Bruno, M. J. Dresser, L. Musib, N. R. Budha Board 290 Recommendations in a new drug application review for dose optimization to potentially improve gastrointestinal tolerability of a tyrosine kinase inhibitor. (Abstract 2574) R. Leong, P. Song, Q. Liu, H. Zhao, G. M. Blumenthal, S. Khozin, Y. Pan, P. Zhao, P. Keegan, B. Booth, N. A. Rahman Board 291 When investigating predictive biomarkers, beware of the qualitative interaction. (Abstract 2575) H. M. Mackey, T. Bengtsson Board 292 Carboplatin dosing based on estimated Glomerular Filtration Rate (GFR) using IDMS creatinine: A comparison of estimated GFR based on IDMS creatinine in the Cockroft-Gault (CG) formula (IDMS-GFR), with measured GFR using 51Cr-EDTA (51Cr-GFR). (Abstract 2576) J. R. Whittle, J. W. Graham, H. Ismail, M. Lichtenstein, R. J. Hicks, O. McNally, L. R. Mileshkin, D. Zannino, M. Rosenthal, D. Rischin, A. L. Hamilton 75 SATURDAY H. Mizuguchi, S. Strychor, J. Fiejdasz, T. Faulkner, L. Pollice, S. Mason, W. Sun, E. Chu, M. Croft, J. Nguteren, C. Tedder, J. H. Beumer Saturday, May 30, 2015 SATURDAY Board 293 Results of OAK: A phase 1, open-label, multicentre study to compare two dosage forms of AZD5363 and to explore the effect of food on the pharmacokinetic (PK) exposure, safety, and tolerability of AZD5363 in patients with advanced solid malignancies. (Abstract 2577) E. J. Dean, U. Banerji, J. H. Schellens, M. Krebs, B. Jimenez, R. van der Noll, A. Foxley, J. W. Yates, N. Taylor, S. Evans, T. Guy, E. Casson, P. Rugman, S. Salim, J. P. Lindemann, P. Lawrence Board 294 Exposure-response (E-R) and case-control analyses of ramucirumab leading to recommendation for dosing optimization in patients with gastric cancer. (Abstract 2578) R. Jin, H. Li, L. H. Zhang, H. Zhao, L. Fashoyin-Aje, S. Lemery, P. Keegan, B. Booth, N. A. Rahman, Y. Wang, V. Sinha, L. Zhao Board 295 Population pharmacokinetic (PK) analysis of TAS-102 in patients (pts) with metastatic colorectal cancer (mCRC): Results from 3 phase 1 trials and the phase 3 RECOURSE trial. (Abstract 2579) J. M. Cleary, R. J. Mayer, E. Van Cutsem, F. Yamashita, K. Yoshisue, I. Ieiri, A. Ohtsu, H. Lenz Board 296 A phase I, first-in-human study of argx-111, a monoclonal antibody targeting c-met in patients with solid tumors. (Abstract 2580) P. G. Aftimos, P. Barthelemy, C. D. Rolfo, V. Hanssens, N. De Jonge, K. Silence, T. Dreier, H. de Haard, M. Peeters, A. Thibault, A. Awada Board 297 Comparison of adult oncology phase 1 trials to pediatric oncology phase 1 trials of targeted therapies. (Abstract 2581) V. Subbiah, J. D. Kawedia, A. Christensen, K. R. Hess, K. Patel, E. Wood, R. D. Bitar, N. C. Daw Board 298 The association of relative survival benefit and approval of oncological drugs: An analysis of oncology drug advisory committee reviews. (Abstract 2582) I. U. Amanam, A. B. Gardner, S. L. James, D. S. Kapp, J. K. Chan Board 299 A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib (V) in combination with the oral MEK inhibitor selumetinib (S) in solid tumors. (Abstract 2583) W. O. Saka, S. Pacey, F. H. Blackhall, J. Garcia-Corbacho, A. Fusi, I. Karydis, M. Hategan, G. Laviste, S. E. Halford, C. Foxton, R. McLeod, S. Wan, D. C. Talbot Board 300 Phase I study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancies. (Abstract 2584) H. Park, I. Garrido-Laguna, A. Naing, S. Fu, G. S. Falchook, S. A. Piha-Paul, J. J. Wheler, D. S. Hong, V. Subbiah, A. M. Tsimberidou, A. O. Kaseb, Y. Oki, R. Zinner, S. Patel, V. M. Velez Bravo, M. A. Fanale, F. Meric-Bernstam, R. Kurzrock, F. Janku Board 301 Dose-escalation of the first-in human phase I/Ib study of ABTL0812, a novel antitumor drug inhibiting the Akt/mTOR pathway in patients with advanced solid tumors. (Abstract 2585) L. Vidal Boixader, L. Gaba, I. Victoria, M. Brunet, P. Paredes, E. Buxo, T. Vilella, G. Riu, M. Cortal, M. Gomez-Ferreria, J. Alfon, C. Domenech, P. Gascon Board 302 Phase I study of pemetrexed and sorafenib in advanced solid tumors. (Abstract 2586) A. S. Poklepovic, D. A. Shafer, J. D. Roberts, C. E. Geyer Jr., P. Dent, R. Moran, M. Tombes, E. Shrader, K. Strickler, W. Wan Board 303 Phase I study of INC280 plus erlotinib in patients with MET expressing adenocarcinoma of the lung. (Abstract 2587) C. E. McCoach, A. Yu, D. R. Gandara, J. Riess, T. Li, P. Lara Jr., P. C. Mack, L. Beckett, E. D. Slosberg, K. Kelly Board 304 Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy. (Abstract 2588) H. V. Rodrigues, J. Lim, B. Stephen, F. Janku, A. M. Tsimberidou, S. A. Piha-Paul, S. Fu, A. Naing, V. Subbiah, G. S. Falchook, R. Kurzrock, J. J. Wheler Board 305 Phase I study of receptor tyrosine kinase (RTK) inhibitor, MGCD265, in patients (pts) with advanced solid tumors. (Abstract 2589) C. K. Kollmannsberger, S. Sharma, G. Shapiro, K. N. Chi, J. Christensen, V. R. Tassell, R. C. Chao, D. Faltaos, H. Hurwitz 76 Board 306 Phase I study of the PI3K/mTOR inhibitor PF-05212384 in combination with other antitumor agents. (Abstract 2590) Z. A. Wainberg, G. Shapiro, G. Curigliano, S. Leong, R. S. Kristeleit, M. Alsina Maqueda, C. D. Britten, M. Milella, M. R. Middleton, A. J. Olszanski, U. N. Vaishampayan, J. A. Lopez-Martin, K. A. Gelmon, N. Brega, K. J. Pierce, R. Perea, B. E. Houk, N. Pathan, A. Gollerkeri, A. R. Razak Board 307 Efficacy, safety, biomarkers, and phase II dose modeling in a phase I trial of the oral selective c-Met inhibitor tepotinib (MSC2156119J). (Abstract 2591) G. S. Falchook, R. Kurzrock, H. M. Amin, S. Fu, S. A. Piha-Paul, F. Janku, H. Zheng, B. Sarholz, A. Johne, D. S. Hong Board 308 A phase 1 first-in-human (FIH) dose-escalation (DE) study of the oral dual PI3K/mTOR inhibitor PQR309 in patients (pts) with advanced solid tumors: Final DE results. (Abstract 2592) R. S. Kristeleit, N. F. Brown, D. Hess, M. Joerger, R. Von Moos, J. Rodón, C. Hierro, A. Childs, A. Stathis, S. Dimitrijevic, M. Stumm, R. Herrmann, C. Sessa, V. Bize, V. Hess, A. Wicki Board 309 A phase Ib dose-escalation study of GSK2256098 (FAKi) plus trametinib (MEKi) in patients with selected advanced solid tumors. (Abstract 2593) H. Arkenau, A. Gazzah, R. Plummer, S. P. Blagden, G. Mak, J. Soria, A. Greystoke, I. Rizzuto, D. Rogan, J. Mazumdar, K. Laubscher, K. R. Auger, L. S. Swartz, M. L. Mattern, N. Nebot, R. P. Singh, R. A. Fleming, L. Yan Board 310 NCIC CTG IND.206: A phase II umbrella trial of sunitinib (S) or temsirolimus (T) in advanced rare cancers. (Abstract 2594) J. Dancey, M. K. Krzyzanowska, D. M. Provencher, W. Y. Cheung, R. J. Macfarlane, T. Alcindor, P. Ghatage, A. A. Gupta, S. A. Laurie, M. B. Sawyer, S. Welch, M. Salim, S. Ellard, D. A. Wall, M. S. Tsao, J. Sederias, H. Xu, T. O. Nielsen, S. L. Asa, H. W. Hirte Board 311 Activity of crizotinib in relapsed MET amplified malignancies: Results of the French AcSé Program. (Abstract 2595) G. Vassal, M. Ledeley, C. Tournigand, T. Aparicio, I. Ray-Coquard, L. Taillandier, B. Escudier, B. You, A. Goncalves, C. Lombard Bohas, J. Seitz, T. Andre, J. Merlio, L. Arnould, G. Ferretti, Y. Menu, T. Mortier, E. Lonchamp, C. Mahier - Ait Oukhatar, D. Moro-Sibilot Board 312 STARTRK-1: Phase 1/2a study of entrectinib, an oral Pan-Trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations. (Abstract 2596) M. R. Patel, T. M. Bauer, S. V. Liu, A. E. Drilon, J. J. Wheler, A. T. Shaw, A. F. Farago, S. I. Ou, D. Luo, L. Yeh, Z. Hornby, A. M. Senderowicz, J. Lim Board 313 Phase I study of combination of crizotinib (C) and dasatinib (D) in patients (pts) with advanced cancer. (Abstract 2597) S. Kato, D. L. Fontes Jardim, F. M. Johnson, V. Subbiah, S. A. Piha-Paul, A. M. Tsimberidou, G. S. Falchook, D. D. Karp, J. J. Wheler, R. Zinner, F. Janku, S. Fu, L. Dandu, E. Browne, F. MericBernstam, D. S. Hong Board 314 A phase 1, open-label study to evaluate the safety and pharmacokinetics of the anti ErbB3 antibody, KTN3379, alone or in combination with targeted therapies in patients with advanced tumors. (Abstract 2598) T. M. Bauer, J. R. Infante, J. P. Eder, P. LoRusso, T. LaVallee, R. Gedrich, C. Sidor, G. S. Falchook Board 315 Phase I study of temsirolimus in combination with cetuximab in patients with advanced solid tumors. (Abstract 2599) A. Hollebecque, R. Bahleda, J. Thery, L. Faivre, M. Le Deley, A. Paci, A. Varga, A. Gazzah, C. Massard, V. Poinsignon, K. Malekzadeh, V. Ribrag, E. Angevin, S. Postel-Vinay, C. A. Gomez-Roca, M. Gharib, F. Dufour, J. Soria, J. Spano Board 316 A phase I study of temsirolimus plus erlotinib in patients with refractory solid tumors. (Abstract 2600) A. Wang-Gillam, B. R. Tan Jr., S. N. Waqar, R. Suresh, D. Morgensztern, B. A. Van Tine, R. Nieman, R. Govindan, A. C. Lockhart Board 317a Pharmacodynamic study using FLT PET/CT in advanced solid malignancies treated with a sequential combination of X-82 and docetaxel. (Abstract TPS2601) M. M. Rampurwala, L. Carmichael, J. C. Eickhoff, J. Kolesar, K. Binger, J. Heideman, S. Perlman, C. Liang, R. Jeraj, G. Liu, J. Y. Bruce 77 SATURDAY Saturday, May 30, 2015 Saturday, May 30, 2015 SATURDAY Board 317b A phase I study of a novel inhibitor of protein phosphatase 2A alone and with docetaxel. (Abstract TPS2602) A. S. Mansfield, V. M. Chung, J. S. Kovach Board 318a First-in-human, dose-escalation, safety, and PK study of a novel 5T4-ADC in patients with advanced solid tumors. (Abstract TPS2603) G. Shapiro, P. LoRusso, U. N. Vaishampayan, M. Kittaneh, J. F. Hilton, J. M. Cleary, K. Velastegui, D. Xuan, S. Hua, R. L. Shazer, H. Borghaei Board 318b A multicenter phase II basket clinical trial of lurbinectedin (PM01183) in selected advanced solid tumors. (Abstract TPS2604) M. Provencio Pulla, J. Tabernero, V. Moreno, J. Trigo Perez, R. Lopez, R. Kristeleit, A. Awada, A. Leary, J. Alexandre, J. Delord, S. Ferrari, A. Santoro, E. Bajetta, V. Subbiah, S. Weitman, V. M. Villalobos, E. Raymond, A. Sundlov, P. Lardelli, S. P. Chawla Board 319a A phase I study of RX-3117, an oral agent activated by uridine cytidine kinase 2, to treat subjects with advanced solid tumors. (Abstract TPS2605) D. W. Rasco, A. Patnaik, A. W. Tolcher, K. P. Papadopoulos, C. Peterson, E. Benaim Board 319b A phase I, dose-escalation, multi-center study of PFK-158 in patients with advanced solid malignancies explores a first-in-man inhbibitor of glycolysis. (Abstract TPS2606) R. A. Redman, P. R. Pohlmann, M. R. Kurman, G. Tapolsky, J. A. Chesney Board 320a Phase I study of procaspase activating compound-1 (PAC-1) in the treatment of advanced malignancies. (Abstract TPS2607) O. C. Danciu, M. K. Nicholas, R. Emmadi, H. Xie, P. J. Hergenrother, T. M. Tarasow, A. Z. Dudek Board 320b A phase 1 study of RX-5902, an oral agent targeting phosphorylated p68, to treat subjects with advanced solid tumors. (Abstract TPS2608) S. G. Eckhardt, W. L. Gluck, M. Gutierrez, C. Peterson, E. Benaim Board 321a A phase Ib study of investigational pan-RAF kinase inhibitor MLN2480 plus investigational TORC1/2 inhibitor MLN0128, investigational Aurora A kinase inhibitor alisertib (MLN8237), or paclitaxel in patients (pts) with advanced solid tumors. (Abstract TPS2609) A. J. Olszanski, M. R. Middleton, R. Bahleda, R. S. Heist, L. Rangachari, X. Zhou, V. Bozón, M. Kneissl, T. Macarulla Board 321b STM-01: Phase I EFFTox study of aurora A kinase inhibitor alisertib (MLN8237) given in combination with selective VEGFR inhibitor pazopanib for therapy of solid tumors. (Abstract TPS2610) A. Z. Dudek, I. Unal, H. Xie, L. E. Feldman, N. K. Venepalli, O. C. Danciu Board 322a A randomized Phase 2a study to assess pharmacodynamics, antitumor activity and safety of intravenous BAL101553, a novel microtubule inhibitor, at two dose levels in adult patients with selected advanced solid tumors. (Abstract TPS2611) R. S. Kristeleit, A. D. Smith, N. R. Haris, I. H. Zubairi, J. W. King, M. de Miguel Luken, M. D’Arcangelo, J. MacDonald, N. F. Brown, A. H. Calvert, A. L. Hannah, S. Anderson, F. Bachmann, M. Maurer, A. Schmitt-Hoffmann, H. A. Lane, M. F. Engelhardt, T. Evans, R. Plummer, L. R. Molife Board 322b Phase I study of ADI-PEG 20 in combination with pemetrexed and cisplatin (TRAP) in patients with ASS1-deficient mesothelioma and non-squamous lung cancer. (Abstract TPS2612) P. W. Szlosarek, J. F. Spicer, T. Szyszko, G. J. Cook, P. Chan, M. Hategan, D. Repana, J. P. Steele, P. Schmid, M. Diaz, A. Johnston, M. Sheaff, R. Khadeir, J. S. Bomalaski, S. Pacey Board 323a A phase 1, dose-escalation, safety, pharmacokinetic, pharmacodynamic study of thioureidobutyronitrile, a novel p53 targeted therapy, in patients with advanced solid tumors. (Abstract TPS2613) G. Shapiro, J. W. Mier, J. F. Hilton, L. Gandhi, N. G. Chau, A. J. Bullock, J. G. Supko, S. J. Verselis, K. Murgo, C. Sze, S. Gotthardt, A. Wolanski, W. J. Alexander, A. Kumar, S. A. Holden, K. Chafai-Fadela, S. Ram, K. E. Menon Board 323b Phase I trial of the combination of bortezomib and clofarabine in adults with refractory solid tumors. (Abstract TPS2614) G. H. O’Sullivan Coyne, S. Kummar, K. T. Do, S. Holbeck, M. G. Hollingshead, Y. Horneffer, L. Juwara, A. K. Srivastava, L. Rubinstein, R. Piekarz, E. Sharon, H. Streicher, B. A. Conley, R. Antony, J. M. Collins, A. Chen, J. H. Doroshow 78 Board 324a First-in-human investigation of the oral first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640. (Abstract TPS2615) A. J. Brenner, D. D. Von Hoff, J. R. Infante, M. R. Patel, S. F. Jones, H. A. Burris III, C. Rubino, W. McCulloch, V. Zhukova-Harrill, G. Kemble Board 324b Phase 1 dose-escalation study of EBC-46 given by intratumoral injection to patients with refractory cutaneous and subcutaneous tumors. (Abstract TPS2616) J. D. Lickliter, B. Panizza, C. S. Karapetis, V. A. Gordon, P. W. Reddell, K. T. Lingard, R. M. Cusack, P. De Souza Board 325a Phase II study of the PARP inhibitor talazoparib (BMN-673) in advanced cancer patients with somatic alterations in BRCA1/2, mutations/deletions in PTEN or PTEN loss, a homologous recombination defect, mutations/deletions in other BRCA pathway genes and germline mutation S in BRCA1/2 (not breast or ovarian cancer). (Abstract TPS2617) S. A. PihaPaul, J. B. Goldstein, K. R. Hess, S. Fu, D. S. Hong, F. Janku, D. D. Karp, A. Naing, V. Subbiah, A. M. Tsimberidou, J. J. Wheler, R. Zinner, G. B. Mills, F. Meric-Bernstam Board 325b A phase I trial of veliparib, an inhibitor of poly(ADP-ribose) polymerase (PARP), and topotecan (TPT) in patients with solid tumors. (Abstract TPS2618) A. E. Wahner Hendrickson, M. E. Menefee, L. C. Hartmann, H. J. Long III, D. W. Northfelt, J. M. Reid, F. Boakye-Agyeman, K. S. Flatten, G. G. Poirier, J. Lensing, C. Erlichman, S. H. Kaufmann, P. Haluska Board 326a A phase I trial of oral 5-azacitidine in combination with romidepsin in advanced solid tumors with an expansion cohort in virally mediated cancers and liposarcoma. (Abstract TPS2619) K. A. Reiss, M. A. Rudek, S. SartoriusMergenthaler, M. Downs, D. Cosgrove, S. Gaillard, S. Baylin, N. Ahuja, N. S. Azad Board 326b Phase I/II study of PF-06463922, an ALK/ROS1 tyrosine kinase inhibitor, in patients with advanced non-small-cell lung cancer harboring specific molecular alterations. (Abstract TPS2620) T. M. Bauer, A. T. Shaw, B. Solomon, B. Besse, L. P. James, J. S. Clancy, G. Mugundu, J. Martini, A. Abbattista, E. Felip Board 327a A first-in-human phase I/Ib study of receptor tyrosine kinase (RTK) inhibitor, MGCD516, in patients with advanced solid tumors. (Abstract TPS2621) G. K. Schwartz, D. Adkins, R. S. Heist, M. Abbott, S. L. Barber, R. C. Chao, S. T. Neuteboom, I. Chen, J. Christensen, T. M. Bauer Board 327b A randomized, open-label, Phase II trial evaluating the clinical benefit of a maintenance treatment targeting tumor molecular alterations in patients with advanced solid tumors. (Abstract TPS2622) M. Toulmonde, C. Le Tourneau, A. Italiano, C. Seigne, I. L. Ray-Coquard, C. Cropet, A. Flechon, F. Desseigne, M. Alt, C. De La Fouchardiere, J. Fayette, E. Borcoman, P. Heudel, L. Jaouen, M. Bernardin, D. Pérol, J. Blay Board 328a First-in-human dose escalation study of oral ONC201 in advanced solid tumors. (Abstract TPS2623) M. N. Stein, T. M. Mayer, R. A. Moss, A. W. Silk, N. Chan, B. G. Haffty, R. S. DiPaola, Y. Beckett, E. Bentlyewski, L. Zheng, B. Fang, J. Allen, J. M. Mehnert Board 328b A first-in-human study of LOXO-101, a highly selective inhibitor of the tropomyosin receptor kinase (TRK) family. (Abstract TPS2624) H. A. Burris, M. S. Brose, A. T. Shaw, T. M. Bauer, A. F. Farago, R. C. Doebele, S. Smith, M. Fernandes, S. Cruickshank, J. A. Low 8:00 AM - 11:30 AM Poster Session Developmental Therapeutics—Immunotherapy Location: S Hall A Abstracts 3009 –3020 will be discussed during the Developmental Therapeutics—Immunotherapy Poster Discussion Session. See page 128 for session information. 79 SATURDAY Saturday, May 30, 2015 Saturday, May 30, 2015 SATURDAY Board 335 Pembrolizumab (MK-3475) plus low-dose ipilimumab (IPI) in patients (pts) with advanced melanoma (MEL) or renal cell carcinoma (RCC): Data from the KEYNOTE-029 phase 1 study. (Abstract 3009) M. B. Atkins, T. K. Choueiri, F. S. Hodi, J. A. Thompson, W. Hwu, D. F. McDermott, M. Brookes, A. Tosolini, S. Ebbinghaus, Z. Yang, C. K. Gause, R. F. Perini, A. Ribas Board 336 Preliminary safety and activity of nivolumab and its combination with ipilimumab in recurrent glioblastoma (GBM): CHECKMATE-143. (Abstract 3010) J. H. Sampson, G. Vlahovic, S. Sahebjam, A. M. Omuro, J. M. Baehring, D. A. Hafler, A. D. Voloschin, P. Paliwal, J. Grosso, V. Coric, T. F. Cloughesy, M. Lim, D. A. Reardon Board 337 Safety and efficacy of MEDI4736, an anti-PD-L1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort. (Abstract 3011) N. H. Segal, S. I. Ou, A. S. Balmanoukian, M. G. Fury, E. Massarelli, J. R. Brahmer, J. Weiss, P. Schoffski, S. J. Antonia, C. Massard, D. P. Zandberg, S. Khleif, X. Li, M. Rebelatto, K. Steele, P. B. Robbins, J. A. BlakeHaskins, M. O. Butler Board 338 Efficacy based on tumor PD-L1 expression in KEYNOTE-002, a randomized comparison of pembrolizumab (pembro; MK-3475) versus chemotherapy in patients (pts) with ipilimumab-refractory (IPI-R) advanced melanoma (MEL). (Abstract 3012) I. Puzanov, R. Dummer, J. Schachter, A. C. Pavlick, R. Gonzalez, P. A. Ascierto, K. A. Margolin, O. Hamid, S. S. Agarwala, M. S. Carlino, J. Utikal, M. Lotem, A. Ribas, P. Mohr, C. M. Roach, M. Dolled-Filhart, X. Li, S. Ebbinghaus, S. P. Kang, A. Daud Board 339 An ongoing phase IIIb/IV safety trial of nivolumab (NIVO) in patients (pts) with advanced or metastatic non-small-cell lung cancer (NSCLC) who progressed after receiving 1 or more prior systemic regimens. (Abstract 3013) T. M. Bauer, M. McCleod, J. C. Chandler, G. R. Blumenschein Jr., L. S. Schwartzberg, H. Burris, D. Waterhouse, R. M. Jotte, M. Hussein, D. R. Spigel, D. S. Thompson, X. Li, C. H. Reynolds Board 340 Phase Ib study of MEDI4736, a programmed cell death ligand-1 (PD-L1) antibody, in combination with tremelimumab, a cytotoxic T-lymphocyteassociated protein-4 (CTLA-4) antibody, in patients (pts) with advanced NSCLC. (Abstract 3014) S. J. Antonia, S. B. Goldberg, A. S. Balmanoukian, R. E. Sanborn, K. Steele, R. Narwal, P. B. Robbins, Y. Gu, J. J. Karakunnel, N. A. Rizvi Board 341 Molecular, immune and histopathological characterization of NSCLC based on PDL1 expression on tumor and immune cells and association with response to the anti-PDL1 antibody MPDL3280A. (Abstract 3015) S. N. Gettinger, M. Kowanetz, H. Koeppen, I. I. Wistuba, M. Kockx, E. E. Kadel III, N. A. Rizvi, A. I. Spira, F. R. Hirsch, Z. Boyd, M. Denker, A. Minn, D. S. Shames, A. Sandler, D. S. Chen, P. S. Hegde, D. R. Spigel Board 342 CEA-targeted engineered IL2: Clinical confirmation of tumor targeting and evidence of intra-tumoral immune activation. (Abstract 3016) J. H. Schellens, J. Tabernero, U. N. Lassen, I. Melero, K. Homicsko, G. Argilés, J. Perez Gracia, M. Sorensen, G. Coukos, E. ANGEVIN, H. Joensuu, E. V. Brummelen, C. W. Menke, T. K. Nayak, S. Romagnoli, B. Reis, S. Soehrman Brossard, S. Evers, J. M. Saro Suarez, H. M. Verheul Board 343 A first-in-human dose escalation study of PEGylated recombinant human IL-10 (AM0010) in advanced solid tumors. (Abstract 3017) J. R. Infante, A. Naing, K. P. Papadopoulos, K. A. Autio, P. A. Ott, D. J. Wong, G. S. Falchook, M. R. Patel, S. Pant, M. Whiteside, J. C. Bendell, T. M. Bauer, F. Janku, M. M. Javle, D. S. Hong, M. Oft Board 344 A phase I study of intratumoral injection of ipilimumab and interleukin-2 in patients with unresectable stage III-IV melanoma. (Abstract 3018) R. C. Bowen, S. Meek, M. Williams, K. F. Grossmann, R. I. Andtbacka, T. L. Bowles, J. R. Hyngstrom, S. A. Leachman, D. Grossman, S. L. Holmen, M. W. VanBrocklin, H. T. Khong Board 345 Immunogenomics-based development of personalized immunotherapy for lung cancers. (Abstract 3019) Y. Daigo, A. Takano, K. Teramoto, Y. Nakamura 80 Board 346 Vaccination of MSI-H colorectal cancer patients with frameshift peptide antigens: A phase I/IIa clinical trial. (Abstract 3020) M. Kloor, M. Reuschenbach, J. Karbach, M. Rafiyan, S. Al-Batran, C. Pauligk, E. Jaeger, M. von Knebel Doeberitz Board 347 Phase I, first-in-human trial of LV305 in patients with advanced or metastatic cancer expressing NY-ESO-1. (Abstract 3021) N. Somaiah, M. S. Block, J. W. Kim, G. Shapiro, P. Hwu, J. P. Eder, R. L. Jones, S. Gnjatic, H. Lu, F. J. Hsu, S. Pollack Board 348 Utility of FDG-PET/CT in lymphoma patients undergoing immunotherapy with autologous CTL019 T-cells. (Abstract 3022) N. N. Shah, D. A. Torigian, M. Farwell, W. Hwang, N. V. Frey, S. Nasta, D. J. Landsburg, A. R. Mato, C. H. June, S. J. Schuster, D. L. Porter, J. Svoboda Board 349 Phase I, open-label, multi-ascending dose trial of avelumab (MSB0010718C), an anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors. (Abstract 3023) K. Shitara, Y. Yamada, K. Yoh, Y. Naito, S. Iwasa, N. Yamamoto, A. von Heydebreck, H. Achiwa, T. Doi Board 350 Phase I study of MEDI0639 in patients with advanced solid tumors. (Abstract 3024) G. S. Falchook, A. Dowlati, A. Naing, M. J. Gribbin, D. W. Jenkins, L. L. Chang, D. W. Lai, D. C. Smith Board 351 Baseline serum predictors of clinical response to CTLA4 inhibitor therapy in melanoma patients. (Abstract 3025) K. Homicsko, N. Bordry, D. Gfeller, D. E. Speiser, O. Michielin Board 352 Correlation of gene expression signatures and clinical outcomes in patients with advanced gastric cancer treated with pembrolizumab (MK-3475). (Abstract 3026) V. Shankaran, K. Muro, Y. Bang, R. Geva, D. V. Catenacci, S. Gupta, J. P. Eder, R. Berger, A. Loboda, A. Albright, R. Cristescu, E. Murphy, T. McClanahan, M. Ayers, M. Nebozhyn, J. K. Lunceford, M. Koshiji, K. Heath, J. D. Cheng, H. Chung Board 353 TCR use and cytokine response in PD-1 blockade. (Abstract 3027) J. M. Zaretsky, S. M. Blum, L. Robert Faja, R. O. Emerson, A. Ribas Board 354 Biomarker analysis of patients treated with anti-CD19 chimeric antigen receptor (CAR) T cells. (Abstract 3028) A. Bot, J. Kochenderfer, A. Mardiros, A. Perez, L. Navale, R. Chang, Y. Wei-Shen, S. Yoder, J. Xiao-Chi, S. A. Rosenberg, W. Y. Go, J. S. Wiezorek, M. Roberts, D. D. Chang Board 355 Immunological long-term follow-up of neuroblastoma stage IV patients after anti-GD2 CH14.18 antibody treatment. (Abstract 3029) S. Kayser, V. Icheva, S. Stevanovic, N. Siebert, J. Feucht, H. N. Lode, R. Handgretinger, T. Feuchtinger Board 356 Association of epithelial-mesenchymal transition with an immunosuppressive, inflammatory tumor microenvironment with elevated levels of checkpoint inhibitors in lung adenocarcinoma. (Abstract 3030) Y. Lou, L. Diao, E. R. Parra Cuentas, W. Denning, L. Chen, Y. H. Fan, J. Rodriguez, L. A. Byers, J. Wang, V. Papadimitrakopoulou, C. Behrens, I. I. Wistuba, P. Hwu, J. Heymach, D. L. Gibbons Board 357 Exploratory analysis of clinical and translational factors associated with the inflamed phenotype in HNSCC. (Abstract 3031) N. Rajasekaran, H. E. Kohrt, Z. Zuo, M. K. Keck, A. Khattri, M. W. Lingen, J. P. Kline, T. Gajewski, E. E. Vokes, T. Y. Seiwert Board 358 A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with candida skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2/3. (Abstract 3032) M. Nakagawa, S. L. Stratton, R. Myrick, R. Vaughn, L. M. Donnalley, H. Coleman, M. Mercado, A. MoermanHerzog, H. J. Spencer, W. C. Hitt, G. Low, N. Manning, S. McKelvey, D. Smith, M. Smith, A. Phillips, C. M. Quick, S. K. Jeffus, L. F. Hutchins, W. Greenfield Board 359 Immunotoxin therapy in animal model of HuD antigen positive small cell lung cancer. (Abstract 3033) B. Wang, W. Lu, P. Dowling 81 SATURDAY Saturday, May 30, 2015 Saturday, May 30, 2015 SATURDAY Board 360 Results of the phase IIb part of TIME study evaluating TG4010 immunotherapy in stage IV non-small cell lung cancer (NSCLC) patients receiving first line chemotherapy. (Abstract 3034) E. A. Quoix, F. Forget, Z. Papai-Szekely, C. H. Ottensmeier, J. J. Nemunaitis, E. Felip, L. Crino, A. Szczesna, A. Tavernaro, G. Lacoste, B. Bastien, J. Limacher Board 361 Comprehensive analysis of variation of tumor infiltrating lymphocytes during neoadjuvant chemotherapy in triple-negative breast cancer. (Abstract 3035) C. Castaneda Altamirano, E. A. Mittendorf, P. Arboleda Ezcurra, S. Casavilca Zambrano, M. T. Nunez Butron, Y. Wu, M. Castillo Garcia, K. I. Rojas, V. Villegas Bernaola, C. Belmar Lopez, K. Dolores Cerna, H. L. Gomez, J. E. Abugattas Saba, J. M. Cotrina, A. M. Gonzalez-Angulo, T. Vidaurre Board 362 Phase I/II study of tecemotide cancer immunotherapy for Japanese patients with unresectable stage III non-small cell lung cancer (NSCLC). (Abstract 3036) H. Nokihara, N. Katakami, T. Hida, F. Imamura, H. Sakai, S. Atagi, M. Nishio, C. Helwig, H. Achiwa, T. Tamura Board 363 Pharmacokinetics and myeloid effector cell engagement of an engineered IgA antibody against the epidermal growth factor receptor. (Abstract 3037) T. Valerius, S. Lohse, S. Meyer, M. J. Jansen, L. A. Meulenbroek, M. Nederend, U. Möginger, A. Kretschmer, K. Klausz, S. Derer, P. Sondermann, D. Kolarich, M. Peipp, J. H. Leusen, M. Gramatzki Board 364 Antibody dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody, avelumab (MSB0010718C), on human tumor cells. (Abstract 3038) K. Tsang, B. Boyerinas, C. Jochems, M. Fantini, C. R. Heery, R. A. Madan, J. L. Gulley, J. Schlom Board 365 Phase I study to evaluate the safety and tolerability of MEDI4736, an antiprogrammed cell death ligand-1 (PD-L1) antibody, in Japanese patients with advanced solid tumors. (Abstract 3039) H. Iguchi, N. Nogami, T. Kozuki, T. Matsumoto, K. Tamura, N. Yamamoto, A. Shimomura, Y. Hoshino, Y. Michibata, M. Nii, Y. Fujiwara Board 366 Strategies for clinical development of monoclonal antibodies beyond first-in-man trials: Tested doses and rationale for dose selection. (Abstract 3040) M. Vinches, A. Cuenant, M. Alexandre, A. Durigova, N. Hayaoui, C. Mollevi, L. Gianni, D. Tosi Board 367 Adoptive immunotherapy of acute myeloid leukemia (AML) with allogenic CAR t-cells targeting CD123. (Abstract 3041) R. Galetto, C. Lebuhotel, P. Francon, A. Gouble, J. Smith Board 368 Tremelimumab, a fully human anti-CTLA-4 monoclonal antibody, optimal dosing regimen for patients with unresectable malignant mesothelioma (MM). (Abstract 3042) R. Narwal, A. DiPietro, R. Ibrahim, L. Calabrò, M. Maio, P. B. Robbins, L. Roskos Board 369 T-cell therapy in metastatic melanoma: TIL 1383I TCR transduced T cells after infusion and activity in vivo. (Abstract 3043) C. Regan, J. Clark, T. Moore, K. Moxley, G. Scurti, A. Lau Clark, B. Dropulic, H. Embree, K. Shirai, E. GarrettMayer, M. Li, K. Tobin Vealey, J. M. Eby, C. Le Poole, M. Nishimura Board 370 Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic or locally advanced solid tumors: assessment of safety and tolerability in a phase I, open-label expansion study. (Abstract 3044) K. Kelly, M. R. Patel, J. R. Infante, N. Iannotti, P. Nikolinakos, J. Leach, D. Wang, J. C. Chandler, G. H. Jerusalem, J. S. Gurtler, H. Arkenau, I. Speit, A. von Heydebreck, K. M. Chin, C. R. Heery, J. L. Gulley Board 371 A phase II study of novel three peptides combination with gemcitabine as a first-line therapy for advanced pancreatic cancer (VENUS-PC study). (Abstract 3045) H. Tanaka, N. Suzuki, H. Iguchi, K. Uesugi, K. Hirakawa, R. Amano, A. Aruga, T. Hatori, I. Hidenobu, Y. Umeda, M. Shimada, K. Yoshimatsu, R. Shimizu, H. Ozasa, H. Hayashi, K. Sakata, T. Ueno, H. Furukawa, S. Hazama, M. Oka 82 Board 372 Effect of denileukin diftitox (DD) on vaccine-induced T-cell responses and depletion of Tregs in melanoma. (Abstract 3046) J. J. Luke, Y. Zha, K. Matijevich, T. Gajewski Board 373 Safety and tolerability results from a phase I study of MEDI4736, a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib in patients (pts) with non-small-cell lung cancer (NSCLC). (Abstract 3047) B. C. Creelan, L. Q. Chow, D. Kim, S. Kim, T. Yeh, J. J. Karakunnel, D. L. Gibbons Board 374 Phase II randomized trial of autologous tumor lysate dendritic cell vaccine (ADC) plus best supportive care (BSC) compared with BSC, in pre-treated advanced colorectal cancer patients. (Abstract 3048) J. Maurel, M. CaballeroBaños, J. Mila, J. Tabera, S. Varea, R. Vilana, L. Bianchi, P. Arguis, E. Pineda, G. Carrera, M. Cuatrecasas, D. Páez, M. Martin-Richard, M. Pagés, J. Ayuso, J. Cid, M. Lozano, X. Garcia-Albeniz, A. Castells, R. Vilella Board 375 A subgroup with improved overall survival from the phase 2 IMPACT study: Maintenance therapy of metastatic colorectal cancer patients with the TLR-9 agonist MGN1703. (Abstract 3049) J. Riera-Knorrenschild, D. Arnold, H. Kopp, F. Mayer, H. Kroening, D. Nitsche, J. Kuhlmann, R. Ziebermayr, J. Andel, A. Zurlo, B. Wittig, W. Scheithauer, H. Schmoll Board 376 CD137 co-stimulation and blocking PD-1 enhances NK cell-mediated target cell lysis by CD30/CD16A TandAb AFM13. (Abstract 3050) X. Zhao, N. Rajasekaran, U. Reusch, J. Marschner, M. Treder, H. E. Kohrt Board 377 Long term survival in IMAGE 1 (Immune Modulation And Gemcitabine Evaluation 1), a randomized, open-label phase II trial comparing gemcitabine with and without IMMⴚ101 in advanced pancreatic cancer. (Abstract 3051) A. G. Dalgleish, The IMAGE 1 Trial Investigators Board 378 Effect of human OX40 ligand fusion protein (MEDI6383) on immune cells of the humoral and cell-mediated immune response in a non-human primate model. (Abstract 3052) M. D. Oberst, S. Eck, N. Buss, A. Pierce, H. Park, H. Kim, A. Sylwester, M. Axhelm, L. Picker, A. Weinberg, L. De Haan, S. A. Hammond Board 379 A retrospective analysis of high-dose aldesleukin (HD IL-2) following immune checkpoint blockade (ICB) in metastatic melanoma (MM) and metastatic renal cell carcinoma (mRCC). (Abstract 3053) A. Gunturi, S. Aung, D. F. McDermott, E. I. Buchbinder Board 380 Targeting the Wnt5a--catenin pathway in the melanoma microenvironment to augment checkpoint inhibitor immunotherapy. (Abstract 3054) B. A. Hanks, F. Zhao, K. Evans, A. Holtzhausen, M. Tsutsui, D. Tyler Board 381 Pharmacokinetic profile and receptor occupancy of avelumab (MSB0010718C), an anti-PD-L1 monoclonal antibody, in a phase I, open-label, dose escalation trial in patients with advanced solid tumors. (Abstract 3055) C. R. Heery, G. H. O’Sullivan Coyne, J. L. Marte, H. Singh, L. M. Cordes, R. A. Madan, R. N. Donahue, I. Grenga, L. Lepone, B. Neuteboom, I. Speit, K. M. Chin, J. Schlom, J. L. Gulley Board 382 Human OX40 ligand fusion protein (MEDI6383) as a potent OX40 agonist and immuno-modulator in vitro and in vivo. (Abstract 3056) S. A. Hammond, C. Morris, C. Auge, Q. Du, K. Mulgrew, K. McGlinchey, S. Eck, N. Buss, J. Hair, C. Stracener, L. De Haan, M. Damschroder, A. Weinberg, M. D. Oberst Board 383 In vitro and in vivo killing of AML using tetravalent bispecific CD33/CD3 TandAbs. (Abstract 3057) L. G. Eissenberg, J. K. RItchey, J. A. Fox, U. Reusch, S. Knackmuss, J. Guenot, J. F. DiPersio Board 384 Population pharmacokinetic (popPK) model of pembrolizumab (pembro; MK-3475) in patients (pts) treated in KEYNOTE-001 and KEYNOTE-002. (Abstract 3058) T. C. Gangadhar, J. Mehnert, A. Patnaik, O. Hamid, M. S. Carlino, F. S. Hodi, C. U. Blank, A. Ribas, C. Robert, A. Kondic, M. Ahamadi, T. Freshwater, R. de Greef, M. van Vugt, G. Lubiniecki, S. Ebbinghaus, S. P. Kang, A. Daud 83 SATURDAY Saturday, May 30, 2015 Saturday, May 30, 2015 SATURDAY Board 385 Phosphatidylserine targeting antibody in combination with anti-PD-1 antibody treatment activates infiltrating T lymphocytes of the spleen and tumor microenvironment in pre-clinical models of melanoma and breast cancer. (Abstract 3059) X. Huang, J. Gong, V. Nguyen, S. Yin, C. Baldwin, R. A. Brekken, S. King, J. Hutchins, B. Freimark Board 386 Activation of CD8ⴙ tumor infiltrating lymphocytes by bavituximab in a 3D ex vivo system of lung cancer patients. (Abstract 3060) S. Altiok, M. Mediavilla Valera, J. Kreahling, D. Noyes, T. N. Razabdouski, N. L. Kallinteris, J. Shan, S. J. Antonia Board 387 A phase I/II study of ipilimumab in women with metastatic or recurrent cervical carcinoma: A study of the Princess Margaret and Chicago N01 Consortia. (Abstract 3061) S. Lheureux, M. O. Butler, B. Clarke, M. C. Cristea, L. P. Martin, K. S. Tonkin, G. F. Fleming, A. Tinker, H. W. Hirte, D. Tsoref, H. Mackay, N. C. Dhani, P. Ghatage, N. Pham, V. Motta, L. Wang, K. Karakasis, S. Udagani, H. Streicher, A. M. Oza Board 388 Second generation antihistamines after breast cancer diagnosis to improve prognosis both in patients with ERⴙ and ER- breast cancer. (Abstract 3062) H. L. Olsson, R. Einefors, P. Broberg Board 389 A phase I study of the toll-like receptor 5 (TLR5) agonist, entolimod in patients (pts) with advanced cancers. (Abstract 3063) H. Bakhribah, G. K. Dy, W. Ma, Y. Zhao, M. Opyrchal, A. Purmal, S. Gollnick, W. E. Brady, G. J. Fetterly, N. Ngamphaiboon, T. Reungwetwattana, S. M. Jacob, C. O’Hara, F. Siedlecki, A. Adjei, L. Burdelya, I. Bespalov, L. L. Miller, A. Gudkov, A. A. Adjei Board 390 MyD88/CD40-based costimulation to enhance survival and proliferation of chimeric antigen receptor (CAR)-modified T cells. (Abstract 3064) A. E. Foster, P. Chang, P. Lin, J. Crisostomo, A. Mahendravada, A. Lu, M. Khalil, K. M. Slawin, D. Spencer Board 391 A phase 1 dose-escalation study of IPH2102 (lirilumab, BMS-986015, LIRI), a fully human anti KIR monoclonal antibody (mAb) in patients (pts) with various hematologic (HEM) or solid malignancies (SOL). (Abstract 3065) N. Vey, A. Goncalves, L. Karlin, S. Lebouvier-Sadot, F. Broussais, D. Marie, D. Berton-Rigaud, P. Andre, R. A. Zerbib, R. Buffet, T. Prébet, A. Charbonnier, J. Rey, A. Pigneux, J. Bennouna, N. Boissel, G. A. Salles Board 392 Preclinical efficacy studies using HuMax-Axl-ADC, a novel antibody-drug conjugate targeting Axl-expressing solid cancers. (Abstract 3066) E. C. Breij, S. Verploegen, A. Lingnau, E. N. van den Brink, M. Janmaat, M. Houtkamp, W. Bleeker, D. Satijn, P. Parren Board 393 Significance of PD-L1, IDO-1, and B7-H4 expression in lung cancer. (Abstract 3067) K. A. Schalper, D. E. Carvajal-Hausdorf, J. F. McLaughlin, M. Altan, K. N. Syrigos, R. S. Herbst, D. L. Rimm Board 394 Model-based analysis of the relationship between pembrolizumab (MK-3475) exposure and efficacy in patients with advanced or metastatic melanoma. (Abstract 3068) R. W. Joseph, T. C. Gangadhar, I. Puzanov, C. Robert, O. Hamid, R. Dummer, A. Ribas, J. M. Mehnert, A. Daud, K. A. Celentano, J. A. Lindia, M. S. Chatterjee, D. C. Turner, K. Mayawala, J. Elassaiss-Schaap, D. P. de Alwis, X. Li, S. Ebbinghaus, S. P. Kang, R. Kefford Board 395 UCART19, an allogeneic “off-the-shelf” adoptive T-cell immunotherapy against CD19ⴙ B-cell leukemias. (Abstract 3069) J. Smith, L. Poirot, B. Philip, C. Schiffer-Mannoui, S. Derniame, H. Zhan, S. Stafford, S. Reynier, S. Arnould, A. Gouble, W. Qasim, K. Peggs, M. Pule, D. Sourdive Board 396 Durability and characteristics of objective tumor responses with the innate immune cell modulator Imprime PGG in combination with standard of care frontline treatment for patients (Pts) with metastatic non-squamous NSCLC. (Abstract 3070) W. Engel-Riedel, F. Schneller, M. Wolf, W. Schuette, M. Ma, P. Mattson, J. R. Lowe, A. H. Braun Board 397 Safety of Imprime PGG, a novel innate immune cell modulator, in adults with stage IV non-small cell lung cancer: an integrated analysis of two 84 Saturday, May 30, 2015 Board 398 Safety, immunogenicity, and clinical activity of the immunotherapeutic vaccine, DPX-Survivac, in a Phase 1/1b trial of women with ovarian, fallopian tube, or peritoneal cancer. (Abstract 3072) J. A. Villella, M. K. Wilson, N. L. Berinstein, J. Brown, S. Lheureux, M. O. Butler, J. Ramsahai, K. Odunsi, M. Karkada, J. J. Nemunaitis, M. Morse, T. Pejovic, J. Bentley, G. Weir, L. MacDonald, M. Stanford, T. Burzykowski, R. Nigam, M. Mansour, A. M. Oza Board 399 A first-in-human phase 1 dose-escalating trial of G305 in patients with solid tumors expressing NY-ESO-1. (Abstract 3073) A. Mahipal, K. Odunsi, S. Gnjatic, S. Kim-Schulze, R. T. Kenney, S. Ejadi Board 400 A sugar engineered non-fucosylated anti-CD40 antibody, SEA-CD40, with enhanced immune stimulatory activity alone and in combination with immune checkpoint inhibitors. (Abstract 3074) S. J. Gardai, A. Epp, G. Linares, L. Westendorf, M. K. Sutherland, H. Neff-LaFord, J. G. Drachman, S. Peng, C. Law Board 401 Effect of CD137 stimulation on ibrutinib antagonism of GA101 dependent NK cell-mediated cytotoxicity. (Abstract 3075) N. Rajasekaran, S. Dutt, A. Marabelle, R. Houot, M. Sadaram, J. Hebb, I. Sagiv-Barfi, S. Ambulkar, A. S. Rajapaksa, C. Chester, E. Waller, H. E. Kohrt Board 402 Transfer of anti-breast cancer immunity induced by infusions of bispecific antibody armed T cells and boosted with ex vivo primed T cells after stem cell transplant in metastatic breast cancer patients. (Abstract 3076) A. Thakur, L. G. Lum, R. Rathore, Z. Al-Kadhimi, E. Tomaszewski, D. Schalk, Q. Liu, J. P. Uberti, V. Ratanatharathorn Board 403 First interim exploratory analysis of immune response in patients with advanced non-small cell lung cancer receiving viagenpumatucel-l (HS-110) in combination with low-dose cyclophosphamide in an ongoing phase II trial. (Abstract 3077) R. B. Cohen, D. Morgensztern, W. V. Walsh, L. Bazhenova, A. M. Melnyk, J. T. Beck, J. J. Nemunaitis, T. H. Schreiber, M. L. Price Board 404 An analysis of phase II and III therapeutic cancer vaccine trials and review of the successes and failures behind 10 different vaccine modalities. (Abstract 3078) H. E. Kohrt, A. C. Tan, A. Goubier Board 405 Anti-tumor efficacy and PD-L1 expression in the tumor microenvironment after poxvirus-based active immunotherapy and PD-1 blockade. (Abstract 3079) S. J. Mandl, S. P. Foy, B. Sennino, T. dela Cruz, E. Gordon, F. Kemp, V. Xavier, R. B. Rountree, A. Franzusoff Board 407 Effect of alphavirus vaccine encoding HER2 during concurrent anti-HER2 therapies on induction of oligoclonal T cell and antibody responses against HER2. (Abstract 3081) W. R. Gwin, A. Hobeika, T. Osada, Z. Hartman, Q. Cheng, G. Broadwater, G. G. Kimmick, K. L. Blackwell, M. Morse, K. Lyerly Board 408 Allogeneic myeloma GVAX with lenalidomide in near complete remission to enhance progression free survival. (Abstract 3082) I. Borrello, K. Noonan, A. K. Ferguson, A. Sidorski, L. Rudrarajuraraju, A. Casildo, C. A. Huff Board 409 Pilot study of intratumoral G100, toll-like receptor-4 (TLR4) agonist, therapy in patients with Merkel cell carcinoma (MCC). (Abstract 3083) S. Bhatia, D. Ibrani, N. Vandeven, N. Miller, M. Shinohara, D. Byrd, U. Parvathaneni, E. Shantha, O. K. Afanasiev, M. Donahue, D. M. Koelle, F. J. Hsu, P. Nghiem Board 410 First-in-human dose-escalating trial of E.coli purine nucleoside phosphorylase and fludarabine gene therapy for advanced solid tumors. (Abstract 3084) T. K. Chung, E. Rosenthal, W. B. Parker, P. Allan, L. Clemons, D. Lowman, J. Hong, F. R. Hunt, J. Richman, R. M. Conry, K. Mannion, W. Carroll, L. Nabell, E. J. Sorscher Board 411 An evaluation of local and systemic immune markers following intratumoral administration of a chimeric adenovirus Ad5/3-D24-GMCSF in refractory cancer patients with solid tumors. (Abstract 3085) S. A. Pesonen, T. Ranki, E. 85 SATURDAY randomized phase 2 studies. (Abstract 3071) F. Schneller, W. Engel-Riedel, M. Thomas, J. Kollmeier, P. Sadjadian, M. Wolf, W. Schuette, C. C. Taitt, R. D. Huhn, M. Ma, P. Mattson, J. R. Lowe, A. H. Braun Saturday, May 30, 2015 Jäger, J. Karbach, C. Wahle, T. K. Joensuu, T. Alanko, K. Partanen, K. Kairemo, R. Turkki, N. Linder, J. Lundin, A. Ristimäki, M. Majumder, A. Kumar, C. Heckman, M. Kankainen, A. Hemminki, M. Von Euler, M. E. Jaderberg SATURDAY Board 412 Immunomodulatory effects of OX40 agonists in a defined antigen challenge in cynomolgus macaques. (Abstract 3086) S. L. Lambert, D. Heeke, K. Patton, R. Lin, C. Shambaugh, S. Aslam, L. Yu, F. Zuo, A. Pierce, X. Paliard Board 413a Phase I, open-label study of MEDI0680, an anti-programmed cell death-1 (PD-1) antibody, in combination with MEDI4736, an anti-programmed cell death ligand-1 (PD-L1) antibody, in patients with advanced malignancies. (Abstract TPS3087) O. Hamid, L. Q. Chow, F. Tavakkoli, S. Marshall, M. J. Gribbin, J. J. Karakunnel, J. E. Gray Board 413b A phase I, multicenter, open-label, first-in-human study to evaluate MEDI0680, an anti-programmed cell death-1 antibody, in patients with advanced malignancies. (Abstract TPS3088) J. R. Infante, S. Goel, F. Tavakkoli, S. Marshall, P. B. Robbins, G. D’Angelo, M. J. Gribbin, J. J. Karakunnel, A. Naing Board 414a First-in-human study assessing safety and tolerability of REGN1979, a novel CD20xCD3 bispecific antibody, in patients with CD20ⴙ B-cell malignancies previously treated with anti-CD20 therapy. (Abstract TPS3089) C. M. Brownstein, L. Adriaens, R. Bannerji, J. C. Chavez, R. Levy, S. M. Ansell, R. H. Advani, S. Patel, A. Kostic, P. Trail, I. Lowy, H. E. Kohrt Board 414b Phase I study to evaluate the safety and efficacy of MEDI4736 in combination with tremelimumab in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). (Abstract TPS3090) L. L. Siu, K. P. Papadopoulos, F. Y. Tsai, A. R. Hansen, P. B. Robbins, X. Li, D. W. Lai, J. A. Blake-Haskins, M. G. Fury Board 415a A phase 1b/2, open-label study to evaluate the safety and tolerability of MEDI6469 in combination with immune therapeutic agents or therapeutic mAbs in patients with selected advanced solid tumors or aggressive B-cell lymphomas. (Abstract TPS3091) J. D. Powderly, M. Gutierrez, D. Wang, Y. Chae, D. Mahadevan, F. S. Braiteh, B. S. Glisson, D. Fu, M. Jordan, J. T. McDevitt, M. C. Lanasa, B. D. Curti Board 415b A phase Ib study of neoadjuvant immune biomarker modulation with cetuximab and motolimod in head and neck cancer (HNC). (Abstract TPS3092) B. A. Kansy, S. P. Gibson, R. M. Srivastava, J. K. Bryan, R. M. Hershberg, R. L. Ferris Board 416a A phase I study of MEDI6383, an OX40 agonist, in adult patients with select advanced solid tumors. (Abstract TPS3093) T. M. Bauer, Y. Chae, S. Patel, S. P. D’Angelo, G. R. Blumenschein Jr., J. Norton, C. Pound, M. C. Lanasa, B. D. Curti Board 416b KEYNOTE-055: A phase II trial of single agent pembrolizumab in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) who have failed platinum and cetuximab. (Abstract TPS3094) S. F. Powell, S. V. Liu, A. Sukari, C. H. Chung, J. Bauml, R. I. Haddad, C. K. Gause, M. Niewood, L. L. Gammage, H. Brown, A. Meister, J. D. Cheng, M. M. Gitau Board 417a A Phase II multicenter trial to evaluate combination ipilimumab and highdose IL-2 in patients with unresectable stage III and IV melanoma. (Abstract TPS3095) H. Kaufman, J. Wang, B. D. Curti, J. Clark, M. S. Ernstoff, A. Silk, J. M. Mehnert, A. Zloza, J. Shih, D. F. McDermott Board 417b Phase I study evaluating high dose ADXS11– 001 treatment in women with carcinoma of the cervix. (Abstract TPS3096) S. A. Ghamande, R. Dobbins, L. Marshall, D. Wheatley, C. Prince, D. J. Mauro, J. E. Janik, S. Khleif Board 418a Phase I study of AMG 211/MEDI-565 administered as continuous intravenous infusion for relapsed/refractory gastrointestinal (GI) adenocarcinoma. (Abstract TPS3097) E. De Vries, V. Heinemann, W. M. Fiedler, T. Seufferlein, H. M. Verheul, D. De Groot, J. C. von Einem, S. Ren, K. Cheung, E. Rasmussen, J. Volkland, G. D. Means, A. Kratzer, A. Wolf, S. Stienen 86 Board 418b A randomized multicenter phase Ib/II study to assess the safety and the immunological effect of chemoradiation therapy (CRT) in combination with pembrolizumab (anti-PD1) to CRT alone in patients with resectable or borderline resectable pancreatic cancer. (Abstract TPS3098) M. H. Katz, T. W. Bauer, G. R. Varadhachary, G. R. Petroni, T. Bullock, C. L. Slingluff Jr., O. E. Rahma Board 419a A phase I study to evaluate the safety and tolerability of MEDI4736, an antiprogrammed cell death-ligand-1 (PD-L1) antibody, in combination with tremelimumab in patients with advanced solid tumors. (Abstract TPS3099) P. A. Ott, M. K. Callahan, K. Odunsi, A. J. Park, L. S. Pan, R. R. Venhaus, J. J. Karakunnel, F. S. Hodi, J. D. Wolchok Board 419b “ARMY”: First-in-human study of the humanized, defucosylated monoclonal antibody (mAb) MEN1112/OBT357 targeting CD157 antigen, in relapsed or refractory (R/R) acute myeloid leukemia (AML). (Abstract TPS3100) A. Venditti, D. Breems, V. Havelange, G. Martinelli, S. Baldini, M. Binaschi, A. Crea, E. Leo, C. A. Maggi, S. Manzini, M. Matera, P. Mazzei, C. Rossi, S. Scartoni, A. Scordari, G. Tonini, K. Wilson, A. Capriati, C. Simonelli Board 420a Phase I expansion cohort trial to investigate the safety and clinical activity of avelumab (MSB0010718C) in patients with metastatic or locally advanced solid tumors. (Abstract TPS3101) C. R. Heery, J. R. Infante, N. Iannotti, K. Kelly, P. Nikolinakos, A. von Heydebreck, K. M. Chin, J. L. Gulley Board 420b Genetically engineered NY-ESO-1 specific T cells in HLA-A201ⴙ patients with advanced cancers. (Abstract TPS3102) M. S. Merchant, M. C. Cristea, E. A. Stadtmauer, W. D. Tap, S. P. D’Angelo, S. A. Grupp, T. Holdich, G. Binder-Scholl, B. K. Jakobsen, K. Odunsi, A. Rapoport, C. Mackall Board 421a Phase I/II study of stereotactic body radiation therapy (SBRT) to metastatic lesions in the liver or lung in combination with monoclonal antibody to OX40 in patients with progressive metastatic breast cancer (mBC) after systemic therapy. (Abstract TPS3103) M. Crittenden, A. K. Conlin, N. Moxon, B. D. Curti Board 421b Study of hTERT and IL-12 DNA immunotherapy using electroporation in patients with solid tumors after definitive surgery and adjuvant therapy. (Abstract TPS3104) R. H. Vonderheide, C. Aggarwal, D. L. Bajor, J. Goldenberg, C. Loch, J. C. Lee, J. Yan, M. P. Morrow, A. DeMichele, C. J. Langer, P. J. O’Dwyer, D. B. Weiner, Z. Yang, M. L. Bagarazzi Board 422a In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy. (Abstract TPS3105) T. U. Marron, A. Binder, N. Bhardwaj, S. Kim-Schulze, T. Keler, T. Davis, E. Crowley, A. M. Salazar, J. Brody Board 422b Phase I study of safety and immunogenicity of ADU-623, a live-attenuated Listeria monocytogenes vaccine (⌬AactA/⌬AinlB) expressing EGFRvIII and NY-ESO-1, in patients with WHO grade III/IV astrocytomas. (Abstract TPS3106) M. Crittenden, K. S. Bahjat, R. Li, P. A. Gore, C. Fountain, B. Hanson, J. Skoble, P. Lauer, A. Murphy, T. W. Dubensky Jr., D. G. Brockstedt, W. J. Urba 9:30 AM - 12:00 PM Special Session Opening Session with Conquer Cancer Foundation Top Donors Recognition, Guest Speaker’s Address, Presidential Address, and David A. Karnofsky Memorial Award and Lecture Location: N Hall B1 9:30 AM William Charles Penley, MD Tennessee Oncology Conquer Cancer Foundation: Welcome Remarks and Top Donor Recognition Awards 87 SATURDAY Saturday, May 30, 2015 Saturday, May 30, 2015 9:45 AM Michael E. Porter, PhD Harvard Business School Guest Speaker’s Address: Value-Based Health Care Delivery 10:30 AM Allen S. Lichter, MD, FASCO American Society of Clinical Oncology Introduction of Peter Paul Yu, MD, FACP, FASCO Peter Paul Yu, MD, FACP, FASCO Palo Alto Medical Foundation Presidential Address: Illumination & Innovation—Transforming Data into Learning 11:15 AM Clifford A. Hudis, MD, FACP Memorial Sloan Kettering Cancer Center Introduction of Suzanne Louise Topalian, MD SATURDAY Suzanne Louise Topalian, MD—Award Lecturer The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins David A. Karnofsky Memorial Award and Lecture: PD-1 Pathway Blockade—A Common Denominator for Cancer Therapy 1:00 PM - 4:15 PM Extended Education Session MOC and Lifelong Learning Workshop: ABIM Module 2013—Ticketed Session Location: E451b Jeffrey M. Peppercorn, MD, MPH Massachusetts General Hospital Lecia V. Sequist, MD, MPH Massachusetts General Hospital Cancer Center Thomas W. Flaig, MD University of Colorado Cancer Center 1:15 PM - 2:30 PM Poster Discussion Session Breast Cancer—HER2/ER Location: N Hall B1 Ian E. Krop, MD, PhD—Co-Chair Dana-Farber Cancer Institute Patrick G. Morris, MD, MSC—Co-Chair Beaumont Hospital 1:15 PM William John Gradishar, MD (Discussion of Abstract(s) 513-515) Lurie Comprehensive Cancer Center of Northwestern University Adjuvant Endocrine Therapy: For Whom, How Long, and at What Cost? 1:27 PM Panel Question and Answer 1:33 PM Jorge Reis-Filho, MD, PhD (Discussion of Abstract(s) 516 –518) Memorial Sloan Kettering Cancer Center The Next Chapter in Biomarker Research 1:45 PM Panel Question and Answer 1:51 PM Rebecca Alexandra Dent, MD (Discussion of Abstract(s) 519 –521) National Cancer Center Singapore Individualizing Treatment in DNA Repair-Deficient Breast Cancer 2:03 PM Panel Question and Answer 88 Saturday, May 30, 2015 2:09 PM Javier Cortes, MD, PhD (Discussion of Abstract(s) 522–524) Vall D’Hebron University Hospital Early-Phase Research on Novel Agents 2:21 PM Panel Question and Answer Posters discussed in this session are on display in the Breast Cancer—HER2/ER Poster Session. See page 51 for poster information. Networking with presenters and discussants will take place right outside of the session room after the discussion. 1:15 PM - 2:30 PM Poster Discussion Session SATURDAY Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics Location: S406 Gerald Steven Falchook, MD, MS—Co-Chair Sarah Cannon Research Institute At HealthONE Robin Kate Kelley, MD—Co-Chair UCSF Helen Diller Family Comprehensive Cancer Center 1:15 PM David Paul Carbone, MD, PhD (Discussion of Abstract(s) 2509-2511) The Ohio State Univeristy Comprehensive Cancer Center Novel Strategies for Attacking Epidermal Growth Factor Receptor 1:27 PM Panel Question and Answer 1:33 PM Robert Wesolowski, MD (Discussion of Abstract(s) 2512–2514) The Ohio State University Exploiting Metabolic Processes as Therapeutic Targets 1:45 PM Panel Question and Answer 1:51 PM James F. Spicer, MD (Discussion of Abstract(s) 2515–2517) King’s College London Signals in Subpopulations: Molecularly Enriched Clinical Trials 2:03 PM Panel Question and Answer 2:09 PM Boon C. Goh, MD (Discussion of Abstract(s) 2518 –2520) National University Hospital Targeting the Interface of the Microenvironment and Immune System 2:21 PM Panel Question and Answer Posters discussed in this session are on display in the Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics Poster Session. See page 70 for poster information. Networking with presenters and discussants will take place right outside of the session room after the discussion. 1:15 PM - 2:30 PM Special Session Pediatric Oncology Award and Lecture Location: S504 Clifford A. Hudis, MD, FACP Memorial Sloan Kettering Cancer Center Presentation of the 2015 Pediatric Oncology Award Stephen E. Sallan, MD Dana-Farber Cancer Institute/Harvard Medical School An Autobiography of “We” 89 Saturday, May 30, 2015 1:15 PM - 2:30 PM Education Session Adjuvant Therapy for Stage II and III Colon Cancer: Patient Selection, Optimal Agents, and Chemoprevention Location: E Hall D2 Zsofia Kinga Stadler, MD Memorial Sloan Kettering Cancer Center Chemotherapy for Stage II Colon Cancer SATURDAY Hanna Kelly Sanoff, MD, MPH The University of North Carolina at Chapel Hill School of Medicine Chemotherapy for Stage III Jeffrey A. Meyerhardt, MD, MPH—Chair Dana-Farber Cancer Institute Chemoprevention Strategies Panel Question and Answer 1:15 PM - 2:30 PM Education Session Challenges in Managing and Coordinating Care in Different Settings for Geriatric Patients with Cancer Location: S100a Arti Hurria, MD—Chair City of Hope Incorporating Geriatric Assessment in Decision Making for Elderly Patients with Cancer Miriam B. Rodin, MD, PhD St. Louis University Medical School Optimizing Communication between Geriatric Care Providers and Oncologists Heidi D. Klepin, MD, MS Wake Forest University, School of Medicine Hands-on Management: Chemotherapy Dosing, Polypharmacy, and Toxicity Assessment in Elderly Patients with Cancer Panel Question and Answer 1:15 PM - 2:30 PM Education Session How to Translate the Wealth of Information in The Cancer Genome Atlas into Improved Outcomes: Data Mining and Biologic Validation Location: E450 Charles M. Perou, PhD—Chair The University of North Carolina at Chapel Hill What Can I Learn about My Tumor by Looking at Yours? The PAN-CAN Project William C. Hahn, MD, PhD Dana-Farber Cancer Institute From TCGA to Signaling Networks: Moving Along the Translational Road 90 Saturday, May 30, 2015 Lynda Chin, MD The University of Texas MD Anderson Cancer Center Biological Validation of Potentially Druggable Targets from The Cancer Genome Atlas Panel Question and Answer 1:15 PM - 2:30 PM Education Session Positive Trials in Lung Cancer: Statistical versus Real Clinical Significance Location: E Hall D1 SATURDAY Rogerio Lilenbaum, MD Yale University School of Medicine Recent Positive Clinical Trials and Data in Context of Study Results, Design, and Endpoints Natasha B. Leighl, MD, MMSc, FRCPC—Chair Princess Margaret Cancer Centre Clinically Meaningful Positive Trials in Lung Cancer Incorporating ASCO Benchmarks, Disparate Populations, the Real-Life Setting, and Community Marcus A. Neubauer, MD The US Oncology Network, McKesson Specialty Health Value in Lung Cancer Care: The Use of Standardized Pathways and Cost-Effectiveness Panel Question and Answer 1:15 PM - 2:30 PM Education Session The Challenge to Stay Current: Incorporating Technology into Practice Location: S404 Jeremy Warner, MD, MS—Chair Vanderbilt-Ingram Cancer Center Advances in Website Information Resources to Aid in Clinical Practice Michael A. Thompson, MD, PhD Aurora Research Institute, Aurora Health Care Using Social Media to Learn and Communicate Laura E. Strong, PhD Quintessence Biosciences, Inc. Electronic Tools for Patient-Reported Outcomes Panel Question and Answer 1:15 PM - 2:30 PM Meet the Professor Session The Older Patient with Glioblastoma—Ticketed Session Location: E451a Wolfgang Wick, MD University of Heidelberg Medical Center Fabio Massaiti Iwamoto, MD Columbia University Medical Center 91 Saturday, May 30, 2015 1:15 PM - 4:15 PM Oral Abstract Session Cancer Prevention, Genetics, and Epidemiology Location: S100bc Habibul Ahsan, MD, MMedSc—Co-Chair The University of Chicago Adam J. Olszewski, MD—Co-Chair Memorial Hospital of Rhode Island SATURDAY 1:15 PM Final updated results of the NRG Oncology/NSABP Protocol P-2: Study of Tamoxifen and Raloxifene (STAR) in preventing breast cancer. (Abstract 1500) D. L. Wickerham, R. S. Cecchini, V. G. Vogel, J. P. Costantino, W. M. Cronin, T. B. Bevers, L. Fehrenbacher, E. R. Pajon, J. L. Wade III, A. Robidoux, R. G. Margolese, J. M. James, C. D. Runowicz, P. A. Ganz, S. E. Reis, W. J. McCaskill-Stevens, L. G. Ford, V. C. Jordan, N. Wolmark 1:27 PM Vasomotor symptoms, BMI, and adherence to tamoxifen in the National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Prevention Trial (P-1). (Abstract 1501) F. L. Walcott, S. R. Land, J. P. Costantino, D. Midthune, B. K. Dunn 1:39 PM Estrogen alone and health outcomes in black women by African ancestry. (Abstract 1502) R. T. Chlebowski, W. Barrington, A. K. Aragaki, J. E. Manson, G. Sarto, M. O’Sullivan, J. A. Cauley, L. Qi, R. B. Wallace, R. L. Prentice 1:51 PM Powel Brown, MD, PhD (Discussion of Abstract(s) 1500 –1502) The University of Texas MD Anderson Cancer Center Chemoprevention in Breast Cancer: Large-Trial Results 2:03 PM Panel Question and Answer 2:15 PM Predisposing germline mutations in high grade ERⴙHER2- breast cancer (BC) patients diagnosed (Dx). (Abstract 1503) J. E. Garber, N. M. Tung, E. P. Elkin, B. Allen, A. Hartman, N. Singh, R. J. Wenstrup, E. P. Winer, N. U. Lin 2:27 PM Uterine cancer (Ut Ca) following risk-reducing salpingo-oophorectomy (RRSO) in women with BRCA mutations (BRCAⴙ): A multicenter, prospective study. (Abstract 1504) C. A. Shu, M. C. Pike, A. R. Jotwani, T. M. Friebel, R. A. Soslow, D. A. Levine, M. E. Robson, J. A. Konner, J. L. Blum, S. L. Neuhausen, J. E. Garber, M. B. Daly, C. Isaacs, R. A. Eeles, P. A. Ganz, C. Aghajanian, K. Offit, S. M. Domchek, T. R. Rebbeck, N. D. Kauff 2:39 PM Initial results of a prospective, multicenter trial to study inherited lung cancer risk associated with germline EGFR T790M: INHERIT EGFR. (Abstract 1505) G. R. Oxnard, J. C. Heng, E. J. Root, I. R. Rainville, A. L. Sable-Hunt, K. P. Shane-Carson, D. P. Carbone, G. L. Wiesner, J. E. Garber 2:51 PM James M. Ford, MD (Discussion of Abstract(s) 1503–1505) Stanford University School of Medicine New Familial Syndromes: Building New Cohorts and Interventions 3:03 PM Panel Question and Answer 3:15 PM Statin use and all-cancer mortality: Prospective results from the Women’s Health Initiative. (Abstract 1506) A. Wang, A. K. Aragaki, J. Y. Tang, A. W. Kurian, J. E. Manson, R. T. Chlebowski, M. S. Simon, P. M. Desai, S. WassertheilSmoller, S. Liu, S. Kritchevsky, H. A. Wakelee, M. L. Stefanick 3:27 PM Post-diagnosis BMI and physical activity in association with triple-negative breast cancer prognosis: Results from 5 prospective cohorts. (Abstract 1507) S. J. Nechuta, B. J. Caan, W. Y. Chen, M. Dwek, M. Gao, S. Flatt, E. Poole, R. E. Patterson, J. P. Pierce, C. Robertson, R. Swann, W. Zheng, X. Shu 92 Saturday, May 30, 2015 3:39 PM Alcohol consumption and prognosis in patients with stage III colon cancer: A correlative analysis of phase III trial NCCTG N0147 (Alliance). (Abstract 1508) A. I. Phipps, Q. Shi, P. J. Limburg, G. D. Nelson, D. J. Sargent, F. A. Sinicrope, E. Chan, S. Gill, R. M. Goldberg, M. S. Kahlenberg, S. Nair, A. F. Shields, P. A. Newcomb, S. R. Alberts 3:51 PM John A. Baron, MD (Discussion of Abstract(s) 1506 –1508) The University of North Carolina at Chapel Hill The Association among Lifestyle, Cancer Risk, and Outcomes 4:03 PM Panel Question and Answer SATURDAY 1:15 PM - 4:15 PM Oral Abstract Session Health Services Research and Quality of Care Location: S102 Helen M. Parsons, PhD, MPH—Co-Chair The University of Texas Health Science Center at San Antonio Ann Partridge, MD, MPH—Co-Chair Dana-Farber Cancer Institute 1:15 PM The Technology Enhanced Navigation (TEN) Trial among low-income patients with breast cancer. (Abstract 6500) K. J. Helzlsouer, S. Appling, S. Scarvalone, S. Manocheh, L. Gallicchio, R. MacDonald, D. Henninger, A. Varanasi 1:27 PM Financial burden of cancer clinical trials: Impact of an equity program intervention. (Abstract 6501) R. D. Nipp, D. Finkelstein, E. Powell, L. Vittorio, N. Birrer, B. A. Chabner, H. Lee, B. Moy 1:39 PM Trends in resource utilization and costs during implementation of a lay navigation program. (Abstract 6502) G. B. Rocque, M. Pisu, B. E. Jackson, E. A. Kvale, A. Acemgil, R. A. Taylor, W. Demark-Wahnefried, K. Kenzik, Y. Li, M. Martin, N. Lisovicz, K. Meneses, M. Fouad, E. E. Partridge 1:51 PM Ann H. Partridge, MD, MPH (Discussion of Abstract(s) 6500-6502) Dana-Farber Cancer Institute Interventions to Improve Equity in Cancer Care Delivery 2:03 PM Panel Question and Answer 2:15 PM How should we estimate costs of care attributable to cancer? (Abstract 6503) A. B. Chen, L. Li, A. Cronin, G. Brooks, B. D. Kavanagh, D. Schrag 2:27 PM Cost of chemotherapy for metastatic colorectal cancer with either bevacizumab or cetuximab: Economic analysis of CALGB/SWOG 80405. (Abstract 6504) D. Schrag, A. C. Dueck, M. J. Naughton, D. Niedzwiecki, C. Earle, J. E. Shaw, A. Grothey, H. S. Hochster, C. D. Blanke, A. P. Venook 2:39 PM Necitumumab in metastatic squamous non-small cell lung cancer (mSqNSCLC): Establishing a value-based cost. (Abstract 6505) D. A. Goldstein, Q. Chen, T. Ayer, D. H. Howard, J. Lipscomb, S. S. Ramalingam, F. R. Khuri, C. Flowers 2:51 PM Peter Bach, MD (Discussion of Abstract(s) 6503– 6505) Memorial Sloan Kettering Cancer Center Cost and Value in Cancer Treatment Choice 3:03 PM Panel Question and Answer 3:15 PM Value of information analyses for real-time prioritization decisions within a cancer clinical trials cooperative group. (Abstract 6506) C. S. Bennette, S. D. Ramsey, D. L. Veenstra, A. Basu, J. J. Carlson 3:27 PM Physician-driven variation in non-recommended imaging for women with early stage breast cancer. (Abstract 6507) A. N. Lipitz Snyderman, C. S. Sima, E. B. Elkin, C. L. Atoria, C. Anderson, V. S. Blinder, P. Bach 93 Saturday, May 30, 2015 3:39 PM Prevalence and consequences of second opinions from medical oncologists for early-stage breast cancer: Results from the iCanCare study. (Abstract 6508) A. W. Kurian, C. R. Friese, I. Bondarenko, R. Jagsi, S. J. Katz 3:51 PM Caprice Christian Greenberg, MD, MPH (Discussion of Abstract(s) 6506 – 6508) University of Wisconsin School of Medicine and Public Health Decision Making in Settings of Uncertainty 4:03 PM Panel Question and Answer 1:15 PM - 4:15 PM Oral Abstract Session SATURDAY Leukemia, Myelodysplasia, and Transplantation Location: E Arie Crown Theater Joseph G. Jurcic, MD—Co-Chair Columbia University Medical Center To Be Determined—Co-Chair 1:15 PM Correlation of acute myeloid leukemia (AML) stem cell phenotype with cytogenetic/molecular features and prognosis. (Abstract 7000) J. M. Gerber, J. F. Zeidner, S. Morse, A. Blackford, B. Perkins, B. Yanagisawa, H. Zhang, L. Morsberger, J. E. Karp, Y. Ning, C. D. Gocke, G. L. Rosner, B. Smith, R. J. Jones 1:25 PM Association between KIR genes and risk of MDS. (Abstract 7001) M. Daher, C. Sobieski, D. Marin, T. Sekine, E. J. Shpall, R. E. Champlin, H. M. Kantarjian, G. Garcia-Manero, K. Rezvani 1:35 PM The international Prognostic Index for patients with CLL (CLL-IPI): An international meta-analysis. (Abstract 7002) N. Kutsch, J. Bahlo, J. C. Byrd, H. Dohner, B. Eichhorst, M. Else, C. Geisler, M. R. Grever, S. Leprêtre, M. Bergman, D. S. Neuberg, D. Oscier, R. Rosenquist, T. Robak, T. D. Shanafelt, S. Stilgenbauer, M. J. Hallek, International CLL-IPI working group 1:45 PM Wendy Stock, MD (Discussion of Abstract(s) 7000 –7002) The University of Chicago Medical Center New Biomarkers and Prognostic Indicators in Leukemia and Myelodysplastic Syndrome 1:57 PM Panel Question and Answer 2:07 PM Results of a first-in-human, phase I/II trial of ASP2215, a selective, potent inhibitor of FLT3/Axl in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML). (Abstract 7003) M. J. Levis, A. E. Perl, J. K. Altman, J. E. Cortes, E. K. Ritchie, R. A. Larson, C. C. Smith, E. S. Wang, S. A. Strickland, M. R. Baer, M. R. Litzow, D. Claxton, G. J. Schiller, C. Ustun, C. Liu, S. Gill, B. Sargent, E. Bahceci 2:17 PM Clinical activity of ERY001 (erythrocyte encapsulated l-asparaginase) and native l-asparaginase (L-ASP) in combination with COOPRALL regimen in phase III randomized trial in patients with relapsed acute lymphoblastic leukemia (ALL). (Abstract 7004) Y. Bertrand, A. Baruchel, X. G. Thomas, N. Blin, E. Tavernier Tardy, Y. Perel, N. Vey, V. Gandemer, V. Cacheux, F. Mazingue, E. Raffoux, G. Plat, M. Poiree, J. Stephan, A. Auvrignon, D. Plantaz, I. Pellier, C. Bonin, I. El-Hariry, A. Ferster 2:27 PM Ibrutinib combined with bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): First results from a randomized, double-blind, placebo-controlled, phase III study. (Abstract LBA7005) A. A. Chanan-Khan, P. Cramer, F. Demirkan, G. Fraser, R. S. Silva, H. Pylypenko, S. Grosicki, A. Janssens, A. Pristupa, J. Mayer, M. Dilhuydy, J. Loscertales, N. L. Bartlett, A. Avigdor, S. Rule, S. Sun, M. Mahler, M. Salman, A. J. Howes, M. J. Hallek 94 2:37 PM Results of the PERSIST-1 phase III study of pacritinib (PAC) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia-myelofibrosis (PET-MF). (Abstract LBA7006) R. A. Mesa, M. Egyed, A. Szoke, A. Suvorov, A. Perkins, J. Mayer, P. Ganly, E. Jourdan, H. C. Schouten, P. Tosi, C. M. Farber, P. Zachee, C. Scheid, J. P. Dean, P. Cernohous, J. Nangalia, J. Kiladjian, A. M. Vannucchi, A. Mead, C. N. Harrison 2:47 PM Lloyd Earl Damon, MD (Discussion of Abstract(s) 7003-LBA7006) University of California, San Francisco Advancements in the Therapy of Hematologic Malignancies 2:59 PM Panel Question and Answer 3:09 PM Long-term follow-up of patients with acute myelogenous leukemia receiving an autologous telomerase-based dendritic cell vaccine. (Abstract 7007) H. J. Khoury, R. Collins, W. G. Blum, P. J. Stiff, J. Lebkowski, E. Wirth III, K. Nishimoto, J. F. DiPersio 3:19 PM Allogeneic transplantation for myelofibrosis: Final analysis of a prospective study after a median follow up of 5 years. (Abstract 7008) U. R. Popat, R. L. Bassett Jr., J. Chen, A. M. Alousi, P. Anderlini, S. O. Ciurea, C. Hosing, R. B. Jones, P. Kebriaei, I. F. Khouri, S. Konoplev, M. J. De Lima, Y. Nieto, B. Oran, M. H. Qazilbash, G. Rondon, E. J. Shpall, S. Verstovsek, B. Andersson, R. E. Champlin 3:29 PM Association of reduced intensity conditioning (RIC) allograft (alloHCT) as first transplant approach in relapsed/refractory grade 3(G-3) follicular lymphoma (FL) with improved outcomes in long-term survivors. (Abstract 7009) E. Klyuchnikov, U. Bacher, N. Kröger, P. Hari, K. W. Ahn, D. G. Maloney, S. M. Smith, A. M. Sureda, J. Carreras, M. Hamadani 3:39 PM Efficacy and safety of CD19-targeted 19 –28z CAR modified T cells in adult patients with relapsed or refractory B-ALL. (Abstract 7010) J. H. Park, I. Riviere, X. Wang, Y. Bernal, T. Purdon, E. Halton, K. J. Curran, C. S. Sauter, M. Sadelain, R. J. Brentjens 3:49 PM Michael R. Bishop, MD, FACP (Discussion of Abstract(s) 7007-7010) The University of Chicago Medical Center Cellular Therapies Including Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T cells for Hematologic Malignancies 4:01 PM Panel Question and Answer 1:15 PM - 4:15 PM Oral Abstract Session Melanoma/Skin Cancers Location: E354b Axel Hauschild, MD—Co-Chair University of Kiel Sekwon Jang, MD—Co-Chair Inova Comprehensive Cancer and Research Institute 1:15 PM Oral nicotinamide to reduce actinic cancer: A phase 3 double-blind randomized controlled trial. (Abstract 9000) A. J. Martin, A. Chen, B. Choy, P. F. Penas, G. Halliday, R. Dalziell, C. McKenzie, R. A. Scolyer, H. M. Dhillon, J. L. Vardy, G. St George, N. Chinniah, D. Damian 1:27 PM Long term follow up of survival in a randomised trial of wide or narrow excision margins in high risk primary melanoma. (Abstract 9001) A. J. Hayes, L. Maynard, R. A’Hern, G. Coombes, J. Newton-Bishop, M. Timmons, M. Cook, J. Theaker, J. Bliss, J. M. Thomas 95 SATURDAY Saturday, May 30, 2015 Saturday, May 30, 2015 SATURDAY 1:39 PM Survival of SLNB-positive melanoma patients with and without complete lymph node dissection: A multicenter, randomized DECOG trial. (Abstract LBA9002) U. Leiter, R. Stadler, C. Mauch, W. Hohenberger, N. Brockmeyer, C. Berking, C. Sunderkötter, M. Kaatz, K. Schulte, P. Lehmann, T. Vogt, J. Ulrich, R. Herbst, W. Gehring, J. Simon, U. Keim, C. Garbe 1:51 PM Surveillance imaging with FDG-PET in the follow-up of melanoma patients at high risk of relapse. (Abstract 9003) J. H. Lewin, A. Sanelli, I. Walpole, D. Kee, M. A. Henderson, D. Speakman, J. Spillane, D. E. Gyorki, V. Estall, L. Te Marvelde, K. Pope, M. Chua, G. A. McArthur, R. J. Hicks, M. J. Shackleton 2:03 PM Daniel G. Coit, MD (Discussion of Abstract(s) 9000 –9003) Memorial Sloan Kettering Cancer Center Primary Prevention and Surgical Management of Early-Stage Skin Cancer 2:15 PM Panel Question and Answer 2:27 PM Clinical response, progression-free survival (PFS), and safety in patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI) vs IPI monotherapy in CheckMate 069 study. (Abstract 9004) F. S. Hodi, M. A. Postow, J. A. Chesney, A. C. Pavlick, C. Robert, K. F. Grossmann, D. F. McDermott, G. P. Linette, N. Meyer, J. K. Giguere, S. S. Agarwala, M. F. Shaheen, M. S. Ernstoff, D. R. Minor, A. Salama, M. H. Taylor, P. A. Ott, C. E. Horak, P. Gagnier, J. D. Wolchok 2:39 PM Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001. (Abstract 9005) A. Daud, A. Ribas, C. Robert, F. S. Hodi, J. D. Wolchok, A. M. Joshua, W. Hwu, J. S. Weber, T. C. Gangadhar, R. W. Joseph, R. S. Dronca, A. Patnaik, H. M. Zarour, R. Kefford, J. A. Lindia, X. Li, S. Ebbinghaus, S. P. Kang, O. Hamid 2:51 PM Svetomir Markovic, MD, PhD (Discussion of Abstract(s) 9004 –9005) Mayo Clinic PD-1 Inhibition in Advanced Melanoma 3:03 PM Panel Question and Answer 3:15 PM Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM: Phase III study of cobimetinib (cobi) plus vemurafenib (vem) in advanced BRAF-mutated melanoma. (Abstract 9006) J. M. Larkin, Y. Yan, G. A. McArthur, P. A. Ascierto, G. Liszkay, M. Maio, M. Mandalà, L. V. Demidov, D. Stroyakovskiy, L. Thomas, L. De La Cruz-Merino, V. Atkinson, C. Dutriaux, C. Garbe, M. Wongchenko, I. A. Rooney, I. Chang, S. P. Hack, B. Dréno, A. Ribas 3:27 PM A phase Ib/II study of BRAF inhibitor (BRAFi) encorafenib (ENCO) plus MEK inhibitor (MEKi) binimetinib (BINI) in cutaneous melanoma patients naive to BRAFi treatment. (Abstract 9007) R. J. Sullivan, J. S. Weber, S. P. Patel, R. Dummer, W. H. Miller Jr., D. Cosgrove, M. S. Carlino, D. S. Tan, C. Lebbe, T. Cipani, E. Élez, H. Maacke, P. Nikolopoulos, M. Aout, L. A. De Parseval, P. A. Ascierto 3:39 PM BRAF inhibitor acquired resistance: A multicenter meta-analysis of the spectrum and clinical implications of resistance mechanisms. (Abstract 9008) D. B. Johnson, A. M. Menzies, L. Zimmer, Z. Eroglu, F. Ye, S. Zhao, A. Sucker, H. Rizos, W. Hugo, R. Gutzmer, R. Kefford, H. Gogas, X. Kong, R. A. Scolyer, L. A. Garraway, J. A. Sosman, A. Ribas, R. Lo, G. V. Long, D. Schadendorf 3:51 PM Michael A. Davies, MD, PhD (Discussion of Abstract(s) 9006 –9008) The University of Texas MD Anderson Cancer Center Response and Resistance with BRAF/MEK Inhibition 4:03 PM Panel Question and Answer 96 Saturday, May 30, 2015 1:15 PM - 4:45 PM Poster Session Genitourinary (Prostate) Cancer Location: S Hall A Board 1 Phase III SYNERGY trial: Docetaxel ⴙ/- custirsen and overall survival in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and poor prognosis. (Abstract 5009) K. N. Chi, C. S. Higano, B. A. Blumenstein, J. A. Reeves, S. Feyerabend, G. Gravis, J. Ferrero, C. Jacobs, J. S. De Bono, SYNERGY Investigators Board 2 A multi-institutional randomized phase II study (NCT01505868) of cabazitaxel (CAB) plus or minus carboplatin (CARB) in men with metastatic castrationresistant prostate cancer (mCRPC). (Abstract 5010) P. G. Corn, S. Tu, A. J. Zurita, S. K. Subudhi, J. C. Araujo, J. Kim, E. Jonasch, L. C. Pagliaro, A. O. Siefker-Radtke, J. Wang, X. Wang, E. I. Heath, C. Logothetis, A. Aparicio Board 3 Efficacy analysis of a phase III study of androgen deprivation therapy (ADT) ⴙ/- docetaxel (D) for men with biochemical relapse (BCR) after prostatectomy. (Abstract 5011) M. J. Morris, P. Hilden, M. E. Gleave, A. J. Armstrong, M. A. Carducci, F. Saad, E. S. Dayan, J. Filipenko, I. Acosta, G. Heller, H. I. Scher Board 4 Effects of radium-223 dichloride (Ra-223) with docetaxel (D) vs D on prostatespecific antigen (PSA) and bone alkaline phosphatase (bALP) in patients (pts) with castration-resistant prostate cancer (CRPC) and bone metastases (mets): A phase 1/2a clinical trial. (Abstract 5012) M. J. Morris, C. S. Higano, H. I. Scher, C. Sweeney, E. S. Antonarakis, D. H. Shevrin, C. J. Ryan, Y. Loriot, K. Fizazi, N. Pandit-Taskar, J. E. Garcia-Vargas, K. Lyseng, M. Bloma, J. A. Carrasquillo Board 5 Association of SLCO transport genes with intraprostatic abiraterone (ABI) levels and pathologic outcomes in men with high-risk localized prostate cancer (PCa). (Abstract 5013) E. A. Mostaghel, E. Cho, J. L. Wright, M. Loda, B. Marck, A. M. Matsumoto, D. Tamae, T. M. Penning, S. P. Balk, P. W. Kantoff, P. Nelson, M. Taplin, R. B. Montgomery Board 6 EARLY CTC decline as a biomarker of response to treatment in castrationresistant prostate cancer (CRPC): Analysis of the COU-AA-301 and IMMC38 trials. (Abstract 5014) D. Lorente, D. Olmos, J. Mateo, D. Bianchini, G. Seed, P. Flohr, M. Crespo, I. Figueiredo, S. Miranda, K. Baeten, T. Pitfield, A. Molina, T. Kheoh, R. T. Mccormack, H. I. Scher, J. S. De Bono Board 7 Genomic analysis of circulating cell-free DNA (cfDNA) to investigate mechanisms of primary and acquired resistance to enzalutamide (ENZ) in metastatic castration-resistant prostate cancer (mCRPC). (Abstract 5015) A. Azad, A. Wyatt, S. Volik, A. Haegert, F. Mo, S. Le Bihan, R. H. Bell, S. A. Anderson, B. McConeghy, R. Shukin, M. E. Gleave, C. Collins, K. N. Chi Board 8 Validation of a genomic classifier for prediction of metastasis following postoperative salvage radiation therapy. (Abstract 5016) R. Den, E. Davicioni, V. Choeurng, L. Howard, A. de Hoedt, M. Du Plessis, K. Yousefi, L. L. Lam, C. Buerki, E. J. Trabulsi, A. Dicker, J. Karnes, S. J. Freedland Board 9 Progression of low- to high-grade prostate cancer: Molecular profiling of tissue obtained by serial targeted biopsy. (Abstract 5017) G. S. Palapattu, A. K. Cani, J. Huang, D. H. Hovelson, D. Lu, D. Margolis, S. Natarajan, R. Mehra, J. S. Montgomery, T. M. Morgan, S. A. Tomlins, L. S. Marks Board 10 Combination statin/metformin and prostate cancer specific mortality: A population-based study. (Abstract 5018) G. L. Lu-Yao, Y. Lin, D. Moore, J. Graff, A. Stroup, K. McGuigan, S. Crystal, S. Amin, K. Demissie, R. S. DiPaola 97 SATURDAY Abstracts 5009 –5020 will be discussed during the Genitourinary (Prostate) Cancer Poster Discussion Session. See page 134 for session information. Saturday, May 30, 2015 SATURDAY Board 11 A phase III trial of short-term androgen deprivation therapy in intermediaterisk prostate cancer treated with radiotherapy. (Abstract 5019) A. Nabid, N. Carrier, E. Vigneault, L. Souhami, C. Lemaire, M. Brassard, B. Bahoric, R. Archambault, F. Vincent, T. Nguyen-Huynh Board 12 HSD3B1 and resistance to androgen deprivation therapy in prostate cancer. (Abstract 5020) J. W. Hearn, G. AbuAli, C. Magi-Galluzzi, C. A. Reddy, K. Chang, E. A. Klein, N. Sharifi Board 13 Association of the prostate cancer risk mutation G84E in HOXB13 with the subtype of ETS fusion negative adenocarcinoma with early age of diagnosis. (Abstract 5021) T. J. Schnoeller, M. Luedeke, A. Rinckleb, J. L. Stanford, L. Fitzgerald, J. Schleutker, T. Wahlfors, R. A. Eeles, Z. Kote-Jarai, S. Weikert, H. Krause, K. Herkommer, J. Hoegel, C. Maier Board 14 Project Data Sphere: A first look at prostate cancer including concomitant medication use, prognosis, and toxicity. (Abstract 5022) A. M. Joshua, B. Gill, L. Khoja, M. Pintilie, K. Abdallah Board 15 PET imaging with 68Gallium-labelled ligand of prostate-specific membrane antigen (68Ga-HBED-PSMA) for staging of biochemical recurrent prostate cancer after radical prostatectomy. (Abstract 5023) T. Maurer, J. Gschwend, H. Wester, M. Souvatzoglou, A. Beer, K. Holzapfel, G. Weirich, B. Haller, H. Kübler, M. Schwaiger, M. Eiber Board 16 Statin use at the time of initiation of androgen deprivation therapy and time to progression in patients with hormone-sensitive prostate cancer. (Abstract 5024) L. C. Harshman, X. Wang, M. Nakabayashi, W. Xie, L. B. Valenca, L. Werner, Y. Yu, A. Kantoff, C. Sweeney, L. A. Mucci, M. Pomerantz, G. M. Lee, P. W. Kantoff Board 17 Phase II trial of the PI3 kinase inhibitor BKM120 with or without enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC). (Abstract 5025) A. J. Armstrong, S. Halabi, P. Healy, J. J. Alumkal, E. Y. Yu, C. Winters, C. Hobbs, C. Soleau, R. Slottke, K. Mundy, D. J. George Board 18 National prostate cancer screening rates following the 2012 United States Preventive Services Task Force recommendation discouraging prostatespecific antigen (PSA)-based screening. (Abstract 5026) M. W. Drazer, D. Huo, S. E. Eggener Board 19 The combination of DNA ploidy status and PTEN/6q15 deletions to provide strong and independent prognostic information in prostate cancer. (Abstract 5027) M. Lennartz, S. Minner, M. Kluth, S. Brasch, H. Wittmann, L. Paterna, H. Heinzer, R. Simon, G. Sauter, T. Schlomm Board 20 Phase 1b study of ARN-509 with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). (Abstract 5028) E. M. Posadas, K. N. Chi, R. De Wit, M. J. De Jonge, G. Attard, T. W. Friedlander, M. K. Yu, P. Hellemans, C. Chien, C. C. Abrams, M. Gonzalez, G. C. Trudel, V. Chauhan, J. Jiao, F. Saad Board 21 STEAP1 as a predictive biomarker for antibody-drug conjugate (ADC) activity in metastatic castration resistant prostate cancer (mCRPC). (Abstract 5029) D. C. Danila, M. Fleisher, J. A. Carrasquillo, H. Gilbert, M. J. Morris, L. P. Bellomo, P. J. Hendrikx, E. Szafer-Glusman, A. Herkal, C. Patel, N. A. Schreiber, K. R. Curtis, D. J. Maslyar, V. Lemahieu, B. M. Fine, M. J. Mamounas, A. J. Ungewickell, M. R. Lackner, H. I. Scher, O. Kabbarah Board 22 Immune responses and clinical outcomes in STAND, a randomized phase 2 study evaluating optimal sequencing of sipuleucel-T (sip-T) and androgen deprivation therapy (ADT) in biochemically-recurrent prostate cancer (BRPC) after local therapy failure. (Abstract 5030) E. S. Antonarakis, A. S. Kibel, G. W. Adams, L. I. Karsh, A. Elfiky, N. D. Shore, N. J. Vogelzang, J. M. Corman, J. C. Maher, T. DeVries, C. McCoy, N. A. Sheikh, C. G. Drake Board 23 Baseline analysis of circulating tumor cell (CTC) enumeration and androgen receptor (AR) localization in men with metastatic castration-resistant prostate cancer (mCRPC) in TAXYNERGY. (Abstract 5031) S. T. Tagawa, G. 98 Saturday, May 30, 2015 Board 25 Performance of CCP assay in an updated series of biopsy samples obtained from commercial testing. (Abstract 5033) J. W. Davis, E. Crawford, N. Shore, P. T. Scardino, J. D. Tward, L. Harrison, B. Evans, L. FitzGerald, S. Stone, M. K. Brawer Board 26 Radium-223 in an international early access program (EAP): Effects of concomitant medication on overall survival in metastatic castration-resistant prostate cancer (mCRCP) patients. (Abstract 5034) F. Saad, J. Carles, S. Gillessen, D. Heinrich, J. Gratt, K. Miller, S. Nilsson, J. O’Sullivan, M. Tucci, M. Wirth, A. Heidenreich Board 27 Circulating tumor cell (CTC) enumeration in men with metastatic castrationresistant prostate cancer (mCRPC) treated with enzalutamide post-chemotherapy (phase 3 AFFIRM study). (Abstract 5035) M. Fleisher, D. C. Danila, K. Fizazi, M. Hirmand, B. Selby, D. Phung, J. S. De Bono, H. I. Scher Board 28 Enzalutamide (ENZA) in men with chemotherapy-Naïve metastatic castrationresistant prostate cancer (mCRPC): Final analysis of the phase 3 PREVAIL study. (Abstract 5036) T. M. Beer, A. J. Armstrong, C. N. Sternberg, C. S. Higano, D. E. Rathkopf, Y. Loriot, F. Saad, A. M. Joshua, J. S. De Bono, P. M. Venner, J. Carles, P. N. Mainwaring, C. P. Evans, T. Parli, H. H. Mansbach, S. Bhattacharya, S. Van Os, D. Phung, B. F. Tombal Board 29 Phase 1 study with expansion cohorts of cabozantinib (C) ⴙ abiraterone (A) in metastatic castration resistant prostate cancer (mCRPC): Investigatorsponsored study. (Abstract 5037) C. Sweeney, K. P. Gray, L. C. Harshman, M. Taplin, A. F. Pace, K. Dumas, J. G. Supko, K. A. Zukotynski, B. D. Bernard, M. Pomerantz, A. Elfiky, P. W. Kantoff Board 30 Acute toxicity and early quality of life after dose intensified salvage radiotherapy for biochemically recurrent prostate cancer after prostatectomy. First results of the randomized trial SAKK 09/10. (Abstract 5038) P. Ghadjar, T. Hoelscher, P. Gut, M. Guckenberger, G. Hildebrandt, A. Mueller, L. Plasswilm, A. Papachristofilou, S. Hayoz, M. Sumila, H. Kranzbuehler, Y. Najafi, P. Ost, N. C. Azinwi, D. R. Zwahlen, C. Reuter, S. Bodis, P. Wust, J. Bernhard, D. M. Aebersold Board 31 Testosterone-guided schedule of androgen deprivation therapy (ADT) as an alternative to a fixed schedule in management of prostate cancer. (Abstract 5039) S. Niraula, F. E. Vera Badillo, A. J. Templeton, A. Dodd, Z. Nugent, I. Tannock Board 32 Immune response from STRIDE, a randomized, phase 2, open label study of sipuleucel-T (sip-T) with concurrent vs sequential enzalutamide (enz) administration in metastatic castration-resistant prostate cancer (mCRPC). (Abstract 5040) D. I. Quinn, C. G. Drake, R. Dreicer, E. S. Antonarakis, N. D. Shore, J. M. Corman, R. S. Concepcion, C. M. Pieczonka, N. N. Chang, T. DeVries, N. A. Sheikh, D. P. Petrylak Board 33 Relationship between abiraterone plasma concentration and PSA response in metastatic castration resistant prostate cancer patients. (Abstract 5041) E. Carton, G. Noe, O. Huillard, J. Giroux, A. Cessot, M. Peyromaure, M. Zerbib, C. Narjoz, A. Thomas-Schoemann, M. Vidal, F. Goldwasser, B. Blanchet, J. Alexandre Board 34 Genomic analysis of circulating tumor cells (CTCs) from men with metastatic castration resistant prostate cancer (mCRPC) in the context of enzalutamide therapy. (Abstract 5042) J. Li, J. Beaver, R. L. Bitting, S. Gregory, A. J. Armstrong Board 35 Nine-year follow-up for a study of diffusion-weighted MRI in a prospective active surveillance cohort for prostate cancer. (Abstract 5043) D. R. Henderson, N. M. DeSouza, K. Thomas, V. A. Morgan, S. F. Riches, S. A. Sohaib, D. P. Dearnaley, C. Parker, N. J. Van As 99 SATURDAY Galletti, E. S. Antonarakis, S. Tasaki, A. Gjyrezi, D. Worroll, L. Portella, B. J. Kirby, J. Stewart, A. Zaher, F. Saad, M. Vanhuyse, S. Suri, T. B. Lannin, C. Gruber, E. Pratt, G. Sonpavde, M. A. Eisenberger, D. M. Nanus, P. Giannakakou Saturday, May 30, 2015 SATURDAY Board 36 Computer automated bone scan index (BSI) as an analytically validated imaging biomarker to quantitate change in bone scan of patients with metastatic prostate cancer. (Abstract 5044) A. Anand, D. Minarik, R. Kaboteh, S. Lindgren Belal, M. Reza, A. Joseffson, L. Edenbrandt, A. Bjartell Board 37 Identification of germline mutations in men with early onset prostate cancer. (Abstract 5045) P. Pilie, A. M. Johnson, K. A. Zuhlke, L. A. Okoth, S. Tomlins, K. A. Cooney Board 38 Influence of prostate cancer disease state and therapeutic selection on peripheral whole-blood RNA signature. (Abstract 5046) B. C. Liaw, U. Chippada-Venkata, Y. Gong, L. Wang, J. Zhu, M. M. Heck, C. Tsao, M. D. Galsky, W. K. Oh Board 40 Prognostic index model (PIM) for overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) without prior chemotherapy treated with abiraterone acetate (AA). (Abstract 5047) C. J. Ryan, T. Kheoh, J. Li, A. Molina, P. De Porre, J. Carles, E. Efstathiou, P. W. Kantoff, P. F. Mulders, F. Saad, T. W. Griffin, K. N. Chi Board 41 Association of single nucleotide polymorphisms (SNPs) in ESR1 and PRMT8 and response to treatment with abiraterone acetate (AA) in men with metastatic castration refractory prostate cancer (mCRPC). (Abstract 5048) N. Agarwal, A. Alex, J. M. Farnham, S. B. Patel, S. K. Tantravahi, C. Teerlink, F. S. Albright, R. A. Stephenson, L. A. Cannon-Albright Board 42 TERRAIN. (Abstract 5049) S. Chowdhury, A. Heidenreich, A. Villers, L. Klotz, D. R. Siemens, D. Phung, F. Wang, D. Forer, S. Van Os, N. D. Shore Board 43 LBH589 (LBH) and bicalutamide (Bic) in castration-resistant prostate cancer (CRPC) patients (pts) progressing on second line anti-androgen (AA): NYU-08479/PCCTC. (Abstract 5050) A. C. Ferrari, J. J. Alumkal, M. N. Stein, T. M. Mayer, S. Torneten, J. Babb, M. Taplin, R. S. DiPaola, T. M. Beer Board 44 Phase 1–2 study of progesterone receptor (PR) inhibition with extendedrelease (ER) onapristone (ONA) in patients (pts) with castration-resistant prostate cancer (CRPC): PK, safety and PR testing results from the dose escalation cohort. (Abstract 5051) A. Jayaram, K. Nowakowska, J. Mateo, D. Nava Rodrigues, R. Riisnaes, A. Zukiwski, S. Proniuk, A. S. Bexon, J. Bisaha, D. Bianchini, Z. Zafeiriou, R. Perez Lopez, N. Tunariu, J. S. De Bono, G. Attard Board 45 Disease burden and outcome in metastatic hormone sensitive prostate cancer (mHSPC). (Abstract 5052) L. Albiges, W. Xie, Y. Chen, J. Boher, L. B. Valenca, B. D. Bernard, S. Culine, M. Habibian, M. A. Carducci, R. S. DiPaola, G. Liu, M. Pomerantz, M. Nakabayashi, P. W. Kantoff, K. Fizazi, G. Gravis, C. Sweeney Board 46 IMAAGEN trial update: Effect of abiraterone acetate and low dose prednisone on PSA and radiographic disease progression in patients with non-metastatic castration-resistant prostate cancer. (Abstract 5053) C. J. Ryan, E. D. Crawford, N. D. Shore, W. Underwood III, A. Londhe, S. C. Black, T. McGowan, P. W. Kantoff Board 47 Tumor-directed PET imaging of metastases in metastatic castration-resistant prostate cancer (mCRPC) using Zr-89 labeled antiprostate-specific membrane antigen (PSMA) antibody J591. (Abstract 5054) J. L. Feldman, M. J. Morris, D. F. Martinez, S. T. Tagawa, D. M. Nanus, S. B. Solomon, J. A. Carrasquillo, V. E. Reuter, J. S. Lewis, J. A. O’ Donoghue, S. F. Slovin, D. E. Rathkopf, M. Gonen, V. Beylergil, J. C. Durack, S. M. Cheal, N. H. Bander, H. I. Scher, S. M. Larson, N. Pandit-Taskar Board 49 Molecular characterization of clinically defined aggressive variant prostate cancer (AVPCa) in prospectively collected tissues and corresponding patient derived xenografts (PDX). (Abstract 5055) A. Aparicio, L. Shen, E. L. Tapia, J. Lu, H. Chen, J. Zhang, G. Wu, X. Wang, P. Troncoso, P. G. Corn, T. C. Thompson, B. M. Broom, K. A. Baggerly, C. Logothetis, S. N. Maity Board 50 A molecular and clinico-pathological model for predicting abiraterone acetate/prednisone (AA/P) efficacy in metastatic castrate resistant prostate 100 Saturday, May 30, 2015 Board 51 Validation of correlation of RECIST changes with survival in metastatic castration-resistant prostate cancer (mCRPC). (Abstract 5057) G. R. Pond, A. J. Templeton, D. P. Petrylak, A. Fandi, B. F. Tombal, M. Rosenthal, G. Sonpavde Board 52 Development of an imaging approach to detect splice variants of androgen receptor in prostate cancer. (Abstract 5058) Y. Imamura, A. H. Tien, J. Kunzhong, J. Pan, K. Lin, R. J. Andersen, M. Sadar Board 53 Tissue-based genomics to augment post-prostatectomy risk stratification in a natural history cohort. (Abstract 5059) A. Ross, M. H. Johnson, K. Yousefi, E. Davicioni, H. L. Fedor, S. Glavaris, V. Choeurng, C. Buerki, L. L. Lam, N. Erho, E. B. Humphreys, G. J. Netto, M. Han, A. W. Partin, B. J. Trock, E. M. Schaeffer Board 54 Evaluation of the contribution of individual gene groups to a 17-gene prognostic prostate cancer signature. (Abstract 5060) D. Knezevic, R. Lu, E. Burke, M. Rothney, N. Zhang, H. Lawrence, P. G. Febbo Board 55 Effects of preoperative abiraterone acetate (AA) plus enzalutamide (E) and leuprolide acetate (LHRHa) versus AA and LHRHa in localized high-risk prostate cancer (LHRPC). (Abstract 5061) E. Efstathiou, P. Troncoso, E. L. Tapia, J. W. Davis, M. A. Titus, A. Hoang, I. N. Prokhorova, S. Wen, C. Logothetis Board 56 Genomic characterization of primary and metastatic prostate cancer (PC) using a targeted next-generation sequencing assay. (Abstract 5062) W. Abida, K. R. Curtis, B. S. Taylor, M. E. Arcila, R. Brennan, D. C. Danila, D. E. Rathkopf, M. J. Morris, S. F. Slovin, D. B. Solit, D. M. Hyman, A. Gopalan, M. F. Berger, N. Schultz, H. I. Scher Board 57 Ra-223 experience in pretreated patients: EAP setting. (Abstract 5063) A. O. Sartor, D. C. Fernandez, M. J. Morris, A. Iagaru, A. Brown Jr., F. Almeida, C. Sweeney, M. R. Smith, A. Dicker, Y. Wong, N. D. Shore, J. Gratt, O. Petrenciuc, J. Germino, N. J. Vogelzang Board 58 Interim performance of a non-DRE urine exosome gene signature to predict Gleason >7 prostate cancer on initial prostate needle biopsy from patients enrolled in a prospective observational trial. (Abstract 5064) M. J. Donovan, M. Noerholm, S. Bentink, S. Belzer, J. Skog, G. A. Brown, J. S. Cochran, V. O’Neill Board 59 Contemporary national trends of prostate cancer screening among privately insured patients in the United States. (Abstract 5065) S. P. Kim, J. Karnes, C. P. Gross, N. J. Meropol, H. K. Van Houten, R. Abouassaly, N. D. Shah Board 60 Safety and efficacy of everolimus (E), bevacizumab (B), and docetaxel (D) for castration resistant prostate cancer (CRPC). (Abstract 5066) M. E. Gross, T. B. Dorff, D. I. Quinn, K. Massopust, P. M. Diaz, O. O. Castellanos, D. B. Agus Board 61 Detecting predictive androgen receptor modifications in circulating prostate cancer cells. (Abstract 5067) J. Steinestel, M. Luedeke, A. Arndt, T. Schnoeller, J. K. Lennerz, C. Maier, M. Cronauer, K. Steinestel, M. Boegemann, A. J. Schrader Board 62 Androgen receptor (AR) amplification in patients (pts) with metastatic castration resistant prostate cancer (mCRPC) resistant to abiraterone (Abi) and enzalutamide (Enz): Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT). (Abstract 5068) R. R. Aggarwal, G. Thomas, J. Youngren, A. Foye, S. Olson, P. Paris, T. M. Beer, C. J. Ryan, O. Witte, C. P. Evans, M. E. Gleave, J. Stuart, J. J. Alumkal, A. Toschi, N. Zona, R. E. Reiter, P. Lara Jr., K. N. Chi, E. J. Small Board 63a Androgen receptor modulation optimized for response: Splice variant (ARMOR3-SV)–Randomized, open-label, multicenter, controlled study of galeterone vs enzalutamide in men with metastatic castration-resistant prostate cancer (mCRPC) expressing AR-V7 splice variant. (Abstract 101 SATURDAY cancer (mCRPC). (Abstract 5056) M. Kohli, R. Qin, L. Wang, H. Sicotte, R. Carlson, W. Tan, R. E. Jimenez, J. Eckel-Passow, B. A. Costello, H. C. Pitot, F. Quevedo, R. S. Dronca, K. Wu, T. J. Moynihan, T. H. Ho, A. H. Bryce, T. D. Atwell, B. P. McMenomy, S. Dehm Saturday, May 30, 2015 TPS5069) M. Taplin, E. S. Antonarakis, D. T. Dransfield, K. J. Ferrante, J. S. De Bono SATURDAY Board 63b Autologous dendritic cell vaccination (DCVAC/PCa) added to docetaxel chemotherapy in a double-blind, randomized phase III trial (VIABLE) in men with advanced (mCRPC) prostate cancer. (Abstract TPS5070) N. J. Vogelzang, T. M. Beer, J. Bartunkova, R. Kuklı́k, K. Miller, W. K. Oh, S. Oudard, H. S. Pandha, A. O. Sartor, R. Spisek, N. G. Borgstein, W. R. Gerritsen Board 64a A phase 3 randomized, placebo-controlled double-blind study of ARN-509 plus abiraterone acetate (AA) in chemotherapy-naïve metastatic castrationresistant prostate cancer (mCRPC). (Abstract TPS5071) D. E. Rathkopf, G. Attard, E. Efstathiou, M. K. Yu, T. W. Griffin, M. B. Todd, D. Wu, T. Kheoh, X. Zhao, F. Saad Board 64b A phase 1/2 open-label study of safety and antitumor activity of EPI-506, a novel AR N-terminal domain inhibitor, in men with metastatic castrationresistant prostate cancer (mCRPC) with progression after enzalutamide or abiraterone. (Abstract TPS5072) R. B. Montgomery, E. S. Antonarakis, M. Hussain, K. Fizazi, A. M. Joshua, G. Attard, M. Sadar, F. Perabo, K. N. Chi Board 65a Phase II multicenter study to analyze the predictive value of fusion gene TMPRSS2-ETS assessed both in tumor and blood sample, as a marker of response to enzalutamide in patients with metastatic castration resistant prostate cancer (CRPC) pre-chemotherapy: PREMIERE-SOGUG Trial. (Abstract TPS5073) E. Grande, E. Gonzalez-Billalabeitia, I. Duran, C. Santander, E. Gallardo Diaz, A. Gonzalez del Alba, J. Puente, A. Rodriguez Sanchez, A. Font, M. Climent, L. Leon Mateos, M. Sáez, B. Mellado, M. J. Méndez-Vidal, S. VazquezEstevez, O. Fernandez Calvo, M. P. Fernandez Perez, T. Alonso, D. E. Castellano Board 65b A randomized phase II study of androgen deprivation therapy with or without PD0332991 in RB-positive metastatic hormone-sensitive prostate cancer. (Abstract TPS5074) P. L. Palmbos, F. Y. Feng, S. A. Tomlins, W. K. Kelly, A. K. Morgans, M. Taplin, N. Agarwal, E. S. Antonarakis, P. Twardowski, J. Jacobson, M. S. Davenport, S. Daignault, K. E. Knudsen, M. Hussain Board 66a A prospective, multicenter, randomized phase II trial of best systemic therapy (BST) or BST plus definitive treatment (Surgery or Radiation) of the primary tumor in metastatic prostate cancer. (Abstract TPS5075) B. F. Chapin, S. E. Mcguire, X. Wang, P. Troncoso, J. W. Davis, N. Navai, S. K. Subudhi, A. J. Zurita, J. C. Araujo, C. A. Pettaway, S. F. Matin, L. L. Pisters, J. F. Ward, S. Tu, J. Wang, O. Le, C. Logothetis, A. Aparicio Board 66b Randomized phase-2 study of sipuleucel-T with or without radium-223 in men with asymptomatic/minimally symptomatic bone-metastatic castrateresistant prostate cancer (CRPC). (Abstract TPS5076) J. Park, A. O. Sartor, R. Sullivan, S. King, E. S. Antonarakis Board 67a Randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer: the ANZUP ENZAMET Trial (ANZUP 1304). (Abstract TPS5077) I. D. Davis, M. R. Stockler, A. J. Martin, V. Marchesin, O. Deignan, R. McDermott, W. R. Parulekar, S. A. North, B. Graham, A. P. Long, F. T. Roncolato, S. Yip, W. Hague, C. Dazo, X. Coskinas, C. Sweeney Board 67b Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised prostate cancer: The ANZUP ENZARAD Trial (ANZUP 1303). (Abstract TPS5078) S. G. Williams, I. D. Davis, C. Sweeney, M. R. Stockler, A. J. Martin, V. Marchesin, O. Deignan, R. McDermott, A. P. Long, F. T. Roncolato, S. Yip, W. Hague, E. Tu, X. Coskinas, P. L. Nguyen Board 68a A randomized phase II study comparing bipolar androgen therapy vs. enzalutamide in asymptomatic men with castration resistant metastatic prostate cancer: The TRANSFORMER trial. (Abstract TPS5079) B. A. Teply, E. S. Antonarakis, M. A. Carducci, C. J. Paller, H. Wang, H. Cao, A. N. Spitz, J. Luo, M. A. Eisenberger, S. R. Denmeade 102 Board 68b ARAMIS trial: Efficacy and safety phase 3 trial of ODM-201 in men with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC). (Abstract TPS5080) K. Fizazi, N. D. Shore, T. L. Tammela, T. Sarapohja, A. Vuorela, I. Kuss, A. Snapir, M. R. Smith, ARAMIS Investigators Board 69a Prospect: A randomized double-blind phase 3 efficacy study of PROSTVACVF immunotherapy in men with asymptomatic/minimally symptomatic metastatic castration-resistant prostate cancer. (Abstract TPS5081) J. L. Gulley, J. L. Giacchino, J. B. Breitmeyer, A. J. Franzusoff, D. Panicali, J. Schlom, P. W. Kantoff Board 69b ERA 223: A phase 3 trial of radium-223 dichloride (Ra-223) in combination with abiraterone acetate (abiraterone) and prednisone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients (pts) with bone predominant metastatic castration-resistant prostate cancer (mCRPC). (Abstract TPS5082) M. R. Smith, C. Parker, B. F. Tombal, K. Miller, F. Saad, F. Fang, A. Zhang, M. Kornacker, C. S. Higano Board 70a The PRESIDE trial: A randomized, double-blind, placebo-controlled phase III efficacy and safety study of continued enzalutamide plus docetaxel after disease progression on enzalutamide alone in patients with metastatic castration-resistant prostate cancer. (Abstract TPS5083) S. Chowdhury, R. Davidson, A. Coppell, H. Mobasheri, A. Stari, R. Snijder, C. Treadwell, A. S. Merseburger Board 70b The role of highly selective androgen receptor (AR) targeted therapy in men with biochemically relapsed hormone sensitive prostate cancer. (Abstract TPS5084) R. R. Aggarwal, J. J. Alumkal, R. Z. Szmulewitz, C. S. Higano, A. H. Bryce, M. K. Yu, C. De Boer, G. Choque-Gonzales, E. J. Small 1:15 PM - 4:45 PM Poster Session Gynecologic Cancer Location: S Hall A Abstracts 5513–5524 will be discussed during the Gynecologic Cancer Poster Discussion Session. See page 135 for session information. Board 71 A phase II open-label, multicenter study of single-agent rucaparib in the treatment of patients with relapsed ovarian cancer and a deleterious BRCA mutation. (Abstract 5513) R. Shapira-Frommer, A. M. Oza, S. M. Domchek, J. Balmaña, M. R. Patel, L. Chen, Y. Drew, H. A. Burris III, J. Korach, M. Flynn, V. L. Bowering, M. A. Morgan, S. P. Watkins, D. Simpson, S. Goble, L. Maloney, R. S. Kristeleit Board 72 Phase I/Ib study of the PARP inhibitor (PARPi) olaparib (O) with carboplatin (C) in heavily pretreated high-grade serous ovarian cancer (HGSOC) at low genetic risk (NCT01445418). (Abstract 5514) V. L. Chiou, E. C. Kohn, C. M. Annunziata, L. M. Minasian, S. Lipkowitz, M. Yu, N. Gordon, N. D. Houston, J. Lee Board 73 Results of a phase I pharmacokinetic study of intraperitoneal bortezomib (B) and carboplatin (C) in patients with persistent or recurrent ovarian cancer (OC): An NRG/Gynecologic Oncology Group study. (Abstract 5515) D. S. Dizon, W. E. Brady, H. A. Lankes, D. A. Jandial, S. B. Howell, R. J. Schilder, J. H. Beumer, S. M. Christner, S. Strychor, M. A. Powell, A. R. Hagemann, K. N. Moore, J. L. Walker, P. DiSilvestro, P. M. Fracasso, NRG Oncology Board 74 A phase Ib dose-escalation study of binimetinib (MEK162) in combination with weekly paclitaxel in patients with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer. (Abstract 5516) R. N. Grisham, M. S. Gordon, W. A. Harb, C. Aghajanian, D. S. McMeekin, K. McKinley, L. R. Anderson, R. Chavira, J. Christy-Bittel, E. Barrett, K. N. Moore 103 SATURDAY Saturday, May 30, 2015 Saturday, May 30, 2015 SATURDAY Board 75 Randomized phase III study comparing paclical-carboplatin with paclitaxelcarboplatin in patients with recurrent platinum-sensitive epithelial ovarian cancer. (Abstract 5517) I. Vergote, A. Brize, A. S. Lisyanskaya, M. Lichinitser Board 76 Preliminary single agent activity of IMGN853, a folate receptor alpha (FR␣)targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Phase I trial. (Abstract 5518) K. N. Moore, L. P. Martin, S. M. Seward, T. M. Bauer, D. M. O’Malley, R. P. Perez, A. M. Oza, W. Jeong, M. W. Kirby, Y. Zhou, M. F. Michenzie, J. Ponte, R. Ruiz-Soto, M. J. Birrer Board 77 Autologous oxidized whole-tumor antigen vaccine in combination with angiogenesis blockade to elicit antitumor immune response in ovarian cancer. (Abstract 5519) J. L. Tanyi, L. Kandalaft, E. Ophir, S. Bobisse, R. Genolet, E. Zsiros, D. A. Torigian, R. Mick, A. Harari, G. Coukos Board 78 MITO (Multicentre Italian Trials in Ovarian cancer): CERV 2 trial—A randomized phase II study of carboplatin and paclitaxel ⴙ/- cetuximab, in advanced and/or recurrent cervical cancer. (Abstract 5520) S. Pignata, G. Scambia, D. Lorusso, U. De Giorgi, M. Nicoletto, R. Lauria, A. Mosconi, C. Sacco, C. Omarini, P. Tagliaferri, G. Ferrandina, S. Cinieri, C. Pisano, S. C. Cecere, M. Di Napoli, V. Salutari, M. Piccirillo, G. Daniele, C. Gallo, F. Perrone Board 79 Effect of sentinel lymph-node biopsy alone on the morbidity of the surgical treatment of early cervical cancer: Results from the prospective randomized study Senticol2. (Abstract 5521) P. Mathevet, F. Lecuru, SENTICOL2 Group Board 80 CT perfusion as an early biomarker of treatment efficacy in advanced ovarian cancer: An ECOG-ACRIN and NRG GOG study. (Abstract 5522) T. Lee, C. S. Ng, Z. Zhang, S. Lee, H. Marques, K. Burgers, F. Su, J. Bauza, R. S. Mannel, J. L. Walker, W. K. Huh, S. C. Rubin, P. DiSilvestro, L. P. Martin, J. K. Chan, M. A. Bookman, R. L. Coleman Board 81 The role of PET-CT in treatment decision making for women with locally advanced cervical cancer. (Abstract 5523) L. M. Elit, A. W. Fyles, C. Gu, G. R. Pond, D. D’Souza, R. Samant, M. Anthes, G. Thomas, M. Fillion, J. Arsenault, I. Dayes, T. J. Whelan, K. Y. Gulenchyn, M. N. Levine Board 82 Utility of PET-CT to evaluate retroperitoneal lymph node metastasis in high risk endometrial cancer. (Abstract 5524) M. Atri, Z. Zhang, F. Dehdashti, W. Koh, S. Ali, R. S. Mannel, K. Moxley, P. DiSilvestro, M. Pearl, S. D. King, M. Plante, x. Zhou, M. Gold Board 83 Randomized phase III trial of carboplatin/paclitaxel alone (CP) or in combination with bevacizumab followed by bevacizumab (CPB) and secondary cytoreduction surgery in platinum-sensitive recurrent ovarian cancer: GOG0213, an NRG Oncology/GOG Study—Analysis of patient reported outcomes (PRO) on chemotherapy randomization. (Abstract 5525) K. Basen-Engquist, H. Q. Huang, T. J. Herzog, D. K. Armstrong, P. Sabbatini, J. L. Walker, B. G. Kim, K. Fujiwara, K. S. Tewari, D. M. O’Malley, R. L. Coleman Board 84 Clinical characteristics and survival outcomes in BRCA1-methylated epithelial ovarian cancer (Bmeth-OC): A pooled analysis of data for 1,278 patients across five studies. (Abstract 5526) R. D. Kalachand, I. Ruscito, D. Dimitrova, P. Benedetti Panici, J. Sehouli, S. Olek, E. I. Braicu, L. Lu, D. Katsaros, H. Yu, M. S. Carey, R. Broaddus, K. H. Lu, G. B. Mills, M. I. Harrell, K. J. Agnew, E. M. Swisher, W. Grogan, B. Stordal, B. Hennessy Board 85 Efficacy and safety comparison between belotecan and topotecan in patients with recurrent or refractory ovarian cancer: A multi-center, randomized, open-labelled, parallel-group phase IIb trial. (Abstract 5527) H. Kim, S. Park, C. Park, Y. Kim, B. Kim, Y. Song, B. G. Kim, C. Cho, J. Kim Board 86 Multicentre trial of carboplatin/paclitaxel versus oxaliplatin/capecitabine, each with/without bevacizumab, as first line chemotherapy for patients with mucinous epithelial ovarian cancer (mEOC). (Abstract 5528) M. E. Gore, A. Hackshaw, W. E. Brady, R. T. Penson, R. J. Zaino, W. G. McCluggage, R. Ganesan, N. Wilkinson, T. Perren, A. Montes, J. Summers, R. Lord, G. G. Dark, 104 Saturday, May 30, 2015 Board 87 Efficacy and safety of olaparib monotherapy in a subgroup of patients with a germline BRCA1/2 mutation and advanced ovarian cancer from a Phase II open-label study. (Abstract 5529) S. M. Domchek, R. Shapira-Frommer, R. K. Schmutzler, M. W. Audeh, M. Friedlander, J. Balmaña, G. Mitchell, G. Fried, S. M. Stemmer, A. Hubert, O. Rosengarten, N. Loman, J. D. Robertson, H. Mann, B. Kaufman Board 88 A GINECO phase I study evaluating lenalidomide (Le) combined with pegylated liposomal doxorubicin (PLD) and carboplatin (C) in late (>6 months) recurrent ovarian cancer (LROC) patients (pts). (Abstract 5530) F. Selle, A. Lesoin, M. Kaminsky, P. Follana, I. Ray-Coquard, D. Berton-Rigaud, A. Floquet, A. Hardy-Bessard, F. Joly, E. Pujade-Lauraine, GINECO Board 89 Phase II randomized trial of neoadjuvant (NA) chemotherapy (CT) with or without bevacizumab (Bev) in advanced epithelial ovarian cancer (EOC) (GEICO 1205/NOVA TRIAL). (Abstract 5531) Y. Garcı́a, A. De Juan, C. Mendiola, P. Barretina-Ginesta, L. Vidal, A. Santaballa, I. Bover, M. Gil-Martin, A. Manzano, M. Rubio, M. Romeo, A. Gomez de Liaño, E. Garcı́a-Martı́nez, A. Gonzalez-Martin Board 90 Use of homologous recombination deficiency (HRD) score to enrich for niraparib sensitive high grade ovarian tumors. (Abstract 5532) K. M. Wilcoxen, M. Becker, C. Neff, V. Abkevich, J. T. Jones, X. Hou, Y. Wang, A. Hartman, M. M. AlHilli, A. Gutin, S. Agarwal, K. Timms, P. Haluska Board 91 The influence of polypharmacy on grade III/IV toxicity, prior discontinuation of chemotherapy and survival in recurrent ovarian cancer patients: An individual participant data meta-analysis of the North-Eastern German Society of Gynecological Oncology (NOGGO) of 1,213 patients. (Abstract 5533) H. Woopen, R. Richter, R. Chekerov, T. Siepmann, J. Sehouli Board 92 Characteristics of homologous recombination deficiency (HRD) in paired primary and recurrent high-grade serous ovarian cancer (HGSOC). (Abstract 5534) J. N. Patel, J. Sehouli, K. Timms, C. Solimeno, J. E. Reid, J. S. Lanchbury, I. Braicu, S. Darb-Esfahani, M. Ganapathi, R. N. Ganapathi Board 93 Role of HE4, CA125, and ultrasound in risk assessment in pelvic mass patients: Results from a prospective, multicentric study. (Abstract 5535) E. I. Braicu, U. Torsten, H. Mecke, R. Richter, K. Ames, L. Hellmeyer, K. Hasenbein, G. Nohe, F. Chen, C. R. Beteta, R. Isermann, R. Chekerov, M. Bustamante, A. Dueckelmann, M. Christophi, M. Bodo, N. Monetaer, M. Zimmermann, J. BonnessZaloum, J. Sehouli, Charité Vivantes Ovarian Cancer Network Board 94 Is it time to change the primary endpoint in clinical trials in recurrent ovarian cancer (ROC)?: Symptom burden and outcomes in patients with platinum resistant/refractory (PRR) and potentially platinum sensitive ROC receiving > 3 lines of chemotherapy (PPS > 3)—The Gynecologic Cancer Intergroup (GCIG) Symptom Benefit Study (SBS). (Abstract 5536) M. Friedlander, M. R. Stockler, R. O’Connell, F. Joly, A. Lanceley, F. Hilpert, A. Okamoto, E. Aotani, S. Pignata, P. P. Donnellan, A. M. Oza, E. Avall-Lundqvist, J. S. Berek, K. M. Sjoquist, K. Gillies, P. Butow, M. T. King Board 95 First-in-human phase I/II dose-escalation study of IMAB027 in patients with recurrent advanced ovarian cancer (OVAR): Preliminary data of phase I part. (Abstract 5537) U. Sahin, D. Jaeger, F. Marme, A. Mavratzas, J. Krauss, J. De Greve, I. Vergote, O. Tureci Board 96 Correlation of baseline clinical characteristics and laparoscopic extent of carcinomatosis of women with initially unresectable ovarian, tubal or peritoneal adenocarcinoma, in ANTHALYA study: A randomized, open-label, phase II study assessing the efficacy and the safety of bevacizumab in neoadjuvant. (Abstract 5538) R. Rouzier, S. Gouy, F. Selle, E. Lambaudie, F. Guyon, V. Fourchotte, C. Pomel, P. E. Colombo, E. Kalbacher, S. Martin, R. Fauvet, P. Follana, A. Lesoin, F. Lecuru, V. Menguy, Y. Ghazi, E. Chereau, S. Zohar, P. H. Cottu, F. Joly 105 SATURDAY G. J. Rustin, M. J. Mackean, N. Reed, S. Kehoe, H. Christensen, J. A. Ledermann, D. M. Gershenson Saturday, May 30, 2015 SATURDAY Board 97 Tumor biopsies in high grade ovarian cancer: Clinical utility and challenges for biomarker-directed therapy. (Abstract 5539) M. K. Wilson, K. Lin, I. A. McNeish, E. M. Swisher, H. Giordano, E. Mann, M. Raponi, L. Maloney, S. Yerganian, M. Mehdi, R. Yelensky, L. Rolfe, A. R. Allen, A. M. Oza Board 98 Molecular profiling of mucinous epithelial ovarian carcinomas (mEOC): Opportunities for clinical trials. (Abstract 5540) M. Friedlander, K. Russell, S. Z. Millis, Z. Gatalica, A. Voss Board 99 Phase I study of intraperitoneal IL-12 plasmid formulated with PEG-PEIcholesterol lipopolymer administered in combination with pegylated liposomal doxorubicin in recurrent or persistent epithelial ovarian, Fallopian tube, or primary peritoneal cancer patients: An NRG/GOG study. (Abstract 5541) P. H. Thaker, W. E. Brady, W. H. Bradley, K. Anwer, R. D. Alvarez Board 100 A phase I/II trial of multiple dose VB-111 and weekly paclitaxel in recurrent platinum-resistant Müllerian cancer. (Abstract 5542) R. T. Penson, S. T. Berlin, P. Konstantinopoulos, C. N. Krasner, U. Matulonis, A. Ambrosio, D. Suzin, S. A. Collins, M. J. Birrer, Y. C. Cohen Board 101 Urinary acetylated polyamines in ovarian cancer. (Abstract 5543) J. U. Maenpaa, R. Niemi, A. Roine, M. Hakkinen, P. Kumpulainen, T. Keinanen, J. Vepsalainen, T. Lehtimaki, N. Oksala Board 102 A phase I trial and pharmacokinetic study of non-pegylated liposomeencapsulated doxorubicin citrate (NPLD) plus carboplatin in patients with recurrent gynecological and primary peritoneal tumors. (Abstract 5544) A. Poveda, A. Oaknin, I. Romero, A. Guerrero, L. Calabuig, J. Del Campo Board 103 Comparison of metachronous epithelial ovarian carcinomas. (Abstract 5545) D. Arguello, C. D. Ackerman, S. K. Reddy, Z. Gatalica, S. D. Richard Board 104 What clinical factors influence advanced BRCA1/2 mutant ovarian cancer patient (BMOC pt) outcomes to poly(ADP-ribose) polymerase inhibitor (PARPi) treatment? (Abstract 5546) S. Rafii, C. Gourley, J. Ang, R. Kumar, E. Geuna, T. Rye, L. Ashcroft, B. Powell, R. Shapira-Frommer, M. Friedlander, L. Chen, U. Matulonis, B. Kaufman, J. De Greve, A. M. Oza, S. N. Banerjee, M. E. Gore, L. R. Molife, S. B. Kaye, T. A. Yap Board 105 Development and validation of a prognostic nomogram to predict overall survival (OS) in platinum-resistant ovarian cancer (PROC): An AURELIA substudy. (Abstract 5547) C. Lee, E. Gibbs, F. T. Roncolato, L. C. Davies, C. Le Maignan, W. Meier, M. Arcusa Lanza, P. Rosenberg, C. Marchetti, I. Vergote, P. Witteveen, A. Bamias, S. Serra, J. Provencal, G. De Rauglaudre, V. Gebski, M. Friedlander, E. Pujade-Lauraine Board 106 Exploratory outcome analyses according to stage and residual disease in the ICON7 trial of front-line carboplatin/paclitaxel (CP) ⴞ bevacizumab (BEV) for ovarian cancer (OC). (Abstract 5548) A. Gonzalez-Martin, A. M. Oza, A. C. Embleton, J. Pfisterer, J. A. Ledermann, E. Pujade-Lauraine, G. Kristensen, M. A. Bertrand, P. J. Beale, A. Cervantes-Ruiperez, E. Kent, R. S. Kaplan, M. M. Parmar, N. Scotto, L. Mitchell, T. Perren Board 107 Single agent vanucizumab (RO5520985) for platinum (Pt)-resistant recurrent ovarian cancer (OC): Results from a single arm extension phase of the phase I FIH study. (Abstract 5549) A. Oaknin, A. Floquet, C. Le Tourneau, I. L. RayCoquard, F. Joly, M. Hidalgo, A. Leary, O. Krieter, A. Lahr, S. Rossomanno, K. Lechner, T. Nayak, C. Boetsch, G. Rasuo, A. Morel, I. Vergote Board 108 Frequency, severity and timing of common adverse events (AEs) with maintenance olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). (Abstract 5550) U. Matulonis, M. Friedlander, A. Du Bois, C. Gourley, I. Vergote, G. J. Rustin, C. L. Scott, W. Meier, R. Shapira-Frommer, T. Safra, D. Matei, A. Fielding, E. McMurtry, S. Spencer, H. Mann, D. Parry, J. A. Ledermann Board 109 Bevacizumab (BEV) with or after chemotherapy (CT) for platinum-resistant recurrent ovarian cancer (PROC): Exploratory analyses of the AURELIA trial. (Abstract 5551) A. Bamias, M. A. Dimopoulos, F. Zagouri, A. Veillard, J. Kosse, A. 106 Saturday, May 30, 2015 Board 110 Prognostic and predictive value of primary vs secondary platinum resistance for bevacizumab treatment in platinum-resistant ovarian cancer in the AURELIA trial. (Abstract 5552) F. Trillsch, S. Mahner, F. Hilpert, L. C. Davies, E. Garcı́a-Martı́nez, G. Kristensen, A. Savarese, P. Vuylsteke, M. Los, F. Zagouri, L. Gladieff, J. Sehouli, C. Lee, V. Gebski, E. Pujade-Lauraine Board 111 Single agent trabectedin in heavily pretreated patients with recurrent ovarian cancer (ROC). (Abstract 5553) F. Boumedien, J. Adam, K. Akkour, N. LeTarte, D. M. Provencher Board 112 Early stage ovarian cancer clinical behavior according to FIGO 2014 Staging changes with a focus on IC subtype: data from prospective GEICO registry. (Abstract 5554) I. Romero, C. M. Churruca, A. Redondo, A. Santaballa, E. Calvo, B. Ojeda, J. Del Campo, N. Laı́nez, E. Garcı́a-Martı́nez, M. Romeo, I. Bover, C. Mendiola, C. Caballero, J. Martinez Sr., A. Herrero, A. Sánchez, A. De Juan, S. Hernando Polo, J. A. Lopez-Guerrero, A. Poveda, GEICO Board 113 Epigenome and genome alterations in platinum resistant ovarian cancer. (Abstract 5555) D. Matei, F. Fang, H. Cardenas, D. F. Miller, A. Buechlein, Q. Yu, S. M. Perkins, Y. Liu, G. Jiang, P. Taverna, H. N. Keer, D. B. Rusch, K. P. Nephew Board 114 Validation of a second-generation mia (MIA2G) for triage of adnexal masses. (Abstract 5556) J. Wolf, T. Pappas, Z. Zhang, A. Smith, T. Hudson, B. Carpenter, D. G. Munroe, L. J. Sokoll Board 115 The PACOVAR-trial: A multicenter phase I trial of pazopanib (GW786034) and metronomic cyclophosphamide in patients with recurrent platinum-resistant ovarian cancer. (Abstract 5557) M. H. Eichbaum, M. Schmidt, E. Grischke, G. Gebauer, H. Fricke, F. Lenz, E. Bischofs, M. Wallwiener, F. Marme, A. Schneeweiss, C. Sohn, J. Rom, C. Mayer Board 116 Phase 1 study of IMGN853, a folate receptor alpha (FR␣)-targeting antibodydrug conjugate (ADC) in patients (Pts) with epithelial ovarian cancer (EOC) and other FRA-positive solid tumors. (Abstract 5558) H. Borghaei, D. M. O’Malley, S. M. Seward, T. M. Bauer, R. P. Perez, A. M. Oza, W. Jeong, M. F. Michenzie, M. W. Kirby, G. Chandorkar, R. Ruiz-Soto, M. J. Birrer, K. N. Moore Board 117 A phase 1 study optimizing the dosing of olaparib tablet formulation combined with cediranib in recurrent ovarian cancer. (Abstract 5559) J. Liu, J. Lee, W. Luo, M. J. Birrer, C. Whalen, N. D. Houston, E. Obermayer, T. Spagnoletti, W. T. Barry, E. C. Kohn, S. P. Ivy, U. Matulonis Board 118 Ovarian carcinosarcoma share similar molecular profile as ovarian serous carcinoma but not endometrial carcinosarcoma. (Abstract 5560) H. Mahdi, J. Xiu, S. K. Reddy, R. Debernardo Board 119 Derivation of a second generation multivariate index assay to improve specificity in pre-surgical evaluation of adnexal masses for risk of ovarian malignancy. (Abstract 5561) Z. Zhang, T. Pappas, L. J. Sokoll, A. Smith, L. Chen, D. W. Chan, D. G. Munroe Board 120 Early drug development in advanced gynecologic cancer based on genetic tumor profiling. (Abstract 5562) A. C. Garrido-Castro, G. Argilés, D. Moreno, M. Vilaro, V. Rodriguez-Freixinos, T. Macarulla, C. Cruz, A. Azaro, E. Élez, M. Alsina, J. M. Perez-Garcia, J. Jimenez, P. Nuciforo, A. Vivancos, J. Seoane, J. Del Campo, J. Rodón, J. Tabernero, A. Oaknin Board 121 Use of neoadjuvant chemotherapy in advanced ovarian cancer. (Abstract 5563) L. Meyer, A. Cronin, C. C. Sun, M. A. Bookman, R. A. Burger, M. C. Cristea, J. J. Griggs, C. F. Levenback, G. Mantia-Smaldone, U. Matulonis, J. C. Niland, D. M. O’Malley, A. A. Wright Board 122 Baseline predictors of early treatment failure in patients with platinum resistant/refractory (PRR) and potentially platinum sensitive (PPS > 3) recurrent ovarian cancer (ROC) receiving > 3 lines of chemotherapy: The Gynaecologic Cancer Intergroup (GCIG) Symptom Benefit Study (SBS). 107 SATURDAY Santaballa, M. R. Mirza, G. Tabaro, I. Vergote, H. Bloemendal, M. Lykka, A. Floquet, C. Lee, V. Gebski, E. Pujade-Lauraine Saturday, May 30, 2015 (Abstract 5564) F. T. Roncolato, R. O’Connell, F. Joly, A. Lanceley, F. Hilpert, A. Okamoto, E. Aotani, S. Pignata, P. P. Donnellan, A. M. Oza, E. Avall-Lundqvist, J. S. Berek, K. M. Sjoquist, K. Gillies, P. Butow, M. R. Stockler, M. T. King, M. Friedlander SATURDAY Board 123 Preliminary phase II results of selinexor, an oral selective inhibitor of nuclear export in patients with heavily pretreated gynecological cancers. (Abstract 5565) I. Vergote, B. Lund, H. Havsteen, Z. Ujmajuridze, K. Leunen, C. Aaquist Haslund, T. Juhler-Noettrup, H. Roed, T. Rashal, A. L. Kranich, Y. Landesman, J. Saint-Martin, R. Carlson, S. Shacham, M. Kauffman, M. R. Mirza Board 124 Genomic characterization of long-term responders to olaparib. (Abstract 5566) S. Lheureux, J. A. Ledermann, S. Runswick, D. R. Hodgson, K. Timms, J. S. Lanchbury, S. B. Kaye, C. Gourley, D. Bowtell, E. C. Kohn, C. L. Scott, U. Matulonis, T. Panzarella, B. A. Dougherty, J. C. Barrett, Z. Lai, M. o’Connor, J. D. Robertson, T. W. Ho, A. M. Oza Board 125 Phase 2 studies of multiple peptides cocktail vaccine for treatment-resistant cervical and ovarian cancer. (Abstract 5567) S. Takeuchi, T. Shoji, M. Kagabu, T. Honda, A. Kojima, Y. Nitta, T. Sugiyama, Y. Nakamura Board 126 Propensity-score analysis of neoadjuvant chemotherapy vs. primary surgery in advanced ovarian cancer: Does surgical quality matter? (Abstract 5568) H. Bae, S. Kang, S. Seong, J. W. Kim, S. Y. Ryu, B. Kim, J. Nam Board 127 Feasibility and outcome of interval debulking surgery (IDS) after carboplatinpaclitaxel-bevacizumab (CPB): Results from a subgroup of patient from the MITO-16A-MANGO OV2A phase 4 trial. (Abstract 5569) G. Daniele, D. Lorusso, G. Scambia, M. Di Napoli, M. Nicoletto, E. Breda, N. Colombo, G. Artioli, B. Daniele, G. Lo Re, F. Raspagliesi, V. Chiappa, V. Salutari, G. Ferrandina, S. Greggi, A. Baldoni, M. Piccirillo, R. Fossati, F. Perrone, S. Pignata Board 128 Durable tumor remission in patients with platinum-resistant ovarian cancer receiving nivolumab. (Abstract 5570) J. Hamanishi, M. Mandai, T. Ikeda, M. Minami, A. Kawaguchi, N. Matsumura, K. Abiko, T. Baba, K. Yamaguchi, A. Ueda, Y. Hosoe, S. Morita, A. Shimizu, T. Honjo, I. Konishi Board 129 A phase 1b, open-label, non-randomized multicenter study of birinapant in combination with conatumumab in subjects with relapsed epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer. (Abstract 5571) E. P. Hamilton, M. J. Birrer, B. A. DiCarlo, S. Gaillard, L. P. Martin, J. J. Nemunaitis, R. P. Perez, R. J. Schilder, C. M. Annunziata, C. G. Begley, S. J. Hager Board 130 Carboplatin hypersensitivity reactions (HSR) in carboplatin retreatment for recurrent ovarian cancer. (Abstract 5572) R. E. O’Cearbhaill, D. M. Hyman, W. P. Tew, A. Iasonos, N. A. Cangemi, C. Aghajanian, K. M. Bell-McGuinn, V. Makker, M. L. Hensley, J. A. Konner, R. N. Grisham, K. Diaz-Macinnis, P. Sabbatini, D. R. Spriggs Board 131 A phase Ib/II trial with expansion of patients at the MTD trial of olaparib plus weekly (metronomic) carboplatin and paclitaxel in relapsed ovarian cancer patients. (Abstract 5573) S. E. Rivkin, D. Iriarte, H. Sloan, C. Wiseman, J. Moon, G. E. Goodman, A. Bondurant, D. Veljovich, P. Y. Jiang, T. A. Wahl, C. Shah, C. Drescher, H. G. Kaplan, W. A. Peters, E. Ellis, M. F. Fer, M. S. Park, E. Johnston Board 132 BL1 gene expression subtype to predict outcome in serous ovarian cancers. (Abstract 5574) R. Seitz, D. R. Hout, S. W. Morris, B. Z. Ring Board 133 Genomic profile and immune infiltrate in paired ovarian cancer (OC) samples pre- and post-neoadjuvant chemotherapy (NC). (Abstract 5575) A. Leary, C. Genestie, J. Adam, A. Le Formal, P. Pautier, C. Lhomme, R. chen-Min-Tao, A. Auguste Board 134 Homologous recombination (HR) deficiency, tumor BRCA1/2 mutations (tmBRCA) and association with response and outcome following platinum monotherapy in high grade serous ovarian cancer (HGSOC). (Abstract 5576) R. Brown, K. Timms, J. Paul, E. Hughes, M. El-Bahrawy, J. H. Steel, S. Kalva, X. 108 Saturday, May 30, 2015 Board 135 Delayed recurrences and survival after relapse in patients initially treated with intraperitoneal chemotherapy for advanced ovarian cancer: A Gynecologic Oncology Group study. (Abstract 5577) D. S. Kapp, J. Java, T. J. Herzog, M. Markman, D. K. Armstrong, B. J. Monk, J. K. Chan Board 136 Part I of GANNET53: A multicenter phase I/II trial of the Hsp90 inhibitor ganetespib (G) combined with weekly paclitaxel (P) in women with highgrade serous, high-grade endometrioid, or undifferentiated, platinumresistant epithelial ovarian, fallopian tube or primary peritoneal cancer. (Abstract 5578) I. Ray-Coquard, I. Braicu, R. Berger, S. Mahner, J. Sehouli, A. G. Zeimet, E. Pujade Lauraine, P. A. Cassier, U. Moll, H. Ulmer, K. Leunen, C. Marth, I. Vergote, N. Concin Board 137 The use of patient-derived xenograft models for prioritizing therapeutic targets. (Abstract 5579) C. L. Scott, M. Topp, A. M. Hadley, V. Heong, M. I. Harrell, O. McNally, S. B. Fox, K. Lodhia, P. Haluska, D. Bowtell, E. M. Swisher, M. Wakefield, Australian Ovarian Cancer Study Board 138 Phase II trial of weekly nab-paclitaxel with GM-CSF as an immune modulator in recurrent platinum resistant ovarian, fallopian tube, and primary peritoneal cancer: Clinical and immune responses. (Abstract 5580) J. B. Liao, R. E. Swensen, J. Reichow, K. J. Ovenell, J. Childs, D. Higgins, B. Buening, B. A. Goff, C. Morishima, M. L. Disis Board 139 Modifiable risk factors for ovarian cancer: A multinational case-control study. (Abstract 5581) M. Shaik, T. Lehman, O. A. Alkharabsheh, R. Modali, B. Hrinczenko Board 140 EP-100 ⴙ paclitaxel to overcome taxane resistance in patients with recurrent LHRH-receptor expressing ovarian cancer. (Abstract 5582) A. M. Nick, R. Urban, M. E. Gordinier, C. Leuschner, T. Rado, L. M. Bavisotto, J. Whisnant, R. L. Coleman Board 141 Combination therapy with temsirolimus and trabectedin for recurrent clear cell carcinoma of the ovary: A phase II study with biomarker analysis. (Abstract 5583) M. Takano, H. Kouta, K. Kudoh, T. Kita, R. Kikuchi, M. Miyamoto, T. Yoshikawa, T. Goto, K. Furuya, Y. Tamada, A. Suga, Y. Kikuchi Board 142 Omentin as a biomarker associated with improved overall survival in serous ovarian cancer. (Abstract 5584) M. Onstad, L. L. Holman, C. Au Yeung, R. Schmandt, S. C. Mok, M. F. Munsell, K. H. Lu Board 143 Utility of PET-CT vs CT alone to evaluate retroperitoneal lymph node metastasis in advanced cervical cancer. (Abstract 5585) M. Atri, Z. Zhang, F. Dehdashti, S. Lee, S. Ali, W. Koh, K. N. Moore, L. M. Landrum, J. Kim, P. DiSilvestro, E. L. Eisenhauer, F. M. Schnell, M. Gold Board 144 Identifying actionable mutations in uterine leiomyosarcoma. (Abstract 5586) T. Soumerai, D. M. Hyman, R. Murali, A. Zehir, R. E. O’Cearbhaill, M. E. Arcila, C. Aghajanian, R. A. Soslow, D. B. Solit, M. L. Hensley Board 145 Phase II study of concurrent chemoradiotherapy with weekly CDDP/PTX in patients with locally advanced uterine cervical cancer: JACCRO-GY-01 trial. (Abstract 5587) M. Takekuma, Y. Hirashima, K. Umayahara, S. Noda, T. Ohno, E. Miyagi, F. Hirahara, E. Hirata, E. Kondo, T. Tabata, Y. Nagai, Y. Aoki, M. Wakatsuki, M. Takeuchi, T. Toita, N. Takeshima, K. Takizawa Board 146 Phase II study of the PI3K inhibitor BKM120 monotherapy in patients with advanced or recurrent endometrial carcinoma: ENDOPIK, GINECO Study. (Abstract 5588) P. Heudel, M. Fabbro, C. Roemer-Becuwe, I. Treilleux, M. Kaminsky, A. Arnaud, F. Joly, S. Roche Forestier, R. Herve, I. Ray-Coquard Board 147 Molecular profiling and targeted therapy in advanced endometrial cancer. (Abstract 5589) M. K. Wilson, P. L. Bedard, A. M. Joshua, H. Mackay, M. O. Butler, N. C. Dhani, S. Lheureux, C. Martin-Lorente, V. Rodriguez-Freixinos, B. 109 SATURDAY Liu, Y. Wang, N. R. Rama, C. Wilhelm-Benartzi, A. Gutin, L. Lewsley, N. Siddiqui, N. Patel, J. S. Lanchbury, H. Gabra, E. A. Stronach Saturday, May 30, 2015 Clarke, P. Shaw, A. Milea, L. Wang, S. Kamel-Reid, T. Stockley, J. Bruce, T. J. Pugh, A. M. Oza SATURDAY Board 148 Synergistic effects of cabozantinib to temozolomide and bevacizumab in patients with heavily pretreated relapsed uterine leiomyosarcoma. (Abstract 5590) S. Ikeda, K. Kudoh, N. Sasaki, M. Takano, T. Goto, R. Kikuchi, M. Sakamoto, T. Kita, N. Susumu, D. Aoki, H. Kouta, Y. Kikuchi Board 149 Optimal debulking surgery in patients with advanced uterine carcinosarcoma: A multi-institutional retrospective study from the Japanese Gynecologic Oncology Group. (Abstract 5591) K. Harano, A. Hirakawa, M. Yunokawa, T. Nakamura, T. Satoh, T. Nishikawa, D. Aoki, K. Ito, T. Nakanishi, N. Susumu, K. Takehara, Y. Watanabe, H. Watari, T. Saito Board 150 Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study. (Abstract 5592) A. P. Myers, V. L. Filiaci, Y. Zhang, M. Pearl, K. Behbakht, V. Makker, P. Hanjani, S. Zweizig, J. J. Burke II, G. Downey, K. K. Leslie, M. J. Birrer, G. F. Fleming Board 151 Onapristone (ONA) in progesterone receptor (PR)-expressing tumors: Efficacy and biomarker results of a dose-escalation phase 1 study. (Abstract 5593) P. H. Cottu, A. Italiano, A. Varga, M. Campone, A. Leary, A. Floquet, D. Berton-Rigaud, M. Sablin, A. Lesoin, C. Lhomme, A. S. Bexon, E. M. Gilles, D. Jackson, J. Bisaha, A. Zukiwski, J. Bosq, J. Bonneterre Board 152 Does metformin use affect transporter, hormone receptor and mTOR pathway target expression in endometrial cancers of women with Type II diabetes mellitus? (Abstract 5594) D. R. Roque, A. M. Dizon, B. S. Rambally, S. O’Connor, P. A. Gehrig, S. Denslow, V. L. Bae-Jump Board 153 Molecular profile comparison of endometrial, renal and ovarian clear cell carcinoma: Is it the same disease at different sites? (Abstract 5595) R. Debernardo, H. Mahdi, K. Russell, J. Xiu, S. Z. Millis, S. K. Reddy, M. Friedlander Board 154 Clinical outcomes in advanced cervical cancer (CC) and endometrial cancer (EC) patients (pts) treated in phase I trials of novel molecularly targeted agents (MTAs). (Abstract 5596) A. George, V. Michalarea, S. Rafii, C. O. Michie, M. Wong, R. Bowen, L. Y. Han, T. van Hagen, G. Rallis, U. Banerji, R. S. Kristeleit, J. S. De Bono, S. N. Banerjee, L. R. Molife, M. E. Gore, S. B. Kaye, T. A. Yap Board 155 PET/MRI in cervical cancer: Insights into tumor biology. (Abstract 5597) K. Pinker-Domenig, P. Baltzer, H. Magometschnigg, S. Polanec, P. Andrezejewski, A. E. Sturdza, D. Georg, S. Polterauer, V. Seebacher, A. Reinthaller, T. Helbich, R. Poetter, P. Georg Board 156 Feasibility of a physical activity intervention for ethnically diverse endometrial cancer survivors. (Abstract 5598) A. Rossi, C. Garber, M. Ortiz, A. Moadel-Robblee, G. Kaur, S. Viswanathan, M. H. Einstein, G. L. Goldberg, N. Nevadunsky Board 157 The use of adjuvant treatment in stage I endometrioid endometrial cancer in the National Cancer Database (NCDB). (Abstract 5599) A. Jain, E. Handorf, G. Mantia-Smaldone Board 158 A limited access phase I trial of paclitaxel, cisplatin and ABT-888 in the treatment of advanced, persistent, or recurrent carcinoma of the cervix: An NRG/GOG study. (Abstract 5600) P. H. Thaker, W. E. Brady, H. A. Lankes, D. E. Cohn, C. Aghajanian, D. G. Mutch, R. S. Mannel, K. M. Bell-McGuinn, P. DiSilvestro, D. Jelovac, J. S. Carter, R. Salani Board 159 Evaluation of biomarker alterations in small cell cervical cancer identifies therapeutic options. (Abstract 5601) J. K. Burzawa, S. Z. Millis, S. K. Reddy, I. A. Astsaturov, R. L. Coleman, J. Brown, M. M. Frumovitz Board 160 Comprehensive genomic profiling (CGP) of cervical squamous cell carcinoma (cSCC) to identifiy targeted therapy options. (Abstract 5602) J. A. Elvin, M. Bailey, B. A. Carneiro, S. M. Ali, J. Vergilio, N. A. Palma, J. Chmielecki, 110 Saturday, May 30, 2015 Board 161 Weekly administration of bevacizumab, eribulin, and oxalilplatin in patients with platinum-resistant ovarian carcinomas: A phase II study with biomarker analysis. (Abstract 5603) Y. Ikeda, M. Takano, H. Kouta, K. Kudoh, T. Kita, R. Kikuchi, M. Miyamoto, T. Yoshikawa, T. Goto, K. Furuya, Y. Tamada, A. Suga, Y. Kikuchi Board 162 Impact of older age on chemotherapy toxicity and quality of life in women with advanced or recurrent cervical cancer: A NRG Oncology—GOG Ancillary Study. (Abstract 5604) E. M. Ko, J. Java, K. Schmitz, M. Randall, J. Bloss, G. F. Fleming, D. H. Moore, B. J. Monk, H. B. Muss, L. Van Le Board 163a EUTROC PiSARRO: A phase Ib study combining APR-246 with standard chemotherapy in platinum sensitive relapsed high grade serous ovarian carcinoma (HGSOC). (Abstract TPS5605) C. Gourley, H. Gabra, I. Vergote, B. Basu, J. Brenton, M. Von Euler, U. Björklund, A. M. Smith, J. Green Board 163b A phase III study of trabectedin (T) plus pegylated liposomal doxorubicin (PLD) versus PLD for treatment of advanced-relapsed epithelial ovarian, primary peritoneal, or fallopian tube cancer. (Abstract TPS5606) R. L. Coleman, B. J. Monk, R. E. Knoblauch, T. V. Parekh, S. Triantos, R. S. Maul, Y. C. Park, T. J. Herzog Board 164a ENGOT-OV24-NSGO/AVANOVA: Niraparib versus bevacizumab-niraparib combination versus bevacizumab and niraparib as sequential therapy in women with platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer. (Abstract TPS5607) M. R. Mirza, C. E. Mortensen, E. AvallLundqvist, L. Bjorge, J. S. Berek, J. Herrstedt, A. Juul Holm, T. Kirkegaard, J. Maenpaa Board 164b Multicenter randomized Phase II study of AZD1775 plus chemotherapy versus chemotherapy alone in patients with platinum-resistant TP53-mutated epithelial ovarian, fallopian tube, or primary peritoneal cancer. (Abstract TPS5608) K. N. Moore, D. S. McMeekin, E. P. Hamilton, D. K. Strickland, S. F. Jones, D. M. Stults, N. Laing, D. R. Spigel, H. A. Burris III Board 165a A phase 2, open-label study of niraparib in women with advanced, relapsed, high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer after >3 previous chemotherapy regimens. (Abstract TPS5609) K. N. Moore, B. Rimel, S. Agarwal, J. Balser, R. E. Martell, B. J. Monk Board 165b The MILO (MEK inhibitor in low-grade serous ovarian cancer)/ENGOT-ov11 study: A multinational, randomized, open-label phase 3 study of binimetinib (MEK162) versus physician’s choice chemotherapy in patients with recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum. (Abstract TPS5610) B. J. Monk, R. N. Grisham, C. Marth, S. N. Banerjee, F. Hilpert, R. L. Coleman, E. Pujade-Lauraine, S. Pignata, M. R. Mirza, A. M. Oza, J. M. del Campo, M. K. Oehler, A. James, J. Christy-Bittel, E. Barrett, A. P. Boyd, I. Vergote Board 166a A phase I/II study of Enadenotucirev, an oncolytic Ad11/Ad3 chimeric group B adenovirus, administered intraperitoneally (IP): Dose finding and proof of concept in platinum-resistant epithelial ovarian cancer. (Abstract TPS5611) I. A. McNeish, A. Michael, C. Twelves, R. Glasspool, M. A. Ajaz, R. Morrison, O. Xeniou, R. Brown, K. Fisher, C. Blanc Board 166b Open label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced non-resectable granulosa cell ovarian tumors: The Greko II study—GETHI 2013– 01. (Abstract TPS5612) J. Rodriguez-Moreno, J. Garcı́aDonas, L. Garrigos, N. Laı́nez, A. Santaballa, A. Redondo, J. F. Cueva, M. Rubio, S. Hernando Polo, I. Bover, I. Palacio, Z. Garcia-Casado, E. Grande, A. Hurtado Board 167a A randomized, placebo-controlled phase II trial comparing gemcitabine monotherapy to gemcitabine in combination with AZD 1775 (MK 1775) in women with recurrent, platinum-resistant epithelial ovarian, primary peritoneal, or Fallopian tube cancers: Trial of Princess Margaret, Mayo, 111 SATURDAY G. M. Frampton, D. Lipson, P. Stephens, V. A. Miller, M. L. Johnson, F. J. Giles, J. S. Ross, O. Dorigo Saturday, May 30, 2015 Chicago, and California consortia. (Abstract TPS5613) S. Lheureux, J. I. Weberpals, A. E. Wahner Hendrickson, G. F. Fleming, A. Olawaiye, I. Brana, H. Mackay, N. C. Dhani, M. K. Wilson, V. Rodriguez-Freixinos, C. Martin-Lorente, J. Ward, K. Chang, L. Wang, V. Speers, K. Karakasis, V. L. Bowering, A. Chen, J. Brenton, A. M. Oza SATURDAY Board 167b Targeting VEGFRi resistance through HIF-1á suppression: Phase II clinical trial evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent platinum resistant ovarian cancer. (Abstract TPS5614) C. N. Krasner, M. J. Birrer, S. T. Berlin, M. K. Buss, S. Eliasof, E. G. Garmey, M. Hennessey, N. S. Horowitz, P. Konstantinopoulos, U. A. Matulonis Board 168a A phase I dose-escalation and pharmacokinetic study of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) carboplatin at the time of primary cytoreductive surgery for advanced ovarian, fallopian tube, and peritoneal carcinomas. (Abstract TPS5615) L. M. Randall, D. Gillen, F. W. Liu, K. S. Tewari, R. H. Eskander, K. R. Penner, R. Bristow Board 168b Phase 2 clinical study of onapristone (ONA) in patients (pts) with uterine endometrioid adenocarcinoma (EC) expressing the activated progesterone receptor (APRpos). (Abstract TPS5616) J. Bonneterre, A. Leary, M. Campone, A. Italiano, M. Sablin, A. Floquet, D. Berton-Rigaud, C. Lhommé, A. Lesoin, D. Chocteau-Bouju, M. Fabbro, L. Favier, L. Gladieff, I. Ray-Coquard, A. S. Bexon, E. M. Gilles, J. Bisaha, A. Zukiwski, P. H. Cottu Board 169a Phase II clinical trial of eribulin in advanced or recurrent cervical cancer (CC). (Abstract TPS5617) J. Garcia, Y. G. Lin, S. Louie, E. Yoo, D. D. Tsao-Wei, K. E. Tierney, L. L. Brunette, K. Matsuo, H. Q. Pham, A. A. Yessaian, S. G. Groshen, G. Facio, K. Watkins, L. D. Roman, L. I. Muderspach, A. A. Garcia Board 169b A single arm, single stage phase II trial of trametinib (GSK1120212) and GSK2141795 in persistent or recurrent cervical cancer. (Abstract TPS5618) U. Matulonis, A. A. Wright, S. A. Collins, S. M. Campos, P. Konstantinopoulos, K. MacNeill, S. Morrissey, V. Patterson, C. Whalen, J. Liu Board 170a Phase I trial of nelfinavir added to cisplatin chemotherapy with concurrent pelvic radiation for locally advanced cervical cancer. (Abstract TPS5619) A. E. Garcia-Soto, N. D. McKenzie, L. Portelance, R. P. Castillo, J. M. Pearson, J. J. Hu, J. A. Lucci, L. L. Lin, F. Simpkins 1:15 PM - 4:45 PM Poster Session Head and Neck Cancer Location: S Hall A Abstracts 6012– 6023 will be discussed during the Head and Neck Cancer Poster Discussion Session. See page 135 for session information. Board 335 Final overall survival analysis of EXAM, an international, double-blind, randomized, placebo-controlled phase III trial of cabozantinib (Cabo) in medullary thyroid carcinoma (MTC) patients with documented RECIST progression at baseline. (Abstract 6012) M. Schlumberger, R. Elisei, S. Müller, P. Schöffski, M. S. Brose, M. H. Shah, L. F. Licitra, B. Jarzab, V. Medvedev, M. Kreissl, E. E. Cohen, L. J. Wirth, H. Y. Ali, C. Hessel, Y. Yaron, D. W. Ball, B. Nelkin, S. I. Sherman Board 336 Efficacy and safety of lenvatinib for the treatment of patients with 131Irefractory differentiated thyroid cancer with and without prior VEGF-targeted therapy. (Abstract 6013) K. Newbold, R. Elisei, M. H. Taylor, M. K. Krzyzanowska, M. H. Shah, A. O. Hoff, B. Robinson, C. Dutcus, J. Song, M. A. Habra Board 337 Pharmacodynamic biomarkers of outcomes in the phase III study of lenvatinib in 131I-refractory differentiated thyroid cancer (SELECT). (Abstract 6014) M. Tahara, M. Schlumberger, R. Elisei, M. A. Habra, N. Kiyota, C. Dutcus, J. 112 Saturday, May 30, 2015 Board 338 Analysis of tumor growth rate for radioiodine (RAI)-refractory differentiated thyroid cancer patients receiving placebo and/or sorafenib in the phase III DECISION study. (Abstract 6015) C. Kappeler, D. P. Healy, C. Baumer, G. Meinhardt, R. Elisei, M. Schlumberger, M. S. Brose Board 339 Enriched expression of PD-L1 and other immune targets after epithelialmesenchymal transition (EMT) in squamous head and neck and lung cancers. (Abstract 6016) M. P. Mak, L. Diao, P. Tong, J. Wang, P. Ng, R. Cardnell, D. N. Hayes, G. Robertson, J. Myers, A. K. El-Naggar, W. N. William Jr., K. R. Coombes, J. N. Weinstein, G. B. Mills, J. Heymach, D. L. Gibbons, L. A. Byers Board 340 Inflamed-phenotype gene expression signatures to predict benefit from the anti-PD-1 antibody pembrolizumab in PD-L1ⴙ head and neck cancer patients. (Abstract 6017) T. Y. Seiwert, B. Burtness, J. Weiss, J. P. Eder, J. Yearley, E. Murphy, M. Nebozhyn, T. McClanahan, M. Ayers, J. K. Lunceford, R. Mehra, K. Heath, J. D. Cheng, L. Q. Chow Board 341 PDL1-expressing circulating tumor cells (CTCs) in head and neck squamous cell carcinoma (HNSCC). (Abstract 6018) G. Koutsodontis, A. Strati, M. Avgeris, E. Maratou, V. Ramfidis, G. Konstantinidis, P. Economopoulou, G. Kotsantis, K. Tsigaridas, E. M. Vagia, N. Haralambakis, C. Sasaki, A. Scorilas, C. Perisanidis, M. Vasilakopoulou, A. Strimpakos, E. Lianidou, A. Psyrri Board 342 Utilization and outcomes of low dose versus high dose cisplatin in head and neck cancer patients receiving concurrent radiation. (Abstract 6019) S. J. Wong, L. Li, L. M. Hess, A. Y. Chen, W. J. Curran Jr., P. M. Harari, R. J. Kimple, B. A. Murphy, L. L. Opincar, A. S. Garden Board 343 Differential impact of cisplatin dose intensity on human papillomavirus (HPV)-related (ⴙ) and HPV-unrelated (ⴚ) locoregionally advanced head and neck squamous cell carcinoma (LAHNSCC). (Abstract 6020) A. Spreafico, S. Huang, W. Xu, R. Granata, C. Liu, J. N. Waldron, E. Chen, J. Ringash, A. Bayley, K. K. Chan, A. J. Hope, A. R. Razak, B. Perez-Ordonez, I. Weinreb, P. Bossi, E. Orlandi, L. F. Licitra, B. O’Sullivan, L. L. Siu, J. J. Kim Board 344 Symptom reduction from IMRT dose deintensification: Results from ECOG 1308 using the Vanderbilt Head and Neck Symptom Survey version 2 (VHNSS V2). (Abstract 6021) A. Cmelak, S. Li, S. Marur, W. Zhao, W. H. Westra, C. H. Chung, M. L. Gillison, J. Gilbert, J. E. Bauman, L. I. Wagner, R. L. Ferris, D. R. Trevarthen, B. A. Murphy, T. Galloway, B. Burtness Board 345 Safety analysis of a phase III randomized trial of chemotherapy with or without bevacizumab (B) in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). (Abstract 6022) A. Argiris, S. Li, P. Savvides, A. A. Forastiere, B. Burtness Board 346 Biomarker analysis in recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients (pts) treated with second-line afatinib versus methotrexate (MTX): LUX-Head & Neck 1 (LUX-H&N1). (Abstract 6023) E. E. Cohen, L. F. Licitra, J. Fayette, T. C. Gauler, P. M. Clement, J. J. Grau, J. Del Campo, A. Mailliez, R. I. Haddad, J. B. Vermorken, M. Tahara, J. Guigay, L. Geoffrois, M. C. Merlano, N. F. Dupuis, B. Burtness, N. Gibson, F. Solca, E. Ehrnrooth, J. H. Machiels Board 347 Ultra-deep targeted sequencing to identify HRAS, TP53, and CDKN2A somatic mutations as molecular prognostic markers in patients with advanced oral squamous cell carcinoma. (Abstract 6024) T. Yen, C. Peng, S. Peng, C. Liao, W. Hsieh Board 348 New aspects regarding the induction chemotherapy with TPF and radio chemotherapy in head and neck cancer. (Abstract 6025) E. Boelke, C. Matuschek, S. Gripp, K. Kammers, W. Budach Board 349 Phase I trial of intravenous attenuated vaccinia virus (GL-ONC1) with concurrent chemoradiotherapy (CRT) for locoregionally advanced head and 113 SATURDAY Xu, J. Zhu, T. Hihara, S. McGrath, M. Matijevic, T. Kadowaki, Y. Funahashi, S. I. Sherman Saturday, May 30, 2015 neck carcinoma. (Abstract 6026) L. K. Mell, Y. A. Yu, K. T. Brumund, G. A. Daniels, S. J. Advani, R. A. Weisman, P. R. Sanghvi, P. J. Martin, M. E. Wright, S. Onyeama, Q. Zhang, A. Pold, T. Chamberlin, A. Frentzen, A. A. Szalay SATURDAY Board 350 Can somatic copy number alterations detected by ultradeep targeted sequencing predict prognosis in oral squamous cell carcinoma? (Abstract 6027) T. Yen, S. Chen, C. Liao, H. Chen, H. Liu Board 351 Adjuvant chemo-radiotherapy (CRT) versus radiotherapy (RT) alone for locally advanced salivary gland carcinoma among older population: SEERMedicare analysis. (Abstract 6028) T. Tanvetyanon, K. Fisher, T. Padhya, K. J. Otto, J. J. Caudell, A. Trotti Board 352 Application of a robust and novel ex vivo platform mimicking patient heterogenous tumor microenvironment for personalized cancer treatment. (Abstract 6029) K. Govind Babu, B. Majumder, S. Thiyagarajan, B. Ulaganathan, R. Surindran, A. Shenoy, M. A. Kuriakose, M. Loda, R. Beroukhim, P. Horowitz, S. Agarwal, P. Radhakrishnan, M. Sundaram, S. Sengupta, P. K. Majumder Board 353 Response rates, toxicity, and quality of life for locally regionally advanced head and neck squamous cell carcinoma after induction chemotherapy with weekly nab-paclitaxel, carboplatin, and cetuximab. (Abstract 6030) J. Weiss, J. Gilbert, J. E. Grilley-Olson, A. M. Deal, B. S. Chera, J. J. Liao, B. A. Murphy, M. C. Weissler, D. N. Hayes Board 354 A phase II study of axitinib in patients with recurrent or metastatic nasopharyngeal carcinoma (NPC). (Abstract 6031) E. P. Hui, B. Ma, F. Mo, M. K. Kam, S. L. Chan, H. H. Loong, R. Ho, S. Leung, A. D. King, K. Wang, A. T. Ahuja, C. Chan, C. W. Hui, C. Wong, A. T. Chan Board 355 A gene expression profile to predict recurrence of advanced tongue squamous cell carcinoma (TSCC): Discovery and external validation. (Abstract 6032) T. Enokida, T. Wakasugi, T. Yamazaki, M. Takahashi, Y. Higuchi, R. Hayashi, S. Fujii, M. Tahara Board 356 Genomic landscape of anaplastic thyroid cancer. (Abstract 6033) J. Capdevila, A. Vivancos, X. Matias-Guiu, C. Iglesias, F. Salva, X. Serres, O. Gonzalez, E. Caubet, J. Jimenez, C. Zafon, F. M. Mancuso, G. Caratu, C. Alvarez, R. Mayor, J. Tabernero, J. Seoane Board 357 The SMART strategy: Subdividing M1 stage and aiming remission for target nasopharyngeal carcinoma patients with metachronous metastasis. (Abstract 6034) L. Shen, P. Wu, Y. Xia, W. Li, C. Chen Board 358 A meta-analysis of weekly cisplatin versus three weekly cisplatin chemotherapy plus current radiotherapy for advanced head and neck cancer. (Abstract 6035) Y. Zhang, J. Guan, Q. Li, N. Xiao, L. Li, M. Chen, M. Yang, Y. Dai, C. Zhang, L. Chen Board 359 A meta-analysis comparing cisplatin-based to carboplatin-based chemotherapy in moderate to advanced squamous cell carcinoma of head and neck (SCCHN). (Abstract 6036) Q. Li, J. Guan, Y. Zhang, M. Chen, L. Li, N. Xiao, M. Yang, Y. Dai, C. Zhang, L. Chen Board 360 Phase II study with conventional radiotherapy (RT) ⴙ cetuximab in patients with advanced larynx cancer who responded to induction chemotherapy (IC): An organ preservation TTCC study. (Abstract 6037) R. Mesia, J. Garcia Saenz, A. Lozano, M. Pastor Sr., J. J. Grau, J. Martinez Trufero, J. J. Lambea- Sorrosal, J. Martinez Galan, J. Mel, B. Gonzalez, S. Vazquez, M. Manos Pujol, M. Taberna, B. Cirauqui, E. del Barco, E. Casado, J. Rubió, A. Rodriguez Jaraiz, J. J. Cruz, Spanish Head and Neck Cancer Cooperative Group Board 361 Bioradiotherapy for head and neck cutaneous squamous cell carcinoma. (Abstract 6038) J. D. Palmer, J. Strasser, A. Hanlon, E. A. Mauer, M. Dzeda, N. Hockstein, R. Witt, C. Schneider, A. Raben Board 362 Alliance A091104: A phase II trial of MK-2206 in patients (pts) with progressive, recurrent/metastatic adenoid cystic carcinoma. (Abstract 6039) 114 Saturday, May 30, 2015 Board 363 Comprehensive genomic profiling of salivary gland adenocarcinomas to reveal frequency of druggable targets. (Abstract 6040) M. J. Hawryluk, K. Wang, D. Khaira, J. Chmielecki, S. M. Ali, J. A. Elvin, J. Vergilio, R. Yelensky, D. Lipson, V. A. Miller, P. J. Stephens, J. S. Ross Board 364 Hepatitis C virus seropositivity and head and neck cancers: A new trio. (Abstract 6041) P. Mahale, E. M. Sturgis, H. A. Torres Board 365 The role of cetuximab in induction chemotherapy: Comparison of APF-C (nab-paclitaxel, cisplatin, 5-FU ⴙ cetuximab) with APF, both followed by chemoradiation therapy (CRT), in patients with locally advanced head and neck squamous cell carcinoma (HNSCC). (Abstract 6042) D. Adkins, J. C. Ley, T. M. Wildes, L. S. Michel, J. Rich, R. Paniello, R. Uppaluri, W. L. Thorstad, H. A. Gay, K. Trinkaus, T. Rachocki, B. Nussenbaum Board 366 A phase I trial of the addition of the CDK 4/6 inhibitor palbociclib to cetuximab in patients with incurable head and neck squamous cell carcinoma (HNSCC). (Abstract 6043) L. S. Michel, J. C. Ley, T. M. Wildes, K. Trinkaus, D. Adkins Board 367 Augmenting pre-operative risk of recurrence stratification in differentiated thyroid carcinoma using machine learning and high dimensional transcriptional data from thyroid FNA. (Abstract 6044) S. I. Sherman, M. Pagan, J. Huang, B. Lin, J. Diggans, E. Tom, B. Haugen, R. M. Tuttle, G. Kennedy Board 368 Prognostic value of HPV detection with three primer sets in 255 Head-Neck cancers. (Abstract 6045) C. Lo Nigro, D. Vivenza, M. Monteverde, M. Fortunato, N. Denaro, L. Lattanzio, F. Tonissi, V. Astesana, E. Russi, M. C. Merlano Board 369 Head and neck cancer (HNSCC) subgroups defined by HPV RNA status, gene expression patterns, and TP53 mutations are associated with lymph node metastasis and survival. (Abstract 6046) A. Dietz, G. Wichmann, M. Rosolowski, K. Krohn, M. Kreuz, A. Boehm, D. Halama, D. Holzinger, M. Pawlita, J. Hess, C. Engel, D. Hasenclever, M. Scholz, P. Ahnert, H. Kirsten, A. Hemprich, C. Wittekind, O. Herbarth, M. Loeffler Board 370 Prognostic value of mid-treatment total lesion glycolysis in p16ⴙ oropharyngeal cancer. (Abstract 6047) E. L. Pollom, J. Song, B. Y. Durkee, S. Aggarwal, T. Bui, R. Li, Q. Le, B. W. Loo, W. Hara Board 371 Effect of age and lenvatinib treatment on overall survival for patients with I-refractory differentiated thyroid cancer in SELECT. (Abstract 6048) M. S. Brose, M. Schlumberger, M. Tahara, L. J. Wirth, B. Robinson, R. Elisei, K. Newbold, N. Kiyota, A. O. Hoff, C. Dutcus, J. Song, S. I. Sherman, M. H. Taylor 131 Board 372 Clinical trials outcomes of combined BKM120 and cetuximab compared to BKM120 in recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M-SCCHN). (Abstract 6049) H. Kim, H. Kang, M. Yun, S. Lim, C. Kim, M. Ahn, J. Sun, J. Kim, S. Paik, B. Cho Board 373 Response-adapted volume de-escalation (RAVD) of radiotherapy (RT) using induction chemotherapy (IC) in locally advanced head and neck squamous cell cancer (LA-HNSCC). (Abstract 6050) V. M. Villaflor, E. E. Cohen, J. M. Melotek, R. J. Brisson, T. Karrison, E. A. Blair, L. Portugal, K. Stenson, J. A. De Souza, A. Langerman, T. Y. Seiwert, E. E. Vokes, D. J. Haraf Board 374 Randomized phase II study of cabazitaxel versus methotrexate in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) previously treated with platinum-based therapy. (Abstract 6051) S. Rottey, A. Van Maanen, J. Vandenbulcke, B. Filleul, E. Seront, S. Henry, L. A. D’Hondt, C. Lonchay, S. Holbrechts, P. Boegner, D. J. Brohee, D. Dequanter, I. Louviaux, B. Sautois, N. Whenham, G. J. Berchem, B. Vanderschueren, C. Fontaine, S. Schmitz, J. H. Machiels Board 375 Predictive and prognostic values of post chemoradiotherapy PET/CT and the effect of salvage surgery on survival in head and neck squamous cell 115 SATURDAY A. L. Ho, N. R. Foster, J. P. Meyers, S. Deraje Vasudeva, N. Katabi, C. R. Antonescu, D. G. Pfister, L. E. Horvath, C. Erlichman, G. K. Schwartz Saturday, May 30, 2015 carcinoma (HNSCC). (Abstract 6052) R. Kim, C. Ock, B. Keam, T. Kim, J. Kim, J. Paeng, S. Lee, T. Kwon, D. Kim, H. Wu, M. Sung, D. S. Heo, J. Hah, S. Kwon SATURDAY Board 376 Quality of life (QOL) in a phase III randomized trial of standard fractionation radiotherapy (SFX) with concurrent cisplatin (CIS) versus accelerated fractionation radiotherapy (AFX) with panitumumab (PMab) in patients (pts) with locoregionally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): NCIC Clinical Trials Group HN.6 (NCT00820248). (Abstract 6053) J. Ringash, J. N. Waldron, L. L. Siu, R. Martino, E. Winquist, J. R. Wright, A. Nabid, J. H. Hay, A. Hammond, K. Sultanem, S. Hotte, C. Leong, A. A. El-Gayed, F. Naz, K. Ramchandar, T. E. Owen, A. Montenegro, B. O’Sullivan, B. E. Chen, W. R. Parulekar Board 377 Long-term outcomes for radiotherapy alone verse combined chemoradiotherapy for patients with stage II nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy. (Abstract 6054) M. Hu, F. Pingping, F. Bingjie, Z. Guoli, L. Xijun, Y. Jinming Board 378 Concurrent chemoradiation using weekly versus tri-weekly cisplatin in locally advanced squamous cell carcinoma of the head and neck (SCCHN): A comparative analysis. (Abstract 6055) A. Mohamed, K. Schrapp, T. K. Owonikoko, C. E. Steuer, Z. Chen, S. Pakkala, R. N. Pillai, J. Wadsworth, K. A. Higgins, S. S. Ramalingam, J. J. Beitler, D. M. Shin, F. R. Khuri, M. Behera, N. F. Saba Board 379 Genomic landscape of salivary gland tumors. (Abstract 6056) S. K. Elkin, S. Kato, M. C. Schwaederle, B. N. Tomson, T. L. Helsten, J. Carter, R. Kurzrock Board 380 The phase III clinical study about the effect of Kangfuxin Solution (Chinese herbal medicine compound preparation) on the radiation induced oral and upper gastrointestinal mucositis in nasopharyngeal carcinoma patients. (Abstract 6057) J. Lang, M. Feng, Y. Luo, Z. Fan Sr., Q. Jiang, H. Bai Sr., Y. Huang Board 381 Mucoadhesive clonidine (Clonidine Lauriad) in the prevention of severe radiomucositis in head and neck cancer patients: A phase II randomized trial. (Abstract 6058) J. Giralt, Y. Tao, R. Bensadoun, R. V. Lalla, E. M. Ozsahin, G. Pajkos, R. Kortmann, J. Contreras-Martinez, P. Ceruse, X. Zasadny, F. Arias de la Vega, P. Attali, B. Vasseur, M. Henke Board 383 Molecular profiling of tumour budding to implicate TGF- mediated epithelial-mesenchymal transition as a therapeutic target. (Abstract 6059) D. H. Jensen, E. Dabelsteen, L. Specht, a. K. Fiehn, M. H. Therkildsen, F. C. Nielsen, L. Joenson, J. Vikesaa, C. von Buchwald Board 384 A randomized phase II trial of the MET inhibitor tivantinib ⴙ cetuximab versus cetuximab alone in patients with recurrent/metastatic head and neck cancer. (Abstract 6060) E. E. Vokes, F. P. Worden, D. Adkins, J. E. Bauman, D. Lim, A. Sukari, K. A. Rao, S. A. Wagner, K. K. Curtis, B. J. Gitlitz, K. A. Price, J. L. Wade III, V. M. Villaflor, J. A. De Souza, T. Karrison, W. M. Stadler, T. Y. Seiwert Board 385 Evaluation of the impact of tumor HPV status on outcome in patients with locally advanced unresectable head and neck squamous cell carcinoma (HNSCC) receiving cisplatin, 5-Fluorouracil with or without docetaxel: retrospective analysis of EORTC24971 study. (Abstract 6061) A. Psyrri, C. Fortpied, G. Koutsodontis, M. Avgeris, J. Menis, L. Herman, L. Giurgea, E. Remenar, J. A. Langendijk, A. Awada, P. H. De Mulder, H. R. Kienzer, M. Degardin, A. Kotsinas, S. Oosting, V. Gregoire, L. F. Licitra, J. B. Vermorken Board 386 Treatment-associated mortality in head and neck cancer receiving chemotherapy and radiation: Meta-analysis of published trials. (Abstract 6062) P. Bossi, C. Resteghini, M. Cinquini, C. Bergamini, E. Orlandi, L. D. Locati, R. Granata, S. Alfieri, N. Iacovelli, C. Fallai, L. F. Licitra Board 387 MLH1, MSH2, MSH3 and EXO1 polymorphisms and head and neck squamous cell carcinoma risk and prognosis. (Abstract 6063) G. J. Lourenco, G. A. Nogueira, C. B. Oliveira, F. A. Marson, L. Lopes-Aguiar, E. F. Costa, T. R. Lima, V. T. Liutti, F. Leal, V. A. Santos, J. A. Rinck Jr., C. S. Lima 116 Board 388 Outcomes of head and neck squamous cell carcinomas (HNSCC) treated with reirradiation (RRT) at Mayo Clinic. (Abstract 6064) K. K. Curtis, H. J. Ross, A. L. Garrett, T. A. Jizba, H. Kosiorek, S. H. Patel, W. Wong, M. Y. Halyard, R. L. Foote Board 389 Use of chemotherapy with IMRT reirradiation: MDACC experience. (Abstract 6065) M. A. Edson, A. S. Garden, V. Takiar, G. B. Gunn, C. D. Fuller, D. I. Rosenthal, M. S. Kies, J. Phan Board 390 Double blind multicenter phase III GORTEC trial evaluating the efficacy of oral immune modulating formulae therapy during adjuvant radiochemotherapy in head and neck squamous cell carcinoma (HNSCC). (Abstract 6066) P. Boisselier, P. Graff-Cailleaud, C. Sire, O. Gallocher, S. Lavau-Denes, M. Garcia-Ramirez, M. Alfonsi, D. Cupissol, M. Kaminsky, S. Fiore, N. Flori, H. de Forges, R. Garrel, C. Janiszewski, S. Thezenas, P. Senesse Board 392 Is there a role for induction chemotherapy in the setting of concomitant chemoradiation in locally advanced head and neck cancer: A systematic review and meta-analysis of randomized controlled trials. (Abstract 6068) A. Popovtzer, I. Ben-Aharon, E. E. Cohen, L. Vidal Board 393 Combination of everolimus and sorafenib in the treatment of thyroid cancer: Update on phase II study. (Abstract 6069) E. J. Sherman, A. L. Ho, M. G. Fury, S. S. Baxi, L. Dunn, J. S. Lee, B. L. Lipson, D. G. Pfister Board 394 Characteristics of PD-L1, PD-1 expressions and CD8ⴙ tumor infiltrating lymphocyte in EBV-associated nasopharyngeal carcinoma. (Abstract 6070) K. -. Mahaprom, N. Larbcharoensub, E. Sirachainan, C. Jiarpinitnun, N. Trachu, J. Leopairut, P. Karnsombut, N. Tubthong, D. Pangpunyakulchai, N. Ngamphaiboon Board 395 A pilot, single arm, prospective trial using neoadjuvant rapamycin prior to definitive therapy in head and neck squamous cell carcinoma. (Abstract 6071) K. Shirai, T. A. Day, E. Szabo, C. Van Waes, P. E. O’Brien, M. G. Matheus, K. Godwin, A. J. Sood, J. A. Vick, D. Martin, L. Vitale-Cross, A. Molinolo, J. S. Gutkind Board 396 A phase II study of everolimus (E) and sorafenib (S) in patients (PTS) with metastatic differentiated thyroid cancer who have progressed on sorafenib alone. (Abstract 6072) M. S. Brose, A. B. Troxel, M. Yarchoan, A. B. Cohen, K. Harlacker, N. A. Dyanick, Z. A. Posey, R. Makani, P. Prajapati, L. M. Zifchak, C. Grande, C. M. Squillante Board 397 Landscape of genetic alterations in non-smoking patients with oral tongue carcinoma: An analysis of The Cancer Genome Atlas (TCGA) head and neck squamous cell carcinoma data. (Abstract 6073) N. F. Saba, S. Newman, M. R. Rossi, C. E. Steuer, H. Zhang, M. Patel, J. Wadsworth, M. El-Deiry, K. R. Magliocca, T. K. Owonikoko, F. R. Khuri, D. M. Shin, Z. G. Chen Board 398 Phase I study of cetuximab, intensity-modulated radiotherapy (C-IMRT), and intratumoral EGFR antisense (AS) DNA in patients with locally advanced head and neck cancer (HNC). (Abstract 6074) J. E. Bauman, U. Duvvuri, W. E. Gooding, D. A. Clump, B. J. Karlovits, A. M. Wehbe, F. R. Miller, J. T. Johnson, R. L. Ferris, S. Kim, D. E. Heron, J. Ohr, J. R. Grandis, A. Argiris Board 399 Effect of the extent of lymph node dissection on overall survival in patients treated for oral cavity squamous cell carcinoma. (Abstract 6075) J. L. Shah, M. Kaplan, V. Divi, Q. Le, W. Hara Board 400 Outcomes of elderly patients treated for oral cavity squamous cell carcinoma. (Abstract 6076) J. L. Shah, M. Kaplan, A. D. Colevas, Q. Le, W. Hara Board 401 Low pre-operative absolute monocyte count to predict overall survival benefit for oral cavity squamous cell carcinoma. (Abstract 6077) T. Bui, J. L. Shah, M. Kaplan, A. D. Colevas, Q. Le, W. Hara Board 402 Patterns of CD8ⴙ T-cell infiltration and immune escape mechanisms in head and neck cancer. (Abstract 6078) V. Saloura, Z. Zuo, A. Khattri, H. E. Kohrt, M. W. Lingen, T. Gajewski, M. Kowanetz, E. E. Vokes, T. Y. Seiwert Board 403 Correlation of specific genetic aberrations and signaling pathways with T-cell inflamed phenotype (TCIP) in head and neck cancer and as novel 117 SATURDAY Saturday, May 30, 2015 Saturday, May 30, 2015 candidate biomarkers for checkpoint blockade therapy. (Abstract 6079) Z. Zuo, V. Saloura, H. E. Kohrt, M. K. Keck, A. Khattri, M. W. Lingen, J. P. Kline, T. Gajewski, E. E. Vokes, T. Y. Seiwert SATURDAY Board 404 Comparison of two large, genetically and clinically annotated head and neck cancer (HNC) cohorts (TCGA, CHGC) and differential treatment effects on TP53 mutated, as well as oral cavity cancers. (Abstract 6080) J. Bragelmann, Z. Zuo, A. Khattri, M. K. Keck, V. M. Villaflor, J. DeSouza, D. J. Haraf, M. W. Lingen, E. E. Vokes, T. Y. Seiwert Board 405 Notch1 mutations to define a subgroup of adenoid cystic carcinoma (ACC): Tumor stage, propensity to bone and liver metastasis, risk of relapse, and overall survival. (Abstract 6081) R. Ferrarotto, Y. Mitani, Y. Cai, L. Diao, J. Wang, M. B. Nilsson, B. S. Glisson, M. S. Kies, W. N. William Jr., M. E. Kupferman, P. A. Zweidler-McKay, A. Futreal, A. K. El-Naggar, J. Heymach Board 406 Systematic review and meta-analysis of the safety and efficacy of minimally invasive compared to open thymectomy for thymic malignancies. (Abstract 6082) A. J. Friedant, E. Handorf, S. Su, W. J. Scott Board 407a A phase I study to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary clinical activity of MEDI0562 in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). (Abstract TPS6083) R. S. Leidner, S. P. Patel, M. G. Fury, R. L. Ferris, J. T. McDevitt, M. C. Lanasa, B. S. Glisson Board 407b KEYNOTE-040: A phase III randomized trial of pembrolizumab (MK-3475) versus standard treatment in patients with recurrent or metastatic head and neck cancer. (Abstract TPS6084) E. E. Cohen, J. H. Machiels, K. J. Harrington, B. Burtness, S. W. Shin, C. K. Gause, A. M. Swift, H. Brown, A. M. Perrone, J. D. Cheng, R. F. Swaby, C. Le Tourneau Board 408a Ceritinib in anaplastic thyroid cancer (ATC) with ALK abnormalities. (Abstract TPS6085) S. A. Khan, J. E. Bauman, B. Burtness, A. E. Frankel, J. Harper, R. S. Hughes, P. Kurian, L. L. Myers, L. A. Nedzi, D. L. Schwartz, B. D. Sumer, J. Truelson, H. Zhu Board 408b A Phase 2, multicenter, single-arm, global study of MEDI4736 monotherapy in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): HAWK (NCT02207530). (Abstract TPS6086) D. P. Zandberg, A. Jarkowski III, U. A. Emeribe, T. Goswami, G. Melillo Board 409a TPExtreme randomized trial: TPEx versus Extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma. (Abstract TPS6087) J. Guigay, U. Keilholz, R. Mesia Sr., N. Vintonenko, J. Bourhis, A. Auperin Board 409b Window of opportunity trial of HPV E7 antigen-expressing Listeria-based therapeutic vaccination prior to robotic surgery for HPV-positive oropharyngeal cancer. (Abstract TPS6088) B. Miles, S. Gnjatic, M. Donovan, E. M. Genden, K. Misiukiewicz, R. Krupar, Y. M. Saenger, E. G. Demicco, M. R. Posner, A. G. Sikora 1:15 PM - 4:45 PM Poster Session Patient and Survivor Care Location: S Hall A Abstracts 9512–9523 will be discussed during the Patient and Survivor Care Poster Discussion Session. See page 136 for session information. Board 171 118 Pilot study of family caregiver burden in home hospice: Stress-induced immune changes. (Abstract 9512) A. Ladha, J. S. Kaur, S. Lee, R. A. Vierkant, W. K. Nevala Board 172 Quality of life and satisfaction with care in caregivers of patients with advanced cancer: Results from a trial of early palliative care. (Abstract 9513) J. C. McDonald, N. Swami, B. Hannon, A. Pope, L. W. Le, A. M. Oza, N. B. Leighl, I. Tannock, M. K. Kryzanowska, G. Rodin, C. Zimmermann Board 173 Depression and anxiety among family caregivers of patients with advanced cancer. (Abstract 9514) J. N. Fishbein, R. D. Nipp, A. El-Jawahri, W. F. Pirl, S. Moran, C. McCarty, J. Eusebio, E. R. Gallagher, E. R. Park, V. A. Jackson, J. A. Greer, J. S. Temel Board 174 Intended and unintended consequences: Ethics, communication, and prognostic disclosure in pediatric oncology. (Abstract 9515) J. M. Marron, A. Cronin, T. I. Kang, J. W. Mack Board 175 A randomized, controlled trial of a cardiopulmonary resuscitation (CPR) video decision support tool for seriously ill hospitalized patients with advanced cancer. (Abstract 9516) A. El-Jawahri, J. S. Temel, K. Ramchandran, V. A. Jackson, Y. Chang, E. Walker-Corkery, E. Mann, A. E. Volandes Board 176 Quality of life and mood in patients with advanced cancer: Associations with prognostic understanding and coping style. (Abstract 9517) R. D. Nipp, A. El-Jawahri, W. F. Pirl, J. N. Fishbein, S. Moran, C. McCarty, J. Eusebio, E. R. Gallagher, E. R. Park, V. A. Jackson, J. A. Greer, J. S. Temel Board 177 Clinical performance of the DigniCap system, a scalp hypothermia system, in preventing chemotherapy-induced alopecia. (Abstract 9518) H. S. Rugo, P. Klein, S. A. Melin, S. A. Hurvitz, M. E. Melisko, A. Moore, G. D. Park, E. Bageman, R. D’Agostino Jr., E. S. Ver Hoeve , T. Cigler Board 178 Chronic health conditions (CHCs) following cisplatin-based chemotherapy (CHEM): A multi-institutional study of 680 testicular cancer survivors (TCS). (Abstract 9519) M. I. Abu Zaid, H. D. Sesso, C. Fung, D. R. Feldman, R. J. Hamilton, D. J. Vaughn, C. Beard, M. J. Moore, D. M. Sahasrabudhe, E. Johnson, S. Fossa, L. H. Einhorn, L. B. Travis, The Platinum Study Group Board 179 Comparison between clinician- and patient-reporting of baseline (BL) and post-BL symptomatic toxicities in cancer cooperative group clinical trials (NCCTG N0591 [Alliance]). (Abstract 9520) T. M. Atkinson, D. V. Satele, J. A. Sloan, D. Mehedint, J. M. Lafky, E. M. Basch, A. C. Dueck Board 180 Long-term safety of fertility preservation by ovarian stimulation and concurrent aromatase inhibitor treatment in women with breast cancer. (Abstract 9521) K. Oktay, V. Turan, J. Kim Board 181 The impact of adjuvant breast cancer (BC) chemotherapy on ovarian reserve and menses. (Abstract 9522) S. B. Goldfarb, G. Bedoschi, E. Grunblatt, S. Goswami, T. Cigler, J. Quistorff, F. Pacheco, R. Stobezki, M. E. Robson, F. Moy, C. A. Hudis, S. Patil, M. N. Dickler, K. Oktay Board 182 Treatment-related amenorrhea among young women one year following diagnosis of early-stage breast cancer. (Abstract 9523) P. D. Poorvu, S. I. Gelber, S. M. Rosenberg, R. M. Tamimi, K. J. Ruddy, S. L. Bober, V. F. Borges, S. E. Come, L. Schapira, A. H. Partridge Board 183 Differences in attitudes and beliefs toward end-of-life treatments between hematologic (Heme) and solid tumor (ST) oncology specialists. (Abstract 9524) D. Hui, S. Bansal, M. Park, A. S. Reddy, J. E. Cortes, F. V. Fossella, E. Bruera Board 184 Quality of life, depression, and end-of-life outcomes in hospitalized patients with advanced cancer. (Abstract 9525) K. E. Hudson, S. P. Wolf, A. P. Abernethy, T. W. LeBlanc Board 185 Trends and regional variation of end-of-life cancer care in the Medicare program. (Abstract 9526) S. Wang, J. Hall, J. B. Long, C. E. Pollack, E. Bradley, K. B. Adelson, C. P. Gross Board 186 Burden of inpatient care and treatments in terminally-ill cancer patients: results from a population-based, retrospective study from administrative 119 SATURDAY Saturday, May 30, 2015 Saturday, May 30, 2015 data in France. (Abstract 9527) L. Morin, R. Aubry, Y. Beaussant, P. Rochigneux, F. Goldwasser, C. Tournigand SATURDAY Board 187 Exploring the preferences for place of death among cancer patients and their caregivers. (Abstract 9528) M. Vidal, A. Rodriguez Nunez, D. Hui, J. Allo, J. L. Williams, M. Park, S. Frisbee-Hume, E. Bruera Board 188 Practice pattern treating older women with early stage breast cancer at Johns Hopkins. (Abstract 9529) Y. G. Pollock, A. Blackford, S. Jeter, A. CiminoMathews, M. Camp, S. Harvey, F. Asrari, J. Wright, V. Stearns Board 189 Frailty and outcomes in older adults undergoing pancreaticoduodenectomy. (Abstract 9530) T. M. Le, G. Nielsen, M. Smolkin, W. Dale, E. E. Ramsdale Board 190 Evaluation of two different doses of weekly nab-paclitaxel (NP) in older breast cancer (BC) patients (pts). (Abstract 9531) L. Biganzoli, L. Orlando, A. Minisini, M. Pistelli, S. Spazzapan, E. Simoncini, E. R. Caremoli, S. Leo, D. Baldari, E. Zafarana, P. Fedele, E. Magnolfi, L. Pavesi, A. Brunello, A. Molino, S. De Placido, D. Tomcikova, A. Di Leo, F. Puglisi Board 191 Novel method to stratify elderly patients with prostate cancer. (Abstract 9532) R. Carmona, K. Zakeri, G. B. Green, D. P. Triplett, J. D. Murphy, L. K. Mell Board 192 Health related quality of life (HRQOL) in older adults with cancer: The potential of a single-item screen. (Abstract 9533) M. Pergolotti, A. M. Deal, G. R. Williams, J. T. Bensen, A. L. Bryant, B. B. Reeve, H. B. Muss Board 193 Novel method to stratify elderly patients with head and neck cancer. (Abstract 9534) R. Carmona, G. B. Green, K. Zakeri, S. Gulaya, B. Xu, R. Verma, C. Williamson, B. S. Rose, J. D. Murphy, F. Vaida, L. K. Mell Board 194 Construction of a frailty index for older adults with cancer using a geriatric assessment. (Abstract 9535) E. J. Guerard, A. M. Deal, G. R. Williams, T. A. Jolly, W. A. Wood, H. B. Muss Board 195 Feasibility of administering a geriatric assessment to older adults with cancer using web-based and touchscreen platforms. (Abstract 9536) J. G. Kim, C. Akiba, D. Mitani, D. D. Smith, M. J. Loscalzo, S. J. Forman, M. Koczywas, S. K. Pal, V. M. Chung, N. Nathwani, M. Fakih, L. Popplewell, B. R. Ferrell, V. Katheria, A. Hurria Board 196 Is standard dose appropriate in elderly non-small cell lung carcinoma (NSCLC) patients treated with erlotinib? (Abstract 9537) F. Bigot, J. Arrondeau, P. Boudou-Rouquette, J. Chapron, A. Thomas-Shoemann, A. Cessot, O. Huillard, C. Tlemsani, A. Le Bel, M. Vidal, J. Alexandre, A. Chahwakilian, D. Dusser, B. Blanchet, F. Goldwasser Board 197 Functional decline during first-line chemotherapy in elderly patients can be predicted by abnormal G8 score and performance status. (Abstract 9538) C. Chakiba, C. A. Bellera, M. Fonck, J. Blanc, J. Ceccaldi, Y. Imbert, L. Cany, J. Dauba, H. Caillou, S. Mathoulin-Pélissier, M. Rainfray, P. Soubeyran Board 198 Association of baseline pro-inflammatory (IL-6, CRP) and coagulation (D-dimer) markers with relative dose intensity (RDI) in women with breast cancer (BC) undergoing (neo) adjuvant chemotherapy (chemo). (Abstract 9539) Y. Yuan, N. L. Vora, D. D. Smith, T. W. Synold, J. E. Mortimer, T. H. Luu, G. Somlo, J. R. Waisman, J. Chao, A. Levi, J. Choi, V. Katheria, V. Tran, S. Mi, L. Zavala, A. Hurria Board 199 Combination of eribulin (E) and capecitabine (C) in elderly metastatic breast cancer (MBC): Update of a new option suitable in older elderly. (Abstract 9540) I. U. Carreca, G. Bronte, A. Carreca, V. Bazan, D. Cova, A. Russo Board 200 Safety of biosimilar filgrastim in elderly patients undergoing neutropeniainducing chemotherapy: a subanalysis of the NEXT study. (Abstract 9541) D. Kamioner, F. Maloisel, S. Leprêtre, C. Berthou, H. Albrand Board 201 Association of geriatric assessment factors with falls in older adults initiating chemotherapy. (Abstract 9542) T. M. Wildes, W. P. Tew, R. J. Maggiore, B. J. Edwards, H. J. Cohen, D. D. Smith, S. G. Mohile, C. Owusu, H. D. 120 Saturday, May 30, 2015 Board 202 Feasibility of a home-based walking program in female breast cancer patients age 60ⴙ during chemotherapy. (Abstract 9543) K. A. Nyrop, A. M. Deal, S. M. Alston, S. A. Dixon, H. Muss Board 203 Do quality of life, physical function, or the Wheatley Index at diagnosis predict 1-year survival with intensive chemotherapy in older and younger acute myeloid leukemia patients? (Abstract 9544) N. Timilshina, H. Breunis, G. A. Tomlinson, J. M. Brandwein, S. M. Alibhai Board 204 Differences between patient and caregiver assessments and their association with caregiver burden in caregivers of older adults with cancer. (Abstract 9545) T. Hsu, M. Loscalzo, R. Ramani, S. J. Forman, L. Popplewell, K. L. Clark, V. Katheria, R. Strowbridge, R. Rinehart, K. Matthews, J. Dillehunt, T. Feng, D. D. Smith, A. Hurria Board 205 Advanced cancer patients’ reported priorities regarding wishes at the end of life: A randomized controlled study. (Abstract 9546) M. O. Delgado-Guay, V. J. De la Cruz, S. Frisbee-Hume, J. L. Williams, J. Wu, D. D. Liu, M. Fisch, E. Bruera Board 206 Evaluation of the MPM2 score versus clinical predictions of mortality in a tertiary cancer center. (Abstract 9547) A. Wiesenthal, V. Dave, H. T. Thaler, P. A. Glare Board 207 Distress in older adult cancer patients approaching end of life. (Abstract 9548) E. A. Kvale, G. B. Rocque, K. S. Bevis, A. Acemgil, R. A. Taylor, W. DemarkWahnefried, K. Kenzik, Y. Li, K. Meneses, M. Martin, M. Fouad, E. E. Partridge, M. Pisu Board 208 “Months, Not Years”: Impact of Clinical Discussions of Advanced Cancer Life-Expectancy on Patient Illness Understanding. (Abstract 9549) A. S. Epstein, H. G. Prigerson, L. Saltz, E. M. O’Reilly, M. A. Shah, P. K. Maciejewski Board 209 Standardizing measurement of tobacco use in cancer clinical trials. (Abstract 9550) S. R. Land, G. W. Warren, C. Moinpour, J. S. Ostroff, J. Crafts, J. Folz, J. L. Gulley, E. Szabo, V. Chollette, T. H. Brandon, S. Duffy, D. K. Hatsukami, C. M. Dresler, E. R. Gritz, R. Schnoll, L. Sarna, N. Rigotti, J. C. Buckner, S. A. Mitchell, B. Toll Board 210 Dissonance reduction as prominent coping strategy in phase I study participants. (Abstract 9551) D. A. van der Biessen, D. Klein, P. G. van der Helm, M. P. Lolkema, R. H. Mathijssen, M. J. De Jonge Board 211 Twelve-month prevalence of mental disorders in cancer patients across major tumor entities. (Abstract 9552) A. Mehnert, S. Kuhnt, E. Brähler, H. Faller, M. Härter, M. Keller, H. Schulz, K. Wegscheider, J. Weis, H. Wittchen, U. Koch Board 212 Psychosocial distress and its effects on the health-related quality of life of primary brain tumor patients. (Abstract 9553) D. M. Randazzo, F. McSherry, J. E. Herndon II, M. L. Affronti, E. S. Lipp, C. Flahiff, E. Miller, S. Woodring, M. Freeman, P. Healy, J. Minchew, S. Boulton, A. Desjardins, G. Vlahovic, H. S. Friedman, S. T. Keir, K. B. Peters Board 213 Patient-reported outcomes following choice for contralateral prophylactic mastectomy. (Abstract 9554) E. S. Hwang, C. Rushing, T. D. Locklear, G. Samsa, A. P. Abernethy, D. M. Atisha Board 214 Relationship between physician-adjudicated adverse events (AE) and patient-reported health-related quality of life (HRQoL) in a phase II clinical trial of patients (pts) with metastatic uveal melanoma (UM). (Abstract 9555) T. M. Atkinson, J. L. Hay, L. A. Doyle, D. Paucar, S. C. Smith, Y. Li, R. D. Carvajal Board 215 Change in second-hand smoke exposure after a lung and head and neck cancer diagnosis and subsequent patient smoking cessation. (Abstract 9556) L. Eng, D. Alton, T. Yoannidis, Y. Song, R. Milne, S. Sarabia, Z. Merali, S. Habbous, M. Brown, A. Vennettilli, F. A. Shepherd, N. Leighl, A. J. Hope, D. Howell, J. M. Jones, P. Selby, W. Xu, D. P. Goldstein, M. E. Giuliani, G. Liu 121 SATURDAY Klepin, C. P. Gross, S. M. Lichtman, A. Gajra, V. Katheria, C. Akiba, A. Hurria, The Cancer and Aging Research Group Saturday, May 30, 2015 SATURDAY Board 216 Psychological distress during hospitalization for hematopoietic stem cell transplantation to predict lower quality of life and high post-traumatic stress disorder symptoms at 6 months post-transplant. (Abstract 9557) H. VanDusen, L. Traeger, J. N. Fishbein, T. Keenan, J. A. Greer, W. F. Pirl, V. A. Jackson, J. Eusebio, E. R. Gallagher, T. A. Graubert, J. M. Peppercorn, T. R. Spitzer, K. K. Ballen, S. L. McAfee, B. Dey, Y. A. Chen, J. S. Temel, A. El-Jawahri Board 217 Treatment-adherence beliefs and behaviors in patients with chronic myeloid leukemia (CML). (Abstract 9558) J. S. Buzaglo, C. Karten, M. F. Miller, J. A. Greer, E. S. Weiss, M. J. Mauro Board 218 Association between oncologists’ dispositional affect and depressive symptoms in their patients with metastatic cancer. (Abstract 9559) W. F. Pirl, J. Lerner, J. Eusebio, L. Traeger, L. Fields, A. El-Jawahri, J. A. Greer, J. S. Temel Board 219 Mild cognitive impairment (MCI) in chemotherapy-treated breast cancer survivors. (Abstract 9560) A. Gifford, J. Lawrence, D. Case, S. Rapp, L. Baker, S. Craft, D. L. Groteluschen, H. Klepin, G. Lesser, M. J. Naughton, B. Sachs, T. A. Samuel, K. Sink, J. Williamson, E. G. Shaw Board 220 The price of survival: Breast cancer patient preferences about fertility. (Abstract 9561) A. Srikanthan, E. Amir, A. A. Gupta, N. N. Baxter, E. D. Kennedy Board 221 Young adult cancer survivors’ expectations of physicians for reproductive and sexual health care. (Abstract 9562) Y. Wang, P. Camateros, W. Y. Cheung Board 222 Second primary malignancies in hepatocellular carcinoma: A populationbased study. (Abstract 9563) B. K. Shah, P. Kandel, A. Khanal Board 223 A comparison of the natural history of oxaliplatin- and paclitaxel-induced neuropathy (NCCTG N08C1, N08CB/Alliance). (Abstract 9564) K. J. Ruddy, D. Pachman, R. Qin, D. K. Seisler, E. M. Smith, S. Puttabasavaiah, P. J. Novotny, L. E. Ta, A. S. Beutler, N. D. Wagner-Johnston, N. Staff, A. Grothey, S. R. Dakhil, C. L. Loprinzi Board 224 Effects of strength training intervention in breast cancer survivors. (Abstract 9565) J. Monterroso, K. Dittus, A. Crocker, N. Kokinda, P. O’Brien Board 225 A randomized controlled trial (RCT) of a supportive care package (SurvivorCare, SC) for survivors of colorectal cancer (CRC). (Abstract 9566) M. Jefford, K. Gough, A. Drosdowsky, L. Russell, S. Aranda, P. N. Butow, J. Phipps-Nelson, J. Young, M. Krishnasamy, A. Ugalde, D. King, A. Strickland, M. E. Franco, R. h. Blum, C. Johnson, V. Ganju, J. D. Shapiro, G. Chong, J. Charlton, P. Schofield Board 226 Results of the ASCO survey of cancer survivorship research: Summary and implications. (Abstract 9567) P. B. Jacobsen, J. H. Rowland, E. D. Paskett, F. Van Leeuwen, C. S. Moskowitz, S. Katta, D. Wollins, L. L. Robison Board 227 Household secondhand smoke exposure among community-dwelling cancer survivors in the United States. (Abstract 9568) O. Akinboro, O. Olorunfemi, I. R. Hantman, P. Basak, E. Phillips, D. Pomerantz, B. Bernhardt, R. A. Gucalp, S. Jesmajian Board 228 Racial differences in upper extremity function for breast cancer survivors. (Abstract 9569) L. T. Dean, A. DeMichele, S. Q. Li, C. Colameco, A. J. StephensShields, M. Coursey, J. J. Mao Board 229 Comprehensive characterization of cisplatin-related hearing loss in U.S. and Canadian Testicular Cancer Survivors (TCS). (Abstract 9570) H. E. Wheeler, L. B. Travis, A. Budnick, D. R. Feldman, L. H. Einhorn, R. J. Hamilton, D. J. Vaughn, C. Beard, C. Fung, E. Johnson, M. J. Moore, D. M. Sahasrabudhe, S. D. Fossa, H. D. Sesso, M. Dolan, R. D. Frisina, The Platinum Study Group Board 230 TOPS: A randomised controlled trial of a multidisciplinary intervention for post-cancer fatigue. (Abstract 9571) C. Sandler, D. Goldstein, S. Horsfield, B. K. Bennett, M. Friedlander, P. A. Bastick, C. R. Lewis, E. Segelov, F. M. Boyle, M. T. Chin, B. K. Barry, K. Webber, A. R. Lloyd, TOPS Investigators 122 Board 231 Phase II feasibility study of a physical activity and dietary change weight loss intervention in a subset analysis of breast cancer survivors (SWOG S1008). (Abstract 9572) H. Greenlee, D. Lew, D. L. Hershman, J. P. Pierce, L. K. Hansen, V. A. Newman, J. Korner, A. Sayegh, L. Fehrenbacher, S. S. Lo, J. R. Klemp, K. Rinn, J. M. Robertson, J. M. Unger, J. Gralow, K. S. Albain, R. S. Krouse, C. J. Fabian Board 232 Survival outcome of cancer patients with pericardial effusions. (Abstract 9573) D. El Haddad, C. Iliescu, W. N. William Jr., E. Mouhayar Board 233 Cancer survivors’ experiences with insurance, employment and personal finances: Results from a multi-site study. (Abstract 9574) L. Nekhlyudov, R. Walker, R. Ziebell, B. Rabin, S. Nutt, J. Chubak Board 234 Distress in cancer survivors attending a multidisciplinary survivorship clinic. (Abstract 9575) T. B. Sanft, L. Epstein, S. Capozza, M. Harrigan, M. A. Jauk, A. Khairallah, J. Jorge, L. Sokoloff, S. Chen, A. B. Chagpar, M. L. Irwin Board 235 Prevalence of hypogonadism in patients with previously treated germ cell tumors. (Abstract 9576) T. J. Miller, L. H. Einhorn, N. H. Hanna, V. Champion, P. Monahan, T. E. Stump, M. J. Brames, S. Case-Eads Board 236 Self-efficacy through survivorship: Results from the LIVESTRONG Cancer Navigation Study. (Abstract 9577) B. Hemingway, S. R. Arvey, R. Rechis, L. Squiers, E. Eargle, K. Treiman Board 237 Cardiac care after myocardial infarction in cancer survivors: A populationbased study. (Abstract 9578) K. K. Chan, A. Yan, W. Y. Cheung, C. Earle, D. Ko Board 238 Healthcare plan and provider ratings among cancer survivors. (Abstract 9579) M. T. Halpern, M. Urato, M. Schwartz, E. E. Kent Board 239 Using survivorship care plans (SCP) to improve cancer communication and care coordination. (Abstract 9580) D. Mayer, A. M. Deal, J. M. Crane, R. C. Chen, G. Asher, L. Hanson, S. B. Wheeler, A. Gerstel, M. Green, D. L. Rosenstein Board 240 Cancer patients’ attitudes, knowledge, and preferences for smoking cessation (SC). (Abstract 9581) L. Eng, D. Alton, T. Yoannidis, Q. Kong, R. Milne, S. Sarabia, Z. Merali, L. Murphy, M. Brown, J. N. Waldron, A. Pierre, A. Bezjak, A. J. Hope, D. Howell, J. M. Jones, P. Selby, W. Xu, D. P. Goldstein, M. E. Giuliani, G. Liu Board 241 Degradation of extracellular matrix measured in serum for predicting mortality risk in women diagnosed with cancer: The Prospective Epidemiologic Risk Factor (PERF I) study. (Abstract 9582) N. Willumsen, S. N. Kehlet, C. L. Bager, K. Dragsbaek, J. Neergaard, H. B. Hansen, A. Bay-Jensen, D. J. Leeming, C. Christiansen, M. A. Karsdal Board 242 Outcomes and predictors of hospital mortality in metastatic cancer patients receiving life sustaining treatments (LSTs). (Abstract 9583) K. Loh, M. Shieh, A. J. Kansagra, P. Lindenauer, P. Pekow, M. Stefan, T. Lagu Board 243 Treatment-specific risks of second malignancy and cardiovascular disease in Hodgkin lymphoma survivors. (Abstract 9584) S. de Vries, F. A. van Nimwegen, M. Schaapveld, P. J. Lugtenburg, A. D. Krol, J. M. Roesink, J. M. Raemaekers, B. M. Aleman, F. Van Leeuwen Board 244 Sexual morbidity and unmet needs among members of a metastatic breast cancer registry. (Abstract 9585) J. S. Buzaglo, M. F. Miller, B. L. Andersen, M. Longacre, P. A. Robinson Board 245 QOL at 3 years after diagnosis in aggressive lymphoma survivors. (Abstract 9586) C. A. Thompson, M. J. Maurer, C. Allmer, S. M. Ansell, R. M. Ferzoco, T. M. Habermann, D. J. Inwards, P. B. Johnston, R. Klebig, W. R. Macon, I. N. Micallef, K. J. Yost, U. Farooq, B. K. Link, J. R. Cerhan Board 246 Employment and quality of life (QOL) in human papillomavirus-related (HPVⴙ) oropharynx cancer treated with definitive chemoradiation (CTRT). (Abstract 9587) S. S. Baxi, H. Xiao, M. G. Fury, C. L. Atoria, L. Dunn, T. Salz, E. J. Sherman, A. L. Ho, N. Y. Lee, D. G. Pfister 123 SATURDAY Saturday, May 30, 2015 Saturday, May 30, 2015 SATURDAY Board 247 Young and strong: A randomized study to improve care for young women with breast cancer. (Abstract 9588) A. H. Partridge, K. J. Ruddy, W. T. Barry, M. Greaney, J. A. Ligibel, K. Sprunck-Harrild, S. M. Rosenberg, E. Baker, J. R. Hoverman, K. Emmons Board 248 A feasibility study of an electronic interface between Internet-based survivorship care plans and electronic medical records (EMR)/tumor registries. (Abstract 9589) C. Hill-Kayser, L. A. Jacobs, S. C. Palmer, M. K. Hampshire, C. Vachani, S. B. Edge, E. J. McNamara, J. M. Metz Board 249 Failure to follow directions for prescription medications to save money among cancer survivors. (Abstract 9590) A. Jemal, Z. Zheng, T. Wang, X. Han Board 250 Prediction models of smoking cessation in lung and head and neck cancer patients: Role of second-hand smoke (SHS) exposure. (Abstract 9591) G. Liu, Y. Song, D. Alton, T. Yoannidis, R. Milne, S. Sarabia, Z. Merali, S. Habbous, M. Brown, A. Vennettilli, A. J. Hope, D. Howell, J. M. Jones, P. Selby, D. P. Goldstein, M. E. Giuliani, W. Xu, L. Eng Board 251 Sexual and marital dysfunction in women with gynecologic cancer: A multi-institutional, cross-sectional trial. (Abstract 9592) S. Guntupalli, D. Flink, J. Sheeder, J. Leifermann, A. I. Tergas, Y. Ioffe, J. D. Wright, K. Behbakht Board 252 National data on sorafenib therapy adherence for veterans with hepatocellular carcinoma. (Abstract 9593) S. Malhotra, D. P. Wu, Y. A. Park Board 253 A phase II randomized, double-blind, placebo-controlled study to evaluate naldemedine for the treatment of opioid-induced constipation (OIC) in patients with cancer pain. (Abstract 9594) N. Boku, N. Katakami, S. Fujita, K. Oda, K. Tauchi, K. Nakata, K. Shinozaki, M. Okuno, Y. Kawai, H. Kikukawa, R. Suzuki, H. Nakazawa, H. Kojima, M. Mizutani, T. Hara, T. Yokota, Y. Suzuki, M. Narabayashi Board 254 Can pregabalin prevent paclitaxel-associated neuropathy?: A pilot trial. (Abstract 9595) S. S. Shinde, D. K. Seisler, G. S. Soori, P. J. Atherton, D. R. Pachman, J. M. Lafky, K. J. Ruddy, C. L. Loprinzi Board 255 Predictors of hand-foot syndrome (HFS) in randomised double-blind, placebo-controlled trial of pyridoxine for prevention of capecitabine induced HFS. (Abstract 9596) Y. Yap, L. Kwok, R. C. Ng, N. Wong, S. Lo, W. Chay, J. W. Chia, C. Tham, S. Tan, V. Z. Mok, J. K. Koh, M. Loh, H. Toh, W. Koo, R. C. Soong, S. Choo Board 256 Should all antiemetic guidelines recommend adding a NK1 receptor antagonist (NK1RA) in patients (pts) receiving carboplatin (carbo)? Efficacy evaluation of NEPA, a fixed combination of the NK1RA, netupitant, and palonosetron. (Abstract 9597) K. Jordan, R. J. Gralla, G. Rizzi Board 257 Palonosetron or granisetron for prevention of CINV in patients with breast cancer receiving dexamethasone and fosaprepitant following anthracycline plus cyclophosphamide (AC) regimen. (Abstract 9598) K. Matsumoto, M. Takahashi, K. Sato, T. Takano, Y. Ryushima, M. Doi, K. Aogi, K. Fujiwara, K. Tamura, M. Hosoda, S. Tokunaga, A. Makiyama, K. Miyamoto, Y. Hozumi, K. Yanagihara, C. K. Imamura, Y. Chiba, S. Nakamura, T. Saeki, WJOG: West Japan Oncology Group Board 258 Use of mobile device technology to collect patient-reported symptoms during radiotherapy for head and neck cancer: A prospective feasibility study. (Abstract 9599) A. D. Falchook, G. Tracton, L. Stravers, M. Fleming, B. B. Reeve, E. M. Basch, B. S. Chera Board 259 Association of severe pain with poor response to opioids, psychological distress, and aberrant drug taking behaviors in a large cohort of cancer patients. (Abstract 9600) V. Dave, R. Roberts, Y. Griffo, N. Moryl, R. Tickoo, K. Cubert, A. Gulati, J. Hung, V. Puttanniah, S. Horn, P. Brown, V. Malhotra, P. A. Glare, C. Inturrisi Board 260 Minimal clinically important differences in the Edmonton Symptom Assessment Scale in cancer patients: A prospective study. (Abstract 9601) D. 124 Saturday, May 30, 2015 Board 261 Safety and efficacy of eltrombopag (EPAG) vs placebo (PBO) for treatment of chemotherapy (CTx)-induced thrombocytopenia (TCP) in patients (Pts) with solid tumors receiving gemcitabine (GEM)-based CTx: A phase 2 study. (Abstract 9602) E. S. Winer, H. Safran, F. Forget, B. Karaszewska, S. Bauer, D. Khan, B. M. Johnson, P. M. Burgess, D. C. Althouse, G. Chan, Y. Mostafa Kamel Board 262 Febrile neutropenia risk factors: A subanalysis of the NEXT study. (Abstract 9603) N. Jovenin, F. Maloisel, S. Leprêtre, D. Kamioner, C. Berthou, H. Albrand Board 263 Pilot trial assessing the efficacy and safety of a supplemental B vitamin complex to reduce the onset and severity of chemotherapy-induced peripheral neuropathy. (Abstract 9604) J. M. Schloss, M. Colosimo, C. Airey, A. W. Linanne, P. Masci, L. Vitetta Board 264 Prospective multicenter study evaluating adrenal suppression after dexamethasone therapy as an antiemetic in cancer patients: a KSWOG (Korean South West Oncology Group) study. (Abstract 9605) H. Han, J. Park, S. Park, K. Lee, S. Bae, H. Kim, S. Kim, H. Yun, W. Bae, H. Shim, J. Hwang, S. Cho, M. Park Board 265 Patient self-evaluation of side-effects related to adjuvant chemotherapy in breast cancer: A prospective study. (Abstract 9606) F. Montemurro, G. Mittica, C. Cagnazzo, M. Foresto, V. Longo, P. Berchialla, G. Solinas, P. Culotta, R. Martinello, A. Calori, B. Grasso, C. Volpone, G. Bertola, G. Parola, M. Del Torre, P. Giuliano, M. Aglietta, A. Ballari Board 266 Identifying predictors of taxane-induced peripheral neuropathy using shotgun proteomics technology. (Abstract 9607) M. S. Trivedi, E. I. Chen, D. Awad, A. Koller, P. Patel, K. Kalinsky, M. A. Maurer, K. D. Crew, D. L. Hershman Board 267 A randomized trial of vitamin D3 in aromatase inhibitor-associated musculoskeletal symptoms. (Abstract 9608) A. C. Shapiro, S. A. Adlis, S. Liang, K. Robien, M. N. Kirstein, E. Anderson, R. E. Lerner Board 268 Usefulness of denosumab to nonsquamous non-small cell lung cancer patients with bone metastases. (Abstract 9609) H. Udagawa, S. Niho, K. Kirita, S. Umemura, S. Matsumoto, K. Yoh, H. Ohmatsu, K. Goto Board 269 Phase II study of preventive effect of topical menthol for chemotherapyinduced peripheral neurotoxicity. (Abstract 9610) K. Nakamura, M. Nakamura, T. Onikubo, K. Uchibori, K. Tauchi Board 270 Longitudinal study of pneumonitis and esophagitis-related symptoms in patients receiving concurrent chemoradiation for NSCLC. (Abstract 9611) X. S. Wang, Q. Shi, C. S. Cleeland, M. O’Reilly, T. Xu, R. H. Bokhari, D. R. Gomez, Q. Nguyen, R. Komaki, R. Mohan, J. D. Cox, Z. X. Liao Board 271 The conversion ratio (CR) for opioid rotation (OR) from strong opioids to transdermal fentanyl (TDF) in cancer patients. (Abstract 9612) A. S. Reddy, A. Haider, S. Tayjasanant, J. Wu, D. D. Liu, S. Yennu, M. De la Cruz, M. Vidal, S. K. Reddy, E. Bruera Board 272 Association of high symptom burden with oral oncolytic agents. (Abstract 9613) J. A. Severson, E. R. Mackler, B. Marini, D. W. Blayney Board 273 Randomized pilot study comparing high-dose (HD) influenza vaccine to standard-dose (SD) influenza vaccine in adult oncology patients younger than 65 receiving chemotherapy. (Abstract 9614) S. Jamshed, A. R. Falsey, L. J. Dimitroff, J. S. Santelli, E. E. Walsh Board 274 Impact of rolapitant on quality of life (QoL) in patients (pts) receiving highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC). (Abstract 9615) M. Chasen, L. Urban, I. Schnadig, B. L. Rapoport, A. Poma, S. Arora, R. M. Navari, L. S. Schwartzberg, C. Gridelli Board 275 Evaluation of brain-derived neurotrophic factor (BDNF) genetic polymorphism (rs6265) on chemotherapy-associated cognitive impairment in 125 SATURDAY Hui, O. M. Shamieh, C. E. Paiva, P. Perez-Cruz, J. Kwon, M. Muckaden, M. Park, S. Yennu, J. Kang, E. Bruera Saturday, May 30, 2015 early-stage breast cancer (ESBC) patients. (Abstract 9616) T. NG, S. Teo, H. Yeo, M. Shwe, Y. Gan, Y. Cheung, Y. Tan, W. Yong, P. Madhukumar, K. Loh, S. Koo, A. Jain, G. Lee, M. Wong, R. A. Dent, Y. Yap, R. C. Ng, C. Khor, H. Ho, A. Chan SATURDAY Board 276 Development and validation of a Clinical Index of Severe Febrile Neutropenia: A prospective multicenter study. (Abstract 9617) J. V. Echaburu, A. Blasco, J. Martinez Sr., C. Font, M. Antonio Rebollo, M. Biosca, A. Ramchandani, J. Hernando-Cubero, E. Martinez de Castro, J. Espinosa Sr., C. Beato, I. Aragon Manrique, F. J. Garcı́a Navalón, I. Ghanem Canete Sr., E. Sevillano, A. Manzano, M. Garrido Sr., E. Castanon, P. Jiménez-Fonseca, A. Carmona Bayonas, Supportive Care Working Group of the Spanish Society of Medical Oncology (SEOM) Board 277 Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients (pts) receiving anthracycline-cyclophosphamide (AC)-based chemotherapy. (Abstract 9618) I. D. Schnadig, M. R. Modiano, A. Poma, S. Arora, L. S. Schwartzberg Board 278 Evaluating the effect of neutropenic diet on infection and mortality rate in cancer patients: A meta-analysis. (Abstract 9619) M. B. Sonbol, B. Firwana, M. Diab, T. E. Witzig Board 279 Risk assessment of anticancer treatments beyond performance status: A prospective study in 277 cancer patients. (Abstract 9620) A. Jouinot, C. Vazeille, J. Durand, N. Neveux, A. Cessot, P. Boudou-Rouquette, J. Giroux, I. Gataa, S. Bellanger, J. Alexandre, L. Cynober, F. Goldwasser Board 280 Clinical predictors of recurrent venous thromboembolism (VTE) in cancer patients from a randomized trial of long-term tinzaparin versus warfarin for treatment: The CATCH study. (Abstract 9621) A. A. Khorana, R. Bauersachs, P. W. Kamphuisen, G. Meyer, M. S. Janas, M. F. Jarner, A. Lee, CATCH Investigators Board 281 Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in moderately emetogenic therapy (MEC). (Abstract 9622) P. J. Hesketh, L. S. Schwartzberg, M. R. Modiano, S. Arora, A. Poma, I. D. Schnadig Board 282 Establishing a new quality of life (QL) / patient reported outcome (PRO) / symptom scale in advanced cancer: Content validity for the “CSS” based on input from 3860 patients. (Abstract 9623) J. C. Shih, P. Chourasia, R. J. Gralla, P. Msaouel, R. Sidlow, P. J. Hollen Board 283 Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a phase 1 clinic. (Abstract 9624) G. George, E. C. Iwuanyanwu, K. O. Anderson, S. A. Piha-Paul, J. J. Wheler, R. Zinner, A. Naing, A. M. Tsimberidou, F. Janku, V. Subbiah, C. S. Cleeland, T. R. Mendoza, D. S. Hong Board 284 Patient-reported experience combining complementary and alternative medicine (CAM) with conventional oncology treatment (COT). (Abstract 9625) A. G. Menendez, A. Saied, N. J. Espat Board 285 Interpreting the febrile neutropenia rates from randomized controlled trials for consideration of primary prophylaxis in the real world: A systematic review and meta-analysis. (Abstract 9626) J. Truong, E. Lee, M. E. Trudeau, K. K. Chan Board 286 Can a homeopathic medicine complex reduce hot flashes induced by adjuvant endocrine therapy in localized breast cancer patients? Results of a randomized placebo-controlled phase III trial. (Abstract 9627) P. Heudel, I. Van Praagh, B. Duvert, I. Cauvin, A. Hardy-Bessard, J. Jacquin, L. Stefani, A. Belliere, L. Vincent, D. Dramais, J. Guastalla, E. Blanc, A. Belleville, E. Lavergne, D. Pérol Board 287 A randomised, open-label trial of a Multimodal Intervention (Exercise, Nutrition and Anti-inflammatory Medication) plus standard care versus standard care alone to prevent / attenuate cachexia in advanced cancer patients undergoing chemotherapy. (Abstract 9628) S. Kaasa, T. Solheim, B. J. Laird, T. Balstad, G. B. Stene, A. Bye, M. T. Fallon, P. Fayers, K. Fearon 126 Board 288 A phase III, randomized, double-blind study of single-dose intravenous fosaprepitant in preventing chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy. (Abstract 9629) B. L. Rapoport, C. Weinstein, E. S. Camacho, S. A. Khanani, E. Beckford-Brathwaite, L. Kevill, W. Vallejos, L. W. Liang, S. J. Noga Board 289 Effective complementary ASCO policy and day to day decision support strategies optimize anti-emetic choices. (Abstract 9630) A. Baranwal, D. Q. Huff, K. B. Knopf, C. L. Bennett, W. S. Shimp, M. L. Fishman, W. J. Hrushesky Board 290 Do cancer patients present with subclinical peripheral neuropathy prior to initiating neurotoxic chemotherapy? (Abstract 9631) S. Ramnarine, L. J. Williams, M. T. Fallon Board 291 Cost communication preferences, financial burden, and health-related quality-of-life (HRQoL). (Abstract 9632) J. A. De Souza, J. O’Connor, B. J. Yap, K. Wroblewski, C. Daugherty Board 292 Randomized trial of a home-based exercise intervention for patients with advanced colorectal cancer: Effects on physical functioning and activity levels. (Abstract 9633) K. Basen-Engquist, P. A. Parker, C. Eng, Y. Li, D. B. Johnson, B. K. Kee, S. S. Thomas, L. Wong, T. S. Crocenzi, J. Song, M. Fisch Board 293a A feasibility trial of geriatric assessment and integrated care plan for older cancer patients. (Abstract TPS9634) M. Puts, S. Sattar, K. McWatters, K. Lee, E. Amir, M. K. Krzyzanowska, A. M. Joshua, J. Monette, D. Wan-Chow-Wah, R. W. Jang, S. M. Alibhai Board 293b VOTRAGE study pazopanib in vulnerable elderly patients after geriatric assessment—A phase I study with geriatric criteria. (Abstract TPS9635) L. Mourey, A. Ravaud, L. Digue, C. Terret, E. Sevin, T. Filleron, L. Balardy Board 294a Cancer-related cognitive dysfunction (CRCD) and psychosocial development in young adult cancer survivors. (Abstract TPS9636) K. Edelstein, N. M. D’Agostino, G. R. Pond, S. Aubin, A. Matthew, K. Wahl, A. A. Gupta, P. Kavan, M. Crump, P. L. Bedard, A. C. Schuh, D. C. Hodgson, T. Vuong, T. Muanza, G. Batist, L. J. Bernstein Board 294b Rehabilitation of cognitive dysfunction in brain tumor patients. (Abstract TPS9637) N. M. Richard, L. J. Bernstein, W. P. Mason, N. Laperriere, C. Chung, B. Millar, C. Maurice, K. Edelstein Board 295a A phase III randomized double-blind study of prophylactic topical dapsone 5% versus moisturizer for cetuximab-induced papulopustular (acneiform) rash. (Abstract TPS9638) M. E. Lacouture, V. Belum, D. Kehn, A. Cercek, N. E. Kemeny Board 295b Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for the prevention of cisplatin-based chemotherapyinduced nausea and vomiting for gynecological cancer: KCOG G-1301 phase II trial. (Abstract TPS9639) M. Abe, Y. Kasamatsu, K. Nobuhiro, S. Kuji, A. Tanaka, N. Takahashi, M. Takekuma, Y. Hirashima, S. Nishio, Y. Itani, Y. Ichikawa, Y. Itonaga, T. Hirakawa, K. Nasu, K. Miyagi, J. Murakami, K. Ito Board 296a TabPRO trial: Tablet-based real-time detection of patient-reported outcomes during adjuvant outpatient chemotherapy for breast cancer. (Abstract TPS9640) M. R. Mallmann, C. M. Domroese, C. Fuhrmann, F. Thangarajah, L. Leitzen, A. Ulhaas, F. Bach, D. Engelhardt, E. D. Beier, M. Keyver-Paik, C. Coch, C. Kaiser, A. Abramian, B. Nuding, W. Malter, S. Kraemer, M. Wirtz, C. Rudlowski, O. Zivanovic, W. C. Kuhn Board 296b Three-arm randomized trial of sodium alginate, orally administered mucoprotective agent, for preventing radiation esophagitis in pts with locally advanced non-small-cell lung cancer (LA-NSCLC) receiving concurrent chemoradiotherapy (CRT): Okayama Lung Cancer Study Group 1401. (Abstract TPS9641) K. Hotta, K. Ninomiya, I. Oze, A. Bessho, T. Murakami, N. Sone, S. Harita, N. Nogami, S. Kuyama, M. Tanimoto, K. Kiura 127 SATURDAY Saturday, May 30, 2015 Saturday, May 30, 2015 Board 297a Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. (Abstract TPS9642) A. Young, J. Phillips, H. Hancocks, A. Marshall, J. Grumett, J. Dunn, O. Chapman Board 297b Phase 3 randomized double blind placebo controlled trial evaluating Omega3 in the prevention of Taxane or Platinum Induced Peripheral Sensory Neuropathy. (Abstract TPS9643) R. Maroun, R. Saleh, J. Asselah, M. Haziza, S. H. Meterissian, N. Bouganim 3:00 PM - 4:15 PM Poster Discussion Session SATURDAY Breast Cancer—Triple-Negative/Cytotoxics/Local Therapy Location: N Hall B1 Tiffany A. Traina, MD—Co-Chair Memorial Sloan Kettering Cancer Center Janice Maria Walshe, MD—Co-Chair St Vincent’s University Hospital 3:00 PM Lodovico Balducci, MD (Discussion of Abstract(s) 1009-1010) Moffitt Cancer Center Determining the Tipping Point in Geriatric Oncology 3:12 PM Panel Question and Answer 3:18 PM Tari A. King, MD (Discussion of Abstract(s) 1011–1013) Memorial Sloan Kettering Cancer Center Drivers of Decision Making in Local Therapy: Choosing Wisely 3:30 PM Panel Question and Answer 3:36 PM Kathy Miller, MD (Discussion of Abstract(s) 1014 –1016) Indiana University Melvin and Bren Simon Cancer Center Novel Agents in Triple-Negative Breast Cancer 3:48 PM Panel Question and Answer 3:54 PM Shridar Ganesan, MD, PhD (Discussion of Abstract(s) 1017–1020) Rutgers Cancer Institute of New Jersey Triple-Negative Breast Cancer: Divide and Conquer 4:06 PM Panel Question and Answer Posters discussed in this session are on display in the Breast Cancer—Triple-Negative/Cytotoxics/Local Therapy Poster Session. See page 62 for poster information. Networking with presenters and discussants will take place right outside of the session room after the discussion. 3:00 PM - 4:15 PM Poster Discussion Session Developmental Therapeutics—Immunotherapy Location: S406 Charlotte Eielson Ariyan, MD, PhD—Co-Chair Memorial Sloan Kettering Cancer Center Gregory Lawrence Beatty, MD, PhD—Co-Chair Hospital of the University of Pennsylvania 3:00 PM Harriet M. Kluger, MD (Discussion of Abstract(s) 3009 –3012) Yale School of Medicine Expanding Indications of Checkpoint Blockade 3:12 PM Panel Question and Answer 128 3:18 PM Matthew David Hellmann, MD (Discussion of Abstract(s) 3013–3015) Memorial Sloan Kettering Cancer Center Optimizing Immunotherapy in Non-Small Cell Lung Cancer 3:30 PM Panel Question and Answer 3:36 PM Michael T. Lotze, MD (Discussion of Abstract(s) 3016 –3018) Hillman Cancer Center Getting More Out of Your Cytokines 3:48 PM Panel Question and Answer 3:54 PM Lillian L. Siu, MD, FRCPC (Discussion of Abstract(s) 3019 –3021) Princess Margaret Cancer Centre Getting Specific: Antigens and Vaccines 4:06 PM Panel Question and Answer Posters discussed in this session are on display in the Developmental Therapeutics—Immunotherapy Poster Session. See page 79 for poster information. Networking with presenters and discussants will take place right outside of the session room after the discussion. 3:00 PM - 4:15 PM Special Session ASCO/European Society for Medical Oncology (ESMO) Joint Session: Global Perspective on Value Location: S100a Rolf A. Stahel, MD—Co-Chair University Hospital Zurich Peter Paul Yu, MD, FACP, FASCO—Co-Chair Palo Alto Medical Foundation Lowell E. Schnipper, MD Beth Israel Deaconess Medical Center ASCO’s Value-Based Framework Elisabeth De Vries, MD, PhD University Medical Center Groningen ESMO’s Magnitude of Clinical Benefit Scale Alexandru E. Eniu, MD, PhD Cancer Institute Ion Chiricuta Cluj-Napoca Disparity of Cancer Medicine Access in Europe Gilberto Lopes, MD, MBA, FAMS Centro Paulista de Oncologia and HCor Onco Essential Drug Compendium Panel Question and Answer 3:00 PM - 4:15 PM Education Session Implications of Intratumor Heterogeneity for Personalized Therapy Location: E450 Michalina Janiszewska, PhD Dana-Farber Cancer Institute Molecular Evolution of Human Breast Tumors 129 SATURDAY Saturday, May 30, 2015 Saturday, May 30, 2015 Charles Swanton, PhD, FRCP—Chair The Francis Crick Institute—Lincoln’s Inn Fields Laboratory Role of Intratumoral Heterogeneity in Understanding Drug Resistance Liran Shlush, MD, PhD Princess Margaret Cancer Centre Clonal Evolution Models of Tumor Heterogeneity Panel Question and Answer 3:00 PM - 4:15 PM Meet the Professor Session SATURDAY Enhancing Communications Skills: The Comskil Training Program—Ticketed Session Location: E451a Philip A. Bialer, MD Memorial Sloan Kettering Cancer Center 3:00 PM - 4:30 PM Special Session Coping with Chaos and Other Challenges in Medicine Location: S404 Linda H. Clever, MD, MACP—Chair RENEW 3:00 PM - 6:00 PM Oral Abstract Session Gastrointestinal (Colorectal) Cancer Location: E Hall D2 Edward Chu, MD—Co-Chair University of Pittsburgh Richard H. Wilson, MD—Co-Chair Queen’s University Belfast 3:00 PM A multi-center randomized controlled trial of mFOLFOX6 with or without radiation in neoadjuvant treatment of local advanced rectal cancer (FOWARC study): Preliminary results. (Abstract 3500) Y. Deng, P. Chi, P. Lan, L. Wang, L. Cui, D. Chen, J. Cao, H. Wei, X. Peng, Z. Huang, G. Cai, R. Zhao, Y. Luo, Y. Zhang, Y. Cai, J. Wang 3:12 PM Radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM): Long-term survival results of a randomized phase II study of the EORTC-NCRI CCSG-ALM Intergroup 40004 (CLOCC). (Abstract 3501) T. Ruers, C. J. Punt, F. van Coevorden, J. Pierie, I. Borel Rinkes, J. A. Ledermann, G. J. Poston, W. O. Bechstein, M. Lentz, M. E. Mauer, E. Van Cutsem, M. P. Lutz, B. Nordlinger 3:24 PM SIRFLOX: Randomized phase III trial comparing first-line mFOLFOX6 ⴞ bevacizumab (bev) versus mFOLFOX6 ⴙ selective internal radiation therapy (SIRT) ⴞ bev in patients (pts) with metastatic colorectal cancer (mCRC). (Abstract 3502) P. Gibbs, V. Heinemann, N. K. Sharma, M. P. Findlay, J. Ricke, V. Gebski, M. Van Buskirk, G. A. Van Hazel, SIRFLOX Study Group 130 3:36 PM Ricky A. Sharma, MA, MB, Bchir, FRCP, FRCR, PhD (Discussion of Abstract(s) 3500 –3502) Gray Institute for Radiation Oncology and Biology, University of Oxford How Many Modalities Are Enough? 3:48 PM Panel Question and Answer 4:00 PM Vitamin D status and survival of metastatic colorectal cancer patients: Results from CALGB/SWOG 80405 (Alliance). (Abstract 3503) K. Ng, A. P. Venook, K. Sato, C. Yuan, B. W. Hollis, D. Niedzwiecki, C. Ye, I. Chang, B. H. O’Neil, F. Innocenti, H. Lenz, C. D. Blanke, R. J. Mayer, C. S. Fuchs, J. A. Meyerhardt 4:12 PM Impact of aspirin as secondary prevention in an unselected cohort of 25,644 patients with colorectal cancer: A population-based study. (Abstract 3504) S. Bains, M. Mahic, M. Cvancarova, S. Yaqub, L. Dørum, B. Bjørnbeth, B. Møller, K. W. Brudvik, K. Tasken 4:24 PM Andrew T. Chan, MD, MPH (Discussion of Abstract(s) 3503–3504) Massachusetts General Hospital Over-the-Counter Therapies for Colon Cancer 4:36 PM Panel Question and Answer 4:48 PM Comprehensive molecular characterization of colorectal cancer reveals genomic predictors of immune cell infiltrates. (Abstract 3505) M. Giannakis, S. Shukla, J. X. Mu, R. Nishihara, M. Yamauchi, Y. Sukawa, Z. Qian, K. Nosho, K. Inamura, S. Bahl, K. Ng, A. T. Chan, J. A. Meyerhardt, S. B. Gabriel, E. Lander, C. Wu, G. Getz, C. S. Fuchs, S. Ogino, L. A. Garraway 5:00 PM Analysis of DNA mismatch repair (MMR) and clinical outcome in stage III colon cancers from patients (pts) treated with adjuvant FOLFOX ⴙ/cetuximab in the PETACC8 and NCCTG N0147 adjuvant trials. (Abstract 3506) A. Zaanan, Q. Shi, J. Taieb, S. R. Alberts, T. C. Smyrk, C. Julie, A. Zawadi, J. Tabernero, E. Mini, R. M. Goldberg, G. Folprecht, J. L. Van Laethem, K. Le Malicot, D. J. Sargent, P. Laurent-Puig, F. A. Sinicrope 5:12 PM Prognostic value of BRAF V600E and KRAS exon 2 mutations in microsatellite stable (MSS), stage III colon cancers (CC) from patients (pts) treated with adjuvant FOLFOXⴙ/- cetuximab: A pooled analysis of 3934 pts from the PETACC8 and N0147 trials. (Abstract 3507) J. Taieb, K. Le Malicot, F. M. Penault-Llorca, O. Bouche Sr., Q. Shi, S. N. Thibodeau, J. Tabernero, E. Mini, R. M. Goldberg, G. Folprecht, J. Van Laethem, D. J. Sargent, S. R. Alberts, P. Laurent-Puig, F. A. Sinicrope 5:24 PM Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial. (Abstract 3508) S. Siena, A. SartoreBianchi, S. Lonardi, L. Trusolino, C. Martino, K. Bencardino, F. Leone, V. Zagonel, E. Valtorta, V. Torri, G. Siravegna, A. Amatu, E. F. Bonazzina, F. Rusconi, S. Ghezzi, F. Ciardiello, S. Veronese, P. M. Comoglio, A. Bardelli, S. Marsoni 5:36 PM Sabine Tejpar, MD, PhD (Discussion of Abstract(s) 3505–3508) University of Leuven, KUL Molecular Profiling to Inform Prognosis and Treatment 5:48 PM Panel Question and Answer 3:00 PM - 6:00 PM Oral Abstract Session Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers Location: E Hall D1 Scott N. Gettinger, MD—Co-Chair Yale School of Medicine Charles M. Rudin, MD, PhD—Co-Chair Memorial Sloan Kettering Cancer Center 131 SATURDAY Saturday, May 30, 2015 Saturday, May 30, 2015 SATURDAY 3:00 PM Bevacizumab 15mg/kg plus cisplatin-pemetrexed (CP) triplet versus CP doublet in Malignant Pleural Mesothelioma (MPM): Results of the IFCT-GFPC0701 MAPS randomized phase 3 trial. (Abstract 7500) G. Zalcman, J. Mazières, J. Margery, L. Greillier, C. Audigier-Valette, D. Moro-Sibilot, O. Molinier, R. Corre, I. Monnet, V. Gounant, H. Janicot, R. Gervais, C. Locher, B. Milleron, Q. Tran, M. Lebitasy, F. Morin, C. Creveuil, J. Parienti, A. Scherpereel, French Cooperative Thoracic Intergroup (IFCT) 3:12 PM Phase III trial (NGR015) with NGR-hTNF plus best investigator choice (BIC) versus placebo plus BIC in previously treated patients with advanced malignant pleural mesothelioma (MPM). (Abstract 7501) R. M. Gaafar, A. G. Favaretto, V. Gregorc, F. Grossi, J. Jassem, A. Polychronis, P. Bidoli, M. Tiseo, M. E. O’Brien, R. Shah, P. Taylor, S. Novello, A. Muzio, A. Bearz, P. Badurak, L. Greillier, A. Lambiase, C. Bordignon 3:24 PM Anna K. Nowak, MBBS, FRACP, PhD (Discussion of Abstract(s) 7500 –7501) Sir Charles Gairdner Hospital New (and Old) Directions in Mesothelioma 3:36 PM Panel Question and Answer 3:48 PM Pembrolizumab (MK-3475) in patients (pts) with extensive-stage small cell lung cancer (SCLC): Preliminary safety and efficacy results from KEYNOTE028. (Abstract 7502) P. A. Ott, M. E. Fernandez, S. Hiret, D. Kim, R. A. Moss, T. Winser, S. Yuan, J. D. Cheng, B. Piperdi, J. M. Mehnert 4:00 PM Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209 – 032. (Abstract 7503) S. J. Antonia, J. C. Bendell, M. H. Taylor, E. Calvo, D. Jaeger, F. G. De Braud, P. A. Ott, M. C. Pietanza, L. Horn, D. T. Le, M. Morse, J. A. Lopez-Martin, P. A. Ascierto, O. Christensen, J. Grosso, J. S. Simon, C. Lin, J. P. Eder 4:12 PM Results from a randomized study of carboplatin and etoposide (CE) with or without palifosfamide (Pa) in extensive stage small cell lung cancer (ESSCLC): The MATISSE study. (Abstract 7504) S. I. Jalal, L. H. Einhorn, G. Lo, P. Lavin, F. M. Lebel 4:24 PM A multicenter, randomised, phase III trial comparing fixed dose versus toxicity-adjusted dose of cisplatin ⴙ etoposide in advanced SCLC patients. The STAD-1 trial. (Abstract 7505) A. Morabito, G. Daniele, A. G. Favaretto, V. Filipazzi, A. Rossi, V. Gebbia, F. Castiglione, L. Cavanna, E. Maiello, G. Valmadre, R. Costanzo, A. Manzo, L. Bonanno, E. Piazza, P. Maione, G. Mancuso, M. Di Maio, M. Piccirillo, C. Gallo, C. Gridelli 4:36 PM Roy S. Herbst, MD, PhD (Discussion of Abstract(s) 7502–7505) Yale School of Medicine Small Cell Lung Cancer: A Glimpse of Light 4:48 PM Panel Question and Answer 5:00 PM Final overall survival (OS) results of the phase III PROCLAIM trial: Pemetrexed (Pem), cisplatin (Cis) or etoposide (Eto), Cis plus thoracic radiation therapy (TRT) followed by consolidation cytotoxic chemotherapy (CTX) in locally advanced nonsquamous non-small cell lung cancer (nsNSCLC). (Abstract 7506) S. Senan, A. M. Brade, L. Wang, J. F. Vansteenkiste, S. R. Dakhil, B. Biesma, M. Martinez Aguillo, J. Aerts, R. Govindan, B. Rubio-Viqueira, C. R. Lewanski, D. R. Gandara, H. Choy, T. Mok, A. Hossain, N. A. Iscoe, J. Treat, A. G. Koustenis, N. Chouaki, E. E. Vokes 5:12 PM Randomized phase III trial of customized adjuvant chemotherapy (CT) according BRCA-1 expression levels in patients with node positive resected non-small cell lung cancer (NSCLS) SCAT: A Spanish Lung Cancer Group trial (Eudract:2007– 000067-15; NCTgov: 00478699). (Abstract 7507) B. Massuti, M. Cobo, J. Rodriguez-Paniagua, A. Ballesteros, T. Moran, R. Arrabal, J. Gonzalez Larriba, I. Barneto, Y. W. Pun, J. De Castro, S. Ponce Aix, C. Baamonde, M. Munoz, G. Lopez-Vivanco, J. Rivas, D. Isla, R. Lopez, J. Sanchez, J. SanchezPaya, R. Rosell, Spanish Lung Cancer Group (GECP/SLCG) 132 Saturday, May 30, 2015 5:24 PM Mark A. Socinski, MD (Discussion of Abstract(s) 7506 –7507) University of Pittsburgh Improving the Cure Rate in Early-Stage Lung Cancer 5:36 PM Panel Question and Answer 3:00 PM - 6:00 PM Oral Abstract Session Pediatric Oncology I Gregory T. Armstrong, MD, MSCE—Co-Chair St. Jude Children’s Research Hospital Maureen Megan O’Brien, MD—Co-Chair Cincinnati Children’s Hospital Medical Center 3:00 PM Morbidity and mortality associated with subsequent meningiomas among childhood cancer survivors exposed to cranial radiotherapy: A report from the Childhood Cancer Survivor Study (CCSS). (Abstract 10000) D. C. Bowers, C. S. Moskowitz, J. F. Chou, C. M. Mazewski, J. P. Neglia, G. T. Armstrong, W. M. Leisenring, L. L. Robison, K. C. Oeffinger 3:12 PM Chemotherapy and brain function in long-term survivors of childhood acute lymphoblastic leukemia (ALL). (Abstract 10001) Y. Cheung, S. Fellah, W. Liu, R. J. Ogg, D. Srivastava, C. I. Kimberg, T. M. Brinkman, C. Pui, L. L. Robison, M. M. Hudson, K. R. Krull 3:24 PM Neurocognitive function of children treated for high-risk B-acute lymphoblastic leukemia (HR-ALL) randomized to Capizzi (CMTX) versus high-dose methotrexate (HDMTX): A report from the Children’s Oncology Group (COG). (Abstract 10002) N. J. Winick, L. M. Embry, K. K. Hardy, J. A. Kairalla, M. Devidas, D. Armstrong, S. Hunger, W. L. Carroll, E. Larsen, E. A. Raetz, M. L. Loh, R. Noll 3:36 PM Sabine Mueller, MD, PhD (Discussion of Abstract(s) 10000 –10002) University of California, San Francisco Central Nervous System-Directed Therapies: Outcomes from a Pediatric Neurologist’s Perspective 3:48 PM Panel Question and Answer 4:00 PM Langerhans cell histiocytosis in children: Correlation of BRAF status with clinical characteristic. (Abstract 10003) S. Héritier, J. Emile, M. Barkaoui, A. Moreau, V. Rigau, F. Dijoud, C. Chassagne, F. Charlotte, K. Mokhtari, S. Boudjemaa, A. Coulomb, M. Peuchmaur, M. Copin, S. Fraitag, T. Molina, E. Jeziorski, C. Thomas, M. de Menthon, J. Haroche, J. Donadieu 4:12 PM Phase 1 study of dabrafenib in pediatric patients (pts) with relapsed or refractory BRAF V600E high- and low-grade gliomas (HGG, LGG), Langerhans cell histiocytosis (LCH), and other solid tumors (OST). (Abstract 10004) M. W. Kieran, D. R. Hargrave, K. J. Cohen, I. Aerts, I. J. Dunkel, T. R. Hummel, I. Jimenez, A. D. Pearson, C. A. Pratilas, J. Whitlock, E. Bouffet, W. V. Shen, A. Broniscer, A. Bertozzi, J. L. Sandberg, A. M. Florance, B. B. Suttle, P. Haney, M. W. Russo, B. Geoerger 4:24 PM Phase I study of ceritinib in pediatric patients (Pts) with malignancies harboring a genetic alteration in ALK (ALKⴙ): Safety, pharmacokinetic (PK), and efficacy results. (Abstract 10005) B. Geoerger, J. Schulte, C. M. Zwaan, M. Casanova, M. Fischer, L. Moreno, T. Trahair, I. Jimenez, H. Kang, A. S. Pappo, E. Schafer, B. D. Weiss, M. Healy, K. Li, T. Lin, A. Boral, A. D. Pearson 4:36 PM Lia Gore, MD (Discussion of Abstract(s) 10003–10005) University of Colorado Cancer Center BRAF and ALK: Emerging Targets in Pediatric Cancer Therapy Across Disease Silos 133 SATURDAY Location: S504 Saturday, May 30, 2015 SATURDAY 4:48 PM Panel Question and Answer 5:00 PM Outcomes of dasatinib plus intensive chemotherapy or stem cell transplant (SCT) for Philadelphia chromosome-positive acute lymphoblastic leukemia (Phⴙ ALL) on Children’s Oncology Group AALL0622. (Abstract 10006) W. B. Slayton, J. A. Kairalla, K. R. Schultz, M. Devidas, S. Helian, M. Pulsipher, B. H. Chang, W. L. Carroll, M. J. Borowitz, V. I. Brown, N. J. Winick, A. J. Carroll, N. A. Heerema, J. M. Gastier-Foster, B. L. Wood, S. L. Mizrahy, S. Hunger 5:12 PM Feasibility of intensive post-Induction therapy incorporating clofarabine (CLOF) in the very high risk (VHR) stratum of patients with newly diagnosed high risk B-lymphoblastic leukemia (HR B-ALL): Children’s Oncology Group AALL1131. (Abstract 10007) M. Burke, M. Devidas, S. Chen, L. Gore, E. Larsen, J. M. Hilden, M. L. Loh, N. J. Winick, W. L. Carroll, E. A. Raetz, S. Hunger, W. L. Salzer 5:24 PM Gemtuzumab ozogamycin (GO) and toxic mortality (TM) in children and adolescents with acute myeloid leukemia (AML) enrolled on Children’s Oncology Group (COG) trial AAML0531. (Abstract 10008) J. A. Tolbert, L. Sung, R. Aplenc, T. A. Alonzo, Y. J. Wang, R. B. Gerbing, S. Meshinchi, A. S. Gamis 5:36 PM Lewis B. Silverman, MD (Discussion of Abstract(s) 10006 –10008) Dana-Farber Cancer Institute New Developments in Pediatric Leukemia 5:48 PM Panel Question and Answer 4:45 PM - 6:00 PM Poster Discussion Session Genitourinary (Prostate) Cancer Location: E Arie Crown Theater Jorge A. Garcia, MD—Co-Chair Cleveland Clinic Neha Vapiwala, MD—Co-Chair University of Pennsylvania 4:45 PM David M. Nanus (Discussion of Abstract(s) 5009 –5012) Weill Medical College of Cornell University Taxanes: Novel Combinations and Clinical States 4:57 PM Panel Question and Answer 5:03 PM Karen E. Knudsen, PhD (Discussion of Abstract(s) 5013–5015) The Kimmel Cancer Center, Thomas Jefferson University Molecular and Genomic Predictors of Response and Resistance to Androgen Receptor-Directed Therapy 5:15 PM Panel Question and Answer 5:21 PM To Be Determined (Discussion of Abstract(s) 5016 –5017) Prognostic Profiling in Prostate Cancer 5:33 PM Panel Question and Answer 5:39 PM Noel W. Clarke, MBBS, FRCS, ChM (Discussion of Abstract(s) 5018 –5020) The Christie at Salford Royal Hospitals Cholesterol and Testosterone in Prostate Cancer 5:51 PM Panel Question and Answer Posters discussed in this session are on display in the Genitourinary (Prostate) Cancer Poster Session. See page 97 for poster information. Networking with presenters and discussants will take place right outside of the session room after the discussion. 134 Saturday, May 30, 2015 4:45 PM - 6:00 PM Poster Discussion Session Gynecologic Cancer Location: E354b Linda R. Duska, MD—Co-Chair University of Virginia Health System 4:45 PM Jonathan A. Ledermann, MD, FRCP (Discussion of Abstract(s) 5513–5514) University College London Cancer Institute Embarassment of Riches: PARP Inhibitors versus Antiangiogenics 4:57 PM Panel Question and Answer 5:03 PM Alexandra Leary, MD (Discussion of Abstract(s) 5515–5519) The Royal Marsden Hospital New Agents in Ovarian Cancer for Platinum-Resistant and/or Platinum-Sensitive Disease 5:15 PM Panel Question and Answer 5:21 PM Sang Young Ryu, MD, PhD (Discussion of Abstract(s) 5520 –5521) Korea Cancer Center Hospital Advancing Cervix Cancer Therapy 5:33 PM Panel Question and Answer 5:39 PM Lawrence H. Schwartz, MD (Discussion of Abstract(s) 5022–5024) Columbia University Medical Center/New York Presbyterian Hospital Through the Glass: PET and CT Imaging in Gynecologic Cancers 5:51 PM Panel Question and Answer Posters discussed in this session are on display in the Gynecologic Cancer Poster Session. See page 103 for poster information. Networking with presenters and discussants will take place right outside of the session room after the discussion. 4:45 PM - 6:00 PM Poster Discussion Session Head and Neck Cancer Location: S406 Anthony Cmelak, MD—Chair Vanderbilt-Ingram Cancer Center 4:45 PM Robert I. Haddad, MD (Discussion of Abstract(s) 6012– 6015) Dana-Farber Cancer Institute The Changing Treatment Landscape for Advanced Thyroid Cancers 4:57 PM Panel Question and Answer 5:03 PM Peter S. Hammerman, MD, PhD (Discussion of Abstract(s) 6016 – 6018) Dana-Farber Cancer Institute The Role of the Immune Microenvironment in Head and Neck Cancer 5:15 PM Panel Question and Answer 5:21 PM Kevin J. Cullen, MD (Discussion of Abstract(s) 6019 – 6021) University of Maryland Greenebaum Cancer Center Dose Intensity: New Answers to an Old Question 5:33 PM Panel Question and Answer 135 SATURDAY Paul Haluska, MD, PhD—Co-Chair Mayo Clinic Saturday, May 30, 2015 5:39 PM John F. Deeken, MD (Discussion of Abstract(s) 6022– 6023) Inova Comprehensive Cancer and Research Institute Progress in the Management of Recurrent and/or Metastatic Head and Neck Cancer 5:51 PM Panel Question and Answer Posters discussed in this session are on display in the Head and Neck Cancer Poster Session. See page 112 for poster information. Networking with presenters and discussants will take place right outside of the session room after the discussion. 4:45 PM - 6:00 PM Poster Discussion Session SATURDAY Patient and Survivor Care Location: S404 Tessa Cigler, MD, MPH—Co-Chair Weill Cornell Breast Center Katherine Van Loon, MD, MPH—Co-Chair University of California, San Francisco 4:45 PM Kavitha Ramchandran, MD (Discussion of Abstract(s) 9512–9514) Stanford Cancer Institute/Stanford University School of Medicine Caregivers: The Forgotten Patient 4:57 PM Panel Question and Answer 5:03 PM Arif Kamal, MD (Discussion of Abstract(s) 9515–9517) Duke University Medical Center Speak Now: Discussing Difficult Topics with Patients 5:15 PM Panel Question and Answer 5:21 PM Charles L. Shapiro, MD (Discussion of Abstract(s) 9518 –9520) The Ohio State University Reporting and Managing Toxicities: Putting Patients First 5:33 PM Panel Question and Answer 5:39 PM Karen L. Smith, MD (Discussion of Abstract(s) 9521–9523) Washington Cancer Institute, MedStar Washington Hospital Center Oh Baby! Fertility after Cancer 5:51 PM Panel Question and Answer Posters discussed in this session are on display in the Patient and Survivor Care Poster Session. See page 118 for poster information. Networking with presenters and discussants will take place right outside of the session room after the discussion. 4:45 PM - 6:00 PM Special Session Payment Reform in Oncology: The Way Forward Location: S100a Jeffery C. Ward, MD—Chair Swedish Cancer Institute Edmonds Moderator Blase N. Polite, MD, MPP The University of Chicago The Push for Value-Based Payment for Oncology: Understanding the Current Payer Environment 136 Saturday, May 30, 2015 Harold D. Miller Center for Healthcare Quality and Payment Reform Better Ways to Pay for Cancer Care: Creating Win-Win-Win Approaches for Oncologists, Cancer Patients, and Payers Barbara L. McAneny, MD New Mexico Oncology Hematology Consultants, LTD Fee-for-Service and Alternative Models: Perspective of AMA and Personal Experiences Panel Question and Answer SATURDAY 4:45 PM - 6:00 PM Education Session Evolution, Medicine, and Cancer Location: S100bc Athena Aktipis, PhD University of California, San Francisco Evolutionary Context of Cancer: Why Do People Get Cancer? Carlo Maley, PhD—Chair University of California, San Francisco Clonal Evolution in Metastasis: How Can Darwin Improve Cancer Outcome? Matthew Breen, PhD North Carolina State University Comparative Oncology: What Can Dogs and Sea Lions Teach Us about Cancer? Panel Question and Answer 4:45 PM - 6:00 PM Education Session New Strategies to Understand and Target Initiation of Aggressive Cancers Location: E450 Victoria Louise Seewaldt, MD—Chair Duke University Medical Center Lessons from Cancer Initiation Studies in Black Women Virginia F. Borges, MD University of Colorado Cancer Center Role of Collagen Cross-Linking in Breast Cancer Initiation Deborah W. Knapp, DVM, DACVIM Purdue University Alternative Models of Gene-Environment Interaction during Cancer Initiation Panel Question and Answer 4:45 PM - 6:00 PM Education Session Tackling Endocrine Resistance: Transforming Biology into Innovative Drugs Location: N Hall B1 137 Saturday, May 30, 2015 Mitchell Dowsett, PhD—Chair The Royal Marsden NHS Foundation Trust Illuminating the Biology of Endocrine Resistance Myles Brown, MD Dana-Farber Cancer Institute Androgen Receptor-Positive Disease: Biology and Clinical Implications Richard S. Finn, MD University of California, Los Angeles Medical Center New Drug Development for Endocrine-Resistant Breast Cancers Panel Question and Answer SATURDAY 4:45 PM - 6:00 PM Education Session The Learning Health Care System: Using Big Data to Inform Clinical Decision Making Location: S102 Lynne Penberthy, MD, MPH—Chair National Cancer Institute at the National Institutes of Health Security and Privacy in the Era of Big Data: Overcoming Challenges Richard L. Schilsky, MD, FASCO American Society of Clinical Oncology CancerLinQ Nuts and Bolts of Computer Learning Systems Anne-Marie Meyer, PhD The University of North Carolina at Chapel Hill Big Data in Practice: Practical Tips for Using Big Data in Cancer Care Panel Question and Answer 4:45 PM - 6:00 PM Meet the Professor Session Ductal Carcinoma In Situ in 2015—Ticketed Session Location: E451a Eun-Sil Shelley Hwang, MD, MPH Duke University Medical Center Gary M. Freedman, MD Perelman School of Medicine of the University of Pennsylvania 4:45 PM - 6:00 PM Clinical Problems in Oncology Session Immunotherapy for Melanoma: Sequencing, Combinations, and Side Effects—Ticketed Session Location: E451b Frances A. Collichio, MD The University of North Carolina at Chapel Hill School of Medicine Immune-Related Adverse Events Associated with CTLA4 and PD1/PDL1 Blockade 138 Saturday, May 30, 2015 Antoni Ribas, MD, PhD David Geffen School of Medicine at the University of California, Los Angeles Immunotherapy-Based Combinations SATURDAY Michael B. Atkins, MD—Chair Lombardi Comprehensive Cancer Center Sequencing of Immunotherapy and Targeted Therapy 139 Sunday, May 31, 2015 7:30 AM - 9:15 AM Highlights of the Day Session Highlights of the Day Session I Including Clinical Trial Participation Awards Location: E Hall D1 Lynn Mara Schuchter, MD—Chair Abramson Cancer Center of the University of Pennsylvania 7:30 AM Clinical Trial Participation Awards 7:45 AM Judy Ellen Garber, MD, MPH Dana-Farber Cancer Institute Cancer Prevention, Genetics, and Epidemiology 8:00 AM Steven J. Cohen, MD Fox Chase Cancer Center Gastrointestinal (Colorectal) Cancer 8:15 AM Richard A. Larson, MD The University of Chicago Leukemia, Myelodysplasia, and Transplantation 8:30 AM Natasha B. Leighl, MD, MMSc, FRCPC Princess Margaret Cancer Centre Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers 8:45 AM Svetomir Markovic, MD, PhD Mayo Clinic Melanoma/Skin Cancers SUNDAY 7:30 AM - 9:30 AM Education Session Training Program Directors’ Breakfast (Training Program Directors and Associate Training Program Directors Only) Location: S404 Helen K. Chew, MD UC Davis Medical Center ASCO Updates Catherine H. Van Poznak, MD University of Michigan Comprehensive Cancer Center Quality Initiatives in Your Training Program Jamie H. Von Roenn, MD American Society of Clinical Oncology Palliative Care Grant Update Jill Gilbert, MD—Chair Vanderbilt University Opportunities for Faculty Development Lisa Johnson, MHS, MT(ASCP)SC American Society of Clinical Oncology ASCO University Updates 8:00 AM - 9:15 AM Education Session Improving Clinical Trial Efficiency: Thinking outside the Box Location: E Arie Crown Theater 140 Sunday, May 31, 2015 Richard Simon, DSc National Institutes of Health Enrichment Design Strategies: Excitement, Caution, and Usefulness Sumithra J. Mandrekar, PhD—Chair Mayo Clinic The Rationale and Logistics of Umbrella Trial Designs Suzanne Eleanor Dahlberg, PhD Dana-Farber Cancer Institute Basket Trial Designs: Identifying the Exceptional Responders Panel Question and Answer 8:00 AM - 9:15 AM Education Session Locoregional Therapies in the Setting of Systemic Treatment Advances: What’s Next? Location: S406 Sanjiv S. Agarwala, MD—Chair St. Luke’s Medical Center A Changing Topography: The Role of Intralesional Therapy in Melanoma SUNDAY Ahmad A. Tarhini, MD, PhD University of Pittsburgh Cancer Institute Neoadjuvant Approaches to Melanoma: Alternatives to Immediate Resection Cornelis Verhoef, MD, PhD Erasmus MC Cancer Institute Perfusion or Infusion in the Era of Effective Systemic Therapy Panel Question and Answer 8:00 AM - 9:15 AM Education Session Managing Ovarian Cancer in the Older Woman: How to Best Select and Sequence Surgery and Chemotherapy for Optimal Outcome Location: E354b Linda R. Duska, MD—Chair University of Virginia Health System Ovarian Cancer Surgery in the Elderly Patient: Keep It Short and Sweet Kathleen N. Moore, MD University of Oklahoma Health Sciences Center Ovarian Cancer Chemotherapy in the Elderly Patient: Less Is More William P. Tew, MD Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College Clinical Trials in the Older Patient: Who, When, and Why? Panel Question and Answer 141 Sunday, May 31, 2015 8:00 AM - 9:15 AM Education Session PI3-Kinase: Genomics to Clinical Practice Location: S100bc Christine H. Chung, MD—Chair The Johns Hopkins University School of Medicine PIK3CA: The Most Common “Targetable” Genetic Alteration in Head and Neck Cancer—Who Might Benefit? Matthew G. Fury, MD Regeneron Pharmaceuticals Optimal Integration of PI3K Targeting into Standard Clinical Regimens J. Silvio Gutkind, PhD National Institute of Dental and Craniofacial Research at the National Institutes of Health Overcoming Resistance to Cetuximab with PIK3CA Mutations Panel Question and Answer 8:00 AM - 9:15 AM Meet the Professor Session SUNDAY Managing the Toxicity of Androgen Deprivation Therapy in Prostate Cancer and Anti-VEGF/mTOR Therapy in Renal Cell Carcinoma—Ticketed Session Location: E451a Thomas Hutson, DO, PharmD Texas Oncology–Baylor Charles A. Sammons Cancer Center Matthew Raymond Smith, MD, PhD Massachusetts General Hospital Cancer Center 8:00 AM - 9:15 AM Clinical Problems in Oncology Session Using Molecular Profiling to Inform Decision Making in Non-GIST Sarcomas: Case-Based Approaches—Ticketed Session Location: E451b William D. Tap, MD—Chair Memorial Sloan Kettering Cancer Center FMS/Kit and Pigmented Villonodular Synovitis Robin Lewis Jones, MD The Royal Marsden Hospital Targeting Platelet-Derived Growth Factor Receptors in Dermatofibrosarcoma David Morgan Thomas, MBBS, PhD Peter MacCallum Cancer Centre Targeting Rank Ligand in Giant Cell Tumor of Bone 142 Sunday, May 31, 2015 8:00 AM - 9:30 AM Clinical Science Symposium Immunotherapy for Central Nervous System Tumors: Biomarkers and Novel Data Location: E450 Eric L. Chang, MD—Co-Chair USC Norris Comprehensive Cancer Center and Keck School of Medicine 8:00 AM ReACT: Overall survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma. (Abstract 2009) D. A. Reardon, J. Schuster, D. D. Tran, K. L. Fink, L. B. Nabors, G. Li, D. A. Bota, R. V. Lukas, A. Desjardins, L. S. Ashby, J. P. Duic, M. M. Mrugala, A. Werner, T. Hawthorne, Y. He, J. A. Green, M. J. Yellin, C. D. Turner, T. A. Davis, J. H. Sampson, The ReACT Study Group 8:12 AM Fabio Massaiti Iwamoto, MD (Discussion of Abstract(s) 2009) Columbia University Medical Center EGFRvIII Vaccines in Glioblastoma 8:24 AM Phase II multicenter study of gene mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma. (Abstract 2010) L. K. Aguilar, L. A. Wheeler, A. G. Manzanera, S. D. Bell, R. Cavaliere, J. M. McGregor, S. Lo, J. C. Grecula, H. B. Newton, B. Badie, T. W. Trask, D. S. Baskin, J. Portnow, P. Z. New, E. Aguilar-Cordova, E. Chiocca 8:36 AM John H. Sampson, MD, PhD (Discussion of Abstract(s) 2010) Duke University Medical Center Viral Therapies for Brain Tumors 8:48 AM Newly diagnosed glioblastoma patients treated with an autologous heat shock protein peptide vaccine: PD-L1 expression and response to therapy. (Abstract 2011) O. Bloch, J. J. Raizer, M. Lim, M. Sughrue, R. Komotar, J. Abrahams, D. O’Rourke, A. D’Ambrosio, J. N. Bruce, A. Parsa 9:00 AM Amy B. Heimberger, MD (Discussion of Abstract(s) 2011) The University of Texas MD Anderson Cancer Center Biomarkers for Immune-Based Therapies in Glioblastoma 9:12 AM Panel Question and Answer 8:00 AM - 9:30 AM Clinical Science Symposium Navigating Racial and Economic Disparities in Cancer Care Delivery Location: S504 Jennifer W. Mack, MD—Co-Chair Dana-Farber/Boston Children’s Blood Disorders Center Craig Evan Pollack, MD—Co-Chair The Johns Hopkins University 8:00 AM Financial insolvency as a risk factor for mortality among patients with cancer. (Abstract 6509) A. Bansal, S. D. Ramsey, C. R. Fedorenko, D. K. Blough, K. A. Overstreet, V. Shankaran, P. A. Newcomb 8:12 AM Yousuf Zafar, MD, MHS (Discussion of Abstract(s) 6509) Duke University Medical Center Going for Broke: Cancer and Personal Finances 143 SUNDAY Albert Lai, MD, PhD—Co-Chair UCLA Neuro-Oncology Program Sunday, May 31, 2015 8:24 AM The impact of patient navigation on racial and ethnic disparities: Results from the patient navigation research program. (Abstract 6510) N. Ko, F. Snyder, P. C. Raich, E. D. Paskett, D. Dudley, J. Lee, P. H. Levine, K. M. Freund 8:36 AM Kim Felder Rhoads, MD, MS, MPH (Discussion of Abstract(s) 6510) Stanford University Navigating Toward Health 8:48 AM Effect of organizational approaches on safety-net hospitals’ cancer care quality. (Abstract 6511) N. A. Bickell, A. Moss, M. Castaldi, A. Shah, A. Sickles, P. J. Pappas, T. Lewis, M. Kemeny, S. Arora, L. Schleicher, A. Srinivasan, L. L. Montgomery, K. Fei, B. Bellacera, R. Franco, A. S. McAlearney 9:00 AM Dawn L. Hershman, MD, MS (Discussion of Abstract(s) 6511) Columbia University Medical Center Improving Quality through Patient-Centered Organizational Structures 9:12 AM Panel Question and Answer 8:00 AM - 9:30 AM Clinical Science Symposium Predicting and Improving Adverse Outcomes in Older Patients with Cancer Location: S102 Monica Alexandra Iriso, MD—Co-Chair Hospital Español SUNDAY Arif Kamal, MD—Co-Chair Duke University Medical Center 8:00 AM Association between renal function and chemotherapy-related toxicity in older adults with cancer. (Abstract 9509) L. L. Peterson, A. Hurria, T. Feng, S. G. Mohile, C. Owusu, H. D. Klepin, C. P. Gross, S. M. Lichtman, A. Gajra, I. G. Glezerman, V. Katheria, L. Zavala, D. D. Smith, W. P. Tew 8:12 AM William W. Tse, MD (Discussion of Abstract(s) 9509) West Virginia University Clinical Trials in the Older Patient: Who, When, and Why? 8:24 AM Evaluation of a web-based cognitive rehabilitation programme (CRP) in cancer survivors reporting cognitive symptoms following chemotherapy. (Abstract 9510) V. J. Bray, H. M. Dhillon, M. Bell, M. Kabourakis, H. Rice, D. Yip, F. M. Boyle, M. Price, J. L. Vardy 8:36 AM Rachel A. Freedman, MD, MPH (Discussion of Abstract(s) 9510) Dana-Farber Cancer Institute Exercise for the Brain 8:48 AM A clinical score to predict early death at 100 days after a comprehensive geriatric assessment (CGA) in elderly cancer patients: A prospective study with 815 patients. (Abstract 9511) R. Boulahssass, S. Gonfrier, J. Ferrero, F. Auben, C. Rambaud, V. Mari, J. Turpin, T. Piche, B. Isabelle, J. Bereder, J. Hannoun Levi, J. Delotte, R. Largillier, L. Evesque, P. Follana, D. Borchiellini, D. Benchimol, J. Guigay, E. Francois, O. Guerin 9:00 AM To Be Determined (Discussion of Abstract(s) 9511) Prediction of Death in Older Patients: Close to the End? 9:12 AM Panel Question and Answer 144 Sunday, May 31, 2015 8:00 AM - 11:00 AM Oral Abstract Session Gastrointestinal (Noncolorectal) Cancer Location: E Hall D2 Emil Lou, MD—Co-Chair University of Minnesota 8:00 AM Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study. (Abstract 4000) D. Cunningham, N. C. Tebbutt, I. Davidenko, A. M. Murad, S. Al-Batran, D. H. Ilson, S. Tjulandin, E. Gotovkin, B. Karaszewska, I. Bondarenko, M. A. Tejani, A. A. Udrea, M. A. Tehfe, N. Baker, K. S. Oliner, Y. Zhang, T. Hoang, R. Sidhu, D. V. Catenacci 8:12 AM Relationship between PD-L1 expression and clinical outcomes in patients with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in KEYNOTE-012. (Abstract 4001) Y. Bang, H. Chung, V. Shankaran, R. Geva, D. V. Catenacci, S. Gupta, J. P. Eder, R. Berger, E. J. Gonzalez, A. Ray, M. Dolled-Filhart, K. Emancipator, K. Pathiraja, J. K. Lunceford, J. D. Cheng, M. Koshiji, K. Muro 8:24 AM Neoadjuvant chemotherapy for resectable oesophageal and junctional adenocarcinoma: Results from the UK Medical Research Council randomised OEO5 trial (ISRCTN 01852072). (Abstract 4002) D. Alderson, R. E. Langley, M. G. Nankivell, J. M. Blazeby, M. Griffin, A. Crellin, H. I. Grabsch, A. F. Okines, C. Goldstein, S. Falk, J. Thompson, R. Krysztopik, F. Y. Coxon, S. Pritchard, R. Langer, S. P. Stenning, D. Cunningham 8:36 AM INTEGRATE: A randomized, phase II, double-blind, placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC): A study by the Australasian Gastrointestinal Trials Group (AGITG)—Final overall and subgroup results. (Abstract 4003) N. Pavlakis, K. M. Sjoquist, E. Tsobanis, A. J. Martin, Y. Kang, Y. Bang, C. J. O’Callaghan, N. C. Tebbutt, S. Y. Rha, J. Lee, J. Cho, L. R. Lipton, M. J. Burnell, T. Alcindor, A. Strickland, J. Kim, S. Yip, J. Simes, J. R. Zalcberg, D. Goldstein 8:48 AM Geoffrey Yuyat Ku, MD, MBA (Discussion of Abstract(s) 4000 – 4003) Memorial Sloan Kettering Cancer Center Searching for Positive Signals in Gastroesophageal Cancer 9:00 AM Panel Question and Answer 9:12 AM SWOG S0518: Phase III prospective randomized comparison of depot octreotide plus interferon alpha-2b versus depot octreotide plus bevacizumab (NSC #704865) in advanced, poor prognosis carcinoid patients (NCT00569127). (Abstract 4004) J. C. Yao, K. Guthrie, C. Moran, J. R. Strosberg, M. H. Kulke, J. A. Chan, N. K. LoConte, R. R. McWilliams, E. M. Wolin, B. I. Mattar, S. McDonough, H. X. Chen, C. D. Blanke, H. S. Hochster 9:24 AM Randomized phase II study of everolimus (E) versus everolimus plus bevacizumab (EⴙB) in patients (Pts) with locally advanced or metastatic pancreatic neuroendocrine tumors (pNET), CALGB 80701 (Alliance). (Abstract 4005) M. H. Kulke, D. Niedzwiecki, N. R. Foster, B. Fruth, P. L. Kunz, H. F. Kennecke, E. M. Wolin, A. P. Venook 9:36 AM Diane Lauren Reidy, MD (Discussion of Abstract(s) 4004 – 4005) Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College Targeting Angiogenic and Other Molecular Pathways in Neuroendocrine Tumors 9:48 AM Panel Question and Answer 145 SUNDAY James Posey, MD—Co-Chair University of Alabama at Birmingham Comprehensive Cancer Center Sunday, May 31, 2015 10:00 AM High response rate and PFS with PEGPH20 added to nab-paclitaxel/gemcitabine in stage IV previously untreated pancreatic cancer patients with high-HA tumors: Interim results of a randomized phase II study. (Abstract 4006) S. R. Hingorani, W. P. Harris, A. E. Hendifar, A. J. Bullock, X. W. Wu, Y. Huang, P. Jiang 10:12 AM CONKO-005: Adjuvant therapy in R0 resected pancreatic cancer patients with gemcitabine plus erlotinib versus gemcitabine for 24 weeks—A prospective randomized phase III study. (Abstract 4007) M. Sinn, T. Liersch, K. Gellert, H. Messmann, W. O. Bechstein, D. Waldschmidt, L. Jacobasch, M. Wilhelm, B. M. Rau, R. Grützmann, A. Weinmann, G. Maschmeyer, U. Pelzer, J. Stieler, J. K. Striefler, B. M. Ghadimi, M. Bahra, H. Oettle, B. Dörken, H. Riess 10:24 AM Preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by chemoradiation (CRT) for borderline resectable (BLR) pancreatic cancer (PDAC): Initial results from Alliance Trial A021101. (Abstract 4008) M. H. Katz, Q. Shi, S. A. Ahmad, J. M. Herman, R. d. Marsh, E. A. Collisson, L. H. Schwartz, R. C. Martin II, W. C. Conway, M. Truty, H. L. Kindler, A. M. Lowy, P. A. Philip, T. S. Bekaii-Saab, D. B. Cardin, N. K. LoConte, A. P. Venook 10:36 AM Kenneth H. Yu, MD (Discussion of Abstract(s) 4006 – 4008) Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College Pancreatic Cancer: The Current State and Future of Research 10:48 AM Panel Question and Answer 8:00 AM - 11:00 AM Oral Abstract Session SUNDAY Lung Cancer—Non-Small Cell Metastatic Location: N Hall B1 Luis Paz-Ares, MD, PhD—Co-Chair Hospital Universitario Doce de Octubre Nithya Ramnath, MD—Co-Chair University of Michigan Comprehensive Cancer Center 8:00 AM AZD9291, a mutant-selective EGFR inhibitor, as first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): Results from a phase 1 expansion cohort. (Abstract 8000) S. S. Ramalingam, J. C. Yang, C. K. Lee, T. Kurata, D. Kim, T. John, N. Nogami, Y. Ohe, Y. Rukazenkov, P. Frewer, M. Cantarini, S. Ghiorghiu, P. A. Janne 8:12 AM Efficacy of rociletinib (CO-1686) in plasma-genotyped T790M-positive non-small cell lung cancer (NSCLC) patients (pts). (Abstract 8001) L. V. Sequist, J. W. Goldman, H. A. Wakelee, D. R. Camidge, H. A. Yu, A. Varga, B. Solomon, G. R. Oxnard, S. I. Ou, V. Papadimitrakopoulou, B. H. Chao, S. V. Liu, K. L. Reckamp, A. I. Spira, Z. Piotrowska, D. Despain, C. A. Karlovich, S. Yurasov, J. Soria 8:24 AM Afatinib (A) vs erlotinib (E) as second-line therapy of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following platinumbased chemotherapy: Overall survival (OS) analysis from the global phase III trial LUX-Lung 8 (LL8). (Abstract 8002) J. Soria, E. Felip, M. Cobo, S. Lu, K. N. Syrigos, K. Lee, E. Goker, V. Georgoulias, W. Li, D. Isla, S. Z. Guclu, A. Morabito, Y. Min, A. Ardizzoni, S. M. Gadgeel, B. Wang, V. K. Chand, G. D. Goss, LUX-Lung 8 Investigators 8:36 AM Cabozantinib (C), erlotinib (E) or the combination (EⴙC) as second- or third-line therapy in patients with EGFR wild-type (wt) non-small cell lung cancer (NSCLC): A randomized phase 2 trial of the ECOG-ACRIN Cancer Research Group (E1512). (Abstract 8003) J. W. Neal, S. E. Dahlberg, H. A. Wakelee, S. C. Aisner, M. Bowden, D. P. Carbone, S. S. Ramalingam 146 8:48 AM Gregory J. Riely, MD, PhD (Discussion of Abstract(s) 8000 – 8003) Memorial Sloan Kettering Cancer Center Targeting the Target in Non–Small Cell Lung Cancer and Squamous Cell Carcinoma 9:00 AM Panel Question and Answer 9:12 AM Randomized phase III study of nedaplatin (N) plus docetaxel (D) versus cisplatin (C) plus D for advanced or relapsed squamous cell carcinoma of the lung (SqLC): WJOG5208L. (Abstract 8004) T. Shukuya, T. Yamanaka, T. Seto, H. Daga, K. Goto, H. Saka, S. Sugawara, T. Takahashi, S. Yokota, H. Kaneda, T. Kawaguchi, S. Nagase, T. Oguri, Y. Iwamoto, T. Nishimura, Y. Hattori, K. Nakagawa, Y. Nakanishi, N. Yamamoto 9:24 AM Whole brain radiotherapy for brain metastases from non-small lung cancer: Quality of life (QoL) and overall survival (OS) results from the UK Medical Research Council QUARTZ randomised clinical trial (ISRCTN 3826061). (Abstract 8005) P. M. Mulvenna, M. G. Nankivell, R. Barton, C. Faivre-Finn, P. Wilson, B. Moore, E. McColl, I. Brisbane, D. Ardron, B. Sydes, C. Pugh, T. Holt, N. Bayman, S. Morgan, C. Lee, K. Waite, R. Stephens, M. M. Parmar, R. E. Langley 9:36 AM David R. Gandara, MD (Discussion of Abstract(s) 8004 – 8005) UC Davis Comprehensive Cancer Center Managing Advanced or Relapsed Disease: Challenging the Convention 9:48 AM Panel Question and Answer 10:00 AM Interim results of a phase II study of the BRAF inhibitor (BRAFi) dabrafenib (D) in combination with the MEK inhibitor trametinib (T) in patients (pts) with BRAF V600E mutated (mut) metastatic non-small cell lung cancer (NSCLC). (Abstract 8006) D. Planchard, H. J. Groen, T. Kim, J. R. Rigas, P. J. Souquet, C. S. Baik, F. Barlesi, J. Mazières, E. A. Quoix, C. M. Curtis Jr., B. Mookerjee, A. N. Bartlett-Pandite, C. Tucker, A. D’Amelio Jr., B. E. Johnson 10:12 AM Phase II study of cabozantinib for patients with advanced RET-rearranged lung cancers. (Abstract 8007) A. E. Drilon, C. S. Sima, R. Somwar, R. Smith, M. S. Ginsberg, G. J. Riely, C. M. Rudin, M. Ladanyi, M. G. Kris, N. A. Rizvi 10:24 AM Efficacy and safety of the ALK inhibitor alectinib in ALKⴙ non-small-cell lung cancer (NSCLC) patients who have failed prior crizotinib: An open-label, single-arm, global phase 2 study (NP28673). (Abstract 8008) S. I. Ou, J. Ahn, L. De Petris, R. Govindan, J. Yang, B. G. Hughes, H. Lena, D. Moro-Sibilot, A. Bearz, S. V. Ramirez, T. Mekhail, A. I. Spira, A. H. Zeaiter, W. Bordogna, B. Balas, S. Golding, P. N. Morcos, D. Kim 10:36 AM Alex A. Adjei, MD, PhD (Discussion of Abstracts(s) 8006-8008) Roswell Park Cancer Institute Prognostic Profiling in Lung Cancer 10:48 AM Panel Question and Answer 8:00 AM - 11:30 AM Poster Session Leukemia, Myelodysplasia, and Transplantation Location: S Hall A Abstracts 7011–7022 will be discussed during the Leukemia, Myelodysplasia, and Transplantation Poster Discussion Session. See page 186 for session information. Board 1 Long-term follow-up of a phase Ib trial of idelalisib (IDELA) in combination with chemoimmunotherapy (CIT) in patients (pts) with relapsed/refractory (R/R) CLL including pts with del17p/TP53 mutation. (Abstract 7011) J. C. Barrientos, S. Coutre, S. De Vos, I. Flinn, N. D. Wagner-Johnston, M. T. Schreeder, J. P. Sharman, T. E. Boyd, K. R. Rai, J. Leonard, B. Sorensen, A. Viggiano, T. M. Jahn, R. R. Furman 147 SUNDAY Sunday, May 31, 2015 Sunday, May 31, 2015 SUNDAY Board 2 Dose adherence and baseline exposure analysis of the ibrutinib 420 mg dose administered to patients with previously treated chronic lymphocytic leukemia (CLL). (Abstract 7012) P. M. Barr, J. R. Brown, P. Hillmen, S. O’Brien, J. C. Barrientos, N. M. Reddy, S. Coutre, S. P. Mulligan, U. Jäger, R. R. Furman, F. Cymbalista, M. Montillo, C. Dearden, T. Robak, C. Moreno, J. Pagel, J. A. Burger, S. Suzuki, D. F. James, J. C. Byrd Board 3 Prognostic testing patterns in CLL pts treated in U.S. practices from the Connect CLL registry. (Abstract 7013) A. Mato, C. Flowers, C. M. Farber, M. A. Weiss, T. J. Kipps, M. Kozloff, C. Nabhan, I. Flinn, D. L. Grinblatt, N. Lamanna, K. A. Sullivan, P. Kiselev, E. Flick, K. A. Foon, A. S. Swern, J. P. Sharman Board 4 Association of relapse of FLT3-ITD AML with normal karyotype with internal tandem duplication allelic burden, base-pair insertion length, and NPM1 status. (Abstract 7014) S. L. Sammons, S. Bentzen, R. Faramand, V. Duong, M. Tidwell, E. A. Sausville, M. R. Baer, A. Emadi Board 5 Activity of the mitochondrial metabolism inhibitor cpi-613 in combination with high dose Ara-C (HDAC) and mitoxantrone in high risk relapsed or refractory acute myeloid leukemia (AML). (Abstract 7015) T. S. Pardee, K. Stadelman, S. Isom, L. R. Ellis, D. Berenzon, D. D. Hurd, D. S. Howard, R. Harrelson, M. Manuel, S. Dralle, S. Lyerly, B. L. Powell Board 6 Safety and tolerability of the combination of ATRA ⴙ arsenic trioxide (ATO) ⴙ gemtuzumab ozogamicin (GO) in high-risk acute promyelocytic leukemia (APL): Initial report of the SWOG/Alliance/ECOG S0535 trial. (Abstract 7016) J. E. Lancet, M. Othus, D. J. DeAngelo, S. Coutre, R. S. Komrokji, M. S. Tallman, M. R. Litzow, F. R. Appelbaum Board 7 Correlation of overall survival (OS) with bone marrow blast (BMBL) response in patients (pts) with myelodysplastic syndrome. (Abstract 7017) L. R. Silverman, P. Fenaux, P. Greenberg, E. P. Demakos, V. Santini, J. F. Seymour, S. C. Navada, M. E. Petrone, B. R. Snyder, N. Azarnia, G. Garcia-Manero Board 8 Effect of long noncoding RNA RUNXOR on the epigenetic regulation of RUNX1 in acute myelocytic leukemia. (Abstract 7018) H. Wang, R. Guo, A. R. Hoffman, J. Hu, W. Li Board 9 NFAT2 to regulate anergy induction in CLL through Lck. (Abstract 7019) M. Maerklin, J. S. Heitmann, F. Truckenmueller, M. Ganser, H. Kopp, S. Wirths, L. Kanz, A. Rao, M. R. Mueller Board 10 GATA-1, FOG-1, and FLI-1 regulation in essential thrombocythemia independently from JAK2 and CALR mutations. (Abstract 7020) C. R. Rinaldi, J. Lally, L. BROWN, C. Graham Board 11 A multi-institution phase I trial of ruxolitinib in chronic myelomonocytic leukemia (CMML). (Abstract 7021) E. Padron, A. E. Dezern, K. Vaddi, P. A. Scherle, Q. Zhang, Y. Ma, M. Balasis, S. Tinsley, H. Ramadan, C. Zimmerman, D. P. Steensma, G. J. Roboz, J. E. Lancet, A. F. List, M. A. Sekeres, R. S. Komrokji Board 12 Propensity score analysis: Frontline therapy with high-dose (HD) imatinib vs. 2nd generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia in chronic phase. (Abstract 7022) K. Sasaki, H. M. Kantarjian, E. Jabbour, F. Ravandi, K. Takahashi, M. Konopleva, G. Borthakur, G. GarciaManero, W. G. Wierda, N. G. Daver, P. Jain, S. Pierce, M. B. Rios, J. E. Cortes Board 13 A multicenter open-label phase 1b/2 study of ibrutinib in steroid dependent or refractory chronic graft versus host disease (cGVHD). (Abstract 7024) D. B. Miklos, M. Arora, C. S. Cutler, R. Nakamura, M. Juretic, Y. Li, L. A. Styles, D. F. James, S. M. Jaglowski Board 14 Symptomatic BK virus as a significant independent predictor of immune suppression and poor overall survival in allogeneic hematopoietic stem cell recipients. (Abstract 7025) A. Abudayyeh, A. Hamdi, H. Y. Lin, M. Abdelrahim, G. Rondon, D. P. Kontoyiannis, A. L. Olson, B. Andersson, R. E. Champlin, E. J. Shpall, K. Rezvani 148 Board 15 The relationship between HIF family gene expression in allogeneic T-cell products and acute graft-versus-host disease. (Abstract 7026) J. Rimando, S. Larrick, N. Fowler, L. Castiello, S. A. Ali, M. Sabatino, D. Stroncek, T. Felizardo, D. H. Fowler Board 16 Physical activity as a predictor of outcomes in hematopoietic stem cell transplantation (HSCT) recipients. (Abstract 7027) A. Mishra, B. Yue, J. Kim, C. Anasetti, J. A. Pidala, M. L. Riches, H. S. Jim Board 17 Association of higher total nucleated cell dose with improved survival in patients receiving donor lymphocyte infusion after allogeneic stem cell transplantation. (Abstract 7028) N. Singh, A. J. Kumar, A. Gao, M. R. Luskin, N. V. Frey, E. O. Hexner, A. W. Loren, S. M. Luger, E. A. Stadtmauer, D. L. Porter, R. Reshef Board 18 A randomized controlled trial of ibandronate for the prevention of bone loss following allogeneic stem cell transplantation. (Abstract 7029) X. Pundole, R. E. Champlin, U. R. Popat, C. P. Escalante, W. A. Murphy Jr., R. F. Gagel, H. Lu Board 19 Outcomes of hematopoietic stem cell transplant (HSCT) in HIV patients in HAART era. (Abstract 7030) K. Mehta, A. P. Im, H. Wang, P. Veldkamp Board 20 Post-transplantation long-term events in a cohort of HIV-positive patients affected by relapsed/refractory lymphoma. (Abstract 7031) E. Zanet, C. Durante, M. Rupolo, M. Mazzucato, S. Zanussi, P. De Paoli, A. Lleshi, M. Taborelli, D. Serraino, U. Tirelli, M. Spina, M. Michieli Board 21 Ratio of total leucocyte count to C-reactive protein: Does it help differentiate engraftment fever from infective fever in patients undergoing autologous stem cell transplant? (Abstract 7032) S. Punatar, A. Gokarn, D. Rajamanickam K., A. Gupta, L. Mathew, S. Kannan, N. Khattry Board 21B Results of a phase III randomized, controlled study evaluating the efficacy and safety of idelalisib (IDELA) in combination with ofatumumab (OFA) for previously treated chronic lymphocytic leukemia (CLL). (Abstract 7023) J. A. Jones, M. Wach, T. Robak, J. R. Brown, A. R. Menter, E. Vandenberghe, L. Ysebaert, N. D. Wagner-Johnston, J. Polikoff, H. S. Salman, K. M. Taylor, S. Coutre, S. E. Spurgeon, S. D. Kendall, I. Flinn, L. Dreiling, R. Dubowy, Y. Cho, S. Peterman, C. Owen Board 22 Chemomobilization with (R)-ICE (rituximab, ifosfamide, carboplatin, etoposide) compared to G-CSF and plerixafor (GⴙP) mobilization in lymphoid malignancies. (Abstract 7033) L. W. Veltri, B. Dhakal, A. K. Singavi, S. Wen, J. Luo, M. D. Craig, A. Cumpston, A. Shillingburg, K. Watkins, J. Esselman, M. C. Pasquini, T. S. Fenske, P. Hari, M. Hamadani, A. S. Kanate Board 23 The impact of HBO on early ALC recovery following high-dose therapy and autologous transplantation. (Abstract 7034) O. S. Aljitawi, M. Markiewicz, A. Seng, T. L. Lin, S. Ganguly, J. Mahnken, A. Singh, L. Shune, S. H. Abhyankar, B. Lipe, D. Allin, J. McGuirk, T. Yankee Board 24 Outcomes of ASCT for cardiac AL-amyloidosis and cardiac light chain deposition disease. (Abstract 7035) A. A. Abdallah, S. Atrash, A. Bakhous, D. Alapat, M. Zangari Board 25 Long-term outcomes of rituximab use prior to autologous stem cell transplant (ASCT) in low-grade follicular lymphoma (FL) at the time of first progression. (Abstract 7036) R. A. Ferro, V. R. Bhatt, L. Smith, M. A. Lunning, P. J. Bierman, J. O. Armitage, G. Bociek, J. Vose Board 26 Overall survival and treatment response in patients with myelodysplastic syndrome and acute myeloid leukemia treated with DNA methyl-transferase inhibitors vs. conventional care regimens: A meta-analysis of 5 randomized trials. (Abstract 7037) S. Yun, N. Vincelette, J. Segar Board 27 Exosome transcriptome analysis provides novel tools for CLL patient stratification. (Abstract 7038) R. Calogero, M. Arigoni, F. Riccardo, A. RodriguezVicente, J. M. Hernandez, F. Zolezzi 149 SUNDAY Sunday, May 31, 2015 Sunday, May 31, 2015 SUNDAY Board 28 Cellular immunotherapy for refractory hematological malignancies. (Abstract 7039) J. L. Reagan, L. D. Fast, K. Mantripragada, M. Nevola, K. Rosati, A. Schumacher, H. Safran, M. I. Quesenberry, E. S. Winer, J. N. Butera, P. J. Quesenberry Board 29 A meta-analysis of randomized clinical trials in acute promyelocytic leukemia (APL). (Abstract 7040) F. Lo-Coco, M. S. Tallman, G. Barnes, I. Guerra, V. Damera, M. Martin, U. W. Mueller Board 30 Impact of unbalanced karyotypes at diagnosis on prognosis of CML. (Abstract 7041) R. Hehlmann, L. Kalmanti, C. Dietz, M. Lauseker, C. Haferlach, B. Schlegelberger, M. Jotterand, M. C. Müller, M. Haenel, C. Köhne, M. Goebeler, M. Pfreundschuh, L. Balleisen, A. Burchert, S. W. Krause, M. Pfirrmann, J. Hasford, A. Hochhaus, S. Saussele, A. Fabarius Board 31 Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia. (Abstract 7042) N. J. Short, M. J. Keating, W. G. Wierda, S. Faderl, A. Ferrajoli, Z. Estrov, S. C. Smith, S. M. O’Brien Board 32 Safety and activity of blinatumomab for older patients (pts) with relapsed/refractory (R/R) B–precursor acute lymphoblastic leukemia (ALL) in two phase 2 studies. (Abstract 7043) H. M. Kantarjian, A. S. Stein, R. C. Bargou, C. Grande, R. A. Larson, M. Stelljes, J. E. Benjamin, C. Jia, M. S. Topp Board 33 Phase 1 study of CWP232291 in relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). (Abstract 7044) J. E. Cortes, S. Faderl, J. Pagel, C. Jung, S. Yoon, Y. Koh, A. D. Pardanani, R. S. Hauptschein, K. Lee, J. Lee Board 34 Impact of nilotinib treatment on subclinical cardiovascular biomakers. (Abstract 7045) M. Gardembas, S. Henni, A. Corby, L. Omarjee, N. Ifrah, G. Leftheriotis Board 35 Survival of de novo and secondary acute promyelocytic leukemia: A propensity matched analysis of the Surveillance, Epidemiology and End Results database. (Abstract 7046) R. Pathak, S. Giri, M. G. Martin, V. R. Bhatt Board 36 Four-year minimum follow-up of ongoing patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) in a phase 1 trial of ponatinib (PON). (Abstract 7047) M. Talpaz, J. E. Cortes, H. M. Kantarjian, N. P. Shah, D. L. Bixby, I. Flinn, T. J. O’Hare, S. Hu, V. M. Rivera, T. P. Clackson, M. G. Conlan, F. G. Haluska, B. J. Druker, M. W. Deininger, M. J. Mauro Board 37 Safety and feasibility of anticoagulation prophylaxis with enoxaparin in acute lymphoblastic leukemia during asparaginase-based intensification therapy. (Abstract 7048) H. A. Sibai, J. T. Seki, N. Sakurai, A. C. Schuh, K. W. Yee, M. D. Minden, A. D. Schimmer, V. Gupta, J. M. Brandwein Board 38 Elevated blood pressure (BP) and adverse events (AEs) of hypertension (HTN) in ponatinib (PON) leukemia trials. (Abstract 7049) H. J. Khoury, M. Baccarani, F. Guilhot, A. Hochhaus, T. P. Hughes, J. H. Lipton, S. Lustgarten, K. Yanase, M. G. Conlan, J. E. Cortes, M. W. Deininger, H. M. Kantarjian, N. P. Shah, M. Talpaz, M. J. Mauro Board 39 Phase I trial of ␣-particle therapy with actinium-225 (225Ac)-lintuzumab (anti-CD33) and low-dose cytarabine (LDAC) in older patients with untreated acute myeloid leukemia (AML). (Abstract 7050) J. G. Jurcic, F. Ravandi, J. M. Pagel, J. H. Park, B. Smith, D. Douer, M. Y. Levy, E. Estey, H. M. Kantarjian, D. Earle, D. Cicic, D. A. Scheinberg Board 40 Re-exposure to blinatumomab after CD19-positive relapse: Experience from three trials in patients (pts) with relapsed/refractory B-precursor acute lymphoblastic leukemia (R/R ALL). (Abstract 7051) M. S. Topp, M. Stelljes, G. Zugmaier, P. Barnette, L. T. Heffner, T. M. Trippett, R. C. Bargou, C. Holland, J. Benjamin, M. R. Litzow Board 41 RAS mutation acquisition at transformation from myelodysplastic syndrome to acute myeloid leukemia to predict outcome. (Abstract 7052) T. Badar, J. E. 150 Sunday, May 31, 2015 Board 42 O-desulfated heparin and chemotherapy for the treatment of AML. (Abstract 7053) T. Kovacsovics, A. S. Mims, M. E. Salama, N. Rao, J. Pantin, M. W. Deininger, T. P. Kennedy, L. M. Bavisotto, K. M. Boucher, S. G. Marcus, P. J. Shami Board 43 A multidrug resistant engineered CAR T cell for allogeneic combination immunotherapy. (Abstract 7054) J. Valton Board 44 Allogeneic hematopoietic cell transplant (HCT) in patients (pts) > 60 years of age with first relapsed or refractory acute myeloid leukemia (R/R AML) after treatment with vosaroxin plus cytarabine (vos/cyt) vs placebo plus cytarabine (pla/cyt): Results from VALOR. (Abstract 7055) G. J. Schiller, E. K. Ritchie, H. Sayar, J. E. Lancet, M. D. Craig, N. Vey, S. A. Strickland, H. P. Erba, A. Pigneux, H. Horst, C. Recher, V. M. Klimek, O. Odenike, A. R. Craig, R. Ward, J. Smith, H. M. Kantarjian, R. K. Stuart, F. Ravandi, VALOR Investigators Group Board 45 Cardiovascular events in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors: A systematic review and metaanalysis. (Abstract 7056) C. Chai-Adisaksopha, C. M. Hillis, W. Lam Board 46 Factors influencing outcomes in patients (Pts) with relapsed/refractory b-precursor acute lymphoblastic leukemia (r/r ALL) treated with blinatumomab in a phase 2 study. (Abstract 7057) H. Kantarjian, N. Gökbuget, S. M. O’Brien, A. S. Stein, C. Jia, S. J. Forman, R. C. Bargou, A. K. Fielding, L. T. Heffner, R. A. Larson, S. Neumann, T. Maniar, D. Nagorsen, M. S. Topp Board 47 Performance status and comorbidities on outcome of hypomethylating therapy in older adults (>60 years old) with acute myeloid leukemia. (Abstract 7058) A. Chana, L. A. Ford, E. A. Griffiths, J. E. Thompson, M. Wetzler, E. S. Wang Board 48 Efficacy and safety of an anti-FLT3 antibody (LY3012218) in patients with relapsed acute myeloid leukemia. (Abstract 7059) D. Sanford, W. G. Blum, F. Ravandi, R. B. Klisovic, G. Borthakur, A. R. Walker, G. Garcia-Manero, G. Marcucci, W. G. Wierda, S. P. Whitman, H. M. Kantarjian, J. E. Cortes Board 49 Association between early promoter methylation changes and outcome in older acute myeloid leukemia patients treated on SWOG S0703 (NCT0065884). (Abstract 7060) S. Nand, N. Achille, M. Othus, K. W. Phelan, S. Zhang, K. A. Cooper, J. E. Godwin, F. R. Appelbaum, J. P. Radich, H. P. Erba, N. Zeleznik-Le Board 50 Azacitidine in older patients with acute myeloid leukemia (AML): Results from the ALMA study according to the MRC risk index score. (Abstract 7061) J. F. Falantes, V. Martinez Robles, J. Bargay, G. Deben, A. Garrido, J. Casano, O. Salamero, J. M. Bergua, E. Colado, R. Garcia, C. Pedro, S. Redondo, M. Tormo, S. Bonanad, M. Diez-Campelo, M. Perez-Encinas, A. de la Fuente, B. Xicoy, P. Montesinos, F. Ramos Board 51 An alvocidib-containing regimen is highly effective in AML patients through a mechanism dependent on MCL1 expression and function. (Abstract 7062) B. D. Smith, S. L. Warner, C. Whatcott, A. Siddiqui-Jain, B. Bahr, E. Dettman, C. Doykan, M. H. Cardone, S. D. Weitman, D. Bearss Board 52 Ethnic differences in survival of elderly chronic myeloid leukemia patients in pre- and post-imatinib era in the United States. (Abstract 7063) D. Uprety, B. K. Shah Board 53 The prognostic impact of combined NPM1ⴙ/FLT3- mutational status in newly diagnosed acute myeloid leukemia (AML) patients with intermediate risk cytogenetics according to age and treatment modality. (Abstract 7064) M. Hefazi, M. A. Siddiqui, M. M. Patnaik, A. P. Wolanskyj, H. Alkhateeb, D. Zblewski, M. A. Elliott, W. J. Hogan, M. R. Litzow, A. Al-Kali Board 54 Infectious complications in AML patients treated with induction vs. hypomethylating therapy. (Abstract 7065) M. M. Jalbut, A. M. Brunner, P. C. 151 SUNDAY Cortes, E. Jabbour, G. Borthakur, M. Konopleva, T. M. Kadia, Z. Bohannan, S. Pierce, F. Ravandi, K. Patel, R. Luthra, H. M. Kantarjian, G. Garcia-Manero Sunday, May 31, 2015 Amrein, E. C. Attar, K. K. Ballen, G. Hobbs, A. M. Perry, C. P. Joseph, D. S. Neuberg, A. T. Fathi SUNDAY Board 55 Digital Fusion-Gene expression profiling in acute leukemia (AL): Clinical validation of throughput molecular technology in laboratory medicine. (Abstract 7066) A. Akhter, F. Rashid-Kolvear, F. Farooq, A. Qureshi, M. ShabaniRad, G. Sinclair, D. A. Stewart, A. Mansoor Board 56 Construction and characterization of novel CD33/CD3 tandem diabodies (TandAbs) for the treatment of acute myeloid leukemia (AML). (Abstract 7067) U. Reusch, K. H. Harrington, C. J. Gudgeon, I. Fucek, K. Ellwanger, M. Weichel, S. Knackmuss, E. Zhukovsky, J. A. Fox, J. Guenot, R. B. Walter Board 57 Long-term bosutinib (BOS) for Philadelphia Chromosome–Positive (Phⴙ) advanced (ADV) chronic myeloid leukemia (CML) after prior tyrosine kinase inhibitor (TKI) failure. (Abstract 7068) C. Gambacorti-Passerini, H. M. Kantarjian, D. Kim, H. J. Khoury, J. H. Lipton, T. H. Brümmendorf, K. Noonan, E. Matczak, E. Leip, J. E. Cortes Board 58 Clinical activity, safety profile, and hepatotoxicity of TGR-1202, a novel once daily PI3K␦ inhibitor, in patients with CLL and B-cell lymphoma. (Abstract 7069) H. A. Burris, M. R. Patel, T. S. Fenske, O. A. O’Connor, C. Deng, D. M. Brander, M. Gutierrez, S. F. Jones, J. G. Kuhn, H. P. Miskin, P. Sportelli, S. V. Vakkalanka, I. Flinn Board 59 A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML). (Abstract 7070) F. Ravandi, I. Gojo, M. M. Patnaik, M. D. Minden, H. M. Kantarjian, A. Levonas, C. Fancourt, R. Lam, A. Meister, M. Jones, R. K. Kemp, C. Knox, S. Rose, P. Shah Patel, R. Tibes Board 60 Development of a bispecific tetravalent CD33/CD3 TandAb for the treatment of AML. (Abstract 7071) U. Reusch, K. Ellwanger, M. Weichel, V. Molkenthin, J. A. Fox, S. Knackmuss, I. Fucek, E. Rajkovic, E. Zhukovsky, J. Guenot, M. Treder Board 61 Serum chemokines and cytokines in CLL patients treated with duvelisib, a PI3K-␦,␥ inhibitor. (Abstract 7072) M. Douglas, K. Allen, J. Sweeney, S. M. O’Brien, I. Flinn, S. M. Horwitz, J. C. Byrd, M. R. Patel, B. S. Kahl, F. M. Foss, P. Porcu, V. Kelly, H. Stern Board 62 The dual SRC-ABL inhibitors in Phⴙ acute lymphoblastic leukemia to enhance synergy between targeted BCR-ABL and BCL-2 inhibitors. (Abstract 7073) J. T. Leonard, S. E. Spurgeon, E. A. Traer, B. M. Hayes-Lattin, M. Loriaux, J. Tyner, B. J. Druker, B. H. Chang Board 63 Early clinical activity and pharmacodynamic effects of duvelisib, a PI3K-␦,␥ inhibitor, in patients with treatment-naïve CLL. (Abstract 7074) M. R. Patel, S. M. O’Brien, K. Faia, K. White, M. Douglas, K. Allen, J. L. Kutok, J. Sweeney, V. Kelly, I. Flinn, J. C. Byrd, H. Stern Board 64 CDA status as predictive marker of aplasia duration and clinical outcome in AML patients receiving cytarabine based chemotherapy. (Abstract 7075) C. Mercier, R. Fanciullino, J. Colle, G. Venton, V. Ivanov, G. Sebahoun, J. Ciccolini, R. Costello Board 65 Long-term bosutinib (BOS) in patients (pt) with chronic phase (CP) chronic myeloid leukemia (CML) after prior imatinib (IM) failure. (Abstract 7076) J. H. Lipton, J. E. Cortes, H. J. Khoury, H. M. Kantarjian, D. Kim, P. Schafhausen, M. Zeremski, N. Bardy-Bouxin, M. Shapiro, E. Leip, C. Gambacorti-Passerini, T. H. Brümmendorf Board 66 First report of a phase I/II study of DFP-10917, a nucleoside analog, given by continuous infusion (CI) in patients (pts) with relapsed or refractory acute leukemia. (Abstract 7077) H. M. Kantarjian, E. Jabbour, G. Garcia-Manero, T. M. Kadia, C. D. Dinardo, N. G. Daver, G. Borthakur, N. Jain, J. Waukau, M. Kwari, B. D. Anderson, K. Iizuka, C. Jin, W. Plunkett Board 67 A phase (Ph) 1/2 trial of rituximab (RX), imprime PGG (IP), and alemtuzumab (AL) in the early treatment of patients (Pts) with high risk chronic 152 Sunday, May 31, 2015 Board 68 Moxetumomab pasudotox and minimal residual disease in hairy cell leukemia. (Abstract 7079) R. J. Kreitman, E. Arons, K. Still, M. S. Tallman, M. Stetler-Stevenson, C. Yuan, D. J. FitzGerald, I. Pastan Board 69 Correlation of genomic analysis by MyAML with chemotherapy drug sensitivity. (Abstract 7080) P. S. Becker, M. W. Schmitt, L. A. Loeb, W. Gu, Q. Wei, Z. Xie, A. R. Carson, T. Martins, C. A. Blau, V. Oehler, K. Y. Yeung Board 70 Phase II trial of the combination of subcutaneous bortezomib (Bortez) and pegylated liposomal doxorubicin (PLD) for the treatment of patients with acute myelogenous leukemia (AML). (Abstract 7081) B. K. Tomlinson, J. M. Tuscano, M. Abedi, J. Welborn, R. O’Donnell, M. Arora, R. Verman, K. Jones, B. A. Jonas Board 71 Lenalidomide added to bendamustine-rituximab for untreated chronic lymphocytic leukemia (CLL): A phase 1 study. (Abstract 7082) J. S. Abramson, M. S. Davids, L. Werner, D. C. Fisher, P. Armand, P. C. Amrein, D. S. Neuberg, E. P. Hochberg, J. R. Brown Board 72 Clinical outcome of adult acute lymphoblastic leukemia based on Philadelphia chromosome status and socioeconomic status. (Abstract 7083) B. D. Dao, J. Y. Law, P. Le, A. Gao, C. Ahn, K. Kumar, L. D. Anderson, R. Collins, H. C. Li, P. A. Patel, N. Sadeghi, M. Vusirikala, H. V. Naina, P. P. Scaglioni Board 73 Prognostic impact of renal insufficiency (RI) at diagnosis in patients with chronic lymphocytic leukemia (CLL). (Abstract 7084) P. Strati, K. G. Chaffee, S. J. Achenbach, S. L. Slager, S. M. Schwager, T. Call, N. Leung, T. D. Shanafelt Board 74 Effect of grade (G) 3 fibrosis on clinical outcome of patients (Pts) with myelodysplastic syndromes (MDS): Mayo Clinic Experience. (Abstract 7085) N. Cheema, F. Baidoun, D. Zblewski, S. Hashmi, N. Gangat, A. P. Wolanskyj, W. J. Hogan, M. R. Litzow, D. Chen, A. Al-Kali Board 75 Up-regulation of CALR in patients with essential thrombocythemia independent from CALR mutations. (Abstract 7086) C. R. Rinaldi, L. Brown, C. Graham, R. Simpson, J. Lally Board 76 Ruxolitinib in polycythemia vera: Follow-up from the RESPONSE trial. (Abstract 7087) S. Verstovsek, A. M. Vannucchi, M. Griesshammer, T. Masszi, S. Durrant, F. Passamonti, C. N. Harrison, F. Pane, P. Zachee, M. Hino, B. Moiraghi, C. B. Miller, V. Rosti, R. A. Mesa, M. M. Jones, H. Zhen, J. Li, N. Francillard, D. Habr, J. Kiladjian Board 77 Case series of hypomethylating agents (HMA) effect on myelodysplastic/myeloproliferative neoplasm unclassified (MDS/MPN-U): Mayo Clinic experience. (Abstract 7088) A. K. Abou Hussein, M. M. Patnaik, D. Zblewski, N. Gangat, S. Hashmi, M. A. Elliott, W. J. Hogan, M. R. Litzow, A. Al-Kali Board 78 Outpatient allogeneic hematopoietic cell transplant following alemtuzumab based reduced intensity conditioning in patients with advanced mycosis fungoides/Sezary syndrome. (Abstract 7089) E. Purev, R. Srinivasan, G. Aue, D. Stroncek, H. Khuu, C. Ramos, L. Cook, E. Cho, M. Schmitt, R. W. Childs Board 79 Hepatitis C virus infection in patients undergoing hematopoietic cell transplantation in the era of direct-acting antiviral agents. (Abstract 7090) A. Kyvernitakis, P. Mahale, U. R. Popat, Y. Jiang, R. E. Champlin, H. A. Torres Board 80 Influence of variant allele frequency (VAF) on the phenotypic penetrance of TP53 mutations in myeloid malignancies. (Abstract 7091) D. A. Sallman, R. S. Komrokji, C. Vaupel, N. Al Ali, J. E. Lancet, A. F. List, J. Hall, E. Padron Board 81 Prognostic and predictive value of IPSS-R in assessing overall survival (OS) in a phase III study of rigosertib in second-line higher-risk (HR) MDS patients. (Abstract 7092) L. R. Silverman, P. Fenaux, A. Al-Kali, M. R. Baer, M. A. Sekeres, G. J. Roboz, G. Gaidano, B. L. Scott, P. Greenberg, U. Platzbecker, D. P. Steensma, K. A. Kreuzer, L. A. Godley, R. Collins, E. L. Atallah, N. Azarnia, G. Garcia-Manero 153 SUNDAY lymphocytic leukemia (CLL). (Abstract 7078) N. Bose, C. Zent, G. J. Weiner, B. LaPlant, N. Ottoson, S. Leonardo, A. Jonas, R. D. Huhn, A. H. Braun, S. M. Ansell Sunday, May 31, 2015 SUNDAY Board 82 Use of dual donor T-cell chimerism to predict prognosis after double cord blood allogeneic transplantation. (Abstract 7093) M. Baljevic, K. Cao, R. E. Champlin, C. Hosing, N. Shah, S. Parmar, K. Rezvani, A. L. Olson, E. J. Shpall, B. Oran Board 83a A phase II, randomized trial of standard of care with or without midostaurin to prevent relapse following allogeneic stem cell transplantation in patients with FLT3-ITD mutated acute myeloid leukemia. (Abstract TPS7094) R. T. Maziarz, B. L. Scott, S. R. Mohan, A. Deol, M. M. Patnaik, K. Haines, B. Elliott, C. S. Paley, H. F. Fernandez Board 83b Randomized, multicenter, open-label, phase 3 study of the BTK inhibitor ibrutinib in combination with obinutuzumab vs. chlorambucil in combination with obinutuzumab in patients with treatment-naïve CLL/SLL (PCYC-1130): iLLUMINATE. (Abstract TPS7095) I. Flinn, C. Moreno, D. S. Gill, T. J. Kipps, Y. Shaw, Y. Li, L. A. Styles, D. F. James, J. G. Gribben Board 84a A multicenter, open-label phase 2a study of ibrutinib with or without cytarabine in patients with acute myeloid leukemia (PCYC-1131). (Abstract TPS7096) J. E. Cortes, E. Estey, A. S. Stein, T. Graef, N. Cavazos, T. Kinoshita, Y. Luan, A. Tawashi Board 84b An international phase 3 randomized, placebo-controlled study of CC-486 (oral azacitidine) maintenance therapy in patients with acute myeloid leukemia (AML) in complete remission (CR): The Quazar AML maintenance trial. (Abstract TPS7097) G. J. Roboz, F. Ravandi, D. Selleslag, P. Montesinos, A. Wei, K. Porkka, A. Almeida, M. R. Savona, S. R. Mohan, J. F. Falantes, M. Voso, K. Kumar, F. Camus, I. La Torre, H. Kantarjian, B. Skikne Board 85a First-in-human study of FLX925, an orally administered FLT3/CDK4/CDK6 inhibitor, in subjects with relapsed or refractory acute myeloid leukemia (AML). (Abstract TPS7098) N. G. Daver, M. Konopleva, H. E. Kohrt, J. S. Fridman, D. Johnson, J. C. Jaen, H. M. Kantarjian, J. E. Cortes Board 85b GRASPA-AML 2012– 01 study (NCT01810705): A multicenter, open, randomized phase 2b trial evaluating ERY001 (L-asparaginase encapsulated in red blood cells) plus low-dose cytarabine vs low-dose cytarabine alone, in treatment of newly diagnosed acute myeloid leukemia (AML) elderly patients, unfit for intensive chemotherapy. (Abstract TPS7099) X. G. Thomas, E. Tavernier Tardy, R. Guieze, P. Chevallier, J. Marolleau, F. Orsini, I. Hitchcock, I. El-Hariry Board 86a A phase 1b trial of duvelisib, a PI3K-␦,␥ inhibitor, in combination with obinutuzumab in patients with CLL/SLL previously treated with a Bruton’s tyrosine kinase inhibitor (BTKi). (Abstract TPS7100) J. S. Blachly, J. R. Brown, J. C. Barrientos, N. Jain, V. Kelly, S. Garnick, J. Rodstrom, J. Sweeney, S. Tang, J. C. Byrd Board 86b Phase III randomized, double-blind, active-controlled study of momelotinib versus ruxolitinib in patients with myelofibrosis. (Abstract TPS7101) E. F. Winton, T. Devos, S. T. Oh, U. Platzbecker, M. Wadleigh, S. Jun, P. Lee, W. Deng, V. Gupta Board 87a Phase III randomized, open-label, active-controlled study of momelotinib versus best available therapy in ruxolitinib-treated patients with myelofibrosis. (Abstract TPS7102) V. Gupta, M. R. Baer, S. T. Oh, C. B. Miller, S. Jun, P. Lee, H. Dong, A. Reiter Board 87b Phase 1 study to evaluate the safety and tolerability of MEDI4736, an antiprogrammed cell death ligand-1 (PD-L1) antibody, in myelodysplastic syndrome (MDS) after treatment with hypomethylating agents. (Abstract TPS7103) G. Garcia-Manero, C. A. Schiffer, L. A. Godley, R. Paquette, U. Platzbecker, P. B. Robbins, J. Norton, J. J. Karakunnel, R. C. Lindsley 154 Sunday, May 31, 2015 8:00 AM - 11:30 AM Poster Session Lymphoma and Plasma Cell Disorders Location: S Hall A Board 335 Combination of everolimus with R-CHOP (ever R-CHOP) as an initial therapy for diffuse large B-cell lymphoma (DLBCL): A phase I and feasibility study (NCCTG N1085 [Alliance]). (Abstract 8518) P. B. Johnston, B. LaPlant, G. S. Nowakowski, I. N. Micallef, S. M. Ansell, T. M. Habermann, J. Colgan, T. E. Witzig Board 336 Multivariate analysis of PFS from the AETHERA trial: A phase III study of brentuximab vedotin consolidation after autologous stem cell transplant for HL. (Abstract 8519) J. A. Walewski, A. Nademanee, T. Masszi, J. Holowiecki, M. Abidi, A. I. Chen, P. J. Stiff, S. Viviani, V. Bachanova, J. W. Sweetenham, S. Lee, D. Huebner, E. K. Larsen, N. N. Hunder, C. H. Moskowitz Board 337 Interim analysis of a phase I study of INCB040093, a PI3K␦ inhibitor, alone or in combination with INCB039110, a selective JAK1 inhibitor, in patients (pts) with relapsed or refractory (r/r) B-cell malignancies. (Abstract 8520) T. J. Phillips, A. Forero-Torres, T. Sher, C. S. Magid Diefenbach, M. Talpaz, P. A. Scherle, R. Schaub, L. Zhou, J. Pulini, L. Leopold, M. A. Spear, P. M. Barr Board 338 A phase I/II trial of the combination of romidepsin and lenalidomide in patients with relapsed/refractory lymphoma and myeloma: Activity in T-cell lymphoma. (Abstract 8521) N. Mehta-Shah, M. A. Lunning, A. M. Boruchov, J. Ruan, S. Nair, P. Lynch, R. Byrne, A. J. Moskowitz, M. J. Matasar, J. F. Gerecitano, P. A. Hamlin, J. Leonard, C. H. Moskowitz, P. L. Myskowski, C. Querfeld, P. Nolan, M. Palomba, D. J. Straus, A. D. Zelenetz, S. M. Horwitz Board 339 Prognostic index for chronic and smoldering types adult T-cell leukemia/lymphoma. (Abstract 8522) H. Katsuya, M. Shimokawa, K. Ishitsuka, K. Kawai, M. Amano, A. Utsunomiya, R. Hino, S. Hanada, T. Jo, K. Tsukasaki, Y. Moriuchi, E. Sueoka, S. Yoshida, H. Suzushima, M. Miyahara, K. Yamashita, T. Eto, T. Yamanaka, J. Suzumiya, K. Tamura Board 340 Updated analysis of CALGB/ECOG/BMT CTN 100104: Lenalidomide (Len) vs. placebo (PBO) maintenance therapy after single autologous stem cell transplant (ASCT) for multiple myeloma (MM). (Abstract 8523) S. A. Holstein, K. Owzar, P. G. Richardson, C. Jiang, C. C. Hofmeister, H. Hassoun, D. D. Hurd, E. A. Stadtmauer, S. Giralt, S. M. Devine, V. Hars, J. R. Postiglione, D. J. Weisdorf, R. Vij, J. S. Moreb, N. S. Callander, T. G. Martin, T. C. Shea, K. C. Anderson, P. L. McCarthy Board 341 FIRST study: Updated overall survival (OS) in stem cell transplant (SCT)ineligible newly diagnosed multiple myeloma (NDMM) patients (pts) treated with continuous lenalidomide plus low-dose dexamethasone (Rd) vs melphalan, prednisone, and thalidomide (MPT). (Abstract 8524) T. Facon, C. Hulin, M. A. Dimopoulos, A. Belch, D. E. Reece, J. V. Catalano, A. Pinto, H. Ludwig, N. J. Bahlis, M. Cavo, P. Moreau, L. Qiu, R. LeBlanc, R. Schots, S. V. Rajkumar, J. Marek, G. Chen, A. L. Ervin-Haynes Board 342 Effect of carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma (RMM) by line of therapy: Secondary analysis from an interim analysis of the phase III study ASPIRE (NCT01080391). (Abstract 8525) M. A. Dimopoulos, A. K. Stewart, S. V. Rajkumar, T. Masszi, A. Oriol, R. Hajek, L. Rosinol, D. S. Siegel, G. Mihaylov, V. Goranova-Marinova, P. Rajnics, A. Suvorov, R. Niesvizky, A. J. Jakubowiak, J. F. San Miguel, H. Ludwig, N. J. Zojwalla, P. Moreau, A. Palumbo Board 343 Panobinostat plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma who received prior bortezomib and IMiDs: A predefined subgroup analysis of PANORAMA 1. (Abstract 8526) 155 SUNDAY Abstracts 8518 – 8529 will be discussed during the Lymphoma and Plasma Cell Disorders Poster Discussion Session. See page 193 for session information. Sunday, May 31, 2015 J. F. San Miguel, V. T. Hungria, S. Yoon, M. Beksac, M. A. Dimopoulos, A. Elghandour, W. W. Jedrzejczak, A. Guenther, T. Na Nakorn, N. Siritanaratkul, R. L. Schlossman, J. Hou, P. Moreau, S. Lonial, J. Lee, H. Einsele, M. Sopala, B. Bengoudifa, C. Corrado, P. G. Richardson SUNDAY Board 344 Updated results from CHAMPION-1, a phase I/II study investigating weekly carfilzomib with dexamethasone for patients (Pts) with relapsed or refractory multiple myeloma (RRMM). (Abstract 8527) J. R. Berenson, A. Cartmell, A. Bessudo, R. M. Lyons, W. A. Harb, D. Tzachanis, M. Coleman, R. V. Boccia, R. M. Rifkin, P. Patel, S. Dixon, J. G. Berdeja Board 345 A phase II study of panobinostat with lenalidomide and weekly dexamethasone in myeloma. (Abstract 8528) A. Chari, H. J. Cho, S. S. Parekh, A. Dhadwal, K. Garcia, G. Morgan, N. Belostotsky, C. Carter, D. Catamero, J. Escalon, D. Verina, M. Yum, L. La, E. Chan, J. Gullie, S. Jagannath Board 346 Idelalisib efficacy and safety in follicular lymphoma patients from a phase 2 study. (Abstract 8529) G. A. Salles, S. J. Schuster, S. De Vos, N. D. WagnerJohnston, A. Viardot, C. Flowers, M. Will, M. Breuleux, W. R. Godfrey, B. Sorensen, A. Gopal Board 347 Lenalidomide and low-dose dexamethasone (Ld) is equivalent to Ld plus autologous stem cell transplant (ASCT) in newly diagnosed multiple myeloma (NDMM): Results of a randomized, phase III trial. (Abstract 8530) S. Lentzsch, S. Miao, J. M. Schecter, K. A. Griffith, D. P. Normolle, M. Y. Mapara, R. L. Redner, N. Villanueva Board 348 Phase 1 open-label dose escalation study of the dual SYK/JAK inhibitor cerdulatinib (PRT062070) in patients with relapsed/refractory B-cell malignancies: Safety profile and clinical activity. (Abstract 8531) I. Flinn, P. A. Hamlin, D. K. Strickland, A. Pandey, M. Birrell, G. Coffey, J. Leeds, J. T. Curnutte, J. A. Burger, N. D. Wagner-Johnston, M. R. Patel Board 349 Idelalisib monotherapy and durable responses in patients with relapsed or refractory Waldenstroms Macroglobulinemia (WM). (Abstract 8532) S. Coutre, J. Leonard, C. Flowers, A. J. Davies, W. Jurczak, J. C. Byrd, S. E. Spurgeon, S. Peterman, L. Holes, Y. Cho, B. Sorenson, W. R. Godfrey, A. K. Gopal Board 350 A phase I study combining bendamustine with rituximab, etoposide and carboplatin (TREC) in patients with aggressive relapsed or refractory lymphoma. (Abstract 8533) L. Budde, D. B. Martin, M. Philip, A. R. Shustov, T. Gooley, T. L. Chen, E. N. Libby, E. Y. Chen, K. Kojouri, A. Langerak, J. E. Roden, B. E. Kammerer, N. L. Knudsen, S. D. Smith, O. W. Press, A. K. Gopal Board 351 A phase I study of gemcitabine and bendamustine in relapsed/refractory Hodgkin’s lymphoma. (Abstract 8534) J. B. Cohen, L. Wei, K. J. Maddocks, L. T. Heffner, A. A. Langston, C. Flowers, S. M. Devine, K. A. Blum Board 352 Interim results from a dose-escalation study of the BCL-2 inhibitor venetoclax (ABT-199/GDC-0199) plus bendamustine (B) and rituximab (R) in patients (pts) with relapsed/refractory (R/R) Non-Hodgkin’s Lymphoma (NHL). (Abstract 8535) S. De Vos, C. Flowers, D. Wang, L. J. Swinnen, N. H. Fowler, E. G. Reid, J. Cordero, M. Gifford, D. D’Amico, M. Dunbar, M. Zhu, A. H. Salem, S. H. Enschede, J. L. Ricker, D. Chien, R. Humerickhouse, M. Kozloff Board 353 Development of the molecular diagnostic (MDx) DLBCL Lymphoma Subtyping Test (LST) on the nCounter Analysis System. (Abstract 8536) B. Wallden, S. Ferree, H. Ravi, N. Dowidar, T. Hood, P. Danaher, A. MashadiHossein, G. Wright, C. Schaper, J. J. Storhoff Board 354 Phase 1 first-in-human trial of oral CUDC-907, a dual inhibitor of PI3K and HDAC, in patients with refractory/relapsed lymphoma or multiple myeloma. (Abstract 8537) J. G. Berdeja, Y. Oki, M. R. Patel, A. Copeland, I. Flinn, S. S. Neelapu, J. Viner, J. Wang, J. F. Gerecitano, A. Younes Board 355 Phase II study of Hyper-CVAD with pegylated liposomal doxorubicin alternating with methotrexate and cytarabine (HCVIDD/MA) in patients with newly diagnosed T- and NK-cell lymphoma (T/NKCL). (Abstract 8538) D. Chihara, B. Pro, S. Loghavi, R. N. Miranda, L. Medeiros, M. A. Fanale, F. B. 156 Sunday, May 31, 2015 Board 356 Pre-treatment circulating tumor DNA as a biomarker for disease burden in diffuse large B cell lymphoma (DLBCL). (Abstract 8539) F. Scherer, D. M. Kurtz, M. R. Green, A. M. Newman, D. M. Klass, L. Zhou, R. Krishnan, C. Liu, C. Glover, R. S. Ohgami, R. J. Hicks, C. Keane, K. A. Kong, M. Faham, M. S. Hertzberg, M. K. Gandhi, R. H. Advani, R. Levy, M. Diehn, A. A. Alizadeh Board 357 Bendamustine and rituximab and lenalidomide (BRR) in the treatment of relapsed and refractory low grade non-Hodgkin lymphoma (NHL): Final results of phase 1 study NCCTG N1088/ALLIANCE. (Abstract 8540) G. S. Nowakowski, B. LaPlant, W. R. Macon, M. A. Gertz, T. M. Habermann, D. J. Inwards, I. N. Micallef, D. B. Wender, J. Leonard, T. E. Witzig Board 358 Telomere profile of Reed-Sternberg and Hodgkin cells in diagnostic biopsy in Hodgkin lymphoma as a predictor of clinical response. (Abstract 8541) J. B. Tompkins, C. Taylor-Kashton, C. Li, M. Klassen, H. Stewart, M. Cheang, P. J. Lambert, M. R. Nasr, C. Morales, H. Knecht, D. A. Wall, S. Mai Board 359 Lenalidome in combination with rituximab for relapsed or refractory mantel cell lymphoma: Updated analysis of a phase 2 trial. (Abstract 8542) Y. Wang, M. Dela Rosa, S. Zhou, M. Badillo, A. Addison, L. Zhang, H. J. Lee, J. E. Romaguera, M. Wang Board 360 Analysis of “double-hit” lymphoma cases by genetic subtype. (Abstract 8543) D. J. Landsburg, A. M. Petrich, J. S. Abramson, A. Sohani, O. W. Press, R. D. Cassaday, J. C. Chavez, K. W. Song, A. D. Zelenetz, M. Gandhi, N. M. Shah, T. Fenske, J. Jasso, L. Medeiros, D. T. Yang, C. Nabhan Board 361 Phase 1 trial of brentuximab vedotin in combination with gemcitabine for pediatric and young adult patients with relapsed or refractory Hodgkin lymphoma, a Children’s Oncology Group report. (Abstract 8544) P. D. Cole, M. Metzger, R. A. Drachtman, T. M. Horton, X. Liu, C. H. Ahern, C. Minard, E. Fox, S. Blaney, B. Weigel, K. M. Kelly Board 362 Survival of subcutaneous panniculitis-like T-cell lymphoma (SPTCL) and peripheral T-cell lymphoma (PTCL): A propensity matched analysis of the Surveillance, Epidemiology and End Results (SEER) database. (Abstract 8545) S. Manandhar, S. Giri, V. R. Bhatt, R. Pathak, G. Bociek, J. O. Armitage, J. Vose Board 363 Treatment of refractory/relapse vitreoretinal lymphoma: Result of a multicenter retrospective study from the LOC network on temozolomide in monotherapy. (Abstract 8546) S. Choquet, M. Baron, C. Soussain, C. Houillier, E. Gyan, N. Cassoux, V. Touitou, C. Fardeau, V. Leblond, K. Hoang-Xuan Board 364 Subgroup analysis of the phase II randomized MCL-002 (SPRINT) study of lenalidomide vs investigator’s choice in relapsed/refractory mantle cell lymphoma. (Abstract 8547) M. Trneny, T. Lamy, J. A. Walewski, D. Belada, J. Mayer, J. A. Radford, W. Jurczak, F. Morschhauser, J. Alexeeva, S. Rule, T. N. Biyukov, M. Patturajan, M. C. Bravo, J. Cabecadas, L. Arcaini, SPRINT Trial Investigators Board 366 Ublituximab plus TGR-1202 activity and safety profile in relapsed/refractory B-cell NHL and high-risk CLL. (Abstract 8548) M. A. Lunning, J. Vose, N. H. Fowler, L. J. Nastoupil, M. T. Schreeder, T. Siddiqi, C. Flowers, J. B. Cohen, S. Blumel, M. Miguel, W. H. Tse, E. K. Pauli, K. Cutter, P. Sportelli, H. P. Miskin, M. S. Weiss, S. V. Vakkalanka, S. Viswanadha, S. M. O’Brien Board 367 Clinical significance of radiotherapy in the treatment of limited stage NK/T cell lymphoma. (Abstract 8549) S. Lee, Y. Chae, B. Kang, S. Yoon, J. Kim, J. Moon, B. Lee, Y. Do, Y. Park, H. Yhim, D. Yang, J. Chung, M. Song, J. Lee, J. Kwak, S. Jeong Board 368 Breast implant-associated anaplastic large cell lymphoma: Proposal for optimal management. (Abstract 8550) M. W. Clemens, C. E. Butler, K. Hunt, 157 SUNDAY Hagemeister, L. Fayad, J. E. Romaguera, F. Samaniego, S. S. Neelapu, A. Younes, N. H. Fowler, M. A. Rodriguez, M. Wang, L. W. Kwak, P. McLaughlin, N. H. Dang, Y. Oki Sunday, May 31, 2015 M. A. Fanale, S. M. Horwitz, H. Liu, C. McCarthy, L. J. Nastoupil, J. Liu, L. Medeiros, R. N. Miranda SUNDAY Board 369 Rituximab maintenance therapy in B-cell lymphoma: A meta-analysis. (Abstract 8551) Y. Wang, Y. Shen, F. Yang, L. J. Sanchez, X. Guan, V. T. Chang, M. Wang Board 370 CD30ⴙ expression in peripheral T-cell lymphomas (PTCLs): A subset analysis from the international, prospective T-Cell Project. (Abstract 8552) M. Federico, M. Bellei, S. Luminari, S. M. Horwitz, S. Montoto, E. Zucca, S. A. Pileri, Y. Ko, P. L. Zinzani, J. M. Connors, F. M. Foss, A. Polliack, M. Cabrera, W. Kim, M. Spina, C. A. De Souza, S. Bobillo Varela, I. Dlouhy, R. H. Advani, J. Vose, T-Cell Project Board 371 A phase I trial of lenalidomide maintenance after autologous stem cell transplant (ASCT) in patients with high-risk relapsed/refractory lymphomas. (Abstract 8553) J. Svoboda, L. Strelec, N. N. Shah, E. A. Chong, K. Montrey, K. Walsh, S. F. Huntington, A. Mato, D. J. Landsburg, S. Nasta, S. J. Schuster Board 372 Outcomes and prognostic factors in marginal zone lymphoma: Case comprehensive cancer center cumulative experience of 358 cases. (Abstract 8554) A. Starr, P. Fu, P. F. Caimi, E. L. Campagnaro, B. W. Cooper, M. J. De Lima, H. M. Lazarus, S. L. Gerson, H. Meyerson, D. Jagadeesh, M. R. Smith, R. M. Dean, B. L. Pohlman, B. T. Hill, B. M. William Board 373 Exercise patterns and quality of life among survivors of aggressive lymphoma. (Abstract 8555) R. M. Ferzoco, J. R. Cerhan, M. J. Maurer, C. Allmer, K. J. Yost, T. M. Habermann, S. M. Ansell, D. J. Inwards, T. E. Witzig, L. F. Porrata, G. S. Nowakowski, W. R. Macon, J. N. Towns, U. Farooq, B. K. Link, C. A. Thompson Board 374 A new class of anti-cancer drugs targeting the tyrosine kinase receptor ROR1 in CLL. (Abstract 8556) H. Mellstedt, S. Khan, M. Hojjat-Farsangi, A. H. Daneshmanesh, J. Vagberg, S. Bystrom, J. Schultz, M. Norin, E. Olsson, C. Lofberg, C. Norstrom, T. Olin, A. Österborg, A. Moshfegh Board 375 BRD4 degraders produce long-lasting loss of BRD4 protein and robust efficacy in Burkitt’s lymphoma cells. (Abstract 8557) K. Coleman, J. Lu, Y. Qian, M. Altieri, K. Raina, H. Dong, J. Wang, J. Hines, A. P. Crew, C. M. Crews Board 376 A phase 1 study of INCB040093, a PI3K␦ inhibitor, alone or in combination with INCB039110, a selective JAK1 inhibitor: Interim results from patients (pts) with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL). (Abstract 8558) A. Forero-Torres, P. M. Barr, C. S. Magid Diefenbach, T. Sher, R. Schaub, L. Zhou, J. Pulini, L. Leopold, M. A. Spear, M. Talpaz, T. J. Phillips Board 377 High throughput in vitro combination sensitivity screen in hematologic malignancies with the phosphoinositide-3 kinase (PI3K)-␦,␥ inhibitor, duvelisib. (Abstract 8559) K. Faia, K. White, J. Proctor, P. Andrade, M. Pink, R. Rickles, J. Grenier, E. Boghaert, A. J. Souers, J. Leverson, V. J. Palombella, K. McGovern, J. L. Kutok Board 378 Early high-dose therapy and autologous stem-cell transplantation in angioimmunoblastic T-cell lymphoma: Outcome study using the National Cancer Data Base. (Abstract 8560) P. K. Karanam, B. M. Parsons, M. AlHamadani, R. S. Go Board 379 Association of hemophagocytic lymphohistiocytosis (HLH) with poor outcomes in adults with NK- and T-cell lymphoma (NKTCL). (Abstract 8561) M. V. Shah, T. E. Witzig, M. O’Byrne, P. Kapoor, A. P. Wolanskyj, A. L. Feldman, B. K. Link, J. R. Cerhan, M. J. Maurer, S. A. Parikh Board 380 Role of radiation (RT) in primary mediastinal large B-cell lymphoma (PMBCL): An analysis of the Surveillance, Epidemiology, and End Results (SEER) database. (Abstract 8562) S. Giri, V. R. Bhatt, R. Pathak, G. Bociek, J. Vose, J. O. Armitage Board 381 Outcomes of anticoagulant (AC) or antiplatelet (AP) use in patients (pts) with chronic lymphocytic leukemia (CLL) or indolent non-Hodgkin’s lymphoma 158 Sunday, May 31, 2015 Board 382 The outcome of ALK positive and ALK negative anaplastic large cell lymphoma (ALCL) following DA-EPOCH. (Abstract 8564) C. Lai, S. Pittaluga, M. Shovlin, S. M. Steinberg, M. J. Roschewski, E. S. Jaffe, W. H. Wilson, K. Dunleavy Board 383 Phase II study of rituximab plus high-dose ara-C (HDAC)-containing chemotherapy (CTX) followed by ASCT in untreated mantle cell lymphoma (MCL): Japan Clinical Oncology Group study (JCOG0406). (Abstract 8565) M. Ogura, K. Tobinai, T. Shibata, K. Ando, M. Kurosawa, H. Gomyo, N. Uike, N. Tsukamoto, N. Fukuhara, T. Shimoyama, M. Taniwaki, K. Nosaka, Y. Matsuno, T. Hotta, K. Tsukasaki, Y. Morishima, K. Yamamoto, Japan Clinical Oncology Group-Lymphoma Study Group (JCOG-LSG) Board 384 Outcome comparison of allogeneic vs. autologous stem cell transplantation in transformed low grade lymphoid malignancies: A meta-analysis of comparative studies. (Abstract 8566) S. Yun, N. Vincelette, J. Segar Board 385 Is rituximab sub-optimally dosed in indolent B cell lymphoma? (Abstract 8567) Y. Sawalha, B. Rouphail, X. Jia, R. M. Dean, B. T. Hill, D. Jagadeesh, B. L. Pohlman, P. Elson, M. R. Smith Board 386 Relationship of distinct B-cell receptor (BCR) isotype in diffuse large b-cell lymphoma (DLBCL) with ABC and GCB genetic signatures and association with signaling molecules of clinical significance. (Abstract 8568) A. Qureshi, A. Akhter, F. Farooq, J. Luider, D. A. Stewart, A. Mansoor Board 387 Overall survival in patients with Hodgkin lymphoma: Disparities by insurance status. (Abstract 8569) R. Parikh, M. L. Grossbard, L. B. Harrison, J. Yahalom Board 388 Distinct early response dynamics of circulating tumor DNA and circulating tumor cells during therapy of B-cell NHL. (Abstract 8570) D. M. Kurtz, F. Scherer, M. R. Green, M. S. Khodadoust, D. M. Klass, L. Zhou, R. Krishnan, C. Glover, C. Liu, K. A. Kong, M. Faham, R. Levy, M. Diehn, A. A. Alizadeh Board 389 Effect of prednisone and rituximab prephase on early toxicity in older DLBCL patients (pts) receiving RCHOP within a NHL specific comprehensive geriatric assessment (CGA) trial. (Abstract 8571) C. N. Owens, A. Iannotta, J. F. Gerecitano, M. J. Matasar, A. Noy, C. H. Moskowitz, P. Drullinsky, M. Palomba, D. J. Straus, S. M. Horwitz, A. D. Zelenetz, C. S. Portlock, A. Kumar, P. A. Hamlin Board 390 Prognostic value of interim 18F-FDG PET/CT in patients with diffuse large B-cell lymphoma treatment with R-CHOP: SUVmax reduction-based assessment at two cycles of chemotherapy. (Abstract 8572) X. Zhang, W. Fan Board 391 A randomized phase II study of bortezomib (Btz)/dexamethasone (dex) with or without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM). (Abstract 8573) A. J. Jakubowiak, M. Offidani, B. Pegourie, J. De La Rubia, L. Garderet, K. Laribi, A. Bosi, R. Marasca, J. Laubach, A. Mohrbacher, A. M. Carella, A. K. Singhal, C. Tsao, M. J. Lynch, E. W. Bleickardt, Y. Jou, A. Palumbo Board 392 A phase I/IIa study of the human anti-CD38 antibody MOR202 (MOR03087) in relapsed or refractory multiple myeloma (rrMM). (Abstract 8574) M. S. Raab, H. Goldschmidt, H. Agis, I. Blau, H. Einsele, M. M. Engelhardt, B. Ferstl, M. Gramatzki, C. Röllig, K. Weisel, P. Kloepfer, D. Weinelt, S. Härtle, C. Peschel Board 393 Analysis of outcomes based on response for patients with relapsed or relapsed and refractory multiple myeloma in the phase 3 PANORAMA 1 study. (Abstract 8575) V. T. Hungria, J. F. San Miguel, S. Yoon, M. Beksac, M. A. Dimopoulos, A. Elghandour, W. W. Jedrzejczak, A. Guenther, T. Na Nakorn, N. Siritanaratkul, R. L. Schlossman, J. Hou, P. Moreau, S. Lonial, J. Lee, H. Einsele, M. Sopala, B. Bengoudifa, C. Corrado, P. G. Richardson Board 394 Phase I interim safety and efficacy of venetoclax (ABT-199/GDC-0199) monotherapy for relapsed/refractory (R/R) multiple myeloma (MM). (Abstract 159 SUNDAY (iNHL) in idelalisib (IDELA) trials. (Abstract 8563) J. C. Barrientos, P. Ghia, J. Pagel, G. A. Salles, J. P. Sharman, S. Stilgenbauer, O. Gurtovaya, Y. Kim, B. Philip, A. D. Zelenetz Sunday, May 31, 2015 8576) S. Kumar, R. Vij, J. L. Kaufman, J. Mikhael, T. Facon, P. Moreau, M. Amiot, S. Alzate, L. J. Morris, J. A. Ross, M. Dunbar, M. Zhu, S. K. Agarwal, J. Leverson, S. H. Enschede, R. Humerickhouse, C. Touzeau SUNDAY Board 395 The prognostic significance of CD45 expression by clonal bone marrow plasma cells in multiple myeloma. (Abstract 8577) W. I. Gonsalves, V. Rajkumar, W. Morice, M. Timm, A. Dispenzieri, F. Buadi, M. Lacy, Y. Lin, D. Dingli, S. R. Hayman, S. R. Zeldenrust, S. J. Russell, N. Leung, P. Kapoor, M. A. Gertz, S. Kumar Board 396 Outcome at first relapse after frontline RVD regimen plus lenalidomide maintenance in transplant eligible MM patients. (Abstract 8578) M. Roussel, B. Hebraud, D. Caillot, X. Leleu, M. Macro, C. Hulin, C. Chaleteix, M. Escoffre Barbe, L. Karlin, G. Marit, L. Garderet, B. Pegourie, A. Stoppa, P. Lenain, B. Royer, H. Avet-Loiseau, M. Attal Board 397 Preliminary safety and efficacy of evofosfamide (TH-302), an investigational hypoxia-activated prodrug, combined with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma (RR MM). (Abstract 8579) J. Laubach, N. S. Raje, A. J. Yee, P. Armand, R. L. Schlossman, J. Rosenblatt, J. A. Hedlund, M. G. Martin, C. H. Reynolds, K. H. Shain, I. Zackon, L. Stampleman, E. Boswell, S. Chuma, R. Liguori, D. Handisides, S. Kroll, K. C. Anderson, P. G. Richardson, I. M. Ghobrial Board 398 Phase 1b interim results: Venetoclax (ABT-199/GDC-0199) in combination with bortezomib (BTZ) and dexamethasone (Dex) in relapsed/refractory (R/R) multiple myeloma (MM). (Abstract 8580) C. Touzeau, A. A. Chanan-Khan, A. W. Roberts, A. Agarwal, T. Facon, D. Lebovic, P. Moreau, D. E. Darden, L. J. Morris, J. A. Ross, A. H. Salem, W. Munasinghe, M. Zhu, J. Leverson, S. H. Enschede, R. Humerickhouse, S. J. Harrison Board 399 Total marrow irradiation (TMI) with helical tomotherapy and peripheral blood progenitor cell rescue (PBPC) following high-dose melphalan (Mel) and PBPC as part of tandem autologous transplant (TAT) for patients with multiple myeloma. (Abstract 8581) G. Somlo, A. Liu, T. E. Schultheiss, P. H. Frankel, R. T. Spielberger, L. Popplewell, K. Zhou, D. Hawkins, A. Y. Krishnan, F. Sahebi, P. M. Parker, S. J. Forman, J. Y. Wong Board 400 Overall survival in newly diagnosed MM patients with del(17p): A report from the Connect MM Registry. (Abstract 8582) J. J. Shah, R. Abonour, B. G. Durie, J. Mehta, M. Narang, H. R. Terebelo, C. Gasparetto, K. Toomey, J. W. Hardin, S. Srinivasan, G. Larkins, R. J. Ricafort, Y. M. Nagarwala, R. M. Rifkin Board 401 Outcomes of high, t(11;14), and standard cytogenetic risk multiple myeloma following early high dose therapy and autologous hematopoietic cell transplantation (SCT). (Abstract 8583) G. P. Kaufman, M. A. Gertz, A. Dispenzieri, M. Lacy, F. Buadi, D. Dingli, S. R. Hayman, P. Kapoor, S. V. Rajkumar, S. Kumar Board 402 A phase I/II trial of very low to low-dose continuous azacitidine in combination with standard doses of lenalidomide and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma. (Abstract 8584) F. J. Reu, D. Grabowski, R. Z. Mahfouz, H. M. Lazarus, R. M. Dean, B. Faiman, J. Reed, M. Karam, K. Hamilton, S. Fada, M. E. Kalaycio, J. N. Valent, C. J. Samaras, R. M. Sobecks, L. McCowen, J. Elberson, H. Liu, Y. Saunthararajah, Y. Chew, M. R. Smith Board 403 The therapeutic benefit and toxicity from multiple myeloma phase I trials, 2004 through 2014. (Abstract 8585) E. Malek, J. J. Driscoll, J. Welge Board 404 Impact of total therapies on clinical outcome of myeloma stratified by risk and molecular subgroups. (Abstract 8586) C. J. Heuck, N. Weinhold, S. Thanendrarajan, C. K. Stein, F. Van Rhee, A. Rosenthal, Y. Jethava, R. Khan, A. Hoering, F. E. Davies, B. Barlogie, G. J. Morgan Board 405 Pre-clinical translational studies of daratumumab in patients with myeloma or AL amyloidosis undergoing autologous hematopoietic stem cell 160 Sunday, May 31, 2015 Board 406 Effect of IMiD compounds on CD38 expression on multiple myeloma cells: MOR202, a human CD38 antibody in combination with pomalidomide. (Abstract 8588) R. Boxhammer, S. Steidl, J. Endell Board 407 Patterns of AKT, mTOR, ERK, and STAT3 pathway activation in MGUS, smoldering multiple myeloma, and multiple myeloma. (Abstract 8589) J. T. Larsen, V. Ramakrishnan, L. Wellik, T. K. Kimlinger, S. V. Rajkumar, S. Kumar Board 408 Assessing clinical response in multiple myeloma (MM) patients treated with monoclonal antibodies (mAbs): Validation of a daratumumab IFE reflex assay (DIRA) to distinguish malignant M-protein from therapeutic antibody. (Abstract 8590) C. McCudden, A. Axel, D. Slaets, S. Frans, J. Bald, J. M. Schecter, T. Ahmadi, T. Plesner, K. Sasser Board 409 Safety and efficacy of pomalidomide (POM), dexamethasone (DEX), and pegylated liposomal doxorubicin (PLD) for patients with relapsed/refractory multiple myeloma (RRMM). (Abstract 8591) J. R. Berenson, L. Stampleman, A. Bessudo, P. Rosen, L. M. Klein, T. B. Woliver, M. S. Flam, S. Eshaghian, Y. Nassir, R. A. Swift, R. A. Vescio Board 410 Clinical outcomes in t(11;14) multiple myeloma. (Abstract 8592) M. Alhaj Moustafa, S. V. Rajkumar, A. Dispenzieri, M. Lacy, M. A. Gertz, F. Buadi, D. Dingli, S. R. Hayman, P. Kapoor, Y. L. Hwa, J. A. Lust, R. S. Go, R. A. Kyle, S. Kumar Board 411 Analyzing the relationship of response and survival in patients with refractory or relapsed and refractory multiple myeloma (RRMM) treated with pomalidomide plus low-dose dexamethasone (POM ⴙ LoDEX) in the MM-003 trial. (Abstract 8593) K. Weisel, P. Moreau, C. J. Gibson, K. W. Song, O. Saunders, L. A. Sternas, K. Hong, M. H. Zaki, M. A. Dimopoulos Board 413 Outcomes and treatment of patients with POEMS syndrome experiencing progression or relapse after first line treatment. (Abstract 8594) T. Kourelis, R. A. Kyle, S. Kumar, M. A. Gertz, M. Lacy, P. Kapoor, F. Buadi, R. S. Go, J. A. Lust, S. R. Hayman, V. Rajkumar, S. R. Zeldenrust, S. J. Russell, D. Dingli, Y. Lin, N. Leung, A. Dispenzieri Board 414 Phase III trial of stem cell transplantation compared to melphalan and dexamethasone in the treatment of immunoglobulin light chain amyloidosis (AL). (Abstract 8595) M. A. Gertz, M. Lacy, A. Dispenzieri, F. Buadi, D. Dingli, S. R. Hayman, S. Kumar, N. Leung, J. A. Lust, S. V. Rajkumar, S. J. Russell, V. Suman, W. J. Hogan Board 415 Survival trends in young patients with Waldenstrom macroglobulinemia (WM). (Abstract 8596) N. Vallumsetla, J. Paludo, M. Gertz, S. M. Ansell, R. S. Go, V. Rajkumar, R. A. Kyle, F. Buadi, A. Dispenzieri, M. Lacy, D. Dingli, S. R. Hayman, N. Leung, S. Kumar, P. Kapoor Board 416 Outcomes of primary plasmacytoma (PP) in United States (US). (Abstract 8597) G. Guru Murthy, R. Venkitachalam, V. R. Bhatt, I. Dhakal, J. Y. Lee, Y. Jethava, P. D. Emanuel, P. Mehta Board 417 A national study on conditional survival and excess mortality after high dose therapy with autologous stem cell transplantation for non-Hodgkin lymphoma. (Abstract 8598) K. B. Smeland, C. E. Kiserud, G. F. Lauritzsen, A. K. Blystad, U. Fagerli, R. S. Falk, O. Fluge, A. Fossa, A. Kolstad, J. H. Loge, M. Maisenholder, S. Kvaløy, H. Holte Board 418a A randomized, double-blind, placebo-controlled, phase 3 study of rituximab with or without ibrutinib for Waldenstrom’s macroglobulinemia (PCYC-1127CA). (Abstract TPS8599) M. A. Dimopoulos, X. Leleu, J. Matous, D. MacDonald, J. Trotman, A. Oriol, C. Shustik, A. Tedeschi, R. Garcia-Sanz, L. T. Heffner, S. Ma, B. Mahe, C. Tam, O. Tournilhac, J. Li, P. Singh, E. Bilotti, T. Graef, S. P. Treon, C. Buske Board 418b Randomized, phase III trial of the efficacy and safety of lenalidomide plus R-CHOP vs R-CHOP in patients with untreated ABC-type diffuse large B-cell 161 SUNDAY transplantation (SCT). (Abstract 8587) C. P. Chaulagain, X. Ma, P. Doshi, S. W. Wong, A. K. Klein, K. A. Sprague, P. Zhou, R. Comenzo Sunday, May 31, 2015 lymphoma. (Abstract TPS8600) G. S. Nowakowski, A. Chiappella, T. E. Witzig, M. Spina, L. Zhang, J. Flament, J. Repici, U. Vitolo SUNDAY Board 419a A phase III study of ibrutinib in combination with either bendamustine and rituximab (BR) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with previously treated follicular lymphoma or marginal zone lymphoma. (Abstract TPS8601) N. H. Fowler, W. Hiddemann, J. Leonard, J. S. Larsen, E. Rose, S. H. Zhuang, J. Vermeulen, S. Sun, L. Mentzer, T. Yeh, G. A. Salles Board 419b A phase I study with an expansion cohort of the combination of ipilimumab and brentuximab vedotin in patients with relapsed/refractory Hodgkin lymphoma: A trial of the ECOG-ACRIN Cancer Research Group (E4412). (Abstract TPS8602) C. S. Magid Diefenbach, H. Li, B. S. Kahl, M. J. Robertson, J. Cohen, R. H. Advani, R. Ambinder, T. S. Fenske, S. M. Ansell Board 420a AUGMENT: A randomized, phase 3 trial in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) to compare efficacy and safety of lenalidomide plus rituximab (R2) versus placebo plus rituximab. (Abstract TPS8603) J. Leonard, J. G. Gribben, M. Trnı̀ný, P. Scheinberg, K. Tobinai, N. H. Fowler, N. Kilavuz, P. Fustier, B. Amoroso, AUGMENT Trial Investigators Board 420b Phase I/II study of intratumoral injection of SD-101, an immunostimulatory CpG, and intratumoral injection of ipillumumab, an anti-CTLA-4 monoclonal antibody, in combination with local radiation in low-grade B-cell lymphomas. (Abstract TPS8604) M. S. Khodadoust, M. P. Chu, D. Czerwinski, K. McDonald, S. Long, H. E. Kohrt, R. T. Hoppe, R. H. Advani, R. Lowsky, R. Levy Board 421a Phase III trial of brentuximab vedotin and CHP versus CHOP in the frontline treatment of patients (pts) with CD30ⴙ mature T-cell lymphomas (MTCL). (Abstract TPS8605) O. A. O’Connor, B. Pro, T. Illidge, L. H. Trumper, E. K. Larsen, T. J. Manley Board 421b MAGNIFY: A randomized, phase 3b trial in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) investigating lenalidomide plus rituximab (R2) induction followed by maintenance R2 followed by lenalidomide versus R2 induction followed by rituximab (R) maintenance. (Abstract TPS8606) D. J. Andorsky, P. J. Franson, J. L. Mouro, J. Li, K. A. Foon, J. P. Sharman, MAGNIFY Trial Investigators Board 422a A phase 2 trial of INCB040093 alone or in combination with INCB039110 in patients (pts) with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL). (Abstract TPS8607) P. M. Barr, T. Sher, T. J. Phillips, D. Lebovic, L. Zhou, J. Pulini, M. A. Spear, A. Forero-Torres Board 422b A randomized open-label study of bortezomib, melphalan, and prednisone (VMP) versus daratumumab (DARA) plus VMP in patients with previously untreated multiple myeloma (MM) who are ineligible for high-dose therapy: 54767414MMY3007 (Alcyone). (Abstract TPS8608) M. Mateos, M. Cavo, A. J. Jakubowiak, R. L. Carson, M. Qi, R. Bandekar, W. Crist, T. Ahmadi, J. F. San Miguel Board 423a Twin randomized studies of daratumumab (DARA; D) plus standard of care (lenalidomide/dexamethasone or bortezomib/dexamethasone [DRd or DVd]) versus Rd or Vd alone in relapsed or refractory multiple myeloma (MM): 54767414MMY3003 (Pollux) and 54767414MMY3004 (Castor). (Abstract TPS8609) A. Palumbo, M. A. Dimopoulos, D. E. Reece, P. Sonneveld, A. Spencer, A. A. Chanan-Khan, H. Goldschmidt, H. Yeh, J. M. Schecter, X. Qin, H. Amin, M. E. Guckert, T. Ahmadi, R. Z. Orlowski Board 423b MM-007: A phase 3 trial comparing the efficacy and safety of pomalidomide (POM), bortezomib (BORT), and low-dose dexamethasone (LoDEX [PVD]) versus BORT and LoDEX (VD) in subjects with relapsed or refractory multiple myeloma (RRMM). (Abstract TPS8610) P. G. Richardson, A. Bensmaine, T. Doerr, J. Wang, M. H. Zaki, MM-007 Study Investigators Board 424a Denosumab compared with zoledronic acid for the treatment of bone disease in adults with newly diagnosed multiple myeloma: An international, 162 Sunday, May 31, 2015 randomized, double-blind trial. (Abstract TPS8611) N. S. Raje, E. Terpos, B. G. Durie, R. Garcia-Sanz, K. Shimizu, W. Willenbacher, L. Zhu, D. J. Warner, A. Palumbo Board 424b A multicenter, randomized, open-label, phase 2 study of carfilzomib with or without ARRY-520 (filanesib) in patients with advanced multiple myeloma. (Abstract TPS8612) J. A. Zonder, N. S. Raje, E. C. Scott, C. C. Hofmeister, N. Lendvai, L. D. Anderson, P. Hari, G. J. Orloff, J. G. Berdeja, S. Singhal, M. Craig, J. N. Valent, M. Ptaszynski, J. Schreiber, R. Aitchison, S. Z. Usmani Board 425a The AFFIRM Study: A multicenter phase 2 study of single-agent filanesib (ARRY-520) in patients with advanced multiple myeloma. (Abstract TPS8613) S. Lonial, M. Delforge, H. Einsele, P. Moreau, M. Kaiser, M. A. Dimopoulos, A. Oriol, M. Gyger, B. Hilder, A. M. Ptaszynski, R. Aitchison, R. Z. Orlowski Board 425b The VITAL study: A randomized, double-blind, placebo-controlled, global, phase III study of NEOD001 in patients with AL amyloidosis and cardiac dysfunction. (Abstract TPS8614) M. Liedtke, G. Merlini, H. J. Landau, R. Comenzo, D. C. Seldin, B. M. Weiss, J. A. Zonder, J. Walling, G. Kinney, M. Koller, M. A. Gertz 8:00 AM - 11:30 AM Poster Session Pediatric Oncology Abstracts 10018 –10029 will be discussed during the Pediatric Oncology Poster Discussion Session. See page 187 for session information. Board 88 Pulmonary function in adult survivors of childhood cancer: A report from the St. Jude Lifetime Cohort Study (SJLIFE). (Abstract 10018) D. M. Green, L. Zhu, M. J. Krasin, S. Srinivasan, D. C. Stokes, D. K. Srivastava, K. K. Ness, B. McCarville, D. A. Mulrooney, G. T. Armstrong, C. Pui, S. L. Spunt, M. Metzger, F. Navid, A. M. Davidoff, B. N. Rao, L. L. Robison, M. M. Hudson Board 89 Second malignancies in neuroblastoma patients: A report from the International Neuroblastoma Risk Group. (Abstract 10019) M. A. Applebaum, T. O. Henderson, W. B. London, N. R. Pinto, S. L. Volchenboum, J. R. Park, A. Naranjo, A. D. Pearson, B. Hero, S. Diskin, S. L. Cohn Board 90 Temporal trends in health status among adults in the Childhood Cancer Survivor Study (CCSS). (Abstract 10020) K. K. Ness, M. M. Hudson, K. E. Jones, W. M. Leisenring, M. Stovall, D. M. Green, J. P. Neglia, T. O. Henderson, J. N. Casillas, J. Ford, K. E. Effinger, K. C. Oeffinger, G. T. Armstrong, L. L. Robison, P. C. Nathan Board 91 Survival and late effects in the risk-stratified hepatoblastoma patients treated by JPLT-2 protocol. (Abstract 10021) E. Hiyama, S. Kurihara, Y. Ueda, T. Hishiki, K. Ida, T. Iehara, T. Oue, M. Yano, K. Watanabe, K. Hoshino, K. Ko, Y. Tanaka Board 92 The DICER1 syndrome: Genotype-phenotype correlation in PPB patients. (Abstract 10022) L. A. Doros, J. Turner, G. M. Williams, C. Rossi, K. P. Schultz, D. Stewart, L. P. Dehner, Y. H. Messinger, D. A. Hill Board 93 Clinical outcome and biological predictors of relapse following nephrectomy only for very low risk Wilms tumor (VLR WT): A report from Children’s Oncology Group AREN0532. (Abstract 10023) C. V. Fernandez, E. Perlman, E. A. Mullen, Y. Chi, T. E. Hamilton, K. W. Gow, F. A. Ferrer, D. C. Barnhart, P. F. Ehrlich, G. Khanna, J. A. Kalapurakal, T. Bocking, V. Huff, Q. An, J. I. Geller, P. E. Grundy, J. R. Anderson, J. S. Dome, R. C. Shamberger, AREN0532 Renal Study Committee Board 94 Loss of STAG2 expression and prognosis in Ewing sarcoma family of tumors. (Abstract 10024) A. Bahrami, J. Wu, M. A. Dyer, O. Delattre, A. S. Pappo 163 SUNDAY Location: S Hall A Sunday, May 31, 2015 SUNDAY Board 95 Activity of Hsp90-inhibitor drug conjugate (HDC) STA-12– 8666 in preclinical models of pediatric sarcoma. (Abstract 10025) C. Heske, A. Mendoza, C. Yeung, D. A. Proia, L. Neckers, L. J. Helman Board 96 RNA helicase DDX3 is a novel therapeutic target for Ewing sarcoma. (Abstract 10026) D. M. Loeb, B. A. Wilky, C. Kim, G. McCarty, L. R. DeVine, R. N. Cole, V. Raman Board 97 The methylome of pediatric acute myeloid leukemia. (Abstract 10027) S. Pounds, X. Cao, S. Raimondi, J. Downing, R. C. Ribeiro, J. E. Rubnitz, J. K. Lamba Board 98 Accuracy of adverse event reporting on a phase III clinical trial for pediatric acute myeloid leukemia: A report from the Children’s Oncology Group. (Abstract 10028) T. P. Miller, Y. Li, M. Kavcic, T. A. Alonzo, M. Hall, Y. Huang, R. B. Gerbing, B. Fisher, S. M. Luger, D. Rubin, A. B. Troxel, L. Sung, A. S. Gamis, R. Aplenc Board 99 Temsirolimus and intensive re-induction chemotherapy for 2nd or greater relapse of acute lymphoblastic leukemia (ALL): A Children’s Oncology Group study. (Abstract 10029) S. R. Rheingold, J. Whitlock, S. K. Tasian, D. T. Teachey, M. J. Borowitz, X. Liu, C. H. Ahern, C. Minard, E. Fox, B. Weigel, S. Blaney Board 100 Association of higher lung dose received during total body irradiation for allogeneic hematopoetic stem cell transplantation in children with acute lymphoblastic leukemia with inferior progression-free and overall survival: A report from the Children’s Oncology Group. (Abstract 10030) N. Esiashvili, X. Lu, S. Hunger, T. E. Merchant, P. A. Brown, D. A. Wall, S. A. Grupp, M. Pulsipher Board 101 Intramuscular (IM) or intravenous (IV): Impact of Erwinia asparaginase route of administration on asparaginase activity. (Abstract 10031) O. O. Okusanya, P. A. Dinndorf, J. Bullock, B. A. Habtemariam, N. Mehrotra, A. B. Deisseroth, G. H. Reaman, N. A. Rahman, A. T. Farrell Board 102 Long-term outcome of six months maintenance chemotherapy for ALL in children: TCCSG L92–13E study. (Abstract 10032) M. Kato, A. Manabe, S. Ishimaru, M. Seki, K. Yoshida, D. Tomizawa, D. Hasegawa, T. Inukai, Y. Arakawa, T. Aoki, M. Okuya, K. Kaizu, K. Kato, Y. Taneyama, S. Ogawa, K. Koh, M. Tsuchida, A. Ohara Board 103 Identification of patients with post-induction CNS 2 status and outcomes in acute lymphoblastic leukemia. (Abstract 10033) A. Gurunathan, A. V. Desai, L. C. Bailey, Y. Li, J. Choi, S. R. Rheingold Board 104 Kidney Injury Molecule-1 and its association with delayed clearance and drug exposure in pediatric oncology patients treated with high dose methotrexate. (Abstract 10034) A. J. Bukowinski, T. Mizuno, T. Fukuda, A. Vinks, S. Goldstein, A. Lane, J. P. Perentesis, M. M. O’Brien Board 105 Association of intravenous (IV) and intramuscular (IM) pegaspargase (PEG) administration with rate of adverse events (AE) in standard risk (SR) Acute Lymphoblastic Leukemia (ALL) Children’s Oncology Group (COG) trials. (Abstract 10035) K. W. Maloney, A. L. Angiolillo, R. J. Schore, M. Devidas, X. Lu, C. Wang, A. M. Friedmann, L. A. Mattano Jr., M. L. Loh, E. A. Raetz, L. C. Stork, N. J. Winick, S. Hunger, W. L. Carroll Board 106 Phase I trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A Children’s Oncology Group Study. (Abstract 10036) R. E. Norris, E. Fox, J. M. Reid, A. T. Ralya, X. Liu, C. H. Ahern, C. Minard, J. Dahl, R. Eubank, B. Weigel Board 107 Exploring Tenascin-C as a novel therapeutic target in pediatric brainstem glioma. (Abstract 10037) A. M. Saratsis Board 108 Diagnostic and prognostic role of circulating miR-206 in rhabdomyosarcoma patients. (Abstract 10038) M. Miyachi, K. Tsuchiya, Y. Nitta, K. Ouchi, H. Yoshida, K. Kikuchi, Y. Kuwahara, T. Iehara, H. Hosoi Board 109 Anti-tumor efficacy in SIOPEL 6: A multi-centre open label randomised phase III trial of the efficacy of sodium thiosulphate (STS) in reducing ototoxicity in patients receiving cisplatin (Cis) monotherapy for standard risk 164 Sunday, May 31, 2015 Board 110 Proton versus conventional radiotherapy for pediatric salivary gland tumors: Acute toxicity and dosimetric characteristics. (Abstract 10040) S. R. Grant, D. Grosshans, A. Mahajan Board 111 Molecular mechanisms for telomere maintenance in neuroblastoma. (Abstract 10041) A. Bahrami, S. Lee, Y. Fan, J. Morris, A. S. Pappo, W. L. Furman Board 112 Outcome of recurrent osteosarcoma patients enrolled in seven phase II trials through CCG, POG, and COG: Learning from the past to move forward. (Abstract 10042) J. P. Lagmay, M. D. Krailo, H. Dang, A. Kim, D. S. Hawkins, O. Beaty, B. C. Widemann, T. Zwerdling, L. Bomgaars, A. Langevin, H. E. Grier, B. Weigel, S. Blaney, R. G. Gorlick, K. A. Janeway Board 113 Vesicular monoamine transporter protein expression in neuroblastoma: A report from the Children’s Oncology Group. (Abstract 10043) S. G. DuBois, W. Temple, L. Mendelsohn, G. E. Kim, E. Nekritz, C. Gustafson, L. Lin, K. Giacomini, A. Naranjo, C. Van Ryn, G. A. Yanik, S. G. Kreissman, M. D. Hogarty, K. K. Matthay Board 114 Meta-analysis of effects of demographic and treatment variables on outcome for localized paratesticular rhabdomyosarcoma (PT RMS) in North America and Europe. (Abstract 10044) D. Walterhouse, D. A. Barkauskas, A. Ferrari, E. Koscielniak, M. Stevens, H. Martelli, G. Seitz, D. A. Rodeberg, M. Shnorhavorian, R. Dasgupta, J. C. Breneman, J. R. Anderson, D. S. Hawkins, V. Minard-Colin Board 115 Treatment outcomes of pediatric and young adult sporadic desmoid tumors. (Abstract 10045) S. Helmig, J. G. Pressey, J. Sorger Board 116 The prognostic significance of MIBG uptake in left supraclavicular lymph nodes in high risk neuroblastoma patients. (Abstract 10046) S. Ash, I. Yaniv, A. Steinmetz, Z. Bar-Sever Board 117 Comparison of 18F-FDG-PET-CT and bone scintigraphy for evaluation of osseous metastases in newly diagnosed and recurrent osteosarcoma. (Abstract 10047) C. Hurley, B. McCarville, B. L. Shulkin, S. Mao, J. Wu, F. Navid, N. C. Daw, A. S. Pappo, M. W. Bishop Board 118 ImmunoPET compared with conventional imaging modalities for the detection of Ewing sarcoma metastases in a preclinical model. (Abstract 10048) A. F. O’Neill, J. L. Dearling, T. Tupper, R. Modiste, G. Dai, Q. Nguyen, A. L. Kung, A. Packard Board 119 Analysis of prognostic factors of clinical outcome in children and adolescents enrolled in phase I trials: A multicentre European collaborative study. (Abstract 10049) F. Carceller Lechon, F. Bautista, I. Jimenez, R. HladunAlvaro, C. Giraud, L. Bergamaschi, M. Dandapani, I. Aerts, F. Doz, D. Frappaz, M. Casanova, B. Morland, D. R. Hargrave, L. V. Marshall, G. Vassal, A. D. Pearson, B. Geoerger, L. Moreno Board 120 Efficacy in six courses of nonmethotrexate three-drug chemotherapy and surgery in osteosarcoma: 25-year experience. (Abstract 10050) R. Kebudi, I. Ayan, H. Ozger, F. B. Cakir, O. Gorgun, S. Buyukkapu Bay, B. Bilgic Board 121 Comparison of clinical features and outcomes in patients with extraskeletal versus skeletal localized Ewing sarcoma: A report from the Children’s Oncology Group. (Abstract 10051) T. Cash, E. McIlvaine, M. D. Krailo, S. L. Lessnick, E. R. Lawlor, N. N. Laack, J. Sorger, N. Marina, H. E. Grier, L. Granowetter, R. B. Womer, S. G. DuBois Board 122 A phase I study of sirolimus in combination with metronomic therapy in children with recurrent and refractory solid/CNS tumors. (Abstract 10052) M. Qayed, T. Cash, M. Tighiouart, T. MacDonald, K. C. Goldsmith, L. S. Kean, P. Church, H. M. Katzenstein 165 SUNDAY hepatoblastoma (SR-HB). (Abstract 10039) P. R. Brock, R. Maibach, M. Childs, K. Rajput, E. A. Neuwelt, D. Roebuck, M. J. Sullivan, V. Laithier, M. Ronghe, L. Lockwood, P. dall’Igna, E. Hiyama, B. Brichard, J. Skeen, M. E. Mateos, M. Fabre, A. A. Rangaswami, M. Capra, P. Czauderna, B. Morland Sunday, May 31, 2015 SUNDAY Board 123 A phase I/II clinical trial of veliparib (ABT-888) and radiation followed by maintenance therapy with veliparib and temozolomide in patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG): A Pediatric Brain Tumor Consortium Interim Report of Phase I Study. (Abstract 10053) P. A. Baxter, J. M. Su, X. Li, A. Onar-Thomas, C. A. Billups, P. A. Thompson, S. Goldman, S. Gururangan, T. Young-Poussaint, E. M. McKeegan, X. Wan, V. L. Giranda, A. Paulino, E. Smith, S. Blaney, J. M. Boyett, M. Fouladi Board 124 Pharmacogenetic markers for efficacy and toxicity of chemotherapy in osteosarcoma patients. (Abstract 10054) H. I. Vos, M. J. Coenen, H. Gelderblom, T. van der Straaten, E. S. de Bont, W. T. van der Graaf, H. Schreuder, F. N. van Leeuwen, H. Guchelaar, D. M. Te Loo Board 125 Developmental pharmacokinetics of topotecan (TPT), a renally excreted drug, in infants and young children with brain tumors. (Abstract 10055) V. M. Daryani, K. E. Harstead, J. F. Scott, D. A. Ward, S. L. Throm, D. C. Bowers, A. E. Bendel, P. G. Fisher, K. D. Wright, A. Broniscer, G. W. Robinson, A. J. Gajjar, C. F. Stewart Board 126 Haploidentical stem cell transplantation and subsequent immunotherapy with antiGD2 antibody for patients with relapsed metastatic neuroblastoma. (Abstract 10056) P. Lang, T. Illhardt, M. Ebinger, P. Schlegel, H. Teltschik, T. Feuchtinger, C. Schwarze, R. L. Ladenstein, H. N. Lode, H. Loibner, W. Schwinger, C. Urban, R. Handgretinger Board 127 Association of pharmacogenetic variants with progressive disease in osteosarcoma patients. (Abstract 10057) H. I. Vos, M. J. Coenen, H. Gelderblom, E. S. de Bont, W. Van Der Graaf, L. C. Kremer, H. Guchelaar, D. M. Te Loo Board 128 Safety and tolerability of crizotinib in combination with chemotherapy for relapsed or refractory solid tumors or anaplastic large cell lymphoma: a Children’s Oncology Group phase I consortium study. (Abstract 10058) E. G. Greengard, Y. P. Mosse, X. Liu, C. H. Ahern, C. Minard, S. Blaney, E. Fox, B. Weigel Board 129 Phase 1 trial of p28 (NSC745104), a non-HDM2 mediated peptide inhibitor of p53 ubiquitination in children with recurrent or progressive CNS tumors: A final report from the Pediatric Brain Tumor Consortium. (Abstract 10059) R. R. Lulla, S. Goldman, C. Beattie, T. Yamada, I. Pollack, P. G. Fisher, S. Wu, J. M. Boyett, M. Fouladi Board 130 Transcriptome based individualized therapy of refractory pediatric cancer in adolescents and young adults. (Abstract 10060) B. Weidenbusch, G. H. Richter, U. Dirksen, T. G. Grunewald, L. Lindner, I. Teichert von Luettichau, U. R. Mansmann, S. Burdach Board 131 Phase II study of nimotuzumab and radiotherapy in children and adolescents with newly diagnosed diffuse intrinsic pontine gliomas (DIPG). (Abstract 10061) S. Epelman, V. Odone, E. Gorender, R. S. Medeiros, L. Martins Board 132 The genomic landscape of anaplastic Wilms tumors with diffuse versus focal anaplasia. (Abstract 10062) G. G. Malouf, L. Dainese, X. Su, A. Verschuur, C. Bergeron, R. Mouawad, A. Blaise, Y. Le Bouc, D. Khayat, A. Coulomb Board 133 Localized vagina/uterus rhabdomyosarcoma (VU RMS): Results of a pooled analysis from four international cooperative groups. (Abstract 10063) V. Minard-Colin, J. R. Anderson, G. Bisogno, D. Schwob, D. A. Rodeberg, M. Stevens, A. Ferrari, H. Martelli, D. Walterhouse, G. De Salvo, C. A. Arndt, A. Rey, O. Oberlin, C. Haie Meder, D. S. Hawkins Board 134 Late outcomes among adult survivors of childhood non-Hodgkin lymphoma (NHL): A report from the St. Jude Lifetime Cohort Study. (Abstract 10064) M. J. Ehrhardt, J. T. Sandlund, N. Zhang, K. K. Ness, W. Chemaitilly, K. R. Krull, T. M. Brinkman, D. B. Crom, L. E. Kun, S. C. Kaste, G. T. Armstrong, D. M. Green, D. K. Srivastava, L. L. Robison, M. M. Hudson, D. A. Mulrooney Board 135 Patterns and predictors of psychological distress in adult survivors of childhood cancer: A Childhood Cancer Survivor Study (CCSS). (Abstract 166 Sunday, May 31, 2015 10065) N. M. D’Agostino, K. Edelstein, N. Zhang, C. J. Recklitis, T. M. Brinkman, D. Srivastava, W. M. Leisenring, L. L. Robison, G. T. Armstrong, K. R. Krull CELF4 variant and anthracycline-related cardiomyopathy (anth-card): A COG Study (ALTE03N1). (Abstract 10066) X. Wang, C. Sun, A. Quinones Lombrana, P. Singh, W. Landier, L. Hageman, M. Mather, L. Chen, S. Armenian, N. J. Winick, J. P. Ginsberg, J. P. Neglia, K. C. Oeffinger, S. M. Castellino, Z. E. Dreyer, M. M. Hudson, L. L. Robison, J. G. Blanco, S. Bhatia Board 137 Longitudinal evaluation of health status and chronic conditions in aging pediatric astrocytoma survivors: A Childhood Cancer Survivor Study (CCSS) report. (Abstract 10067) K. E. Effinger, P. G. Fisher, K. K. Ness, K. R. Krull, N. Marina, M. Stovall, K. C. Oeffinger, G. T. Armstrong, L. L. Robison, P. C. Nathan, W. M. Leisenring, M. M. Hudson Board 138 Quality of life assessment in retinoblastoma: A cross-sectional study of 122 survivors. (Abstract 10068) A. Batra, M. Kumari, R. Paul, D. Dhawan, S. Bakhshi Board 139 Risk stratification to guide long-term follow up of teenage and young adult survivors of childhood cancer. (Abstract 10069) S. J. Stanway, R. Windsor, S. Depani, E. Potter, K. Khabra, M. Taj Board 140 Long-term outcomes by race/ethnicity in the Childhood Cancer Survivor Study (CCSS) cohort. (Abstract 10070) S. Bhatia, Q. Liu, W. M. Leisenring, K. K. Ness, T. M. Gibson, L. L. Robison, G. T. Armstrong, Y. Yasui Board 141 Intestinal obstruction in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS). (Abstract 10071) A. L. Madenci, S. Fisher, L. Diller, R. E. Goldsby, W. M. Leisenring, K. C. Oeffinger, L. L. Robison, C. A. Sklar, M. Stovall, R. Weathers, G. T. Armstrong, Y. Yasui, C. B. Weldon Board 142 Neurocognitive, emotional, and quality of life outcomes in long-term survivors of rhabdomyosarcoma: A report from the Childhood Cancer Survivor Study (CCSS). (Abstract 10072) M. Schapiro, R. J. Hayashi, W. Liu, D. K. Srivastava, D. Jeffe, S. M. Perkins, G. T. Armstrong, L. L. Robison, M. Stovall, W. M. Leisenring, K. R. Krull Board 143 Adverse fat depots, marrow adiposity, and skeletal deficits in long-term survivors of pediatric hematopoietic stem cell transplantation. (Abstract 10073) S. Mostoufi-Moab, J. Magland, E. Isaacoff, W. Sun, C. S. Rajapakse, B. Zemel, F. Wehrli, K. Shekdar, J. Baker, J. Long, M. B. Leonard Board 144 Temporal changes in treatment exposures in the Childhood Cancer Survivor Study (CCSS). (Abstract 10074) A. Mertens, J. Whitton, J. P. Neglia, D. M. Green, T. M. Gibson, M. Stovall, M. M. Hudson, L. L. Robison, G. T. Armstrong, Y. Yasui, W. M. Leisenring Board 145 Longitudinal smoking patterns in survivors of childhood cancer: A Childhood Cancer Survivor Study (CCSS) update. (Abstract 10075) T. M. Gibson, W. Liu, G. T. Armstrong, D. K. Srivastava, M. M. Hudson, W. M. Leisenring, A. Mertens, R. Klesges, K. C. Oeffinger, P. C. Nathan, L. L. Robison Board 146 The effect of sociodemographic factors and therapy on survival in pediatric liver cancers: A SEER population study. (Abstract 10076) M. Xing, H. S. Kim Board 147 Palonosetron vs ondansetron: Prevention of chemotherapy-induced nausea and vomiting in pediatric patients in a multicycle study. (Abstract 10077) E. Kabickova, A. Wachtel, E. Basharova, T. Spinelli, P. Nicolas, G. Kovacs Board 148 Risk assessment in children presenting with fever and chemotherapyinduced neutropenia. (Abstract 10078) K. Schratz, M. Beauchemin, Z. Jin, A. Lee, M. L. Sulis Board 149a A multicentric study of interval compressed multiagent chemotherapy and metronomic chemotherapy for patients with Ewing sarcoma family of tumors: The Latin American Pediatric Oncology Group trial. (Abstract TPS10079) L. J. Gregianin, M. Scopinaro, A. Rose, E. Boldrini, S. Ferman, A. S. Petrilli Sr., C. M. Costa, D. Kirst, G. Dufort, M. Villarroel, C. Salgado, M. A. Almeida, M. Valero, M. Rizzatti, L. A. Castillo, L. Siqueira, D. Lustosa, M. Pizza, G. Rey, A. Brunetto SUNDAY Board 136 167 Sunday, May 31, 2015 Board 149b Long-term infusion of anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 (IL2) activity and efficacy in high-risk relapsed/refractory neuroblastoma patients. (Abstract TPS10080) H. N. Lode, D. Valteau-Couanet, A. Garaventa Sr., J. Gray, V. Castel, I. Yaniv, N. Siebert, C. Jensen, S. Endres, L. Pill, C. Eger, D. Seidel, M. Juettner, S. Kietz, K. Ehlert, E. Janzek, H. Loibner, I. Mueller, R. L. Ladenstein Board 150a A phase II study of pazopanib in children, adolescents, and young adults with refractory solid tumors. (Abstract TPS10081) A. Lee, J. Glade Bender, B. Weigel, E. Fox, A. C. Huff, H. Tada, S. M. Blaney, P. Langmuir Board 150b A randomised phase IIb trial of bevacizumab added to temozolomide ⴞ irinotecan for children with refractory/relapsed neuroblastoma - BEACONNeuroblastoma, a European Innovative Therapies for Children with Cancer (ITCC) - International Society of Paediatric Oncology Europe Neuroblastoma Group (SIOPEN) trial. (Abstract TPS10082) L. Moreno, J. Laidler, V. Moroz, C. Owens, H. Rubie, P. Berlanga, A. Castellano, K. Nysom, R. L. Ladenstein, J. Rossler, C. M. Zwaan, M. Elliott, G. Makin, D. Murphy, S. A. Burchill, N. Jerome, R. F. Rousseau, P. Kearns, K. Wheatley, A. D. Pearson Board 151a Early detection of transformation of plexiform neurofibromas to malignant peripheral nerve sheath tumors in neurofibromatosis type 1. (Abstract TPS10083) S. Bhaumik, D. Stewart, A. Pemov, P. L. Choyke, E. Dombi, J. Glod, M. Miettinen, J. Khan, S. M. Steinberg, A. Goodwin, A. Baldwin, B. C. Widemann 8:00 AM - 11:30 AM Poster Session SUNDAY Sarcoma Location: S Hall A Abstracts 10508 –10519 will be discussed during the Sarcoma Poster Discussion Session. See page 194 for session information. Board 152 The somatic mutational landscape in soft tissue sarcoma: Early results from TCGA data. (Abstract 10508) A. S. Brohl, H. R. Shah, Y. Wang, A. Kasarskis, R. G. Maki Board 153 Next generation sequencing of synovial sarcomas. (Abstract 10509) M. Vlenterie, M. H. Hillebrandt-Roeffen, U. E. Flucke, P. J. Groenen, B. B. Tops, W. Van Der Graaf, Y. M. Versleijen-Jonkers Board 154 Clinical application of prognostic gene expression signature in fusion gene-negative rhabdomyosarcoma: A report from the Children’s Oncology Group. (Abstract 10510) P. Hingorani, E. Missiaglia, J. Shipley, J. R. Anderson, T. J. Triche, M. Delorenzi, J. M. Gastier-Foster, M. Wing, D. S. Hawkins, S. Skapek Board 155 The who and what of imaging in sarcoma and correlation with survival. (Abstract 10511) V. S. Koshkin, V. Bolejack, L. H. Schwartz, B. Zhao, R. Chugh, R. L. Wahl, D. K. Reinke, L. J. Helman, S. Patel, S. Schuetze, L. H. Baker Board 156 Event-free survival and overall survival in 2,253 patients with osteosarcoma registered to EURAMOS-1. (Abstract 10512) S. Smeland, J. Whelan, S. S. Bielack, N. Marina, G. Jovic, T. Butterfass-Bahloul, G. Calaminus, M. Eriksson, H. Gelderblom, R. G. Gorlick, P. C. Hogendoorn, J. Hook, L. Kager, M. D. Krailo, T. Kühne, R. Randall, K. Sundby Hall, L. A. Teot, M. R. Sydes, M. L. Bernstein, EURAMOS Investigators Board 157 Forty years of randomized trials in advanced/metastatic soft tissue sarcoma (STS): Endpoint selection, surrogacy and quality of reporting. (Abstract 10513) A. Zer, R. M. Prince, E. Amir, A. R. Razak Board 158 A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with pazopanib in patients with advanced soft tissue sarcoma (STS). (Abstract 10514) S. Attia, R. F. Riedel, S. I. Robinson, R. M. Conry, K. Sankhala, B. K. Seon, D. Alvarez, B. J. Adams, C. P. Theuer, R. G. Maki 168 Board 159 A phase II study of tivozanib in patients with metastatic and non-resectable soft tissue sarcomas. (Abstract 10515) M. Agulnik, M. M. Milhem, A. Rademaker, C. Humphreys, S. E. Abbinanti, L. E. Nye, R. Cehic, A. Polish, C. R. Vintilescu, T. McFarland, K. M. Skubitz, S. I. Robinson, S. H. Okuno, B. A. Van Tine Board 160 A phase I/II clinical trial of belinostat (PXD101) in combination with doxorubicin in patients with soft tissue sarcomas (STS). (Abstract 10516) J. Vitfell-Rasmussen, M. Lind-Hansen, A. Safwat, P. Rossen, P. Knoblauch, R. L. Jones, I. R. Judson, A. Krarup-Hansen Board 161 Detection of KIT mutants in circulating tumor DNA (ctDNA) and their association with ponatinib anti-tumor activity in patients (pts) with advanced gastrointestinal stromal tumors (GIST). (Abstract 10517) M. C. Heinrich, J. Hodgson, M. von Mehren, G. D. Demetri, J. A. Fletcher, J. G. Sun, J. R. Pritchard, S. Zhang, V. M. Rivera, S. George Board 162 Plasma sequencing to detect a multitude of secondary KIT resistance mutations in metastatic gastrointestinal stromal tumors (GIST). (Abstract 10518) S. Bauer, T. Herold, T. Mühlenberg, A. Reis, J. Falkenhorst, M. Backs, J. Ketzer, F. Breitenbuecher, M. H. Schuler, S. Grunewald Board 163 An NGS assay strategy with FFPE and cfDNA to determine primary and secondary mutations across the initial diagnosis and subsequent recurrence/progression of patients with localized, recurrent and metastatic GIST. (Abstract 10519) N. Somasundaram, R. Lim, J. Chng, D. Ho, A. Gan, C. W. Chua, M. Farid, S. B. Ng, I. B. Tan, R. H. Quek Board 164 A phase II trial of sorafenib (SO) in advanced chordoma patients (pt). (Abstract 10520) E. Amela, E. Bompas, A. Le Cesne, E. Tresch, A. Italiano, S. Piperno-Neumann, O. Collard, D. Vansteene, J. Domont, E. Saada, N. Isambert, S. Salas, C. Chevreau, F. Bertucci, S. C. Delaine, J. Blay, N. Penel Board 165 Patient-reported outcome instruments meaningful and relevant for tenosynovial giant cell tumor (TGCT): A qualitative study. (Abstract 10521) H. Gelhorn, S. Tong, G. Maclaine, J. H. Healey, S. V. Bukata, V. L. Keedy, S. P. Anthony, A. J. Wagner, D. D. Von Hoff, A. S. Singh, C. Becerra, J. Hanlon, W. Lenderking, L. Murray, H. H. Hsu, P. S. Lin, W. D. Tap Board 166 Pilot trial of vigil immunotherapy in Ewing’s sarcoma. (Abstract 10522) M. Ghisoli, M. A. Barve, R. Schneider, R. G. Mennel, C. Lenarsky, G. Wallraven, P. Kumar, D. Nemunaitis, A. Roth, N. N. Senzer, F. A. Fletcher, J. J. Nemunaitis Board 167 Perioperative chemotherapy with cisplatin (CP) and doxorubicin (DOX) with and without high-dose methotrexate (HDM) in adult osteosarcoma (AOT): Is methotrexate warranted? (Abstract 10523) L. S. Rocha, M. V. Negrao, D. d. Girardi, V. P. Camargo, L. B. Alban, P. M. Hoff, O. Feher Board 168 Prognostic relevance of miRNA let-7e in localized intestinal GIST: A Spanish Group for Research on Sarcoma (GEIS) Study. (Abstract 10524) J. Martin Broto, A. Fernandez-Serra, J. Duran, S. Calabuig-Fariñas, A. Gutierrez, I. FelipeAbrio, D. Sanchez-Izquierdo, J. Martinez-Trufero, A. Casado Herraez, A. Poveda, L. Rubio Martinez Sr., C. Balana, F. Losa, C. M. Valverde, J. Rubió, J. Cruz, L. Gonzalez de Sande, C. Tous, R. Cubedo, J. A. Lopez-Guerrero Board 169 Stem cell rescue from irradiation of multiple tumor sites combined with high-dose chemotherapy, followed by reduced intensity conditioning and allogeneic stem cell transplantation in patients with advanced pediatric sarcomas: Preliminary results of the MetaEICESS 2007 protocol. (Abstract 10525) S. Burdach, U. Thiel, A. Wawer, I. Teichert von Luettichau, F. Blaeschke, T. G. Grunewald, M. Steinborn, B. Roeper, M. Molls, C. Salat, T. Klingebiel, P. Bader, E. Koscielniak, P. Lang, U. Dirksen, H. Jurgens, H. Kolb Board 170 Prognostic factors analysis of extraskeletal osteosarcoma: Updated results of an EMSOS study. (Abstract 10526) A. Longhi, A. Leithner, S. S. Bielack, D. Biau, A. Krieg, F. M. Klenke, J. Casanova, C. Gerrand, S. Hecker-Nolting, G. Bisogno, C. Ferrari, A. Righi, S. Ferrari 169 SUNDAY Sunday, May 31, 2015 Sunday, May 31, 2015 SUNDAY Board 171 High dose ifosfamide in metastatic high-grade osteosarcoma, after failure of standard multimodal chemotherapy. (Abstract 10527) E. Palmerini, P. Picci, E. Marchesi, E. L. Staals, M. Cesari, A. Longhi, A. Paioli, D. Vanel, A. Comandone, D. M. Donati, S. Ferrari Board 172 Sustained response of complex giant cell tumors with denosumab: Single center 8-year experience. (Abstract 10528) N. S. Chawla, S. V. Bukata, K. K. Sankhala, W. E. Mendanha, V. Narasimhan, L. Menendez, N. Bernthal, E. W. Brien, V. S. Chua, S. P. Chawla Board 173 Functional and clinical long-term outcome of Ewing sarcoma treatment. (Abstract 10529) A. Ranft, C. Hoffmann, C. Winter, A. Warby, D. Rosenbaum, U. Dirksen, H. Juergens Board 174 Phase II trial of gemcitabine plus rapamycin as second line in advanced osteosarcoma: A Spanish Group for Sarcoma Research (GEIS) Study. (Abstract 10530) J. Martin Broto, A. Redondo, C. M. Valverde, M. Á. Vaz Salgado, J. Mora, X. Garcia del Muro, M. Sancho Marquez, J. Martinez-Trufero, R. Diaz Beveridge, A. Gutierrez, P. Blay, C. Tous, P. Luna Fra, A. Lopez-Pousa Board 175 Clinical characteristics and treatment outcomes of clear cell chondrosarcomas: MD Anderson Cancer Center Series. (Abstract 10531) A. P. Conley, R. L. Satcher, W. Wang, A. J. Lazar, P. S. Fox, P. P. Lin, B. Moon, J. E. Bird, D. M. Araujo, V. Ravi, N. Somaiah, S. Patel, R. S. Benjamin, V. O. Lewis Board 176 Anti-tumor effects of dovitinib in patient-derived gastrointestinal stromal tumor (GIST) xenograft models. (Abstract 10532) Y. K. Gebreyohannes, T. Van Looy, A. Wozniak, J. Wellens, H. Li, J. Cornillie, U. Vanleeuw, L. Vreys, M. Squires, A. Rodriguez, M. Debiec-Rychter, R. Sciot, P. Schoffski Board 177 ReGISTry study of high risk GIST patients after complete resection: The adjuvant therapy and pathological diagnosis in Japan. (Abstract 10533) T. Nishida, Y. Kitagawa, Y. Kurokawa, Y. Komatsu, C. Ishioka, T. Doi, Y. Yamada, M. Ozaka, H. Cho, T. Kanda, T. Sugiyama, A. Sawaki, Y. Kakeji, T. Hirai, S. Hato, H. Baba, K. Shirao, S. Hirota, T. Kagimura Board 178 Selective indications of surgery in esophageal gastrointestinal stromal tumors: A retrospective study of the French Sarcoma Group (FSG). (Abstract 10534) F. Duffaud, P. Meeus, F. Bertucci, j. Delhorme, E. Stoeckle, N. Isambert, E. Bompas, J. Gagniere, O. Bouche Sr., M. Toulmonde, S. Salas, J. Blay, S. Bonvalot, French Sarcoma Group Board 179 Ponatinib efficacy and safety in patients (pts) with advanced gastrointestinal stromal tumors (GIST) after tyrosine kinase inhibitor (TKI) failure: Results from a phase 2 study. (Abstract 10535) M. C. Heinrich, M. von Mehren, G. D. Demetri, J. A. Fletcher, J. G. Sun, D. Kerstein, M. G. Conlan, S. George Board 180 Clinicopathological impact of protein phosphatase 2, regulatory subunit A, alpha mutations in gastrointestinal stromal tumors. (Abstract 10536) M. Ishii, Y. Suehara, K. Akaike, K. Mukaihara, D. Kubota, T. Okubo, T. Takagi, T. Yao, K. Kaneko, T. Saito Board 181 Adjuvant imatinib (IM) for patients (pts) with primary gastrointestinal stromal tumor (GIST) at significant risk of recurrence: PERSIST-5 planned 3-year interim analysis. (Abstract 10537) C. P. Raut, N. J. Espat, R. G. Maki, D. M. Araujo, C. H. Keir, T. F. Williams, R. P. DeMatteo Board 182 Treatment of advanced gastrointestinal stromal tumors (GIST): Are results of second-line sunitinib therapy related to duration of response of first-line imatinib? (Abstract 10538) D. Katz, S. Greenberg-Dotan, I. Feldhamer, H. Bitterman, A. Hammerman Board 183 Identification of therapy options for rare and resistant gastrointestinal stromal tumors (GIST). (Abstract 10539) R. Feldman, S. K. Reddy, Z. Gatalica, M. J. Pishvaian Board 184 Does aggressive local treatment have an impact on survival in children with metastatic rhabdomyosarcoma? (Abstract 10540) M. W. Ben Arush, V. Minard-Colin, V. Mosseri, A. Desfachelles, C. Bergeron, N. Algret, S. Fassola, N. 170 Sunday, May 31, 2015 Board 185 Combined sunitinib and IMRT for preoperative treatment of locally advanced soft tissue sarcoma: Results of a phase I trial of the German Interdisciplinary Sarcoma Group GISG 03. (Abstract 10541) J. Jakob, A. Simeonova, B. Kasper, U. Ronellenfitsch, G. Rauch, F. K. Wenz, P. Hohenberger Board 186 Activity of crizotinib (C) in patients (pts) with clear cell sarcoma (CCSA) in EORTC phase II trial 90101 “CREATE”. (Abstract 10542) P. Schoffski, A. Wozniak, S. Stacchiotti, P. Rutkowski, M. Debiec-Rychter, R. Sciot, J. Blay, L. Lindner, S. J. Strauss, D. A. Anthoney, M. G. Leahy, P. Reichardt, S. Marreaud, S. Collette, J. Steuve, T. Raveloarivahy, S. Bauer Board 187 High-risk soft tissue sarcoma of extremity and trunk wall: A retrospective comparison of local control in patients treated with or without radiation therapy at a single reference center. (Abstract 10543) M. Fiore, C. Sangalli, E. Palassini, S. Radaelli, C. Colombo, C. Morosi, D. Callegaro, A. P. Fontana, P. G. Casali, A. Gronchi Board 188 Association of hematological toxicity (tox) and outcome to doxorubicin (DOX) in advanced soft tissue sarcoma (STS): A retrospective analysis of the EORTC-Soft Tissue and Bone Sarcoma Group database. (Abstract 10544) S. Sleijfer, E. Rizzo, S. Litière, R. H. Mathijssen, I. R. Judson, H. Gelderblom, A. Italiano, W. Van Der Graaf, A. Gronchi Board 189 Metastatic soft tissue sarcoma, an analysis of systemic therapy and impact on survival. (Abstract 10545) S. J. Harris, M. Maruzzo, K. Thway, O. Al-Muderis, R. L. Jones, A. Miah, C. Benson, I. R. Judson Board 190 Longer term cardiac safety of aldoxorubicin. (Abstract 10546) S. P. Chawla, K. Sankhala, S. Wieland, D. J. Levitt Board 191 Surrogate properties of survival endpoints in metastatic soft-tissue sarcoma: A meta-analysis. (Abstract 10547) M. Savina, S. Litière, N. Penel, V. Rondeau Sr., T. Burzykowski, M. Toulmonde, A. Italiano, S. Mathoulin-Pélissier, C. A. Bellera Board 192 Cost-effectiveness analysis of preoperative versus postoperative radiotherapy in resectable extremity soft tissue sarcoma. (Abstract 10548) M. Qu, A. V. Louie, N. Wasif Board 193 Epidemiology, treatment (tx) patterns and outcomes in Asian soft tissue sarcoma (STS) patients: Results from the Soft Tissue Sarcoma in the Asia Pacific Region (STAR) study. (Abstract 10549) R. H. Quek, M. Farid, E. Wang, A. Asavamongkolkul, A. Leung, N. Prayogo, T. Punyaratabandhu, E. Yeoh, S. Shantakumar, S. Manson, R. K. Ngan Board 194 Targeted next generation sequencing in well-differentated/dedifferentiated liposarcoma (WD/DD LPS): Multiple gene amplifications but few mutations. (Abstract 10550) N. Somaiah, H. Beird, K. R. Shaw, W. Wang, A. P. Conley, V. Ravi, K. E. Torres, D. Ingram, C. L. Roland, V. Subbiah, B. W. Feig, A. J. Lazar, R. S. Benjamin, S. Patel, P. Hwu, A. Futreal, F. Meric-Bernstam, D. S. Hong Board 195 A retrospective analysis of patients with soft tissue sarcoma treated longterm with trabectedin. (Abstract 10551) E. J. Davis, R. Chugh, S. Patel, S. Schuetze Board 196 Multimodal treatment of pulmonary artery sarcoma: A single center experience. (Abstract 10552) S. Secondino, V. Grazioli, R. Dore, F. Valentino, M. Pin, G. C. Callegari, M. Paulli, P. Pedrazzoli, A. D’Armini Board 197 Metastatic dermatofibrosarcoma protuberans (DFSP) and fibrosarcomatous DFSP (FS-DFSP): Sensitivity to imatinib (IM) and gene expression profile. (Abstract 10553) S. Stacchiotti, M. A. Pantaleo, T. Negri, A. Astolfi, E. Conca, G. Dagrada, V. Indio, M. Urbini, P. Collini, C. Morosi, M. Fiore, C. Colombo, E. Palassini, A. P. Dei Tos, B. Vincenzi, F. Grosso, U. Pastorino, A. Gronchi, S. Pilotti, P. G. Casali 171 SUNDAY Andre, E. Thebaud, N. Corradini, V. Bernier, H. Martelli, D. Ranchere-Vince, D. Orbach Sunday, May 31, 2015 SUNDAY Board 198 Natural history and outcome in a large series of primary dermatofibrosarcoma protuberans (DFSP) treated at a reference institution. (Abstract 10554) A. P. Fontana, C. Colombo, M. Fiore, S. Radaelli, S. Stacchiotti, V. Colia, P. Collini, M. Barisella, G. Dagrada, S. Pilotti, P. G. Casali, A. Gronchi Board 199 The lipogenic phenotype reprograms the epigenome in sarcomas. (Abstract 10555) W. A. Chow, M. Guan Board 200 Primary high-grade myxofibrosarcoma/pleomorphic malignant fibrous histiocytoma: Percent myxoid component to improve outcome prediction. (Abstract 10556) A. Y. Lee, N. P. Agaram, L. Qin, M. F. Brennan, S. Singer Board 201 Postoperative morbidity and mortality in a large series of primary retroperitoneal sarcoma (RPS) treated at 8 tertiary centers: A study from the Transatlantic RPS Working Group. (Abstract 10557) D. C. Strauss, D. Callegaro, S. Bonvalot, R. Miceli, C. J. Swallow, P. Hohenberger, F. van Coevorden, R. L. Haas, P. Rutkowski, R. E. Pollock, M. Fiore, A. J. Hayes, M. Fairweather, C. P. Raut, A. Gronchi Board 202 Validation of the Royal Marsden Hospital (RMH) prognostic score in 100 patients with advanced sarcoma enrolled in early phase clinical trials at a major cancer center. (Abstract 10558) M. Wagner, K. R. Hess, D. S. Hong, C. Tang, A. Naing, S. Fu, F. Janku, S. A. Piha-Paul, R. Zinner, J. J. Wheler, A. M. Tsimberidou, S. Patel, N. Somaiah, V. Ravi, R. S. Benjamin, F. Meric-Bernstam, V. Subbiah Board 203 The benefit of adjuvant radiotherapy in high-grade retroperitoneal sarcoma: A SEER analysis. (Abstract 10559) J. E. Bates, A. Mazloom, S. Dhakal, L. S. Constine Board 204 A phase II study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcomas. (Abstract 10560) C. F. Meyer, K. A. Thornton, M. M. Trucco, B. A. Wilky, U. Shafique, M. CarreraHaro, P. Shah, A. R. Chen, J. Powell, D. M. Loeb Board 205 Imatinib mesylate (IM) activity in patients (pts) with locally advanced tenosynovial giant cell tumor/pigmented villonodular synovitis (TGCT). (Abstract 10561) P. A. Cassier, R. G. Maki, A. J. Wagner, E. Bompas, H. Gelderblom, J. R. Kroep, D. M. Thomas, A. Italiano, B. M. Seddon, W. Van Der Graaf, J. Domont, J. Blay, S. Stacchiotti Board 206 Sunitinib malate in advanced alveolar soft part sarcoma (ASPS): A final update after the closure of the named use program. (Abstract 10562) N. Hindi, S. Pilotti, R. Maestro, A. P. Dei Tos, E. Palassini, C. Morosi, A. Messina, S. Provenzano, T. Negri, M. Fiore, A. Gronchi, M. Brenca, P. G. Casali, S. Stacchiotti Board 207 Phase II trial of PF-03084014 in adults with desmoid tumors/aggressive fibromatosis. (Abstract 10563) S. Kummar, K. T. Do, G. H. O’Sullivan Coyne, B. Turkbey, P. S. Meltzer, E. Polley, Y. Horneffer, L. Juwara, R. Antony, P. L. Choyke, S. A. Mitchell, L. J. Helman, A. Chen, J. H. Doroshow Board 208 A phase I trial of the human double minute 2 (HDM2) inhibitor MK-8242 in patients (pts) with advanced solid tumors. (Abstract 10564) A. J. Wagner, U. Banerji, A. Mahipal, N. Somaiah, H. A. Hirsch, C. Fancourt, A. Levonas, R. Lam, A. Meister, R. K. Kemp, C. Knox, S. Rose, D. S. Hong Board 209 Clinical pattern and implication of PD-L1 expression in soft-tissue sarcoma. (Abstract 10565) C. Kim, E. Kim, J. Han, H. Chon, S. Heo, Y. Lee, Y. Cho, J. Suh, K. Shin, J. Ahn, H. Chung, S. Y. Rha, S. Kim, H. Kim Board 210 Time to secondary resistance (TTSR) after rechallenge with trabectedin (T) in myxoid round cell liposarcoma (MRCLPS) patients. (Abstract 10566) R. Sanfilippo, V. Colia, E. Fumagalli, R. Bertulli, C. Morosi, A. Messina, S. Pilotti, A. P. Dei Tos, A. Gronchi, P. G. Casali Board 211 Pazopanib for soft tissue sarcoma (STS) in the first- line setting with denosumab. (Abstract 10567) H. Narahara, K. Yasuda, K. Morita, H. Matsumoto, Y. Yasunaga, Y. Inui, S. Kawata, K. Takahashi, S. Teraoka 172 Board 212 A new simple low-cost multiplexed targeted sequencing assay to detect recurrent fusion genes in sarcomas. (Abstract 10568) E. Angot, P. Ruminy, V. Marchand, F. Blanchard, E. Colas, j. Picquenot, M. Cornic, C. Bastard, J. Sabourin, F. Jardin Board 213 A phase 1b study with selinexor, a first in class selective inhibitor of nuclear export (SINE) in patients with advanced sarcomas: An efficacy analysis. (Abstract 10569) M. M. Gounder, A. Zer, W. D. Tap, A. A. Gupta, M. Keohan, M. A. Dickson, S. P. D’Angelo, P. Chi, L. R. Tanner, T. Konen, T. Rashal, D. McCauley, J. Saint-Martin, R. Carlson, T. Marshall, S. Shacham, M. R. Mirza, M. Kauffman, G. Schwartz, A. R. Razak Board 214 Pattern of relapse in limb/girdle low-grade liposarcoma/atypical lipomatous tumor (ALT) during guidelines-suggested follow up (FU). (Abstract 10570) R. Piana, L. D’Ambrosio, E. Maldi, A. Boglione, D. Galizia, M. Boffano, E. Bellato, U. Albertini, P. Bergnolo, P. Boccone, E. Palesandro, A. Linari, A. Comandone Board 215 Primary chest wall soft tissue sarcomas: Predictors of survival following surgical resection in a large population cohort. (Abstract 10571) S. Rehmani, A. M. Al-Ayoubi, R. M. Flores, F. Y. Bhora Board 216 Local control following resection of primary retroperitoneal sarcoma with and without preoperative radiotherapy. (Abstract 10572) C. J. Swallow, A. Cannell, B. Dickson, S. Burtenshaw, P. W. Chung, R. A. Gladdy, B. O’Sullivan, C. N. Catton Board 217 Phase 2 study of gemcitabine, docetaxel, and doxorubicin in patients with advanced, unresectable, and/or metastatic sarcoma who have failed prior therapies. (Abstract 10573) A. E. Hendifar, N. S. Chawla, K. K. Sankhala, X. Zhang, D. V. Quon, V. S. Chua, L. Fernandez, W. E. Mendanha, S. P. Chawla Board 218 Metastatic non-uterine leiomyosarcoma: Prognostic factors, overall survival, and chemotherapy outcomes. (Abstract 10574) S. P. D’Angelo, A. N. Shoushtari, J. Landa, D. Kuk, A. J. Sanchez, B. Lala, M. A. Dickson, M. M. Gounder, M. Keohan, W. D. Tap Board 219a A randomized phase II/III study, comparing perioperative adriamycin plus ifosfamide versus gemcitabine plus docetaxel for operable high grade soft tissue sarcomas in extremity or trunk: JCOG1306. (Abstract TPS10575) K. Tanaka, K. Kataoka, J. Mizusawa, T. Yonemoto, H. Morioka, H. Hiraga, H. Chuuman, T. Ohno, A. Matsumine, S. Abe, K. Matuso, M. Takahashi, K. Hiraoka, H. Fukuda, Y. Iwamoto Board 219b EPAZ: A randomized phase II trial comparing pazopanib with doxorubicin as first line treatment in elderly patients with metastatic or advanced soft tissue sarcoma of the Working Group Medical Oncology (AIO) and German Interdisciplinary Sarcoma Group (GISG). (Abstract TPS10576) V. Gruenwald, A. Kunitz, M. K. Schuler, H. Kopp, B. Kasper, L. Lindner, J. Chemnitz, A. Stein, P. Schöffski, B. Steffen, S. Bauer, G. Egerer, M. Kneba, M. Crysandt, A. Koch Board 220a A study of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft tissue sarcoma. (Abstract TPS10577) S. P. Chawla, P. Schoffski, J. Blay, R. L. Jones, H. Gelderblom, S. Attia, B. Chmielowski, B. A. Van Tine, J. C. Trent II, S. Patel, A. J. Wagner, J. K. Viele, R. Chugh, A. Le Cesne, G. Tinoco, K. K. Sankhala, J. Falcone, C. Schweizer, S. Weil, R. G. Maki Board 220b SARC 028: A phase II study of the anti-PD1 antibody pembrolizumab (P) in patients (Pts) with advanced sarcomas. (Abstract TPS10578) M. A. Burgess, J. Crowley, D. K. Reinke, R. F. Riedel, S. George, S. Movva, B. A. Van Tine, L. E. Davis, S. Schuetze, J. Hu, S. Attia, D. A. Priebat, D. R. Reed, S. P. D’Angelo, S. H. Okuno, R. G. Maki, S. Patel, L. H. Baker, H. A. Tawbi 173 SUNDAY Sunday, May 31, 2015 Sunday, May 31, 2015 8:00 AM - 11:30 AM Poster Session Tumor Biology Location: S Hall A Abstracts 11010 –11021 will be discussed during the Tumor Biology Poster Discussion Session. See page 187 for session information. SUNDAY Board 222 Next-generation sequencing to reveal somatic mutations that confer sensitivity to everolimus. (Abstract 11010) S. Lim, H. Park, S. Kim, N. Kwon, J. Lee, M. Ryu, J. Ahn, H. Kim, H. Chung, J. Kim, Y. Kang, B. Cho Board 223 Next generation sequencing (NGS) to identify targetable recurring mutations and exceptional responders in relapsed and high-risk childhood and adolescent/young adult (AYA) malignancies. (Abstract 11011) B. Turpin, R. Karns, M. Sarangdhar, B. D. Weiss, J. I. Geller, M. Absalon, M. M. O’Brien, R. Nagarajan, C. L. Phillips, L. M. Chow, M. D. DeWire, D. Adams, K. C. Burns, T. R. Hummel, M. Fouladi, A. M. Hammill, J. Mangino, J. G. Pressey, B. Aronow, J. P. Perentesis Board 224 Skeletal tumor burden on baseline 18F-fluoride PET/CT to predict bone marrow failure after radium-223. (Abstract 11012) E. Etchebehere, J. C. Araujo, D. Milton, P. S. Fox, N. Swanston, H. A. Macapinlac, E. Rohren Board 225 Imaging peritoneal metastasis of gastric cancer with PET/CT and the radiotracer 18F-fluorothymidine (18F-FLT): Proof-of-concept study. (Abstract 11013) Y. Honma, T. Terauchi, U. Tateishi, D. Kano, K. Nagashima, N. T. Okita, A. Takashima, S. Iwasa, K. Kato, T. Hamaguchi, Y. Shimada, N. Boku, Y. Yamada Board 226 Phenotypic correlation of tumor uptake of exogenous glutamine radiotracer versus tumor mutational status. (Abstract 11014) M. Dunphy, J. J. Harding, J. S. Lewis, I. K. Mellinghoff, A. M. Omuro, J. Hsieh, H. Zhang, P. Zanzonico, S. Venneti, S. Carlin, A. Younes, J. F. Gerecitano, S. K. Lyashchenko, L. Harris, A. Lashley, H. Kung, C. B. Thompson, D. P. Kelsen Board 227 Subjects’ views on compensation for donating biospecimens. (Abstract 11015) R. D. Pentz, T. R. Deal, T. White, M. Dixon, K. A. Hendershot Board 228 Progesterone receptor isoform ratio to define the molecular signature of luminal breast cancers and their antiprogestin responsiveness. (Abstract 11016) M. May, P. Rojas, G. Sequeira, A. Elia, P. Martinez Vazquez, P. Gonzalez, M. C. Abba, A. Molinolo, S. M. Hewitt, C. M. Perou, H. Gass, C. Lanari Board 229 A head-to-head comparison of Mammaprint and Oncotype Dx: A McGill University Health Center Experience. (Abstract 11017) R. Maroun, R. Saleh, J. Asselah, A. Omeroglu, A. Gulbeyaz, S. H. Meterissian, N. Bouganim Board 230 Circulating tumor cell (CTC) EMT and stem cell biomarker expression predict overall survival (OS) in mCRC by a combined immunomagnetic qRT-PCR approach. (Abstract 11018) Y. Ning, W. Zhang, D. L. Hanna, A. Mendez, D. Yang, Y. Sunakawa, S. Stremitzer, S. Matsusaka, S. Okazaki, A. Parekh, R. E. El-Khoueiry, B. Flores, S. Hauch, A. Barzi, A. B. El-Khoueiry, H. Lenz Board 231 Prospective study comparing outcomes in patients with advanced malignancies on molecular alteration-matched versus non-matched therapy. (Abstract 11019) J. J. Wheler, R. Yelensky, B. Stephen, D. S. Hong, R. Zinner, V. Subbiah, S. Fu, D. D. Karp, G. S. Falchook, A. Naing, A. M. Tsimberidou, S. A. Piha-Paul, F. Janku, Y. Li, J. Lee, V. A. Miller, F. Meric-Bernstam, R. Kurzrock Board 232 Comprehensive genomic profiling of sarcomas from 267 adolescents and young adults to reveal a spectrum of targetable genomic alterations. (Abstract 11020) D. Morosini, J. Chmielecki, M. Goldberg, J. S. Ross, P. J. Stephens, V. A. Miller, L. E. Davis Board 233 Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients. (Abstract 11021) R. Ogiya, N. Kumaki, G. Bianchini, T. Iwamoto, N. Hayashi, T. Tanaka, N. Niikura, Y. Tokuda 174 Board 234 Complications following immediate breast reconstruction and influence on breast cancer recurrence rates. (Abstract 11022) S. M. Beecher, D. P. O’leary, C. Malone, R. McLaughlin, K. Sweeney, A. Hussey, M. J. Kerin Board 235 Inhibition of AKT3 to increase migration and metastasis by upregulation of S100A4 protein expression. (Abstract 11023) F. Ewald, A. Grottke, T. Lange, U. Schumacher, B. Nashan, M. Juecker Board 236 Evaluation of a novel c-MET based circulating tumor cell (CTC) biomarker in patients with gastrointestinal (GI) and genitourinary (GU) malignancies. (Abstract 11024) T. Zhang, R. Boominathan, B. Foulk, M. C. Connelly, C. Rao, G. Kemeny, J. H. Strickler, J. L. Abbruzzese, M. R. Harrison, D. J. George, H. Hurwitz, M. A. Garcia-Blanco, A. J. Armstrong Board 237 Circulating tumor DNA (ctDNA) as a prognostic marker for recurrence in resected pancreas cancer. (Abstract 11025) J. S. Wang, M. Sausen, S. ParpartLi, D. M. Murphy, V. E. Velculescu, L. D. Wood, S. Solt-Linville, E. Sugar, B. Bartlett, C. Blair, T. Dauses, E. M. Jaffee, R. H. Hruban, D. Laheru, L. A. Diaz Jr. Board 238 Emergence of KRAS mutation in detection of circulating tumor DNA during treatments for metastatic gastrointestinal cancer patients. (Abstract 11026) Y. Takayama, K. Suzuki, T. Daito, K. Ichida, T. Fukui, Y. Muto, N. Kakizawa, H. Imoto, Y. Taniyama, Y. Kaneda, H. Tanaka, F. Watanabe, T. Kato, F. Hasegawa, M. Saito, S. Tsujinaka, Y. Miyakura, H. Noda, F. Konishi, T. Rikiyama Board 239 Subclassification of prostate cancer circulating tumor cells (CTCs) by nuclear size reveals very-small nuclear CTCs in patients with visceral metastases. (Abstract 11027) Y. Lu, J. Chen, H. Ho, J. Lichterman, L. W. Chung, K. Li, Z. Ke, H. Tseng, E. M. Posadas Board 240 Molecular profiling of circulating tumor cells in non-metastatic breast cancer. (Abstract 11028) V. Forte, W. Zhu, D. Barrak, A. Ring, V. Punj, D. Tripathy, M. Yu, A. Raghavendra, G. Yang, J. E. Lang Board 241 Applying a mitotic index to circulating tumor cells and its prognostic significance: A cytological approach to patient stratification. (Abstract 11029) D. L. Adams, S. S. Martin, S. Chumsri, M. Charpentier, R. K. Alpaugh, M. Cristofanilli, C. Tang, C. C. Haudenschild Board 242 Exploring the intra-patient PIK3CA mutational heterogeneity of circulating tumour cells by massive parallel sequencing in patients with metastatic hormone receptor-positive breast cancer. (Abstract 11030) B. De Laere, D. J. Peeters, R. Salgado, P. B. Vermeulen, P. A. van Dam, S. J. Van Laere, L. Y. Dirix Board 243 Vemurafenib to eliminate BRAF-mutated circulating epithelial tumor cells (CETCs) from blood of patients with malignant melanoma. (Abstract 11031) D. Zimon, M. Pizon, E. Stein, U. A. Pachmann, K. Pachmann Board 244 Folate receptor-positive circulating tumor cell detected by LT-PCR based method as a diagnostic biomarker for non-small cell lung cancer. (Abstract 11032) X. Chen, F. Zhou, X. Li, G. Yang, L. Zhang, S. Ren, C. Zhao, Q. Deng, W. Li, G. Gao, A. Li, C. Zhou Board 245 ERCC1 induction after oxaliplatin exposure may depend on KRAS mutational status in colorectal cancer patient: Preliminary data from liquid biopsy. (Abstract 11033) M. Di Salvatore, C. Paolillo, A. Orlandi, M. Rodriquenz, E. Rossi, M. Basso, A. Strippoli, F. Aroldi, C. Bagalà, E. D. Capoluongo, C. Pozzo, A. Cassano, C. Barone Board 246 EpCAM-independent isolation of EMT- circulating tumor cells in patients with primary breast cancer who receive primary systemic therapy. (Abstract 11034) F. Le Du, T. Fujii, D. W. Davis, W. Wu, S. Jackson, M. Chavez-Mac Gregor, C. H. Barcenas, J. L. Murray, V. Valero, D. Tripathy, J. M. Reuben, N. T. Ueno Board 247 Intra-patient genomic heterogeneity of single circulating tumor cells (CTCs) associated to phenotypic CTC heterogeneity in metastatic castrate resistant prostate cancer (mCRPC). (Abstract 11035) M. Landers, S. Greene, N. A. Schreiber, A. Rodriguez, R. M. Bambury, D. C. Danila, D. E. Rathkopf, M. Fleisher, J. Louw, A. Jendrisak, D. Marrinucci, R. V. Dittamore, H. I. Scher 175 SUNDAY Sunday, May 31, 2015 Sunday, May 31, 2015 SUNDAY Board 248 Centrosome amplification and prognosis in breast cancer. (Abstract 11036) R. A. Denu, M. E. Burkard Board 249 SOD2 rs4880 CT/CC genotype to predict poor survival for Chinese gastric cancer patients received platinum and fluorouracil based adjuvant chemotherapy. (Abstract 11037) Z. Xu, Y. Chen, N. Lee, M. Wang, J. Chen Board 250 Clinical impact of expanded BRAF mutational status on the outcome for metastatic colorectal cancer patients with anti-EGFR antibody: An analysis of the BREAC trial (Biomarker Research for Anti-EGFR Monoclonal Antibodies by Comprehensive Cancer Genomics). (Abstract 11038) S. Yuki, T. Yoshino, K. Tsuchihara, E. Shinozaki, K. Muro, T. Nishina, K. Yamaguchi, K. Akagi, K. Yamazaki, T. Yamanaka, S. Nomura, S. Fujii, H. Esumi, Y. Abe, A. Ohtsu Board 251 TLR6 polymorphism associated with overall survival in metastatic colorectal cancer (mCRC) patients treated with FOLFIRI/bevacizumab enrolled in FIRE3. (Abstract 11039) S. Okazaki, S. Stintzing, V. Heinemann, S. Cao, W. Zhang, D. Yang, Y. Ning, Y. Sunakawa, S. Stremitzer, S. Matsusaka, R. Elkhoueiry, A. Mendez, A. Parekh, H. Lenz Board 253 Stratification markers for the risk of recurrence after curative resection of stage II or III gastric cancer and potential clinical applications. (Abstract 11040) T. Oshima, K. Sakamaki, Y. Miyagi, T. Yoshikawa, M. Shiozawa, H. Cho, Y. Rino, C. Kunisaki, A. Tsuburaya, T. Imada, M. Masuda Board 254 Effect of mutant TP53 genotypes on the outcome of breast cancer (BC) patients in different clinical tumor subtypes. (Abstract 11041) G. Fountzilas, M. A. Dimopoulos, G. Kouvatseas, E. Timotheadou, G. E. Pentheroudakis, H. Gogas, D. G. Pectasides, C. Christodoulou, E. Charalambous, A. Lyberopoulou, H. Linardou, C. Papandreou, A. Psyrri, G. Aravantinos, C. Markopoulos, V. Venizelos, I. Efstratiou, K. T. Kalogeras, S. Lakis, V. Kotoula Board 255 PI3K/PTEN/Akt/mTOR pathway aberrations and co-incidence of hormone receptors and HER2 in 19,784 diverse solid tumors. (Abstract 11042) S. Z. Millis, S. Ikeda, D. Arguello, R. Feldman, R. T. Maney, J. Xiu, S. K. Reddy, R. Kurzrock Board 256 piRNA-651 as a prognostic marker in surgically resected non-small-cell lung cancer. (Abstract 11043) N. Vinolas, F. Aya, A. Navarro, R. M. Marrades, A. Cordeiro, A. Fernandez, N. Chic, J. M. Gimferrer, J. Ramirez, L. Molins, M. Monzo Board 257 Does age influence the intrinsic biology of breast cancer? (Abstract 11044) T. Osako, S. McKinney, D. Yap, G. Turashvili, S. Aparicio Board 258 Identification of novel prognostic markers of glioblastoma using computational strategies on four genomic datasets. (Abstract 11045) H. Itakura, O. Gevaert Board 259 Assessment of circulating free DNA concentration as a prognostic and predictive biomarker in a large cohort of non-small cell lung cancer treated by platinum-based chemotherapy. (Abstract 11046) C. Tissot, A. Toffart, S. Villar, P. J. Souquet, P. Merle, D. Moro-Sibilot, M. Pérol, J. Zavadil, C. Brambilla, M. Olivier, S. Couraud Board 260 APC mutations in myeloid malignancies: Incidence and impact on leukemogenesis. (Abstract 11047) A. Nazha, B. Przychodzen, H. Makishima, M. Narkhede, M. E. Kalaycio, D. J. Seastone, H. Carraway, A. T. Gerds, S. Mukherjee, A. S. Advani, J. Carew, M. A. Sekeres, J. P. Maciejewski Board 261 Low frequency KRAS G12/13 mutations in urine cell-free (cf) DNA from patients with BRAF V600E-mutant advanced cancers. (Abstract 11048) F. Janku, C. T. Vibat, G. S. Falchook, H. J. Huang, D. S. Hong, S. A. Piha-Paul, V. Subbiah, N. M. Ramzanali, S. Hancock, A. Naing, D. D. Karp, G. Nitti, G. Cabrilo, R. Luthra, S. P. Patel, M. J. Overman, S. Kopetz, M. G. Erlander, V. Melnikova, F. Meric-Bernstam Board 262 Prosigna (PAM50) to predict response to neoadjuvant chemotherapy (NAC) in HRⴙ/HER2- early breast cancer (EBC) patients. (Abstract 11049) B. Jimenez Rodriguez, A. Lavado Fernandez, N. Ribelles, P. Sanchez-Rovira, L. 176 Sunday, May 31, 2015 Board 263 Evaluation of invasive breast cancer using a 12-chemokine gene expression score (CS): Correlation with clinical outcomes. (Abstract 11050) S. Prabhakaran, V. T. Rizk, W. J. Fulp, A. E. Berglund, J. J. Mule’, H. H. Soliman Board 264 Prognostic significance of stromal versus intratumoral infiltrating CD8ⴙ lymphocytes in resected non-small cell lung cancer. (Abstract 11051) M. Ameratunga, K. Asadi, M. Walkiewicz, C. Murone, P. Mitchell, T. John Board 265 Analysis of the prognostic value of the tumor immunologic profile in resectable NSCLC. (Abstract 11052) M. Usó, E. Jantus-Lewintre, R. Sirera, S. Calabuig-Fariñas, A. Blasco, R. Guijarro, E. Pastor, C. Camps Board 266 Wild type VHL clear cell renal cell carcinomas: A distinct morphological and clinical entity with PD-L1 expression. (Abstract 11053) L. Crouzet, A. Brunot, J. Dagher, A. Pladys, J. Edeline, B. Laguerre, P. Kerbrat, G. Verhoest, K. Bensalah, P. Bellaud, R. Viel, F. Jouan, N. Rioux-Leclercq, S. Kammerer-Jacquet Board 267 Immune response triggered by a novel molecular crosstalk of major hallmarks of cancer: Angiogenesis, mismatch repair, and immune pathways. (Abstract 11054) S. Graver, S. Stremitzer, Y. Sunakawa, W. Edelmann, M. Kockx, M. Schartl, S. J. Scherer, H. Lenz, M. Mazzone Board 268 Detection of rare somatic mutational profiles in metastatic colorectal cancer (mCRC) during routine RAS sequencing using next generation sequencing (NGS). (Abstract 11055) J. Merlin, M. Husson, M. Rouyer, A. Leroux, A. Harle Board 269 [18F]FMAU for PET imaging in breast cancer patients. (Abstract 11056) P. Conti, K. Chen, D. Tripathy, H. Jadvar Board 270 Clinical impact of high-throughput sequencing in patients with advanced cancer: Lessons learned from the Michigan Oncology Sequencing Center. (Abstract 11057) E. F. Cobain, D. R. Robinson, Y. Wu, F. P. Worden, D. C. Smith, S. Schuetze, R. Chugh, N. Ramnath, A. F. Schott, D. F. Hayes, A. M. Chinnaiyan, M. Talpaz Board 271 Allowance of tumor-educated platelets for multiclass liquid biopsy-based diagnosis of cancer. (Abstract 11058) M. Best, N. Sol, I. Kooi, J. Nilsson, B. Westerman, B. Ylstra, J. Dorsman, E. F. Smit, H. M. Verheul, J. C. Reijneveld, B. A. Tannous, P. Wesseling, T. Wurdinger Board 272 Improvement in imaging of metastatic breast cancer (BC) with a novel pretargeted immuno-PET targeting CEA: First clinical results. (Abstract 11059) C. Rousseau, A. Rauscher, A. Faivre-Chauvet, T. Carlier, L. Ferrer, D. M. Goldenberg, R. M. Sharkey, J. Barbet, F. Kraeber-Bodere, M. Campone Board 273 Predictive value of coexisting KRAS and TP53 mutations on response to chemotherapy in non-small cell lung cancer (NSCLC). (Abstract 11060) P. Tomasini, K. Jao, S. Kamel-Reid, T. Stockley, M. S. Tsao, G. Liu, N. B. Leighl, R. Feld, P. A. Bradbury, M. Pintilie, C. Mascaux, F. A. Shepherd Board 274 Detection of low abundant somatic mutations in circulating exosomal RNA and cfDNA with next-generation sequencing. (Abstract 11061) V. J. O’Neill, D. Enderle, J. J. Wheler, T. Koestler, C. Berking, J. Skog, M. Noerholm, K. Flaherty, F. Janku Board 275 Assessing HER2 testing quality in breast cancer (BC): Variables that influence HER2-positivity from a large, multicenter, observational study in Germany. (Abstract 11062) J. Ruschoff, A. Lebeau, H. H. Kreipe, H. Sinn, C. D. Gerharz, W. Koch, J. Ammann, M. Untch Board 276 Towards rapid and cost-effective point-of-care detection of TMPRSS2:ERG fusion transcripts in urine via a novel methodology. (Abstract 11063) E. J. Wee, K. M. Koo, P. N. Mainwaring, M. Trau Board 277 Preliminary direct evidence of a dose-response relationship for [Y-90]microsphere selective internal radionuclide therapy (SIRT) in hepatic 177 SUNDAY Vicioso, M. Alvarez, V. de Luque, C. Ramirez Tortosa, W. Buckingham, C. Schaper, A. Jeiranian, N. Dowidar, S. Ferree, E. Villar, I. Zarcos, A. SanchezMuñoz, C. Gonzalez-Hermoso, C. Llacer Perez, A. Prat, E. Alba Sunday, May 31, 2015 malignancy. (Abstract 11064) D. L. Bailey, K. P. Willowson, E. J. Bernard, D. Chan, N. Pavlakis, S. J. Clarke SUNDAY Board 278 Development of a PD-L1 immunohistochemistry (IHC) assay for use as a companion diagnostic for pembrolizumab (MK-3475) in non-small cell lung cancer (NSCLC). (Abstract 11065) M. Dolled-Filhart, C. M. Roach, G. Toland, J. Musser, G. M. Lubiniecki, G. Ponto, K. Emancipator Board 279 [18F]AA-7: PET imaging in patients with suspected glioma. (Abstract 11066) S. Nozaki, T. Oshita, Y. Nakatani, Y. Sasano, K. Yamamoto, W. Hume, Y. Wada, A. Ishii, M. Tanaka, S. Shiomi, N. Tsuyuguchi, K. Kodama, Y. Watanabe Board 281 Non-invasive determination of HER2-expression in metastatic breast cancer by using 68Ga-ABY025 PET/CT. (Abstract 11067) H. Lindman, A. Wennborg, I. Velikyan, J. Feldwisch, V. Tolmachev, D. Sandberg, H. Olofsson, M. Sandstrom, M. Lubberink, J. Carlsson, J. Sorensen Board 282 A prospective evaluation of cell free DNA (cfDNA) genotyping and circulating tumor cells (CTC) in EGFR mutant NSCLC patients (pts) treated with erlotinib. (Abstract 11068) M. Yanagita, C. Paweletz, A. O’Connell, D. M. Jackman, Y. Kuang, G. R. Oxnard, P. A. Janne Board 283 Contrast-enhanced spectral mammography (CESM) compared with breast MRI for breast cancer detection. (Abstract 11069) L. Liao, L. Li, P. Germaine, E. Tinney Board 285 Identification of novel and potentially targetable receptor tyrosine kinase alterations in colorectal carcinoma using a 341 gene hybrid capture-based next-generation sequencing assay. (Abstract 11071) J. F. Hechtman, M. E. Arcila, D. T. Cheng, D. B. Solit, R. D. Yaeger, D. M. Hyman, M. F. Berger, J. Shia, E. Vakiani, A. Zehir, M. Ladanyi Board 286 Analysis of cell-free circulating tumor DNA in patients with glioblastoma and other primary brain tumors. (Abstract 11072) D. E. Piccioni, R. B. Lanman, R. J. Nagy, A. Talasaz, S. C. Pingle, S. Kesari Board 287 Raise and decline of KRAS mutant clones in colorectal cancers (CRCs) treated with multiple rounds of anti-EGFR antibodies. (Abstract 11073) G. Siravegna, B. Mussolin, M. Buscarino, G. Corti, G. Crisafulli, A. Ponzetti, C. Cremolini, S. Lamba, A. Avallone, G. Rospo, S. Veronese, A. Budillon, C. Montagut, P. Racca, R. B. Corcoran, F. Di Nicolantonio, F. Loupakis, S. Siena, A. Sartore-Bianchi, A. Bardelli Board 288 The Prospective Epidemiologic Risk Factor (PERF I) Study: A serum biomarker reflecting collagen type I degradation as an early detection tool for cancer. (Abstract 11074) C. L. Bager, S. N. Kehlet, N. Willumsen, A. Bay-Jensen, J. Neergaard, K. Dragsbaek, D. J. Leeming, H. B. Hansen, C. Christiansen, M. A. Karsdal Board 289 A phase I, first-in-human dose study of the dual PI3K/mTOR inhibitor LY3023414 (LY) in patients (pts) with advanced cancer. (Abstract 11075) K. N. Moore, A. M. Varghese, D. M. Hyman, S. Callies, J. Lin, V. Wacheck, S. Pant, T. M. Bauer, J. C. Bendell Board 290 Lung cancer patients with HER2 mutations treated with chemotherapy and HER2 targeted drugs: Results form the EUHER2 cohort study. (Abstract 11076) J. Mazières, F. Barlesi, T. Filleron, B. Besse, I. Monnet, M. Beau-Faller, S. Peters, E. Dansin, M. Frueh, M. Pless, N. Karachaliou, M. Wislez, P. Fournel, V. Westeel, F. Cappuzzo, A. B. Cortot, D. Moro-Sibilot, J. Milia, O. Gautschi Board 291 Protein tyrosine phosphatase non receptor 11 (PTPN11/Shp2) as a driver oncogene and a novel therapeutic target in non-small cell lung cancer (NSCLC). (Abstract 11077) Y. Elamin, S. Toomey, A. Carr, K. Gately, S. Rafee, W. Grogan, P. G. Morris, O. S. Breathnach, J. Crown, K. O’Byrne, B. Hennessy Board 292 Identifying driver mutations in squamous cell lung cancer (SCC): The Lung Cancer Genomics Ireland (LCGI) study. (Abstract 11078) S. Rafee, S. Toomey, Y. Elamin, A. Carr, K. Gately, S. Finn, S. Nicholson, S. Cuffe, J. Crown, P. G. 178 Sunday, May 31, 2015 Board 293 The anti-proliferative effects of RF EMF amplitude-modulated at tumor specific frequencies and mediation by calcium. (Abstract 11079) H. Jimenez, J. W. Zimmerman, R. D’Agostino Jr., X. Yi, I. Brezovich, M. Wang, M. J. Pennison, D. Chen, N. Kuster, F. Costa, A. Barbault, C. F. Blackman, B. Pasche Board 294 TBCRC-010: Phase I/II study of dasatinib in combination with zoledronic acid (ZA) for the treatment of breast cancer bone metastasis (MBC-bone). (Abstract 11080) Z. I. Mitri, R. Nanda, K. L. Blackwell, C. Costelloe, I. Hood, A. M. Brewster, N. K. Ibrahim, K. H. Koenig, G. N. Hortobagyi, C. H. Van Poznak, M. F. Rimawi, S. L. Moulder Board 295 Prognostic significance of 2 adrenergic receptor expression in the patients with non-small cell lung cancer. (Abstract 11081) T. Yazawa, K. Kaira, A. Shimizu, T. Nagashima, Y. Ohtaki, K. Obayashi, T. Asao, T. Oyama, I. Takeyoshi, K. Shimizu Board 296 Mutant HRAS as novel target for MEK and mTOR inhibitors. (Abstract 11082) M. Kiessling, A. Curioni Fontecedro, P. Samaras, M. Scharl, G. Rogler Board 297 Stereotactic ablative radiotherapy (SABR) as re-irradiation for an isolated infield lymph node recurrence. (Abstract 11083) N. Bhatt, N. E. Dunlap, X. Wu, S. Rai, A. E. Dragun Board 298 Germline variants in cancer risk genes detected by NGS-based comprehensive tumor genomic profiling (CGP). (Abstract 11084) M. J. Hall, M. B. Daly, E. A. Ross, J. Boyd, E. M. Sanford, J. Sun, P. Stephens, D. Liss, S. Chen, V. A. Miller, R. Yelensky, V. N. Giri Board 299 Higher CD3 cell counts in apheresis collection in relation to superior survival in patients with multiple myeloma. (Abstract 11085) S. Kim, M. Gertz, A. Dispenzieri, M. Lacy, F. Buadi, S. R. Hayman, D. Dingli, P. Kapoor, J. Winters, D. A. Gastineau, W. J. Hogan, L. F. Porrata, S. Kumar Board 300 CTEP #8850: A phase I trial of riluzole and sorafenib in patients with advanced solid tumors. (Abstract 11086) K. R. Spencer, J. M. Mehnert, A. R. Tan, R. A. Moss, K. Levinson, M. N. Stein, L. Huzzy, M. P. Kane, D. Gibbon, J. J. Wright, J. Aisner, R. S. DiPaola, S. Chen, Y. Wen, J. Goydos Board 301 Identification and functional characterization of a long non-coding RNA driving hormone-independent prostate cancer progression. (Abstract 11087) F. Crea, A. Parolia, H. Xue, P. Frumento, Y. Wang, A. Haegert, K. N. Chi, A. Zoubeidi, C. Collins Board 302 Characterization of LASEP3 as a serological and prognostic biomarker and a therapeutic target for lung cancer. (Abstract 11088) A. Takano, Y. Nakamura, Y. Daigo Board 303 A prospective validation of plasma ddPCR for rapid EGFR and KRAS genotyping of advanced NSCLC patients (pts). (Abstract 11089) A. G. Sacher, C. Paweletz, R. Alden, A. O’Connell, S. L. Mach, P. A. Janne, G. R. Oxnard Board 304 Ocular toxicity with MEK inhibitors in phase I trials: A single centre experience across six clinical trials. (Abstract 11090) V. Michalarea, M. de Miguel Luken, N. Diamantis, A. Garg, L. Maubon, T. A. Yap, L. R. Molife, J. S. De Bono, P. Ursell, U. Banerji Board 305 Investigation of non-V600 BRAF mutations commonly found in NSCLC for their sensitivity to dabrafenib or trametinib. (Abstract 11091) A. Noeparast, G. Verschelden, I. Umelo, S. De Brakeleer, L. Decoster, E. Teugels, J. De Greve Board 306 A functional kinome screen to identify pathways of anthracycline resistance in patient-derived breast cancer cells. (Abstract 11092) H. Richards, O. Nikolova, K. Gurley, C. Grandori, K. Christopher, V. K. Gadi Board 307 Genomics, transcriptomics, and proteomics in the clinical setting: Integrating whole genome and RNA sequencing with quantitative proteomics to better inform clinical treatment selection. (Abstract 11093) S. Rabizadeh, 179 SUNDAY Morris, W. Grogan, O. S. Breathnach, E. Kay, A. O’Grady, B. Hennessy, K. O’Byrne Sunday, May 31, 2015 S. C. Benz, J. Burrows, T. A. Hembrough, J. Z. Sanborn, C. J. Vaske, P. SoonShiong SUNDAY Board 308 Measurement of soluble programmed death-ligand 1 (soluble PD-L1) to predict survival in biliary tract cancer patients treated with chemotherapy. (Abstract 11094) H. Ha, A. Nam, J. Bang, Y. Choi, D. Oh, T. Kim, K. Lee, S. Han, S. Im, Y. Bang Board 309 Correlation of cancer-associated macrophage-like cells with systemic therapy and pathological stage in numerous malignancies. (Abstract 11095) D. L. Adams, R. C. Bergan, S. S. Martin, S. Chumsri, M. Charpentier, R. G. Lapidus, R. K. Alpaugh, M. Cristofanilli, S. Tsai, C. Tang, M. J. Edelman Board 310 Effect of the timing of sunitinib administration on the predictive value of biomarkers in renal cell cancer (mRCC). (Abstract 11096) J. M. Ebos, M. Mastri, J. M. Hudson, C. R. Lee, A. Tracz, K. Attwood, P. N. Burns, R. S. Kerbel, G. A. Bjarnason Board 311 Personalized therapy in diverse cancers: Meta-analysis of 32,149 patients in phase II clinical trials. (Abstract 11097) M. C. Schwaederle, M. M. Zhao, J. Lee, A. Eggermont, R. L. Schilsky, J. Mendelsohn, V. Lazar, R. Kurzrock Board 312 Identification of subtypes of triple negative breast cancer (TNBC) that are sensitive to CDK4/6 inhibition. (Abstract 11098) U. Asghar, M. T. HerreraAbreu, R. Cutts, I. Babina, A. Pearson, N. C. Turner Board 313 Squamousness: Next-generation sequencing to reveal shared molecular features across squamous tumor types. (Abstract 11099) M. C. Schwaederle, S. K. Elkin, B. N. Tomson, J. Carter, R. Kurzrock Board 314 Association of paclitaxel-induced sensory peripheral neuropathy with the ABCB1 genetic variant and age. (Abstract 11100) C. Shimizu, Y. Tanabe, A. Hamada, M. Yunokawa, T. Takano, S. Koganemaru, O. Yukinori, N. Tamura, Y. Fujiwara, K. Tamura Board 315 Exosomes isolation and characterization in non small cell lung carcinoma patients: Proof of concept study. (Abstract 11101) C. D. Rolfo, M. Giallombardo, M. Castiglia, J. Jorge Chacartegui, M. Provencio, R. Alessandro, A. Carreca, P. Roca, J. Oliver, I. Bover, J. P. Van Meerbeeck, A. Russo, M. Peeters, P. Pauwels Board 316 Impact of BMI on survival and toxicity in early breast cancer: An exploratory analysis of prospective randomized phase III study N-SAS BC02 and 03. (Abstract 11102) Y. Naito, Y. Ohashi, I. Yokota, T. Watanabe, H. Iwata, S. Ohsumi, S. Ohno, Y. Hozumi, S. Yamamoto, M. Takahashi, T. Aihara, H. Mukai Board 317 Precision oncology: the UC San Diego Moores Cancer Center PREDICT experience. (Abstract 11103) B. A. Parker, M. C. Schwaederle, R. B. Schwab, G. A. Daniels, D. E. Piccioni, T. L. Helsten, L. Bazhenova, P. T. Fanta, S. M. Lippman, R. Kurzrock Board 319 Pharmacodynamic (PD) assessment using FLT-PET/CT imaging in patients treated with an interrupted high-dose axitinib schedule. (Abstract 11105) L. Cavalcante, M. Scarpelli, L. Carmichael, J. Heideman, S. Perlman, R. Jeraj, G. Liu, J. Y. Bruce Board 320 The long term outcome of clinical trial-based treatment comparing standard treatment for metastatic breast cancer. (Abstract 11106) G. Kim, J. Sohn, S. Park, H. Park, S. Kim Board 321 Theranostic biomarkers involved in immunomodulation and the PI3KCA signal transduction pathway in HPV-induced cervical, oropharyngeal, and anal carcinoma. (Abstract 11107) N. Hashemi Sadraei, R. Feldman, Z. Gatalica, S. K. Reddy, P. M. Boland, K. S. Tewari Board 322 Drug efflux pump expression in 50,000 molecularly-profiled cancer patients. (Abstract 11108) R. Feldman, B. L. Abbott, S. K. Reddy, M. Castro Board 323 Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with 180 Sunday, May 31, 2015 refractory cancer: Results of the SHIVA trial. (Abstract 11113) C. Le Tourneau, J. Delord, A. Goncalves, C. Gavoille, C. Dubot, N. Isambert, M. Campone, O. Tredan, C. Mauborgne, S. Armanet, N. Servant, I. Bieche, V. Bernard, D. Gentien, P. Jézéquel, V. Attignon, S. Boyault, A. Vincent-Salomon, M. Kamal, X. Paoletti The DETECT Study Program: Personalized treatment in advanced breast cancer based on circulating tumor cells (CTCs). (Abstract TPS11109) A. Schramm, T. W. Friedl, S. Albrecht, J. B. Huober, B. K. Rack, E. K. Trapp, P. A. Fasching, F. Taran, A. D. Hartkopf, A. Schneeweiss, V. Mueller, B. Aktas, K. Pantel, F. Meier-Stiegen, W. Janni, T. N. Fehm Board 324b The genomics of Young Lung Cancer Study. (Abstract TPS11110) B. J. Gitlitz, D. Morosini, A. L. Sable-Hunt, B. J. Addario, M. B. Jennings, S. L. Mach, G. R. Oxnard Board 325a MyPathway: An open-label phase IIa study of trastuzumab/pertuzumab, erlotinib, vemurafenib, and vismodegib in patients who have advanced solid tumors with mutations or gene expression abnormalities targeted by these agents. (Abstract TPS11111) H. A. Burris, H. Hurwitz, E. A. Perez, D. Spigel, C. Swanton, J. D. Hainsworth, L. Leon, M. Beattie, M. Brammer, C. Sweeney Board 325b NRG Oncology/NSABP B-51/RTOG 1304: Phase III trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to breast RT post breast-conserving surgery (BCS) will reduce invasive cancer events in patients (pts) with positive axillary (Ax) nodes who are ypN0 after neoadjuvant chemotherapy (NC). (Abstract TPS11112) E. P. Mamounas, H. Bandos, J. R. White, T. B. Julian, A. J. Khan, S. F. Shaitelman, M. A. Torres, S. A. McCloskey, F. A. Vicini, P. A. Ganz, S. Paik, N. Gupta, J. P. Costantino, W. J. Curran Jr., N. Wolmark SUNDAY Board 324a 9:45 AM - 11:00 AM Special Session ASCO/American Association for Cancer Research (AACR) Joint Session: Translating Biology into Therapeutics Location: E354b Carlos L. Arteaga, MD—Co-Chair Vanderbilt-Ingram Cancer Center Peter Paul Yu, MD, FACP, FASCO—Co-Chair Palo Alto Medical Foundation Andrew H. Ko, MD UCSF Helen Diller Family Comprehensive Cancer Center Hedgehog Pathway in Pancreatic Cancer Maha Hussain, MD, FACP, FASCO University of Michigan Comprehensive Cancer Center Angiogenesis and Prostate Cancer Alan Ashworth, PhD, FRS UCSF Helen Diller Family Comprehensive Cancer Center PARP Inhibitors in BRCA-Deficient Cancers Panel Question and Answer 181 Sunday, May 31, 2015 9:45 AM - 11:00 AM Special Session B. J. Kennedy Award and Lecture for Scientific Excellence in Geriatric Oncology Location: S102 Clifford A. Hudis, MD, FACP Memorial Solan Kettering Cancer Center Presentation of the 2015 B.J. Kennedy Award for Scientific Excellence in Geriatric Oncology Silvio Monfardini, MD Istituto Palazzolo Fondazione Don Gnocchi Transforming Data into Activities Designed for Older Cancer Patients 9:45 AM - 11:00 AM Education Session Best of the Rest: Top Head and Neck Abstracts from 2014–2015 Oncology Meetings Location: S100bc Quynh-Thu Le, MD—Chair Stanford University Medical Center Best of the American Society for Radiation Oncology SUNDAY Amanda Psyrri, MD, PhD Attikon Hospital and National Kapodistrian University of Athens Best of ESTRO/ECCO Tanguy Y. Seiwert, MD The University of Chicago Best of the American Association for Cancer Research Panel Question and Answer 9:45 AM - 11:00 AM Education Session Cutaneous Squamous, Basal, and Merkel Cell Cancers Location: S406 Danny Rischin, MBBS, MD, FRACP—Chair Peter MacCallum Cancer Centre Current Approaches and Future Directions in the Management of Merkel Cell Carcinoma Sandro V. Porceddu, MD Princess Alexandra Hospital Adjuvant Radiation Based on Histology and Other Risk Factors: What Is Currently Known? Jean Y. Tang, MD, PhD Stanford University School of Medicine Hedgehog Inhibitors and Other Management of Basal Cell Carcinoma Panel Question and Answer 9:45 AM - 11:00 AM Education Session Epidemiology: From Genetics to Practice Location: S100a 182 Sunday, May 31, 2015 James M. Foran, MD—Chair Mayo Clinic Epidemiology in Practice: From Risk Factor to Clinical Outcome Karen H. Lu, MD The University of Texas MD Anderson Cancer Center Value of Family History in Common Cancers Thomas A. Sellers, PhD Moffitt Cancer Center Risk and Relevance: Why Does Epidemiology Matter? Panel Question and Answer 9:45 AM - 11:00 AM Education Session Let the Sunshine In: Industry’s Impact on Oncology Research and Practice Location: S504 Richard Gaynor, MD Eli Lilly and Company Industry Perspectives: Toward Fair and Fruitful Interactions SUNDAY Beverly Moy, MD, MPH—Chair Massachusetts General Hospital Cancer Center and Harvard Medical School Increasing Prominence of Financial Relationships with Industry in Oncology Reshma Jagsi, MD, DPhil University of Michigan Health System Pitfalls of Direct-to-Consumer Advertising in Oncology for Clinical Practice Mark J. Ratain, MD The University of Chicago Implications of the Sunshine Act for Oncologists and Researchers Panel Question and Answer 9:45 AM - 11:00 AM Education Session Value Concepts in the Management of Ovarian Cancer Location: E450 Usha Menon, MD University College London, Institute for Women’s Health Early Ovarian Cancer: Can We Find It, Can We Stop It, Can We Afford It? Douglas A. Levine, MD Memorial Sloan Kettering Cancer Center Personalized Treatment in Ovarian Cancer: Fancy Science or Expensive Hype? David R. Spriggs, MD—Chair Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College Crossroads in Treatment: Primary Treatment Choices, Consolidation, and the Postplatinum Endgame Panel Question and Answer 183 Sunday, May 31, 2015 9:45 AM - 11:00 AM Meet the Professor Session Understanding Inherited High-Risk Cancer Genes and When to Refer Families for Genetic Testing—Ticketed Session Location: E451a Judy Ellen Garber, MD, MPH Dana-Farber Cancer Institute 9:45 AM - 11:00 AM Clinical Problems in Oncology Session Acute Myeloid Leukemia: State-of-the-Art Management in 2015—Ticketed Session Location: E451b Charles Alan Schiffer, MD—Chair Wayne State University Consideration in the Management of Acute Myeloid Leukemia in Elderly Patients Jessica K. Altman, MD Northwestern University Choosing the Best Frontline Regimen in Acute Myeloid Leukemia: Integrating Clinical and Genomic Features SUNDAY John F. DiPersio, MD, PhD Washington University School of Medicine in St. Louis Postremission Therapy for Acute Myeloid Leukemia: Transplant and Beyond 9:45 AM - 11:15 AM Clinical Science Symposium Targeted Therapies: Does the Disease Still Matter? Location: E Hall D1 Richard M. Goldberg, MD—Chair The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute 9:45 AM Overall survival in COMBI-d, a randomized, double-blinded, phase III study comparing the combination of dabrafenib and trametinib with dabrafenib and placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma. (Abstract 102) G. V. Long, D. Stroyakovskiy, H. Gogas, E. Levchenko, F. G. De Braud, J. M. Larkin, C. Garbe, T. Jouary, A. Hauschild, J. Grob, V. Chiarion-Sileni, C. Lebbe, M. Mandalà, M. Millward, D. J. DeMarini, J. G. Irani, F. Jin, R. S. Swann, B. Mookerjee, K. Flaherty 9:57 AM Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC). (Abstract 103) C. E. Atreya, E. Van Cutsem, J. C. Bendell, T. Andre, J. H. Schellens, M. S. Gordon, A. J. McRee, P. J. O’Dwyer, K. Muro, J. Tabernero, R. van Geel, R. Sidhu, J. G. Greger, F. A. Rangwala, M. Motwani, Y. Wu, K. W. Orford, R. B. Corcoran 10:09 AM Scott Kopetz, MD, PhD, FACP (Discussion of Abstract(s) 102–103) The University of Texas MD Anderson Cancer Center 184 Sunday, May 31, 2015 10:21 AM A pharmacokinetic (PK) and pharmacodynamic (PD) biomarker-driven phase I study of intermittent, low dose intensity schedules of the dual MEK/RAF inhibitor, RO5126766 (RO) in patients (pts) with advanced solid tumors. (Abstract 104) M. de Miguel Luken, D. Roda, R. Perez Lopez, B. Jimenez, H. Hassam, N. Sathiyayogan, M. Parmar, A. J. Turner, E. Hall, N. Tunariu, L. R. Molife, T. A. Yap, J. S. De Bono, U. Banerji 10:33 AM Phase I study of combination vemurafenib, carboplatin, and paclitaxel in patients (pts) with BRAF-mutant advanced cancer. (Abstract 105) S. Kato, F. Janku, S. A. Piha-Paul, A. Naing, D. D. Karp, A. M. Tsimberidou, V. Subbiah, R. Zinner, W. Hwu, M. M. Javle, K. L. Parkhurst, N. M. Ramzanali, R. Kurzrock, F. Meric-Bernstam, Y. Chae, K. Kim, G. S. Falchook 10:45 AM David B. Solit, MD (Discussion of Abstract(s) 104 –105) Memorial Sloan Kettering Cancer Center 10:57 AM Panel Question and Answer 9:45 AM - 12:45 PM Oral Abstract Session Genitourinary (Prostate) Cancer Location: E Arie Crown Theater Channing Judith Paller, MD—Co-Chair The Johns Hopkins University 9:45 AM The Prostate Cancer Working Group 3 (PCWG3) consensus for trials in castration-resistant prostate cancer (CRPC). (Abstract 5000) H. I. Scher, M. J. Morris, W. M. Stadler, C. S. Higano, S. Halabi, M. R. Smith, E. M. Basch, K. Fizazi, C. J. Ryan, E. S. Antonarakis, P. G. Corn, G. Liu, J. S. De Bono, L. H. Schwartz, T. M. Beer, W. K. Kelly, M. Hussain, A. O. Sartor, P. W. Kantoff, A. J. Armstrong 9:57 AM Docetaxel and/or zoledronic acid for hormone-naïve prostate cancer: First overall survival results from STAMPEDE (NCT00268476). (Abstract 5001) N. D. James, M. R. Sydes, M. D. Mason, N. W. Clarke, D. P. Dearnaley, M. R. Spears, R. Millman, C. Parker, A. W. Ritchie, J. M. Russell, J. Staffurth, R. J. Jones, S. P. Tolan, J. Wagstaff, A. Protheroe, R. Srinivasan, A. J. Birtle, J. M. O’Sullivan, R. Cathomas, M. M. Parmar, STAMPEDE Investigators 10:09 AM A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521). (Abstract LBA5002) H. M. Sandler, C. Hu, S. A. Rosenthal, O. Sartor, L. G. Gomella, M. Amin, J. Purdy, J. M. Michalski, M. Garzotto, N. Pervez, A. G. Balogh, G. Rodrigues, L. Souhami, M. N. Reaume, S. G. Williams, R. Hannan, E. M. Horwitz, A. Raben, R. Paulus, W. U. Shipley 10:21 AM Ian Tannock, MD, PhD (Discussion of Abstract(s) 5000-LBA5002) Princess Margaret Cancer Centre, University of Toronto Clinical Trial Design and Chemotherapy Use in Prostate Cancer: Correcting Old Mistakes, Making New Ones 10:33 AM Panel Question and Answer 10:45 AM Characterization of neuroendocrine prostate cancer (NEPC) in patients with metastatic castration resistant prostate cancer (mCRPC) resistant to abiraterone (Abi) or enzalutamide (Enz): Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT). (Abstract 5003) E. J. Small, J. Huang, J. Youngren, A. Sokolov, R. R. Aggarwal, G. Thomas, L. D. True, L. Zhang, A. Foye, J. J. Alumkal, C. J. Ryan, M. Rettig, C. P. Evans, M. E. Gleave, R. Baertsch, J. Stuart, R. E. Reiter, P. Lara Jr., K. N. Chi, T. M. Beer 185 SUNDAY Daniel Costin Danila, MD—Co-Chair Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College Sunday, May 31, 2015 SUNDAY 10:57 AM Defining a molecular subclass of treatment resistant prostate cancer. (Abstract 5004) H. Beltran, D. Prandi, J. Mosquera, E. Giannopoulou, L. Puca, C. Marotz, D. M. Nanus, S. T. Tagawa, O. Elemento, E. M. Van Allen, A. Sboner, L. A. Garraway, M. A. Rubin, F. Demichelis 11:09 AM Biological heterogeneity in localized high-risk prostate cancer (LHRPC) from a study of neoadjuvant abiraterone acetate plus leuprolide acetate (LHRHa) versus LHRHa. (Abstract 5005) E. Efstathiou, W. Li, M. Gormley, R. McMullin, D. S. Ricci, J. W. Davis, E. M. Li Ning Tapia, P. Troncoso, M. A. Titus, A. Hoang, S. Wen, A. J. Zurita, N. Tran, W. Peng, T. Kheoh, A. Molina, C. Logothetis 11:12 AM Scott Tomlins, MD, PhD (Discussion of Abstract(s) 5003–5005) University of Michigan Genomics as Classifiers and Predictors for Prostate Cancer: Implications for the Field 11:33 AM Panel Question and Answer 11:45 AM Interest of short hormonotherapy (HT) associated with radiotherapy (RT) as salvage treatment for biological relapse (BR) after radical prostatectomy (RP): Results of the GETUG-AFU 16 phase III randomized trial—NCT00423475. (Abstract 5006) C. Carrie, A. Hasbini, G. De Laroche, M. Habibian, P. Richaud, S. Guérif, I. Latorzeff, S. Supiot, M. Bosset, J. L. Lagrange, V. Beckendorf, F. Lesaunier, B. Dubray, J. P. Wagner, T. N’Guyen, J. Suchaud, G. Crehange, N. Barbier, A. Ruffion, S. Dussart 11:57 AM TROG 03.06 and VCOG PR 01– 03: The “timing of androgen deprivation therapy in prostate cancer patients with a rising PSA (TOAD)” collaborative randomised phase III trial. (Abstract 5007) G. M. Duchesne, J. Bassett, C. D’Este, M. Frydenberg, L. Ledwich, J. L. Millar, R. L. Milne, R. Smith, N. Spry, M. R. Stockler, R. Syme, S. Turner, K. H. Tai, H. Woo, TROG & Cancer Council Victoria 12:09 PM Long-term consequences of intermittent and continuous androgen deprivation in older patients with metastatic prostate cancer. (Abstract 5008) D. L. Hershman, J. M. Unger, J. D. Wright, S. D. Ramsey, C. Till, C. M. Tangen, W. E. Barlow, C. D. Blanke, I. M. Thompson Jr., M. Hussain 12:21 PM Celestia S. Higano, MD, FACP (Discussion of Abstract(s) 5006 –5008) University of Washington/Fred Hutchinson Cancer Research Center Early Androgen Deprivation Therapy for Prostate Cancer: Finding the Optimal Timing and Interval 12:33 PM Panel Question and Answer 11:30 AM - 12:45 PM Poster Discussion Session Leukemia, Myelodysplasia, and Transplantation Location: E354b Andrew S. Artz, MD, MS—Co-Chair The University of Chicago Medical Center Rebecca Leah Olin, MD—Co-Chair University of California, San Francisco 11:30 AM Charalambos Andreadis, MD, MSCE (Discussion of Abstract(s) 7011–7013) University of California, San Francisco Incorporating Novel Agents into the Treatment of Chronic Lymphocytic Leukemia 11:42 AM Panel Question and Answer 11:48 AM Alexander E. Perl, MD (Discussion of Abstract(s) 7014 –7016) University of Pennsylvania Biologically Based Management of Acute Myeloid Leukemia 12:00 PM Panel Question and Answer 186 Sunday, May 31, 2015 12:06 PM Mark G. Frattini, MD, PhD (Discussion of Abstract(s) 7017–7019) Columbia University Medical Center An Evolving Understanding of the Biology of Leukemia 12:18 PM Panel Question and Answer 12:24 PM Vikas Gupta, MD, FRCP, FRCPath (Discussion of Abstract(s) 7020 –7022) Princess Margaret Cancer Center Biology and Management of Myeloproliferative Neoplasms 12:36 PM Panel Question and Answer Posters discussed in this session are on display in the Leukemia, Myelodysplasia, and Transplantation Poster Session. See page 147 for poster information. Networking with presenters and discussants will take place right outside of the session room after the discussion. 11:30 AM - 12:45 PM Poster Discussion Session Pediatric Oncology Location: S504 Stephen Hunger, MD—Co-Chair Children’s Hospital of Philadelphia 11:30 AM To Be Determined (Discussion of Abstract(s) 10018 –10020) Examining Late Effects and Overall Health of Pediatric Cancer Survivors 11:42 AM Panel Question and Answer 11:48 AM Alberto S. Pappo, MD (Discussion of Abstract(s) 10021–10023) St. Jude Children’s Research Hospital Rare Tumors: Imporving Outcomes in the Modern Era 12:00 PM Panel Question and Answer 12:06 PM Jeffrey Toretsky, MD (Discussion of Abstract(s) 10024 –10026) Georgetown University Hospital Transitioning Ewing Sarcoma Research from the Bench to the Bedside: A Long Strange Trip 12:18 PM Panel Question and Answer 12:24 PM Stephen Hunger, MD (Discussion of Abstract(s) 10027–10029) Children’s Hospital of Philadelphia Exploring the Childhood Leukemia Frontier 12:36 PM Panel Question and Answer SUNDAY To Be Determined—Co-Chair Posters discussed in this session are on display in the Pediatric Oncology Poster Session. See page 163 for poster information. Networking with presenters and discussants will take place right outside of the session room after the discussion. 11:30 AM - 12:45 PM Poster Discussion Session Tumor Biology Location: S406 Robert Bachoo, MD, PhD—Co-Chair The University of Texas Southwestern Medical Center Victoria Louise Seewaldt, MD—Co-Chair Duke University Medical Center 187 Sunday, May 31, 2015 11:30 AM Wolfgang Michael Korn, MD (Discussion of Abstract(s) 11010 –11011) University of California, San Francisco Next-Generation Sequencing: Making Sense of Genomic Complexity 11:42 AM Panel Question and Answer 11:48 AM Lawrence H. Schwartz, MD (Discussion of Abstract(s) 11012–11014) New York-Presbyterian/Columbia University Medical Center New Strategies for Molecular Imaging 12:00 PM Panel Question and Answer 12:06 PM Andrew B. Nixon, PhD (Discussion of Abstract(s) 11015–11017) Duke University Medical Center The Promises and Pitfalls of Molecular Diagnostics 12:18 PM Panel Question and Answer 12:24 PM Susan M. Domchek, MD (Discussion of Abstract(s) 11018 –11020) Perelman School of Medicine at the University of Pennsylvania Actionable Targets: Finding the Needle in the Haystack 12:36 PM Panel Question and Answer Posters discussed in this session are on display in the Tumor Biology Poster Session. See page 174 for poster information. Networking with presenters and discussants will take place right outside of the session room after the discussion. 11:30 AM - 12:45 PM Education Session SUNDAY Beyond the Concept: The Patient-Centered Medical Home in Oncology Location: S404 Ray D. Page, DO, PhD—Chair The Center for Cancer and Blood Disorders Beyond the Concept: The Patient-Centered Medical Home in Oncology John David Sprandio, MD Consultants in Medical Oncology and Hematology Impact of Patient-Centered Oncology Care: A PCORI-Funded Study Lee Nisley Newcomer, MD United Health Group United Healthcare Bundling Demonstration Project Barbara L. McAneny, MD New Mexico Oncology Hematology Consultants, LTD COME HOME Project Data: What It Really Shows Panel Question and Answer 11:30 AM - 12:45 PM Education Session Enrolling Patients in Early-Phase Clinical Trials: An Ethical Dilemma Location: E450 Steven Joffe, MD, MPH—Chair University of Pennsylvania Enrolling Patients with Cancer in Early-Phase Clinical Trials: The Ethical Perspective 188 Sunday, May 31, 2015 Stuart M. Lichtman, MD Memorial Sloan Kettering Cancer Center The Role of Geriatric Oncology and Palliative Care in Clinical Trials Carlos H. Barrios, MD Latin American Cooperative Oncology Group The Conduct of Clinical Trials Globally: Challenges and Opportunities Panel Question and Answer 11:30 AM - 12:45 PM Education Session Genetic Testing in 2015: Who Owns the Data, How Do You Return Results, and Other Clinical Dilemmas Location: S100a Wendy Kohlmann, MS—Chair Huntsman Cancer Institute at the University of Utah Role of the Genetic Counselor in Testing and Returning Results William Foulkes, MBBS, PhD Segal Cancer Center, Lady Davis Institute, Jewish General Hospital Who Owns the Data: The Patient, the Doctor, or the Company? SUNDAY Mark E. Robson, MD Memorial Sloan Kettering Cancer Center The Ethics of Germline Genetic Testing, Incidental Findings, and Sharing Results Panel Question and Answer 11:30 AM - 12:45 PM Education Session Locally Advanced Rectal Cancer: Time for Change? Location: E Hall D1 Martin R. Weiser, MD—Chair Memorial Sloan Kettering Cancer Center Is Chemotherapy, Radiation, and Surgery Necessary in Everyone? Zhen Zhang, MD, PhD Fudan University, Shanghai Cancer Center Radiation: Short or Long Course? Deborah Schrag, MD, MPH Dana-Farber Cancer Institute Total Neoadjuvant Therapy: What Is the Rationale and Data? Panel Question and Answer 11:30 AM - 12:45 PM Education Session The Value Proposition in Oncology: Different Approaches to Understanding Value in Cancer Care Location: S102 189 Sunday, May 31, 2015 Beverly E. Canin Breast Cancer Options, Inc. Patient Priorities on Value in Treatment Choices Lowell E. Schnipper, MD—Chair Beth Israel Deaconess Medical Center ASCO’s Value Initiative: A Case-Based Approach Neal J. Meropol, MD University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University Case Considerations: Valuing Clinician Priorities Jennifer Malin, MD, PhD Anthem, Inc. Case Considerations: Value from the Payer Perspective Panel Question and Answer 11:30 AM - 12:45 PM Education Session Updates in the Multimodality Management of Stage III Lung Cancer Location: S100bc SUNDAY Nasser H. Hanna, MD Indiana University Melvin and Bren Simon Cancer Center Current Standards and Clinical Trials in Systemic Therapy for Stage III Lung Cancer: What Is New? Walter John Curran, MD—Chair Winship Cancer Institute of Emory University Radiation Therapy for Stage III Lung Cancer: What Is the Role of Proton Therapy? David Jablons, MD University of California, San Francisco Surgical Management of Stage III Non-Small Cell Lung Cancer: New Techniques and Data Panel Question and Answer 11:30 AM - 12:45 PM Meet the Professor Session Translating Melanoma Immunology into Practice—Ticketed Session Location: E451a Jeffrey S. Weber, MD, PhD Moffitt Cancer Center 11:30 AM - 12:45 PM Clinical Problems in Oncology Session Optimal Treatment Strategies of the Geriatric Patient with Head and Neck Cancer—Ticketed Session Location: E451b 190 Sunday, May 31, 2015 Beatriz Korc-Grodzicki, MD, PhD—Chair Memorial Sloan Kettering Cancer Center Risk Assessment and Treatment Considerations in the Elderly Patient with Head and Neck Cancer Konstantinos N. Syrigos, MD, MBBS, PhD Athens School of Medicine Systemic Treatment Options/Alterations for the Geriatric Patient with Head and Neck Cancer Kevin J. Harrington, MBBS, PhD Institute of Cancer Research and The Royal Marsden Hospital Radiotherapy Integration into Multimodality Therapy: Strategies to Minimize Toxicities in the Geriatric Patient 11:30 AM - 1:00 PM Clinical Science Symposium Predicting Response in Triple-Negative and HER2-Positive Breast Cancer: Unlocking Pieces to Solve the Puzzles Location: E Hall D2 Cornelia Liedtke, MD—Co-Chair University of Schleswig-Holstein Campus Luebeck 11:30 AM Meta-analysis of breast cancer expression data using published gene signatures to reveal key cellular processes implicated in chemosensitivity and resistance. (Abstract 509) D. G. Stover, L. M. Selfors, J. L. Coloff, J. S. Brugge, E. P. Winer 11:42 AM Prognostic significance of tumor-infiltrating CD8ⴙ and FOXP3ⴙ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer. (Abstract 510) M. Miyashita, H. Sasano, K. Tamaki, H. Hirakawa, G. Watanabe, H. Tada, A. Suzuki, T. Ishida, C. Ishioka, N. Ohuchi 11:54 AM Aleix Prat, MD, PhD (Discussion of Abstract(s) 509 –510) Vall d’Hebron Instituto de Oncologica Challenges in Response and Outcome Prediction in Triple-Negative Breast Cancer 12:06 PM Correlation of PIK3CA mutation with pathological complete response in primary HER2-positive breast cancer: Combined analysis of 967 patients from three prospective clinical trials. (Abstract 511) S. Loibl, I. Majewski, V. Guarneri, V. Nekljudova, E. M. Holmes, E. Bria, C. Denkert, H. Eidtmann, C. Sotiriou, S. Loi, F. Andre, M. Untch, P. F. Conte, M. J. Piccart-Gebhart, G. Von Minckwitz, J. Baselga 12:18 PM Predictive biomarkers of everolimus efficacy in HER2ⴙ advanced breast cancer: Combined exploratory analysis from BOLERO-1 and BOLERO-3. (Abstract 512) D. J. Slamon, S. A. Hurvitz, D. Chen, F. Andre, L. Tseng, G. H. Jerusalem, S. Wilks, R. O’Regan, C. Isaacs, M. Toi, H. A. Burris III, W. He, M. Riester, D. Robinson, T. Taran, L. Gianni 12:42 PM Panel Question and Answer 1:00 PM - 4:00 PM Plenary Session Plenary Session Including the Science of Oncology Award and Lecture Location: N Hall B1 (Simulcast Location: E Hall D1) 191 SUNDAY Alexandra Thomas, MD, FACP—Co-Chair University of Iowa Sunday, May 31, 2015 Alan P. Venook, MD—Co-Chair University of California, San Francisco Peter Paul Yu, MD, FACP, FASCO—Co-Chair Palo Alto Medical Foundation 1:00 PM Clifford A. Hudis, MD, FACP Memorial Sloan Kettering Cancer Center Presentation of the 2015 Science of Oncology Award James Patrick Allison, PhD—Science of Oncology Award Lecturer The University of Texas MD Anderson Cancer Center Immune Checkpoint Blockade in Cancer Therapy: New Insights, Opportunities, and Prospects for a Cure SUNDAY 1:35 PM Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067). (Abstract LBA1) J. D. Wolchok, V. Chiarion-Sileni, R. Gonzalez, P. Rutkowski, J. Grob, C. L. Cowey, C. D. Lao, D. Schadendorf, P. Ferrucci, M. Smylie, R. Dummer, A. G. Hill, J. B. Haanen, M. Maio, G. A. McArthur, A. Yang, L. Rollin, C. E. Horak, J. M. Larkin, F. S. Hodi 1:50 PM Michael B. Atkins, MD (Discussion of Abstract(s) LBA 1) Lombardi Comprehensive Cancer Center 2:05 PM Reduction in late mortality among 5-year survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS). (Abstract LBA2) G. T. Armstrong, Y. Yasui, Y. Chen, W. M. Leisenring, T. M. Gibson, A. Mertens, M. Stovall, M. M. Hudson, K. C. Oeffinger, S. Bhatia, K. R. Krull, P. C. Nathan, J. P. Neglia, D. M. Green, L. L. Robison 2:20 PM Michael Paul Link, MD (Discussion of Abstract(s) LBA2) Stanford University School of Medicine 2:35 PM Elective versus therapeutic neck dissection in the clinically node negative early oral cancer: A randomised control trial (RCT). (Abstract LBA3) A. D’Cruz, M. Dandekar, R. Vaish, S. Arya, G. Pantvaidya, P. Chaturvedi, D. Chaukar, P. S. Pai, A. Deshmukh, S. Kane, D. Nair, S. V. Nair, A. Patil, R. W. Hawaldar, M. Dhopeshwarkar, J. Agarwal 2:50 PM Hisham Mehanna, PhD, MD, (Discussion of Abstract(s) LBA3) Institute of Head and Neck Studies and Education, University of Birmingham 3:05 PM NCCTG N0574 (Alliance): A phase III randomized trial of whole brain radiation therapy (WBRT) in addition to radiosurgery (SRS) in patients with 1 to 3 brain metastases. (Abstract LBA4) P. D. Brown, A. L. Asher, K. V. Ballman, E. Farace, J. H. Cerhan, S. Anderson, X. W. Carrero, F. G. Barker II, R. L. Deming, S. Burri, C. Menard, C. Chung, V. W. Stieber, B. E. Pollock, E. Galanis, J. C. Buckner, K. A. Jaeckle 3:20 PM Andrew B. Lassman, MD (Discussion of Abstract(s) LBA4) Department of Neurology and Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center 3:35 PM Leonard B. Saltz, MD Memorial Sloan Kettering Cancer Center Discussion 4:00 PM - 4:30 PM Special Session Post-Plenary Discussion I: Melanoma/Skin Cancers Location: S100bc Svetomir Markovic, MD, PhD—Chair Mayo Clinic 192 Sunday, May 31, 2015 Jedd D. Wolchok, MD, PhD Memorial Sloan Kettering Cancer Center Michael B. Atkins, MD Lombardi Comprehensive Cancer Center Caroline Robert, MD, PhD Gustave Roussy 4:30 PM - 5:00 PM Special Session Post-Plenary Discussion II: Survivorship Location: S100a Lisa Diller, MD—Chair Dana-Farber Cancer Institute Gregory T. Armstrong, MD, MSCE St. Jude Children’s Research Hospital Michael Paul Link, MD, FASCO Stanford University School of Medicine SUNDAY Patricia A. Ganz, MD University of California, Los Angeles 4:30 PM - 5:45 PM Poster Discussion Session Lymphoma and Plasma Cell Disorders Location: E354b Amit Balkrishna Agarwal, MD, PhD—Chair University of Arizona 4:30 PM Mehdi Hamadani, MD (Discussion of Abstract(s) 8518 – 8520) Medical College of Wisconsin Moving the Needle: Potential Effects of Novel Drug Combinations on Care in Lymphoma 4:42 PM Panel Question and Answer 4:48 PM Michelle A. Fanale, MD (Discussion of Abstract(s) 8521– 8522) The University of Texas MD Anderson Cancer Center Moving Beyond CHOP in Front-line Management of Mature T-Cell Lymphoma 5:00 PM Panel Question and Answer 5:06 PM Antonio Palumbo, MD (Discussion of Abstract(s) 8523– 8524) A. O. U. San Giovanni Battista di Torino - Ospedale Molinette Continuous versus Fixed-Duration Front-line Therapy in Multiple Myeloma 5:18 PM Panel Question and Answer 5:24 PM Jatin J. Shah, MD (Discussion of Abstract(s) 8525– 8528) The University of Texas MD Anderson Cancer Center Role of Proteasome and Histone Deacetylase Inhibition in Myeloma Therapy 5:36 PM Panel Question and Answer Posters discussed in this session are on display in the Lymphoma and Plasma Cell Disorders Poster Session. See page 155 for poster information. Networking with presenters and discussants will take place right outside of the session room after the discussion. 193 Sunday, May 31, 2015 4:30 PM - 5:45 PM Poster Discussion Session Sarcoma Location: S404 Brian Andrew Van Tine, MD, PhD—Co-Chair Washington University in St. Louis Breelyn A. Wilky, MD—Co-Chair University of Miami Miller School of Medicine SUNDAY 4:30 PM To Be Determined (Discussion of Abstract(s) 10508 –10510) Discovery and Application of Targets in Clinical Research and Patient Care 4:42 PM Panel Question and Answer 4:48 PM Stefan Sleijfer, MD, PhD (Discussion of Abstract(s) 10511–10513) Erasmus MC Optimal Surrogate Markers for Patient Outcomes in Sarcoma 5:00 PM Panel Question and Answer 5:06 PM Rashmi Chugh, MD (Discussion of Abstract(s) 10514 –10516) University of Michigain Health System Early Clinical Trials for Refractory Soft Tissue Sarcoma Patients 5:18 PM Panel Question and Answer 5:24 PM To Be Determined (Discussion of Abstract(s) 10517–10519) Potential Value of Circulating Tumor DNA 5:36 PM Panel Question and Answer Posters discussed in this session are on display in the Sarcoma Poster Session. See page 168 for poster information. Networking with presenters and discussants will take place right outside of the session room after the discussion. 4:30 PM - 5:45 PM Education Session Emerging Topics in Immunotherapy and Cellular Therapy Location: S504 Stephan A. Grupp, MD, PhD—Chair The Children’s Hospital of Philadelphia Immunotherapy for Childhood Leukemia Crystal Mackall, MD National Cancer Institute at the National Institutes of Health Immunotherapy for Solid Tumors Ian Pollack, MD Pittsburgh Children’s Hospital Immunotherapy for Central Nervous System Tumors Panel Question and Answer 4:30 PM - 5:45 PM Education Session ICD-10: History, Implementation, and Opportunities Location: S102 194 Sunday, May 31, 2015 Risë Marie Cleland—Chair Washington State Medical Oncology Society Historical Perspective Stuart Staggs McKesson Specialty Health Practical Implementation: Before and after October 1, 2015 Sue Bowman, MJ, RHIA, CCS, FAHIMA American Health Information Management Association What Opportunities Does ICD-10 Provide? Panel Question and Answer 4:30 PM - 5:45 PM Education Session Overcoming Drug Resistance in Targeted Therapy of Cancer Location: E Arie Crown Theater Mothaffar F. Rimawi, MD—Chair Baylor College of Medicine Resistance to Anti-HER2 Therapies in Breast Cancer SUNDAY Christine Marie Lovly, MD, PhD Vanderbilt-Ingram Cancer Center Resistance to Tyrosine Kinase Inhibitors in Lung Cancer Josep Tabernero, MD, PhD Vall d’Hebron University Hospital Resistance to Targeted Therapies in Gastrointestinal Cancers Panel Question and Answer 4:30 PM - 5:45 PM Education Session Targeted Molecular Therapy in Melanoma Location: S406 Ryan J. Sullivan, MD Massachusetts General Hospital Cancer Center and Harvard Medical School Targeting the Wild-Type Patient Reinhard Dummer, MD University Hospital Zurich Targeting Patients with the BRAF Mutation: Is Combination Therapy the New Standard? Alan Haruo Bryce, MD—Chair Mayo Clinic, Scottsdale, AZ Genomic Approaches in the Discovery of Novel Targets for Melanoma Panel Question and Answer 195 Sunday, May 31, 2015 4:30 PM - 5:45 PM Meet the Professor Session Clinical and Translational Research in Older Patients with Cancer—Ticketed Session Location: E451a Harvey Jay Cohen, MD Duke University Medical Center Lodovico Balducci, MD Moffitt Cancer Center 4:30 PM - 5:45 PM Clinical Problems in Oncology Session Controversies in Management of High-Grade Glioma—Ticketed Session Location: E451b Roger Stupp, MD—Chair University Hospital Zurich and University of Zurich Medical Management of Newly Diagnosed Glioblastoma: Back to the Future SUNDAY Andrew B. Lassman, MD Department of Neurology and Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center Anaplastic (WHO Grade III Gliomas): Should Practice-Changing Data Change Clinical Practice? Nicholas A. Butowski, MD University of California, San Francisco Recurrent High-Grade Glioma: One Patient, Many Options 4:30 PM - 6:00 PM Clinical Science Symposium Immunotherapy in Lung Cancer: A Paradigm Shift Location: E Hall D1 Geoffrey R. Oxnard, MD—Co-Chair Dana-Farber Cancer Institute Nathan A. Pennell, MD, PhD—Co-Chair Cleveland Clinic 4:30 PM A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 [PD-1]) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC). (Abstract 8009) D. R. Spigel, K. L. Reckamp, N. A. Rizvi, E. Poddubskaya, H. J. West, W. E. Eberhardt, P. Baas, S. J. Antonia, A. Pluzanski, E. E. Vokes, E. Holgado, D. M. Waterhouse, N. Ready, J. F. Gainor, O. R. Aren, L. Horn, L. Paz-Ares, C. Baudelet, B. J. Lestini, J. R. Brahmer 4:42 PM Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR). (Abstract 8010) A. I. Spira, K. Park, J. Mazières, J. F. Vansteenkiste, A. Rittmeyer, M. Ballinger, D. Waterkamp, M. Kowanetz, A. Mokatrin, L. Fehrenbacher 196 Sunday, May 31, 2015 4:54 PM Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D. (Abstract 8011) A. Patnaik, M. A. Socinski, M. A. Gubens, L. Gandhi, J. Stevenson, R. D. Bachman, J. Bourque, J. Yang Ge, E. Im, S. M. Gadgeel 5:06 PM Marina Chiara Garassino, MD (Discussion of Abstract(s) 8009 – 8011) Fondazione IRCCS Istituto Nazionale Dei Tumori Changes in the Standard of Care for Non–Small Cell Lung Cancer 5:18 PM Clinical correlation and frequency of programmed death ligand-1 (PD-L1) expression in EGFR-mutant and ALK-rearranged non-small cell lung cancer (NSCLC). (Abstract 8012) J. F. Gainor, L. V. Sequist, A. T. Shaw, C. G. Azzoli, Z. Piotrowska, T. Huynh, L. Fulton, K. Schultz, A. N. Hata, J. A. Engelman, M. Mino-Kenudson 5:30 PM Keith M. Kerr, BSc, MB, ChB, FRCPath, FRCPE (Discussion of Abstract(s) 8012) Aberdeen Royal Infirmary Biomarkers for Immune Checkpoint Inhibitors 5:42 PM Panel Question and Answer 4:30 PM - 6:00 PM Clinical Science Symposium SUNDAY To Lump or To Split: Molecular, Anatomic, and Etiologic Subtyping of Noncolorectal Gastrointestinal Malignancies and Potential Therapeutic Implications Location: E Hall D2 Ghassan K. Abou-Alfa, MD—Co-Chair Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College Andrew H. Ko, MD—Co-Chair UCSF Helen Diller Family Comprehensive Cancer Center 4:30 PM Comprehensive genomic profiling of biliary tract cancers to reveal tumorspecific differences and frequency of clinically relevant genomic alterations. (Abstract 4009) J. S. Ross, K. Wang, M. M. Javle, D. V. Catenacci, R. T. Shroff, S. M. Ali, J. A. Elvin, J. Chmielecki, R. Yelensky, D. Lipson, V. A. Miller, P. J. Stephens, F. Meric-Bernstam 4:42 PM Melanie B. Thomas, MD (Discussion of Abstract(s) 4009) Gibbs Cancer Center and Research Institute Tumor-Specific Differences of Biliary Tract Cancers 4:54 PM Pembrolizumab (MK-3475) for patients (pts) with advanced esophageal carcinoma: Preliminary results from KEYNOTE-028. (Abstract 4010) T. Doi, S. A. Piha-Paul, S. I. Jalal, H. Mai-Dang, S. Yuan, M. Koshiji, I. Csiki, J. Bennouna 5:06 PM Charles S. Fuchs, MD, MPH (Discussion of Abstract(s) 4010) Dana-Farber Cancer Institute Potential Practice Effects of Gastric and Esophageal Cancer Subtyping 5:18 PM Hepatitis B- and C-associated hepatocellular carcinoma in a large U.S. cancer center: Do clinicopathologic features or patient outcomes differ by the potentially causative viruses? (Abstract 4011) M. I. Uemura, A. O. Kaseb, R. Abdel-Wahab, K. P. Raghav, G. Botrus, E. Hawk, R. A. Wolff, J. Morris, M. Hassan 5:30 PM Ghassan K. Abou-Alfa, MD (Discussion of Abstract(s) 4011) Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College Similarities and Differences in Hepatocellular Carcinoma: Etiology and Other Factors 5:42 PM Panel Question and Answer 197 Sunday, May 31, 2015 5:00 PM - 5:30 PM Special Session Post-Plenary Discussion III: Head and Neck Cancer Location: S100bc Quynh-Thu Le, MD—Chair Stanford University Medical Center Anil D’Cruz, MBBS, MS, FRCS Tata Memorial Hospital Hisham Mehanna, PhD, MD Institute of Head and Neck Studies and Education, University of Birmingham Robert L. Ferris, MD, PhD University of Pittsburgh Cancer Institute 5:30 PM - 6:00 PM Special Session Post-Plenary Discussion IV: Central Nervous System Tumors Location: S100a SUNDAY Andrew B. Lassman, MD Department of Neurology and Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center Paul D. Brown, MD The University of Texas MD Anderson Cancer Center Minesh P. Mehta, MD University of Maryland Medical Systems Patrick Y. Wen, MD Dana-Farber Cancer Institute 198 Monday, June 1, 2015 7:30 AM - 9:15 AM Highlights of the Day Session Highlights of the Day Session II Including Partners in Progress Award Location: E Hall D1 John Vernon Cox, DO, MBA, FACP—Chair The University of Texas Southwestern Medical Center 7:30 AM Clifford A. Hudis, MD, FACP Memorial Sloan Kettering Cancer Center Presentation of the 2015 Partners in Progress Award Mary Lou Smith, JD, MBA—Partners in Progress Award Recipient Research Advocacy Network 7:40 AM Eileen Mary O’Reilly, MD David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center Gastrointestinal (Noncolorectal) Cancer 8:00 AM Robert Dreicer, MD, MS University of Virginia School of Medicine Genitourinary (Prostate) Cancer 8:20 AM Blase N. Polite, MD, MPP The University of Chicago Health Services Research and Quality of Care 8:40 AM Edward B. Garon, MD David Geffen School of Medicine at University of California, Los Angeles/Translational Research in Oncology-US Network Lung Cancer—Non-Small Cell Metastatic 8:00 AM - 9:15 AM Education Session Antibody-Drug Conjugates: New Horizons to Maximize Efficacy and Minimize Toxicity Location: S406 MONDAY Beverly A. Teicher, PhD—Chair National Cancer Institute at the National Institutes of Health Overview of Antibody-Drug Conjugates in Solid Tumors: History and Mechanism of Action Francisco J. Esteva, MD, PhD NYU Langone Medical Center Integration of Antibody-Drug Conjugates in Clinical Practice Kathy Miller, MD Indiana University Melvin and Bren Simon Cancer Center Novel Antibody-Drug Conjugates and Rational Combination Panel Question and Answer 8:00 AM - 9:15 AM Education Session Burnout in Oncology Health Care Providers: Identifying Silent Despair and Maintaining Purpose Location: S404 199 Monday, June 1, 2015 Anthony Back, MD—Chair Seattle Cancer Care Alliance What Is Burnout? Tait D. Shanafelt, MD Mayo Clinic Fixing Burnout: Mind-Body Therapies for Health Care Providers Cynda H. Rushton, PhD, RN, FAAN Johns Hopkins University School of Nursing Oncology Registered Nurse Burnout and Strategies to Improve Effectiveness Panel Question and Answer 8:00 AM - 9:15 AM Education Session Integrating New Approaches in Complicated Bladder Cancer Location: E Hall D2 Dan Theodorescu, MD, PhD University of Colorado Cancer Center Detection and Monitoring of Bladder Cancer: Impact of the Genomic Revolution Andrea Borghese Apolo, MD National Cancer Institute at the National Institutes of Health Neoadjuvant and Adjuvant Chemotherapy in Muscle-Invasive Bladder Cancer: Challenges in Applying the Data Nicholas J. Vogelzang, MD—Chair Carolina Urologic Research Center, The US Oncology Network Practical Considerations in the Treatment of the Frail Patient with Bladder Cancer Panel Question and Answer 8:00 AM - 9:15 AM Education Session MONDAY Progress and Challenges in Chronic Lymphocytic Leukemia Location: E Arie Crown Theater Stephan Stilgenbauer, MD University Hospital Ulm Upfront Approach: Focus on Identifying and Managing High-Risk Chronic Lymphocytic Leukemia Richard R. Furman, MD Weill Cornell Medical College, New York Presbyterian Hospital Incorporating Novel Therapies in the Management of Relapsed/Refractory Chronic Lymphocytic Leukemia Clive Zent, MD—Chair University of Rochester Management of Complications of Chronic Lymphocytic Leukemia Panel Question and Answer 200 Monday, June 1, 2015 8:00 AM - 9:15 AM Education Session Quality Measurement in Health Care: Tools to Improve Care Location: S100a Helen Burstin, MD, MPH—Chair National Quality Forum How to Evaluate Quality in Health Care Craig Earle, MD, MSc Institute for Clinical Evaluative Sciences The Current Quality Measure Landscape in Oncology Lawrence N. Shulman, MD Dana-Farber Cancer Institute Quality Improvement in Action Panel Question and Answer 8:00 AM - 9:15 AM Education Session Rare Tumors of the Central Nervous System: More Similar than Different Location: E450 Jaishri O’Neill Blakeley, MD—Chair Johns Hopkins University School of Medicine Rare Diseases Informing Neuro-oncology Clinical Practice: What We Are Learning from the Tumors of Neurogenetic Syndromes? Mark R. Gilbert, MD Center for Cancer Research, National Cancer Institute Challenges in Ependymoma Management: Recurrent Disease and Adult Patients Matthias Preusser, MD Medical University of Vienna Management of Atypical and Anaplastic Meningioma: Implications for Secondary Malignancies and Sporadic and Syndromic Tumors Panel Question and Answer 8:00 AM - 9:15 AM Meet the Professor Session Choosing the Best Initial Therapy for Advanced Lung Cancer—Ticketed Session Location: E451a Ramaswamy Govindan, MD Washington University School of Medicine 201 MONDAY Scott Randall Plotkin, MD, PhD Massachusetts General Hospital Cancer Center Neurofibromatosis Type 2: A Model for Integrating Genetics and Functional Endpoints for Multiple Nervous System Tumors Monday, June 1, 2015 8:00 AM - 9:15 AM Meet the Professor Session Using Adaptive Therapy to Treat Cancer—Ticketed Session Location: E451b To Be Determined 8:00 AM - 9:30 AM Clinical Science Symposium New Evidence on the Role of Surgery and PET Scans after Primary Chemoradiotherapy Location: S100bc Robert I. Haddad, MD—Chair Dana-Farber Cancer Institute MONDAY 8:00 AM PET-NECK: A multi-centre, randomized, phase III, controlled trial (RCT) comparing PETCT guided active surveillance with planned neck dissection (ND) for locally advanced (N2/N3) nodal metastases (LANM) in patients with head and neck squamous cell cancer (HNSCC) treated with primary radical chemoradiotherapy (CRT). (Abstract 6009) H. M. Mehanna, W. L. Wong, C. C. McConkey, J. K. Rahman, M. Robinson, A. G. Hartley, C. Nutting, N. Powell, H. Al-Booz, E. Junor, C. Hulme, A. F. Smith, P. Hall, J. Dunn 8:12 AM Richard F. Wahl, MD (Discussion of Abstract(s) 6009) Washington University School of Medicine in St. Louis The Role of PET in the Surgical Management of Head and Neck Cancer 8:24 AM Is PET-CT guided management for patients with locally advanced head and neck squamous cell cancer (HNSCC) cost-effective? Results from a UK non-inferiority phase III randomized trial. (Abstract 6010) A. F. Smith, P. Hall, C. Hulme, J. Dunn, J. K. Rahman, C. C. McConkey, H. Mehanna 8:36 AM John N. Waldron, MD, FRCPC (Discussion of Abstract(s) 6010) Princess Margaret Cancer Centre Establishing the Value of PET 8:48 AM Establishing quality indicators for neck dissection: Correlating the number of lymph nodes with oncologic outcomes, NRG Oncology/RTOG 9501– 0234. (Abstract 6011) V. Divi, J. Harris, P. M. Harari, J. S. Cooper, J. B. McHugh, D. Bell, E. M. Sturgis, A. Cmelak, M. Suntharalingam, D. Raben, H. E. Kim, S. Spencer, G. E. Laramore, A. Trotti, R. L. Foote, C. J. Schultz, W. L. Thorstad, Q. Zhang, Q. Le, F. C. Holsinger 9:00 AM Brian Nussenbaum, MD (Discussion of Abstract(s) 6011) Washington University School of Medicine in St. Louis Determining the Necessary Number of Nodes 9:12 AM Panel Question and Answer 8:00 AM - 11:00 AM Oral Abstract Session Breast Cancer—HER2/ER Location: N Hall B1 Tufia C. Haddad, MD—Co-Chair Mayo Clinic Priya Rastogi, MD—Co-Chair University of Pittsburgh Medical Center 202 8:00 AM Primary results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole (A) versus tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy. (Abstract LBA500) R. G. Margolese, R. S. Cecchini, T. B. Julian, P. A. Ganz, J. P. Costantino, L. Vallow, K. S. Albain, P. W. Whitworth, M. E. Cianfrocca, A. Brufsky, H. M. Gross, G. S. Soori, J. O. Hopkins, L. Fehrenbacher, K. Sturtz, T. F. Wozniak, T. E. Seay, E. P. Mamounas, N. Wolmark 8:12 AM Phase III trial evaluating the addition of bevacizumab to letrozole as first-line endocrine therapy for treatment of hormone-receptor positive advanced breast cancer: CALGB 40503 (Alliance). (Abstract 501) M. N. Dickler, W. T. Barry, C. T. Cirrincione, M. J. Ellis, M. Moynahan, F. Innocenti, A. Hurria, H. S. Rugo, D. Lake, O. M. Hahn, B. P. Schneider, D. Tripathy, E. P. Winer, C. A. Hudis 8:24 AM PALOMA3: A double-blind, phase III trial of fulvestrant with or without palbociclib in pre- and post-menopausal women with hormone receptorpositive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy. (Abstract LBA502) N. C. Turner, J. Ro, F. Andre, S. Loi, S. Verma, H. Iwata, N. Harbeck, S. Loibl, C. H. Bartlett, K. Zhang, C. Giorgetti, S. Randolph, M. Koehler, M. Cristofanilli 8:36 AM Joseph A. Sparano, MD (Discussion of Abstract(s) LBA500-LBA502) Montefiore Medical Center Novel Approaches to Hormone Receptor–Positive Disease 8:48 AM Panel Question and Answer 9:00 AM Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG/Alliance/ECOG-ACRIN/NCIC Clinical Trials Group/NRG Oncology study S0307. (Abstract 503) J. Gralow, W. E. Barlow, A. H. Paterson, D. Lew, A. Stopeck, D. F. Hayes, D. L. Hershman, M. Schubert, M. J. Clemons, C. H. Van Poznak, E. C. Dees, J. N. Ingle, C. I. Falkson, A. D. Elias, M. J. Messino, J. H. Margolis, S. R. Dakhil, H. K. Chew, R. B. Livingston, G. N. Hortobagyi 9:12 AM Adjuvant denosumab in breast cancer: Results from 3,425 postmenopausal patients of the ABCSG-18 trial. (Abstract 504) M. Gnant, G. Pfeiler, P. C. Dubsky, M. Hubalek, R. Greil, R. Jakesz, V. Wette, M. Balic, F. Haslbauer, E. Melbinger-Zeinitzer, V. Bjelic Radisic, J. C. Bergh, F. Fitzal, D. Egle, B. Mlineritsch, G. G. Steger, S. Talbot, D. J. Warner, C. Fesl, C. F. Singer, ABCSG 9:24 AM Robert E. Coleman, MBBS, MD, FRCP (Discussion of Abstract(s) 503–504) University of Sheffield, Weston Park Hospital Optimizing Adjuvant Therapy with Bone-Modifying Agents 9:36 AM Panel Question and Answer 9:48 AM Five-year analysis of the phase II NeoSphere trial evaluating four cycles of neoadjuvant docetaxel (D) and/or trastuzumab (T) and/or pertuzumab (P). (Abstract 505) L. Gianni, T. Pienkowski, Y. Im, L. Tseng, M. Liu, A. Lluch, E. Staroslawska, J. de la Haba-Rodriguez, S. Im, J. L. Pedrini, B. Poirier, P. Morandi, V. Semiglazov, V. Srimuninnimit, G. V. Bianchi, V. McNally, H. Douthwaite, G. Ross, P. Valagussa 10:00 AM Efficacy of 12-weeks of neoadjuvant TDM1 with or without endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer: WSGADAPT HER2ⴙ/HRⴙ phase II trial. (Abstract 506) N. Harbeck, O. Gluz, M. Christgen, M. W. Braun, S. Kummel, J. Potenberg, B. Aktas, C. Schumacher, H. Forstbauer, D. Augustin, S. Kraemer, M. Just, J. Tio, A. Kleine-Tebbe, C. Liedtke, R. E. Kates, D. Hofmann, R. Wuerstlein, H. H. Kreipe, U. Nitz, West German Study Group ADAPT HER2⫹/HR⫹ Investigators 10:12 AM Phase III, randomized study of trastuzumab emtansine (T-DM1) ⴞ pertuzumab (P) vs trastuzumab ⴙ taxane (HT) for first-line treatment of HER2-positive MBC: Primary results from the MARIANNE study. (Abstract 507) P. A. Ellis, C. H. Barrios, W. Eiermann, M. Toi, Y. Im, P. F. Conte, M. Martin, T. Pienkowski, X. B. Pivot, H. A. Burris III, A. Strasak, M. Patre, E. A. Perez 203 MONDAY Monday, June 1, 2015 Monday, June 1, 2015 10:24 AM Neratinib after adjuvant chemotherapy and trastuzumab in HER2-positive early breast cancer: Primary analysis at 2 years of a phase 3, randomized, placebo-controlled trial (ExteNET). (Abstract 508) A. Chan, S. Delaloge, F. Holmes, B. Moy, H. Iwata, V. J. Harvey, N. J. Robert, T. Silovski, E. Gokmen, G. Von Minckwitz, B. Ejlertsen, S. K. Chia, J. Mansi, C. H. Barrios, M. Gnant, A. Wong, R. Bryce, B. Yao, M. Martin 10:36 AM Shanu Modi, MD (Discussion of Abstract(s) 505–508) Memorial Sloan Kettering Cancer Center HER2-Positive Breast Cancer: Beyond Trastuzumab 10:48 AM Panel Question and Answer 8:00 AM - 11:00 AM Oral Abstract Session Gynecologic Cancer Location: E354b John K. Chan, MD—Co-Chair Palo Alto Medical Foundation Rebecca Sophie Kristeleit, MD, PhD—Co-Chair University College London Cancer Institute MONDAY 8:00 AM A randomized phase II study of paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, and ixabepilone/carboplatin/bevacizumab as initial therapy for measurable stage III or IVA, stage IVB or recurrent endometrial cancer, GOG-86P. (Abstract 5500) C. Aghajanian, V. L. Filiaci, D. S. Dizon, J. Carlson, M. A. Powell, A. A. Secord, K. S. Tewari, D. Bender, D. M. O’Malley, A. Stuckey, J. Rotmensch, D. A. Levine, H. A. Lankes, K. N. Moore 8:12 AM Adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer: Toxicity and quality-of-life results of the randomized PORTEC-3 trial. (Abstract 5501) C. L. Creutzberg, S. M. de Boer, H. Putter, M. Powell, L. R. Mileshkin, D. Katsaros, P. Bessette, C. HaieMeder, J. A. Ledermann, P. B. Ottevanger, P. Khaw, A. Colombo, A. W. Fyles, M. Baron, H. W. Nijman, R. A. Nout, V. T. Smit, K. Verhoeven-Adema, R. F. Kruitwagen, H. C. Kitchener 8:24 AM Randomized phase II trial of carboplatin-paclitaxel (CP) compared to carboplatin-paclitaxel-bevacizumab (CP-B) in advanced (stage III-IV) or recurrent endometrial cancer: The MITO END-2 trial. (Abstract 5502) D. Lorusso, G. Ferrandina, N. Colombo, S. Pignata, V. Salutari, G. Maltese, C. Pisano, M. Lapresa, A. Savarese, P. Tagliaferri, R. Sorio, S. Cinieri, E. Breda, R. Sabbatini, S. Lepori, C. Conte, S. C. Cecere, F. Raspagliesi, G. Scambia 8:36 AM Rebecca Sophie Kristeleit, MD, PhD (Discussion of Abstract(s) 5500 –5502) University College London Cancer Institute Endometrial Cancer: Catching up on Recent Data 8:48 AM Panel Question and Answer 9:00 AM Impact of trebananib plus weekly paclitaxel on overall survival (OS) in patients (pts) with recurrent ovarian cancer and ascites: Results from the phase III TRINOVA-1 study. (Abstract 5503) B. J. Monk, A. Poveda, I. Vergote, F. Raspagliesi, K. Fujiwara, D. Bae, A. Oaknin, I. Ray-Coquard, D. M. Provencher, B. Y. Karlan, C. Lhommé, G. Richardson, D. Gallardo Rincon, R. L. Coleman, A. Brize, K. Zhang, F. D. Vogl, B. A. Bach, A. M. Oza 204 Monday, June 1, 2015 Efficacy and safety of chemotherapy (CT) ⴞ pertuzumab (P) for platinumresistant ovarian cancer (PROC): AGO-OVAR 2.20/ENGOT-ov14/PENELOPE double-blind placebo-controlled randomized phase III trial. (Abstract 5504) C. Kurzeder, I. Bover, F. Marmé, J. Rau, P. Pautier, N. Colombo, D. Lorusso, P. Ottevanger, M. Bjurberg, C. Marth, P. Barretina-Ginesta, I. Vergote, A. Floquet, J. Del Campo, S. Mahner, L. Bastiere-Truchot, L. Mitchell, S. Polleis, A. Du Bois, A. Gonzalez-Martin 9:24 AM Retrospective analysis of candidate predictive tumor biomarkers (BMs) for efficacy in the GOG-0218 trial evaluating front-line carboplatin–paclitaxel (CP) ⴞ bevacizumab (BEV) for epithelial ovarian cancer (EOC). (Abstract 5505) M. J. Birrer, Y. Choi, M. F. Brady, R. S. Mannel, R. A. Burger, W. WEI, A. Husain, C. Bais, NRG Oncology/Gynecologic Oncology Group 9:36 AM Don S. Dizon, MD (Discussion of Abstract(s) 5503–5505) Massachusetts General Hospital Added Value or Splitting Hairs? Adding Targeted Therapy to the Mix 9:48 AM Panel Question and Answer 10:00 AM An international, biomarker-directed, randomized, phase II trial of AZD1775 plus paclitaxel and carboplatin (P/C) for the treatment of women with platinum-sensitive, TP53-mutant ovarian cancer. (Abstract 5506) A. M. Oza, J. I. Weberpals, D. M. Provencher, E. Grischke, M. Hall, D. Uyar, M. D. EstevezDiz, F. Marmé, A. Kuzmin, P. Rosenberg, R. M. Wenham, J. Qiu, M. A. Lee, J. Liu, S. Rose, K. N. Moore 10:12 AM A phase I study of continuous veliparib in combination with IV carboplatin/paclitaxel or IV/IP paclitaxel/cisplatin and bevacizumab in newly diagnosed patients with previously untreated epithelial ovarian, fallopian tube, or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. (Abstract 5507) K. M. Bell-McGuinn, W. E. Brady, R. J. Schilder, P. M. Fracasso, K. N. Moore, J. L. Walker, L. R. Duska, C. A. Mathews, A. Chen, S. P. Shepherd, V. L. Giranda, C. Aghajanian 10:24 AM Results of ARIEL2: a Phase 2 trial to prospectively identify ovarian cancer patients likely to respond to rucaparib using tumor genetic analysis. (Abstract 5508) I. A. McNeish, A. M. Oza, R. L. Coleman, C. L. Scott, G. E. Konecny, A. Tinker, D. M. O’Malley, J. Brenton, R. S. Kristeleit, K. Bell-McGuinn, A. Oaknin, A. Leary, K. Lin, M. Raponi, H. Giordano, S. Goble, L. Rolfe, R. Yelensky, A. R. Allen, E. M. Swisher 10:36 AM Elise C. Kohn, MD (Discussion of Abstract(s) 5506 –5508) National Cancer Institute at the National Institutes of Health A Wee Bit of DNA Repair Inhibition 10:48 AM Panel Question and Answer MONDAY 9:12 AM 8:00 AM - 11:00 AM Oral Abstract Session Patient and Survivor Care Location: S102 Shari Beth Goldfarb, MD—Co-Chair Memorial Sloan Kettering Cancer Center Karen L. Smith, MD—Co-Chair Washington Cancer Institute, MedStar Washington Hospital Center 8:00 AM Phase III trials of anamorelin in patients with advanced non-small cell lung cancer (NSCLC) and cachexia (ROMANA 1 and 2). (Abstract 9500) J. S. Temel, D. C. Currow, K. Fearon, Y. Yan, J. Friend, A. P. Abernethy 205 Monday, June 1, 2015 MONDAY 8:12 AM CALGB 70604 (Alliance): A randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer. (Abstract 9501) A. L. Himelstein, R. Qin, P. J. Novotny, D. K. Seisler, J. L. Khatcheressian, J. D. Roberts, S. S. Grubbs, T. O’Connor, D. Weckstein, C. L. Loprinzi, C. L. Shapiro 8:24 AM Olanzapine versus fosaprepitant for the prevention of nausea and vomiting in patients receiving concurrent chemoradiation treatment. (Abstract 9502) R. M. Navari, C. K. Nagy 8:36 AM Jamie H. Von Roenn, MD (Discussion of Abstract(s) 9500 –9502) American Society of Clinical Oncology Evidenced-Based Symptom Management: Worth the Weight 8:48 AM Panel Question and Answer 9:00 AM Chemotherapy-related cognitive impairment (CRCI), and neurotransmitter signaling, longevity, and inflammation pathways in 366 breast cancer (BC) patients and 366 age-matched cancer-free controls: A prospective, nationwide, longitudinal URCC NCORP study. (Abstract 9503) M. C. Janelsins, S. Yao, K. M. Mustian, L. J. Peppone, C. E. Heckler, B. Esparaz, J. K. Giguere, R. Irwin, B. Neilan, T. Ahles, C. B. Ambrosone, G. R. Morrow 9:12 AM EXCAP exercise effects on cognitive impairment and inflammation: A URCC NCORP RCT in 479 cancer patients. (Abstract 9504) K. M. Mustian, M. C. Janelsins, L. J. Peppone, C. S. Kamen, J. J. Guido, C. E. Heckler 9:24 AM To Be Determined (Discussion of Abstract(s) 9503–9504) Cognition: Something to Think About 9:36 AM Panel Question and Answer 9:48 AM Randomized trial of exercise on quality of life and fatigue in women diagnosed with ovarian cancer: The Women’s Activity and Lifestyle Study in Connecticut (WALC). (Abstract 9505) Y. Zhou, L. Gottlieb, B. Cartmel, F. Li, E. A. Ercolano, M. Harrigan, R. McCorkle, J. A. Ligibel, V. E. Von Gruenigen, R. Gogoi, P. E. Schwartz, H. A. Risch, M. L. Irwin 10:00 AM Results of the exercise and nutrition to enhance recovery and good health for you (ENERGY) trial: A behavioral weight loss intervention in overweight or obese breast cancer survivors. (Abstract 9506) C. L. Rock, S. Flatt, T. Byers, G. A. Colditz, W. Demark-Wahnefried, P. A. Ganz, K. Y. Wolin, A. D. Elias, H. Krontiras, J. Liu, M. Naughton, B. Pakiz, B. A. Parker, R. L. Sedjo, H. Wyatt, Exercise and Nutrition to Enhance Recovery and Good Health for You (ENERGY) Trial Group 10:12 AM The impact of physical activity on fatigue and quality of life in lung cancer patients: A randomised controlled trial (RCT). (Abstract 9507) J. L. Vardy, M. Bell, H. van der Ploeg, J. Turner, M. Kabourakis, L. Spencer, C. R. Lewis, R. Hui, P. L. Blinman, S. J. Clarke, M. J. Boyer, H. M. Dhillon 10:24 AM Impact of the LIVESTRONG at the YMCA Program on physical activity, fitness, and quality of life in cancer survivors. (Abstract 9508) M. L. Irwin, B. Cartmel, M. Harrigan, T. B. Sanft, C. Wong, M. Hughes, N. Hootsmans, B. Winterhalter, L. Shockro, K. O’Connor, S. M. Tolaney, E. L. Mayer, R. L. Yung, R. A. Freedman, J. A. Ligibel 10:36 AM Lee Jones, PhD (Discussion of Abstract(s) 9505–9507) Memorial Sloan Kettering Cancer Center Fit for Life 10:48 AM Panel Question and Answer 206 Monday, June 1, 2015 8:00 AM - 11:00 AM Oral Abstract Session Pediatric Oncology II Location: S504 Lisa Diller, MD—Co-Chair Dana-Farber Cancer Institute and Harvard Medical School 8:00 AM Augmentation of therapy for favorable-histology Wilms tumor with combined loss of heterozygosity of chromosomes 1p and 16q: A report from the Children’s Oncology Group studies AREN0532 and AREN0533. (Abstract 10009) D. B. Dix, C. V. Fernandez, Y. Chi, J. R. Anderson, E. A. Mullen, J. I. Geller, E. J. Gratias, G. Khanna, J. A. Kalapurakal, E. J. Perlman, N. Seibel, P. F. Ehrlich, M. H. Malogolowkin, K. W. Gow, T. E. Hamilton, P. E. Grundy, J. Dome 8:12 AM Outcome and prognostic factors in stage III favorable histology Wilms tumor (FHWT): A report from the Children’s Oncology Group (COG) study AREN0532. (Abstract 10010) C. V. Fernandez, E. A. Mullen, P. F. Ehrlich, J. A. Kalapurakal, G. Khanna, Y. Chi, E. Perlman, A. Paulino, T. E. Hamilton, K. W. Gow, F. A. Ferrer, Z. Tochner, Q. An, F. A. Hoffer, J. Withycombe, R. C. Shamberger, J. I. Geller, J. R. Anderson, P. E. Grundy, J. S. Dome, AREN0532 Study Committee 8:24 AM Omission of lung radiation in patients with stage IV favorable histology Wilms tumor (FHWT) showing complete lung nodule response after chemotherapy: A report from Children’s Oncology Group study AREN0533. (Abstract 10011) D. B. Dix, E. J. Gratias, N. Seibel, J. R. Anderson, E. A. Mullen, J. I. Geller, G. Khanna, J. A. Kalapurakal, E. J. Perlman, P. F. Ehrlich, M. H. Malogolowkin, P. E. Grundy, J. S. Dome 8:36 AM Daniel M. Green, MD (Discussion of Abstract(s) 10009 –10011) St. Jude Children’s Research Hospital Impact of Improved Risk Stratification in Wilms Tumor 8:48 AM Panel Question and Answer 9:00 AM Risk-based treatment for synovial sarcoma in patients under 30 years of age: Children’s Oncology Group study ARST0332. (Abstract 10012) R. Venkatramani, J. R. Anderson, L. Million, C. M. Coffin, B. McCarville, R. Randall, D. Parham, S. C. Kao, A. A. Hayes-Jordan, S. L. Wolden, S. A. Terezakis, J. O. Black, F. Laurie, R. A. Speights, S. Skapek, D. S. Hawkins, S. L. Spunt 9:12 AM Long-term risks for chronic medical conditions and premature mortality in survivors of pediatric soft tissue sarcoma: A report from the Childhood Cancer Survivor Study (CCSS). (Abstract 10013) E. L. Mueller, R. J. Hutchinson, P. Goodman, W. M. Leisenring, C. A. Sklar, M. M. Hudson, K. K. Ness, G. T. Armstrong, L. L. Robison, M. Stovall, K. C. Oeffinger, P. C. Nathan 9:24 AM Association of recurrent or progressive p of form types II and III pleuropulmonary blastoma (PPB) with poor outcome: A report from the international PPB registry. (Abstract 10014) K. P. Schultz, G. M. Williams, D. Stewart, P. S. Rosenberg, L. A. Doros, L. P. Dehner, D. A. Hill, Y. H. Messinger 9:36 AM Steven G. DuBois, MD (Discussion of Abstract(s) 10012–10013) University of California, San Francisco Rare Pediatric Solid Tumors: From Infancy to Survivorship 9:48 AM Panel Question and Answer 10:00 AM Early results from Children’s Oncology Group (COG) ARST08P1: Pilot studies of cixutumumab or temozolomide with intensive multiagent chemotherapy for patients with metastatic rhabdomyosarcoma (RMS). (Abstract 10015) S. Malempati, B. Weigel, J. R. Anderson, D. Parham, L. A. Teot, D. A. Rodeberg, T. I. Yock, B. L. Shulkin, D. S. Hawkins 207 MONDAY Noah Federman, MD—Co-Chair University of California, Los Angeles Monday, June 1, 2015 10:12 AM Banked EBV-specific T-cells from HLA-partially matched normal donors to induce durable remissions rituximab refractory EBVⴙ B-cell lymphomas post hematopoietic and organ allografts. (Abstract 10016) S. Prockop, E. Doubrovina, K. Baroudy, F. Boulad, R. Khalaf, E. B. Papadopoulos, C. S. Sauter, V. Szenes, S. Suser, G. Wasilewski, J. Ruggiero, R. J. O’Reilly 10:24 AM A feasibility and phase II study of the hu14.18-IL2 immunocytokine in combination with GM-CSF and isotretinoin in patients with recurrent or refractory neuroblastoma: A Children’s Oncology Group study. (Abstract 10017) S. Shusterman, W. B. London, J. A. Hank, M. T. Parisi, B. L. Shulkin, S. Servaes, A. Naranjo, H. Shimada, J. Gan, S. Gillies, J. M. Maris, J. R. Park, P. M. Sondel 10:36 AM Crystal Mackall, MD (Discussion of Abstract(s) 10014 –10017) National Cancer Institute at the National Institutes of Health Antibody and Cellular Therapy in Pediatric Oncology: Mechanisms and Future Directions 10:48 AM Panel Question and Answer 8:00 AM - 11:30 AM Poster Session Gastrointestinal (Colorectal) Cancer Location: S Hall A Abstracts 3509 –3520 will be session during the Gastrointestinal (Colorectal) Cancer Poster Discussion Session. See page 254 for session information. MONDAY Board 1 Exploring the poor outcomes of BRAF mutant (BRAF mut) advanced colorectal cancer (aCRC): Analysis from 2,530 patients (pts) in randomized clinical trials (RCTs). (Abstract 3509) J. F. Seligmann, D. Fisher, F. Elliott, S. Richman, R. Butler, J. Cheadle, R. A. Adams, P. Quirke, T. Maughan, M. T. Seymour, G. W. Middleton Board 2 FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as initial treatment for metastatic colorectal cancer (TRIBE study): Updated survival results and final molecular subgroups analyses. (Abstract 3510) F. Loupakis, C. Cremolini, C. Antoniotti, S. Lonardi, M. Ronzoni, A. Zaniboni, G. Tonini, L. Salvatore, S. Chiara, C. Carlomagno, C. Banzi, F. Negri, L. Marcucci, C. Barone, G. Fontanini, N. Borrelli, M. Giordano, E. Macerola, L. Boni, A. Falcone Board 3 Phase Ib study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated metastatic colorectal cancer and advanced cancers. (Abstract 3511) D. S. Hong, V. K. Morris II, B. E. El Osta, S. Fu, M. J. Overman, S. A. Piha-Paul, V. Subbiah, B. K. Kee, A. M. Tsimberidou, R. Zinner, D. R. Fogelman, J. Bellido, I. Shureiqi, F. Meric-Bernstam, S. Kopetz Board 4 Randomized phase III study of adjuvant chemotherapy with S-1 versus capecitabine (cape) in patients with stage III colon cancer (CC): Results of Japan Clinical Oncology Group study (JCOG0910). (Abstract 3512) T. Hamaguchi, Y. Shimada, J. Mizusawa, Y. Kinugasa, Y. Kanemitsu, M. Ohue, S. Fujii, N. Takiguchi, T. Yatsuoka, Y. Takii, H. Ojima, H. Masuko, Y. Kubo, H. Mishima, T. Yamaguchi, H. Bandou, T. Sato, T. Kato, K. Nakamura, H. Fukuda, JCOG Colorectal Cancer Study Group Board 5 Cochrane systematic review and meta-analysis of adjuvant therapy for stage II colon cancer. (Abstract 3513) B. M. Meyers, H. O. Al-Shamsi, A. T. Figueredo Board 6 Toxicity and quality of life data from SCOT: An international phase III randomized (1:1) noninferiority trial comparing 3 vs 6 months of oxaliplatinbased adjuvant chemotherapy. (Abstract 3514) T. Iveson, R. Kerr, M. P. Saunders, A. M. Waterston, N. H. Hollander, L. C. Medley, J. Tabernero, C. Wilson, R. Ellis, S. Essapen, A. M. Haydon, A. S. Dhadda, R. Hughes, S. Falk, S. Abdel-Raouf, B. Glimelius, K. Allan, W. Barlow, A. Briggs, J. Paul 208 Board 7 A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC). (Abstract 3515) A. Murata, K. Yoshida, K. Maeda, K. Ikejiri, Y. Munemoto, K. Sasaki, C. Matsuda, M. Kotake, T. Suenaga, H. Matsuda, H. Baba, C. Hamada, E. Oki, Y. Emi, S. Saji, Y. Maehara Board 8 S0713: A phase II study of cetuximab (CET) added to induction chemotherapy (ICT) of oxaliplatin (OX) and capecitabine (CAP), followed by neoadjuvant chemoradiation (NACR) for locally advanced rectal cancer (LARC). (Abstract 3516) C. G. Leichman, S. L. McDonough, S. R. Smalley, K. G. Billingsley, H. Lenz, M. A. Beldner, A. F. Hezel, M. R. Velasco, K. A. Guthrie, C. D. Blanke, H. S. Hochster Board 9 Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer (LARC): Final results of a phase Ib study. (Abstract 3517) M. Michael, M. F. Mulcahy, D. A. Deming, H. Vaghefi, G. S. Jameson, A. DeLuca, H. Xiong, W. Munasinghe, M. W. Dudley, P. Komarnitsky, K. D. Holen, B. G. Czito Board 10 Compliance to chemoradiation (CRT) using mitomycin (MMC) or cisplatin (CisP), with or without maintenance 5FU/CisP chemotherapy (CT) in squamous cell carcinoma of the anus (SCCA) according to radiotherapy (RT) dose, overall treatment time (OTT) and chemotherapy (CT) and their impact on long-term outcome: Results of ACT II. (Abstract 3518) R. Glynne-Jones, H. M. Meadows, A. Lopes, R. A. Adams, D. Sebag-Montefiore Board 11 Comprehensive multiplatform biomarker analysis of 212 anal squamous cell carcinomas. (Abstract 3519) P. M. Boland, J. Wang, D. Arguello, S. Z. Millis, Z. Gatalica, S. K. Reddy, J. E. Meyer, T. R. Halfdanarson Board 12 Checkpoint kinase (CHK) 1/2 inhibitor LY2606368 in a phase I, dose-expansion study in patients (pts) with metastatic squamous cell carcinoma (mSCC) of the anus. (Abstract 3520) J. C. Bendell, C. Eng, K. N. Moore, H. A. Burris III, F. Meric-Bernstam, S. F. Jones, S. A. Piha-Paul, J. R. Infante, V. Subbiah, T. M. Bauer, L. Golden, J. Lin, R. Martinez, S. Wijayawardana, A. K. Lin, D. S. Hong Board 13 Role of race and socioeconomic status in overall and cancer-specific survival of anal cancer patients. (Abstract 3521) J. Belmonte, T. H. Taylor, J. Carmichael, J. A. Zell Board 14 Comprehensive genomic profiling of anal squamous cell carcinoma to reveal frequency of clinically relevant genomic alterations in the PI3K/mTOR pathway. (Abstract 3522) E. M. Sanford, S. M. Ali, J. A. Elvin, G. M. Frampton, J. Sun, N. A. Palma, J. Chmielecki, R. Yelensky, D. Lipson, V. A. Miller, P. J. Stephens, J. S. Ross Board 15 Programmed cell death-Ligand 1 (PD-L1) expression and outcome in patients with squamous cell cancer of anal canal (SCCAC). (Abstract 3523) S. Gujja, S. K. Williamson, A. Batra, A. M. Saeed, K. Lai, B. J. Fogel, J. D. James, E. R. Siegel, R. Govindarajan Board 16 Sequential liver and lung resection for colorectal cancer metastases: In which patients should surgery be proposed? (Abstract 3524) M. Rajakannu, P. Magdeleinat, E. Vibert, P. F. Innominato, O. Ciacio, G. Pittau, M. Gelli, A. Sa Cunha, D. Cherqui, F. Levi, D. Castaing, J. F. Morere, R. Adam Board 17 Impact of UGT1A1 genotype on prognosis in Japanese advanced colorectal cancer patients treated by irinotecan-based regimens. (Abstract 3525) W. Ichikawa, K. Uehara, K. Minamimura, C. Tanaka, Y. Takii, H. Miyauchi, S. Sadahiro, K. Shinozaki, K. Fukumoto, T. Otsuji, T. Kambara, S. Morita, Y. Ando, Y. Okutani, M. Sugihara, T. Sugiyama, Y. Ohashi, Y. Sakata Board 18 Masitinib plus FOLFIRI for second line treatment of metastatic colorectal cancer: An open label phase Ib/II trial. (Abstract 3526) J. Taieb, C. Borg, T. Lecomte, C. Lepère, T. Chatellier, D. M. Smith, P. Dubreuil, C. Mansfield, A. Moussy, O. Hermine 209 MONDAY Monday, June 1, 2015 Monday, June 1, 2015 MONDAY Board 19 A phase II study of NK012, a polymeric micelle formulation of SN-38, in colorectal cancer patients who had received prior oxaliplatin-based regimen. (Abstract 3527) A. Tsuji, T. Hamaguchi, K. Yamaguchi, K. Takeda, H. Uetake, T. Esaki, K. Amagai, N. Sugimoto, H. Baba, M. Kimura, Y. Matsumura, Y. Nambu Board 20 Can we use radiofrequency ablation for liver metastases from colorectal cancer over 25 mm initially but downsized by systemic chemotherapy? (Abstract 3528) L. Benhaim, F. Peschaud, M. El hajjam, R. Malafosse, J. Sellier, C. Julie, A. Beauchet, P. Rougier, B. Nordlinger Board 21 Long-term follow-up of bone marrow micrometastases in colon cancer patients. (Abstract 3529) C. T. Viehl, U. Guller, M. Ramser, S. Dell-Kuster, B. Weixler, G. Sauter, L. Terracciano, R. Rosenthal, D. Oertli, M. Zuber Board 22 Phase I study of anti-VEGF receptor-3 (VEGFR-3) monoclonal antibody (mab) LY3022856/IMC-3C5 (3C5). (Abstract 3530) W. M. Saif, J. A. Knost, E. G. Chiorean, S. Kambhampati, D. Yu, B. Pytowski, A. Qin, J. S. Kauh, B. H. O’Neil Board 23 Relationship between metformin use and recurrence and survival in patients (pts) with resected stage III colon cancer (CC) receiving adjuvant chemotherapy: Results from NCCTG N0147 (Alliance). (Abstract 3531) P. Singh, Q. Shi, N. R. Foster, A. Grothey, S. Nair, E. Chan, A. F. Shields, R. M. Goldberg, S. Gill, M. S. Kahlenberg, F. A. Sinicrope, D. J. Sargent, S. R. Alberts Board 24 DPYD c.1905ⴙ1G>A and c.2846A>T and UGT1A1*28 allelic variants as predictors of toxicity: Pharmacogenetic translational analysis from the phase III TRIBE study in metastatic colorectal cancer. (Abstract 3532) M. Del Re, C. Cremolini, F. Loupakis, F. Marmorino, V. Citi, M. Palombi, F. Bergamo, M. Schirripa, D. Rossini, E. Cortesi, G. Tomasello, R. Spadi, A. Buonadonna, D. Amoroso, S. Vitello, S. Di Donato, C. Granetto, M. D’Amico, R. Danesi, A. Falcone Board 25 Dual targeting of vascular endothelial growth factor-A (VEGF-A) and angiopoietins (Ang) without chemotherapy in metastatic colorectal cancer (mCRC): Results of the VENGEANCE study. (Abstract 3533) J. Mooi, G. Chong, S. Brown, R. Wong, T. J. Price, E. Skrinos, N. C. Tebbutt Board 27 Tumor response outcomes in first-line treatment of wild-type (WT) RAS metastatic colorectal carcinoma (mCRC) following modified FOLFOX6 (mFOLFOX6) ⴙ either panitumumab (pmab) or bevacizumab (bev). (Abstract 3535) F. Rivera, M. Karthaus, J. R. Hecht, G. Fasola, J. Canon, R. Koukakis, J. Terwey, L. S. Schwartzberg Board 28 Expression of amphiregulin (AREG) and response to first-line panitumumab (pmab) ⴙ FOLFIRI in metastatic colorectal cancer (mCRC). (Abstract 3536) C. Kohne, R. D. Hofheinz, L. Mineur, H. Letocha, R. Greil, J. Thaler, B. Twomey, K. S. Oliner, M. Boedigheimer, J. Terwey, M. Karthaus Board 29 A phase II, randomized, double-blinded, placebo-controlled study of simtuzumab or placebo in combination with FOLFIRI for the second line treatment of metastatic KRAS mutant colorectal adenocarcinoma. (Abstract 3537) J. R. Hecht, J. C. Bendell, D. Vyushkov, K. Bencardino, U. N. Verma, Y. Yang, D. L. Thai Board 30 Population-based assessment of surrogate endpoints (SE) in stage I-III colon (CCa) and rectal cancers (RCa). (Abstract 3538) R. M. Lee-Ying, C. Speers, G. Gresham, Y. J. McConnell, W. Y. Cheung, H. F. Kennecke Board 31 Risk factors for interval advanced colorectal neoplasia after screening colonoscopy. (Abstract 3539) L. W. Musselwhite, C. M. Thomas, D. H. Abbott, E. R. Hauser, L. K. Wagner, S. F. Morris, D. G. Weiss, D. A. Lieberman, D. T. Provenzale Board 32 A phase Ib study of AUY922 and cetuximab in patients with KRAS wild-type (WT) metastatic colorectal cancer (mCRC). (Abstract 3540) S. Subramaniam, G. E. Goodman, B. Boatman, A. W. Smith, D. Iriarte, P. J. Gold Board 33 PRODIGE 20: Bevacizumab ⴙ chemotherapy (BEV-CT) versus chemotherapy alone (CT) in elderly patients (pts) with untreated metastatic colorectal cancer (mCRC)—A randomized phase II trial. (Abstract 3541) T. Aparicio, O. 210 Monday, June 1, 2015 Board 34 A prospective, multi-center study of individualized, pharmacokinetically (PK)-guided dosing of 5-fluorouracil (5-FU) in metastatic colorectal cancer (mCRC) patients treated with weekly or biweekly 5-FU/oxaliplatin containing regimens. (Abstract 3542) V. Kunzmann, K. Link, M. C. Miller, S. Holdenrieder, T. Bertsch, L. Mueller, Y. Ko, O. J. Stoetzer, I. Suttmann, J. Braess, U. Jaehde, M. Roessler, B. Moritz, S. Kraff, A. Fritsch, S. J. Salamone, M. Wilhelm Board 35 The PRIME trial: Quality-adjusted survival in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) receiving first-line therapy with panitumumab plus FOLFOX versus FOLFOX alone. (Abstract 3543) J. Wang, J. Dong, G. Hechmati, A. Rong, G. Maglinte, B. L. Barber, J. Douillard Board 36 An investigator initiated multicenter phase I/II study of TAS-102 with bevacizumab for metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE). (Abstract 3544) Y. Kuboki, T. Nishina, E. Shinozaki, K. Yamazaki, K. Shitara, W. Okamoto, T. Kajiwara, T. Matsumoto, T. Tsushima, N. Mochizuki, M. Fukutani, M. Nakamoto, H. Hasegawa, A. Sugama, S. Nomura, A. Sato, A. Ohtsu, T. Yoshino Board 37 Association between c-Met expression, miR-31–3p expression and progression free survival in the New EPOC study. (Abstract 3545) S. A. Pugh, J. A. Bridgewater, K. Moutasim, G. Thomas, P. Laurent-Puig, R. Thiébaut, F. Liebaert, A. H. Mirnezami, M. Lopez, T. Mellows, S. Falk, M. Finch-Jones, J. W. Valle, M. Rees, J. Hornbuckle, L. Stanton, O. J. Garden, D. Cunningham, T. Maughan, J. N. Primrose Board 38 Therapy of gastrointestinal malignancies with an anti-Trop-2-SN-38 antibody drug conjugate (ADC) (sacituzumab govitecan): Phase I/II clinical experience. (Abstract 3546) A. Starodub, A. J. Ocean, W. A. Messersmith, V. J. Picozzi, M. J. Guarino, A. Bardia, S. S. Thomas, J. Berlin, M. A. Shah, P. P. Maliakal, W. A. Wegener, R. M. Sharkey, F. Wilhelm, D. M. Goldenberg Board 39 Evaluation of miR 31 3p as a biomarker of prognosis and panitumumab benefit in RAS-wt advanced colorectal cancer (aCRC): Analysis of patients (pts) from the PICCOLO trial. (Abstract 3547) P. Laurent-Puig, S. Paget-Bailly, D. Vernerey, C. Vazart, V. Decaulne, K. Fontaine, F. Rousseau, F. Elliott, P. Quirke, S. Richman, J. Seligman, M. T. Seymour, F. Bonnetain, F. Liebaert, R. Thiébaut Board 40 C-reactive protein and interleukin-6 as markers of systemic inflammatory response and as prognostic factors for metastatic colorectal cancer. Data from the randomized phase III NORDIC-VII study. (Abstract 3548) M. Thomsen, C. Kersten, H. Sorbye, E. Skovlund, T. Ikdahl, J. S. Johansen, P. Pfeiffer, B. Glimelius, K. Tveit, T. Guren Board 41 Epidermal growth factor receptor mutations may confer resistance or cross-resistance to cetuximab and panitumumab and can be detected in circulating tumor DNA. (Abstract 3549) M. Binder, F. Braig, A. Schieferdecker, A. Schulte, A. Stein, T. Grob, M. Kriegs, E. Engel, U. J. Vanhoefer, S. Loges, K. Riecken, B. Fehse, C. Bokemeyer Board 42 PIK3CA mutations in colorectal and endometrial cancer with double somatic mismatch repair mutations compared to Lynch syndrome. (Abstract 3550) S. Shiovitz, E. Turner, M. Beightol, A. Jacobson, T. Gooley, S. J. Salipante, S. Haraldsdottir, J. F. Tait, W. M. Grady, E. H. Lin, A. De La Chapelle, D. E. Cohn, P. J. Goodfellow, M. Arnold, H. Hampel, C. C. Pritchard Board 43 A simplified nomogram to predict long-term survival after conversion chemotherapy followed by hepatectomy for initially unresectable colorectal liver metastases. (Abstract 3551) K. Imai, M. Allard, C. Castro Benitez, E. Vibert, A. Sa Cunha, D. Cherqui, D. Castaing, H. Baba, R. Adam Board 44 Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcome of bevacizumab (bev)-based treatment in patients with 211 MONDAY Bouche Sr., E. Francois, E. Maillard, S. Kirscher, J. Taïeb, P. Etienne, R. Faroux, F. Khemissa, F. El Hajbi, C. Locher, Y. Rinaldi, T. Lecomte, S. Lavau-Denes, M. Baconnier, A. Oden-Gangloff, D. Genet, E. Paillaud, F. Retornaz, L. Bedenne Monday, June 1, 2015 metastatic colorectal cancer (mCRC): Results from TRIBE and FIRE3 trials. (Abstract 3552) Y. Sunakawa, S. Stintzing, V. Heinemann, C. Cremolini, A. Falcone, S. Cao, D. Yang, W. Zhang, S. Yamauchi, Y. Ning, S. Stremitzer, S. Matsusaka, A. Parekh, S. Graver, A. Mendez, S. Okazaki, R. Elkhoueiry, S. J. Scherer, F. Loupakis, H. Lenz MONDAY Board 45 Comprehensive genomic profiling of clinically advanced colorectal carcinoma to reveal frequent opportunities for targeted therapies. (Abstract 3553) J. S. Ross, K. Wang, D. Khaira, A. Johnson, J. Chmielecki, S. M. Ali, J. A. Elvin, J. Vergilio, R. Yelensky, D. Lipson, V. A. Miller, P. J. Stephens Board 46 Genetic variant of TWEAK to predict clinical outcome in mCRC patients (pts) treated with first line FOLFIRI and Bevacizumab (FOLFIRI/BEV) in FIRE-3 and TRIBE cohorts. (Abstract 3554) A. Parekh, Y. Ning, S. Stintzing, F. Loupakis, W. Zhang, D. Yang, Y. Sunakawa, S. Stremitzer, S. Matsusaka, S. Okazaki, R. Elkhoueiry, A. Mendez, A. Barzi, M. Schirripa, V. Heinemann, H. Lenz Board 47 Calculators for overall survival (OS) and progression-free survival (PFS) in metastatic colorectal cancer (mCRC): Construction from 19,678 ARCAD patients. (Abstract 3555) K. M. Sjoquist, C. Bokemeyer, L. A. Renfro, J. Simes, N. C. Tebbutt, S. J. Clarke, R. Adams, C. J. Punt, E. Van Cutsem, J. Douillard, J. R. Hecht, V. Heinemann, I. Sougklakos, E. Diaz-Rubio, R. Porschen, J. P. Meyers, W. I. Gonsalves, D. J. Sargent, A. De Gramont, J. R. Zalcberg, Fondation Aide et Récherce en Cancerologie Digestive (ARCAD) Group Board 48 Predicting individualized post-operative survival for colorectal cancer using a new mobile application derived from the National Cancer Database. (Abstract 3556) E. M. Gabriel, P. Thirunavukarasu, E. Al-Sukhni, K. Attwood, S. J. Nurkin Board 49 Impact of primary tumor stage on survival following resection of metachronous liver and/or lung metastases in colorectal cancer. (Abstract 3557) H. Wong, V. Boolell, S. Kosmider, K. M. Field, R. Wong, J. D. Shapiro, P. Cooray, I. Hayes, I. Faragher, M. Steel, P. Gibbs Board 50 Molecular subtypes and outcomes in regorafenib-treated patients with metastatic colorectal cancer (mCRC) enrolled in the CORRECT trial. (Abstract 3558) M. Teufel, S. Schwenke, H. Seidel, G. Beckmann, J. Reischl, R. Vonk, H. Lenz, J. Tabernero, S. Siena, A. Grothey, E. Van Cutsem, M. Jeffers, S. Wilhelm, A. Wagner, D. Laurent, S. Kobina, M. D. Rutstein, P. Wirapati, J. Guinney, S. Tejpar Board 51 Two-stage hepatectomy for extensive colorectal liver metastases: How to predict the failure to complete both sequential procedures? (Abstract 3559) K. Imai, C. Castro Benitez, M. Allard, E. Vibert, A. Sa Cunha, D. Cherqui, D. Castaing, H. Baba, R. Adam Board 52 Effects of regorafenib (REG) therapy on health-related quality of life (HRQoL) in patients with metastatic colorectal cancer (mCRC) in the phase III CONCUR trial. (Abstract 3560) J. Chang, C. Ngai, D. Odom, C. Radder, C. Kappeler, R. Xu, S. Qin, T. Kim, J. Li Board 53 Moving foward and beyond the standard through a non-operative management in rectal cancer? Our watch and wait approach experience in Co-Recto. (Abstract 3561) I. S. Iseas, M. Carballido, M. Coraglio, F. Leiro, A. Dieguez, M. Eleta, R. Bianchi, C. Bertoncini, G. A. Mendez, M. E. Barugel, E. L. Roca Board 54 Effect of genetic variation on overall survival in a clinical trial of metastatic colorectal cancer (mCRC). (Abstract 3562) H. Lenz, F. Schumacher, F. Loupakis, C. Cremolini, Y. Ning, S. Stremitzer, Y. Sunakawa, S. Matsusaka, S. Okazaki, W. Zhang, A. Falcone Board 55 Improvement in long-term survival in patients with metastatic colorectal cancer (CRC) after liver resection with modern chemotherapy and hepatic arterial infusion (HAI). (Abstract 3563) N. E. Kemeny, J. F. Chou, T. M. Boucher, M. Capanu, R. P. DeMatteo, W. R. Jarnagin, T. P. Kingham, P. J. Allen, Y. Fong, A. Cercek, M. I. D’Angelica 212 Board 56 Phase 3 RECOURSE trial of TAS-102 versus placebo with best supportive care in patients with metastatic colorectal cancer: Geographic subgroups. (Abstract 3564) A. Ohtsu, T. Yoshino, M. M. Wahba, F. M. Benedetti, R. J. Mayer, E. Van Cutsem, RECOURSE Study Group Board 57 Using mutational load in next generation sequencing (NGS) to identify mismatch repair (MMR) deficiency in colorectal cancer (CRC). (Abstract 3565) F. Battaglin, Z. K. Stadler, A. Cercek, R. D. Yaeger, N. H. Segal, A. M. Varghese, N. E. Kemeny, M. R. Weiser, J. Garcia-Aguilar, J. Shia, M. F. Berger, J. F. Hechtman, M. E. Arcila, D. B. Solit, L. Saltz Board 58 Genomic analysis of colitis-associated cancers. (Abstract 3566) R. D. Yaeger, V. A. Miller, J. R. Kelsen, K. Wang, Y. He, E. M. Sanford, S. Balasubramanian, L. H. Tang, D. P. Kelsen Board 59 FOLFOX-aflibercept followed by maintenance therapy with fluoropyrimidineaflibercept as first-line therapy in patients with metastatic colorectal cancer: A GERCOR single-arm phase II study (VELVET). (Abstract 3567) B. Chibaudel, T. Andre, J. Bachet, D. Auby, J. Desramé, G. Deplanque, C. Lecaille, C. Louvet, C. Tournigand, V. Lebrun-Ly, J. Dauba, G. Lledo, M. Garcia, N. Baba Hamed, M. Wagner, M. Attia, A. Meurisse, A. Tijeras-Raballand, F. Bonnetain, A. De Gramont, GERCOR Board 60 Cetuximab biweekly plus mFOLFOX6 as first-line therapy in patients (pts) with KRAS wild-type (wt) (exon 2) metastatic colorectal cancer (mCRC): Primary endpoint and subgroup analysis of the CEBIFOX trial. (Abstract 3568) S. Kasper, J. Meiler, H. Knipp, T. Hoehler, P. Reimer, T. Steinmetz, W. Berger, G. Linden, S. Ting, P. Markus, A. Paul, A. Dechene, B. Schumacher, K. Kosbade, K. Worm, K. W. Schmid, T. Herold, M. H. Schuler, T. Trarbach Board 61 Phase I study of preoperative chemoradiation with temozolomide and capecitabine in patients with locally advanced rectal cancer. (Abstract 3569) Y. Hong, S. Park, J. Kim, K. Kim, J. Lee, J. Park, C. Yu, T. Kim Board 62 S-1 as adjuvant chemotherapy for stage III colon cancer: Updated outcomes of ACTS-CC trial. (Abstract 3570) Y. Kinugasa, M. Ishiguro, E. Nakatani, T. Endo, H. Shinozaki, Y. Takii, Y. Takahashi, H. Mochizuki, K. Kotake, S. Kameoka, K. Takahashi, T. Watanabe, M. Watanabe, N. Boku, N. Tomita, K. Sugihara, ACTSCC Study Group Board 63 Immunohistochemistry to initiate a complex screening cascade in the detection of Lynch syndrome. (Abstract 3571) G. O’Kane, T. P. McVeigh, D. Keegan, D. Flannery, K. O’Connor, M. P. Farrell, C. Shields, B. Meighan, P. McCormick, D. C. Winter, N. Mulligan, C. Muldoon, R. Geraghty, A. J. Green, M. J. Kennedy, K. Sheahan, D. J. Gallagher Board 64 Cost-effectiveness for extended RAS/RAF testing in metastatic colorectal cancer. (Abstract 3572) M. R. Al-hajeili, F. Elkhider, M. Tiba Board 65 Molecular classification of the invasive front in colorectal cancer. (Abstract 3573) D. McArt, P. Dunne, E. Kay, A. O’Grady, H. Barrett, K. Arthur, D. Longley, P. W. Hamilton, D. J. Waugh, M. Lawler, P. G. Johnston, M. Salto-Tellez, S. Van Schaeybroeck Board 66 Zonal differences in PD-1 expression in centre of tumour versus periphery in microsatellite stable and unstable colorectal cancer. (Abstract 3574) G. O’Kane, M. Lynch, S. Hooper, J. Aird, C. Muldoon, N. Mulligan, C. Loscher, D. J. Gallagher Board 67 A phase III, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of pregabalin in the prevention and reduction of oxaliplatin-induced painful neuropathy (PreOx). (Abstract 3575) D. C. de Andrade, M. J. Teixeira, R. Galhardoni, K. A. Ferreira, P. B. Malieno, N. Scisci, R. P. Riechelmann, W. G. Teixeira, D. F. Saragiotto, V. A. Silva, I. Raicher, I. de Castro, D. Parravano, J. T. Fukushima, J. Lefaucheur, D. Bouhassira, R. S. Macarenco, E. S. de Mello, P. M. Hoff, PreOx Workgroup Board 68 Placebo-controlled, double-blinded multi-center phase III trial of XELIRI/FOLFIRI plus simvastatin in metastatic colorectal cancer. (Abstract 213 MONDAY Monday, June 1, 2015 Monday, June 1, 2015 3576) S. Lim, T. Kim, S. Han, H. Kang, I. Hwang, J. Lee, M. Lee, H. Kim, S. Kim, J. Park, S. Park, Y. Park, H. Lim, J. Ham, S. Byeon, W. Kang MONDAY Board 69 A randomized controlled trial to evaluate laparoscopic versus open with Japanese D3 dissection for stage II,III colorectal cancer (CRC): First efficacy results from Japan Clinical Oncology Group Study JCOG0404. (Abstract 3577) T. Akagi, M. Inomata, H. Katayama, J. Mizusawa, T. Yamaguchi, T. Masaki, Y. Fukunaga, K. Murata, M. Okajima, Y. Munakata, T. Sato, H. Bandou, M. Yasui, M. Sekimoto, M. Watanabe, K. Sugihara, F. Konishi, T. Etoh, Y. Shimada, S. Kitano Board 70 Effect of Sym004 on acquired resistance to cetuximab in colorectal cancer (CRC) in a novel mouse avatar model. (Abstract 3578) D. B. Vangala, S. T. Liffers, M. Pohl, C. Teschendorf, A. Tannapfel, W. H. Schmiegel, S. Hahn Board 72 Long-term outcome after R1 resection for colorectal liver metastases: Is a cure possible? (Abstract 3579) I. Hosokawa, O. Ciacio, G. Pittau, M. Gelli, M. Allard, M. Sebagh, P. F. Innominato, D. Cherqui, A. Sa Cunha, E. Vibert, F. Levi, J. F. Morere, D. Castaing, R. Adam Board 73 Continuing single-agent capecitabin as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer. (Abstract 3580) R. Xu, Y. Li, H. Luo, W. Wang, Z. Wang, X. Yuan, F. Wang, D. Zhang, D. Ma, D. Lin, J. Jia, X. Hu, J. Peng Board 74 Baseline carcinoembryonic antigen (CEA) serum levels to predict bevacizumab-based treatment response in patients with KRAS exon wildtype metastatic colorectal cancer (mCRC) receiving 1st-line therapy with FOLFIRI plus cetuximab or bevacizumab (AIO KRK0306, FIRE3 trial). (Abstract 3581) M. Michl, L. Fischer von Weikersthal, T. Decker, A. Kiani, U. Vehling-Kaiser, S. Al-Batran, T. Heintges, C. Lerchenmueller, C. Kahl, G. Seipelt, F. Kullmann, M. Stauch, W. Scheithauer, J. Hielscher, M. Scholz, D. P. Modest, S. Stintzing, T. Kirchner, A. Jung, V. Heinemann Board 75 A phase III multicenter trial comparing two different sequences of second/third line therapy (irinotecan/cetuximab followed by FOLFOX-4 vs. FOLFOX-4 followed by irinotecan/cetuximab in K-RAS wt metastatic colorectal cancer (mCC) patients refractory to FOLFIRI/Bevacizumab. (Abstract 3582) S. Cascinu, G. Rosati, G. Nasti, S. Lonardi, A. Zaniboni, P. Marchetti, M. Aglietta, D. Bilancia, R. V. Iaffaioli, V. Zagonel, M. Giordano, D. C. Corsi, F. Ferraú, R. Labianca, M. Ronzoni, I. C. Floriani Board 76 HER3 as a biomarker of prognosis and panitumumab (Pan) benefit in RAS-wt advanced colorectal cancer (aCRC). (Abstract 3583) J. F. Seligmann, F. Elliott, B. Jacobs, A. J. Hatch, A. Sibley, S. Richman, C. Jiang, J. Barrett, K. Owzar, P. Quirke, H. Hurwitz, M. T. Seymour, A. B. Nixon Board 77 DYPD genotyping to predict toxicity in patients with stage III colon cancer treated with 5-fluorouracil-based adjuvant chemotherapy in the PETACC-8 phase III trial. (Abstract 3584) V. Boige, M. Vincent, P. Alexandre, J. Stoehlmacher, S. Tejpar, S. Landolfi, K. Le Malicot, R. Greil, P. A. Cuyle, M. K. Yilmaz, R. Faroux, A. Matzdorff, R. Salazar, E. Sanches, L. Mineur, C. Lepage, J. Taïeb, P. Laurent-Puig Board 78 Outcomes for FOLFIRI plus bevacizumab (BEV) or cetuximab (CET) in patients previously treated with oxaliplatin-based adjuvant therapy: A combined analysis of data from FIRE-3 and CALGB 80405. (Abstract 3585) V. Heinemann, D. Niedzwiecki, R. V. Pearline, A. Grothey, H. S. Hochster, R. M. Goldberg, F. Innocenti, R. J. Mayer, R. L. Schilsky, C. D. Blanke, M. M. Bertagnolli, A. P. Venook, S. Stinzing, B. H. O’Neil Board 79 Final results from ASPECCT: Randomized phase 3 non-inferiority study of panitumumab (pmab) vs cetuximab (cmab) in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC). (Abstract 3586) T. J. Price, M. Peeters, T. Kim, J. Li, S. Cascinu, P. Ruff, A. V. Suresh, A. L. Thomas, S. Tjulandin, K. Zhang, R. Sidhu, S. Murugappan 214 Board 80 Randomized phase 3 study of panitumumab (pmab) vs cetuximab (cmab) in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC): outcomes by hypomagnesemia (hypomag) in ASPECCT. (Abstract 3587) M. Peeters, T. J. Price, T. Kim, J. Li, S. Cascinu, P. Ruff, A. V. Suresh, A. L. Thomas, S. Tjulandin, K. Zhang, R. Sidhu, S. Murugappan Board 81 A single arm phase II study of neoadjuvant transarterial regional therapy (TACE) using preloaded Irinotecan Beads in patients with resectable colorectal liver metastases (CRLM). (Abstract 3588) R. P. Jones, H. Z. Malik, S. W. Fenwick, T. Gruenberger, S. Stremitzer, M. Rees, G. Plant, J. Figueras, M. Albiol, R. Adam, S. Awad, M. Terlizzo, E. O’Grady, G. J. Poston Board 82 Treatment until progression: Data of the “on-treatment” population of the FIRE-3 (AIO KRK-0306) study. (Abstract 3589) S. Stintzing, L. Fischer von Weikersthal, T. Decker, A. Kiani, U. Vehling-Kaiser, S. Al-Batran, T. Heintges, C. Lerchenmueller, C. Kahl, G. Seipelt, F. Kullmann, M. Stauch, C. Hielscher, S. Held, D. P. Modest, M. H. Moehler, W. Scheithauer, A. Jung, T. Kirchner, V. Heinemann Board 83 Influence of molecular alterations on site-specific (ss) time to recurrence (TTR) following adjuvant therapy in resected colon cancer (CC) (Alliance Trial N0147). (Abstract 3590) R. E. Wilcox, Q. Shi, F. A. Sinicrope, D. J. Sargent, N. R. Foster, J. P. Meyers, R. M. Goldberg, S. Nair, A. F. Shields, E. Chan, S. Gill, M. S. Kahlenberg, S. R. Alberts Board 84 Patients’ and physicians’ risk-benefit trade-off preferences for metastatic colorectacl cancer treatments. (Abstract 3591) J. M. Gonzalez, R. Morlock, S. Ogale, N. Sommer, J. Posner, A. Grothey Board 85 Phase II trial of preoperative radiation with concurrent capecitabine, oxaliplatin, and bevacizumab followed by surgery and postoperative 5fluorouracil, leucovorin, oxaliplatin (FOLFOX), and bevacizumab in patients with locally advanced rectal cancer: 5-year clinical outcomes of a trial of the ECOG-ACRIN Cancer Research Group (E3204). (Abstract 3592) J. C. Landry, Y. Feng, R. S. Prabhu, S. J. Cohen, C. A. Staley, R. M. Whittington, E. R. Sigurdson, H. S. Nimeiri, U. N. Verma, A. B. Benson III Board 86 Time-dependent patterns of recurrence and death in resected colon cancer (CC): Pooled analysis of 12,223 patients from modern trials in the ACCENT database containing oxaliplatin. (Abstract 3593) L. A. Renfro, M. A. Shah, C. J. Allegra, T. Andre, A. De Gramont, F. A. Sinicrope, H. Schmoll, D. G. Haller, S. R. Alberts, G. Yothers, D. J. Sargent Board 87 Monitoring minimal residual disease (MRD) by KRAS mutation burden in urinary or plasma circulating tumor (ct) DNA in colorectal cancer (CRC) patients with resectable liver metastases. (Abstract 3594) C. T. Vibat, V. Melnikova, M. Minarik, B. Belsanova, S. Hancock, L. Hassaine, E. Samuelsz, T. T. Lu, M. G. Erlander, L. Benesova Board 88 TAS-102 vs placebo (PBO) in patients (pts) >65 years (y) with metastatic colorectal cancer (mCRC): An age-based analysis of the RECOURSE trial. (Abstract 3595) E. Van Cutsem, F. M. Benedetti, H. Mizuguchi, R. J. Mayer, A. Ohtsu, RECOURSE Study Group Board 89 Phase I study of ganetespib (G), capecitabine (C), and radiation (RT) in rectal cancer. (Abstract 3596) B. F. El-Rayes, C. A. Staley, R. Diaz, P. S. Sullivan, W. L. Shaib, J. C. Landry Board 90 Therapeutic biomarker differences between MSI-H and MSS colorectal cancers. (Abstract 3597) Z. Gatalica, N. Vijayvergia, S. Vranic, J. Xiu, S. K. Reddy, C. L. Snyder, H. T. Lynch, W. S. El-Deiry Board 91 Measuring the impact of Next Generation Sequencing (NGS) technique implementation in metastatic colorectal cancer (mCRC) drug development program. (Abstract 3598) C. Ortiz, G. Argilés, E. Élez, J. Matito, L. Mendizabal, D. Lo Giacco, F. M. Mancuso, E. Sanz-Garcia, T. Macarulla, M. Alsina, J. Capdevila, T. Saurı́, A. Azaro, C. Cruz, C. Hierro, S. Ramon y Cajal, P. Nuciforo, J. Rodón, J. Tabernero, A. Vivancos 215 MONDAY Monday, June 1, 2015 Monday, June 1, 2015 MONDAY Board 92 A genome-wide association study (GWAS) of overall survival (OS) in 609 metastatic colorectal cancer (mCRC) patients treated with chemotherapy and biologics in CALGB 80405. (Abstract 3599) F. Innocenti, K. Owzar, C. Jiang, A. Sibley, D. Niedzwiecki, H. Lenz, M. M. Bertagnolli, P. N. Friedman, Y. Furukawa, M. Kubo, M. J. Ratain, C. D. Blanke, A. P. Venook, H. L. McLeod Board 93 Modified FOLFIRI (Irinotecan 150 mg/m2) compared to FOLFIRI (Irinotecan 180 mg/m2) in Korean patients with gastrointestinal cancer. (Abstract 3600) K. Kim, T. Kim, Y. Hong, S. Kim, S. Park, B. Nam, K. Lee, J. Kim, I. Chung, Y. Park Board 94 Clinical utility of a circulating cell-free DNA assay for clinical trial enrollment in refractory metastatic colorectal cancer patients. (Abstract 3601) V. K. Morris, M. Morelli, F. Janku, M. J. Overman, B. K. Kee, D. R. Fogelman, E. Vilar Sanchez, I. Shureiqi, C. R. Garrett, K. P. Raghav, C. Eng, S. Manuel, R. A. Wolff, H. Eltoukhy, R. B. Lanman, A. Talasaz, S. Kopetz Board 95 Outcome evolution of matched molecular targeted agents (MTAs) in metastatic colorectal cancer (CRC) patients (pts): VHIO experience. (Abstract 3602) G. Argilés, E. Élez, C. Ortiz, E. Sanz-Garcia, T. Macarulla, M. Alsina, J. Capdevila, A. Azaro, C. Cruz, C. Hierro, M. Vilaro, D. Moreno, R. Dienstmann, S. Landolfi, P. Nuciforo, A. Vivancos, J. Rodón, J. Tabernero Board 96 Retrospective study of patients (pts) who were managed with Watch and Wait strategy (W&W) after neoadjuvant chemoradiation (NCRT) for Locally Advanced Rectal Cancer (LARC). (Abstract 3603) S. Vatandoust, Y. Lam, A. C. Roy, D. Wattchow, P. Hollington, C. S. Karapetis Board 97 Predictors of clonal evolution in metastatic colorectal cancer patients. (Abstract 3604) M. Morelli, M. J. Overman, B. K. Kee, E. Vilar Sanchez, V. K. Morris II, D. R. Fogelman, F. Janku, C. R. Garrett, I. Shureiqi, K. P. Raghav, C. Eng, S. Manuel, R. A. Wolff, H. Eltoukhy, R. B. Lanman, A. Talasaz, S. Kopetz Board 98 Prognostic and predictive value of tumour budding in stage II colorectal carcinoma. (Abstract 3605) B. Mitrovic, K. Handley, N. Assarzadegan, H. H. Li Chang, H. Dawson, A. Grin, G. Hutchins, L. Magill, P. Quirke, R. Riddell, R. G. Gray, R. Kirsch, QUASAR Collaborative Group Board 99 Risk of colorectal cancer after diagnosis of prostate cancer: A populationbased study. (Abstract 3606) D. N. Desautels, Z. Nugent, A. Demers, S. Mahmud, P. Czaykowski, H. Singh Board 100 A phase II study of 5-fluorouracil (5-FU), ziv-aflibercept, and radiation for the preoperative and adjuvant treatment of patients (pts) with stage II/III rectal cancer. (Abstract 3607) P. Acs, D. S. Thompson, M. B. Hemphill, D. Wenk, J. C. Bendell, A. S. Kennedy Board 101 Prospective evaluation of a 409-gene next generation sequencing platform to facilitate genotype-matched clinical trial enrollment. (Abstract 3608) S. Kopetz, B. Litzenburger, W. Kinyua, B. Sajan, V. Subbiah, R. Zinner, J. J. Wheler, D. S. Hong, A. M. Tsimberidou, M. J. Overman, L. C. Pagliaro, N. L. Busaidy , S. N. Westin, B. S. Glisson, J. Heymach, F. Meric-Bernstam, K. R. Shaw, J. Lee, R. Broaddus Board 102 A phase II single arm feasibility trial of neoadjuvant chemotherapy (NAC) with oxaliplatin/fluorouracil (OxMdG) then short-course preoperative radiotherapy (SCPRT) then immediate surgery in operable rectal cancer (ORC): COPERNICUS (NCT01263171). (Abstract 3609) S. Gollins, D. SebagMontefiore, R. Adams, M. P. Saunders, R. Grieve, N. Scott, G. Brown, P. Quirke, L. Butlin, R. Ray, G. Griffiths, C. Hurt Board 103 Characterization of the immune microenvironment of synchronous primary tumor and liver colorectal metastases. (Abstract 3610) M. Van Den Eynde, B. Mlecnik, J. H. Machiels, D. Debetancourt, G. Bindea, A. Jouret-Mourin, C. Sempoux, J. Carrasco, J. Gigot, C. Hubert, Y. Humblet, N. Haicheur, F. Marliot, F. Pages, J. Galon Board 104 Reduced PD-1/PD-L1 expression in KRAS-mutant versus wild-type microsatellite instable (MSI-H) colorectal cancer (CRC) and association of 216 Monday, June 1, 2015 Board 105 Proteomic signatures of colorectal cancer to identify distinct and reproducible subgroups and to reflect prognosis. (Abstract 3612) M. S. Lee, C. Clarke, Z. Jiang, G. C. Manyam, F. Tian, Y. Lu, J. Morris, B. M. Broom, D. Menter, E. Vilar Sanchez, I. Shureiqi, K. P. Raghav, C. Eng, G. J. Chang, I. Simon, R. Bernards, G. B. Mills, M. J. Overman, D. M. Maru, S. Kopetz Board 106 Genetic variants of kinases suppressors of Ras (KSR) to predict tumor response to first-line cetuximab in patients with mCRC: Prospective analysis in the FIRE 3 trial. (Abstract 3613) L. Benhaim, W. Zhang, T. Wakatsuki, A. Gerger, D. Yang, D. Paez, Y. Ning, R. E. El-Khoueiry, F. Loupakis, P. O. Bohanes, S. Stintzing, V. Heinemann, H. Lenz Board 107 Phase II trial of autophagy inhibition using hydroxychloroquine (HCQ) with FOLFOX/bevacizumab in the first-line treatment of advanced colorectal cancer. (Abstract 3614) A. Loaiza-Bonilla, M. H. O’Hara, M. Redlinger, N. Damjanov, U. R. Teitelbaum, I. Vasilevskaya, M. A. Rosen, D. F. Heitjan, R. K. Amaravadi, P. J. O’Dwyer Board 108 Phase 1 extension study of BBI503, a first-in-class cancer stemness kinase inhibitor, in patients with advanced colorectal cancer. (Abstract 3615) D. J. Jonker, S. A. Laurie, G. M. Cote, K. Flaherty, C. S. Fuchs, R. Chugh, D. C. Smith, W. J. Edenfield, P. R. Conkling, J. W. Mier, R. A. Goodwin, E. L. Kwak, T. A. Abrams, R. Goel, J. M. Cleary, W. Li, Y. Li, J. Jemison, M. Hitron, C. Li Board 109 A phase Ib study of BBI608 in combination with FOLFIRI with and without bevacizumab in patients (pts) with advanced colorectal cancer (CRC). (Abstract 3616) J. M. Hubbard, D. J. Jonker, B. H. O’Neil, T. R. Halfdanarson, A. Grothey, Y. Li, L. Borodyansky, C. Li Board 110 A phase Ib/II study of cancer stem cell inhibitor BBI608 administered with panitumumab in KRAS wild-type (wt) patients (pts) with metastatic colorectal cancer (mCRC) following progression on anti-EGFR therapy. (Abstract 3617) K. K. Ciombor, W. J. Edenfield, J. M. Hubbard, P. J. O’Dwyer, C. Becerra, T. Larson, A. I. Spira, A. Grothey, D. Manoharan, W. Li, Y. Li, L. Borodyansky, C. Li, T. S. Bekaii-Saab Board 111 Phase I/II study of everolimus (E) with irinotecan (Iri) and cetuximab (C) in 2nd line metastatic colorectal cancer (mCRC): Hoosier Cancer Research Network GI05–102. (Abstract 3618) E. G. Chiorean, J. Picus, T. Breen, R. H. Ansari, W. A. Harb, M. Burns, A. J. Spittler, P. J. Loehrer Sr. Board 112 Programmed death-ligand 1 (PD-L1) expression in small bowel adenocarcinomas (SBA). (Abstract 3619) K. Pedersen, T. C. Smyrk, S. Harrington, R. R. McWilliams Board 113a A phase III study of the impact of a physical activity program on disease-free survival in patients with high-risk stage II or stage III colon cancer: A randomized controlled trial (NCIC CTG CO.21). (Abstract TPS3620) C. M. Booth, J. L. Vardy, C. J. O’Callaghan, S. Gill, D. J. Jonker, C. Friedenreich, R. M. Meyer, M. D. Brundage, R. Wong, H. M. Dhillon, P. O’Brien, B. Baylock, N. S. Chua, S. Lipichuk, M. S. Sanatani, S. Begbie, T. Bonaventura, M. E. Burge, D. Tu, K. S. Courneya Board 113b Genotype-directed phase II study of irinotecan dosing in metastatic colorectal cancer (mCRC) patients receiving FOLFIRI ⴙ bevacizumab: The GENIC study. (Abstract TPS3621) G. R. Williams, F. Innocenti, W. A. Wood, J. N. Patel, G. B. Sherrill, B. H. O’Neil, J. C. Boles, E. M. Basch, H. K. Sanoff Board 114a Treatment strategies in colorectal cancer patients with initially unresectable liver-only metastases: The randomized phase III CAIRO5 study of the Dutch Colorectal Cancer Group. (Abstract TPS3622) J. Huiskens, T. M. van Gulik, K. P. van Lienden, M. R. Engelbrecht, G. A. Meijer, N. C. van Grieken, J. Schriek, A. Keijser, L. Mol, I. Q. Molenaar, C. Verhoef, K. P. de Jong, C. H. Dejong, G. Kazemier, T. Ruers, J. de Wilt, H. van Tinteren, C. J. Punt 217 MONDAY wnt pathway corepressor TLE-3. (Abstract 3611) N. Vijayvergia, J. Innocent, A. K. Bhatia, R. Shameem, J. Xiu, Z. Gatalica, S. Grivennikov, W. S. El-Deiry Monday, June 1, 2015 MONDAY Board 114b Phase II study of ruxolitinib with regorafenib for relapsed/refractory (r/r) metastatic colorectal cancer (mCRC). (Abstract TPS3623) D. R. Fogelman, M. D. Kochenderfer, G. B. Saylors, F. S. Braiteh, J. J. Nemunaitis, A. L. Cohn, P. O’Neill, L. Zhou, J. C. Switzky, A. Assad, J. C. Bendell Board 115a FOLFOXIRI with or without bevacizumab as first-line treatment for unresectable liver-only metastatic colorectal cancer patients with RAS mutation-type. (Abstract TPS3624) Y. Deng, H. Hu, G. Liu, Y. Cai, J. Zhang, M. Huang, L. Wang, L. Ping, J. Wang Board 115b LUME-Colon 1: A double-blind, randomized phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer (CRC) refractory to standard therapies. (Abstract TPS3625) H. Lenz, J. Tabernero, T. Yoshino, Z. Oum’Hamed, S. Vlassak, M. Sassi, E. Van Cutsem Board 116a Induction mFOLFOX6 with or without aflibercept followed by chemoradiation (CRT) and surgery in high risk rectal cancer: Phase II randomized, multicenter, openlabel trial—The GEMCAD RIA study. (Abstract TPS3626) C. Fernandez-Martos, V. Alonso, I. Busquier, J. Capdevila, A. C. Gracian, J. Gallego Plazas, I. Guasch, L. Layos, F. Losa, J. Maurel, M. Martin-Richard, M. Martinez Villacampa, B. Massuti, C. Montagut Viladot, M. Nogue, C. Pericay, M. Safont, N. Salas, A. Salud Salvia, R. Vera Board 116b SWOG S0820/PACES (Preventing Adenomas of the Colon with Eflornithine and Sulindac): A randomized, double-blind, placebo-controlled phase III clinical trial. (Abstract TPS3627) J. A. Zell, J. M. Unger, G. L. Anderson, E. D. Cook, R. S. Krouse, M. P. Lance, L. M. Minasian, L. Ford, P. Brown Board 117a Multi-center, randomized, controlled, open-label effectiveness study of primary tumor resection or not in asymptomatic colorectal cancer with unresectable metastatic disease. (Abstract TPS3628) G. Chen, R. Zhang, Y. Li, J. Lin, L. Kong, Z. Wang, P. Ding, D. Wan, Z. Pan, Y. Deng, H. Wang, J. Peng, M. Qiu, C. Wang, J. Zhang, W. Li, Y. Yuan, W. Wang Board 117b Phase IB/II study of neoadjuvant chemoradiotherapy with CRLX101 and capecitabine for locally advanced rectal cancer. (Abstract TPS3629) A. Wang, H. K. Sanoff, A. J. McRee, B. H. O’Neil, B. F. Calvo, M. G. Hennessy, C. Murphy, M. T. Tynan, A. W. Blackstock, E. G. Garmey, J. E. Tepper Board 118a The CAIRO4 study: The role of surgery of the primary tumour with few or absent symptoms in patients with synchronous unresectable metastases of colorectal cancer—A randomized phase III study of the Dutch Colorectal Cancer Group (DCCG). (Abstract TPS3630) J. ’t Lam - Boer, L. Mol, C. Verhoef, M. K. Yilmaz, T. de Haan, C. J. Punt, J. de Wilt, M. Koopman Board 118b The ORCHESTRA trial: A phase III trial of adding tumor debulking to systemic therapy versus systemic therapy alone in (mCRC) multi-organ metastatic colorectal cancer. (Abstract TPS3631) E. C. Gootjes, T. E. Buffart, M. Tol, J. Burger, D. J. Grunhagen, E. P. van der Stok, M. R. Meijerink, A. J. Ten Tije, E. V. Meerten, P. M. van de Ven, J. Nuyttens, C. J. Haasbeek, C. Verhoef, H. M. Verheul Board 119a MErCuRIC1: A Phase I study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in RAS MT and RAS WT (with aberrant c-MET) metastatic colorectal cancer (mCRC) patients. (Abstract TPS3632) S. Van Schaeybroeck, C. D. Rolfo, E. Élez, S. Kelly, J. Houlden, L. Collins, S. Love, T. Andre, M. Lawler, F. Di Nicolantonio, M. Grayson, V. C. Popovici, A. Bardelli, P. Laurent-Puig, M. Salto-Tellez, T. Maughan, J. Tabernero, M. Peeters, R. H. Wilson, M. R. Middleton Board 119b Development of a phase Ib/IIa proof-of-concept study of imalumab (BAX69), a first-in-class anti-macrophage migration inhibitory factor (MIF) antibody, as the 3rd or 4th line treatment in metastatic colorectal cancer (mCRC). (Abstract TPS3633) X. Liu, D. R. Adib, H. Barak, R. M. Goldberg, S. Yazji Board 120a Phase III study of regorafenib versus placebo as maintenance therapy in RAS wild type metastatic colorectal cancer (RAVELLO trial). (Abstract TPS3634) E. Martinelli, T. Troiani, F. Venturini, A. Cervantes, J. Douillard, A. Falcone, G. 218 Monday, June 1, 2015 Folprecht, C. Kohne, J. Taieb, J. Tabernero, C. Cardone, V. Sforza, G. Martini, S. Napolitano, A. Capuano, F. Auricchio, F. Ciardiello Board 120b A phase 3 open-label, randomized, multicenter study of imprime PGG in combination with cetuximab in patients with KRAS wild type metastatic colorectal cancer. (Abstract TPS3635) R. D. Huhn, J. Lowe, M. M. Grady, C. C. Taitt, A. H. Braun 8:00 AM - 11:30 AM Poster Session Gastrointestinal (Noncolorectal) Cancer Location: S Hall A Board 121 METGastric: A phase III study of onartuzumab plus mFOLFOX6 in patients with metastatic HER2-negative (HER2-) and MET-positive (METⴙ) adenocarcinoma of the stomach or gastroesophageal junction (GEC). (Abstract 4012) M. A. Shah, Y. Bang, F. Lordick, J. Tabernero, M. Chen, S. P. Hack, S. Phan, D. S. Shames, D. Cunningham Board 122 FOLFOX alone or combined to rilotumumab or panitumumab as first-line treatment in patients (pts) with advanced gastroesophageal adenocarcinoma (AGEA): An open-label, randomized phase II trial (PRODIGE 17 ACCORD 20 MEGA). (Abstract 4013) D. Malka, F. Castan, E. Francois, O. Bouche Sr., J. Bennouna, F. Ghiringhelli, C. De La Fouchardiere, C. Borg, E. Samalin, J. Bachet, J. Raoul, F. Cvitkovic, L. Miglianico, L. Bengrine-Lefevre, L. Dahan, C. Lecaille, T. Aparicio, H. Perrier, S. Gourgou, J. Taïeb, Unicancer, Fédération Francophone de Cancérologie Digestive (FFCD), Association des Gastro-Entérologues Oncologues (AGEO) Board 123 A randomized, open-label phase II study of AZD4547 (AZD) versus Paclitaxel (P) in previously treated patients with advanced gastric cancer (AGC) with Fibroblast Growth Factor Receptor 2 (FGFR2) polysomy or gene amplification (amp): SHINE study. (Abstract 4014) Y. Bang, E. Van Cutsem, W. Mansoor, R. D. Petty, Y. Chao, D. Cunningham, D. Ferry, D. Landers, P. Stockman, N. R. Smith, C. Geh, E. Kilgour Board 124 Untreated metastatic diffuse gastric adenocarcinoma (DGAC): Randomized phase III study of S-1 and cisplatin vs. 5-FU and cisplatin (the DIGEST trial). (Abstract 4015) J. A. Ajani, M. Abramov, V. Bondar, I. Bondarenko, Y. V. Shparyk, V. Gorbunova, H. Anatoliy, Y. Vinnyk, M. Alsina, S. Lazarev, J. Feliu, A. Elme, V. Esko, G. Rosati, K. C. Abdalla, U. N. Verma, F. M. Benedetti, T. Aoyama, H. Mizuguchi, L. Makris, DIGEST Study Group Board 125 Pathological response to neoadjuvant 5-FU, oxaliplatin, and docetaxel (FLOT) versus epirubicin, cisplatin, and 5-FU (ECF) in patients with locally advanced, resectable gastric/esophagogastric junction (EGJ) cancer: Data from the phase II part of the FLOT4 phase III study of the AIO. (Abstract 4016) C. Pauligk, A. Tannapfel, J. Meiler, K. B. Luley, H. Kopp, N. Homann, R. D. Hofheinz, H. Schmalenberg, S. Probst, G. Haag, M. Egger, D. M. Behringer, J. Stoehlmacher, N. Prasnikar, A. Block, J. Trojan, M. Koenigsmann, W. Schmiegel, E. Jäger, S. Al-Batran Board 126 A phase III study of laparoscopy-assisted versus open distal gastrectomy with nodal dissection for clinical stage IA/IB gastric cancer (JCOG0912): Analysis of the safety and short-term clinical outcomes. (Abstract 4017) M. Takagi, H. Katai, J. Mizusawa, K. Nakamura, T. Yoshikawa, M. Terashima, S. Ito, S. Teshima, K. Koeda, T. Sano, N. Fukushima, T. Yasuda, Y. Asao, Y. Fujiwara, M. Sasako, Japan Clinical Oncology Group Board 127 A randomized, double-blind, placebo-controlled phase III study of S-1 in patients with sorafenib-refractory advanced hepatocellular carcinoma 219 MONDAY Abstracts 4012– 4023 will be discussed during the Gastrointestinal (Noncolorectal) Cancer Poster Discussion Session. See page 291 for session information. Monday, June 1, 2015 (S-CUBE). (Abstract 4018) M. Kudo, M. Moriguchi, K. Numata, H. Hidaka, H. Tanaka, M. Ikeda, S. Kawazoe, S. Ohkawa, Y. Sato, T. Okusaka MONDAY Board 128 The protective effect of hormonal intake on risk of hepatocellular carcinoma in the United States. (Abstract 4019) G. Botrus, A. S. Shalaby, A. O. Kaseb, R. Lenzi, R. Abdel-Wahab, R. A. Wolff, M. Hassan Board 129 Multi-institutional phase II study of high dose, hypofractionated proton beam therapy (HF-PBT) for unresectable primary liver cancers: Long term outcomes in patients (pts) with intrahepatic cholangiocarcinoma (ICC). (Abstract 4020) T. S. Hong, J. Y. Wo, B. Y. Yeap, E. Ben-Josef, E. I. McDonnell, L. C. Drapek, L. S. Blaszkowsky, E. L. Kwak, J. W. Clark, L. Goyal, D. P. Ryan, M. M. Javle, J. A. Wolfgang, R. Arellano, J. T. Mullen, C. Ferrone, K. Tanabe, T. F. DeLaney, C. H. Crane, A. X. Zhu Board 130 Quantification of tumor stroma as a biomarker in pancreatic adenocarcinoma. (Abstract 4021) R. J. Torphy, K. E. Volmar, R. Naim, S. R. Cader, J. S. Johansen, M. A. Hollingsworth, E. A. Collisson, J. Yeh Board 131 Prognostic value of plasma circulating tumor (ct) DNA KRAS mutations and serum CA19 –9 in unresectable pancreatic cancer (PC) patients. (Abstract 4022) J. S. Johansen, C. T. Vibat, S. Hancock, I. M. Chen, L. Hassaine, E. Samuelsz, E. A. Collisson, B. V. Jensen, T. T. Lu, V. Melnikova, M. G. Erlander Board 132 Allelic ratio of KRAS mutations in pancreatic ductal adenocarcinoma. (Abstract 4023) J. K. Lennerz, A. Stenzinger Board 133 A phase II study of sequential capecitabine plus oxaliplatin (XELOX) followed by docetaxel plus capecitabine (TX) in patients with unresectable gastric adenocarcinoma: The TCOG T3211 trial. (Abstract 4024) M. Chen, J. Lin, C. Hsiao, Y. Shan, Y. Chen, L. Chen, T. Liu, C. Li, Y. Chao Board 134 Risk of death due to heart disease after radiotherapy for esophageal cancer: A SEER study. (Abstract 4025) J. E. Frandsen, D. Boothe, D. K. Gaffney, B. Wilson, S. Lloyd Board 135 Phase I/II study of a combination of capecitabine, cisplatin, and intraperitonealdocetaxel (XP ID) in patients with advanced gastric cancer with peritoneal metastasis. (Abstract 4026) H. Cho, M. Ryu, C. Yoo, B. Ryoo, S. Park, K. Kim, B. Kim, M. Yoo, J. Yook, Y. Kang Board 136 Masitinib plus irinotecan for second line treatment of esophagogastric adenocarcinoma: An open label phase Ib/II trial. (Abstract 4027) A. Zaanan, J. Bennouna, S. Hiret, J. Douillard, O. Bouche Sr., D. Tougeron, T. Lecomte, C. Lepère, C. Mansfield, A. Moussy, P. Dubreuil, O. Hermine, J. Taieb Board 137 Prognostic factor analysis of overall survival (OS) in gastric cancer from two phase III studies of second-line ramucirumab (RAM) (REGARD and RAINBOW) using pooled individual patient (pt) data. (Abstract 4028) C. S. Fuchs, K. Muro, J. Tomasek, E. Van Cutsem, J. Y. Cho, S. Oh, H. Safran, G. Bodoky, I. Chau, Y. Shimada, F. Dumitru, S. Al-Batran, R. Passalacqua, A. Ohtsu, M. Emig, D. Ferry, K. Chandrawansa, Y. Hsu, A. Sashegyi, H. Wilke Board 138 Candidate biomarker analyses in gastric or gastro-esophageal junction carcinoma: REGARD trial of single-agent ramucirumab (RAM) vs. placebo (PL). (Abstract 4029) C. S. Fuchs, J. Tabernero, J. Tomasek, I. Chau, B. Melichar, H. Safran, M. A. Tehfe, F. Dumitru, E. Topuzov, L. Schlittler, A. A. Udrea, W. Campbell, S. Brincat, M. Emig, S. A. Melemed, R. R. Hozak, D. Ferry, W. Caldwell, J. A. Ajani Board 139 Phase I study of GS-5745 alone and in combination with chemotherapy in patients with advanced solid tumors. (Abstract 4030) J. C. Bendell, A. Starodub, M. A. Shah, S. Sharma, Z. A. Wainberg, D. L. Thai Board 140 Adaptive immune resistance in gastro-esophageal cancer: Correlating tumoral/stromal PDL1 expression with CD8ⴙ cell count. (Abstract 4031) R. J. Kelly, E. Thompson, M. Zahurak, T. Cornish, N. Cuka, E. Abdelfatah, J. M. Taube, S. Yang, M. Duncan, N. Ahuja, A. Murphy, R. A. Anders 220 Board 141 Laparoscopic D2 distal gastrectomy versus conventional open surgery for advanced gastric cancer: The safety analysis from a multicenter prospective randomized controlled trial in China (CLASS-01 Trial). (Abstract 4032) Y. Hu, C. Huang, Y. Sun, X. Su, Z. Li, Y. Xue, J. Hu, X. He, K. Tao, G. Zhao, J. Suo, H. Wei, W. Hu, M. Ying, X. Du, P. Chen, G. Li, Chinese Laparoscopic Gastrointestinal Surgery Study (CLASS) Group Board 142 Pazopanib and 5-FU/oxaliplatin as first-line treatment in advanced gastric cancer: PaFLO, a randomized phase II study from the AIO (Arbeitsgemeinschaft Internistische Onkologie). (Abstract 4033) P. C. Thuss-Patience, S. Al-Batran, J. T. Siveke, N. Homann, P. Malfertheiner, D. Glaeser, A. Stein, I. Tamm, S. Daum, J. Potenberg, A. Florschütz, A. Vogel, K. Ridwelski, M. Ritgen, M. Geissler, H. Schmalenberg, P. Schlattmann, M. Lorenz, K. Breithaupt, U. Pichlmeier Board 143 MET as a prognostic biomarker of survival in a large cohort of patients with gastroesophageal cancer (GEC). (Abstract 4034) D. V. Catenacci, R. Tang, K. S. Oliner, A. Ang, R. D. Loberg, E. O’Day, P. Xu, L. Henderson, A. Ruzzo, F. Graziano Board 144 Randomized phase II study of recombinant human endostatin combined with definitive chemoradiotherapy in locally advanced esophageal squamous cell carcinoma. (Abstract 4035) J. Lv, T. Li, X. Deng, F. Li, Y. Song, C. Li, J. Wang Board 145 Estrogen receptor beta (ER) gene polymorphisms as a predictor of overall survival in patients with gastric cancer (GC) from Japan and Los Angeles County (LAC). (Abstract 4036) A. Parekh, Y. Sunakawa, S. Cao, S. Matsusaka, D. Yang, W. Zhang, T. Wakatsuki, Y. Ning, S. Stremitzer, A. Mendez, S. Okazaki, R. Elkhoueiry, S. Iqbal, A. Barzi, M. Azuma, M. Watanabe, W. Koizumi, A. H. Wu, H. Lenz Board 146 A phase I dose-escalating and safety study of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinoma. (Abstract 4037) A. L. Thomas, M. M. Eatock, N. Coupe, N. McGregor, S. Love, C. Ciria, L. Collins, C. McDowell, M. R. Middleton Board 147 Multicenter phase 2: Capecitabine (CAP) ⴙ oxaliplatin (OX) ⴙ bevacizumab (BEV) ⴙ trastuzumab (TRAS) for patients (pts) with metastatic esophagogastric cancer (MEGCA). (Abstract 4038) P. C. Enzinger, T. A. Abrams, J. A. Chan, N. J. McCleary, H. Zheng, E. L. Kwak, M. Yurgelun, L. S. Blaszkowsky, J. M. Cleary, B. M. Wolpin, J. A. Meyerhardt, E. Regan, C. Graham, K. Straw, C. S. Fuchs, R. J. Kelly Board 148 Prognostic impact of Forkhead box-F1 (FOXF1) polymorphisms on the clinical outcome in gastric cancer patients. (Abstract 4039) S. Matsusaka, A. H. Wu, S. Cao, N. Mizunuma, K. Chin, W. Zhang, D. Yang, Y. Ning, S. Stremitzer, Y. Sunakawa, S. Okazaki, A. Parekh, R. E. El-Khoueiry, A. Mendez, H. Lenz Board 149 The role of panitumumab in combination with ECX in perioperative chemotherapy of unselected patients with locally advanced gastroesophageal adenocarcinomas: Randomized phase II study of the German Cancer Society. (Abstract 4040) M. H. Moehler, F. Lordick, A. L. Mihaljevic, S. Kanzler, T. Hoehler, P. C. Thuss-Patience, S. P. Moenig, V. Kunzmann, S. Schroll, H. Meyer, A. Sandermann, C. Schumacher, H. Wilke, A. Tannapfel, M. Stahl Board 150 Analysis of patients with esophageal cancer following trimodality therapy: Pathological complete remission (PathCR) versus non-PathCR. (Abstract 4041) M. A. Blum, L. Xiao, A. M. Correa, R. Wadhwa, E. Elimova, H. D. Skinner, R. Komaki, J. H. Lee, M. S. Bhutani, B. Weston, Z. X. Liao, D. C. Rice, S. Swisher, W. L. Hofstetter, J. A. Ajani Board 151 Prognostic significance of tumor infiltrating immune cells and PD-L1 expression in gastric carcinoma in Chinese patients. (Abstract 4042) R. Geng, C. Dai, A. Wong, M. Qing, J. Hu, Y. Sun, A. W. Lo, J. Li 221 MONDAY Monday, June 1, 2015 Monday, June 1, 2015 MONDAY Board 152 Clinical characteristics and treatment outcomes of patients with metastatic, MET-amplified esophagogastric cancers. (Abstract 4043) E. L. Kwak, J. K. Lennerz, J. Szymonifka, R. B. Corcoran, J. W. Clark, A. L. Russo, D. R. Borger, L. S. Blaszkowsky, L. E. Dias, J. E. Faris, J. E. Murphy, P. Fidias, I. T. Lennes, C. G. Azzoli, J. F. Gainor, J. T. Mullen, G. Y. Lauwers, D. P. Ryan, A. J. Iafrate, T. S. Hong Board 153 A phase II single-arm pilot study of second-line icotinib treatment in advanced esophageal cancer with EGFR over-expression or amplification. (Abstract 4044) J. Huang, Q. Fan, P. Lu, J. Ying, C. Ma, W. Liu, J. Liu, Y. Liu, F. Tan, Y. Sun Board 154 Patterns of local-regional relapse after complete response by definitive chemoradiotherapy for stage II/III (non–T4) esophageal squamous cell carcinoma. (Abstract 4045) K. Sudo, K. Kato, H. Kuwabara, Y. Sasaki, N. Takahashi, H. Shoji, S. Iwasa, Y. Honma, N. T. Okita, A. Takashima, T. Hamaguchi, Y. Yamada, N. Boku Board 155 Multicenter retrospective analysis for elderly patients with advanced gastric cancer (AGC) received first-line chemotherapy in clinical practice. (Abstract 4046) K. Kunieda, A. Makiyama, M. Noguchi, T. Kajiwara, T. Tamura, K. Takeda, Y. Tsuji, K. Minashi, T. Moriwaki, N. Sugimoto, M. Nagase, Y. Negoro, T. Tsuda, H. Shimodaira, N. Okano, D. Sakai, K. Yanagihara, N. Boku, I. Hyodo, T. Esaki Board 156 A phase I dose expansion trial of avelumab (MSB0010718C), an anti-PD-L1 antibody, in Japanese patients with advanced gastric cancer. (Abstract 4047) Y. Yamada, T. Nishina, S. Iwasa, K. Shitara, K. Muro, T. Esaki, S. Hironaka, K. Yamaguchi, N. Machida, T. Satoh, A. von Heydebreck, H. Achiwa, T. Doi Board 158 Evaluation of tumor MET protein expression, MET gene amplification, and HER2 expression in Chinese patients with advanced gastric or gastroesophageal junction (G/GEJ) cancer. (Abstract 4048) R. Xu, M. Qiu, Y. Zhou, D. Wang, D. Zhang, F. Wang, Y. Li, J. Huang, H. Zhou, E. Tang, Z. Du, F. Zhang Board 159 Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer. (Abstract 4049) M. Lee, S. Kim, J. Lee, S. Park, Y. Park, H. Lim, W. Kang, J. Park Board 160 Quantitative measurement of HER2 levels by multiplexed mass spectrometry to predict survival in gastric cancer patients treated with trastuzumab. (Abstract 4050) C. Ock, E. An, D. Oh, T. Kim, K. Lee, S. Han, S. Im, W. Liao, F. Cecchi, A. Blackler, S. P. Thyparambil, W. A. Hoos, W. Kim, J. Burrows, T. A. Hembrough, Y. Bang Board 161 First-line capecitabine (X) monotherapy versus capecitabine plus oxaliplatin (XELOX) in elderly patients with advanced gastric cancer (AGC): results from the first interim analysis. (Abstract 4051) I. Hwang, H. Lee, J. Ji, J. Kang, S. Lee, S. Kim, J. Lee, S. Park, W. Kang Board 162 Comparison of open esophagectomy with minimally invasive esophagectomy: An observational nationwide study in Japan. (Abstract 4052) H. Takeuchi, H. Miyata, S. Ozawa, H. Udagawa, H. Osugi, H. Matsubara, Y. Kitagawa Board 163 Phase II study of FOLFOX plus regorafenib (REGO) in patients with unresectable or metastatic esophagogastric (EG) cancer. (Abstract 4053) Y. Y. Janjigian, G. Y. Ku, J. F. Chou, M. Capanu, M. Siebel, S. B. Chalasani, M. S. Boyar, Z. Goldberg, A. M. Desai, D. P. Kelsen, T. Imtiaz, D. H. Ilson Board 164 Changing chemotherapy (C) with concurrent radiation (RT) followed by surgery after sub-optimal FDG-PET response to induction chemotherapy improves outcomes in locally advanced (LA) esophageal adenocarcinoma (EA). (Abstract 4054) A. Kriplani, Y. Y. Janjigian, D. P. Kelsen, V. W. Rusch, M. S. Bains, N. P. Rizk, J. F. Chou, M. Capanu, A. J. Wu, K. A. Goodman, D. H. Ilson, G. Y. Ku Board 165 Clinical outcomes following neoadjuvant nab-paclitaxel and cisplatin chemotherapy for locally advanced esophageal squamous cell carcinoma. 222 Monday, June 1, 2015 Board 166 Comprehensive characterization of PDL-1 and CTLA-4 in gastric cancer. (Abstract 4056) H. A. Schloesser, U. Drebber, M. Thelen, M. Kloth, S. Rothschild, M. Garcia-Marquez, S. Zoghi, A. Urbanski, H. Alakus, A. Schauss, S. Theurich, U. Warnecke-Eberz, D. L. Stippel, A. H. Hölscher, T. Zander, S. P. Moenig, M. S. von Bergwelt-Baildon Board 167 Phase II study of everolimus as a salvage treatment after failure of fluoropyrimidine and platinum in patients with metastatic gastric cancer positive for pS6Ser240/4 expression. (Abstract 4057) J. Park, M. Ryu, Y. Park, S. Hong, B. Ryoo, S. Park, C. Yoo, Y. Kang Board 168 The prognostic impact of extracapsular lymph node involvement after neoadjuvant therapy and esophagectomy . (Abstract 4058) S. M. Lagarde, M. Navidi, J. Sultan, H. W. Van Laarhoven, S. S. Gisbertz, S. L. Meijer, A. Immanuel, M. Griffin, M. I. van Berge Henegouwen Board 169 Comparison of HER2 gene amplification (AMP) in primary esophageal and gastroesophageal junction adenocarcinomas (EAC) and their metastatic regional lymph nodes (MLNs). (Abstract 4059) H. H. Yoon, Q. Shi, W. R. Sukov, C. A. Sattler, A. E. Wiktor, R. B. Diasio, T. Wu, R. B. Jenkins, F. A. Sinicrope Board 170 A serum microRNA biomarker panel for detection of gastric cancer. (Abstract 4060) J. So, R. Zou, L. Zhou, H. Too, F. Zhu, Y. Teo, C. T. Yap, S. Y. Rha, K. Kono, J. Yoong, K. Yeoh, W. Yong Board 171 NeoFLOT II: Multicenter phase II study with short time neoadjuvant chemotherapy (stNACT) with 5-FU, FA, oxaliplatin, and docetaxel in rectable adenocarcinoma of the gastresophageal junction and gastric adenocarcinoma (T3, T4, and/or LNⴙ) with high R0 resection rate over 91.5%. (Abstract 4061) K. Ridwelski, T. Heina, J. Fahlke, H. Kroening, W. Asperger, C. Kahl, U. Halm, P. Stuebs, C. Meissner, R. Otto, K. Zierau, M. Krueger Board 172 Prognostic value of tumor infiltrating lymphocytes in Epstein-Barr virusassociated gastric cancer. (Abstract 4062) S. Yoon, S. Lee, Y. Chae, B. Kang, J. Kim, A. Seo, H. Bae, W. Yu, H. Chung, O. Kwon, S. Jeon, H. Lee Board 173 Knocking on molecular alterations in advanced gastric cancer (AGC). (Abstract 4063) F. Racca, C. Hierro, D. Moreno, M. Vilaro, S. Landolfi, A. Vivancos, J. Jimenez, T. Macarulla, J. Capdevila, E. Élez, G. Argilés, T. Saurı́, C. Cruz, A. Azaro, S. Castro, P. Nuciforo, J. Rodón, J. Tabernero, M. Alsina Board 174 Accuracy of EUS-FNA for distant regional lymph nodes in the initial staging of esophageal cancer (EC). (Abstract 4064) Y. Shimodaira, E. Elimova, H. Shiozaki, R. Wadhwa, N. Charalampakis, V. Planjery, M. A. Blum, Q. Nguyen, H. D. Skinner, R. Slack, D. M. Maru, W. L. Hofstetter, B. Weston, M. S. Bhutani, J. H. Lee, J. A. Ajani Board 175 A phase II study of the c-Met inhibitor tivantinib (tiv) in combination with FOLFOX for the treatment of patients (pts) with previously untreated metastatic adenocarcinoma of the distal esophagus, gastroesophageal (GE) junction, or stomach. (Abstract 4065) S. Pant, M. R. Patel, C. Kurkjian, M. B. Hemphill, M. C. Flores, D. S. Thompson, J. C. Bendell Board 176 The prognostic value of a modified tumor regression grade after neoadjuvant chemoradiotherapy and resection of esophageal carcinoma. (Abstract 4066) M. C. Anderegg, S. M. Lagarde, W. A. Borstlap, S. S. Gisbertz, S. L. Meijer, M. Hulshof, J. Bergman, O. R. Busch, H. W. Van Laarhoven, M. I. van Berge Henegouwen Board 177 Signet ring cell (SRC) histology of localized gastric adenocarcinoma (LGAC) to predict response to preoperative chemoradiation. (Abstract 4067) N. Charalampakis, G. M. Nogueras-Gonzalez, E. Elimova, R. Wadhwa, H. Shiozaki, Y. Shimodaira, M. A. Blum, J. E. Rogers, J. Garris, A. Matamoros Jr., T. L. Sagebiel, P. Das, J. Estrella, B. D. Badgwell, J. A. Ajani 223 MONDAY (Abstract 4055) F. Yun, J. Y. Hua Sr., Z. X. Min, C. Q. Xun, H. Z. Yu, G. Lei, Y. H. Yuan, L. j. Shi, C. P. Chen, Z. Qiang, W. Mao Monday, June 1, 2015 MONDAY Board 178 Association of high tumor infiltrating cytotoxic T cells with absence of lymph node involvement in resected colorectal and gastric cancer: Implications for immunosurveillance. (Abstract 4068) T. Dai, S. S. Kim, P. Thakkar, Y. Liu, B. He, N. C. Panarelli, M. A. Shah Board 179 Phase Ib/II study of cancer stem cell (CSC) inhibitor BBI608 combined with paclitaxel in advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. (Abstract 4069) C. Becerra, J. Stephenson Jr., D. J. Jonker, A. L. Cohn, T. R. Asmis, T. S. Bekaii-Saab, P. R. Conkling, L. E. Garbo, H. Lenz, D. A. Richards, A. I. Spira, S. Mikhail, R. A. Goodwin, H. H. Yoon, S. Hume, M. Hitron, C. Li Board 181 Randomized phase II crossover trial exploring the clinical benefit from targeting EGFR or VEGF with combination chemotherapy in patients with non-resectable biliary tract cancer. (Abstract 4071) L. H. Jensen, E. Fernebro, J. Ploen, J. Eberhard, J. Lindebjerg, A. K. Jakobsen Board 182 Pazopanib (P) and trametinib (T) in advanced cholangiocarcinoma (CC): A phase Ib study. (Abstract 4072) R. T. Shroff, A. O’Connor, D. Gallagher, M. Zahurak, G. L. Rosner, C. Ohaji, S. Sartorius-Mergenthaler, R. Zinner, N. S. Azad Board 183 A phase II clinical trial on combined axitinib and transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC): Final results and evaluation of clinical predictor for response. (Abstract 4073) S. L. Chan, W. Yeo, F. Mo, L. Li, K. Lee, A. W. Chan, E. P. Hui, P. B. Lai, T. Mok, A. T. Chan, S. Yu Board 184 Efficacy and safety of nintedanib (N) versus sorafenib (S) in Caucasian and Asian patients with advanced hepatocellular carcinoma (HCC): Pooled analysis of two randomized phase II trials. (Abstract 4074) T. Meyer, D. H. Palmer, Y. Chao, C. Choi, A. Deptala, L. Fartoux, Y. Feng, J. S. Graham, J. Hocke, T. Kim, D. Lin, Y. Ma, M. Peck-Radosavljevic, P. J. Ross, B. Ryoo, A. Wenz, C. Yen, A. Loembe, A. Cheng Board 185 Proposal of a new staging system for intrahepatic cholangiocarcinoma: Analysis of surgical patients from a nationwide survey of Liver Cancer Study Group of Japan. (Abstract 4075) Y. Sakamoto, N. Kokudo, Y. Matsuyama, M. Sakamoto, M. Kadoya, S. Kaneko, Y. Ku, M. Kudo, T. Takayama, O. Nakashima, The Liver Cancer Study Group of Japan Board 186 Sorafenib plus intra-arterial cisplatin versus sorafenib alone in patients with advanced hepatocellular carcinoma: A randomized phase II trial. (Abstract 4076) M. Ikeda, S. Shimizu, T. Sato, M. Morimoto, Y. Inaba, Y. Kojima, A. Hagihara, M. Kudo, S. Nakamori, S. Kaneko, R. Sugimoto, T. Tahara, T. Ohmura, K. Yasui, K. Sato, H. Ishii, J. Furuse, T. Okusaka Board 187 Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome (PFO) results from the phase 3 REACH study. (Abstract 4077) I. Chau, M. Peck-Radosavljevic, C. Borg, P. Malfertheiner, J. Seitz, J. Park, B. Ryoo, C. Yen, M. Kudo, R. T. Poon, D. Pastorelli, J. Blanc, H. Chung, A. D. Baron, T. Okusaka, Z. L. Cui, A. C. Girvan, P. Abada, L. Yang, A. X. Zhu Board 188 Gemcitabine (G), capecitabine (C) and bevacizumab (BV) in patients with advanced biliary cancers (ABC): final results of a multicenter phase II study. (Abstract 4078) R. V. Iyer, A. Groman, W. Ma, U. Malhotra, D. Iancu, C. Grande, T. S. Bekaii-Saab Board 189 Evaluation of the value of serum glycomics (GlycoCirrhoTest) for risk prediction of hepatocellular carcinoma in compensated cirrhosis. (Abstract 4079) X. Verhelst, D. Vanderschaeghe, L. Castera, A. Geerts, N. Goutte, C. Francoz, F. Durand, N. Callewaert, H. Van Vlieberghe Board 190 A multicenter cohort study on transarterial chemoembolization with or without sorafenib for intermediate-stage hepatocellular carcinoma: Reconsidering combination-therapy trial design. (Abstract 4080) Y. Zhao, H. 224 Monday, June 1, 2015 Board 191 A pilot study of tremelimumab – a monoclonal antibody against CTLA-4 – in combination with either trans catheter arterial chemoembolization (TACE) or radiofrequency ablation (RFA) in patients with hepatocellular carcinoma (HCC). (Abstract 4081) A. G. Duffy, O. V. Makarova-Rusher, S. P. Kerkar, D. E. Kleiner, S. Fioravanti, M. Walker, S. Carey, W. D. Figg, S. M. Steinberg, V. Anderson, N. Abi-Jaoudeh, E. Levi, B. J. Wood, T. F. Greten Board 192 Panitumumab in combination with gemcitabine/cisplatin (GemCis) for patients with advanced kRAS WT biliary tract cancer: A randomized phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). (Abstract 4082) A. Vogel, S. Kasper, W. Weichert, M. Bitzer, A. Block, H. Riess, H. SchulzeBergkamen, M. H. Moehler, K. E. Merx, V. Endris, E. Schnoy, J. T. Siveke, P. Michl, D. Waldschmidt, J. Kuhlmann, M. Geissler, C. Kahl, S. Kubicka Board 193 A phase 1/2 study of TRC105 in combination with sorafenib in hepatocellular carcinoma (HCC). (Abstract 4083) A. G. Duffy, C. Ma, S. V. Ulahannan, O. V. Makarova-Rusher, S. Fioravanti, M. Walker, B. Turkbey, J. Trepel, L. Cao, S. M. Steinberg, W. D. Figg, T. F. Greten Board 194 Objective response by mRECIST to predict survival in hepatocellular carcinoma: A multivariate, time-dependent analysis from the phase III BRISK-PS study. (Abstract 4084) J. M. Llovet, J. Park, F. Torres, T. Decaens, E. Boucher, J. Raoul, M. Kudo, C. Chang, V. Boige, E. Assenat, Y. Kang, H. Lim, I. Walters, R. Lencioni Board 195 Changes in plasma biomarkers over time in patients (pts) with advanced biliary tract cancer (ABC) treated in the UK ABC-03 randomized phase II trial. (Abstract 4085) A. C. Backen, M. G. McNamara, A. Lopes, H. Wasan, D. H. Palmer, M. Duggan, D. Cunningham, A. Anthoney, P. Corrie, S. Madhusudan, A. Maraveyas, P. J. Ross, J. S. Waters, W. P. Steward, C. Rees, S. Beare, J. A. Bridgewater, C. Dive, J. W. Valle Board 196 Molecular characterization of 350 hepatocellular carcinomas to identify biomarker aberrations with potential novel therapeutic options. (Abstract 4086) C. Ang, J. T. Miura, T. C. Gamblin, S. Z. Millis, J. Xiu, Z. Gatalica, S. K. Reddy, N. S. Yee Board 197 The influence of tumor-infiltrating lymphocytes (TILs) and their prognostic value in cholangiocarcinoma. (Abstract 4087) Y. Suleiman, D. Coppola, T. Juan, J. K. Lee, H. H. Soliman, M. P. Malafa, R. D. Kim Board 198 A phase II trial of bevacizumab and erlotinib as second line therapy for advanced hepatocellular carcinoma. (Abstract 4088) A. O. Kaseb, H. O. Al-Shamsi, J. Morris, M. Iwasaki, L. Xiao, R. Abdel-Wahab, K. P. Raghav, M. Hassan, H. M. Hassabo, R. A. Wolff Board 199 Prognostic score in high-grade gastrointestinal neuroendocrine tumours (GI-NETs). (Abstract 4089) A. Lamarca, J. Barriuso, M. G. McNamara, R. Hubner, J. W. Valle Board 200 Association of progression-free survival with overall survival (OS) in patients (pts) with neuroendocrine tumor (NET) treated with somatostatin analogs. (Abstract 4090) M. Ter-Minassian, N. V. Brooks, L. K. Brais, J. A. Chan, D. C. Christiani, X. Lin, S. Gabriel, J. Dinet, M. H. Kulke Board 201 Everolimus in patients with advanced, progressive pancreatic neuroendocrine tumors: Overall survival results from the phase III RADIANT3 study after adjusting for crossover bias. (Abstract 4091) M. E. Pavel, C. Lombard-Bohas, E. Van Cutsem, D. H. Lam, T. Kunz, U. Brandt, J. Capdevila, E. De Vries, P. Tomassetti, T. J. Hobday, R. F. Pommier, J. C. Yao Board 203 Phase Ib study of pasireotide (P), everolimus (E), and selective internal radioembolization therapy (SIRT) for unresectable neuroendocrine hepatic metastases. (Abstract 4092) B. F. El-Rayes, W. L. Shaib, R. S. Williams, Z. Chen, P. Ganji, E. Brutcher, H. S. Kim 225 MONDAY Li, W. Bai, J. Liu, W. Lv, S. Guan, X. Qin, W. Wang, W. Ren, W. Mu, W. Guo, S. Gu, Y. Ma, Z. Yin, Y. Wang, J. Xia, R. Duran, D. Fan, G. Han Monday, June 1, 2015 MONDAY Board 204 Novel score to predict outcome in resected pancreatic neuroendocrine tumors (pNET). (Abstract 4093) A. Viudez, D. A. Laheru, A. Stark, N. S. Azad, C. L. Wolfgang, S. Baylin, J. G. Herman, Z. Maleki, A. De Jesus-Acosta Board 205 Study of the therapeutic management of gastric carcinoid tumors from data of the French national cohort of neuroendocrine tumors: CARGAS study. (Abstract 4094) S. Manfredi, B. Leconte, T. Uguen, S. le Sourd, C. Cernon, J. Morcet, F. Laine, E. Baudin, G. Cadiot Board 206 Characteristics, prognosis and treatments of 294 patients with poorly differentiated neuroendocrine carcinoma: The FFCD-GTE national cohort. (Abstract 4095) T. Walter, D. Tougeron, E. Baudin, K. Le Malicot, T. Lecomte, J. Guigay, O. Hentic, S. Manfredi, I. Bonnet, R. Guimbaud, R. Coriat, P. Rougier, C. Desauw, A. Thirot-Bidault, L. Dahan, G. Roquin, T. Aparicio, C. Lombard-Bohas, C. Lepage, G. Cadiot Board 207 Multicenter prospective phase II trial of bevacizumab (bev) for progressive pancreatic neuroendocrine tumor (PNET). (Abstract 4096) T. J. Hobday, J. Yin, A. Pettinger, J. R. Strosberg, D. L. Reidy, H. X. Chen, C. Erlichman Board 208 Bronchial neuroendocrine neoplasms: A Surveillance Epidemiology and End Results (SEER) database review of demographics and survival in 187,991 cases. (Abstract 4097) M. A. Lewis, J. C. Yao Board 209 Bronchial neuroendocrine neoplasms: A Surveillance Epidemiology and End Results (SEER) database review of treatment outcomes. (Abstract 4098) M. A. Lewis, J. C. Yao Board 210 Identification of response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors. (Abstract 4099) J. R. Strosberg, M. Cives, M. Brelsford, M. Black, A. Meeker, M. Ghayouri Board 211 A phase II study of axitinib in advanced carcinoid tumors: Preliminary results. (Abstract 4100) M. Cives, J. R. Strosberg, T. Campos, T. Weber, M. Nickerson, C. E. Atreya, A. P. Venook, R. K. Kelley, T. Valone, D. Coppola, E. K. Bergsland Board 212 Randomized, phase III trial of adjuvant adeforvir vs. therapeutic lamivudine in post-operative BCLC stage 0 or A HBV-related HCC: The Taiwan Cooperative Oncology Group T1206 study. (Abstract 4101) L. Chen, L. Jeng, C. Hsiao, C. Wu, W. Lee, T. Wang, P. Lee, C. Chen, I. Chen, K. Lee, C. Hsieh, W. Hwang, M. Yang, Y. Yang, D. Lin, M. Chen, P. Chen, Taiwan Cooperative Oncology Group Board 213 Phase II studies of BEZ235 in patients with advanced pancreatic neuroendocrine tumors (pNET). (Abstract 4102) R. Salazar, C. Verslype, E. Baudin, S. K. Libutti, J. C. Yao, R. Buzzoni, L. Antonuzzo, R. Hubner, R. Garcı́aCarbonero, A. B. Custodio, E. M. Wolin, S. Turri, D. Dey, P. Aimone, J. Sulovski, N. Mukherjee, F. Herbst, N. Fazio Board 214 Lanreotide depot/autogel (LAN) vs. placebo (PBO) for carcinoid syndrome (CS) in patients with neuroendocrine tumors (NETs): Subgroup analysis of the ELECT study. (Abstract 4103) A. Vinik, E. M. Wolin, H. Audry, E. GomezPanzani, G. A. Fisher, ELECT Study Group Board 215 Lanreotide depot/autogel (LAN) in midgut neuroendocrine tumors (NETs): A subgroup analysis from the CLARINET study. (Abstract 4104) A. Dasari, A. T. Phan, M. E. Caplin, M. E. Pavel, J. B. Cwikla, M. Raderer, E. Sedlackova, G. Cadiot, E. M. Wolin, J. Capdevila, L. Wall, G. Rindi, A. Langley, E. GomezPanzani, P. B. Ruszniewski, CLARINET Study Group Board 216 Low objective response and high toxicity to single-agent mitotane in patients with metastatic adrenocortical carcinoma (ACC): A 25 year experience at MSKCC. (Abstract 4105) B. Y. Lung, E. Valentino, S. R. Gerst, B. R. Untch, S. Katz, V. E. Strong, N. P. Raj, K. Olino, L. Saltz, D. L. Reidy Board 217 Clinical diagnostic utility of a blood-based multi-transcriptome assay for gastroenteropancreatic disease. (Abstract 4106) I. M. Modlin, D. Alaimo, S. Callahan, H. Aslanian, C. Lepensky, N. S. Teixeira, L. Bodei, I. Drozdov, M. S. Kidd 226 Board 218 Recurrence following surgical resection of gastroenteropancreatic neuroendocrine tumors (NETs): An analysis from the NCCN oncology outcomes database. (Abstract 4107) K. Van Loon, L. Zhang, J. M. Creasman, M. A. Choti, J. C. Yao, M. H. Kulke, E. K. Nakakura, M. Bloomston, A. B. Benson III, M. H. Shah, J. R. Strosberg, C. C. Zornosa, S. Bobiak, E. K. Bergsland Board 219 Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Analysis of REACH pts by Child-Pugh (CP) score. (Abstract 4108) A. X. Zhu, A. D. Baron, P. Malfertheiner, M. Kudo, S. Kawazoe, D. Pezet, F. Weissinger, G. Brandi, C. Barone, T. Okusaka, Y. Wada, J. Park, B. Ryoo, J. Y. Cho, H. C. Chung, C. Li, C. Yen, K. Lee, L. Yang, I. Chau Board 220 A phase I/II study of bavituximab and sorafenib in advanced hepatocellular carcinoma (HCC). (Abstract 4109) A. C. Yopp, A. G. Singal, Y. E. Arriaga, U. N. Verma, J. Shan, N. L. Kallinteris, M. S. Beg, J. C. Mansour, H. Zhu Board 221 Prospective identification of potentially actionable molecular alterations in cancers of unknown primary. (Abstract 4110) A. M. Varghese, D. M. Hyman, A. Zehir, E. Vakiani, D. S. Klimstra, M. Ladanyi, M. F. Berger, D. B. Solit, L. Saltz Board 222 Long-term outcomes of cytoreduction and HIPEC for malignant peritoneal mesothelioma. (Abstract 4111) G. E. Bates, M. D. Kluger, Z. Jin, J. A. Chabot, J. Leinwand, T. Bressler, M. Rae, R. N. Taub, A. C. Borczuk, M. Hesdorffer Board 223 Importance of tumor grade in stage III mucinous appendiceal carcinoma: An analysis of the SEER Database. (Abstract 4112) O. Fukui, K. W. Carpenter, Y. Han, M. Salvino, J. C. Salo, E. S. Kim, J. S. Hill Board 224 Prognostic impact of different FDG-PET uptake according to histology in advanced gastric cancer. (Abstract 4113) H. Chon, A. Cho, C. Kim, S. Heo, H. C. Chung, S. Noh, M. Yun, S. Y. Rha Board 225 Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of necuparanib combined with nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer: Phase 1 results. (Abstract 4114) E. M. O’Reilly, D. Mahalingam, J. M. Roach, B. C. Schultes, M. E. Rosano, P. J. Miller, J. Wolf, K. Flaherty, D. P. Ryan Board 226 A multicenter, phase II trial of preoperative gemcitabine and nab-paclitaxel for resectable pancreas cancer: The AGITG GAP study. (Abstract 4115) A. Barbour, N. O’Rourke, M. D. Chandrasegaram, Y. Chua, J. Kench, J. S. Samra, N. Pavlakis, K. S. Haghighi, S. Yip, J. Fawcett, M. Donoghoe, K. Walker, M. E. Burge, S. Gananadha, M. Harris, M. Aghmesheh, W. L. Joubert, V. Gebski, J. Simes, D. Goldstein Board 227 Randomized phase II study of S-1 and concurrent radiotherapy with versus without induction chemotherapy of gemcitabine for locally advanced pancreatic cancer (JCOG1106). (Abstract 4116) A. Fukutomi, J. Mizusawa, H. Katayama, S. Nakamura, Y. Ito, N. Hiraoka, T. Ioka, M. Ueno, M. Ikeda, K. Sugimori, K. Shimizu, T. Okusaka, M. Ozaka, H. Yanagimoto, S. Nakamori, T. Azuma, A. Hosokawa, N. Sata, T. Mine, J. Furuse, Japan Clinical Oncology Group (JCOG) Board 228 A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer. (Abstract 4117) A. J. Scott, B. H. O’Neil, W. Ma, S. J. Cohen, D. Aisner, A. R. Menter, M. A. Tejani, J. K. Cho, P. Rubin, A. L. Coveler, O. O. Olowokure, J. C. Baranda, M. Cusnir, P. A. Philip, J. Boles, R. T. Maguire, F. Wilhelm, M. Maniar, C. Gomes, W. A. Messersmith Board 229 A phase Ib study of the anti-cancer stem cell agent demcizumab (DEM) & gemcitabine (GEM) ⴙ/- paclitaxel protein bound particles (nab-paclitaxel) in pts with pancreatic cancer. (Abstract 4118) M. Hidalgo, P. Cooray, M. B. Jameson, A. Carrato, F. Parnis, M. Jeffery, P. S. Grimison, R. J. Stagg, A. M. Kapoun, J. Dupont, N. C. Tebbutt Board 231 SWOG S1115: Randomized phase II trial of selumetinib (AZD6244; ARRY 142886) hydrogen sulfate (NSC-748727) and MK-2206 (NSC-749607) vs. 227 MONDAY Monday, June 1, 2015 Monday, June 1, 2015 mFOLFOX in pretreated patients (Pts) with metastatic pancreatic cancer. (Abstract 4119) V. M. Chung, S. L. McDonough, P. A. Philip, D. B. Cardin, A. Wang-Gillam, L. Hui, A. M. Lowy, K. Guthrie, C. D. Blanke, H. S. Hochster MONDAY Board 232 Effectiveness and tolerability of maintenance capecitabine administrated to patients with metastatic pancreatic cancer treated with first line FOLFIRINOX. (Abstract 4120) J. Reure, P. Follana, J. Gal, L. Evesque, G. Cavaglione, A. Saint, E. Francois Board 233 A prospective, single-arm, phase I/II trial of RAS peptide vaccine TG01/GMCSF and gemcitabine as adjuvant therapy for patients with resected pancreatic adenocarcinoma. (Abstract 4121) D. H. Palmer, S. Dueland, J. W. Valle, T. Otterhaug, J. A. Eriksen, H. Muller, B. Iversen, R. M. Miller Board 234 DocOx (AIO-PK0106): A phase II trial with docetaxel and oxaliplatin as a second-line systemic therapy for patients with advanced and/or metastatic adenocarcinoma of the pancreas—Final results. (Abstract 4122) T. J. Ettrich, L. Perkhofer, V. Kaechele, A. W. Berger, M. Guethle, R. Muche, G. von Wichert, T. M. Gress, P. Michl, M. Geissler, H. F. Hebart, P. Buechner-Steudel, T. Seufferlein Board 235 Nab paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after failure of folfirinox: Results of an AGEO multicenter prospective cohort. (Abstract 4123) A. Portal, S. Pernot, C. Arbaud, D. Tougeron, A. Thirot-Bidault, C. De La Fouchardiere, P. Hammel, T. Lecomte, J. Dreanic, R. Coriat, J. Bachet, O. Dubreuil, L. Marthey, L. Dahan, J. Legoux, C. Locher, C. Lepère, P. Rougier, F. Bonnetain, J. Taieb Board 236 Multiplatform molecular profiling of pancreatic adenocarcinomas to identify BRCA1/2 mutations and PD-1/PD-L1 status with therapeutic implications. (Abstract 4124) S. Z. Millis, B. L. Abbott, E. H. Baker, R. Bender, J. Swensen, Z. Gatalica, S. K. Reddy, A. Rosemurgy, D. A. Iannitti Board 237 A retrospective single institution review of 90 pancreatic adenosquamous cancer (PASC) patients (pts). (Abstract 4125) J. B. Goldstein, G. M. NoguerasGonzalez, M. M. Javle, M. H. Katz, G. R. Varadhachary, D. R. Fogelman, M. J. Overman, R. A. Wolff, R. T. Shroff Board 238 A quantitative analysis of funding for pancreatic cancer research. (Abstract 4126) A. E. Hendifar, X. Zhang, R. Aizenberg, M. McCurrach, P. Morin, R. Tuli, L. Matrisian, L. Davies Board 239 Discovery of new potentially actionable mutations in pancreatic ductal adenocarcinoma by next generation sequencing. (Abstract 4127) M. Di Marco, S. Durante, S. Vecchiarelli, E. Grassi, A. Palloni, V. Indio, A. Astolfi, R. Panzacchi, D. Santini, R. Casadei, C. Ricci, G. Taffurelli, G. Ercolani, N. Pagano, L. Calculli, C. Serra, F. Minni, A. Pinna, M. A. Pantaleo, G. Biasco Board 240 Dendritic cells generated with PDL-1 checkpoint blockade for treatment of advanced pancreatic cancer. (Abstract 4128) J. Nesselhut, D. Marx, N. Cillien, H. Lange, G. Regalo, M. Herrmann, T. Hupfeld, R. Y. Chang, T. Nesselhut Board 241 Targeting Sema3D in pancreatic cancer: A novel therapeutic strategy. (Abstract 4129) A. Murphy, J. Kleponis, A. Rucki, E. M. Jaffee, L. Zheng, K. Foley Board 243a A randomized, double-blind, placebo-controlled phase III study of cisplatin plus a fluoropyrimidine with or without ramucirumab as first-line therapy in patients with metastatic gastric or gastroesophogeal junction (GEJ) adenocarcinoma (RAINFALL, NCT02314117). (Abstract TPS4131) C. S. Fuchs, J. Tabernero, S. Al-Batran, I. Chau, D. H. Ilson, E. Van Cutsem, D. Ferry, M. Emig, A. S. Melemed, V. Vanvoorden, Y. Hsu, Y. Xu, A. Sashegyi, M. Das, M. A. Shah Board 243b Perioperative chemotherapy and cytoreductive surgery with versus without HIPEC in gastric cancer with limited peritoneal metastases: A randomized phase III study (GASTRIPEC). (Abstract TPS4132) B. Rau, M. Loeffler, H. Rau, U. Sulkowski, J. Kuhlmann, A. Weimann, T. Keck, M. Angele, S. A. Topp, A. Koenigsrainer, E. Kuhnt, A. Kretzschmar, W. Knoefel, P. C. Thuss-Patience 228 Board 244a Perioperative chemotherapy vs. adjuvant chemotherapy for potentially resectable gastric cancer: A randomized and multicenter phase III study in locally advanced gastric cancer with D2 dissection. (Abstract TPS4133) Q. Zhao, Y. Li, C. Lian, B. Li, W. Li, Z. Huo, Z. Wang, Y. Wang, Y. Tian, S. Xie, S. Li Board 244b The Nationwide Cancer Genome Screening Projects for Gastrointestinal Cancer in Japan (SCRUM-Japan GI-SCREEN): Efficient identification of actionable cancer genome alterations in advanced colorectal and noncolorectal gastrointestinal cancer (GI Screen 2013– 01-CRC and 2015– 01-Non CRC). (Abstract TPS4134) K. Shitara, I. Miki, T. Sudo, S. Fujii, T. Kuwata, W. Okamoto, T. Denda, T. Kajiwara, S. Yuki, T. E. Nakajima, A. Takashima, K. Kawasaki, T. Tamura, T. Esaki, T. Yamanaka, A. Ochiai, T. Doi, A. Ohtsu, T. Hotta, T. Yoshino Board 245a Multicohort phase II KEYNOTE-059 study of pembrolizumab (MK-3475) for recurrent or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. (Abstract TPS4135) C. S. Fuchs, A. E. Denker, J. Tabernero, E. Van Cutsem, A. Ohtsu, B. Lam, M. Koshiji, Y. Bang Board 245b A randomized phase III study of neoadjuvant chemotherapy with docetaxel(D), oxaliplatin(O), and S-1(S) (DOS) followed by surgery and adjuvant S-1 vs. surgery and adjuvant S-1 for resectable advanced gastric cancer (PRODIGY). (Abstract TPS4136) Y. Kang, J. Yook, M. Ryu, J. Lee, Y. Park, I. Chung, M. Jung, Y. Kim, M. Kim, S. Oh, S. Kim, J. Kim, H. Song, S. Ryu, S. Roh, M. Kook, K. Shim, G. Kim, S. Noh Board 246a A randomized phase III study of adjuvant capecitabine vs observation in curatively resected stage IB (by AJCC 6th edition) gastric cancer (CATALYSIS; KCSG ST14 – 05). (Abstract TPS4137) M. Ryu, J. Y. Cho, D. Zang, W. Lee, K. Lee, D. Shin, B. Nam, S. Lee, H. Lee, J. Kim, I. Hwang, J. Baek, C. Yoo, Y. Kang Board 246b A phase III study to compare efficacy and safety of DHP107 (oral paclitaxel) versus IV paclitaxel in patients with metastatic or recurrent gastric cancer after failure of first-line chemotherapy (DREAM). (Abstract TPS4138) S. Oh, M. Ryu, S. Park, B. Ryoo, J. Kim, I. Chung, Y. Park, S. Rha, M. Kang, J. Y. Cho, S. Kang, Y. Hong, B. Nam, Y. Jo, K. Yoon, Y. Kang Board 247a The BRIGHTER trial: A phase III randomized double-blind study of BBI608 ⴙ weekly paclitaxel versus placebo (PBO) ⴙ weekly paclitaxel in patients (pts) with pretreated advanced gastric and gastro-esophageal junction (GEJ) adenocarcinoma. (Abstract TPS4139) M. A. Shah, K. Muro, K. Shitara, N. C. Tebbutt, Y. Bang, F. Lordick, L. Borodyansky, C. Li Board 247b Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1): A randomized, multidisciplinary, multinational phase III trial. (Abstract TPS4140) A. Stein, D. Arnold, W. O. Bechstein, J. A. Bridgewater, D. Goldstein, L. H. Jensen, S. Kasper, H. Klümpen, V. Kunzmann, U. Lindig, A. W. Lohse, B. Nashan, J. N. Primrose, R. Markus, J. A. Shannon, M. Sinn, W. Karl-Heinz, H. Wege Board 248a Randomised phase III study of gemcitabine, cisplatin plus S-1 (GCS) compared with gemcitabine plus cisplatin (GC) for unresectable or recurrent biliary tract cancer (KHBO1401-MITSUBA). (Abstract TPS4141) T. Ioka, M. Kanai, S. Kobayashi, D. Sakai, A. Kitasato, H. Yamaue, H. Hayashi, N. Chayahara, M. Takahashi, T. Yamada, E. Hatano, T. Goto, J. Fujimoto, M. Murakami, K. Kamei, K. Yoshimura, KHBO1401-MITSUBA Study Group Board 248b SWOG S1310: Randomized phase II trial of single agent MEK inhibitor trametinib vs. 5-fluorouracil or capecitabine in refractory advanced biliary cancer. (Abstract TPS4142) R. D. Kim, S. McDonough, A. B. El-Khoueiry, T. S. Bekaii-Saab, K. Guthrie, H. S. Hochster Board 249a Randomized phase III study of etoposide plus cisplatin versus irinotecan plus cisplatin in advanced neuroendocrine carcinoma of the digestive system: A Japan Clinical Oncology Group study (JCOG1213). (Abstract TPS4143) C. Morizane, N. Machida, Y. Honma, T. Okusaka, N. Boku, K. Kato, J. 229 MONDAY Monday, June 1, 2015 Monday, June 1, 2015 Mizusawa, H. Katayama, N. Hiraoka, H. Taniguchi, M. Ikeda, Y. Shibuya, A. Hosokawa, N. Mizuno, T. Sano, M. Tsuda, O. Yokosuka, Y. Kitagawa, M. Sasako, J. Furuse, Japan Clinical Oncology Group (JCOG) MONDAY Board 250a A randomized phase II trial of epigenetic therapy following adjuvant treatment in patients with resected pancreatic cancer and high risk for recurrence. (Abstract TPS4144) K. A. Reiss, N. Ahuja, S. Baylin, L. A. Mauro, S. Linden, S. White, D. A. Laheru, J. M. Herman, C. L. Wolfgang, M. J. Weiss, J. L. Cameron, M. Makary, N. S. Azad Board 250b A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211). (Abstract TPS4145) P. L. Kunz, P. J. Catalano, H. S. Nimeiri, G. A. Fisher, T. A. Longacre, I. Schrijver, D. L. Reidy, J. R. Strosberg, P. J. O’Dwyer, A. B. Benson III Board 251a JANUS 2: A phase III study of survival, tumor response, and symptom response with ruxolitinib plus capecitabine or placebo plus capecitabine in patients with advanced or metastatic pancreatic cancer (mPC) who failed or were intolerant to first-line chemotherapy. (Abstract TPS4146) E. M. O’Reilly, C. Walker, J. Clark, K. J. Brill, F. W. Dawkins, J. C. Bendell Board 251b JANUS 1: A phase 3, placebo-controlled study of ruxolitinib plus capecitabine in patients with advanced or metastatic pancreatic cancer (mPC) after failure or intolerance of first-line chemotherapy. (Abstract TPS4147) H. Hurwitz, W. M. Garrett, J. Clark, K. J. Brill, F. W. Dawkins, M. Hidalgo, E. Van Cutsem Board 252a Randomized phase II study of the safety, efficacy, and immune response of GVAX pancreas vaccine (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (STELLAR). (Abstract TPS4148) D. T. Le, T. S. Crocenzi, J. N. Uram, E. R. Lutz, D. A. Laheru, E. A. Sugar, R. H. Vonderheide, G. A. Fisher, A. H. Ko, A. L. Murphy, K. McDougall, S. Ferber, D. G. Brockstedt, E. M. Jaffee Board 252b POLO: A randomized phase III trial of olaparib tablets in patients with metastatic pancreatic cancer (mPC) and a germline BRCA1/2 mutation (g BRCA m) who have not progressed following first-line chemotherapy. (Abstract TPS4149) H. L. Kindler, G. Y. Locker, H. Mann, T. Golan Board 253a ACCEPT: Afatinib as cancer therapy for exocrine pancreatic tumors–An explorative randomized phase II trial. (Abstract TPS4150) M. Haas, S. H. Boeck, D. Waldschmidt, A. Reinacher-Schick, J. Freiberg-Richter, T. Seufferlein, S. Kanzler, R. Mahlberg, J. T. Siveke, V. Heinemann Board 253b Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus surgery-first for resectable pancreatic carcer (Prep-02/JSAP05). (Abstract TPS4151) M. Unno, F. Motoi, T. Kosuge, H. Ueno, H. Yamaue, S. Satoi, M. Sho, G. Honda, I. Matsumoto, K. Wada, J. Furuse, T. Furukawa, K. Ishida, K. Takase, Y. Matsuyama, K. Nakagawa, Y. Katayose Board 254a Randomized multicenter phase II/III study with adjuvant gemcitabine versus neoadjuvant/adjuvant FOLFIRINOX in resectable pancreatic cancer: The NEPAFOX trial. (Abstract TPS4152) W. Hozaeel, C. Pauligk, N. Homann, K. Luley, T. W. Kraus, J. Trojan, W. O. Bechstein, K. Grimm, B. Heise, W. Schmiegel, D. Pink, S. Al-Batran Board 254b nab-paclitaxel (nab-P) plus gemcitabine (Gem) vs Gem alone as adjuvant treatment for resected pancreatic cancer (PC) in a phase III trial (APACT). (Abstract TPS4153) M. A. Tempero, D. B. Cardin, A. Biankin, D. Goldstein, M. Moore, E. M. O’Reilly, P. A. Philip, H. Riess, T. Macarulla, L. Yung, M. Li, B. Lu 230 Monday, June 1, 2015 8:00 AM - 11:30 AM Poster Session Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers Location: S Hall A Board 255 Final results of phase Ib of tarextumab (TRXT, OMP-59R5, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC). (Abstract 7508) M. Pietanza, A. I. Spira, R. M. Jotte, S. M. Gadgeel, A. C. Mita, L. L. Hart, W. L. Gluck, A. C. Chiang, S. V. Liu, A. M. Kapoun, L. Xu, D. Hill, J. Dupont, D. R. Spigel, L. Zhou Board 256 Lurbinectedin (PM01183) with doxorubicin (DOX), an active treatment as second-line therapy in small cell lung cancer (SCLC). (Abstract 7509) M. Forster, E. Calvo, M. Olmedo Garcia, M. Lopez Criado, V. Moreno, A. Soto-Matos, E. Holgado, N. F. Brown, M. Flynn, V. Boni, E. Guerra Alia, S. A. Szyldergemajn Board 257 Pazopanib (P) or placebo in completely resected stage I NSCLC patients: Survival results of the phase II trial IFCT-0703. (Abstract 7510) B. Besse, J. Mazières, L. Ribassin-Majed, F. Barlesi, J. Bennouna, R. Gervais, L. Moreau, H. Berard, D. Debieuvre, O. Molinier, D. Moro-Sibilot, P. J. Souquet, J. Pignon Sr., E. Amour, A. Celebic, F. Morin, B. Milleron, G. Zalcman, J. Soria, French Cooperative Thoracic Intergroup (IFCT) Board 258 ARQ 197 in patients with previously-treated malignant mesothelioma (MM): A phase II trial from the University of Chicago Phase II Consortium. (Abstract 7511) S. B. Maron, T. Karrison, R. Kanteti, K. A. Rao, D. R. Gandara, M. Koczywas, R. Salgia, H. L. Kindler Board 259 A randomized phase II study of TS-1 plus cisplatin versus vinorelbine plus cisplatin with concurrent thoracic radiotherapy for locally advanced nonsmall cell lung cancer (LA-NSCLC): WJOG 5008L. (Abstract 7512) T. Seto, T. Sasaki, T. Yamanaka, N. Kunitake, J. Shimizu, T. Kodaira, M. Nishio, T. Kozuka, T. Takahashi, H. Harada, N. Yoshimura, S. Tsutsumi, H. Kitajima, M. Kataoka, K. Nakagawa, Y. Nishimura, Y. Nakanishi Board 260 Survival following stereotactic body radiation therapy or conventionally fractionated radiation for definitive non-operative treatment of stage I non-small cell lung cancer: A review of the National Cancer Data Base. (Abstract 7513) C. G. Robinson, A. Patel, J. D. Bradley, T. A. DeWees, S. Rehman, M. C. Roach, D. Morgensztern, T. Crabtree, V. Puri Board 261 Trimodality therapy in the treatment of stage IIIA non-small cell lung cancer (NSCLC): Analysis of the National Cancer Database. (Abstract 7514) M. Behera, C. E. Steuer, F. Fernandez, Y. Liu, C. Fu, T. W. Gillespie, K. A. Higgins, N. F. Saba, R. N. Pillai, S. Force, S. Pakkala, D. M. Shin, T. K. Owonikoko, C. P. Belani, W. J. Curran Jr., F. R. Khuri, S. S. Ramalingam Board 262 Programmed cell death 1 (PD-1) and its ligand (PD-L1) expression in thymic epithelial tumors (TETs): Impact on the treatment efficacy and alteration in expression after chemotherapy (C). (Abstract 7515) Y. Katsuya, H. Horinouchi, T. Asao, S. Kitahara, K. Sunami, Y. Seki, Y. Goto, S. Kanda, Y. Fujiwara, H. Nokihara, N. Yamamoto, K. Tsuta, S. Watanabe, Y. Ohe Board 263 Defining the immunologic phenotype of thymic epithelial tumors. (Abstract 7516) J. Naidoo, K. Steele, C. S. Sima, J. Yuan, P. B. Robbins, A. L. Moreira, M. Pietanza, J. D. Wolchok, G. J. Riely, N. A. Rizvi Board 264 Evaluating causes of screen failure (SF) in non-small cell lung cancer (NSCLC) clinical trials requiring specific biomarker (BioM) results for enrollment. (Abstract 7517) D. J. Nameth, J. W. Goldman, B. R. Wolf, D. J. 231 MONDAY Abstracts 7508 –7519 will be discussed during the Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers Poster Discussion Session. See page 255 for session information. Monday, June 1, 2015 Wong, B. A. Ledezma, M. A. Mendenhall, O. Oshodi, S. R. Carrasco, C. R. Adame, P. A. Abarca, M. Han, W. Sago, M. L. Spiegel, J. M. Horton, D. D. Pan, D. Gaut, C. Diamant, S. M. Rosales, E. B. Garon MONDAY Board 265 Prospective molecular analysis of small cell lung cancer (SCLC) using next generation sequencing (NGS). (Abstract 7518) M. Pietanza, H. H. Won, N. Rekhtman, L. Wang, W. D. Travis, L. M. Krug, A. M. Varghese, P. K. Paik, G. J. Riely, M. F. Zakowski, M. Ladanyi, M. F. Berger, M. G. Kris, C. M. Rudin Board 266 Genomic profiling of large-cell neuroendocrine carcinoma of the lung. (Abstract 7519) T. Miyoshi, S. Umemura, Y. Matsumura, S. Mimaki, S. Tada, G. Ishii, S. Matsumoto, K. Yoh, S. Niho, H. Ohmatsu, K. Aokage, T. Hishida, J. Yoshida, K. Nagai, K. Goto, M. Tsuboi, K. Tsuchihara Board 267 Adjuvant chemotherapy for patients with T2N0M0 non-small cell lung cancer. (Abstract 7520) D. Morgensztern, S. N. Waqar, A. Patel, S. Devarakonda, S. H. Waqar, F. Gao, C. G. Robinson, J. D. Bradley, M. Q. Baggstrom, R. Govindan, V. Puri Board 268 Prognostic effect of single versus multiple somatic mutations in non-small cell lung cancer (NSCLC). (Abstract 7521) K. Jao, P. Tomasini, S. Kamel-Reid, M. S. Tsao, G. J. Korpanty, C. Mascaux, G. Liu, N. B. Leighl, R. Feld, P. A. Bradbury, M. Ennis, F. A. Shepherd Board 269 Validation of a cell cycle progression score for 5-year mortality risk in patients with stage I non-small cell lung cancer. (Abstract 7522) T. Eguchi, K. Kyuichi, B. Evans, C. S. Sima, T. Davis, S. A. Hamilton, K. Yager, K. A. Kolquist, J. T. Jones, A. Hartman, P. S. Adusumili Board 270 The effect of platinum based adjuvant chemotherapy on survival in the surgically resected lung adenocarcinoma according to the expression of EGFR mutation specific antibody and c-MET. (Abstract 7523) I. Kim, J. Lee, S. Kim, H. An, S. Chun, E. Jeon, S. Hong, T. Kim, K. Lee, S. Sung, J. Park, Y. Kim, J. Kim, J. Kang Board 271 Therapeutic Interventional Mapping System (TIMS): A novel strategy for the selection of tri-targeted therapy combinations for non-small cell lung cancer (NSCLC). (Abstract 7524) J. Mendelsohn, V. Lazar, E. Rubin, Y. Pawitan, C. Bresson, J. Soria, A. Eggermont, F. Wunder, J. Scoazec, W. K. Hong, J. Blay, R. L. Schilsky, R. Kurzrock Board 272 Prognostic value of cytokine profile on survival in non-small cell lung cancer patients treated with radiotherapy. (Abstract 7525) S. Wang, J. Chen, R. Ten Haken, P. Stanton, F. Kong Board 273 Final overall survival (OS) analysis of a multicenter phase II study of concurrent high-dose (72Gy) three-dimensional conformal radiotherapy (3D-RT) without elective nodal irradiation with chemotherapy using cisplatin (CDDP) and vinorelbine (VNR) in patients with stage III non-small cell lung cancer (NSCLC). (Abstract 7526) H. Horinouchi, I. Sekine, M. Sumi, T. Soejima, M. Satouchi, H. Nagakura, H. Isobe, N. Nishiyama, M. Harada, N. Ishizuka, T. Tamura, Y. Ohe Board 274 Incomplete non-small-cell lung cancer (NSCLC) resections in the National Cancer Data Base (NCDB): Predictors, prognosis and value of adjuvant therapy. (Abstract 7527) R. U. Osarogiagbon, C. Lin, M. Smeltzer, A. Jemal Board 275 Phase II trial of neoadjuvant bevacizumab plus pemetrexed and carboplatin in patients with unresectable stage III lung adenocarcinoma (GASTO 1001). (Abstract 7528) S. Wang, W. Ou, N. Li, S. Zhang, Q. Liu, P. Xu, C. Yuan, B. Wang Board 276 Phase I study of bi-weekly nab—paclitaxel and carboplatin with concurrent thoracic radiotherapy for locally advanced non-small cell lung cancer. (Abstract 7529) Y. Hasegawa, D. Miura, T. Ota, J. Yokouchi Board 277 Genomic heterogeneity of lung cancers and its potential clinical implications. (Abstract 7530) J. Zhang, Y. Liu, D. R. Gomez, J. Fujimoto, C. Behrens, A. M. Correa, C. Gumbs, X. Mao, S. Seth, X. Song, J. Heymach, J. Lee, S. Swisher, W. N. William Jr., W. K. Hong, Y. Gao, I. I. Wistuba, A. Futreal 232 Board 278 The impact of a Bim deletion polymorphism on the survival of patients with completely resected non-small cell lung cancer. (Abstract 7531) J. Atsumi, K. Shimizu, K. Kaira, T. Nagashima, Y. Ohtaki, K. Obayashi, S. Kakegawa, O. Kawashima, M. Kamiyoshihara, M. Sugano, I. Takeyoshi Board 279 Prognostic value of miRNAs in resected lung adenocarcinomas. (Abstract 7532) S. Gallach, E. Jantus-Lewintre, S. Calabuig-Fariñas, A. Blasco, R. Guijarro, M. Martorell, C. Camps Board 280 “The burden upon me”: The complexity of healthcare utilization among Medicare patients undergoing curative lung cancer treatment. (Abstract 7533) C. J. Presley, P. R. Soulos, J. B. Yu, C. P. Gross Board 281 Effects of obesity and smoking on survival in non-small cell lung cancer. (Abstract 7534) D. M. Hansra, T. Koru-Sengul, W. Zhao, F. Miao, S. L. Tannenbaum, A. P. Monedero, D. J. Lee, J. Antunez de Mayolo, J. Hurley, M. M. Byrne Board 282 Association between the EGFR or KRAS mutation status and the FDG-PET findings in surgically resected lung adenocarcinoma. (Abstract 7535) K. Takamochi, K. Mogushi, K. Imashimizu, M. Fukui, S. Oh, M. Itoh, Y. Hayashizaki, K. Suzuki, H. Kawaji Board 283 Comparison of concurrent use of carboplatin-Paclitaxel versus cisplatinetoposide with thoracic radiation for stage III NSCLC patients: A systematic review. (Abstract 7536) C. E. Steuer, M. Behera, K. A. Higgins, N. F. Saba, D. M. Shin, S. Pakkala, R. N. Pillai, T. K. Owonikoko, W. J. Curran Jr., C. P. Belani, F. R. Khuri, S. S. Ramalingam Board 284 Pulmonary sarcomatoid carcinoma: An analysis of the National Cancer Database. (Abstract 7537) C. E. Steuer, M. Behera, Y. Liu, C. Fu, T. W. Gillespie, N. F. Saba, D. M. Shin, R. N. Pillai, S. Pakkala, T. K. Owonikoko, F. R. Khuri, S. S. Ramalingam Board 285 Association between radiation dose and outcomes with postoperative radiotherapy for N0-N1 non-small-cell-lung cancer. (Abstract 7538) E. H. Wang, C. D. Corso, H. S. Park, A. B. Chen, A. W. Kim, L. D. Wilson, R. H. Decker, J. B. Yu Board 286 Common and rare EGFR mutations (EGFR m) in the RADIANT trial: Final follow-up with 5 year data. (Abstract 7539) F. A. Shepherd, W. E. Eberhardt, N. K. Altorki, M. E. O’Brien, J. Wang, J. Wu, S. Gill, K. Iwata, F. C. Richardson, J. D. Horan, M. A. Foley, K. Kelly Board 287 Final follow-up (f/u) results from RADIANT: A randomized double blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection in patients (pts) with stage IB–IIIA EGFR positive (IHC/FISH) non-small cell lung cancer (NSCLC). (Abstract 7540) M. E. O’Brien, K. Kelly, N. K. Altorki, W. E. Eberhardt, D. R. Spigel, L. Crino, C. Tsai, J. Kim, E. Cho, P. C. Hoffman, S. Keshavjee, S. Orlov, P. Serwatowski, J. Wang, M. A. Foley, J. D. Horan, F. A. Shepherd Board 288 A phase II study of concurrent chemoradiotherapy with cisplatin and oral S-1, followed by surgery for locally advanced non-small cell lung cancer. (Abstract 7541) T. Tsuchiya, Y. Nakamura, N. Hayashi, K. Matsumoto, T. Miyazaki, K. Tabata, J. Fukuoka, N. Yamasaki, T. Nagayasu Board 289 Retrospective analysis between PD-L1 expression and prognosis for stage III non-small cell lung cancer patients who received concurrent chemoradiotherapy. (Abstract 7542) T. Tokito, K. Azuma, H. Ishii, K. Yamada, T. Hoshino Board 290 Correlation between high-resolution computed tomography findings and IASLC/ATS/ERS classification of small lung adenocarcinomas in Japanese patients. (Abstract 7543) Y. Kudo, J. Matsubayashi, Y. Shimada, S. Akata, Y. Kato, M. Kakihana, N. Kajiwara, T. Ohira, T. Nagao, N. Ikeda 233 MONDAY Monday, June 1, 2015 Monday, June 1, 2015 MONDAY Board 291 Comprehensive analysis of driver mutations in Chinese squamous cell lung carcinomas by targeted next-generation sequencing. (Abstract 7544) S. Yang, D. Tao, D. Wu, N. Zhang, L. Wang, Y. Liu, X. Han, Y. Shi Board 292 Prognostic significance of a diagnosis of multiple lung cancers. (Abstract 7545) J. Naidoo, K. Woo, C. S. Sima, D. J. Finley, W. D. Travis, V. W. Rusch, M. G. Kris, M. G. Zauderer Board 293 Patterns and effectiveness of surveillance after curative intent surgery in stage I-IIIA non-small cell lung cancer. (Abstract 7546) C. A. Ciunci, E. C. Paulson, N. Mitra, C. M. Veenstra, J. Yang, C. J. Langer, A. J. Epstein, A. Vachani Board 294 Prognostic role of expression levels of FABP3 and AKR1B10 genes in adenocarcinoma stage I patients. (Abstract 7547) V. Ludovini, A. Siggillino, F. Bianconi, L. Pistola, R. Chiari, G. Metro, F. R. Tofanetti, J. Vannucci, S. Treggiari, G. Bellezza, A. Sidoni, F. Puma, L. Crino Board 295 Utility of 18F-FDG PET and CT to assess response to neoadjuvant chemotherapy. (Abstract 7548) J. E. Chaft, J. Naidoo, M. Dunphy, K. Woo, C. S. Sima, R. J. Downey, W. D. Travis, M. G. Kris Board 296 Aneuploidy of anaplastic lymphoma kinase (ALK) gene and association with non squamous lung cancer patient characteristics and outcomes. (Abstract 7549) T. K. Owonikoko, M. Nelson, S. Y. Park, S. Kim, C. E. Steuer, M. Behera, Z. Chen, E. Han, M. Kumar, V. Ernani, N. F. Saba, F. R. Khuri, S. S. Ramalingam, M. R. Rossi Board 298 Conditional survival estimates for lung cancer histologic subtypes in the U.S. (2004 –2008). (Abstract 7550) K. Mosalpuria, Y. Xing, C. Hu, V. R. Bhatt, A. Ganti Board 299 PD-L1, PD-1, and CTLA-4 as prognostic biomarkers in resected non-small cell lung cancer. (Abstract 7551) T. K. Owonikoko, J. Kowalski, S. Kim, B. Dwivedi, Z. Chen, M. Behera, W. Mayfield, R. C. Hermann, L. Chen, F. R. Khuri, S. S. Ramalingam, G. Sica Board 300 A phase II feasibility study of preoperative chemotherapy with bevacizumab for resectable stage II/IIIA non-squamous non-small cell lung cancer. (Abstract 7552) Y. Miyata, Y. Tsutani, K. Suzuki, K. Takamochi, F. Tanaka, H. Nakayama, Y. Yamashita, M. Tsuboi, M. Oda, M. Okada Board 301 Phase I study of vorinostat with concurrent chemoradiotherapy (CRT) for locally advanced non-squamous non-small cell lung cancer (NSCLC). (Abstract 7553) R. Mehra, A. Turaka, J. E. Meyer, B. L. Egleston, T. Tanvetyanon, M. C. Pinder, T. J. Dilling, C. C. Williams, J. E. Gray, K. Shirai, R. K. Alpaugh, D. Riordan, N. Somaiah, P. C. Shah, W. J. Scott, G. R. Simon, H. Borghaei Board 302 Clinicopathological characteristics of squamous cell carcinoma of the lung with programmed cell death ligand 1 (PD-L1) protein expression. (Abstract 7554) T. Huynh, A. Chi, V. Morales Oyarvide, J. F. Gainor, A. N. Hata, M. Lanuti, E. J. Mark, J. A. Engelman, M. Mino-Kenudson Board 303 Clinicopathological and molecular parameters of lung adenocarcinomas (ADC) associated with programmed cell death ligand 1 (PD-L1) protein expression. (Abstract 7555) T. Huynh, V. Morales Oyarvide, H. Uruga, E. Bozkurtlar, J. F. Gainor, A. N. Hata, E. J. Mark, M. Lanuti, J. A. Engelman, M. Mino-Kenudson Board 304 Isolated Thoracic Perfusion with Chemofiltration (ITP-F) for progressive and pre-treated malignant pleural mesothelioma. (Abstract 7556) K. R. Aigner, E. Selak, A. Sendler Board 305 Treatment-free interval (TFI) after first-line therapy as a prognostic and predictive factor in malignant pleural mesothelioma (MPM): Findings from the NGR015 phase III trial with NGR-hTNF plus best investigator choice (BIC) versus placebo plus BIC. (Abstract 7557) V. Gregorc, D. Ghio, C. Sallemi, A. Bulotta, G. Rossoni, M. G. Viganò, F. Fontana, S. Colombi, A. Lambiase, C. Bordignon Board 306 Prognostic and predictive value of neutrophil-to-lymphocyte ratio (NLR) in previously treated patients with malignant pleural mesothelioma (MPM) 234 Monday, June 1, 2015 Board 307 Phase I study of intra-pleural administration of GL-ONC1, an oncolytic vaccinia virus, in patients with malignant pleural effusion. (Abstract 7559) L. M. Krug, M. G. Zauderer, P. S. Adusumili, E. McGee, K. Sepkowitz, M. Klang, Y. A. Yu, P. Scigalla, V. W. Rusch Board 308 The association of T cells with survival in mesothelioma. (Abstract 7560) S. J. Chee, M. Lopez, T. Mellows, A. Alzetani, G. Thomas, C. H. Ottensmeier Board 309 Activity and safety of trabectedin in patients with sarcomatoid / biphasic malignant pleural mesothelioma (MPM). (Abstract 7561) D. L. Cortinovis, L. H. Hollander, I. C. Floriani, F. Grosso, A. Marinello, G. L. Ceresoli, I. Pacchetti, P. A. Zucali, M. D’Incalci, S. Canova, M. I. Abbate, F. Ugo, S. Vukcaj, P. Bidoli Board 310 MicroRNA prognostic signature in malignant pleural mesothelioma. (Abstract 7562) F. Grossi, A. Truini, E. Nadal, C. Genova, E. Rijavec, G. Barletta, F. Biello, S. Coco, M. Dal Bello, I. Vanni, A. Alama, D. G. Beer Board 311 High throughput therapeutic screening of malignant pleural mesothelioma (MPM) to identify correlation of sensitivity to FGFR inhibitors with BAP1 inactivation. (Abstract 7563) C. Alifrangis, J. Quispel Janssen, J. Badhai, F. Iorio, L. Schunselaar, K. Kolluri, P. Baas, M. Garnett, U. McDermott Board 312 Confirmation of high prevalence of BAP1 inactivation in mesothelioma. (Abstract 7564) A. Cercek, M. G. Zauderer, A. Rimner, V. W. Rusch, P. S. Adusumili, G. M. Nash, J. Hmeljak, M. Ladanyi, L. M. Krug Board 313 Mesothelin-targeted immunotherapy CRS-207 in combination with standard of care chemotherapy as treatment for malignant pleural mesothelioma (MPM). (Abstract 7565) R. Hassan, S. J. Antonia, E. W. Alley, H. L. Kindler, T. Jahan, J. J. Grous, S. Honarmand, K. McDougall, C. C. Whiting, N. Nair, E. Lemmens, A. L. Murphy, A. Thomas, D. G. Brockstedt Board 314 Immune escape correlates with an inflamed phenotype in malignant mesothelioma. (Abstract 7566) A. Khattri, Z. Zuo, A. N. Husain, H. L. Kindler, T. Y. Seiwert Board 315 Evaluation of CXCR4 expression on tumor and circulating tumor cells (CTCs) as predictive response marker for CXCR4 antagonist LY2510924 in combination with carboplatin-etoposide in extensive– disease small cell lung cancer (ED-SCLC). (Abstract 7567) R. Salgia, R. W. Weaver, M. McCleod, J. R. Stille, S. B. Yan, S. Roberson, O. Hamid, J. Polzer, A. Flynt, E. Raddad, D. R. Spigel Board 316 Prophylactic cranial irradiation (PCI) and consolidation thoracic radiotherapy (TRT) for extensive stage small cell lung cancer (ES-SCLC): A systematic review and meta-analysis. (Abstract 7568) Y. Soon, W. Koh, C. Leong, I. W. Tham Board 317 Loss of somatostatin receptor 2 expression and lung cancer growth. (Abstract 7569) J. Lehman, M. Hoeksema, H. Chen, C. Shi, R. Eisenberg, P. P. Massion Board 318 New ARCHITECT plasma pro-gastrin-releasing peptide assay and lung cancer: Implications for diagnosis, follow-up, and prognosis. (Abstract 7570) B. Nisman, H. Nechushtan, H. Biran, N. Peled, H. Gantz-Sorotsky, V. Doviner, M. Perelman, J. Bar, B. Uziely, T. Peretz-Yablonski Board 319 Survival impact of switching to different topoisomerase I or II inhibitorsbased regimens (topo-I or topo-II) in extensive-disease small cell lung cancer (ED-SCLC): supplemental analysis from JCOG0509. (Abstract 7571) S. Nomura, S. Umemura, K. Yoh, T. Shinozaki, T. Shibata, K. Nakamura, M. Satouchi, Y. Ohe, H. Fukuda Board 320 Phase II study of topotecan and cisplatin with sequential radiotherapy in elderly small cell lung cancer patients (Okayama Lung Cancer Study Group; OLCSG 0102). (Abstract 7572) T. Kubo, S. Harita, T. Okada, H. Kamei, S. 235 MONDAY enrolled in the NGR015 phase 3 trial. (Abstract 7558) A. Bulotta, V. Gregorc, M. G. Viganò, G. Rossoni, F. Fontana, C. Ammannati, S. Colombi, A. Lambiase, C. Bordignon Monday, June 1, 2015 Hosokawa, T. Maeda, T. Kozuki, K. Fujiwara, K. Hotta, N. Takigawa, M. Tanimoto, K. Kiura MONDAY Board 321 Detection of circulating tumor cells in the peripheral blood of patients with small cell lung cancer (SCLC) using both the CellSearch platform and immunofluorescence: Correlation with clinicopathological features. (Abstract 7573) I. Messaritakis, D. Stoltidis, E. Politaki, S. Apostolaki, E. Dermitzaki, M. Sfakianaki, A. Kotsakis, S. Agelaki, L. Vamvakas, K. Kalbakis, E. Lagoudaki, D. Mavroudis, V. Georgoulias, I. Souglakos Board 322 Distribution and clinical significance of CTLA4, PD-1 and PD-L1 in peripheral blood of patients with small-cell lung cancer. (Abstract 7574) Y. Cheng, H. Li, Y. Liu, L. Ma, X. Liu, J. Liu, S. Zhang Board 323 Clinical correlation of genomic mutations in small cell lung cancer. (Abstract 7575) A. Dowlati, P. Fu, M. Lipka, G. Wildey Board 324 Identification of RICTOR amplification as a recurrent and potentially actionable alteration in small cell lung cancer patients. (Abstract 7576) S. Dabir, G. Wildey, K. McColl, P. Fu, Y. Feng, A. Dowlati Board 325 Conditional survival estimates for small cell lung cancer receiving prophylactic cranial irradiation in the U.S. (1988 –1997). (Abstract 7577) Y. Xing, K. Mosalpuria, C. Hu, V. R. Bhatt, A. Ganti Board 326 Small cell lung cancer: Why has it become an orphan disease? (Abstract 7578) S. M. Malik, E. Korn, A. Thomas Board 327 Impact of accurate staging with 18F-FDG-PET and brain MRI on clinical benefit of prophylactic cranial irradiation (PCI) in patients with limited stage (LS) small cell lung cancer (SCLC). (Abstract 7579) M. Choi, Y. Lee, S. Moon, J. Han, H. Kim, J. Lee Board 328 Phase II trial of single agent amrubicin (A) in patients (pts) with previously treated advanced thymic malignancies (TM). (Abstract 7580) H. A. Wakelee, S. K. Padda, M. Burns, A. J. Spittler, J. Riess, M. San Pedro-Salcedo, K. Ramchandran, M. A. Gubens, J. W. Neal, P. J. Loehrer Sr. Board 329 Somatostatin analogs as mainteinance therapy in heavily pretreated thymic epithelial tumors. (Abstract 7581) G. Palmieri, M. Ottaviano, L. Nappi, P. Rescigno, M. Marino, L. Montella, M. Micillo, G. Palumbo, S. Del Vecchio, V. Damiano Board 330 Effectiveness of somatostatin analogs plus prednisone in aggressive histotype and advanced stage of thymic epithelial tumors. (Abstract 7582) M. Ottaviano, V. Damiano, L. Nappi, P. Rescigno, L. Montella, M. Marino, S. Del Vecchio, I. Tucci, C. Von Arx, G. Palmieri Board 331a ALCHEMIST: a clinical trial platform to bring genomic discovery and molecularly targeted therapies to early-stage lung cancer. (Abstract TPS7583) D. E. Gerber, G. R. Oxnard, S. J. Mandrekar, S. E. Dahlberg, S. M. Malik, M. M. Mooney, J. S. Abrams, P. A. Janne, T. Li, S. S. Ramalingam, E. E. Vokes, R. Govindan Board 331b Neoadjuvant erlotinib in stage III NSCLC patients (pts) with activating EGFR mutations (EVENT trial). (Abstract TPS7584) C. Inal, B. Piperdi, S. M. Keller, B. Halmos, M. Stoopler, S. A. Limaye, B. P. Levy, B. J. Schneider, M. Kim, J. Sides, R. Perez-Soler, H. Cheng Board 332a NCI 9448: Phase I study of trametinib in combination with chemoradiation for KRAS-mutant non-small cell lung cancer. (Abstract TPS7585) S. H. Lin, I. Mok, D. Leos, M. G. Pasia, P. F. Thall, H. Y. Lin, M. X. Welliver, M. A. Villalona-Calero, J. C. Yao, F. Meric-Bernstam, R. Komaki, H. X. Chen, G. R. Blumenschein Jr. Board 332b Phase I/II study of tumor-infiltrating lymphocyte (TIL) infusion and low-dose interleukin-2 (IL-2) in patients with advanced malignant pleural mesothelioma (MPM). (Abstract TPS7586) M. Doherty, N. B. Leighl, R. Feld, P. A. Bradbury, L. Wang, J. Nie, P. Yen, M. Pniak, L. T. Nguyen, M. O. Butler, M. de Perrot 236 Monday, June 1, 2015 8:00 AM - 11:30 AM Poster Session Lung Cancer—Non-Small Cell Metastatic Location: S Hall A Board 335 First-in-human phase I study of EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor, in advanced non-small cell lung cancer (NSCLC) harboring T790M. (Abstract 8013) D. S. Tan, T. Seto, N. B. Leighl, G. J. Riely, L. V. Sequist, E. Felip, J. Wolf, J. C. Yang, I. Matushansky, X. Yu, S. H. Schmitz, X. Cui, D. Kim Board 336 ASP8273, a mutant-selective irreversible EGFR inhibitor in patients (pts) with NSCLC harboring EGFR activating mutations: Preliminary results of first-inhuman phase I study in Japan. (Abstract 8014) Y. Goto, H. Nokihara, H. Murakami, T. Shimizu, T. Seto, A. P. Krivoshik, A. T. Keating, K. Uegaki, K. Takeda, K. Komatsu, S. Morita, M. Fukuoka, K. Nakagawa Board 337 Activity of AUY922 in NSCLC patients with EGFR exon 20 insertions. (Abstract 8015) Z. Piotrowska, D. B. Costa, M. Huberman, G. R. Oxnard, J. F. Gainor, R. S. Heist, A. Muzikansky, A. T. Shaw, M. J. Niederst, L. Fulton, J. A. Engelman, L. V. Sequist Board 338 AZD3759, an EGFR inhibitor with blood brain barrier (BBB) penetration for the treatment of non-small cell lung cancer (NSCLC) with brain metastasis (BM): Preclinical evidence and clinical cases. (Abstract 8016) D. Kim, J. C. Yang, K. Chen, Z. Cheng, L. Yin, P. D. Martin, Z. Yang, H. Jiang, M. Ahn Board 339 A phase I study of twice weekly pulse dose and daily low dose erlotinib as initial treatment for patients (pts) with EGFR-mutant lung cancers. (Abstract 8017) H. A. Yu, C. S. Sima, D. Reales, S. Jordan, C. M. Rudin, M. G. Kris, F. Michor, W. Pao, G. J. Riely Board 340 Clinical activity and safety of PF-06463922 from a dose escalation study in patients with advanced ALKⴙ or ROS1ⴙ NSCLC. (Abstract 8018) A. T. Shaw, T. M. Bauer, E. Felip, B. Besse, L. P. James, J. S. Clancy, G. Mugundu, J. Martini, A. Abbattista, B. J. Solomon Board 341 A phase II, open-label, multicenter study of the ALK inhibitor alectinib in an ALKⴙ non-small-cell lung cancer (NSCLC) U.S./Canadian population who had progressed on crizotinib (NP28761). (Abstract 8019) L. Gandhi, A. Shaw, S. M. Gadgeel, G. Riely, J. Cetnar, H. J. West, D. R. Camidge, M. A. Socinski, A. Chiappori, T. Mekhail, B. H. Chao, H. Borghaei, K. A. Gold, A. H. Zeaiter, W. Bordogna, B. Balas, O. Puig, V. Henschel, S. I. Ou, NP28761 Study Investigators Board 342 Detection of frequent MET Exon 14 skipping events in pulmonary sarcomatoid carcinoma and response to targeted inhibition. (Abstract 8020) X. Liu, Y. Jia, Y. Shen, J. Chen, M. Mansukhani, H. Cheng, S. Koul, A. C. Borczuk, B. Halmos Board 343 Response to crizotinib and cabozantinib in stage IV lung adenocarcinoma patients with mutations that cause MET exon 14 skipping. (Abstract 8021) P. K. Paik, A. E. Drilon, H. A. Yu, L. M. Krug, N. Rekhtman, L. Borsu, M. S. Ginsberg, M. F. Berger, M. Ladanyi, C. M. Rudin Board 344 Clinical and molecular characteristics of NF1 mutant lung cancer. (Abstract 8022) A. J. Redig, S. L. Mach, M. Capelletti, C. Fontes, Y. Shi, P. Chalasani, S. E. Dahlberg, P. A. Janne Board 345 Assessing the performance of Watson for oncology, a decision support system, using actual contemporary clinical cases. (Abstract 8023) M. G. Kris, A. Gucalp, A. S. Epstein, A. D. Seidman, J. Fu, J. Keesing, A. Caroline, M. Megerian, T. Eggebraaten, R. DeLima, M. Setnes, M. G. Zauderer Board 346 Electronic medical record as a research tool: Virtual clinical trial comparing pemetrexed and gemcitabine, both given with cisplatin, in patients with lung 237 MONDAY Abstracts 8013– 8024 will be discussed during the Lung Cancer—Non-Small Cell Metastatic Poster Discussion Session. See page 291 for session information. Monday, June 1, 2015 adenocarcinomas. (Abstract 8024) A. Grigorenko, P. May, N. Kastango, H. T. Thaler, I. Wagner, A. Caroline, M. G. Kris, M. G. Zauderer MONDAY Board 347 First-line monotherapy with nivolumab (NIVO; anti-programmed death-1 [PD-1]) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy and correlation of outcomes with PD-1 ligand (PD-L1) expression. (Abstract 8025) S. N. Gettinger, M. D. Hellmann, F. A. Shepherd, S. J. Antonia, J. R. Brahmer, L. Q. Chow, J. W. Goldman, R. A. Juergens, H. Borghaei, N. Ready, D. E. Gerber, F. E. Nathan, Y. Shen, C. Harbison, N. A. Rizvi Board 348 Optimizing PD-L1 as a biomarker of response with pembrolizumab (pembro; MK-3475) as first-line therapy for PD-L1–positive metastatic non-small cell lung cancer (NSCLC): Updated data from KEYNOTE-001. (Abstract 8026) N. A. Rizvi, E. B. Garon, N. Leighl, M. D. Hellmann, A. Patnaik, L. Gandhi, J. P. Eder, R. A. Rangwala, G. Lubiniecki, J. Zhang, K. Emancipator, C. M. Roach, R. Rutledge, R. Hui, M. Ahn, L. Horn, E. Felip, E. Carcereny Costa Board 349 Phase II studies of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced squamous (sq) or nonsquamous (non-sq) non-small cell lung cancer (NSCLC). (Abstract 8027) M. Nishio, T. Hida, K. Nakagawa, H. Sakai, N. Nogami, S. Atagi, T. Takahashi, H. Nokihara, H. Saka, M. Takenoyama, S. Fujita, H. Tanaka, K. Takeda, M. Satouchi, H. Isobe, M. Maemondo, K. Goto, T. Hirashima, K. Minato, T. Tamura Board 350 Clinical activity and safety from a phase II study (FIR) of MPDL3280A (antiPDL1) in PD-L1–selected patients with non-small cell lung cancer (NSCLC). (Abstract 8028) D. R. Spigel, J. E. Chaft, S. N. Gettinger, B. H. Chao, L. Y. Dirix, P. Schmid, L. Q. Chow, C. Chappey, M. Kowanetz, A. Sandler, R. P. Funke, N. A. Rizvi Board 351 Clinical activity, safety and predictive biomarkers of the engineered antibody MPDL3280A (anti-PDL1) in non-small cell lung cancer (NSCLC): update from a phase Ia study. (Abstract 8029) L. Horn, D. R. Spigel, S. N. Gettinger, S. J. Antonia, M. S. Gordon, R. S. Herbst, L. V. Sequist, C. Chappey, M. Kowanetz, A. Sandler, J. Soria Board 352 Safety and efficacy of MPDL3280A (anti-PDL1) in combination with platinumbased doublet chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). (Abstract 8030) S. V. Liu, J. D. Powderly II, D. R. Camidge, N. Ready, R. S. Heist, F. S. Hodi, G. Giaccone, B. Liu, J. Wallin, R. P. Funke, D. Waterkamp, S. N. Gettinger Board 353 Pembrolizumab (pembro; MK-3475) plus platinum doublet chemotherapy (PDC) as front-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 Cohorts A and C. (Abstract 8031) V. Papadimitrakopoulou, A. Patnaik, H. Borghaei, J. Stevenson, L. Gandhi, M. A. Gubens, J. C. Yang, L. V. Sequist, J. Yang Ge, J. Bourque, R. D. Bachman, E. Im, S. M. Gadgeel Board 354 Safety and clinical activity of MEDI4736, an anti-programmed cell deathligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC). (Abstract 8032) N. A. Rizvi, J. R. Brahmer, S. I. Ou, N. H. Segal, S. Khleif, W. Hwu, M. Gutierrez, P. Schoffski, O. Hamid, J. Weiss, J. Lutzky, M. Maio, J. J. Nemunaitis, D. Jaeger, A. S. Balmanoukian, M. Rebelatto, K. Steele, X. Li, J. A. Blake-Haskins, S. J. Antonia Board 355 Development of a PD-L1 companion diagnostic assay for treatment with MEDI4736 in NSCLC and SCCHN patients. (Abstract 8033) M. Rebelatto, A. Mistry, C. Sabalos, J. Walker, A. Midha, K. Steele, P. B. Robbins, X. Li, L. Shi, J. A. Blake-Haskins, R. A. Ibrahim, L. Richman Board 356 Avelumab (MSB0010718C), an anti-PD-L1 antibody, in advanced NSCLC patients: A phase 1b, open-label expansion trial in patients progressing after platinum-based chemotherapy. (Abstract 8034) J. L. Gulley, D. Spigel, K. Kelly, J. C. Chandler, A. Rajan, R. Hassan, D. J. Wong, J. Leach, W. J. Edenfield, D. Wang, N. Vrindavanam, G. J. Weiss, J. S. Gurtler, H. J. Grote, A. von Heydebreck, K. M. Chin, N. Iannotti 238 Board 357 Activity and safety of pembrolizumab in patients with metastatic non-small cell lung cancer with untreated brain metastases. (Abstract 8035) S. B. Goldberg, S. N. Gettinger, A. Mahajan, R. S. Herbst, A. C. Chiang, A. J. Tsiouris, A. Vortmeyer, L. Jilaveanu, S. Speaker, M. Madura, E. Rowen, H. Gerrish, E. Knapp-Perry, X. Yao, V. Chiang, H. M. Kluger Board 358 Validation of ERCC1 (E1) for response prediction to platinum-gemcitabine. (Abstract 8036) G. Bepler, W. Chen, S. Patrick, S. H. Astrow, C. Stephens, D. R. Gandara, R. Rosell, J. Ramirez, G. V. Scagliotti, S. Busso, M. Volante, S. Novello Board 359 Pre-treatment 5-methyltetrahydrofolate levels and response to pemetrexed in stage IV adenocarcinoma of the lung. (Abstract 8037) S. J. Bagley, C. J. Langer, C. Aggarwal, T. L. Evans, E. W. Alley, R. B. Cohen, S. Zhang, L. Werner, I. A. Blair, A. S. Whitehead, A. Vachani Board 360 Smoking status to predict sensitivity to PARP inhibitor, veliparib, in patients with advanced NSCLC. (Abstract 8038) S. S. Ramalingam, N. Blais, J. Mazières, M. Reck, C. Jones, E. Juhasz, L. Urban, S. Orlov, F. Barlesi, E. A. Kio, U. Keilholz, J. Qian, Q. Qin, M. Dunbar, H. Xiong, R. K. Mittapalli, P. Ansell, M. D. McKee, V. L. Giranda, V. Gorbunova Board 361 An open-label, randomized, multicenter, phase III study of S-1 and cisplatin versus docetaxel and cisplatin in patients with untreated advanced nonsmall-cell lung cancer. (Abstract 8039) J. He, Y. Shi, J. Chang, M. Wang, B. Han, X. Liu, G. Chen, C. Zhou, J. Liu, H. Pan, C. Huang, S. Zhang, J. Feng, X. Lin, J. Wang, J. Huang, F. Li, S. Qin, Z. Wang, L. Wang Board 362 SWOG 0709: A randomized phase II “pick-the-winner” trial of erlotinib (ERL) vs. ERL plus carboplatin/paclitaxel (C/T) in patients (pts) with advanced non-small cell lung cancer (NSCLC) and impaired performance status (PS 2) as selected by serum proteomics. (Abstract 8040) P. Lara, J. Moon, P. J. Hesketh, M. W. Redman, S. K. Williamson, F. R. Hirsch, P. C. Mack, D. R. Gandara Board 364 A randomized Phase 3 study comparing first-line pemetrexed plus cisplatin followed by gefitinib maintenance (PC/G) with gefitinib monotherapy (G) in East Asian patients (pts) with locally advanced or metastatic nonsquamous non-small cell lung cancer (nSqNSCLC): Final survival results. (Abstract 8041) J. C. Yang, V. Srimuninnimit, M. Ahn, C. Lin, S. Kim, C. Tsai, T. Mok, M. Orlando, T. Puri, X. Wang, K. Park Board 365 Intercalating and maintenance use of gefitinib plus chemotherapy versus chemotherapy alone in selected advanced NSCLC(ISCAN,CTONG-1102): A multicentre, open-label, randomised, phase 3 study. (Abstract 8042) S. Lu, H. Jian, W. Li, M. Z. Yong, J. Huang, J. Feng, Y. Song, B. Gao, H. Zhu, M. Tao, C. Bai, M. Shenglin, H. Pan, S. Qin, D. Hua Board 366 Maintenance therapy with gefitinib (G)/pemetrexed (P) versus P alone after induction therapy with P/platinum for metastatic lung adenocarcinoma (MLADC) harboring no sensitizing epidermal growth factor receptor mutation (sEGFRm): A phase II multicenter randomized open-label study (GENIUS trial). (Abstract 8043) C. Tsai, C. Lai, C. Chiu, T. Hsia, C. Chen, G. Chang, J. Shih, C. Ho, Y. Chen, J. C. Yang Board 367 Pharmacodynamic separation (PDS) of pemetrexed (Pem) and erlotinib (Erl) in patients (pts) with advanced, EGFR wild-type (wt) Non-Small Cell Lung Cancer (NSCLC): A randomized phase II trial. (Abstract 8044) T. Li, B. Piperdi, W. V. Walsh, M. Kim, L. A. Beckett, H. Wen, K. Zhou, R. A. Gucalp, M. Haigentz Jr., V. G. Bathini, S. Gajavelli, M. Sreedhara, P. Lara Jr., D. R. Gandara, R. Perez-Soler Board 368 A phase 1b study of the anti-cancer stem cell agent demcizumab (DEM), pemetrexed (PEM) & carboplatin (CARBO) in pts with 1st line non-squamous NSCLC. (Abstract 8045) D. Kotasek, B. G. Hughes, B. Markman, M. Millward, E. Holgado, M. B. Jameson, D. L. Harris, R. J. Stagg, A. M. Kapoun, J. Dupont, M. J. McKeage 239 MONDAY Monday, June 1, 2015 Monday, June 1, 2015 MONDAY Board 369 A phase Ib study of selumetinib in patients (pts) with previously untreated metastatic Non-Small Cell Lung Cancer (NSCLC) receiving standard chemotherapy: NCIC Clinical Trials Group IND.215. NCT01783197. (Abstract 8046) G. A. Nicholas, J. R. Goffin, S. A. Laurie, A. G. Robinson, G. D. Goss, M. N. Reaume, M. Mates, P. Wheatley-Price, P. M. Ellis, R. A. Juergens, A. T. Tomiak, R. W. Gregg, B. L. Melosky, D. Tu, H. Ritter, L. Seymour, P. A. Bradbury Board 370 A phase Ib study of abemaciclib in combination with multiple single agents in stage IV NSCLC. (Abstract 8047) E. S. Kim, K. Kelly, J. W. Goldman, P. Garrido Lopez, S. I. Jalal, D. Mahadevan, M. Gutierrez, M. Provencio Pulla, E. S. Schaefer, M. F. Shaheen, E. L. Johnston, N. Cai, W. J. John, L. Paz-Ares Board 371 Individual patients data analysis (IPD) of three randomized studies comparing erlotinib (E) with chemotherapy (CT) in patients with advanced wild-type epidermal growth factor receptor (wtEGFR) non-small cell lung cancer (NSCLC). (Abstract 8048) V. Torri, M. Ando, E. Rulli, I. C. Floriani, T. Kawaguchi, S. Isa, V. Gregorc, S. Novello, S. Barni, M. Cinquini, S. Marsoni, G. Farina, M. C. Garassino Board 372 Randomized phase III trial of erlotinib vs. docetaxel in patients with advanced squamous cell non-small cell lung cancer (SqNSCLC) failing first line platinum based doublet chemotherapy stratified by VeriStrat Good vs VeriStrat Poor: The European Thoracic Oncology Platform (ETOP) EMPHASIS trial. (Abstract 8049) S. Peters, E. F. Smit, U. Dafni, S. Ponce Aix, B. Massuti, O. Gautschi, L. Coate, A. López Martı́n, R. van Heemst, T. Berghmans, P. Meldgaard, M. Cobo Dols, J. G. Noguera, I. C. Floriani, M. Kassapian, Y. Chittazhathu Kurian Kuruvilla, A. Gasca-Ruchti, C. Zielinski, V. Gregorc, R. A. Stahel, EMPHASIS Collaborative Group Board 374 Open-label, randomized study of individualized, pharmacokinetically (PK)guided dosing of paclitaxel combined with carboplatin in advanced nonsmall cell lung cancer (NSCLC) patient. (Abstract 8051) M. Joerger, J. Von Pawel, S. Kraff, J. R. Fischer, W. Eberhardt, T. C. Gauler, L. Mueller, N. Reinmuth, M. Reck, M. Kimmich, F. Mayer, H. Kopp, D. M. Behringer, Y. Ko, M. Frueh, R. A. Hilger, M. Roessler, B. Moritz, U. Jaehde Board 375 Paclitaxel (PTX) dose individualization by exposure optimization in Chinese patients with advanced non small-cell lung cancer (NSCLC) receiving first-line paclitaxel-carboplatin (PC) chemotherapy. (Abstract 8052) J. Zhang, H. Qi, C. Zhou, H. Ni, Y. Li Board 376 Exposure-response relationship for ramucirumab (RAM) from the randomized, double-blind, phase III REVEL trial (docetaxel [DOC] vs DOC plus RAM) in second-line treatment of metastatic non-small cell lung cancer (NSCLC). (Abstract 8053) E. F. Smit, M. Perol, M. Reck, F. Cappuzzo, P. Bidoli, R. B. Cohen, L. Gao, C. Ernest II, P. Lee, A. Zimmermann, D. Ferry, J. Treat, A. S. Melemed, E. B. Garon Board 377 Docetaxel ⴙ ramucirumab (DR) versus docetaxel ⴙ placebo (D) as secondline treatment for advanced non-small cell lung cancer (NSCLC): A randomized, phase II, double-blind, multicenter trial in Japan. (Abstract 8054) Y. Hosomi, K. Yoh, K. Kasahara, K. Yamada, T. Takahashi, K. Tanaka, T. Hida, H. Yoshioka, T. Kato, K. Takeda, M. Nishio, H. Sakai, M. Maemondo, M. Takenoyama, H. Nokihara, M. Tatsumi, T. Nakamura, S. Enatsu, T. Tamura, K. Nakagawa Board 378 Exploratory analysis of safety by histology and efficacy in a nonsquamous NSCLC subgroup in REVEL: A randomized phase III study of ramucirumab (RAM) plus docetaxel (DOC) vs DOC for second-line treatment of stage IV non-small-cell lung cancer (NSCLC). (Abstract 8055) L. Paz-Ares, M. Perol, T. Ciuleanu, R. D. Kowalyszyn, M. Reck, C. R. Lewanski, K. N. Syrigos, O. Arrieta, K. Prabhash, K. Park, J. Pikiel, T. Göksel, P. S. Lee, A. Zimmerman, J. Treat, D. Ferry, A. S. Melemed, G. Cuyun Carter, E. Alexandris, E. B. Garon Board 379 Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non–small cell lung cancer (WJOG 5910L): An open-label, randomized, phase II trial. 240 Monday, June 1, 2015 Board 380 Efficacy and safety of BCD-021, bevacizumab biosimilar candidate, compared to Avastin: Results of international multicenter randomized double blind phase III study in patients with advanced non-squamous NSCLC. (Abstract 8057) O. Filon, S. Orlov, O. Burdaeva, M. V. Kopp, B. Kotiv, S. Alekseev, A. Pecheniy, D. Stroyakovskiy, O. Gladkov, A. Khorinko, M. Matrosova, R. Galiulin, P. Skopin, G. Mukhametsina, S. Odarchenko, S. Kulik, J. Kulyaba, G. Adamchuk, Y. Vinnyk, S. Tjulandin Board 381 Comparative efficacy of ceritinib and crizotinib in previously treated crizotinib-naïve anaplastic lymphoma kinase-positive (ALKⴙ) advanced or metastatic non-small cell lung cancer (NSCLC): An adjusted indirect comparison. (Abstract 8058) D. S. Tan, A. Araujo, J. Zhang, J. E. Signorovitch, Z. Zhou, X. Cai, G. Liu Board 382 ASCEND-2: A single-arm, open-label, multicenter phase II study of ceritinib in adult patients (pts) with ALK-rearranged (ALKⴙ) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ). (Abstract 8059) T. Mok, D. Spigel, E. Felip, F. deMarinis, M. Ahn, H. J. Groen, H. A. Wakelee, T. Hida, L. Crino, M. Nishio, G. V. Scagliotti, F. Branle, C. Emeremni, M. Quadrigli, J. Zhang, A. T. Shaw Board 383 ASCEND-3: A single-arm, open-label, multicenter phase II study of ceritinib in ALKi-naïve adult patients (pts) with ALK-rearranged (ALKⴙ) non-small cell lung cancer (NSCLC). (Abstract 8060) E. Felip, S. Orlov, K. Park, C. Yu, C. Tsai, M. Nishio, M. Cobo Dols, M. J. McKeage, W. Su, T. Mok, G. V. Scagliotti, D. Spigel, F. Branle, C. Emeremni, M. Quadrigli, A. T. Shaw Board 384 A phase I/II study with a CNS-penetrant, selective ALK inhibitor alectinib in ALK-rearranged non-small cell lung cancer (ALK ⴙ NSCLC) patients (pts): Updates on progression free survival (PFS) and safety results from AF001JP. (Abstract 8061) Y. Ohe, M. Nishio, K. Kiura, T. Seto, K. Nakagawa, M. Maemondo, A. Inoue, T. Hida, H. Yoshioka, M. Harada, N. Nogami, H. Murakami, K. Takeuchi, T. Shimada, H. Kuriki, T. Tanaka, T. Tamura Board 385 Safety and efficacy of brigatinib (AP26113) in advanced malignancies, including ALKⴙ non–small cell lung cancer (NSCLC). (Abstract 8062) D. R. Camidge, L. Bazhenova, R. Salgia, C. J. Langer, K. A. Gold, R. Rosell, A. T. Shaw, G. J. Weiss, N. I. Narasimhan, D. J. Dorer, V. M. Rivera, T. P. Clackson, M. G. Conlan, D. Kerstein, F. G. Haluska, S. N. Gettinger Board 386 Phase (Ph) 1/2a study of TSR-011, a potent inhibitor of ALK and TRK, in advanced solid tumors including crizotinib-resistant ALK positive non-small cell lung cancer. (Abstract 8063) H. Arkenau, J. C. Sachdev, M. M. Mita, R. Dziadziuszko, C. Lin, J. Yang, J. R. Infante, S. P. Anthony, M. Voskoboynik, W. Su, J. De Castro, R. B. Natale, Z. Zhang, L. Hughes, D. Bobilev, G. J. Weiss Board 387 A phase 1 study of crizotinib and ganetespib (STA-9090) in ALK positive lung cancers. (Abstract 8064) G. J. Riely, H. A. Yu, D. Stephens, M. Pietanza, S. Smith-Marrone, J. J. Fiore, M. Goldstein, C. S. Sima, M. G. Kris, M. S. Ginsberg Board 388 Crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC). Preliminary results of the ACSé phase II trial. (Abstract 8065) D. Moro-Sibilot, L. Faivre, G. Zalcman, M. Pérol, F. Barlesi, J. Otto, I. Monnet, A. B. Cortot, M. Wislez, H. Lena, J. Mazières, X. Durando, S. Lantuejoul, I. Rouquette, A. McLeer Florin, G. Ferretti, N. Hoog Labouret, F. Nowak, M. Jimenez, G. Vassal Board 389 ROS1 rearrangement in non-small cell lung cancer (NSCLC): Prognostic and predicitve impact and genetic variability. (Abstract 8066) M. Scheffler, A. M. Schultheis, C. Teixido, S. Y. Michels, D. Morales-Espinosa, S. Viteri, S. Merkelbach-Bruse, R. Fischer, J. Fassunke, M. Sebastian, M. H. Serke, W. Randerath, U. Gerigk, Y. Ko, S. Krüger, R. Schnell, A. Rothe, R. Rosell, R. Büttner, J. Wolf, NGM ROS1 Group 241 MONDAY (Abstract 8056) M. Takeda, T. Seto, H. Hayashi, M. Okada, K. Azuma, S. Sugawara, H. Daga, T. Hirashima, K. Yonesaka, Y. Urata, H. Murakami, H. Saito, A. Kubo, T. Sawa, E. Miyahara, N. Nogami, T. Yamanaka, Y. Nakanishi, K. Nakagawa, I. Okamoto, West Japan Oncology Group Monday, June 1, 2015 MONDAY Board 390 Defining the spectrum and “overlap” of HER2 aberrations in lung cancers: Associations of HER2 protein overexpression, HER2 amplification, and HER2 mutation. (Abstract 8067) B. T. Li, D. S. Ross, J. E. Chaft, M. Hsu, S. Kako, D. L. Aisner, M. G. Kris, M. Varella-Garcia, M. E. Arcila Board 391 Outcomes with chemotherapies and molecular characteristics of HER2mutant lung cancers. (Abstract 8068) J. Eng, B. T. Li, M. Hsu, J. E. Chaft, M. E. Arcila, M. G. Kris Board 392 EGFR mutation pattern in African American population in a communitybased academic center. (Abstract 8069) H. Cheng, C. Inal, Y. Yang, R. A. Gucalp, M. Haigentz Jr., S. H. Packer, C. Zhu, K. Wilson, R. Perez-Soler Board 393 EGFR mutations in Latinos from the United States and Latin America. (Abstract 8070) A. Lopez-Chavez, M. Evbuomwan, L. Xi, G. Chun, T. Vidaurre, O. Arrieta, G. Oblitas III, A. B. Oton, A. R. Calvo, A. Rajan, P. Amarapurkar, M. Raffeld, S. M. Steinberg, L. Arze-Aimaretti, G. Giaccone Board 394 Clinical predictors of 5-year survival in patients with EGFR-mutant metastatic NSCLC treated with EGFR-TKIs. (Abstract 8071) J. J. Lin, S. Cardarella, C. A. Lydon, S. E. Dahlberg, D. M. Jackman, P. A. Janne, B. E. Johnson Board 395 The impact on overall survival (OS) of first-line gefitinib (G) and erlotinib (E) and of clinical factors in advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor mutations (EGFR mut) based on meta-analysis of 1,231 patients (pts) enrolled in 6 major randomized trials. (Abstract 8072) C. Lee, L. C. Davies, Y. Wu, T. Mitsudomi, A. Inoue, R. Rosell, C. Zhou, K. Nakagawa, S. Throngprasert, M. Fukuoka, R. J. Gralla, V. Gebski, T. Mok, J. C. Yang Board 397 Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRmⴙ) non-small cell lung cancer (NSCLC). (Abstract 8073) J. C. Yang, M. Ahn, N. J. Dickgreber, B. Halmos, V. Hirsh, M. J. Hochmair, B. P. Levy, F. De Marinis, T. Mok, K. O’Byrne, I. Okamoto, M. H. Schuler, M. Sebastian, R. N. Shah, E. Tan, N. Yamamoto, A. Marten, D. Massey, S. Wind, D. P. Carbone Board 398 Reduced-dose versus full-dose erlotinib for advanced EGFR-mutant nonsmall cell lung carcinoma (NSCLC): A retrospective analysis. (Abstract 8074) B. L. Lampson, A. Santos, P. A. Janne, G. R. Oxnard Board 399 Single institution experience with 75 mg dose of erlotinib in Latin American patients with mutated metastatic non-small cell lung cancer. (Abstract 8075) O. R. Aren, R. Silva, H. Cerda, J. M. Arancibia, C. Rojas, M. Reyes, R. A. Ascui, P. Banchero, M. E. Burotto Pichun Board 400 A phase II trial of erlotinib for EGFR mutant NSCLC to prospectively assess biopsy feasibility and acquired resistance at disease progression. (Abstract 8076) A. J. Redig, M. Taibi, G. R. Oxnard, D. Boucher, M. S. Rabin, J. Marcoux II, L. Gandhi, M. Huberman, D. Rangachari, J. V. Lucca, L. K. Morse, M. Andan, B. E. Johnson, D. B. Costa, P. A. Janne, D. M. Jackman Board 401 Clinical implications of repeat tumor biopsy (RTB) in patients (pts) with advanced lung cancer (LC): The Cleveland Clinic (CC) experience. (Abstract 8077) E. S. Agwa, F. Almeida, A. Haddad, B. R. Bastos, R. Lee, X. Jia, P. Ma Board 402 Dynamic serial monitoring of EGFR mutations in plasma DNA samples in EGFR mutant NSCLC patients treated with EGFR TKI. (Abstract 8078) M. Ahn, J. Lee, S. Lim, M. Lee, H. Kim, S. Byeon, J. Ham, B. Yali, W. Xiumin, H. Lee, J. Sun, J. Ahn, E. Cho, Y. Min, D. Kim, K. Park, X. Qing, M. Mao Board 403 Early prediction of response to tyrosine kinase inhibitors by quantification of EGFR mutations in plasma of non-small cell lung cancer patients. (Abstract 8079) A. Marchetti, J. F. Palma, L. Felicioni, T. M. De Pas, R. Chiari, M. Del Grammastro, G. Filice, V. Ludovini, A. A. Brandes, A. Chella, F. Malorgio, F. Guglielmi, M. De Tursi, A. Santoro, L. Crino, F. Buttitta Board 404 Association of plasma EGFR T790M ctDNA status with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance. (Abstract 242 Monday, June 1, 2015 Board 405 Kinetic monitoring of EGFR T790M in urinary circulating tumor DNA to predict radiographic progression and response in patients with metastatic lung adenocarcinoma. (Abstract 8081) H. Husain, K. Kosco, C. T. Vibat, V. Melnikova, M. G. Erlander, E. E. Cohen, S. M. Lippman, R. Kurzrock Board 406 EML4-ALK rearrangement in blood platelets and outcome to crizotinib in non-small-cell lung cancer patients. (Abstract 8082) N. Karachaliou, R. A. Nilsson, J. Berenguer, A. Gimenez Capitan, P. Schellen, C. Teixido, J. L. Kuiper, E. Drees, M. Grabowska, M. van Keulen, J. M. Tannous, D. Heideman, E. Thunnissen, A. C. Dingemans, S. Viteri Ramirez, B. A. Tannous, A. Drozdowskyj, E. F. Smit, T. Wurdinger, R. Rosell Board 407 Phase I dose escalation study of ASP8273, a mutant-selective irreversible EGFR inhibitor, in subjects with EGFR mutation positive NSCLC. (Abstract 8083) H. A. Yu, G. R. Oxnard, A. I. Spira, L. Horn, J. Weiss, Y. Feng, H. J. West, G. Giaccone, T. L. Evans, R. J. Kelly, T. Fleege, S. Poondru, F. Jie, K. Aoyama, M. A. Foley, D. Whitcomb, A. T. Keating, A. P. Krivoshik Board 408 Updated safety and efficacy results from phase I/II study of HM61713 in patients (pts) with EGFR mutation positive non-small cell lung cancer (NSCLC) who failed previous EGFR-tyrosine kinase inhibitor (TKI). (Abstract 8084) K. Park, J. Lee, K. Lee, J. Kim, Y. Min, J. Y. Cho, J. Han, B. Kim, D. Lee, J. Kang, E. Cho, I. Jang, J. Jung, H. Kim, H. Sin, J. Son, J. Woo, D. Kim Board 409 A phase II, single-arm, efficacy and safety study of poziotinib (NOV120101) in Korean patients with advanced or metastatic lung adenocarcinoma who have acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors. (Abstract 8085) J. Han, J. Lee, K. Lee, S. Kim, Y. Min, E. Cho, Y. Lee, S. Lee, H. Kim, G. Lee, B. Nam, J. Kim, J. Jung Board 410 A phase Ib/II study of afatinib in combination with nimotuzumab in non-small cell lung cancer patients with acquired resistance to gefitinib or erlotinib. (Abstract 8086) M. Ahn, J. Lee, J. Sun, B. Ku, J. Koh, S. Lim, M. Lee, H. Kim, J. Ahn, K. Park Board 411 Biomarker analysis of a phase II trial of cabozantinib and erlotinib in patients (pts) with EGFR-mutant NSCLC with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) resistance: A California Cancer Consortium Phase II Trial (NCI 9303). (Abstract 8087) K. L. Reckamp, P. C. Mack, N. Ruel, P. H. Frankel, B. J. Gitlitz, T. Li, M. Koczywas, S. M. Gadgeel, M. C. Cristea, C. P. Belani, E. M. Newman, D. R. Gandara, P. Lara Jr. Board 412 Genetic variability and clinical presentation of patients with non-small cell lung cancer (NSCLC) harboring MET-amplifications. (Abstract 8088) A. Eisert, M. Scheffler, S. Y. Michels, A. M. Schultheis, R. Frank, K. Koenig, S. MerkelbachBruse, R. Fischer, M. H. Serke, Y. Ko, U. Gerigk, T. Geist, L. C. Heukamp, R. Büttner, J. Wolf Board 413 Response to tyrosine kinase inhibtors in non-small-cell lung cancer with concomitant c-MET overexpression and driver genes. (Abstract 8089) N. Lou, J. Yang, X. Zhang, Q. Zhou, H. Chen, Z. Wang, J. Su, Z. Xie, B. Jiang, Z. Chen, X. Bai, Y. Wu Board 414 Crizotinib in advanced non-small-cell lung cancer with de novo c-Met overexpression. (Abstract 8090) A. N. Li, J. Yang, X. Zhang, Y. Wu Board 415 Targeting c-Met overexpression for overcoming acquired resistance to EGFR TKIs in NSCLC. (Abstract 8091) L. Gou, Y. Wu, J. Yang, X. Zhang Board 416 Phase I/II study of rilotumumab (R) and erlotinib (E) in previously treated patients (pts) with metastatic NSCLC. (Abstract 8092) A. A. Tarhini, I. Rafique, P. Tran, W. E. Gooding, L. C. Villaruz, T. F. Burns, D. Friedland, G. R. Tarabay, A. D. Laman, D. R. Mehta, M. G. Sulecki, D. P. Petro, M. S. Georgiadis, K. M. Kane, S. M. Peracha, K. K. Rajasenan, A. Megaludis, L. Dai, M. A. Socinski 243 MONDAY 8080) D. Zheng, X. Ye, M. Zhang, Y. Sun, J. Wang, J. Ni, H. Zhang, L. Zhang, J. Luo, J. Zhang, L. Tang, B. Su, G. Chen, G. Zhu, Y. Gu, J. Xu Monday, June 1, 2015 Nationwide genomic screening network for the development of novel targeted therapies in advanced non-small cell lung cancer (LC-SCRUMJapan). (Abstract 8093) S. Matsumoto, K. Yoh, T. Seto, T. Yokoyama, H. Murakami, E. Iwama, S. Sugawara, Y. Ohe, K. Takeda, M. Nishio, M. Satouchi, M. Shingyoji, D. Harada, T. Okuyama, N. Okamoto, T. Kohno, K. Tsuta, G. Ishii, K. Tsuchihara, K. Goto Board 418 Migration to next-generation sequencing and the identification of RET and ROS1 rearrangements plus PTEN and MET protein expression in tumor specimens from patients with lung adenocarcinomas: Lung Cancer Mutation Consortium (LCMC 2.0). (Abstract 8094) M. G. Kris, B. E. Johnson, D. J. Kwiatkowski, I. I. Wistuba, L. D. Berry, E. B. Haura, M. A. Socinski, S. S. Ramalingam, B. S. Glisson, S. N. Waqar, G. A. Otterson, J. H. Schiller, E. B. Garon, J. P. Cetnar, K. A. Politi, J. R. Brahmer, L. V. Sequist, C. M. Lovly, K. Kugler, P. A. Bunn Jr. Board 419 Clinical implementation of anchored multiplex PCR with targeted nextgeneration sequencing for detection of ALK, ROS1, RET and NTRK1 fusions in non-small cell lung carcinoma. (Abstract 8095) A. F. Farago, Z. Zheng, A. Muzikansky, J. F. Gainor, A. J. Iafrate, J. A. Engelman, L. P. Le, A. T. Shaw Board 420 Feasibility of next-generation sequencing (NGS) for squamous non-small cell lung cancer (NSCLC): Implications for the NCI LungMAP study. (Abstract 8096) A. G. Sacher, L. M. Sholl, S. L. Mach, B. E. Johnson, P. S. Hammerman, P. A. Janne, G. R. Oxnard Board 422 KEAP1-mutations in patients with non-small cell lung cancer (NSCLC). (Abstract 8097) R. Frank, M. Scheffler, S. Y. Michels, A. Eisert, R. Fischer, K. Koenig, S. Merkelbach-Bruse, M. H. Serke, Y. Ko, U. Gerigk, T. Geist, L. C. Heukamp, R. Büttner, J. Wolf Board 423 Clinical and molecular characteristics of non-small cell lung cancer in patients harboring CTNNB1 mutations. (Abstract 8098) L. Gogl, M. Scheffler, I. Michaela, S. Y. Michels, R. Fischer, M. H. Serke, U. Gerigk, C. Womper, S. Krüger, B. Kaminsky, W. Schulte, G. Höffken, S. Merkelbach-Bruse, R. Büttner, J. Wolf Board 424 Maximum severity score (MSS) of baseline patient-reported Lung Cancer Symptom Scale (LCSS) as a prognostic and predictive factor for overall survival (OS) in the Phase III SQUIRE study. (Abstract 8099) M. Reck, R. J. Gralla, P. Bonomi, M. A. Socinski, V. Soldatenkova, J. Shahidi, P. Peterson, J. Brown, C. K. Obasaju, N. Thatcher Board 425 Afatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following first-line platinum-based chemotherapy: Patient-reported outcome (PRO) data from the LUX-Lung 8 Phase III global trial. (Abstract 8100) S. M. Gadgeel, M. Cobo Dols, E. Felip, J. Soria, K. Lee, S. Lu, V. Georgoulias, A. Fulop, E. Goker, K. N. Syrigos, A. Morabito, H. Coskun, S. Z. Guclu, W. Li, S. Popat, A. Ardizzoni, J. Lungershausen, B. Wang, V. K. Chand, G. D. Goss, LUX-Lung 8 Investigators Board 426 Impact of crizotinib on patient-reported general health status compared with chemotherapy in patients with no prior systemic treatment for advanced non-squamous ALK-positive non-small cell lung cancer (NSCLC). (Abstract 8101) E. Felip, F. H. Blackhall, T. Mok, F. Cappuzzo, K. D. Wilner, A. Reisman, S. Iyer, B. J. Solomon Board 427a A randomized, phase III study (FLAURA) of AZD9291, a novel EGFR-TKI, versus gefitinib or erlotinib in treatment-naïve patients with advanced non-small cell lung cancer and an EGFR-TKI-sensitizing mutation. (Abstract TPS8102) S. S. Ramalingam, Y. Rukazenkov, K. Thomas, J. Soria Board 427b KEYNOTE-024: Phase III trial of pembrolizumab (MK-3475) vs platinum-based chemotherapy as first-line therapy for patients with metastatic non-small cell lung cancer (NSCLC) that expresses programmed cell death ligand 1 (PD-L1). (Abstract TPS8103) J. R. Brahmer, E. S. Kim, J. Zhang, M. M. Smith, R. A. Rangwala, M. E. O’Brien MONDAY Board 417 244 Board 428a A phase III study of MEDI4736 (M), an anti-PD-L1 antibody, in monotherapy or in combination with Tremelimumab (T), versus standard of care (SOC) in patients (pts) with advanced non-small cell lung cancer (NSCLC) who have received at least two prior systemic treatment regimens (ARCTIC). (Abstract TPS8104) D. Planchard, M. Shtivelband, K. Shi, R. Ibrahim, M. Ballas, J. Soria Board 428b Phase 3 KEYNOTE-042 trial of pembrolizumab (MK-3475) versus platinum doublet chemotherapy in treatment-naive patients (pts) with PD-L1–positive advanced non-small cell lung cancer (NSCLC). (Abstract TPS8105) T. Mok, Y. Wu, P. A. Watson, J. Zhang, R. A. Rangwala, G. Lopes Board 429a A phase 3 randomized trial of veliparib (ABT-888) plus carboplatin and paclitaxel versus investigator’s choice of standard chemotherapy in previously untreated patients with metastatic/advanced non-squamous (NSq) non-small cell lung cancer (NSCLC). (Abstract TPS8106) M. D. McKee, M. Pedersen, A. DeLuca, Q. Qin, J. Qian, J. Irving, P. Ansell, T. Leahy, C. Caskey, V. L. Giranda Board 429b Veliparib (ABT-888) or placebo combined with carboplatin and paclitaxel in patients with previously untreated advanced/metastatic squamous (Sq) non-small cell lung cancer (NSCLC): A randomized phase 3 trial. (Abstract TPS8107) M. D. McKee, I. Bondarenko, S. Z. Guclu, V. Gorbunova, L. Urban, P. Clingan, K. Leśniewski-Kmak, J. Mazières, S. S. Ramalingam, M. Pedersen, A. DeLuca, C. Nickner, Q. Qin, V. L. Giranda Board 430a TIGER 1: A randomized, open-label, phase 2/3 study of rociletinib (CO-1686) or erlotinib as first-line treatment for EGFR-mutant non-small cell lung cancer (NSCLC). (Abstract TPS8108) D. R. Camidge, J. Wolf, J. B. Litten, L. A. Higashi, J. D. Isaacson, T. Mok Board 430b TIGER-3: A phase 3, open-label, randomized study of rociletinib vs cytotoxic chemotherapy in patients (pts) with mutant EGFR non-small cell lung cancer (NSCLC) progressing on prior EGFR TKI therapy and doublet chemotherapy. (Abstract TPS8109) J. C. Yang, S. Popat, P. Georgiou, E. Miyamoto, J. D. Isaacson, H. A. Wakelee Board 431a IFCT-1003 LADIE trial: Randomized phase II trial evaluating treatment with EGFR-TKI versus EGFR-TKI associated with anti-estrogen in women with non-squamous advanced stage NSCLC. (Abstract TPS8110) J. Mazières, F. Barlesi, O. Molinier, I. Monnet, C. Audigier-Valette, B. Besse, A. Toffart, P. Renault, P. Masson, B. Mennecier, S. Moreau Fraboulet, S. Hiret, V. Westeel, P. Dumont, A. B. Cortot, E. Pichon, M. Lebitasy, F. Morin, G. Zalcman, French Cooperative Thoracic Intergroup (IFCT) Board 431b Addition of apatorsen, an inhibitor of Hsp27, to first-line gemcitabine/carboplatin in advanced squamous cell lung cancer: Design of the Cedar study. (Abstract TPS8111) P. Schmid, D. Muthukumar, F. H. Blackhall, J. F. Lester, S. Khan, M. Illsley, J. Adams, A. Garcia-Alonso, C. MacDonald-Smith, S. M. Lee, C. Jacobs, G. W. Middleton, C. James, K. Mousa, S. Sarker, L. Lim 9:45 AM - 11:00 AM Special Session ASCO/Society of Nuclear Medicine and Molecular Imaging (SNMMI) Joint Session: Targeted Radionuclide Therapy Location: S404 Hossein Jadvar, MD, PhD, MPH, MBA—Co-Chair University of Southern California Positron Emission Tomography Center Targeted Radionuclide Therapy in Prostate Cancer Peter Paul Yu, MD, FACP, FASCO—Co-Chair Palo Alto Medical Foundation 245 MONDAY Monday, June 1, 2015 Monday, June 1, 2015 Richard L. Wahl, MD Washington University School of Medicine Targeted Radionuclide Therapy in Lymphoma Alexander James Baird McEwan, MBBS Cross Cancer Institute Targeted Radionuclide Therapy in Neuroendocrine Tumors Panel Question and Answer 9:45 AM - 11:00 AM Education Session Beyond Second-Line Treatment in Non-Small Cell Lung Cancer and Small Cell Lung Cancer: What to Do When the Data End? Location: E Hall D2 Gregory J. Riely, MD, PhD Memorial Sloan Kettering Cancer Center Current Treatments, Upcoming Clinical Trials, and Use of Molecular Profiling in Second Line and Beyond Renato Martins, MD, MPH University of Washington The Value of Therapy Beyond Second-Line Treatment in Non-Small Cell Lung Cancer and Small Cell Lung Cancer Craig H. Reynolds, MD—Chair Ocala Oncology Center Moderator: Presenting Both Sides and the Ethics of Therapy versus Best Supportive Care Panel Question and Answer 9:45 AM - 11:00 AM Meet the Professor Session MONDAY Controversial Topics in HPV-Related Head and Neck Cancer—Ticketed Session Location: E451a Eric Michael Genden, MD Icahn School of Medicine at Mount Sinai Anthony Cmelak, MD Vanderbilt-Ingram Cancer Center 9:45 AM - 11:00 AM Meet the Professor Session Multidisciplinary Approach to Low-Grade Glioma—Ticketed Session Location: E451b Brigitta G. Baumert, MD, PhD, MBA University of Bonn Medical Centre Jan C. Buckner, MD Mayo Clinic 246 Monday, June 1, 2015 9:45 AM - 11:15 AM Clinical Science Symposium A Tale of Two Genomes: Interpreting Somatic and Germ-Line Sequencing Results Together Location: S100bc Eric Andrew Collisson, MD—Co-Chair University of California, San Francisco Brian M. Wolpin, MD, MPH—Co-Chair Dana-Farber Cancer Institute Tumor relevant germline findings in targeted tumor sequencing using matched normal DNA of 1,570 unselected cases. (Abstract 1509) K. A. Schrader, D. T. Cheng, J. Vijai, M. Prasad, M. Walsh, A. Zehir, T. Thomas, R. Benayed, Z. K. Stadler, A. Ashraf, M. E. Arcila, D. B. Solit, D. M. Hyman, L. Zhang, D. Klimstra, M. Ladanyi, K. Offit, M. F. Berger, M. E. Robson 9:57 AM Robert R. McWilliams, MD (Discussion of Abstract(s) 1509) Mayo Clinic Interpreting Germ-Line and Somatic Mutations Together in Tumor Sequencing 10:09 AM Prevalence of incidental actionable germline mutations in 1,000 advanced cancer patients on a prospective somatic genomic profiling program. (Abstract 1510) F. Meric-Bernstam, L. Brusco, M. S. Daniels, L. C. Strong, K. R. Shaw, K. H. Lu, Y. Qi, H. Lara-Guerra, J. K. Litton, H. Zhao, A. K. Eterovic, B. Arun, M. Routbort, F. Janku, M. A. Davies, S. Kopetz, J. Mendelsohn, G. B. Mills, K. Chen 10:21 AM Stacy W. Gray, MD (Discussion of Abstract(s) 1510) Dana-Farber Cancer Institute Incidental Germ-Line Findings: What Do the Physician and Patient Want and Need to Know? 10:33 AM Characteristics of high risk breast cancer patients with mutations identified by multiplex panel testing. (Abstract 1511) K. N. Maxwell, B. Wenz, B. Wubbenhorst, K. P. D’Andrea, B. Garman, B. Weathers, N. Goodman, C. Colameco, J. M. Long, J. Powers, J. Stopfer, A. R. Bradbury, A. DeMichele, S. M. Domchek, K. L. Nathanson 10:45 AM Allison W. Kurian, MD, MSc (Discussion of Abstract(s) 1511) Stanford University Medical Center Germ-Line Mutations in High-Risk Breast Cancer: Beyond BRCA 1/2 10:57 AM Panel Question and Answer MONDAY 9:45 AM 9:45 AM - 11:15 AM Clinical Science Symposium New Diagnostics: When Actionable Is Objectionable Location: E Hall D1 Miguel Angel Villalona-Calero, MD—Chair The Ohio State University 9:45 AM Alan P. Venook, MD University of California, San Francisco Case Presentation 9:50 AM Successful implementation of a novel trial model: The Signature program. (Abstract 106) J. A. Peguero, J. A. Knost, T. M. Bauer, M. H. Taylor, F. S. Braiteh, J. P. Eder, H. Safran, B. H. O’Neil, A. S. Alva, L. Nadauld, P. Joshi, F. Miranda, R. Sidhu, J. Ero, E. D. Slosberg, C. Lebedinsky, B. Kang, S. Parasuraman, S. A. Piha-Paul 247 Monday, June 1, 2015 10:05 AM Richard L. Schilsky, MD, FASCO (Discussion of Abstract(s) 106) American Society of Clinical Oncology Is Your Patient’s Tumor Signature Legible? 10:20 AM Circulating tumor cells (CTC) and pathological complete response (pCR) as independent prognostic factors in inflammatory breast cancer (IBC) in a pooled analysis of two multicentre phase II trials (BEVERLY 1 & 2) of neoadjuvant chemotherapy combined with bevacizumab. (Abstract 108) J. Pierga, F. Bidard, A. Autret, T. Petit, F. Andre, F. Dalenc, C. Levy, J. Ferrero, G. Romieu, J. Bonneterre, F. Lerebours, T. D. Bachelot, P. Kerbrat, E. CharafeJaufret, J. Lemonnier, P. Viens 10:35 AM Prospective evaluation of circulating tumor DNA sequencing in pancreatobiliary carcinomas. (Abstract 107) E. A. Collisson, O. Zill, C. Greene, J. Leng, L. Siew, M. A. Vu, R. K. Kelley, A. H. Ko, C. E. Atreya, K. Van Loon, T. G. Bivona, M. A. Tempero, D. Sebisanovic, P. N. Munster, A. Talasaz 10:50 AM Geoffrey R. Oxnard, MD (Discussion of Abstract(s) 107–108) Dana-Farber Cancer Institute Replacing Tumor Biopsies with Liquid Biopsies: Close but Not Quite 11:05 AM Panel Question and Answer 9:45 AM - 12:45 PM Oral Abstract Session Genitourinary (Nonprostate) Cancer Location: E Arie Crown Theater Ana M. Molina, MD—Co-Chair Memorial Sloan Kettering Cancer Center Guru Sonpavde, MD—Co-Chair University of Alabama at Birmingham Comprehensive Cancer Center MONDAY 9:45 AM Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma (mRCC): Association of biomarkers with clinical outcomes. (Abstract 4500) T. K. Choueiri, M. N. Fishman, B. Escudier, D. F. McDermott, H. M. Kluger, W. M. Stadler, J. L. Perez-Gracia, D. G. McNeel, B. D. Curti, M. R. Harrison, E. R. Plimack, L. J. Appleman, L. Fong, C. G. Drake, T. C. Young, S. D. Chasalow, P. Ross-Macdonald, J. S. Simon, D. Walker, M. Sznol 9:57 AM A phase Ia study of MPDL3280A (anti-PDL1): Updated response and survival data in urothelial bladder cancer (UBC). (Abstract 4501) D. P. Petrylak, T. Powles, J. Bellmunt, F. S. Braiteh, Y. Loriot, C. Cruz Zambrano, H. A. Burris III, J. W. Kim, S. Teng, J. Bruey, P. Hegde, O. O. Abidoye, N. J. Vogelzang 10:09 AM Pembrolizumab (MK-3475) for advanced urothelial cancer: Updated results and biomarker analysis from KEYNOTE-012. (Abstract 4502) E. R. Plimack, J. Bellmunt, S. Gupta, R. Berger, R. B. Montgomery, K. Heath, J. Juco, K. Emancipator, K. Pathiraja, J. K. Lunceford, R. F. Perini, P. H. O’Donnell 10:21 AM Noah M. Hahn, MD (Discussion of Abstract(s) 4500 – 4502) The Johns Hopkins Medical Institutions Immune Therapy in Genitourinary Cancers: The Beginning of the End or the End of the Beginning? 10:33 AM Panel Question and Answer 10:45 AM First-line randomized phase II study of gemcitabine/cisplatin plus apatorsen or placebo in patients with advanced bladder cancer: The International Borealis-1 trial. (Abstract 4503) J. Bellmunt, B. J. Eigl, E. Senkus-Konefka, Y. Loriot, P. Twardowski, D. E. Castellano, N. Blais, S. S. Sridhar, C. N. Sternberg, M. Retz, B. A. Blumenstein, C. Jacobs, P. S. Stewart, D. P. Petrylak 248 Monday, June 1, 2015 Eribulin in advanced urothelial cancer (AUC) patients (pts): A California Cancer Consortium trial—NCI/CTEP 7435. (Abstract 4504) D. I. Quinn, N. Ruel, P. Twardowski, S. G. Groshen, T. B. Dorff, S. K. Pal, W. M. Stadler, A. Aparicio, P. Lara Jr., E. M. Newman 11:09 AM A phase II/III, double-blind, randomized trial comparing maintenance lapatinib versus placebo after first line chemotherapy in HER1/2 positive metastatic bladder cancer patients. (Abstract 4505) T. Powles, R. A. Huddart, T. Elliott, R. Jones, S. A. Hussain, S. J. Crabb, C. Ackerman, S. Jagdev, J. D. Chester, S. Hilman, M. Beresford, A. Macdonald, S. Sundar, J. A. Frew, A. Stockdale, S. Sarker, D. Berney, S. Chowdhury 11:21 AM Maria De Santis, MD (Discussion of Abstract(s) 4503– 4505) University of Warwick Moving Beyond Platinum for Bladder Cancer 11:33 AM Panel Question and Answer 11:45 AM Randomized phase II, three-arm trial of lenvatinib (LEN), everolimus (EVE), and LENⴙEVE in patients (pts) with metastatic renal cell carcinoma (mRCC). (Abstract 4506) R. Motzer, T. Hutson, H. Glen, D. Michaelson, A. M. Molina, T. Eisen, J. Jassem, J. Zolnierek, P. Maroto, B. Mellado, B. Melichar, J. Tomasek, H. Kim, K. Wood, C. Dutcus, J. M. Larkin 11:57 AM Final clinical results of a randomized phase II international trial of everolimus vs. sunitinib in patients with metastatic non-clear cell renal cell carcinoma (ASPEN). (Abstract 4507) A. J. Armstrong, S. Broderick, T. Eisen, W. M. Stadler, R. J. Jones, J. A. Garcia, U. N. Vaishampayan, J. Picus, R. E. Hawkins, J. D. Hainsworth, C. K. Kollmannsberger, T. F. Logan, I. Puzanov, L. M. Pickering, C. W. Ryan, A. Protheroe, C. M. Lusk, S. Oberg, S. Halabi, D. J. George 12:09 PM Dose analysis of ASSURE (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase 3 trial. (Abstract 4508) N. B. Haas, J. Manola, K. Flaherty, R. G. Uzzo, M. B. Atkins, J. P. Dutcher, C. G. Wood, C. J. Kane, M. A. Jewett, B. Coomes, S. F. Matin, T. Kuzel, W. J. Sexton, Y. Wong, T. K. Choueiri, R. Pili, I. Puzanov, M. Kohli, W. M. Stadler, R. S. DiPaola, ECOG/ACRIN 2805 Authors Group 12:21 PM Cora N. Sternberg, MD, FACP (Discussion of Abstract(s) 4506 – 4508) San Camillo Forlanini Hospital Improving Outcomes with Pathway-Directed Therapy 12:33 PM Panel Question and Answer MONDAY 10:57 AM 9:45 AM - 12:45 PM Oral Abstract Session Lymphoma Location: E450 Grzegorz S. Nowakowski, MD—Co-Chair Mayo Clinic Owen A. O’Connor, MD, PhD—Co-Chair Columbia University Medical Center 9:45 AM Phase IIa study of single-agent MOR208 in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL). (Abstract 8500) W. Jurczak, P. L. Zinzani, A. Goy, M. Provencio, Z. Nagy, T. Robak, K. J. Maddocks, C. Buske, R. Korolkiewicz, M. Winderlich, K. A. Blum 249 Monday, June 1, 2015 MONDAY 9:57 AM Safety and activity of the chemotherapy-free triplet of ublituximab, TGR-1202, and ibrutinib in relapsed B-cell malignancies. (Abstract 8501) N. H. Fowler, L. J. Nastoupil, M. A. Lunning, J. Vose, T. Siddiqi, C. Flowers, J. B. Cohen, M. T. Schreeder, M. Miguel, S. Blumel, B. Phye, W. H. Tse, E. K. Pauli, K. Cutter, P. Sportelli, H. P. Miskin, M. S. Weiss, S. V. Vakkalanka, S. Viswanadha, S. M. O’Brien 10:09 AM GADOLIN: Primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximabrefractory indolent non-Hodgkin lymphoma. (Abstract LBA8502) L. H. Sehn, N. S. Chua, J. Mayer, G. S. Dueck, M. Trnı̀ný, K. Bouabdallah, N. H. Fowler, V. Delwail, O. W. Press, G. A. Salles, J. G. Gribben, A. Lennard, P. J. Lugtenburg, N. Franklin, E. Wassner Fritsch, G. Fingerle-Rowson, B. D. Cheson 10:21 AM Two doses of polatuzumab vedotin (PoV, anti-CD79b antibody-drug conjugate) in patients (pts) with relapsed/refractory (RR) follicular lymphoma (FL): Durable responses at lower dose level. (Abstract 8503) R. H. Advani, I. Flinn, J. P. Sharman, C. S. Magid Diefenbach, K. S. Kolibaba, O. W. Press, L. H. Sehn, A. I. Chen, G. A. Salles, H. Tilly, B. D. Cheson, S. E. Assouline, M. H. Dreyling, A. Hagenbeek, P. L. Zinzani, C. Jones, Y. Chu, J. Hirata, M. Wenger, F. Morschhauser 10:33 AM Grzegorz S. Nowakowski, MD (Discussion of Abstract(s) 8500 – 8503) Mayo Clinic What Does Drug Conjugation Add to the Unconjugated Antibody? 10:45 AM Panel Question and Answer 10:57 AM Evaluation of complete response rate at 30 months (CR30) as a surrogate for progression-free survival (PFS) in first-line follicular lymphoma (FL) studies: Results from the prospectively specified Follicular Lymphoma Analysis of Surrogacy Hypothesis (FLASH) analysis with individual patient data (IPD) of 3,837 patients (pts). (Abstract 8504) D. J. Sargent, Q. Shi, S. De Bedout, C. Flowers, N. H. Fowler, T. Fu, A. Hagenbeek, M. Herold, E. Hoster, J. Huang, E. Kimby, M. Ladetto, F. Morschhauser, T. Nielsen, K. Takeshita, N. Valente, U. Vitolo, E. Zucca, G. A. Salles, the FLASH (Follicular Lymphoma Analysis of Surrogacy Hypothesis) group 11:09 AM Brentuximab vedotin plus AVD for non-bulky limited stage Hodgkin lymphoma: A phase II trial. (Abstract 8505) J. S. Abramson, J. E. Arnason, A. S. LaCasce, R. Redd, J. A. Barnes, L. Sokol, R. Joyce, D. Avigan, D. S. Neuberg, T. Takvorian, E. P. Hochberg, C. M. Bello 11:21 AM Updated results of a phase II trial of brentuximab vedotin combined with R-CHOP in frontline treatment of patients (pts) with high-intermediate/highrisk diffuse large B-cell lymphoma (DLBCL). (Abstract 8506) N. L. Bartlett, C. M. Farber, C. A. Yasenchak, S. M. Ansell, R. H. Advani, M. H. Knapp, L. Fayad, K. S. Kolibaba, D. Patel-Donnelly, M. Seetharam, H. A. Yimer, T. J. Manley, J. M. Burke, B. Holkova, L. Budde, A. S. Halwani 11:33 AM Owen A. O’Connor, MD, PhD (Discussion of Abstract(s) 8504 – 8506) Columbia University Medical Center Explaining Why CD30-Negative Disease Responds to CD30-Targeted Therapy 11:45 AM Panel Question and Answer 11:57 AM Allogeneic or autologous transplantation as first-line therapy for younger patients with peripheral T-cell lymphoma: Results of the interim analysis of the AATT trial. (Abstract 8507) N. Schmitz, M. Nickelsen, B. Altmann, M. Ziepert, K. Bouabdallah, C. Gisselbrecht, S. Maury, G. Cartron, E. Gyan, A. Jaccard, L. Sanhes, P. Gaulard, A. Rosenwald, L. Truemper, B. Glass, P. Reimer, W. Herr, M. Wilhelm, O. Tournilhac 12:09 PM Francine M. Foss, MD (Discussion of Abstract(s) 8507) Yale Cancer Center The Potential Role of Allogeneic Stem Cell Transplantation in Peripheral T-Cell Lymphoma 12:21 PM Panel Question and Answer 250 Monday, June 1, 2015 11:30 AM - 12:45 PM Special Session ASCO/American Cancer Society Award and Lecture Location: S102 Clifford A. Hudis, MD, FACP Memorial Sloan Kettering Cancer Center Presentation of the 2015 ASCO/American Cancer Society Award Ernest Hawk, MD, MPH—Award Lecturer The University of Texas MD Anderson Cancer Center Cancer Prevention as Our First Best Hope: Action in Prevention Research and Cancer Control 11:30 AM - 12:45 PM Education Session Cervical Cancer from Diagnosis to Survivorship Location: E354b Linda R. Mileshkin, MBBS, MD, MBioeth Peter MacCallum Cancer Centre Chemoradiotherapy in the Outback Era: Pitfalls and Potentials Helen Mackay, MD—Chair Princess Margaret Cancer Centre, University Health Network Recurrent and Metastatic Cervical Cancer: Facing the Challenge of Developing New Therapies in an Under-resourced Patient Population Lari B. Wenzel, PhD University of California, Irvine Quality of Life after Treatment for Patients with Cervical Cancer Panel Question and Answer Controversies in Neoadjuvant Therapy for Breast Cancer: Surgery, Radiation, and Therapeutic Trials Location: N Hall B1 Angela DeMichele, MD, MSCE—Chair Abramson Cancer Center of the University of Pennsylvania Are We Using the Right Endpoints for Neoadjuvant Chemotherapy? Julia R. White, MD NRG Oncology and The Ohio State University Postmastectomy Radiation Therapy after Neoadjuvant Chemotherapy: Who Needs It? Tari A. King, MD Memorial Sloan Kettering Cancer Center Axillary Management after Neoadjuvant Chemotherapy Panel Question and Answer 251 MONDAY 11:30 AM - 12:45 PM Education Session Monday, June 1, 2015 11:30 AM - 12:45 PM Education Session New Therapies for Histologies Other than Adenocarcinoma Location: E Hall D2 Paul K. Paik, MD Memorial Sloan Kettering Cancer Center Updates in Therapy for Squamous Histology of Non-Small Cell Lung Cancer David E. Gerber, MD—Chair The University of Texas Southwestern Medical Center Updates in Therapy and Clinical Trials for Other Histologies (Including Neuroendocrine and Large Cell) Afshin Dowlati, MD Case Western Reserve University Updates in Therapy and Clinical Trials in Small Cell Lung Cancer Panel Question and Answer 11:30 AM - 12:45 PM Education Session Nutritional Support in Gastrointestinal Malignancies Location: E Hall D1 Vincent J. Picozzi, MD—Chair Virginia Mason Medical Center Nutritional Deficiency in Gastrointestinal Malignancy: Degree, Direction, and Data Maria Q. B. Petzel, RD, CSO The University of Texas MD Anderson Cancer Center Nutritional Support for Gastrointestinal Malignancy: Weighing the Options for Intervention Egidio Del Fabbro, MD Virginia Commonwealth University Overcoming Cancer Cachexia: Existing Data and Investigational Approaches MONDAY Panel Question and Answer 11:30 AM - 12:45 PM Education Session Optimizing Treatment Modalities for Cancers of the Oral Cavity Location: S100bc Stephen Yenzen Lai, MD, PhD—Chair The University of Texas MD Anderson Cancer Center Surgical Techniques, Functional Reconstruction, Sentinal Node Mapping Allen M. Chen, MD University of California, Los Angeles Adjuvant and Definitive Radiotherapy Techniques and Outcomes in Oral Cavity Cancers 252 Monday, June 1, 2015 Kumar Prabhash, MD, DM Tata Memorial Centre Preoperative Chemotherapy, Metronomic Scheduling, and Interventions for Premalignant Lesions Panel Question and Answer 11:30 AM - 12:45 PM Education Session Precision Medicine through Molecular Profiling: Are We There Yet? Location: S406 Sameek Roychowdhury, MD, PhD—Chair The Ohio State University Clinical Tumor Sequencing: Opportunities and Challenges for Precision Cancer Medicine Michael F. Berger, PhD Memorial Sloan Kettering Cancer Center Enterprise-Level Molecular Testing at Academic Institutions: Advantages of Doing It Yourself versus Outsourcing Martine J. Piccart-Gebhart, MD, PhD Jules Bordet Institute Clinical Trials of Precision Medicine through Molecular Profiling Panel Question and Answer 11:30 AM - 12:45 PM Education Session Translating Survivorship Research into Health Surveillance Guidelines Location: S504 MONDAY Saro Armenian, DO, MPH—Chair City of Hope National Medical Center Surveillance for Subsequent Neoplasms Leontien C. M. Kremer, MD, PhD Emma Children’s Hospital and Academic Medical Center Surveillance for Cardiotoxicity Charles A. Sklar, MD Memorial Sloan Kettering Cancer Center Surveillance for Gonadal Failure and Thyroid Disease Panel Question and Answer 11:30 AM - 12:45 PM Education Session Trends, Anecdotes, and Predictions: Oncology Practices Today Location: S404 Anupama Kurup Acheson, MD Providence Oncology and Hematology Care Clinic ASCO National Oncology Census Design and Results 253 Monday, June 1, 2015 Michael P. Kosty, MD, FACP—Chair Scripps Research Institute Describing the Oncology Workforce and Potential Interventions Eric Daniel Tetzlaff, MHS, PA-C Fox Chase Cancer Center Challenges Facing Midlevel Oncology Providers: Integration into Clinical Practices Panel Question and Answer 11:30 AM - 12:45 PM Meet the Professor Session GIST: Imatinib and Beyond—Ticketed Session Location: E451a Suzanne George, MD Dana-Farber/Brigham and Women’s Cancer Center 11:30 AM - 12:45 PM Meet the Professor Session How to Create a Successful Survivorship Program—Ticketed Session Location: E451b Maria Alma Rodriguez, MD The University of Texas MD Anderson Cancer Center 12:00 PM - 1:00 PM Special Session ASCO Annual Business Meeting (ASCO Members Only) Location: S100a MONDAY 1:15 PM - 2:30 PM Poster Discussion Session Gastrointestinal (Colorectal) Cancer Location: E Hall D1 Bert H. O’Neil, MD—Co-Chair Indiana University Health University Hospital Thomas John Semrad, MD, MAS—Co-Chair University of California, Davis 1:15 PM Chloe Evelyn Atreya, MD, PhD (Discussion of Abstract(s) 3509 –3511) University of California, San Francisco Understanding the Role of BRAF in Colorectal Cancer 1:27 PM Panel Question and Answer 1:33 PM Gunnar Folprecht, MD (Discussion of Abstract(s) 3512–3514) University Hospital Carl Gustav Carus Improving Adjuvant Therapy for Colon Cancer 1:45 PM Panel Question and Answer 254 Monday, June 1, 2015 1:51 PM Cathy Eng, MD (Discussion of Abstract(s) 3515–3517) The University of Texas MD Anderson Cancer Center “New” Drugs in Localized Rectal Cancer 2:03 PM Panel Question and Answer 2:09 PM Andrew Wang, MD (Discussion of Abstract(s) 3518 –3520) The University of North Carolina at Chapel Hill Recent Progress in Anal Cancer Research 2:21 PM Panel Question and Answer Posters discussed in this session are on display in the Gastrointestinal (Colorectal) Cancer Poster Session. See page 208 for poster information. Networking with presenters and discussants will take place right outside of the session room after the discussion. 1:15 PM - 2:30 PM Poster Discussion Session Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers Location: E Hall D2 Tom John, MBBS, PhD, FRACP—Co-Chair Olivia Newton-John Cancer and Wellness Centre 1:15 PM Leena Gandhi, MD, PhD (Discussion of Abstract(s) 7508 –7511) Dana-Farber Cancer Institute Targeted Therapies in Unselected Populations 1:27 PM Panel Question and Answer 1:33 PM Benjamin Movsas, MD, PhD (Discussion of Abstract(s) 7512–7514) Henry Ford Health System Combined Modality Therapy for Non-Small Cell Lung Cancer 1:45 PM Panel Question and Answer 1:51 PM Giuseppe Giaccone, MD, PhD (Discussion of Abstract(s) 7515–7517) Lombardi Comprehensive Cancer Center, Georgetown University Biomarkers in Trial Design: Promise and Peril 2:03 PM Panel Question and Answer 2:09 PM Ramaswamy Govindan, MD (Discussion of Abstract(s) 7518 –7519) Washington University School of Medicine Molecular Similarity of Neuroendocrine Cancers 2:21 PM Panel Question and Answer MONDAY Feng Ming Kong, MD, PhD—Co-Chair GRU Cancer Center and Medical College of Georgia Posters discussed in this session are on display in the Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers Poster Session. See page 231 for poster information. Networking with presenters and discussants will take place right outside of the session room after the discussion. 1:15 PM - 2:30 PM Special Session ASCO Book Club: The End of Your Life Book Club by Will Schwalbe Location: S102 Teresa Gilewski, MD—Chair Memorial Sloan Kettering Cancer Center 255 Monday, June 1, 2015 Will Schwalbe Author The End of Your Life Book Club 1:15 PM - 2:30 PM Education Session Challenging Issues in Metastatic Disease Location: N Hall B1 Fabrice Andre, MD, PhD—Chair Institut Gustave Roussy The Use of Molecular Profiling in Metastatic Breast Cancer Maxine S. Jochelson, MD Memorial Sloan Kettering Cancer Center Advanced Imaging for Metastatic Disease: How and When Joseph Kamel Salama, MD Duke University Medical Center Ablation of Oligometastases by Radiation or Surgery: Good Idea? Panel Question and Answer 1:15 PM - 2:30 PM Education Session Shared Learning to Improve Cancer Outcomes in Adolescents and Young Adults: Pediatric versus Adult Approaches Location: S504 A. Lindsay Frazier, MD, ScM—Chair Dana-Farber Cancer Institute Germ Cell Tumors in Adolescents and Young Adults: Coordinating Research across the Age Barrier MONDAY Wendy Stock, MD The University of Chicago Medical Center Leukemia and Lymphoma in Adolescent and Young Adults with Cancer: Improving Outcomes through Research and Collaboration Robert G. Maki, MD, PhD Icahn School of Medicine at Mount Sinai Choice of Treatment of Sarcomas for the Adolescent and Young Adult Population: Adult versus Pediatric Regimens Panel Question and Answer 1:15 PM - 2:30 PM Education Session Translating Knowledge into Therapeutic Progress in Myelodysplastic Syndromes Location: E450 Olatoyosi Odenike, MD—Chair The University of Chicago Frontline Therapy in Myelodysplastic Syndrome: A Risk-Stratified Approach 256 Monday, June 1, 2015 Francesco Onida, MD University of Milan Transplant in Patients with Myelodysplastic Syndrome: Timing and Eligibility Eric Padron, MD Moffitt Cancer Center Diagnosis and Management of MDS/MPN Overlap Syndromes Panel Question and Answer 1:15 PM - 2:30 PM Education Session Understanding the Targets in Immunotherapy Location: E354b Jeffrey S. Weber, MD, PhD Moffitt Cancer Center Understanding the Concept of Antitumor Immunity James Patrick Allison, PhD—Chair The University of Texas MD Anderson Cancer Center Harnessing T-Cell Costimulation and Coinhibition for Clinical Benefit Leisha A. Emens, MD, PhD The Johns Hopkins University Where Are We with Cancer Vaccines? Panel Question and Answer 1:15 PM - 2:30 PM Meet the Professor Session Adjuvant Therapy for Corpus-Confined Endometrial Cancer: Who Do We Treat?—Ticketed Session Location: E451b MONDAY Carien L. Creutzberg, MD, PhD Leiden University Medical Center Gini F. Fleming, MD University of Chicago Medical Center 1:15 PM - 2:30 PM Meet the Professor Session Biliary Tract Cancer: Understanding What We Know and What We Don’t Know—Ticketed Session Location: E451a Juan W. Valle, MD Institute of Cancer Studies, University of Manchester, The Christie Hospital Andrew X. Zhu, MD, PhD Massachusetts General Hospital Cancer Center 257 Monday, June 1, 2015 1:15 PM - 4:15 PM Oral Abstract Session Developmental Therapeutics—Immunotherapy Location: S406 Lawrence Fong, MD—Co-Chair UCSF Helen Diller Family Comprehensive Cancer Center Zihai Li, MD, PhD—Co-Chair Medical University of South Carolina MONDAY 1:15 PM Atypical patterns of response in patients (pts) with metastatic melanoma treated with pembrolizumab (MK-3475) in KEYNOTE-001. (Abstract 3000) J. D. Wolchok, O. Hamid, A. Ribas, C. Robert, R. Kefford, W. Hwu, J. S. Weber, A. M. Joshua, T. C. Gangadhar, R. S. Dronca, A. Daud, A. Patnaik, R. W. Joseph, H. M. Zarour, X. Li, D. Xue, S. Ebbinghaus, S. P. Kang, A. M. Perrone, F. S. Hodi 1:27 PM Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature. (Abstract 3001) A. Ribas, C. Robert, F. S. Hodi, J. D. Wolchok, A. M. Joshua, W. Hwu, J. S. Weber, H. M. Zarour, R. Kefford, A. Loboda, A. Albright, S. P. Kang, S. Ebbinghaus, J. Yearley, E. Murphy, M. Nebozhyn, J. K. Lunceford, T. McClanahan, M. Ayers, A. Daud 1:39 PM Density of immunogenic antigens and presence or absence of the T cellinflamed tumor microenvironment in metastatic melanoma. (Abstract 3002) T. Gajewski, Y. Zha, K. Hernandez, Y. Li, R. Bao, P. Alexieff, J. Andrade, J. J. Luke, S. Spranger 1:51 PM Jonathan S. Cebon, MBBS, FRACP, PhD (Discussion of Abstract(s) 3000 –3002) Ludwig Institute for Cancer Research, Austin Hospital The Role of the Microenvironment in Response Prediction 2:03 PM Panel Question and Answer 2:15 PM Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma. (Abstract 3003) A. Ribas, M. Butler, J. Lutzky, D. P. Lawrence, C. Robert, W. Miller, G. P. Linette, P. A. Ascierto, T. Kuzel, A. P. Algazi, M. A. Postow, P. D. Nathan, B. D. Curti, P. B. Robbins, X. Li, J. A. Blake-Haskins, M. S. Gordon 2:27 PM A phase I study of PF-05082566 (anti-4 –1BB) ⴙ rituximab in patients with CD20ⴙ NHL. (Abstract 3004) A. K. Gopal, N. L. Bartlett, R. Levy, R. Houot, S. D. Smith, N. H. Segal, A. D. Thall, G. Mugundu, B. Huang, C. Davis, H. E. Kohrt 2:39 PM Phase I study of RG7155, a novel anti-CSF1R antibody, in patients with advanced/metastatic solid tumors. (Abstract 3005) C. A. Gomez-Roca, P. A. Cassier, A. Italiano, M. Cannarile, C. Ries, A. Brillouet, C. Mueller, A. Jegg, G. Meneses-Lorente, M. Baehner, K. Abiraj, D. Loirat, M. Toulmonde, S. P. D’Angelo, K. Weber, M. Campone, D. Ruettinger, J. Blay, J. Delord, C. Le Tourneau 2:51 PM Zihai Li, MD, PhD (Discussion of Abstract(s) 3003–3005) Medical University of South Carolina Broadening the Approach to Immunotherapy 3:03 PM Panel Question and Answer 3:15 PM Immunotherapy with CD19-specific chimeric antigen receptor (CAR)-modified T cells of defined subset composition. (Abstract 3006) C. J. Turtle, C. Berger, D. Sommermeyer, T. Budiarto, L. Hanafi, K. Melville, B. Pender, N. Steevens, C. Chaney, S. Heimfeld, S. Cherian, B. L. Wood, L. Soma, X. Chen, M. Jensen, S. R. Riddell, D. G. Maloney 3:27 PM Safety and antitumor activity of chimeric antigen receptor modified T cells in patients with chemotherapy refractory metastatic pancreatic cancer. (Abstract 3007) G. L. Beatty, M. H. O’Hara, A. M. Nelson, M. McGarvey, D. A. Torigian, S. F. Lacey, J. J. Melenhorst, B. Levine, G. Plesa, C. H. June 258 Monday, June 1, 2015 3:39 PM Autologous HER2 CMV bispecific CAR T cells for progressive glioblastoma: Results from a phase I clinical trial. (Abstract 3008) N. M. Ahmed, V. S. Brawley, O. Diouf, A. Ghazi, J. Yi, H. Liu, C. M. Rooney, G. Dotti, A. P. Gee, R. Grossman, Y. Kew, D. S. Baskin, A. Ashoori, J. Zhang, J. Hicks, S. Powell, W. Wels, M. K. Brenner, H. E. Heslop, S. M. Gottschalk 3:51 PM To Be Determined (Discussion of Abstract(s) 3006 –3008) Engineering the Effector 4:03 PM Panel Question and Answer 1:15 PM - 4:15 PM Oral Abstract Session Head and Neck Cancer Location: S100bc 1:15 PM Phase III randomized trial of standard fractionation radiotherapy (SFX) with concurrent cisplatin (CIS) versus accelerated fractionation radiotherapy (AFX) with panitumumab (PMab) in patients (pts) with locoregionally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): NCIC Clinical Trials Group HN.6 trial. (Abstract 6000) L. L. Siu, J. N. Waldron, B. E. Chen, E. Winquist, J. R. Wright, A. Nabid, J. H. Hay, J. Ringash, G. Liu, A. Johnson, G. Shenouda, M. Chasen, A. Pearce, J. B. Butler, S. Breen, E. X. Chen, T. J. Childs, A. Montenegro, B. O’Sullivan, W. R. Parulekar 1:27 PM Weekly paclitaxel, carboplatin, cetuximab (PCC), and cetuximab, docetaxel, cisplatin, and fluorouracil (C-TPF), followed by risk-based local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma (LAHNSCC). (Abstract 6001) E. Massarelli, R. I. Haddad, J. Lee, H. Y. Lin, A. S. Garden, G. R. Blumenschein Jr., W. N. William Jr., R. B. Tishler, B. S. Glisson, K. A. Gold, F. M. Johnson, G. Rabinowits, L. E. Ginsberg, M. D. Williams, J. Myers, M. S. Kies, V. Papadimitrakopoulou 1:39 PM Long-term results of GORTEC 2000 – 01: A multicentric randomized phase III trial of induction chemotherapy with cisplatin plus 5-fluorouracil, with or without docetaxel, for larynx preservation. (Abstract 6002) G. Janoray, Y. Pointreau, P. Garaud, S. Chapet, M. Alfonsi, C. Sire, C. Tuchais, G. Calais 1:51 PM The effect of age on outcome in prospective, phase III NRG Oncology/RTOG trials of radiotherapy (XRT) ⴙ/- chemotherapy in locally advanced (LA) head and neck cancer (HNC). (Abstract 6003) J. A. Kish, Q. Zhang, C. J. Langer, F. Nguyen-Tan, D. I. Rosenthal, R. S. Weber, M. A. List, S. J. Wong, A. S. Garden, J. S. Cooper, A. Trotti, J. A. Bonner, C. U. Jones, S. S. Yom, J. M. Michalski, C. J. Schultz, J. A. Ridge, G. Shenouda, Q. Le 2:03 PM Lisa F. Licitra, MD (Discussion of Abstract(s) 6000 – 6003) Fondazione IRCCS Istituto Nazionale Tumori Management of Locally Advanced Disease: An Update 2:15 PM Panel Question and Answer 2:27 PM A prospective phase II trail of de-intensified chemoradiotherapy for low-risk HPV-associated oropharyngeal squamous cell carcinoma. (Abstract 6004) B. S. Chera, R. J. Amdur, J. E. Tepper, R. L. Green, B. F. Qaqish, D. N. Hayes, M. C. Weissler, J. Weiss, T. Hackman, A. M. Zanation, S. Patel, J. Zevallos, J. E. Grilley-Olson, W. K. Funkhouser Jr., N. C. Sheets, W. M. Mendenhall 2:39 PM Prognostic implication of persistent HPV16 DNA detection in oral rinses for HPV-positive oropharyngeal carcinoma. (Abstract 6005) E. M. Rettig, A. Wentz, M. R. Posner, N. D. Gross, R. I. Haddad, M. L. Gillison, H. Quon, A. G. Sikora, W. Stott, J. H. Lorch, C. G. Gourin, B. Miles, J. Richmon, K. Misiukiewicz, C. H. Chung, C. Fakhry, G. D’Souza 259 MONDAY Vassiliki Papadimitrakopoulou, MD—Chair The University of Texas MD Anderson Cancer Center Monday, June 1, 2015 2:51 PM Mutational patterns of HPVⴙ and HPV- squamous cell carcinomas of the head and neck (SCCHN) and their interference with outcome after adjuvant chemoradiation: A multicenter biomarker study of the German Cancer Consortium Radiation Oncology Group. (Abstract 6006) I. Tinhofer, V. Budach, A. Linge, F. Lohaus, E. Gkika, M. Stuschke, P. Balermpas, C. Rödel, M. Avlar, A. Grosu, A. Abdollahi, J. Debus, C. Belka, S. Pigorsch, S. E. Combs, D. Mönnich, D. Zips, W. Weichert, M. Krause, M. Baumann, DKTK-ROG 3:03 PM Serial early post-IMRT undetectable plasma EBV DNA to predict outcomes in non-metastatic nasopharyngeal cancer. (Abstract 6007) V. H. Lee, D. L. Kwong, T. Leung, C. Choi, S. C. Ng, K. Lam, C. Sze, C. Tong, P. P. Ho, W. W. Chan, L. Wong, D. K. Leung, A. S. Chan, F. Chan, K. Lau 3:15 PM Barbara Burtness, MD (Discussion of Abstract(s) 6004 – 6007) Yale School of Medicine HPV and Epstein–Barr Virus-Related Head and Neck Cancer: Deintensification and Surveillance 3:27 PM Panel Question and Answer 3:39 PM Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort. (Abstract LBA6008) T. Y. Seiwert, R. I. Haddad, S. Gupta, R. Mehra, M. Tahara, R. Berger, S. Lee, B. Burtness, D. T. Le, K. Heath, A. Blum, M. Dolled-Filhart, K. Emancipator, K. Pathiraja, J. D. Cheng, L. Q. Chow 3:51 PM Julie E. Bauman, MD, MPH (Discussion of Abstract(s) LBA6008) University of Pittsburgh Immunotherapy for Head and Neck Cancer 4:03 PM Panel Question and Answer 1:15 PM - 4:45 PM Poster Session Cancer Prevention, Genetics, and Epidemiology Location: S Hall A Abstracts 1512–1523 will be discussed during the Cancer Prevention, Genetics, and Epidemiology Poster Discussion Session. See page 298 for session information. MONDAY Board 335 Identification of ERCC2 as novel susceptibility gene for hereditary breast and ovarian cancer. (Abstract 1512) P. Wimberger, A. Benet-Pages, S. Schubert, R. Janavicius, J. D. Kuhlmann, A. Tzschach, K. Kast, A. Meindl, E. Holinski-Feder, S. Emmert, E. Schrock, A. Rump Board 336 Clinical impact of multi-gene panel testing for hereditary breast and ovarian cancer risk assessment. (Abstract 1513) L. W. Ellisen, A. W. Kurian, A. J. Desmond, M. Mills, S. E. Lincoln, K. M. Shannon, M. Gabree, N. M. Tung, J. M. Ford Board 337 Assessment of the clinical presentation of patients with at least two deleterious mutations on multi-gene panel testing. (Abstract 1514) J. N. Weitzel, K. R. Blazer, B. Nehoray, J. Kidd, T. P. Slavin Jr., I. Solomon, M. NiellSwiller, C. Rybak, J. Saam Board 338 Outcomes of clinical testing for 50,000 patients utilizing a panel of 25 genes associated with increased risk for breast, ovarian, colorectal, endometrial, gastric, pancreatic, melanoma, and prostate cancers. (Abstract 1515) E. T. Rosenthal, H. McCoy, J. Kidd, B. Evans, K. Brown, J. Saam, S. Manly, R. J. Wenstrup Board 339 Sarcoma: A Lynch syndrome (LS)-associated malignancy? (Abstract 1516) J. M. Kaczmar, J. Everett, K. Ruth, E. M. Stoffel, J. Stoll, S. Kupfer, H. Hampel, Z. K. Stadler, P. Gaddam, C. Rybak, T. P. Slavin Jr., J. P. Terdiman, A. Blanco, M. J. Hall 260 Board 340 A comparison of ascertainment of Lynch syndrome in colorectal cancer patients via reflex testing vs. hereditary guideline-based testing. (Abstract 1517) S. Samimi, R. M. Lee-Ying, D. Schaeffer, R. Wolber, D. J. Renouf, W. Y. Cheung, K. A. Schrader, G. Mitchell, H. J. Lim Board 341 Usefulness of the patient self-administered cancer family history questionnaire in identification of gynecological cancer patients suspected of Lynch syndrome: KCOG-G1302 study. (Abstract 1518) R. Nishikawa, K. Oseto, H. Nishikawa, A. Arakawa, K. Kai, K. Nasu, M. Morii-Kashima, H. Tsubamoto, K. Ito, N. Furukawa Board 342 Recreational activity and sedentary behavior in relation to lung cancer incidence and mortality in the Women’s Health Initiative. (Abstract 1519) A. Wang, F. Qin, H. Hedlin, M. Desai, R. T. Chlebowski, S. L. Gomez, C. Eaton, K. Johnson, L. Qi, J. Wactawski-Wende, C. Womack, H. A. Wakelee, M. L. Stefanick Board 343 Modifiable metabolic markers c-peptide (C-PEP), highly sensitive c-reactive protein (hsCRP), leptin (LEP)] and lung cancer (LC) risk: A matched casecontrol study nested in the prostate, lung, colorectal and ovarian (PLCO) cancer screening study. (Abstract 1520) P. J. Goodwin, M. Tammemagi, V. Stambolic, R. J. Dowling, C. Williams, M. Moore, A. Lohmann, F. A. Shepherd Board 345 Epidemiology and management of HIV-related non-Hodgkin lymphoma (NHL) in the United States (US): Analysis of the National Cancer Data Base (NCDB). (Abstract 1521) A. J. Olszewski, J. Fallah, J. J. Castillo Board 346 Family history of breast cancer in Hodgkin disease and future risk for breast cancer. (Abstract 1522) S. V. Colonna, K. Curtin, W. Kohlmann, J. A. Wright, S. Tavtigian, J. D. Schiffman Board 347 Hereditary implications of somatic tumor testing. (Abstract 1523) P. Funchain, D. Sohal, A. A. Khorana, J. Abraham, N. A. Pennell, B. I. Rini, R. Dreicer, B. J. Bolwell, C. Eng Board 348 Clinical outcomes based on multigene profiling in metastatic breast cancer patients. (Abstract 1524) R. K. Basho, D. D. Gagliato, N. T. Ueno, R. H. Alvarez, C. Wathoo, H. Chen, C. Wei, A. A. Sahin, S. Roy-Chowdhuri, S. L. Moulder, M. Chavez-Mac Gregor, J. K. Litton, V. Valero, R. Luthra, K. R. Shaw, J. Mendelsohn, G. B. Mills, D. Tripathy, F. Meric-Bernstam Board 349 Whole exome sequencing to identify potentially causative gene variants in hereditary gastric cancer. (Abstract 1525) Y. Huang, K. Tan, H. Yap, S. G. Ow, H. Yang, J. So, S. Lee Board 350 Amplification of CRKL in human cancer: A rare event associated with potential sensitivity to targeted therapy. (Abstract 1526) K. Wang, A. Johnson, I. Garrido-Laguna, J. Chmielecki, R. Yelensky, D. Lipson, J. A. Elvin, J. Vergilio, S. M. Ali, V. A. Miller, P. J. Stephens, J. S. Ross Board 351 Germline testing in hereditary cancer genes subsequent to the identification of mutations in tumor specimens. (Abstract 1527) V. Speare, J. S. Dolinsky, H. Laduca, C. Horton, L. Panos, C. Mason, E. Dalton, E. Chao Board 352 Comparison of genotyping performance in DNA extracted from matched FFPE tumor, FFPE lymph node, and whole blood for pharmacogenetic analyses. (Abstract 1528) D. L. Hertz, K. M. Kidwell, J. N. Thibert, C. L. Gersch, M. M. Regan, T. C. Skaar, N. L. Henry, D. Hayes, C. Van Poznak, J. M. Rae Board 353 Personalized Genomic Analyses for Cancer Mutation Discovery and Interpretation. (Abstract 1529) V. Anagnostou, S. Jones, K. Lytle, S. Parpart-Li, M. Nesselbush, V. Adleff, D. Riley, M. Shukla, B. Chesnick, M. Kadan, E. Papp, K. Galens, D. M. Murphy, T. Zhang, L. Kann, M. Sausen, S. Angiuoli, L. A. Diaz Jr., V. E. Velculescu Board 354 The landscape for genetic eligibility to basket clinical trials. (Abstract 1530) T. C. Knepper, C. M. Walko, G. C. Bell, E. Padron, J. K. Teer, H. L. McLeod Board 355 Patient-reported outcomes associated with population-based Jewish genetic testing for BRCA1 and BRCA2. (Abstract 1531) K. A. Metcalfe, A. Poll, M. Llacuachaqui, S. Virani, S. Nanda, P. Sun, S. Narod 261 MONDAY Monday, June 1, 2015 Monday, June 1, 2015 MONDAY Board 356 Somatic mutation profiling of advanced breast and ovarian cancers according to germline BRCA1/2 mutation status. (Abstract 1532) N. Stjepanovic, M. K. Wilson, A. M. Oza, B. Clarke, H. K. Berman, E. Amir, H. Mackay, P. Shaw, M. O. Butler, A. Mulligan, A. Milea, L. Ahmed, A. Volenik, L. Wang, T. J. Pugh, T. Stockley, R. H. Kim, L. L. Siu, S. Kamel-Reid, P. L. Bedard Board 357 Multi-gene panel testing in an unselected endometrial cancer cohort. (Abstract 1533) K. L. Ring, A. S. Bruegl, B. Allen, E. P. Elkin, N. Singh, A. Hartman, R. Broaddus Board 358 Evaluation of rapid whole-body magnetic resonance as screening strategy for early cancer detection in 57 Brazilian Li-Fraumeni syndrome patients. (Abstract 1534) D. Paixao, M. D. Guimaraes, A. F. Nobrega, D. Malkin, R. Chojniak, M. W. Achatz Board 359 Comprehensive genomic profiling of advanced stage esophageal squamous cell carcinomas (ESCC) and esophageal adenocarcinomas (EAC). (Abstract 1535) A. Johnson, S. M. Ali, R. Yelensky, J. Chmielecki, J. A. Elvin, D. Lipson, V. A. Miller, P. J. Stephens, J. S. Ross, K. Wang Board 360 Is there a role for multi-gene screening panels in patients who previously underwent noninformative genetic testing? (Abstract 1536) M. K. Frey, S. H. Kim, J. Martineau, R. Yee Bassett, S. V. Blank Board 361 Do women with BRCA1 or BRCA2 mutations have reduced ovarian reserve? (Abstract 1537) K. Phillips, I. M. Collins, R. L. Milne, R. Fisher, C. Stern, G. Kannemeyer, C. Smith, M. Friedlander, S. McLachlan, M. Hickey, J. L. Hopper, kConFab Investigators Board 362 Predictors of BRCA mutation in male breast cancer. (Abstract 1538) C. Ardic, A. M. Gutierrez-Barrera, N. Elsayegh, J. Song, J. Profato, J. K. Litton, S. H. Giordano, D. Tripathy, B. Arun Board 363 Solid tumor profiling via next-generation sequencing to identify tumorspecific actionable variants. (Abstract 1539) S. E. Patterson, C. S. Potter, G. A. Stafford, X. Y. Woo, V. Spotlow, T. Mitchell, R. Liu, G. Ananda, G. J. Tsongalis, S. M. Mockus Board 364 Germline variation in NFE2L2, CUL3, KEAP1 and risk of head and neck squamous cell carcinoma (HNSCC). (Abstract 1540) S. Sheth, J. L. Weissfeld, M. Romkes, R. L. Ferris, J. R. Grandis, J. E. Bauman, B. Diergaarde Board 365 Genetic testing decisions of breast cancer patients: Results from the iCanCare study. (Abstract 1541) R. Jagsi, A. W. Kurian, K. A. Griffith, A. S. Hamilton, K. C. Ward, S. T. Hawley, M. Morrow, S. J. Katz Board 366 Assessment of functional impact of germline BRCA1/2 variants located in noncoding regions in families with breast-ovarian cancer predisposition. (Abstract 1542) E. Santana dos Santos, M. Gendrot, S. Caputo, A. Briaux, M. Breault, L. Castera, D. Vaur, S. Krieger, C. Houdayer, I. Bieche, D. StoppaLyonnet, F. Lallemand, E. Rouleau Board 367 Transgenerational genomic effect of chemotherapy exposure in testicular cancer survivors. (Abstract 1543) E. M. Van Allen, G. Kryukov, C. Bielski, K. Samocha, M. Fromer, S. Seepo, C. Gentry, B. Neale, C. Sweeney, L. A. Garraway, M. Taplin Board 368 Somatic mutations in Luminal HER2 negative tumors from young breast cancer patients. (Abstract 1544) G. Encinas, M. D. Estevez-Diz, E. C. Lyra, M. H. Katayama, F. S. Pasini, S. Maistro, V. Sabelnykova, P. Boutros, M. Brentani, R. Basso, A. R. Chaves De Gouvea, R. Chammas, J. G. Sampaio Goes, M. A. Koike Folgueira Board 369 Patient interest and willingness-to-pay (WTP) out-of-pocket (OOP) for comprehensive tumor genetic profiling (CGP). (Abstract 1545) J. Innocent, E. Handorf, J. M. Matro, Y. Wong, Y. Chertock, M. B. Daly, M. J. Hall Board 370 Evaluation of family history in newly diagnosed children with cancer. (Abstract 1546) K. Garfield, W. Kohlmann, C. C. Mason, J. D. Schiffman 262 Board 371 Missense variants in Lynch Syndrome genes in endometrial cancer patients characterized by The Cancer Genome Atlas (TCGA) project. (Abstract 1547) C. S. Walsh, B. Karlan, D. Hazelett Board 372 Rare germline TP53 variants in lung adenocarcinoma. (Abstract 1548) E. M. Parry, D. L. Gable, S. E. Stanley, M. Y. Armanios Board 373 Women with breast and uterine cancer in relation to genetic mutation risk: A case-control analysis. (Abstract 1549) M. R. Milam, M. Stany, S. Li, K. Fulk, E. Chao, H. Laduca Board 374 The impact of a molecular tumor board on treatment decisions for 35 patients: The Dartmouth experience. (Abstract 1550) L. J. Tafe, I. P. Gorlov, F. B. Blumental de Abreu, J. A. Lefferts, X. Liu, J. R. Pettus, K. J. Bloch, J. D. Marotti, V. A. Memoli, A. A. Suriawinata, J. D. Peterson, G. J. Tsongalis, B. M. Holderness, C. R. Morgan, T. W. Miller, M. D. Chamberlin Board 375 Polymorphisms in the estrogen pathway, estrogen receptor alpha gene (ESR1), daily cycling estrogen and mammographic density. (Abstract 1551) F. N. Fjeldheim, H. Frydenberg, V. G. Flote, A. McTiernan, P. T. Ellison, E. S. Barrett, G. Jasienska, K. W. Makar, G. Ursin, E. A. Wist, I. Thune Board 376 Genetic testing for hereditary breast cancer: The decision to decline. (Abstract 1552) B. White, K. Showers, C. S. Menendez, L. Amacker-North, K. W. Carpenter, S. Lenarcic, L. McNeely, C. Harwood, B. Dellinger, R. L. White Jr. Board 377 Identification of tropomyosin kinase receptor (TRK) mutations in cancer. (Abstract 1553) N. Nanda, T. Fennell, J. A. Low Board 378 Next-generation sequencing as an informing phenotype: A TP53 example. (Abstract 1554) R. O Shea, M. P. Farrell, R. Clarke, B. Eileen, D. J. Gallagher Board 379 The influence of BRCA variants of uncertain significance in cancer risk management decision-making. (Abstract 1555) J. Chern, S. S. Lee, M. K. Frey, R. Bassett, J. Martineau, S. Blank Board 380 First one thousand families: Our multidisciplinary experience in the heredofamilial cancer unit from a Spanish University Hospital. (Abstract 1556) I. Marquez Rodas, S. Luque Molina, M. Sanz, M. Peligros, C. Flores Sanchez, C. Mata, M. Die Trill, S. Lizarraga, P. Rincon, O. Bueno, S. Lopez-Tarruella, Y. Jerez Gilarranz, A. J. Muñoz Martin, A. Calvo, C. Lopez, P. Menchen, J. Pajares, C. Gonzalez Asanza, J. Solera, M. Martin Board 381 DNA repair landscape of discordant sibling pairs from hereditary breast cancer families. (Abstract 1557) Y. Ji, T. Rounds, J. Dragon, J. Bond, S. Wallace, J. Sweasy, M. Wood Board 382 Intratumoral heterogeneity of cancer driver genomic alterations across several tumor types. (Abstract 1558) K. Wang, A. Johnson, D. Khaira, J. Sun, B. Katzman, T. Brennan, C. McMahon, K. Gowen, S. Balasubramanian, S. M. Ali, J. A. Elvin, D. Lipson, V. A. Miller, P. J. Stephens, J. S. Ross, R. Yelensky Board 383 Feasibility of using memantine in smoking cessation among cancer survivors. (Abstract 1559) J. Spangler, K. E. Weaver, D. Case, G. Lesser, G. V. Burton, I. A. Dy, C. Dul, P. Reddy, J. L. Wade III, B. Esparaz, E. G. Shaw Board 384 Hormonal and lifestyle factors as modifiers of risk of breast cancer (BC) in BRCA1 and BRCA2 carriers (C). (Abstract 1560) A. Torres, T. Ramón y Cajal, G. Llort, D. Fisas, C. Yague, C. López, M. León, M. Pollán Board 385 Physical activity, hormone replacement therapy and breast cancer risk: A meta-analysis of prospective studies. (Abstract 1561) C. Pizot, M. Boniol, P. Mullie, A. Koechlin, P. Boyle, P. Autier Board 386 Impact of prior knowledge of mutation status on tumor stage in BRCA1/2 mutation carriers with newly diagnosed breast cancer. (Abstract 1562) C. Yam, J. Stopfer, A. Brandt, J. Powers, J. M. Long, K. N. Maxwell, A. R. Bradbury, K. L. Nathanson, S. M. Domchek 263 MONDAY Monday, June 1, 2015 Monday, June 1, 2015 MONDAY Board 387 Development and external validation of a melanoma risk prediction model using self-assessed risk factors. (Abstract 1563) K. Vuong, A. E. Cust, B. K. Armstrong, K. McGeechan Board 388 Aspirin and risks of non-colorectal second primary cancer in patients with prior colorectal cancer. (Abstract 1564) Y. Lee, C. Teng, J. Liu, T. Chiou, P. Chen, C. Tzeng, C. Liu Board 389 Cancer screening in France: Reaching a plateau? New edition of an iterative nationwide survey. (Abstract 1565) J. Viguier, J. F. Morere, C. Touboul, F. Eisinger, S. Couraud, L. Greillier, A. B. Cortot, J. Blay, C. Lhomel, X. B. Pivot Board 390 The influence of inflammation on mammographic breast density in women at increased risk of breast cancer. (Abstract 1566) S. S. Ambrale, T. Rounds, B. L. Sussman, M. Rincon, D. Kontos, B. M. Keller, Y. Ji, B. Sprague, M. Wood Board 391 Impact of a risk model based on routine lab results on colorectal cancer screening in average risk population. (Abstract 1567) S. B. Boursi, R. Mamtani, K. Haynes, Y. Yang Board 392 Trends in CRC screening by average-risk Medicare enrollees over age 75: 2002–2010. (Abstract 1568) C. L. Bennett, J. Bian, D. Fisher Board 393 Prediction models for primary melanoma: an independent external validation study in an Australian population. (Abstract 1569) K. Vuong, A. E. Cust, B. K. Armstrong, K. McGeechan Board 394 Beliefs and behavior regarding e-cigarettes in a large cross-sectional survey. (Abstract 1570) S. Couraud, A. B. Cortot, C. Touboul, X. B. Pivot, F. Eisinger, J. F. Morere, J. Viguier, J. Blay, C. Lhomel, L. Greillier Board 395 Omentin as a potential biomarker related to exercise and cancer risk. (Abstract 1571) M. Onstad, K. Basen-Engquist, R. Schmandt, S. C. Mok, C. Au Yeung, S. Scruggs, K. H. Lu Board 396 Effect of green tea catechins in prostate cancer chemoprevention. (Abstract 1572) N. B. Kumar, J. Pow-Sang, K. Egan, P. E. Spiess, S. I. Dickinson, R. Salup, M. Helal, J. McLarty, C. R. Williams, F. J. Schreiber III, H. Parnes, S. Sebti, A. Kazi, L. Kang, G. P. Quinn, T. Smith, B. Yue, G. Chornokur, T. Crocker, M. J. Schell Board 397 Do patients with longstanding IBD have higher cancer risk compared to the general population? Results from the IBSEN study. (Abstract 1573) M. Cvancarova, O. Hovde, M. Wanderaas, B. Moum Board 398 Association between geriatric assessment findings and clinical depression in 1092 older patients with cancer: The ELCAPA Cohort study. (Abstract 1574) C. Tournigand, F. Canoui-Poitrine, N. Reinald, M. Laurent, E. Guery, P. Caillet, J. David, J. Lagrange, S. Bastuji-Garin, C. Lemogne, E. Paillaud Board 400 Comparison of breast cancer risk in women with and without systemic lupus erythematosus in a Medicare population. (Abstract 1576) W. Khaliq, R. Qayyum, J. Clough, D. Vaidya, D. M. Becker Board 401 Factors associated with early mortality in metastatic breast cancer (MBC) in a population based cohort. (Abstract 1577) I. V. Luis, N. U. Lin, N. L. Keating, J. Lii, W. T. Barry, E. P. Winer, R. A. Freedman Board 402 Breast cancer in male AYA. (Abstract 1578) R. Bawa, D. C. Flaherty, C. Sadler, M. Goldfarb Board 403 Treatment intensity differences in screen-detected and community-detected early stage breast cancer (ESBC). (Abstract 1579) K. J. Elder, S. Cooke, D. Machalek, A. Rose, A. Mou, J. P. Collins, C. Nickson, A. Park, B. Mann Board 404 Association of body mass index with survival outcome in three breast cancer subtypes. (Abstract 1580) T. Fujii, T. Kogawa, C. Wei, T. M. Fouad, K. Harano, Y. Park, B. Lim, D. Tripathy, N. T. Ueno, J. K. Litton Board 405 Incidence, prevalence, and risk factors of malignancy in lung transplant recipients. (Abstract 1581) V. K. Singh, V. D. Villgran, L. Beesley, A. Petraglia, K. M. Kane, C. Gries, M. George 264 Monday, June 1, 2015 Board 406 Novel algorithms to predict the occurrence of in-hospital venous thromboembolism in cancer patients: Machine learning classifiers developed from the 2012 national inpatient sample. (Abstract 1582) S. L. James, K. Mody, J. J. Shatzel Board 407 Male breast cancer as a second primary cancer (SPC): Increased risk following hematologic malignancies. (Abstract 1583) D. E. Farr, A. Thomas, S. L. Sugg, W. J. Gradishar, S. A. Khan, M. C. Schroeder Board 408 Pre-diabetes and breast cancer outcomes: Abrogating the confounding effect of anti-diabetic therapy. (Abstract 1584) V. Kaur, A. M. Safar, E. R. Siegel, J. Fariba, S. Medarametla, T. Kieber-Emmons, K. M. Behjatolah Board 409 “Fight fat with fat”: The impact of brown adipose tissue (BAT) on breast cancer prognosis–A retrospective analysis. (Abstract 1585) O. E. Silva, S. M. Warsch, A. E. Torres, A. Gomez Arteaga, G. Westin, R. Dawar, Q. R. Sparrow, D. M. Hansra, K. Hernandez, M. Torroella, P. Doshi, A. N. Serafini, M. E. Lippman Board 410 Development of CNS metastasis and subsequent survival in patients with inflammatory breast cancer. (Abstract 1586) J. T. French, K. R. Hess, D. D. Liu, K. P. Raghav, G. N. Hortobagyi, B. Arun, V. Valero, N. T. Ueno, R. H. Alvarez, W. A. Woodward, B. G. Debeb, S. L. Moulder, B. Lim, D. Tripathy, N. K. Ibrahim Board 411 Prevalence of malnutrition in PS 0 –1 cancer patients: Results of the NutriCancer2 one-day national survey in 2,197 cancer patients. (Abstract 1587) J. Durand, X. Hebuterne, B. Raynard, J. Lacau Saint Guily, F. Goldwasser Board 412 The long-term use of calcium channel blockers and the risk of breast cancer. (Abstract 1588) S. V. Soldera, N. Bouganim, J. Asselah, H. Yin, R. Maroun, L. Azoulay Board 413 Overall survival in solid tumor patients with abnormal renal function or renal insufficiency. (Abstract 1589) V. Launay-Vacher, N. Janus, I. L. Ray-Coquard, P. Beuzeboc, J. Thariat, G. Deray Board 414 Determinants for no definitive therapy for early-stage non-small cell lung cancer in U.S. population. (Abstract 1590) Y. Chen, A. Y. Chang, C. Chen, Y. Chiu, Y. Feng, S. Lin, Y. Sheu, Y. Lin Board 416 Effect of current smoking on risk of triple negative breast cancer. (Abstract 1592) D. Prabhakar, L. Harris, C. L. Thompson Central Nervous System Tumors Location: S Hall A Abstracts 2012–2023 will be discussed during the Central Nervous System Tumors Poster Discussion Session. See page 298 for session information. Board 1 Brain Tumor Trials Collaborative Bayesian Adaptive Randomized Phase II trial of bevacizumab plus vorinostat versus bevacizumab alone in adults with recurrent glioblastoma (BTTC-1102). (Abstract 2012) V. K. Puduvalli, J. Wu, Y. Yuan, T. S. Armstrong, M. D. Groves, J. J. Raizer, P. Giglio, H. Colman, D. M. Peereboom, T. Walbert, N. G. Avgeropoulos, F. M. Iwamoto, M. C. Chamberlain, N. Paleologos, K. L. Fink, R. Merrell, W. A. Yung, M. R. Gilbert Board 2 Randomized, placebo-controlled, phase II study of dasatinib with standard chemo-radiotherapy for newly diagnosed glioblastoma (GBM), NCCTG N0877 (Alliance). (Abstract 2013) N. N. Laack, E. Galanis, S. Anderson, C. Leinweber, J. C. Buckner, C. Giannini, F. J. Geoffroy, D. R. Johnson, G. J. Lesser, K. A. Jaeckle, J. N. Sarkaria Board 3 A phase II study of galunisertib monotherapy or galunisertib plus lomustine compared to lomustine monotherapy in recurrent glioblastoma. (Abstract 2014) A. A. Brandes, A. F. Carpentier, S. Kesari, J. Sepulveda, H. Wheeler, O. L. 265 MONDAY 1:15 PM - 4:45 PM Poster Session Monday, June 1, 2015 Chinot, L. Cher, J. P. Steinbach, P. Specenier, A. Cleverly, C. Smith, I. Gueorguieva, S. C. Guba, D. Desaiah, M. M. Lahn, W. Wick MONDAY Board 4 Onartuzumab plus bevacizumab versus placebo plus bevacizumab in recurrent glioblastoma (GBM): HGF and MGMT biomarker data. (Abstract 2015) T. F. Cloughesy, G. Finocchiaro, C. Belda, L. Recht, A. A. Brandes, E. Pineda, T. Mikkelsen, O. L. Chinot, C. Balana, D. R. Macdonald, M. Westphal, K. Hopkins, M. Weller, B. Liu, J. Bruey, W. Verret Board 5 Phase I study of ABT-414 mono- or combination therapy with temozolomide (TMZ) in recurrent glioblastoma (GBM). (Abstract 2016) H. K. Gan, K. P. Papadopoulos, L. Fichtel, A. B. Lassman, R. Merrell, M. J. Van Den Bent, P. Kumthekar, A. M. Scott, M. Pedersen, E. J. Gomez, J. S. Fischer, W. Ames, H. Xiong, H. Lee, W. Munasinghe, L. Roberts-Rapp, P. Ansell, K. D. Holen, R. Lai, D. A. Reardon Board 6 Defining the cutoff value of MGMT gene promoter methylation and its predictive capacity. (Abstract 2017) A. Rocca, G. Brigliadori, D. Calistri, F. Foca, M. Dall’Agata, C. Rengucci, S. Cerasoli, M. Faedi Board 7 Impact of bevacizumab added to temozolomide-chemoradiation on time to health-related quality of life deterioration in unresectable glioblastoma: Results of a phase II randomized clinical trial. (Abstract 2018) F. Bonnetain, T. S. Dabakuyo, A. Pozet, L. Feuvret, L. Taillandier, D. Frappaz, H. Taillia, R. Schott, J. Honnorat, M. Fabbro, I. Tennevet, F. Ghiringhelli, C. Campello, D. Castera, M. Frenay, C. Dalban, J. Skrzypski, O. L. Chinot, B. Chauffert, A. Anota Board 8 Outcome of neurofibromatosis type 1 patients treated with first line vinblastine for optic pathway gliomas: A Canadian multicenter study. (Abstract 2019) A. Lassaletta, K. Scheinemann, S. M. Zelcer, J. Hukin, B. Wilson, N. Jabado, A. Carret, L. Lafay Cousin, V. Larouche, C. Hawkins, G. R. Pond, K. Poskitt, E. Barlev, D. Keene, D. Johnston, U. K. Bartels, U. Tabori, E. Bouffet Board 9 A multi-institutional prospective observational study of stereotactic radiosurgery (SRS) for patients with multiple brain metastases (BMs): Updated results of the JLGK0901 Study—Long-term results of irradiationrelated complications and neurocognitive function (NCF). (Abstract 2020) M. Yamamoto, T. Serizawa, Y. Higuchi, Y. Sato, J. Kawagishi, K. Yamanaka, T. Shuto, A. Akabane, H. Jokura, S. Yomo, O. Nagano, H. Aoyama Board 10 Results of a randomized, global, multi-center study of whole-brain radiation therapy (WBRT) plus veliparib or placebo in patients (pts) with brain metastases (BM) from non-small cell lung cancer (NSCLC). (Abstract 2021) P. Chabot, J. Ryu, V. Gorbunova, C. Belda, D. Ball, E. A. Kio, M. Mehta, K. Papp, Q. Qin, J. Qian, K. D. Holen, V. L. Giranda, J. H. Suh Board 11 A phase II study of temozolomide in the treatment of adult patients with supratentorial low-grade glioma. (Abstract 2022) M. T. Wahl, J. Aicardi, D. A. Haas-Kogan, N. A. Butowski, J. L. Clarke, M. Prados, J. J. Phillips, M. S. Berger, S. M. Chang Board 12 Phase I/II study of dianhydrogalactitol in patients with recurrent malignant glioma. (Abstract 2023) K. C. Shih, M. R. Patel, N. A. Butowski, J. A. Bacha, D. Brown, A. Steino, R. S. Schwartz, S. Kanekal, L. Lopez, S. F. Jones, H. A. Burris III Board 13 ACRIN 6684: Assessment of tumor hypoxia in newly diagnosed GBM using FMISO PET and MRI. (Abstract 2024) E. R. Gerstner, Z. Zhang, J. R. Fink, M. Muzi, L. Hanna, E. Greco, A. Mintz, L. Kostakoglu, E. A. Eikman, M. Prah, K. M. Schmainda, G. A. Sorensen, D. Barboriak, D. A. Mankoff Board 14 Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma. (Abstract 2025) X. Cai, V. Chandra, Y. Ou, K. E. Emblem, A. Muzikansky, J. Evans, J. Kalpathy-Cramer, J. Dietrich, A. S. Chi, P. Y. Wen, B. R. Rosen, T. Batchelor, E. R. Gerstner Board 15 Characteristics and outcomes of breast cancer patients with leptomeningeal metastasis at Memorial Sloan Kettering Cancer Center (MSKCC). (Abstract 2026) A. Morikawa, L. Jordan, R. Rozner, S. Patil, A. A. Boire, E. Pentsova, A. D. Seidman 266 Board 16 Histopathological markers at craniotomy and outcome in breast cancer brain metastases. (Abstract 2027) M. J. McKee, D. G. Trembath, A. M. Deal, K. Keith, B. R. Midkiff, N. Nikolaishvilli-Feinberg, A. Garrett, K. L. Blackwell, J. P. Leone, R. L. Hamilton, A. Brufsky, A. Morikawa, E. Brogi, A. D. Seidman, M. G. Ewend, S. J. Moschos, C. K. Anders Board 17 Determining viability of using APNG status as a prognostic marker in patients with glioblastoma multiforme. (Abstract 2028) R. H. Dahlrot, S. Hellwege, S. Fosmark, K. L. Jensen, J. Lohse, H. Derand, J. Hjelmborg, S. Hansen, B. W. Kristensen Board 18 A phase I trial of intravenous liposomal irinotecan in patients with recurrent high-grade gliomas. (Abstract 2029) J. L. Clarke, A. M. Molinaro, A. A. DeSilva, J. E. Rabbitt, D. C. Drummond, S. M. Chang, N. A. Butowski, M. Prados Board 19 Differential molecular expression profile according to glioblastoma (GB) location. (Abstract 2030) E. Denicolai, E. Tabouret, C. Colin, P. Metellus, I. Nanni, C. Boucard, A. Tchoghandjian, N. Baeza-Kallee, F. Fina, O. L. Chinot, D. Figarella-Branger Board 20 Use of a novel radio-sensitizer for treatment of GBM. (Abstract 2031) J. L. Gainer, J. Sheehan, J. M. Larner, D. R. Jones Board 21 Long-term survival in patients with primary CNS lymphoma: Results from the G-PCNSL-SG1 trial. (Abstract 2032) P. Roth, P. Martus, E. Thiel, A. Korfel, M. Weller, G-PCNSL-SG1 study group Board 22 Timed-sequential therapy with mibefradil and temozolomide in patients with recurrent high-grade gliomas: A phase I Adult Brain Tumor Consortium study. (Abstract 2033) M. Holdhoff, X. Ye, L. B. Nabors, A. S. Desai, T. Mikkelsen, G. Lesser, W. L. Read, F. S. Lieberman, J. Supko, J. D. Fisher, S. Desideri, S. A. Grossman, D. Schiff, ABTC Investigators Board 23 Phase II study of bevacizumab and vorinostat for recurrent glioblastoma. (Abstract 2034) A. Ghiaseddin, D. A. Reardon, W. Massey, A. Mannerino, E. S. Lipp, J. E. Herndon II, F. McSherry, A. Desjardins, D. M. Randazzo, G. Vlahovic, H. S. Friedman, K. B. Peters Board 24 Patterns of response and relapse of primary central nervous system lymphomas (PCNSL) following first line of high-dose methotrexate-based chemotherapy (hdMTX): Analysis of a prospective ANOCEF randomized phase II trial. (Abstract 2035) E. Tabouret, C. Houillier, N. Martin-Duverneuil, M. Blonski, C. Soussain, H. Ghesquieres, R. Houot, V. Delwail, P. Soubeyran, R. Gressin, E. Gyan, O. L. Chinot, L. Taillandier, M. Tanguy, A. M. Omuro, K. HoangXuan Board 25 Comparative impact of treatment on clinical benefit in patients with glioblastoma (GBM) enrolled in the phase II trial of ICT-107. (Abstract 2036) T. S. Armstrong, P. Y. Wen, D. A. Reardon, S. Phuphanich, R. Aiken, J. C. Landolfi, W. T. Curry, J. Zhu, M. J. Glantz, D. M. Peereboom, J. Markert, R. V. LaRocca, D. O’Rourke, K. L. Fink, L. J. Kim, M. L. Gruber, G. J. Lesser, E. Pan, S. Kesari, J. Yu Board 26 Correlation of dynamic 18FET-PET with IDH 1 mutation for prediction of outcome in anaplastic astrocytoma WHO° III independently from tumor vascularisation. (Abstract 2037) B. Suchorska, N. L. Jansen, T. Kraus, A. Giese, P. Bartenstein, J. Tonn Board 27 Prognostic model of lower grade gliomas. (Abstract 2038) K. Aoki, H. Suzuki, H. Nakamura, K. Motomura, M. Mizoguchi, T. Abe, Y. Muragaki, T. Wakabayashi, S. Ogawa, A. Natsume Board 28 Phase I study of vorinostat combined with isotretinoin and temozolomide in adults with recurrent malignant gliomas. (Abstract 2039) M. Penas-Prado, K. R. Hess, V. A. Levin, J. F. De Groot, H. Colman, M. D. Groves, C. A. Conrad, M. E. Loghin, K. Hunter, M. R. Gilbert, W. A. Yung, V. K. Puduvalli 267 MONDAY Monday, June 1, 2015 Monday, June 1, 2015 MONDAY Board 29 The impact of the time to start radiotherapy (TRT) on overall survival in newly diagnosed glioblastoma. (Abstract 2040) V. Montes Santos, M. Coelho Mesquita, M. D. Estevez-Diz, G. N. Marta, O. Feher Board 30 Does extent of resection matter in recurrent glioblastoma? Lessons from the DIRECTOR trial. (Abstract 2041) B. Suchorska, M. Weller, G. Tabatabai, C. Senft, P. Hau, M. Sabel, U. Herrlinger, R. Ketter, U. S. Schlegel, C. Marosi, G. Reifenberger, W. Wick, J. Tonn, H. Wirsching Board 31 Effectiveness of transcranial magnetic stimulation in neurooncological patients. (Abstract 2042) D. P. Atmachidi, A. I. Shikhlyarova, E. E. Rostorguev, T. P. Protasova, E. P. Korobeynikova Board 32 Mutational analysis of matched initial and recurrent TP53 WT primary GBM. (Abstract 2043) D. M. Ashley, A. Muscat, J. Yin, E. Algar, K. Drummond, M. Khasraw, K. M. Field, N. Wong, M. Rosenthal, K. L. McDonald Board 33 A phase 2 study on efficacy, safety and intratumoral pharmacokinetics of oral selinexor (KPT-330) in patients with recurrent glioblastoma (GBM). (Abstract 2044) U. N. Lassen, M. Mau-Soerensen, A. L. Kung, P. Y. Wen, E. Q. Lee, S. R. Plotkin, A. Muhic, T. Rashal, T. Williams, D. McCauley, J. Ellis, J. SaintMartin, R. Carlson, R. Frenkel, S. Shacham, M. R. Mirza, M. Kauffman, A. B. Lassman Board 35 IDH 1 /2 status and low grade gliomas (LGG): Correlation with outcome upfront Pignatti criteria and molecular profile in a retrospective analysis of a single-centre cohort from Spain. (Abstract 2046) O. Etxaniz, C. Carrato, I. de Aguirre, C. Queralt, A. Munoz, J. Ramirez, R. Rosell, S. Villà, R. Diaz, A. Estival, P. Teixidor, A. Indacochea, S. Ahlal, L. V. Martinez, C. Balana Board 36 Time to response (TTR) and early tumor shrinkage (ETS) in recurrent glioblastoma patients treated with bevacizumab: an exploratory analysis of the prospective randomized AVAREG (ML25739) phase II study. (Abstract 2047) E. Franceschi, G. Finocchiaro, V. Zagonel, M. Reni, A. Fabi, C. Caserta, M. Clavarezza, E. Maiello, G. Carteni, G. Rosti, R. Agati, A. Tosoni, A. Paccapelo, E. Proietti, A. A. Brandes Board 37 The role of salvage radiation in recurrent glioblastoma after bevacizumab failure. (Abstract 2048) N. Sarmey, S. T. Chao, E. S. Murphy, J. S. Yu, D. M. Peereboom, G. Stevens, J. H. Suh, M. S. Ahluwalia Board 38 Graded prognostic assessment index for colorectal cancer with brain metastases. (Abstract 2049) V. Karivedu, V. Alva Venur, I. Kim, S. T. Chao, J. H. Suh, D. Sohal, A. A. Khorana, X. Jia, M. S. Ahluwalia Board 39 Phase II trial of dovitinib in recurrent glioblastoma. (Abstract 2050) M. S. Ahluwalia, N. Papadantonakis, V. Alva Venur, C. Schilero, D. M. Peereboom, G. Stevens, S. Rosenfeld, M. A. Vogelbaum, P. Elson, A. B. Nixon, K. McCrae Board 40 Incidence of pseudo-progression in low-grade gliomas treated with radiotherapy. (Abstract 2051) S. E. van West, H. G. de Bruin, B. van de Langerijt, A. T. Swaak-Kragten, M. J. Van Den Bent, W. Taal Board 41 Delineation of MGMT promoter hypermethylation as a predictive biomarker for the A071102 clinical trial of veliparib combined with temozolomide (TMZ) using patient-derived xenograft (PDX) GBM models. (Abstract 2052) J. N. Sarkaria, S. Gupta, S. H. Kizilbash, B. Carlson, A. Mladek, K. Bakken, M. A. Schroeder, P. A. Decker, E. P. Sulman, J. Eckel-Passow, G. Kitange, R. B. Jenkins Board 42 The role of temozolomide (TMZ) in the management of anaplastic astrocytoma (AA): A comparison of survival in the era prior to and following TMZ. (Abstract 2053) I. Abuali, R. E. Strowd, Y. Lu, X. Ye, S. A. Grossman Board 43 GLIOSTRY (GLIOblastoma regiSTRY) of the AINO (Italian Association of Neuro-Oncology): Analysis of factors influencing survival in glioblastoma patients receiving the nitrosourea fotemustine at first relapse following Stupp regimen. (Abstract 2054) R. Ruda, G. Lombardi, S. Scoccianti, M. Fabrini, M. Santoni, A. Pace, A. Silvani, A. Marinelli, I. Lolli, M. Balducci, M. Arcicasa, M. Salvati, A. Sponghini, S. Vallarelli, M. Caroli, F. Imbesi, D. Bilancia, M. Faedi, S. Cascinu, R. Soffietti 268 Board 44 Phase II trial of bevacizumab in patients with surgery and radiation refractory progressive meningioma. (Abstract 2055) S. A. Grimm, P. Kumthekar, M. C. Chamberlain, D. Schiff, P. Y. Wen, F. M. Iwamoto, D. A. Reardon, B. Purow, J. J. Raizer Board 45 Can Diffusion and Perfusion Weighted Imaging predict 1p/19q codeled lower grade gliomas? (Abstract 2056) M. Eoli, V. Cuccarini, R. Paterra, M. Farinotti, L. Cuppini, A. Erbetta, F. DI Meco, G. Filippini, G. Finocchiaro, M. Bruzzone Board 46 Is Next Generation Sequencing (NGS) Ready for Routine Clinical Practice in Gliomas? Results of a Prospective Study Utilizing the MSK-IMPACT Assay (Abstract 2057) A. M. Omuro, A. Zehir, D. T. Cheng, M. F. Berger, D. M. Hyman, D. B. Solit, J. Baselga, M. Ladanyi, M. E. Arcila, M. Hameed, P. Sabbatini, L. M. DeAngelis, P. H. Gutin, M. Rosenblum, I. K. Mellinghoff, V. Tabar, T. A. Chan, S. Briggs, J. T. Huse, C. W. Brennan Board 47 Tumor profiling on 1245 gliomas and paired tumor study on 19 high grade gliomas. (Abstract 2058) J. Xiu, D. Spetzler, R. Bender, A. Ghazalpour, Z. Gatalica, S. K. Reddy, D. E. Piccioni, J. L. Hu, M. J. Glantz, S. Kesari Board 48 Tumor infiltrating lymphocytes associated with brain metastasis in breast cancer. (Abstract 2059) N. O. Williams, C. L. Thompson, S. Parsai, V. Varadan, K. Miskimen, J. Barnholtz-Sloan, P. Silverman, S. Vinayak, L. R. Rogers, A. E. Sloan, L. Harris, H. L. Gilmore Board 49 Tumor profiles of brain metastases from NSCLC, breast cancer, and melanoma. (Abstract 2060) S. Kesari, J. Xiu, J. L. Hu, M. E. Salacz, D. E. Piccioni, S. K. Reddy Board 50 A phase I trial everolimus and sorafenib in patients with recurrent high-grade gliomas: Brain Tumor Treatment Collaborative trial 09 – 01. (Abstract 2061) J. J. Raizer, S. A. Grimm, M. Penas-Prado, I. Tremont-Lukats, W. A. Yung, N. G. Avgeropoulos, T. Walbert, M. E. Loghin, M. R. Gilbert Board 51 Phase IB trial of carboxyamidotriazole orotate (CTO) and radiotherapy (RT) with concurrent and adjuvant temozolomide (TMZ) in newly diagnosed glioblastoma (GBM). (Abstract 2062) A. A. Thomas, K. Beal, K. A. McNeill, T. J. Kaley, L. M. DeAngelis, I. K. Mellinghoff, E. L. Diamond, T. A. Chan, R. J. Young, J. Arevalo Perez, Y. Yamada, B. D. Anderson, M. Lamson, B. Burch, R. A. Karmali, A. M. Omuro Board 52 Decision support needs analysis in newly diagnosed malignant glioma. (Abstract 2063) L. K. Ronan, C. E. Fadul, H. Wishart Board 53 Clinical outcome of adult brainstem glioma treated with concurrent chemoradiotherapy: An institutional experience. (Abstract 2064) H. Kunhiparambath, S. Gupta, S. Mallick, M. Annamalai, D. Sharma, P. K. Julka, G. K. Rath Board 54 A phase II study of the combination of BKM120 (buparlisib) and bevacizumab in patients with relapsed/refractory glioblastoma multiforme (GBM). (Abstract 2065) K. C. Shih, S. A. Chowdhary, K. P. Becker, J. M. Baehring, W. H. Liggett, H. A. Burris III, J. D. Hainsworth Board 55 The effect of regadenoson-induced transient disruption of the blood brain barrier on temozolomide delivery to rat brain parenchyma. (Abstract 2066) S. Jackson, N. Anders, A. Mangraviti, T. Wanjiku, H. Brem, B. Tyler, M. A. Rudek, S. A. Grossman Board 56 Carboxyamidotriazole orotate (CTO) in combination with bevacizumab (BEV) for adult patients with recurrent malignant glioma post-BEV failure: Phase 1. (Abstract 2067) A. Desjardins, K. B. Peters, G. Vlahovic, D. Randazzo, S. Boulton, W. C. Massey, E. S. Lipp, J. E. Herndon II, P. Healy, E. Miller, R. A. Karmali, H. S. Friedman Board 57 Oncolytic polio/rhinovirus recombinant (PVSRIPO) against recurrent glioblastoma (GBM): Optimal dose determination. (Abstract 2068) A. Desjardins, J. H. Sampson, K. B. Peters, G. Vlahovic, D. Randazzo, S. Threatt, 269 MONDAY Monday, June 1, 2015 Monday, June 1, 2015 J. E. Herndon II, S. Boulton, D. Lally-Goss, F. McSherry, E. S. Lipp, A. H. Friedman, H. S. Friedman, D. D. Bigner, M. Gromeier MONDAY Board 58 Targeting dopamine receptor 2 (DRD2) signaling in combination with temozolomide chemotherapy as a novel therapeutic concept in glioblastomas. (Abstract 2069) T. A. Johannessen, A. Grudic, H. Zhu, H. Saed, J. Varughese, N. Yang, T. Sundstrom, B. Janji, J. Wang, M. Lund-Johansen, R. Bjerkvig, L. Prestegarden Board 59 A phase 1b/2 study of the combination of the IDO pathway inhibitor indoximod and temozolomide for adult patients with temozolomide-refractory primary malignant brain tumors: Safety analysis and preliminary efficacy of the phase 1b component. (Abstract 2070) H. Colman, F. Mott, A. I. Spira, T. S. Johnson, Y. Zakharia, N. N. Vahanian, C. J. Link, E. P. Kennedy, R. F. Sadek, D. Munn, O. Rixe Board 60 Identification of glioblastoma patients who stand to benefit from PARP inhibitor therapy. (Abstract 2071) K. L. McDonald, M. Khasraw, D. M. Ashley Board 62 Prospective validation of cerebrospinal fluid (CSF) circulating tumor cells (CTC) to diagnose leptomeningeal metastasis (LM) from epithelial tumors. (Abstract 2072) X. Lin, M. Fleisher, A. M. Omuro, L. Shagabayeva, E. Pentsova Board 63 IDH1 mutation status and outcome in clinical trials for recurrent glioblastoma. (Abstract 2073) J. J. Mandel, D. Cachia, D. D. Liu, K. D. Aldape, G. Fuller, J. F. De Groot Board 64 Analysis of BRAF alterations and molecular profiling in glioblastoma and astrocytoma . (Abstract 2074) N. Faiq, J. Chmielecki, M. Goldberg, P. Stephens, R. Kurzrock, S. Kesari, D. E. Piccioni Board 65 Targeting PTBP1 as a therapeutic strategy to reverse lineage-specific splicing of ANXA7 and ensuing EGFR activation in glioblastoma. (Abstract 2075) M. Bredel, R. Ferrarese, N. K. Thudi, V. K. Puliyappadamba, E. Bug, H. Trummell, J. Anderson, C. D. Willey, E. S. Yang, W. Beck, J. A. Bonner, M. Carro Board 66a A phase I study of TPI 287 concurrent with fractionated stereotactic radiotherapy (FSRT) in treatment of brain metastases from advanced breast and non-small cell lung cancer (NSCLC). (Abstract TPS2076) S. Sahebjam, N. D. Tran, H. H. Soliman, J. Arrington, T. Tanvetyanon, S. K. Raj, D. Chen, J. Cooksey, M. Hayes, M. E. Montejo, P. A. Forsyth, N. G. Rao, G. Farmer, P. A. Johnstone Board 66b Phase II study to evaluate the clinical efficacy and safety of MEDI4736 in patients with glioblastoma (GBM). (Abstract TPS2077) D. A. Reardon, J. Dietrich, T. J. Kaley, H. K. Gan, G. P. Dunn, T. F. Cloughesy, M. Lim, J. L. Clarke, A. J. Park, L. S. Pan, D. W. Lai, J. J. Karakunnel, P. B. Robbins, R. Narwal, R. R. Venhaus Board 67a An oxygenation agent and radiation sensitizer, dodecafluoropentane, for the treatment of glioblastoma multiforme. (Abstract TPS2078) J. D. Lickliter, D. B. Wilson, H. Hendrickson, N. Raghunand, S. Khor, O. Longacre, E. C. Unger Board 67b CoaGlio IV Trial: Randomized, controlled, triple-blind, multinational phase III study of adjuvant prophylactic anticoagulation in patients with glioblastoma WHO IV. (Abstract TPS2079) S. A. Kuhn, C. Marosi, I. Pabinger, L. Bullinger, R. Goldbrunner, A. A. Khorana, M. S. Ahluwalia, F. R. Rickles, G. H. Lyman, P. Vajkoczy Board 68a Phase I study of plerixafor and bevacizumab in recurrent high-grade glioma. (Abstract TPS2080) E. Q. Lee, A. Muzikansky, E. R. Gerstner, J. G. Kuhn, D. A. Reardon, L. Nayak, A. D. Norden, L. M. Doherty, J. Rifenburg, D. C. LaFrankie, J. Pulverenti, T. Vardam-Kaur, D. Stokes, K. H. Smith, C. S. McCluskey, S. C. Gaffey, T. Batchelor, D. G. Duda, R. K. Jain, P. Y. Wen Board 68b A phase I study of convection-enhanced delivery of nanoliposomal irinotecan using real-time imaging in patients with recurrent high grade glioma. (Abstract TPS2081) N. A. Butowski, S. Han, J. W. Taylor, M. K. Aghi, M. Prados, S. M. Chang, J. L. Clarke, K. Bankiewicz, D. C. Drummond, J. Fitzgerald 270 Monday, June 1, 2015 1:15 PM - 4:45 PM Poster Session Genitourinary (Nonprostate) Cancer Location: S Hall A Board 182 Association of p53-ness with chemo-resistance in urothelial cancers treated with neoadjuvant gemcitabine plus cisplatin. (Abstract 4512) R. Seiler, W. Choi, L. L. Lam, N. Erho, C. Buerki, E. Davicioni, G. N. Thalmann, D. J. McConkey, P. C. Black Board 183 Whole exome sequencing reveals chemotherapy-driven evolution of platinum-resistant metastatic urothelial cancer. (Abstract 4513) B. Faltas, H. Beltran, D. Prandi, K. Eng, C. Pauli, B. D. Robinson, J. Mosquera, D. M. Nanus, S. T. Tagawa, O. Elemento, F. Demichelis, M. A. Rubin Board 184 Defects in DNA repair genes and sensitivity to cisplatin based neoadjuvant chemotherapy (NAC) for bladder cancer. (Abstract 4514) Y. Wong, R. Dunbrack Jr., T. Brennan, M. D. Andrake, Y. Zhou, I. Serebriiskii, E. Dulaimi, J. H. Hoffman-Censits, M. Bilusic, A. Kutikov, R. Viterbo, R. E. Greenberg, D. Y. Chen, C. D. Lallas, E. J. Trabulsi, R. Yelensky, V. A. Miller, E. Golemis, E. A. Ross, E. R. Plimack Board 185 Phase Ib/II study of an IL-2/T-cell receptor fusion protein in combination with gemcitabine and cisplatin in advanced or metastatic chemo-refractory urothelial cancer (UC). (Abstract 4515) M. N. Fishman, D. A. Vaena, P. Singh, J. Picus, U. N. Vaishampayan, J. Slaton, J. F. Mahoney, S. S. Agarwala, C. J. Rosser, D. Landau, J. Hajdenberg, P. J. Van Veldhuizen, R. A. Parikh, S. Alter, L. Hernandez, P. Rhode, H. C. Wong Board 186 Expanded cohort results from CheckMate 016: A phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). (Abstract 4516) H. J. Hammers, E. R. Plimack, J. R. Infante, B. I. Rini, D. F. McDermott, M. Ernstoff, M. H. Voss, P. Sharma, S. K. Pal, A. R. Razak, C. K. Kollmannsberger, D. Y. Heng, J. L. Spratlin, Y. Shen, P. Gagnier, A. Amin Board 187 Impact of gemcitabine ⴙ cisplatin ⴙ ipilimumab on circulating immune cells in patients (pts) with metastatic urothelial cancer (mUC). (Abstract 4586) M. D. Galsky, N. M. Hahn, C. Albany, M. T. Fleming, A. Starodub, P. Twardowski, R. J. Hauke, G. Sonpavde, M. Merad, S. Gnjatic, N. Bhardwaj, U. ChippadaVenkata, W. K. Oh, S. Kim-Schulze Board 188 RECORD-4: A multicenter, phase II trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC). (Abstract 4518) R. Motzer, A. Alyasova, D. Ye, A. Karpenko, H. Li, B. Y. Alekseev, L. Xie, G. P. Kurteva, R. D. Kowalyszyn, Y. Neron, T. Cosgriff, L. Collins, T. Brechenmacher, S. Segal, L. M. Morgan, L. Yang Board 189 Activating genomic mutations in the mTOR pathway predict responses to everolimus and temsirolimus in patients with metastatic renal cell carcinoma (mRCC): Results from a large multi-institutional cohort. (Abstract 4519) A. P. Fay, D. J. Kwiatkowski, K. P. Gray, A. Thorner, B. I. Rini, N. Agarwal, T. H. Ho, J. Song, P. M. Barrios, L. Albiges, E. M. Van Allen, K. M. Krajewski, C. Porta, S. K. Pal, J. Bellmunt, D. F. McDermott, D. Y. Heng, S. Signoretti, T. K. Choueiri Board 190 Comprehensive genomic profiling of 443 patients with advanced renal cell carcinoma (RCC) reveals clinically relevant genomic alterations and aids in classification of rare subtypes. (Abstract 4520) S. K. Pal, S. M. Ali, Z. Chalmers, J. A. Karam, J. A. Elvin, J. Chmielecki, R. Yelensky, E. M. Van Allen, D. Lipson, K. Wang, A. P. Fay, V. A. Miller, P. Stephens, J. S. Ross, T. K. Choueiri Board 191 Distinct MET alterations induce a common phenotype and define a METdriven subset of papillary RCC: Results from the Cancer Genome Atlas (TCGA) Kidney Renal Papillary (KIRP) Working Group. (Abstract 4521) L. 271 MONDAY Abstracts 4512– 4523 will be discussed during the Genitourinary (Nonprostate) Cancer Poster Discussion Session. See page 299 for session information. Monday, June 1, 2015 Albiges, B. Murray, A. Brooks, A. Cherniack, A. Berger, C. J. Creighton, C. Ricketts, D. P. Bottaro, R. Srinivasan, L. S. Schmidt, M. Meyerson, P. Spellman, W. M. Linehan, T. K. Choueiri, The Cancer Genome Atlas (TCGA) Kidney Renal Papillary (KIRP) working group MONDAY Board 192 A phase II trial of everolimus (E) and bevacizumab (B) in advanced non-clear cell renal cell cancer (ncRCC) to show efficacy in patients (pts) with papillary features. (Abstract 4522) M. H. Voss, Y. Chen, J. Chaim, D. T. Coskey, K. Woo, A. Redzematovic, P. Wang, W. Lee, S. Patil, A. M. Molina, J. Hsieh, R. Motzer, D. R. Feldman Board 193 SWOG 1107: Parallel (randomized) phase II evaluation of tivantinib (ARQ-197) and tivantinib in combination with erlotinib in patients (Pts) with papillary renal cell carcinoma (pRCC). (Abstract 4523) P. Twardowski, M. Plets, E. R. Plimack, N. Agarwal, C. M. Tangen, N. J. Vogelzang, I. M. Thompson Jr., P. Lara Jr. Board 194 Adjuvant chemotherapy for residual disease after neoadjuvant chemotherapy for muscle invasive urothelial cancer (MIUC). (Abstract 4524) L. C. Harshman, L. Werner, Y. Wong, E. Y. Yu, A. S. Alva, S. J. Crabb, T. Powles, J. E. Rosenberg, J. Baniel, U. N. Vaishampayan, D. R. Berthold, S. Ladoire, S. A. Hussain, M. I. Milowsky, N. Agarwal, A. Necchi, S. K. Pal, F. Recine, J. Bellmunt, M. D. Galsky, RISC Investigators Board 195 JEVTCC: Phase II trial of cabazitaxel (Cbz) in patients (pt) with advanced or metastatic transitional-cell carcinoma (mTCC), who progressed before 12 months after cisplatin-based chemotherapy—A Spanish Oncologic Genitourinary Group (SOGUG) study. (Abstract 4525) J. Arranz Arija, X. Garcia del Muro, B. Perez-Valderrama, S. Vazquez-Estevez, N. Sala, M. Juan Fita, N. Laı́nez, E. Noguerón, A. Font, M. Sáez, P. Maroto, E. Gallardo Diaz, M. J. MéndezVidal, M. Lopez Criado, A. Pinto, M. Lázaro Quintela, A. Gonzalez del Alba, R. Luque, M. Lopez Brea, I. Duran Board 196 Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder to reveal frequency of clinically relevant genomic alterations. (Abstract 4526) M. J. Hawryluk, K. Wang, S. M. Ali, H. Fisher, B. Mian, T. Nazeer, J. A. Elvin, J. Chmielecki, R. Yelensky, D. Lipson, V. A. Miller, P. J. Stephens, J. S. Ross Board 197 Effectiveness of adjuvant chemotherapy (AC) versus observation in patients with > pT3 and/or pNⴙ bladder cancer (BCa). (Abstract 4517) M. D. Galsky, K. Stensland, E. L. Moshier, J. Sfakianos, R. B. McBride, C. Tsao, M. F. Casey, S. J. Hall, P. Boffetta, W. K. Oh, J. P. Wisnivesky Board 198 Externally validated improved 5-factor prognostic model in patients (pts) receiving salvage systemic therapy for advanced urothelial carcinoma (UC). (Abstract 4527) G. Sonpavde, G. R. Pond, J. E. Rosenberg, D. F. Bajorin, A. M. Regazzi, S. A. Mullane, G. Niegisch, P. Albers, A. Necchi, G. di Lorenzo, R. Fougeray, Y. Ko, A. Rozzi, K. Matsumoto, J. Lee, H. Kitamura, H. Kume, M. I. Milowsky, T. K. Choueiri, J. Bellmunt Board 199 Molecular characterization of bladder cancer in smokers versus non-smokers. (Abstract 4528) M. Joshi, S. Z. Millis, D. L. Lamm, S. K. Reddy, S. L. Holder, N. J. Vogelzang, J. J. Drabick Board 200 Maintenance vinflunine post cisplatin chemotherapy (CT) in patients with advanced urothelial carcinoma (UC): Preliminary analysis of a randomized placebo controlled phase II trial (MAJA trial)—SOGUG 2011– 02. (Abstract 4529) J. Bellmunt, B. Perez Valderrama, A. Font, J. Virizuela, M. Climent, S. Hernando Polo, B. Mellado, N. Laı́nez, A. Gonzalez del Alba, J. Arranz, J. Villa Guzman, M. LLorente, D. E. Castellano, E. Gallardo, X. Garcia del Muro, U. Anido, M. Domenech, J. Puente, J. Perez Gracia, J. Garcı́a-Donas Board 201 Role of miR-21, miR372, and E2F1 as biomarkers predicting outcome in cisplatin-treated bladder cancer patients. (Abstract 4530) C. W. Zhou, S. A. Mullane, L. Werner, M. Taplin, A. P. Fay, T. K. Choueiri, D. Y. Takeda, M. Bowden, J. Bellmunt 272 Board 203 The basal subtype to predict clinical benefit from neoadjuvant chemotherapy: Final results from a phase II clinical trial of DDMVAC ⴙ bevacizumab. (Abstract 4531) A. O. Siefker-Radtke, W. Choi, S. Porten, Y. Shen, A. M. Kamat, S. F. Matin, R. E. Millikan, C. P. Dinney, B. Czerniak, D. J. McConkey Board 204 Association of somatic mutations in DNA damage repair (DDR) genes with efficacy of platinum-based chemotherapy in advanced urothelial carcinoma. (Abstract 4532) R. M. Bambury, E. Jordan, E. C. Zabor, N. Bouvier, H. AlAhmadie, M. E. Boyd, S. A. Mullane, E. K. Cha, I. Ostrovnaya, D. M. Hyman, B. H. Bochner, M. E. Arcila, D. B. Solit, D. F. Bajorin, J. Bellmunt, M. F. Berger, G. Iyer, J. E. Rosenberg Board 206 Germ cell cancer and multiple relapses: Toxicity and survival. (Abstract 4533) J. Lauritsen, M. G. Gundgaard Kier, M. S. Mortensen, M. Bandak, R. Gupta, N. V. Holm, M. Agerbaek, G. Daugaard Board 207 Wilms’ tumor gene 1 (WT1) aberrations in testicular germ cell tumors (TGCTs). (Abstract 4534) L. Boublikova, V. Bakardjieva-Mihaylova, K. Skvarova Kramarzova, D. Kuzilkova, T. Buchler, P. Dusek, M. Grega, B. Rosova, Z. Vernerova, P. Klezl, R. Zachoval, M. Pesl, M. Krolupper, M. Kubecova, V. Stahalova, M. Babjuk, J. Abrahamova, R. Kodet, J. Trka Board 208 Impact of response to induction chemotherapy (CT) and prior paclitaxel (TXL)-based CT on the outcome of salvage high-dose chemotherapy (HDCT) for relapsed germ-cell tumors (GCT) in the modern era: An EBMT Solid Tumors Working Party study. (Abstract 4535) A. Necchi, R. Miceli, M. Bregni, K. Oechsle, E. Kanfer, C. Massard, A. Flechon, D. Laszlo, F. Arpaci, P. Wuchter, M. M. Crysandt, A. Unal, A. Nagler, A. Wahlin, M. Michieli, K. Pflueger, M. Ringhoffer, M. Badoglio, P. Pedrazzoli, F. Lanza, EBMT-Solid Tumors Working Party Board 209 Prognostic significance of thromboembolic events in chemotherapy-treated germ cell tumors. (Abstract 4536) E. Gonzalez-Billalabeitia, J. Guma, D. E. Castellano, M. Luengo, J. Aparicio, A. Sanchez Munoz, B. Mellado, A. Saenz, C. M. Valverde, A. Fernandez, M. Margeli, I. Duran, S. Fernandez Arrojo, J. Sastre, S. Ros, J. P. Maroto Rey, A. Carmona Bayonas, F. Ayala, D. Hervas, J. R. GermaLluch, Spanish Germ-Cell Cancer Group (Grupo Germinal) and the Spanish Oncology Genitourinary Group (SOGUG) Board 210 Clinical outcomes of late relapse in stage I seminoma. (Abstract 4537) A. Hosni, P. R. Warde, P. L. Bedard, M. A. Jewett, R. J. Hamilton, M. J. Moore, R. Huang, M. O’Malley, J. Sweet, P. W. Chung Board 211 Perioperative morbidity and mortality with bleomycin in primary mediastinal non seminomatous germ cell tumor (PMNSGCT). (Abstract 4538) P. Ranganath, K. Kesler, J. Dentel, L. H. Einhorn Board 212 A retrospective analysis of patients with metastatic germ cell tumor (GCT) treated at Indiana University (IU) from 2000 to 2012. (Abstract 4539) K. Ku, S. Ibrahim, N. Adra, S. Althouse, N. H. Hanna, L. H. Einhorn, C. Albany Board 213 Bleomycin-induced pulmonary changes on restaging CT scans: Frequency and correlation with fibrosis markers. (Abstract 4540) N. Westerink, S. Lubberts, M. W. den Hollander, A. Bongaerts, R. Wolf, R. Altena, J. Nuver, S. Oosting, E. De Vries, A. M. Walenkamp, C. Meijer, J. A. Gietema Board 214 Early changes in renal function and late cardiovascular disease risk in testicular cancer survivors with 25 years follow-up. (Abstract 4541) S. Lubberts, J. A. Kampman, H. Boer, C. Meijer, G. J. Navis, J. A. Gietema Board 215 Bevacizumab (Bev) alone or in combination with TRC105 for metastatic renal cell cancer (mRCC): A California Cancer Consortium clinical trial. (Abstract 4542) T. B. Dorff, J. Longmate, S. K. Pal, W. M. Stadler, M. N. Fishman, U. N. Vaishampayan, A. R. Rao, J. Hu, D. I. Quinn, P. Lara Jr. Board 216 HIF inhibition in metastatic renal cell carcinoma (mRCC): Final results of a phase Ib /IIa clinical trial evaluating the nanoparticle drug conjugate (NDC), CRLX101, in combination with bevacizumab (bev). (Abstract 4543) S. M. Keefe, J. H. Hoffman-Censits, R. Mamtani, M. Walicki, J. Robinson, A. Smith, O. 273 MONDAY Monday, June 1, 2015 Monday, June 1, 2015 Gunnarsson, A. Piscitelli, M. Hennessey, L. Jayaraman, A. B. Nixon, S. Eliasof, R. B. Cohen, D. J. Vaughn, E. G. Garmey, N. B. Haas MONDAY Board 217 Cardiovascular toxicity following anti-angiogenic therapy in persons over age 65 with advanced renal cell carcinoma. (Abstract 4544) S. Jang, C. Zheng, H. Tsai, A. z. Fu, A. Barac, M. B. Atkins, A. N. Freeman, L. M. Minasian, A. L. Potosky Board 218 Overall survival analysis from a randomized phase II study of axitinib with or without dose titration for first-line metastatic renal cell carcinoma. (Abstract 4545) B. I. Rini, Y. Tomita, B. Melichar, T. Ueda, V. Grünwald, M. N. Fishman, H. Uemura, M. Oya, A. H. Bair, G. Andrews, D. Pavlov, E. Jonasch Board 219 Analysis of real world treatment compliance in a cohort of 2,395 patients with metastatic renal cell carcinoma (mRCC). (Abstract 4546) J. Margolis, N. Princic, J. Doan, G. Lenhart, R. Motzer Board 220 Randomized phase II study of sunitinib ⴙ CXCR4 inhibitor LY2510924 versus sunitinib alone in first-line treatment of patients with metastatic renal cell carcinoma. (Abstract 4547) J. D. Hainsworth, J. R. Mace, J. A. Reeves, E. J. Crane, O. Hamid, J. R. Stille, A. Flynt, J. Polzer, A. Milner, S. Roberson, E. Arrowsmith Board 221 CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma. (Abstract 4548) M. Diekstra, J. J. Swen, E. Boven, D. E. Castellano, H. Gelderblom, R. H. Mathijssen, C. Rodriguez-Antona, J. Garcı́a-Donas, B. I. Rini, H. Guchelaar Board 222 Randomized phase II study of two different doses of AVE0005 (VEGF Trap, aflibercept) in patients (pts) with metastatic renal cell carcinoma (RCC): An ECOG-ACRIN study [E4805]. (Abstract 4549) R. Pili, J. Manola, M. A. Carducci, J. P. Dutcher, L. J. Appleman, D. L. Groteluschen, R. S. DiPaola Board 223 Pancreatic metastases from renal cell carcinoma: Prognostic relevance and outcome in patients treated with targeted agents. (Abstract 4550) P. Grassi, L. S. Doucet, P. Giglione, V. Gruenwald, B. Melichar, L. Galli, U. De Giorgi, A. Guida, C. Ortega, M. Santoni, A. Bamias, E. Verzoni, A. Necchi, L. Derosa, H. Studentova, M. Pacifici, F. G. De Braud, C. Porta, B. J. Escudier, G. Procopio Board 224 Early tumor shrinkage (eTS) as a predictive and prognostic factor in metastatic renal cell carcinoma (mRCC). (Abstract 4551) V. Gruenwald, X. Lin, D. Kalanovic, R. Simantov Board 225 Novel chromosome copy number changes to predict clinical response to sunitinib in patients with advanced renal cell carcinoma. (Abstract 4552) C. Lee, R. Motzer, A. Hoetker, O. Akin, A. M. Molina, T. M. Gold, S. Patil, B. Gowrishankar, J. Houldsworth Board 227 Updated survival results from a randomized, dose-ranging phase II study of nivolumab (NIVO) in metastatic renal cell carcinoma (mRCC). (Abstract 4553) E. R. Plimack, H. J. Hammers, B. I. Rini, D. F. McDermott, B. Redman, T. Kuzel, M. R. Harrison, U. N. Vaishampayan, H. A. Drabkin, S. George, T. F. Logan, K. A. Margolin, L. Xu, I. Waxman, R. Motzer Board 228 Final overall survival analysis for the RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (mRCC). (Abstract 4554) J. J. Knox, C. H. Barrios, T. Kim, T. Cosgriff, V. Srimuninnimit, K. B. Pittman, R. Sabbatini, S. Y. Rha, T. W. Flaig, R. D. Page, J. T. Beck, F. Cheung, S. Yadav, P. M. Patel, L. Geoffrois, E. Schiff, J. Niolat, N. Berkowitz, M. Voi, R. Motzer Board 229 Phase II study of individualized sunitinib as first-line therapy for metastatic renal cell cancer (mRCC). (Abstract 4555) G. A. Bjarnason, J. J. Knox, C. K. Kollmannsberger, D. Soulieres, D. S. Ernst, C. M. Canil, E. Winquist, P. Zalewski, S. J. Hotte, S. A. North, D. Y. Heng, R. J. Macfarlane, P. M. Venner, I. Tannock, A. Kapoor, B. J. Eigl, A. R. Hansen, P. Czaykowski, B. Boyd, N. S. Basappa 274 Board 230 Molecular analysis of sarcomatoid renal cell carcinoma (sRCC). (Abstract 4556) T. H. Ho, S. Z. Millis, D. Bryant, Z. Gatalica, S. K. Reddy, M. L. Stanton, E. P. Castle, R. W. Joseph, N. J. Vogelzang Board 231 Tivozanib vs sorafenib targeted therapy for advanced renal cell carcinoma: Final results of a phase III trial (901) and efficacy results of a 2nd line tivozanib extension study (902). (Abstract 4557) T. Hutson, D. Nosov, P. Tomczak, I. Bondarenko, O. N. Lipatov, C. N. Sternberg, M. N. Needle, T. Eisen Board 232 Characteristics of metastatic renal cell carcinoma (mRCC) patients treated with delayed targeted therapy: results from the International mRCC Consortium (IMDC). (Abstract 4558) H. Li, T. K. Choueiri, C. Wells, N. Agarwal, F. Donskov, J. Lee, R. J. Broom, T. Yuasa, B. I. Rini, S. K. Pal, L. Wood, D. S. Ernst, C. K. Kollmannsberger, U. N. Vaishampayan, S. Y. Rha, G. A. Bjarnason, J. J. Knox, S. Saleem, B. Beuselinck, D. Y. Heng Board 233 A phase I study of buparlisib (BKM120) with bevacizumab (BEV) in patients (pts) with metastatic renal cell carcinoma (mRCC) progressing on prior vascular endothelial growth factor (VEGF) therapies. (Abstract 4559) R. R. McKay, L. Werner, L. C. Harshman, J. Bellmunt, C. Sweeney, J. E. Rosenberg, E. VanAllen, M. K. Walsh, U. N. Vaishampayan, D. F. McDermott, T. K. Choueiri Board 234 Prognostic value of genomic signatures in metastatic Clear Cell Renal Cell Carcinoma (mRCC) using The Cancer Genome Atlas (TCGA) data. (Abstract 4560) G. de Velasco, A. P. Fay, A. Culhane, A. A. Hakimi, M. H. Voss, N. M. Tannir, P. Tamboli, L. J. Appleman, J. Bellmunt, K. Rathmell, L. K. Albiges, J. Hsieh, D. Y. Heng, S. Signoretti, T. K. Choueiri Board 235 Metastatic chromophobe renal cell carcinoma treated with target therapies: A Renal Cross Chanel Group (RCCG) study. (Abstract 4561) E. Colomba, L. Albiges, G. Le Teuff, T. Eisen, G. Stewart, K. Fife, A. Srinivasan Jr., J. M. Larkin, A. Biondo, L. M. Pickering, H. J. Boyle, L. Derosa, C. Ralph, C. Saldana, J. Bernhard, P. Barthelemy, F. Recine, B. Escudier, Renal Cross Chanel Group (RCCG) Board 236 Clinical effect of TKI dose-escalation after disease progression in patients with metastatic renal cell carcinoma. (Abstract 4562) M. C. Ornstein, P. Elson, J. A. Garcia, T. D. Gilligan, L. S. Wood, K. D. Allman, A. Martin, B. I. Rini Board 237 Clinical impact of loss of H3K36me3 expression in patients with clear cell renal cell carcinoma. (Abstract 4563) A. Swaika, T. H. Ho, P. Kapur, D. Serie, J. Eckel-Passow, J. Brugarolas, A. S. Parker, R. W. Joseph Board 238 Precision medicine approach in kidney cancer: A pan renal cell carcinoma (RCC) study across three cancer genome atlas (TCGA) datasets for clinically relevant target identification. (Abstract 4564) B. Murray, L. Albiges, E. M. Van Allen, A. Cherniack, A. P. Fay, M. Meyerson, T. K. Choueiri Board 239 Extension of overall survival (OS) beyond objective responses (OR) in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with high dose interleukin-2 (HD IL-2). (Abstract 4565) D. D. Stenehjem, M. Toole, J. Merriman, K. Parikh, S. Daignault, S. Scarlett, P. Esper, K. Skinner, A. Udager, S. K. Tantravahi, A. M. Straubhar, A. M. Agarwal, J. Van Atta, K. F. Grossmann, W. E. Samlowski, B. G. Redman, N. Agarwal, A. S. Alva Board 240 Efficacy and safety of endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors (TKI) after programmed cell death 1 (PD-1) inhibitor treatment in patients with metastatic clear cell renal cell carcinoma (mccRCC). (Abstract 4566) R. Nadal, A. Amin, D. M. Geynisman, M. H. Voss, M. Weinstock, J. Doyle, Z. Zhang, A. Viudez, E. R. Plimack, D. F. McDermott, R. Motzer, B. I. Rini, H. J. Hammers Board 241 The DART Study: Part 1 results from the dalantercept plus axitinib dose escalation and expansion cohorts in patients with advanced renal cell carcinoma (RCC). (Abstract 4567) M. H. Voss, E. R. Plimack, B. I. Rini, M. B. Atkins, R. Alter, R. S. Bhatt, J. T. Beck, M. Mutyaba, K. M. Pappas, D. Wilson, X. Zhang, M. L. Sherman, S. S. Pandya Board 242 Impact of salvage surgery and radiotherapy on overall survival in patients with recurrent primary urethral cancer. (Abstract 4568) G. Gakis, T. M. 275 MONDAY Monday, June 1, 2015 Monday, June 1, 2015 Morgan, S. Daneshmand, K. A. Keegan, R. H. Clayman, J. Mischinger, H. B. Zaid, J. Hrbacek, B. Ali-El-Dein, S. Galland, K. Olugbade Jr., M. Rink, H. Fristche, M. Burger, S. Chang, M. Babjuk, G. N. Thalmann, A. Stenzl, J. A. Efstathiou MONDAY Board 243 Multi-institutional validation of the predictive value of Ki-67 in patients with high-grade urothelial carcinoma of the upper urinary tract. (Abstract 4569) L. Krabbe, A. Bagrodia, A. Haddad, P. Kapur, D. Khalil, L. S. Hynan, C. G. Wood, J. A. Karam, A. Z. Weizer, J. D. Raman, M. Remzi, N. Rioux-Leclercq, A. Haitel, M. Roscigno, C. Bolenz, K. Bensalah, A. I. Sagalowsky, S. F. Shariat, Y. Lotan, V. Margulis Board 244a Design of an open label, randomized, phase II study of paclitaxel and panitumumab compared to paclitaxel alone in patients with relapsed or refractory urothelial cancer. (Abstract TPS4570) A. Necchi, L. Mariani, P. Giannatempo, D. Raggi, G. Calareso, F. Crippa, E. Togliardi, R. Salvioni, F. G. De Braud Board 244b KEYNOTE-045: Randomized phase 3 trial of pembrolizumab (MK-3475) versus paclitaxel, docetaxel, or vinflunine for previously treated metastatic urothelial cancer. (Abstract TPS4571) J. Bellmunt, G. Sonpavde, R. De Wit, T. K. Choueiri, A. O. Siefker-Radtke, E. R. Plimack, N. M. Lewis, H. Brown, Y. Mai, C. K. Gause, D. R. Kaufman, D. F. Bajorin Board 245a KEYNOTE-052: Phase 2 study of pembrolizumab (MK-3475) as first-line therapy for patients (pts) with unresectable or metastatic urothelial cancer ineligible for cisplatin-based therapy. (Abstract TPS4572) D. F. Bajorin, E. R. Plimack, A. O. Siefker-Radtke, T. K. Choueiri, R. De Wit, G. Sonpavde, A. Gipson, H. Brown, Y. Mai, L. Pang, R. F. Perini, J. Bellmunt Board 245b A multicenter randomized phase II trial comparing nab-paclitaxel to paclitaxel in patients with advanced urothelial cancer progressing on or after a platinum containing regimen: NCIC Clinical Trials Group BL 12 (NCT02033993). (Abstract TPS4573) S. S. Sridhar, N. Blais, S. A. North, B. Tran, K. N. Chi, J. W. Robinson, M. N. Reaume, G. Liu, G. T. McDonald, K. Ding, W. R. Parulekar Board 246a Phase II randomised placebo controlled neoadjuvant chemotherapy study of nintedanib with gemcitabine and cisplatin in locally advanced muscle invasive bladder cancer. (Abstract TPS4574) S. A. Hussain, R. Jackson, A. Shields, L. Dickinson, P. Cornford, R. J. Jones, J. F. Lester, J. D. Chester, A. J. Birtle, T. Powles, S. J. Crabb, D. Mazhar, R. A. Huddart, A. Protheroe, F. Azam, N. Vasudev, M. Butt, N. D. James Board 246b A phase 2 study of the histone deacetylase (HDAC) inhibitor mocetinostat in patients with urothelial carcinoma (UC) and inactivating alterations of acetyltransferase genes. (Abstract TPS4575) N. M. Hahn, J. Picus, R. M. Bambury, S. K. Pal, L. L. Hart, P. Grivas, M. I. Milowsky, A. S. Alva, G. Sonpavde, A. Mortazavi, J. Bellmunt, E. A. Guancial, S. Gupta, R. C. Chao, M. A. Collier, J. Christensen, I. Chen, J. E. Rosenberg Board 247a A phase I/II multi-center study of intravesical nanoparticle albumin-bound rapamycin (ABI-009) in the treatment of BCG refractory non-muscle invasive bladder cancer. (Abstract TPS4576) J. M. McKiernan, D. Lascano, J. Ahn, R. Ghandour, J. S. Pak, A. RoyChoudhury, S. Chang, G. J. DeCastro, N. Desai Board 247b The Borealis-2 clinical trial: A randomized phase 2 study of OGX-427 (Apatorsen) plus docetaxel versus docetaxel alone in relapsed/refractory metastatic urothelial cancer. (Abstract TPS4577) T. K. Choueiri, N. M. Hahn, A. S. Alva, R. C. Lauer, R. Dreicer, J. Picus, R. Pili, A. V. Balar, G. Sonpavde, J. H. Hoffman-Censits, E. A. Guancial, R. Alter, M. M. Regan, C. Jacobs, P. S. Stewart, S. K. Pal, J. E. Rosenberg Board 248a CheckMate 214: A phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in patients with previously untreated metastatic renal cell carcinoma. (Abstract TPS4578) H. J. Hammers, E. R. Plimack, C. Sternberg, D. F. McDermott, J. M. Larkin, A. Ravaud, B. I. Rini, P. Sharma, P. Bhagavatheeswaran, P. Gagnier, R. Motzer 276 Monday, June 1, 2015 Board 248b Randomized phase 2 study to assess the safety and efficacy of CRLX101 in combination with bevacizumab in patients (pts.) with metastatic renal cell carcinoma (RCC) versus standard of care (SOC). (Abstract TPS4579) M. H. Voss, A. Coates, E. G. Garmey, N. B. Haas, T. Hutson, S. M. Keefe, R. Motzer, A. Piscitelli, N. J. Vogelzang, R. A. Figlin Board 249a A multicenter, open-label, proof of concept phase 1b/2 study to evaluate the safety and efficacy of RX-0201 in combination with everolimus to treat subjects with advanced renal cell carcinoma. (Abstract TPS4580) C. Peterson, E. Benaim Board 249b A randomized, open label, multicenter phase 2 study to evaluate the efficacy of sorafenib in patients (pts) with advanced Renal Cell Carcinoma (RCC) after a radical resection of the metastases. (Abstract TPS4581) E. Verzoni, P. Grassi, R. Montone, C. Maggi, F. Cognetti, M. Milella, A. Bearz, C. Ortega, F. Morelli, V. E. Chiuri, A. Necchi, F. G. De Braud, G. Procopio Board 250a Patient identification and eligibility insights in the synchronous metastatic RCC population: An update from the ongoing ADAPT* phase 3 study experience. (Abstract TPS4582) R. A. Figlin, C. G. Wood Board 250b The DART Study: A phase 2 randomized double-blind study of dalantercept plus axitinib versus placebo plus axitinib in advanced clear cell renal cell carcinoma (RCC). (Abstract TPS4583) M. H. Voss, E. R. Plimack, B. I. Rini, M. B. Atkins, R. Alter, R. S. Bhatt, J. T. Beck, M. Mutyaba, K. M. Pappas, D. Wilson, X. Zhang, M. L. Sherman, S. S. Pandya Board 251a Phase II study of pazopanib and weekly paclitaxel in metastatic or locally advanced squamous penile carcinoma patients previously treated with cisplatin-based chemotherapy: PAZOPEN study. (Abstract TPS4584) M. Climent, J. Puente, S. Vazquez-Estevez, M. J. Méndez-Vidal, E. GonzalezBillalabeitia, N. Laı́nez, J. P. Maroto Rey, J. Rodriguez-Moreno, X. Garcia del Muro Board 251b ATR-101 phase 1 clinical study for adrenocortical carcinoma. (Abstract TPS4585) A. Naing, S. Fu, M. A. Habra, R. Chugh, E. Kebebew, J. Russell, D. Welshans, M. Fassnacht, M. Kroiss, M. Goebeler, M. Ijzerman, M. R. Plaunt, P. Mohideen, M. Phillips, D. C. Smith 1:15 PM - 4:45 PM Poster Session Location: S Hall A Abstracts 6512– 6523 will be discussed during the Health Services Research and Quality of Care Poster Discussion Session. See page 299 for session information. Board 69 Development of cost and quality composites for the 2012 ASCO Choosing Wisely measures: Methods and evidence. (Abstract 6512) M. K. Simon, A. Milstein, K. L. Kreizenbeck, C. R. Fedorenko, S. D. Ramsey Board 70 Trends in antineoplastic receipt after Medicare payment reform: Implications for future oncology payment design. (Abstract 6513) H. M. Parsons, S. Schmidt, A. J. Davidoff, L. L. Tenner, B. A. Virnig Board 71 A randomized controlled trial (RCT) to improve enrollment to cancer clinical trials. (Abstract 6514) C. Parker, J. L. Millar, D. M. Dilts, M. Jefford, R. Wolfe, R. D. Snyder Board 72 Psychosocial outcomes of the electronic self-report assessment for cancer-II randomized trial. (Abstract 6515) D. L. Berry, F. Hong, B. Halpenny Board 73 Patient-reported care coordination and outcomes of colorectal cancer surgery. (Abstract 6516) S. T. Hawley, S. E. Regenbogen, C. M. Veenstra, A. M. Morris 277 MONDAY Health Services Research and Quality of Care Monday, June 1, 2015 MONDAY Board 74 Family perspectives on aggressive cancer care near the end of life. (Abstract 6517) A. A. Wright, N. L. Keating, J. Ayanian, E. A. Chrischilles, K. L. Kahn, C. Ritchie, C. Earle, M. B. Landrum Board 75 Use of online communication and social media by newly diagnosed breast cancer patients: Results from the iCanCare Study. (Abstract 6518) S. T. Hawley, N. K. Janz, L. P. Wallner, S. J. Katz Board 76 Email communication practices and preferences among patients and providers in a large comprehensive cancer center. (Abstract 6519) N. Cook, A. Dobriyal, M. Maganti, M. Sheinis, A. C. Wei, J. Ringash, M. K. Krzyzanowska Board 77 Disease-specific hashtags for online communication about cancer care. (Abstract 6520) M. S. Katz, A. Utengen, P. F. Anderson, M. A. Thompson, M. Fisch, C. Johnston, D. J. Attai, L. Aase, R. S. Miller, T. Lee, D. S. Dizon Board 78 Machine-learning prediction of cancer survival: A prospective study examining the impact of combining clinical and genomic data. (Abstract 6521) D. M. Ashley, S. Gupta, T. Tran, L. Wei, P. K. Lorgelly, D. M. Thomas, S. B. Fox, S. Venkatesh Board 79 Predicting low accrual in the Clinical Trials Cooperative Group Program’s phase II/III oncology trials. (Abstract 6522) C. S. Bennette, S. D. Ramsey, C. L. McDermott, J. J. Carlson, A. Basu, D. L. Veenstra Board 80 Colonoscopy versus less invasive approaches for colorectal cancer (CRC) screening (Scr): A strategic perspective. (Abstract 6523) A. Barzi, H. Lenz, D. I. Quinn, S. Sadeghi Board 81 Developing a CAncer genomics Digital Educational Tool to assess the knowledge and expectations of patients with advanced solid tumors (CADET). (Abstract 6524) H. H. Loong, A. Spreafico, N. Cook, K. K. Chan, G. D. Krishna, H. Chow, C. Yu, S. Kang, P. S. Blanchette, P. L. Bedard, A. R. Razak, L. L. Siu Board 82 Utilization of palliative chemotherapy for advanced bladder cancer: Patterns of care in routine clinical practice. (Abstract 6525) A. G. Robinson, X. Wei, W. J. Mackillop, C. M. Booth Board 83 Is online patient information at NCI cancer centers too complex for broad general readership? (Abstract 6526) S. Rosenberg, D. Francis, C. Hullett, Z. S. Morris, J. Brower, M. Fisher, B. M. Anderson, M. F. Bassetti, R. J. Kimple Board 84 A discrete choice experiment to examine the preferences of patients with cancer and their willingness to pay for different types of health care appointments. (Abstract 6527) S. Wong, R. Norman, T. L. Dunning, D. M. Ashley, M. Khasraw, P. K. Lorgelly Board 85 Impact of age on the associations between genomic testing in breast cancer (BrCA) and chemotherapy (chemo) use and costs. (Abstract 6528) Y. Wong, A. J. Epstein, N. Mitra, A. Vachani, S. Hin, L. Yang, A. Smith-McLallen, K. Armstrong, P. W. Groeneveld Board 86 The influence of hospital and surgeon factors on the prevalence of axillary evaluation in ductal carcinoma in situ. (Abstract 6529) E. J. Coromilas, J. D. Wright, Y. Huang, S. M. Feldman, A. I. Neugut, L. Chen, D. L. Hershman Board 87 Improving veteran access to lung cancer care (IVaLuCancerCare): A quality improvement project at the Louis Stokes Cleveland VA Medical Center (LSVAMC). (Abstract 6530) R. Manochakian, J. Smith, S. Mervar, D. Fox, K. Woods, M. Driscol, D. Whittlesey, A. Ludin, F. Jacono, B. Jesberger, N. Alvarado, J. Robke, S. Berman, J. Dimick, S. Curry, M. Barnum, M. Vallette, A. Howard, J. A. Bokar, L. M. Arfons Board 88 Cancer pain management practices and their impact on quality of life for Asian cancer patients. (Abstract 6531) Y. C. Kim, H. Moon, J. S. Ahn, M. M. P. Calimag, T. C. Chao, K. Y. Ho, L. M. Tho, Z. J. Xia, and L. Ward 278 Board 89 State variation in Medicare Part D and choice of initial endocrine therapy for breast cancer. (Abstract 6532) L. E. Pezzin, J. A. Charlson, E. McGinley, P. Laud, J. M. Neuner, A. Nattinger Board 90 Analysis of home care coordination activities in oncology: A mixed methods study. (Abstract 6533) F. Yatim, G. Moutel, P. Cristofalo, M. Ferrua, M. Di Palma, E. Minvielle Board 91 Patients with advanced non-small cell lung cancer (NSCLC): Are research biopsies a barrier to participation in clinical trials? (Abstract 6534) C. H. Lim, M. Sung, N. Z. Nouriany, M. Sawczak, T. Paul, N. Perera-Low, R. Feld, G. Liu, F. A. Shepherd, N. B. Leighl Board 92 Validation of a clinical trial accrual predictive model. (Abstract 6535) W. R. Tate, L. D. Cranmer III Board 93 Emergency diagnosis of lung cancer: An international problem. (Abstract 6536) T. Newsom-Davis, R. Berardi, N. Cassidy, L. Coate, A. Figueiredo, G. Gamerith, G. Giblin, M. Jakopović, C. Van Der Leest, D. Pouessel, M. Tiseo, A. Toffart, C. Hughes Board 94 Healthcare resource utilization and cost considerations in patients with soft tissue sarcoma treated with chemotherapy. (Abstract 6537) C. M. Kozma, T. L. Slaton, R. S. McKenzie Board 95 Disparity by insurance status and race in receipt of aggressive and advanced treatments for high risk prostate cancer/PCa. (Abstract 6538) B. R. Baker, R. Basak, J. J. Mohiuddin, R. C. Chen Board 96 Impact of health insurance transitions on cancer survivors and those with no cancer history. (Abstract 6539) K. S. Virgo, C. Lin, A. J. Davidoff, HEROIC workgroup Board 97 Comprehensive genomic profiling of rare tumors in a dedicated community clinic. (Abstract 6540) W. J. Edenfield Board 98 Precision oncology: molecular testing and targeted treatment beyond indication. (Abstract 6541) J. J. Carlson, B. Ely, R. N. Hansen, G. H. Lyman Board 99 Social-ecological perspectives on breast cancer care seeking patterns in Karnataka, India. (Abstract 6542) A. S. Shet, S. Krishnan, S. M. Travasso, G. Raju, S. Meleth, S. Kumar Board 100 Medical Oncologists’ and Surgeons’ approaches to communication of breast cancer recurrence risk. (Abstract 6543) A. Sabolch, B. Zikmund-Fisher, N. K. Janz, S. T. Hawley, K. A. Griffith, R. Jagsi Board 101 A systematic approach to smoking cessation in Ontario’s Regional Cancer Programs. (Abstract 6544) W. K. Evans, R. Presutti, M. Haque, R. Truscott, M. Bassier-Paltoo, A. Peter, L. Rabeneck Board 102 The impact of chemotherapy on hospitalizations and emergency care in older adults with advanced cancer. (Abstract 6545) E. B. Elkin, C. O’Neill, C. L. Atoria, E. M. O’Reilly, P. Bach Board 103 Wealth, health expenditure, and cancer: A national perspective. (Abstract 6546) J. Chahoud, A. G. Rieber, A. Semaan Board 104 How TNM stage affects surveillance intensity after treatment for breast cancer. (Abstract 6547) D. Wu, E. S. Allam, K. S. Virgo, L. Chen, J. A. Margenthaler, F. E. Johnson Board 105 Racial differences in 20-year cardiovascular outcomes among childhood and young adult cancer survivors. (Abstract 6548) A. M. Berkman, L. Jones, A. Crocker, A. M. Brewster, S. G. Lakoski Board 106 Factors associated with the large disparities in BRCA testing among high risk Black women. (Abstract 6549) T. Pal, D. Cragun, D. Bonner, L. P. Camperlengo, E. Robinson, S. T. Vadaparampil 279 MONDAY Monday, June 1, 2015 Monday, June 1, 2015 MONDAY Board 107 Perceptions of clinical trial participation in African American cancer patients. (Abstract 6550) D. M. Geynisman, L. Fleisher, S. B. Bass, A. Washington, A. Nicholson, L. Maurer Board 108 Racial disparities in attrition among oncology clinical trial participants. (Abstract 6551) L. Chen, B. J. Eigl, J. Grant, W. Y. Cheung Board 109 Evaluation of hematology/oncology patient and physician expectations for integrative oncology in an ethnically diverse population. (Abstract 6552) D. M. Hansra, J. Ramdial, F. Farooq, J. Antunez de Mayolo, E. Ahn, A. Mehta Board 110 Genomic landscape of primary breast cancer in black vs. white women and association with tumor recurrence. (Abstract 6553) T. Keenan, B. Moy, E. A. Mroz, K. Ross, A. Niemierko, J. W. Rocco, S. J. Isakoff, L. W. Ellisen, A. Bardia Board 111 Treatment and characteristics of stage II colon cancer patients residing in CDC Specialized Registry areas. (Abstract 6554) M. E. O’Neil, C. Eheman, F. Babcock, C. Morris, V. Chen, T. Styles Board 112 The impact of the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) in reducing outcome disparities based on race. (Abstract 6555) M. A. Fiala, T. M. Wildes Board 113 Religious beliefs and stage at diagnosis in a biracial sample of newly diagnosed colon cancer patients. (Abstract 6556) B. N. Polite, T. M. Cipriano, F. J. Hlubocky, P. Jean-Pierre, K. Brewer, Y. Cheng, G. H. Rauscher, G. Fitchett Board 114 Impact of racial residential segregation (RRS) on stage at diagnosis and survival after diffuse large B-cell lymphoma (DLBCL). (Abstract 6557) L. J. Nastoupil, C. Flowers, D. Lichtensztajn, S. L. Gomez, J. Williams, C. A. Clarke, T. H. Keegan Board 115 Effect of demographic factors and histology on stage IV non-small cell lung cancer (NSCLC): A National Cancer Database review. (Abstract 6558) B. Slostad, J. Gries, A. Ganti, P. T. Silberstein Board 116 Patient navigation as a model to increase minority participation in cancer clinical trials. (Abstract 6559) M. Fouad, A. Acemgil, S. Bae, A. Forero, M. Martin, G. R. Oates, E. E. Partridge, S. M. Vickers Board 117 Endocrine therapy adherence, side effects, and risk perception among racially diverse breast cancer patients. (Abstract 6560) S. B. Wheeler, C. C. Murphy, K. E. Reeder-Hayes, J. Earp, L. A. Carey, A. Olshan Board 118 Disparities in hospice use among patients with cancer in the Deep South. (Abstract 6561) B. E. Jackson, G. B. Rocque, E. A. Kvale, K. Kenzik, A. Acemgil, R. A. Taylor, M. Martin, W. Demark-Wahnefried, N. Lisovicz, Y. Li, K. Meneses, M. Fouad, E. Partridge, M. Pisu Board 119 Utility of surveillance following curative intent resection of metastases. (Abstract 6562) R. M. Lee-Ying, D. J. Renouf, H. J. Lim, H. F. Kennecke, S. Gill, C. Speers, W. Y. Cheung Board 120 Trends in use of PET imaging in surveillance of lung and colorectal cancer. (Abstract 6563) C. M. Veenstra, A. Vachani, A. J. Epstein, C. A. Ciunci, H. M. Zafar, E. C. Paulson Board 121 Young adult cancer survivors’ expectations of physicians for follow-up and general health care: Implications for health services delivery. (Abstract 6564) P. Camateros, Y. Wang, W. Y. Cheung Board 122 Effect of improving guideline-based prophylactic growth factor (pGCSF) use with chemotherapy (CT) on the risk of febrile neutropenia (FN) in non-small cell lung cancer (NSCLC) patients (pts): A Cleveland Clinic Taussig Cancer Institute (TCI) Quality Improvement (QI) Project. (Abstract 6565) L. M. Goodman, M. Moeller, C. K. Dalby, A. Azzouqa, A. E. Guthrie, M. A. Earl, V. Velcheti, M. A. Shapiro, N. A. Pennell, J. Stevenson Board 123 Utility of pre-operative PET/CT staging in sentinel lymph node-positive melanoma. (Abstract 6566) B. Scheier, C. D. Lao, K. M. Kidwell, B. G. Redman 280 Board 124 Developing oncology goals and objectives for medical students: A national Delphi process. (Abstract 6567) V. C. Tam, P. A. Gfeller-Ingledew, S. R. Berry, S. Verma, M. E. Giuliani Board 125 Quality of life EQ-5D results from the AETHERA trial: A phase III study of brentuximab vedotin consolidation following autologous stem cell transplant for HL. (Abstract 6568) S. D. Ramsey, A. Nademanee, T. Masszi, J. Holowiecki, M. Abidi, A. I. Chen, P. J. Stiff, S. Viviani, Y. Zhu, V. Bonthapally, E. Thomas, N. N. Hunder, J. A. Walewski Board 126 Evaluation of a pharmacist-driven oral chemotherapy adherence program. (Abstract 6569) I. C. Zhao, J. Lai, B. Seiki, M. Wilson, L. A. Brennan, T. Li, T. Wun Board 128 Impact of enhanced reimbursement on provider participation a cancer care quality program and adherence to cancer treatment pathways in a commercial health plan. (Abstract 6571) J. Malin, A. NGUYEN, S. E. Ban, V. Willey, R. Quimbo, J. Barron, P. Inches, B. Spevak, M. Fisch Board 129 Avoiding overtreatment in rectal cancer when the benefit of adjuvant chemotherapy is unclear. (Abstract 6572) J. M. Loree, H. F. Kennecke, H. J. Lim, D. J. Renouf, M. M. Vickers, C. Speers, W. Y. Cheung Board 130 Can oncology readmissions be reduced? The Cleveland Clinic experience. (Abstract 6573) A. J. Montero, J. Stevenson, A. E. Guthrie, C. Best, L. M. Goodman, A. Parala, R. Lagman, B. J. Bolwell, M. E. Kalaycio, A. A. Khorana Board 131 How well do surrogate endpoints and overall survival endpoints in clinical trials predict real-world survival? (Abstract 6574) J. Shafrin, R. Brookmeyer, D. Peneva, J. Park, J. Zhang, R. A. Figlin, D. N. Lakdawalla Board 132 Time to treatment (TTT) and breast cancer survival in the United States. (Abstract 6575) R. J. Bleicher, K. Ruth, E. R. Sigurdson, J. R. Beck, E. A. Ross, Y. Wong, S. A. Patel, M. Boraas, E. I. Chang, N. S. Topham, B. L. Egleston Board 133 Are conflict of interest (COI) slides displayed long enough to comprehend? (Abstract 6576) J. A. Talcott, A. D’Silva, J. Shulman, D. Lucido Board 134 An analysis of corrective action plans to address slow accruing NCI-held IND early phase trials. (Abstract 6577) H. A. Massett, E. Godwin, L. Rubinstein, P. Ivy, K. DiPiazza, J. Zwiebel, S. Friedman, A. Denicoff, G. E. Mishkin, J. Abrams Board 135 Prevalence and prognostic impact of prior cancer in locally advanced lung cancer. (Abstract 6578) D. E. Gerber, A. L. Laccetti, L. Xuan, E. Halm, S. Pruitt Board 136 Outcomes and predictors of life sustaining treatments in patients with metastatic cancer. (Abstract 6579) K. Loh, M. Shieh, A. J. Kansagra, P. Lindenauer, P. Pekow, M. Stefan, T. Lagu Board 137 Determinants of early mortality in 37,568 colon cancer patients participating in 25 clinical trials of the ACCENT database. (Abstract 6580) W. Y. Cheung, L. A. Renfro, G. Yothers, R. G. Gray, D. G. Haller, C. Twelves, T. Andre, E. Van Cutsem, L. Saltz, A. Grothey, R. Labianca, S. R. Alberts, H. Schmoll, K. Guthrie, A. De Gramont, C. J. Allegra, D. J. Sargent, ACCENT Collaborative Group Board 138 Hospital treatment patterns and survival for metastatic colorectal cancer. (Abstract 6581) R. W. Krell, S. E. Regenbogen, M. Banerjee, S. L. Wong Board 139 Association between Oncologic Drugs Advisory Committee (ODAC) members’ financial conflicts of interest (FCOIs) and recommendations for drug approval by the U.S. Food and Drug Administration (FDA). (Abstract 6582) A. Tibau Martorell, A. Ocana, B. Seruga, A. J. Templeton, A. Barnadas, E. Amir Board 140 Frequency and predictors of hospitalization during chemotherapy: a systematic review. (Abstract 6583) R. M. Prince, M. K. Krzyzanowska, E. G. Atenafu Board 141 Choosing wisely: Treatment recommendations from 36 Michigan Oncology Clinical Treatment Pathways practices. (Abstract 6584) A. H. Seung, L. M. Hamel, P. J. Stella, J. F. Klamerus, D. W. Blayney 281 MONDAY Monday, June 1, 2015 Monday, June 1, 2015 MONDAY Board 142 Prospective clinical study of precision oncology in solid tumors. (Abstract 6585) D. Sohal, B. I. Rini, A. A. Khorana, R. Dreicer, J. Abraham, G. Procop, Y. Saunthararajah, N. A. Pennell, J. Stevenson, R. J. Pelley, B. N. Estfan, D. R. Shepard, P. Funchain, D. J. Adelstein, B. J. Bolwell Board 143 Breast cancer progression and workplace productivity. (Abstract 6586) W. Yin, R. Horblyuk, J. J. Perkins, S. Sison, G. Smith, J. Thornton Snider, Y. Wu, T. J. Philipson Board 144 Uncontrolled chronic conditions prior to cancer diagnosis in older adults as a predictor of unplanned hospitalizations during cancer care: A Medicare claims analysis. (Abstract 6587) N. A. VanderWalde, T. Li, C. Kaplan, E. Kaplan, L. Stevens, J. Webster, B. L. McAneny, T. Waters Board 145 Potentially inappropriate medication use in elderly breast cancer patients. (Abstract 6588) M. S. Karuturi, H. M. Holmes, X. Lei, M. L. Johnson, S. H. Giordano Board 146 Creating a national collaborative strategy to enhance trial accrual in NCI’s National Clinical Trials Network (NCTN) in the era of precision medicine. (Abstract 6589) A. Denicoff, H. A. Massett, G. E. Mishkin, R. Bangs, J. Berlin, M. B. Bischoff, F. DeSanto, A. Duli, L. E. Horvath, M. S. Katz, R. Lambersky, B. S. Mann, W. J. McCaskill-Stevens, N. Seibel, S. H. Stine, W. Williams, M. M. Mooney, J. S. Abrams Board 147 Does paid sick leave affect the unmeasured costs of colorectal cancer treatment? (Abstract 6590) C. M. Veenstra, S. E. Regenbogen, S. T. Hawley, J. J. Griggs, A. M. Morris Board 148 Impact of maternal death from female cancers on child mortality. (Abstract 6591) R. Mailhot Vega, O. Balogun, S. Formenti Board 149 Nationwide utilization of cardiac imaging in patients undergoing cardiotoxic chemotherapy. (Abstract 6592) M. A. Dinan, Y. Li, S. D. Reed, W. Y. Cheung Board 150 A prospective evaluation of radiotherapy (RT) related skin reactions in a multi-racial/ethnic population of women with newly diagnosed breast cancer (BC). (Abstract 6593) J. J. Urbanic, D. Case, L. Baez-Diaz, D. R. Brown, J. Strasser, G. Enevold, M. Naughton, K. E. Weaver, K. Baglan, D. Bryant, C. Langefeld, T. E. Lad, L. Lee, G. Rine, A. E. Curtis, C. D. Koprowski, W. V. Tomlinson, G. J. Lesser, E. G. Shaw, J. J. Hu Board 151 PROSPECT eligibility and clinical outcomes: Results from the pan-Canadian rectal cancer consortium. (Abstract 6594) D. Bosse, J. Mercer, S. Raissouni, K. Dennis, R. A. Goodwin, M. Jiang, E. D. Powell, A. Kumar, R. M. Lee-Ying, J. A. Price Hiller, D. Y. Heng, P. A. Tang, A. MacLean, W. Y. Cheung, M. M. Vickers Board 152 Conflicts of interest in pharmaceutical sponsored economic studies of breast cancer therapies: An empirical study. (Abstract 6595) J. D. Lane, M. W. Friedberg, C. L. Bennett Board 153 Cancer mortality and published research output: Is there any relationship? (Abstract 6596) F. Patafio, S. C. Brooks, X. Wei, Y. Peng, J. Biagi, C. M. Booth Board 154 Trends in the costs and utilization of targeted cancer therapies for the privately insured non-elderly: 2001–2011. (Abstract 6597) F. Smieliauskas, Y. T. Shih, D. M. Geynisman, R. J. Kelly, T. J. Smith Board 155 Target wise and pound foolish: A simple technique to evaluate the trade-off between economic burden and clinical benefit of monoclonal antibodies. (Abstract 6598) M. C. Brennan, T. J. Brown, K. M. Koller, M. K. Vasekar, P. H. Cygan, J. M. Sivik, M. J. Glantz Board 156 Serum tumor marker utilization in patients with advanced solid tumors. (Abstract 6599) M. K. Accordino, J. D. Wright, S. Vasan, A. I. Neugut, A. I. Tergas, D. L. Hershman Board 157 Assessing financial toxicity in insured patients with multiple myeloma. (Abstract 6600) S. F. Huntington, B. M. Weiss, D. T. Vogl, A. D. Cohen, A. L. Garfall, J. A. Doshi, E. A. Stadtmauer 282 Board 158 Impact of site of service on chemotherapy costs: Influence of geographic location and diagnosis. (Abstract 6601) M. A. Kolodziej, B. Cullum, K. Hastings, M. Sipala, A. Supraner, C. Dubois, H. Paz, I. Klein Board 159 Quantifying the relative value of drug therapy options in HER2ⴙ, ER-/PRbreast cancer. (Abstract 6602) J. Whang, A. R. Steinkellner, J. M. Borne, E. N. Piana, W. Wong, R. E. Aubert, N. C. Selby Board 160 Real-world treatment patterns, healthcare resource utilization (HRU), and costs of initial line of therapy (LOT1) in multiple myeloma (MM). (Abstract 6603) S. D. Byfield, T. Bancroft, E. Ma, V. Bonthapally, A. H. Teitelbaum Board 161 H-TArget model: Early technology assessment for ext generation sequencing in oncology. (Abstract 6604) V. Retel, M. A. Joore, B. Ramaekers, M. M. van den Heuvel, M. S. Van Der Heijden, W. van Harten Board 162 Economic evaluation for the United States (US) of gemcitabine (GEM), nab-paclitaxel plus gemcitabine (NAB-PⴙGEM), and FOLFIRINOX as first-line treatment for metastatic pancreatic cancer (MPC). (Abstract 6605) M. Gharaibeh, A. McBride, J. Bootman, L. D. Cranmer III, I. Abraham Board 163 Price migration of oncology drugs launched in the United States between 2010 and 2015. (Abstract 6606) A. Bastian, J. Li, A. Asabere Board 164 Patient-reported symptoms and Canadian Health Utility scores in esophageal cancer patients. (Abstract 6607) M. Doherty, Y. Leung, H. Naik, D. Patel, L. Eng, Q. Q. Kong, C. Brown, O. Espin-Garcia, A. Vennettilli, D. J. Renouf, O. O. Faluyi, J. J. Knox, H. Mackay, R. Wong, D. Cella, G. E. Darling, D. Howell, N. Mittmann, W. Xu, G. Liu Board 165 Financial hardship associated with cancer in the United States. (Abstract 6608) K. R. Yabroff, E. Dowling, G. Guy, M. Banegas, T. S. McNeel, A. J. Davidoff, N. Chawla, D. B. Hartigan, X. Han, E. E. Kent, C. Li, K. S. Virgo, J. Rodriguez, J. de Moor, Z. Zheng, A. Jemal, D. U. Ekwueme Board 166 Impact of a Stage IV NSCLC care pathway on front-line (FL) and maintenance (M) chemotherapy use at the Cleveland Clinic Taussig Cancer Institute (TCI). (Abstract 6609) M. A. Shapiro, J. Stevenson, E. Van Wagoner, K. Glass, C. W. Cummings, N. A. Pennell, P. C. Ma, V. Velcheti, B. R. Bastos, B. J. Bolwell, A. Haddad Board 167 Cost-effectiveness of trastuzumab emtansine (T-DM1) for HER2-positive advanced breast cancer (ABC). (Abstract 6610) Q. A. Le, Y. Bae Board 168 A network meta-analysis-based cost-effectiveness analysis of systematic therapies in advanced pancreatic cancer. (Abstract 6611) K. K. Chan, Y. Ko, K. Shah, K. Lien, H. Lam, D. Coyle Board 169 Costs and resource utilization associated with skeletal related events in Medicare patients with prostate cancer metastatic to bones. (Abstract 6612) J. A. McDougall, B. Goulart, A. Bansal, S. D. Sullivan, J. S. McCune, A. Karnopp, C. R. Fedorenko, A. Valdarrama, S. D. Ramsey Board 170 Cost-effectiveness analysis of regorafenib for metastatic colorectal cancer. (Abstract 6613) D. A. Goldstein, B. B. Ahmad, Q. Chen, T. Ayer, D. H. Howard, J. Lipscomb, B. F. El-Rayes, C. Flowers Board 171 Stage specific health utility index scores of Canadian cancer patients. (Abstract 6614) H. Naik, D. Howell, J. Su, X. Qiu, C. Brown, A. Vennettilli, M. Irwin, V. Pat, H. Solomon, T. Wang, H. Hon, L. Eng, M. Mahler, H. Thai, V. Ho, W. Xu, S. Seung, N. Mittmann, G. Liu Board 172 Disclosure of industry payments to oncologists: Early open payments data. (Abstract 6615) D. C. Marshall, M. E. Jackson, J. A. Hattangadi Board 173 Improving the value of PSA prostate cancer screening with “smarter” strategies and increased use of active surveillance. (Abstract 6616) J. A. Roth, R. Gulati, J. L. Gore, M. R. Cooperberg, R. D. Etzioni 283 MONDAY Monday, June 1, 2015 Monday, June 1, 2015 Board 174 Hepatitis B virus screening before adjuvant chemotherapy in patients with early stage breast cancer: A cost-effectiveness analysis. (Abstract 6617) W. Wong, L. K. Hicks, H. Tu, M. Krahn, K. I. Pritchard, J. J. Feld, K. K. Chan Board 175 Grading financial toxicity based upon its impact on health-related quality of life (HRQol). (Abstract 6618) J. A. De Souza, K. Wroblewski, B. J. Yap, J. O’Connor, B. Brockstein, M. T. Pho, M. J. Ratain, C. Daugherty, D. Cella Board 176 Medical expenditures and productivity loss among colorectal, breast, and prostate cancer survivors in the US. (Abstract 6619) Z. Zheng, A. Jemal, G. Guy, X. Han, M. Banegas, C. Li, D. U. Ekwueme, K. R. Yabroff Board 177 Contribution of cancer care to total spending among high-cost Medicare beneficiaries. (Abstract 6620) M. Kim, B. M. Alexander, L. Burke, A. Jha Board 178 A framework to assess the cost effectiveness of predictive biomarkers in oncology: Test Incremental Cost Effectiveness Ratio (TICER). (Abstract 6621) A. Safonov, W. Shi, J. Platt, B. Aktas, T. Kurita, L. Pusztai, C. Hatzis Board 179 Cost-sharing and financial burden for Medicare patients with newly diagnosed cancer. (Abstract 6622) A. Narang, L. Nicholas Board 180 Out-of-pocket cost trends for Medicare patients with newly diagnosed cancer. (Abstract 6623) A. Narang, L. Nicholas Board 181a Patients’ competence in oral cancer therapies. (Abstract TPS6624) C. Riese, A. Beylich, M. Welslau, J. Benser, U. Borges Jr., W. Baumann Board 181b Health and economic outcomes of two different follow up strategies in effectively cured advanced head and neck cancer patients. (Abstract TPS6625) L. F. Licitra, F. Favales, E. Sesenna, G. Spriano, M. Ansarin, M. Benazzo, P. Nicolai, R. Corvò, C. Grandi, G. Grando, M. Squadrelli, C. Marchetti, F. Ionna, C. Simon, A. Richetti, L. Presutti, M. Meregaglia, L. Mariani, C. Rognoni, P. Bossi 1:15 PM - 4:45 PM Poster Session Melanoma/Skin Cancers Location: S Hall A Abstracts 9009 –9020 will be discussed during the Melanoma/Skin Cancers Poster Discussion Session. See page 300 for session information. MONDAY Board 252 Safety and activity of pembrolizumab in melanoma patients with untreated brain metastases. (Abstract 9009) H. M. Kluger, S. B. Goldberg, M. Sznol, J. Tsiouris, A. Vortmeyer, L. Jilaveanu, A. L. Ralabate, A. L. Rivera, M. M. Burke, U. P. Hegbe, J. V. Cohen, X. Yao, S. Speaker, M. Madura, E. Knapp-Perry, A. Mahajan, V. Chiang Board 253 The use of pembrolizumab for the treatment of metastatic uveal melanoma. (Abstract 9010) L. A. Kottschade, R. R. McWilliams, S. Markovic, M. S. Block, J. Villasboas Bisneto, A. Q. Pham, R. S. Dronca Board 254 Response to anti-PD1/PDL1 therapy in patients with metastatic desmoplastic melanoma. (Abstract 9011) Z. Eroglu, D. W. Kim, D. B. Johnson, A. P. Algazi, R. R. Munhoz, E. Liniker, B. Kong, N. Khurana, B. Chmielowski, J. A. Sosman, R. A. Scolyer, M. S. Carlino, M. A. Postow, W. Hwu, G. V. Long, A. Ribas Board 255 Deep profiling of tumor immune microenvironment (TME) with fluorescence activated cell sorting (FACS) in advanced melanoma. (Abstract 9012) K. Loo, K. K. Tsai, M. Rosenblum, N. Khurana, J. Hwang, R. Sanchez, M. Broz, M. Krummel, P. Tumeh, A. P. Algazi, A. Daud Board 256 Bim as a predictive T-cell biomarker for response to anti-PD-1 therapy in metastatic melanoma (MM). (Abstract 9013) R. S. Dronca, S. Markovic, L. A. Kottschade, R. R. McWilliams, M. S. Block, W. K. Nevala, M. A. Thompson, H. Dong 284 Board 257 Effect of melanoma intrinsic -catenin signaling on immune exclusion and resistance to immunotherapies. (Abstract 9014) S. Spranger, Y. Zha, T. Gajewski Board 258 Quantitative assessment of BRAF V600 mutant cell-free tumor DNA from plasma as a diagnostic and therapeutic biomarker in pts with BRAF V600 mutant melanoma. (Abstract 9015) M. Schreuer, G. Meersseman, Y. Jansen, T. Seremet, I. Chevolet, A. Bott, S. Wilgenhof, G. Maertens, B. Neyns Board 259 Circulating melanoma cells and recurrence in stage III melanoma patients. (Abstract 9016) A. Lucci, C. S. Hall, M. Karhade, B. A. Laubacher, J. B. Bauldry, R. E. Royal, J. Upshaw, C. L. Roland, M. I. Ross Board 260 Plasma-based monitoring of BRAF mutations during therapy for malignant melanoma (MM) using combined exosomal RNA and cell-free DNA analysis. (Abstract 9017) R. J. Sullivan, V. J. O’Neill, K. Brinkmann, D. Enderle, T. Koestler, A. Spiel, J. Emenegger, M. Noerholm, J. Skog, C. Berking, K. Flaherty Board 261 Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): A pooled analysis. (Abstract 9018) J. S. Weber, S. J. Antonia, S. L. Topalian, D. Schadendorf, J. M. Larkin, M. Sznol, H. Y. Liu, I. Waxman, C. Robert Board 262 Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders. (Abstract 9019) D. B. Johnson, N. I. Khushalani, I. Puzanov, T. Mudigonda, H. Kaufman, J. A. Sosman, J. M. Mehnert, J. Clark Board 263 Extended follow-up results of phase Ib study (BRIM7) of vemurafenib (VEM) with cobimetinib (COBI) in BRAF-mutant melanoma. (Abstract 9020) A. C. Pavlick, A. Ribas, R. Gonzalez, O. Hamid, T. Gajewski, A. Daud, I. Puzanov, J. J. Hsu, N. W. Choong, G. A. McArthur Board 264 Quality-of-life (QOL) assessment in patients (pts) with metastatic melanoma receiving vemurafenib (V) and cobimetinib (C). (Abstract 9021) B. Dréno, K. Bartley, P. A. Ascierto, V. Atkinson, G. Liszkay, M. Maio, M. Mandalà, L. V. Demidov, D. Stroyakovskiy, L. Thomas, L. De La Cruz-Merino, C. Dutriaux, C. Garbe, I. Chang, S. P. Hack, J. M. Larkin, G. A. McArthur, A. Ribas Board 265 Determination of locally advanced basal cell carcinoma (BCC) in the first 285 patients enrolled in the RegiSONIC disease registry study. (Abstract 9022) S. S. Yoo, J. Y. Tang, G. S. Rogers, T. Olencki, M. E. Lacouture, R. R. Kudchadkar, J. Guillen, Y. Mun, K. L. Dawson, A. Sekulic Board 266 The RegiSONIC disease registry: Preliminary effectiveness and safety in the first 66 newly diagnosed locally advanced basal cell carcinoma (BCC) patients treated with vismodegib. (Abstract 9023) M. E. Lacouture, J. Y. Tang, G. S. Rogers, T. Olencki, R. R. Kudchadkar, S. S. Yoo, J. Guillen, Y. Mun, K. L. Dawson, A. Sekulic Board 267 Impact of treatment breaks on vismodegib patient outcomes: Exploratory analysis of the STEVIE study. (Abstract 9024) R. Dummer, N. Basset-Seguin, J. Hansson, J. Grob, R. Kunstfeld, B. Dréno, L. Mortier, P. A. Ascierto, L. F. Licitra, C. Dutriaux, T. Jouary, N. Meyer, B. Guillot, K. Fife, D. S. Ernst, S. Williams, A. G. Fittipaldo, I. Xynos, A. Hauschild Board 268 De novo versus nevus-associated melanomas: Differences in associations with prognostic indicators and survival. (Abstract 9025) R. M. Cymerman, K. Wang, E. C. Murzaku, L. A. Penn, I. Osman, Y. Shao, D. Polsky Board 269 PD1/PDL-1 and VEGF expression in lymph node microenvironment and relation with tumor burden and survival in cutaneous melanomas. (Abstract 9026) V. L. Vazquez, C. Viana, C. Scapulatempo, S. V. Serrano, C. Alessi Board 270 Effect of nivolumab (NIVO) on quality of life (QoL) in patients (pts) with treatment-naïve advanced melanoma (MEL): Results of a phase III study (CheckMate 066). (Abstract 9027) G. V. Long, V. Atkinson, P. A. Ascierto, C. Robert, J. C. Hassel, P. Rutkowski, K. J. Savage, F. Taylor, C. Coon, I. Gilloteau, H. Dastani, I. Waxman, A. P. Abernethy 285 MONDAY Monday, June 1, 2015 Monday, June 1, 2015 Nivolumab in resected and unresectable melanoma: Immune-related adverse events and association with survival outcomes. (Abstract 9028) M. L. Freeman-Keller, J. S. Weber Board 272 Effect of nivolumab (NIVO) in combination with ipilimumab (IPI) versus IPI alone on quality of life (QoL) in patients (pts) with treatment-naïve advanced melanoma (MEL): Results of a phase II study (CheckMate 069). (Abstract 9029) A. P. Abernethy, M. A. Postow, J. A. Chesney, K. F. Grossmann, F. Taylor, C. Coon, I. Gilloteau, H. Dastani, P. Gagnier, C. Robert Board 273 Final data from CALM: A phase II study of Coxsackievirus A21 (CVA21) oncolytic virus immunotherapy in patients with advanced melanoma. (Abstract 9030) R. I. Andtbacka, B. D. Curti, H. Kaufman, G. A. Daniels, J. J. Nemunaitis, L. E. Spitler, S. Hallmeyer, J. Lutzky, S. M. Schultz, E. D. Whitman, K. Zhou, R. Karpathy, J. I. Weisberg, M. Grose, D. Shafren Board 274 Clinical characteristics predictive of response to pembrolizumab in advanced melanoma. (Abstract 9031) K. K. Tsai, K. Loo, N. Khurana, A. P. Algazi, J. Hwang, R. Sanchez, M. Krummel, M. Rosenblum, P. Tumeh, A. Daud Board 275 A single-arm, open-label, phase II study to evaluate the safety of vemurafenib (VEM) followed by ipilimumab (IPI) in BRAF V600-mutated metastatic melanoma (MM). (Abstract 9032) A. Amin, D. H. Lawson, A. K. Salama, H. B. Koon, T. H. Guthrie, S. S. Thomas, S. O’Day, M. F. Shaheen, B. Zhang, S. Francis, F. S. Hodi Board 276 Clinical features of cobimetinib (COBI)–associated serous retinopathy (SR) in BRAF-mutated melanoma patients (pts) treated in the coBRIM study. (Abstract 9033) L. De La Cruz-Merino, L. Di Guardo, J. Grob, A. Venosa, J. M. Larkin, G. A. McArthur, A. Ribas, S. Eng, J. J. Hsu, G. Barteselli, N. W. Choong, B. Dréno Board 277 Prognostic relevance of baseline neutrophils and derived neutrophil to lymphocyte ratio for ipilimumab-treated advanced melanoma patients. (Abstract 9034) P. Ferrucci, D. Giannarelli, S. Gandini, E. Cocorocchio, M. Del Vecchio, V. Picasso, J. Pigozzo, A. Di Giacomo, E. Simeone, V. Chiarion-Sileni, P. Queirolo, M. Maio, P. A. Ascierto, C. Martinoli Board 278 An adjuvant clinical trial of SCIB1, a DNA vaccine that targets dendritic cells in vivo, in fully resected melanoma patients. (Abstract 9035) P. M. Patel, C. Ottensmeier, C. Mulatero, P. Lorigan, R. Plummer, D. Hannaman, M. Cunnell, R. Metheringham, V. Brentville, I. Daniels, L. Machado, L. G. Durrant Board 279 Updated overall survival (OS) results for BRF113220, a phase I–II study of dabrafenib alone versus combined dabrafenib and trametinib in patients with BRAF V600 metastatic melanoma (MM). (Abstract 9036) A. Daud, J. S. Weber, J. A. Sosman, K. Kim, R. Gonzalez, O. Hamid, J. R. Infante, J. S. Cebon, L. M. Schuchter, G. V. Long, A. P. Algazi, R. R. Kudchadkar, I. Puzanov, D. P. Lawrence, R. Kefford, A. S. Kline, H. L. Del Buono, P. Sun, D. O. McDowell, K. Flaherty Board 280 Prognostic value of BRAFV600 mutations in American Joint Committee on Cancer (AJCC) stage 3 cutaneous melanoma patients in the MelanCohort prospective cohort. (Abstract 9037) P. Saiag, P. Aegerter, C. Lebbe, P. Wolkenstein, N. Dupin, V. Descamps, S. Aractingi, M. Battistella, Z. HeliasRodzewicz, S. Mourah, J. Emile, MelanCohort Group Board 281 XPC, XPF, TP53 and GSTP1 polymorphisms in prognosis of cutaneous melanoma patients. (Abstract 9038) C. S. Lima, G. V. Gomez, C. Oliveira, G. J. Lourenco, J. A. Rinck Jr., A. M. Moraes Board 282 A global genomic and small molecule inhibitor interrogation of KIT mutant melanoma to reveal underlying biology and novel molecular targets. (Abstract 9039) J. Oba, W. Wang, A. K. Eterovic, C. C. Stephan, J. Roszik, C. R. Kale, C. L. Haymaker, M. Routbort, L. E. Haydu, C. Bernatchez, M. A. Davies, A. J. Lazar, E. A. Grimm, S. E. Woodman Board 283 Patient-reported outcomes (PROs) in KEYNOTE-002, a randomized study of pembrolizumab vs chemotherapy in patients (pts) with ipilimumab-refractory MONDAY Board 271 286 Monday, June 1, 2015 Board 284 Melanoma-specific MHC-II expression to predict response to ␣-PD-1 therapy. (Abstract 9041) J. M. Balko, D. B. Johnson, M. V. Estrada, V. Sanchez, M. Sanders, M. C. Kelley, C. M. Lovly, J. A. Sosman Board 285 Multiplatform biomarker analysis on non-sun exposed mucosal melanoma. (Abstract 9042) A. H. Bryce, D. Arguello, S. Z. Millis, R. Bender, S. K. Reddy, Z. Gatalica, R. Gonzalez Board 286 Analysis of CTLA4 expression on T regulatory cells in patients with advanced stage melanoma in the setting of high dose IL-2 (HDIL-2). (Abstract 9043) M. L. Diller, C. E. Eysmans, D. H. Lawson, K. A. Delman, R. R. Kudchadkar, M. Ford Board 287 Association of PD-L1 expression in melanoma with response and prognosis to ipilimumab. (Abstract 9044) C. Brueggemann, B. Weide, S. M. Goldinger, A. Konrad, M. Erdmann, D. Schadendorf, R. S. Croner, L. Kraehenbuehl, K. C. Kaehler, C. Hafner, W. Leisgang, F. Kiesewetter, R. Dummer, G. Schuler, M. Stürzl, L. Heinzerling Board 288 Evaluation of the impact of infliximab use for the treatment of ipilimumab related diarrhoea on the outcome of patients with advanced melanoma. (Abstract 9045) E. Arriola, M. J. Wheater, A. Warrier, I. Karydis, C. H. Ottensmeier Board 289 Safety of infusing ipilimumab (ipi) over 30 minutes (min). (Abstract 9046) P. Momtaz, V. Park, K. Panageas, J. D. Guillen, M. A. Postow, M. K. Callahan, J. D. Wolchok, P. B. Chapman Board 290 Efficacy of high-dose adjuvant interferon therapy in high-risk melanoma harboring gene mutations. (Abstract 9047) X. Wang, L. L. Mao, L. Si, Z. Chi, C. Cui, X. N. Sheng, B. LIAN, B. Tang, X. Yan, J. Guo Board 291 Evaluation of genetic heterogeneity in paired lymph node metastases from melanoma patients using next-generation sequencing (NGS) approaches. (Abstract 9048) G. Palmieri, A. Cossu, C. Caraco, P. A. Ascierto, N. Mozzillo, G. Botti, A. Lissia, S. Canzanella, M. Sini, A. Manca, M. Colombino, M. Casula Board 292 Analysis of mTOR Mutations in Chinese Melanoma Patients and Evaluation of Their Sensitivity to PI3K-AKT-mTOR Pathway Inhibitors. (Abstract 9049) Y. Kong, L. Si, Y. q. Li, X. w. Wu, X. W. Xu, J. Dai, H. Tang, M. Ma, Z. Chi, X. N. Sheng, C. Cui, J. Guo Board 293 Association of immune-related thyroid disorders with pembrolizumab (pembro, MK-3475) in patients (pts) with advanced melanoma treated in KEYNOTE-001. (Abstract 9050) C. Robert, A. M. Joshua, R. Kefford, R. W. Joseph, J. D. Wolchok, F. S. Hodi, O. Hamid, J. S. Weber, T. C. Gangadhar, R. S. Dronca, A. Patnaik, H. M. Zarour, W. Hwu, P. Hersey, A. Daud, M. Giannotti, X. Li, S. Ebbinghaus, S. P. Kang, A. Ribas Board 294 Utility of PET/CT for surveillance of asymptomatic patients with resected stage III or IV melanoma. (Abstract 9051) R. A. Leon-Ferre, L. A. Kottschade, V. J. Lowe, S. Markovic Board 295 Identification of a predictive signature based on immunohistochemical (IHC), RNA-seq and epigenetic profiling of melanoma metastases for response to ipilimumab-based immunotherapy. (Abstract 9052) T. Seremet, A. Koch, S. Wilgenhof, M. Schreuer, Y. Jansen, D. Lienard, V. Del Marmol, K. Thielemans, N. Van Baren, P. Coulie, T. De Meyer, W. Van Criekinge, B. Neyns Board 296 A multi-center phase II study of high dose IL-2 (HD IL-2) sequenced with vemurafenib in patients with BRAF-V600E mutation positive advanced melanoma. (Abstract 9053) J. Clark, M. S. Ernstoff, M. M. Milhem, C. D. Lao, D. H. Lawson, L. E. Flaherty, T. L. Luna, S. Aung Board 297 Triple wild type melanoma profiling in the Caris Molecular Intelligence registry. (Abstract 9054) K. Homicsko, K. Russell, A. Voss, O. Michielin 287 MONDAY (IPI-R) metastatic melanoma (MEL). (Abstract 9040) D. Schadendorf, R. Dummer, A. Hauschild, C. Robert, O. Hamid, A. Daud, A. J. van den Eertwegh, L. D. Cranmer III, S. O’Day, I. Puzanov, J. Schachter, C. U. Blank, A. K. Salama, C. Loquai, J. M. Mehnert, Y. Wang, S. Ebbinghaus, S. P. Kang, W. Zhou, A. Ribas Monday, June 1, 2015 MONDAY Board 298 Survival, biomarker, and toxicity analysis of nivolumab (NIVO) in patients that progressed on ipilimumab (IPI). (Abstract 9055) J. S. Weber, G. T. Gibney, B. Yu, P. Cheng, A. J. Martinez, J. Kroeger, J. Freed, A. Richards, X. Zhao, M. J. Schell Board 299 A phase I study of vemurafenib and decitabine in metastatic melanoma. (Abstract 9056) S. D. Phadke, E. S. Engelman, R. A. Leon-Ferre, L. I. Abushahin, S. C. Mott, Y. Zakharia, M. M. Milhem Board 300 Demographics, tumor characteristics, and clinical outcomes associated with somatic mutations in 201 cancer-related genes in advanced melanoma patients (pts). (Abstract 9057) M. A. Davies, A. Joon, R. L. Bassett Jr., J. Roszik, A. Siroy, L. E. Haydu, K. Chen, F. Stingo, V. Baladandayuthapani, K. R. Shaw, F. Meric-Bernstam, M. T. Tetzlaff, J. E. Gershenwald, S. E. Woodman, A. J. Lazar Board 301 Trends in demographics, incidence, and survival in children, adolescents and young adults (AYA) with melanoma: A Surveillance, Epidemiology and End Results (SEER) population-based analysis. (Abstract 9058) D. K. Mitsis, A. Groman, L. M. Beaupin, K. E. Salerno, V. Francescutti, J. J. Skitzki, J. M. Kane III, N. I. Khushalani Board 302 Efficacy and toxicity of treatment with the anti-CTLA-4 antibody Ipilimumab in patients with metastatic melanoma who have progressed on anti-PD-1 therapy. (Abstract 9059) P. Prithviraj, G. A. McArthur, V. Atkinson, P. Parente, M. C. Andrews, S. Parakh, J. S. Cebon, O. Klein Board 303 Adoptive Cell Therapy for metastatic melanoma: A UK centre experience. (Abstract 9060) M. R. Pillai, R. Guest, N. Kirillova, S. Chow, P. Lorigan, R. E. Hawkins Board 304 The expression quantitative trait loci (eQTLs) and their association with melanoma clinical outcomes. (Abstract 9061) M. Vogelsang, C. N. Martinez, A. Romanchuk, C. Hecht, O. Richardson, R. L. Shapiro, R. S. Berman, I. Osman, T. Kirchhoff Board 305 One-year overall survival (OS) and biomarker correlates from a phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM). (Abstract 9062) R. Jamal, L. Van Kempen, P. Thebault, K. Belanger, J. E. Friedmann, J. M. Ayoub, E. Cocolakis, S. Kazemi, J. Dionne, C. Lambert, H. Le, C. Grange, J. Cailhier, A. Spatz, R. Lapointe, W. H. Miller Jr. Board 306 Survival, safety, and response patterns in a phase 1b multicenter trial of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma. (Abstract 9063) I. Puzanov, M. M. Milhem, R. I. Andtbacka, D. R. Minor, O. Hamid, A. Li, J. Chou, H. Kaufman Board 307 Identification of potentially actionable mutations in RTKs in melanoma detected by next generation sequencing (NGS). (Abstract 9064) J. Kemnade, J. Roszik, A. Joon, F. Stingo, V. Baladandayuthapani, A. J. Lazar, S. E. Woodman, M. A. Davies Board 308 The effect of ipilimumab on natural killer cells identifies the subset of advanced melanoma patients with clinical response. (Abstract 9065) I. E. Pires Da Silva, A. Gallois, K. P. Lui, R. L. Shapiro, A. C. Pavlick, N. Bhardwaj, I. Osman Board 309 Continued evaluation of a 31-gene expression profile test (GEP) for prediction of distant metastasis (DM) in cutaneous melanoma (CM). (Abstract 9066) D. H. Lawson, R. W. Cook, C. Johnson, M. C. Russell, R. N. Amaria, J. Wilkinson, P. Gerami, D. Maetzold, L. Ferris, K. M. Oelschlager, A. Greisinger, R. Gonzalez, T. C. Windham, B. Middlebrook, K. A. Delman, S. Lyle Board 310 Long-term results of ultrasound (US)-guided fine needle aspiration cytology (FNAC) in conjunction with sentinel node biopsy (SNB) to support step-wise approach in melanoma. (Abstract 9067) A. C. Van Akkooi, P. Siegel, A. Schoengen, J. Roewert-Huber, A. M. Eggermont, C. A. Voit 288 Board 311 Phase II trial of trametinib in combination with the AKT inhibitor GSK 2141795 in BRAF wild-type melanoma. (Abstract 9068) A. P. Algazi, A. H. Muthukumar, K. O’Brien, A. Lencioni, K. K. Tsai, M. Kadafour, P. B. Chapman, A. Daud Board 312 Changes in blood eosinophilia during anti-PD1 therapy as a predictor of long term disease control in metastatic melanoma. (Abstract 9069) L. Gaba, I. Victoria, E. Pineda, A. Fernandez, F. Aya, A. Prat, A. Arance Board 313 Immunologic profile of melanoma brain metastases (MBM) in patients (pts) with prolonged survival. (Abstract 9070) K. P. Lui, I. E. Silva, S. A. Weiss, S. W. Han, F. Darvishian, A. C. Pavlick, J. Golfinos, D. Moogk, M. Krogsgaard, I. Osman Board 314 A novel algorithm applicable to cancer next-generation sequencing panels to predict total tumor mutation load and correlation with clinical outcomes in melanoma. (Abstract 9071) J. Roszik, A. Joon, A. Siroy, L. E. Haydu, F. Stingo, V. Baladandayuthapani, P. Hwu, M. T. Tetzlaff, J. A. Wargo, J. Q. Chen, L. G. Radvanyi, C. Bernatchez, J. E. Gershenwald, A. J. Lazar, M. A. Davies, S. E. Woodman Board 315 Low vemurafenib plasma exposure as a short-term predictive parameter of progression disease in metastatic BRAFV600mut melanoma. (Abstract 9072) L. Goldwirt, I. Chami, J. Feugeas, F. Brunet-Possenti, C. Pagès, C. Allayous, B. Baroudjian, I. Madelaine, H. Sauvageon, S. Mourah, C. Lebbe Board 316 Patterns of response to anti-PD1 treatment: Comparison of three radiological response criteria and effect on overall survival (OS) in metastatic melanoma patients (MM). (Abstract 9073) M. Kibiro, L. Khoja, D. Hogg, M. O. Butler, U. Metser, E. G. Atenafu, A. M. Joshua Board 317 Tumor size and clinical outcomes in melanoma patients (MEL pts) treated with talimogene laherparepvec (T-VEC). (Abstract 9074) H. Kaufman, T. Amatruda, J. J. Nemunaitis, J. A. Chesney, K. A. Delman, L. E. Spitler, F. A. Collichio, M. I. Ross, Y. Zhang, M. Shilkrut, R. I. Andtbacka Board 318 Investigation of intrapatient heterogeneity in the tumor infiltrating T cell repertoire in patients with metastatic melanoma treated with pembrolizumab. (Abstract 9075) R. R. Munhoz, T. Merghoub, R. O. Emerson, M. K. Callahan, J. D. Wolchok, M. A. Postow Board 319 Phase I trial of the CDK 4/6 inhibitor, P1446A-05 (voruciclib) in combination with the BRAF inhibitor (BRAFi), vemurafenib in advanced, BRAF-mutant melanoma. (Abstract 9076) A. Diab, A. Martin, L. Simpson, A. P. Algazi, P. Chawla, D. W. Kim, S. Santra, V. Patel, N. Jadhav, D. Abhyankar, M. A. Davies, S. C. Buch, K. Kim, A. Daud Board 320 Next generation sequencing of solid tumor and circulating tumor DNA (ctDNA) in metastatic melanoma. (Abstract 9077) E. L. Carpenter, S. S. Yee, D. Soucier, J. J. Morrissette, W. Xu, S. R. Harmon, N. Salathia, Y. Zhao, J. Waters, J. Fan, L. M. Schuchter, R. K. Amaravadi, G. C. Karakousis, T. C. Gangadhar Board 321 Factors associated with worse outcome for patients with AJCC stage IIC relative to stage IIIA melanoma. (Abstract 9078) C. C. Kim, J. S. Najita, S. Y. Tan, S. Varada, L. X. Tong, H. Dunbar, M. Lee, V. J. Seery, E. I. Buchbinder, N. E. Tawa Jr., J. Fuller, R. A. Frankenthaler, D. F. McDermott, S. J. Lee, M. B. Atkins Board 322a A randomized phase II study of ipilimumab induction in patients with melanoma brain metastases receiving stereotactic radiosurgery. (Abstract TPS9079) A. W. Silk, Y. Cao, D. Gomez-Hassan, B. G. Redman, J. Hayman, J. Heth, C. D. Lao Board 322b A multi-center phase II open-label study (CheckMate 204) to evaluate safety and efficacy of nivolumab (NIVO) in combination with ipilimumab (IPI) followed by NIVO monotherapy in patients (pts) with melanoma (MEL) metastatic to the brain. (Abstract TPS9080) K. A. Margolin, H. A. Tawbi, M. S. Ernstoff, F. S. Hodi, D. F. McDermott, R. Edwards, A. Avila, M. B. Atkins Board 323a A multicenter, open–label trial of talimogene laherparepvec (T-VEC) plus pembrolizumab vs pembrolizumab monotherapy in previously untreated, 289 MONDAY Monday, June 1, 2015 Monday, June 1, 2015 unresected, stage IIIB-IV melanoma. (Abstract TPS9081) A. Ribas, I. Puzanov, T. Gajewski, G. V. Long, R. Dummer, J. M. Kirkwood, A. VanderWalde, J. S. Cebon, G. A. McArthur, C. K. Gause, L. Chen, D. R. Kaufman, J. Chou, R. I. Andtbacka, F. S. Hodi MONDAY Board 323b Phase III multicenter trial of eltrapuldencel-T: Autologous dendritic cells loaded with irradiated autologous tumor cells (DC-TC) in granulocytemacrophage colony stimulating factor (GM-CSF) in patients with metastatic melanoma (INTUS trial). (Abstract TPS9082) R. O. Dillman, M. E. Bayer, J. A. Langford, C. Y. Hseih, T. J. Wyatt, G. Liang, D. J. Carbonyell, A. N. Cornforth Board 324a A single-arm, open-label, multicenter phase II trial (CheckMate 172) of nivolumab (NIVO) safety in European patients (pts) with advanced melanoma (MEL) who have progressed after ipilimumab therapy (IPI). (Abstract TPS9083) D. Schadendorf, P. A. Ascierto, E. Espinosa, J. B. Haanen, F. Hermann, P. D. Nathan Board 324b Phase 1 dose escalation and expansion safety study of BLZ-100 in subjects with skin cancer. (Abstract TPS9084) D. M. Miller, M. Yamada, M. Lowe, C. Rowe, D. Wood, K. Byrnes-Blake, T. Prow, L. Spelman Board 325a SWOG S1404: A phase III randomized trial comparing high dose interferon to pembrolizumab in patients with high risk resected melanoma. (Abstract TPS9085) K. F. Grossmann, M. Othus, A. A. Tarhini, S. P. Patel, J. M. Kirkwood, J. Moon, V. K. Sondak, A. Ribas Board 325b A phase II, open-label, multicenter trial to investigate the clinical activity and safety of avelumab (MSB0010718C) in patients with metastatic Merkel cell carcinoma. (Abstract TPS9086) H. Kaufman, O. Hamid, S. P. D’Angelo, G. Yuan, K. M. Chin, S. Bhatia, J. Cuillerot, P. Nghiem Board 326a Randomized phase II study comparing the MET inhibitor cabozantinib to temozolomide (TMZ) or dacarbazine (DTIC) in ocular melanoma: A091201. (Abstract TPS9087) J. J. Luke, J. B. Allred, L. E. Horvath, B. R. Bastos, C. Erlichman, G. K. Schwartz Board 326b Phase 2 study of cobimetinib in combination with vemurafenib in active melanoma brain metastases (coBRIM-B). (Abstract TPS9088) M. K. Yee, Y. Lin, V. C. Gorantla, L. H. Butterfield, H. M. Kluger, P. B. Chapman, T. C. Gangadhar, M. M. Milhem, A. C. Pavlick, R. K. Amaravadi, L. M. Schuchter, A. A. Tarhini, J. M. Kirkwood, H. A. Tawbi Board 327a A Phase 2 biomarker-enriched study of evofosfamide (TH-302) in patients with advanced melanoma. (Abstract TPS9089) E. McWhirter, O. Hamid, B. Chmielowski, R. D. Carvajal, D. A. Jaffray, B. Driscoll, T. Shek, I. Yeung, H. Keller, T. D. McKee, T. E. Pearce, S. Kroll, A. M. Joshua Board 327b A randomized, phase III study of fotemustine versus the combination of fotemustine and ipilimumab or the combination of ipilimumab and nivolumab in patients with metastatic melanoma with brain metastasis: the NIBIT-M2 trial. (Abstract TPS9090) A. Di Giacomo, D. Annesi, P. A. Ascierto, L. Calabrò, V. Chiarion-Sileni, R. Danielli, M. Del Vecchio, V. Ferraresi, P. Ferrucci, E. Fonsatti, M. Guida, D. Giannarelli, M. Guidoboni, M. Mandalà, P. Quaglino, P. Queirolo, C. Maccalli, G. Parmiani, M. Maio Board 328a Neoadjuvant BRAF (dabrafenib) and MEK (trametinib) inhibition for high-risk resectable stage III and IV melanoma. (Abstract TPS9091) J. A. Wargo, R. N. Amaria, M. I. Ross, R. P. Saw, J. E. Gershenwald, P. Hwu, S. P. Patel, I. C. Glitza, A. Diab, R. Kefford, R. A. Scolyer, H. Rizos, J. F. Thompson, K. Shannon, A. Spillane, M. S. Carlino, A. Guminski, L. Simpson, M. A. Davies, G. V. Long Board 328b A pilot study of neoadjuvant cetuximab in locally advanced squamous cell carcinomas of skin (SCCS). (Abstract TPS9092) K. R. Spencer, A. D. Kaveney, J. Goydos, S. Kim, V. P. Koshenkov, S. Goyal, A. J. Khan, E. M. Castrorao, A. W. Silk, H. Kaufman, L. Huzzy, M. L. Ruppert, S. Ganesan, J. M. Mehnert Board 329a SWOG S1320: A randomized phase II trial of intermittent versus continuous dosing of dabrafenib and trametinib in BRAFV600E/k mutant melanoma. 290 Monday, June 1, 2015 (Abstract TPS9093) A. P. Algazi, M. Othus, A. Daud, J. M. Mehnert, C. D. Lao, R. R. Kudchadkar, K. F. Grossmann, R. Lo, J. Moon, J. M. Kirkwood, A. Ribas Board 329b Phase 2, multicenter, randomized, open-label trial assessing efficacy and safety of talimogene laherparepvec (T-VEC) neoadjuvant treatment (tx) plus surgery vs surgery for resectable stage IIIB/C and IVM1a melanoma (MEL). (Abstract TPS9094) R. I. Andtbacka, M. Chastain, A. Li, M. Shilkrut, M. I. Ross 3:00 PM - 4:15 PM Poster Discussion Session Gastrointestinal (Noncolorectal) Cancer Location: E Hall D1 3:00 PM Syma Iqbal, MD (Discussion of Abstract(s) 4012– 4015) University of Southern California/Norris Comprehensive Cancer Center Gastroesophageal Cancers: Finding the Right Targets 3:12 PM Panel Question and Answer 3:18 PM David H. Ilson, MD, PhD (Discussion of Abstract(s) 4016 – 4017) Memorial Sloan Kettering Cancer Center Resectable Gastric and Esophageal Cancer: Increasing the Likelihood of Cure 3:30 PM Panel Question and Answer 3:36 PM Robin Kate Kelley, MD (Discussion of Abstract(s) 4018 – 4020) UCSF Helen Diller Family Comprehensive Cancer Center Hepatobiliary Cancers: Looking through the Prism 3:48 PM Panel Question and Answer 3:54 PM Emil Lou, MD, PhD (Discussion of Abstract(s) 4021– 4023) University of Minnesota Outside of the Proverbial Box: Molecular and Cellular Heterogeneity in Pancreatic Cancer 4:06 PM Panel Question and Answer Posters discussed in this session are on display in the Gastrointestinal (Noncolorectal) Cancer Poster Session. See page 219 for poster information. Networking with presenters and discussants will take place right outside of the session rooms after the discussion. 3:00 PM - 4:15 PM Poster Discussion Session Lung Cancer—Non-Small Cell Metastatic Location: E Hall D2 Jhanelle Elaine Gray, MD—Co-Chair Moffitt Cancer Center Jonathan Riess, MD, MS—Co-Chair UC Davis Comprehensive Cancer Center 3:00 PM Heather A. Wakelee, MD (Discussion of Abstract(s) 8013– 8015) Stanford Cancer Institute/Stanford University School of Medicine New Insights in Epidermal Growth Factor Receptor Inhibition 3:12 PM Panel Question and Answer 291 MONDAY Milind M. Javle, MD—Chair The University of Texas MD Anderson Cancer Center Monday, June 1, 2015 3:18 PM Jean-Charles Soria, MD, PhD (Discussion of Abstract(s) 8016 – 8019) Gustave-Roussy Cancer Campus Breaking Barriers: Tyrosine Kinase Inhibitors for Management of Lung Cancers with Central Nervous System Penetration 3:30 PM Panel Question and Answer 3:36 PM Christine Marie Lovly, MD, PhD (Discussion of Abstract(s) 8020 – 8022) Vanderbilt-Ingram Cancer Center Skipping Toward a New Target 3:48 PM Panel Question and Answer 3:54 AM David Michael Jackman, MD (Discussion of Abstract(s) 8023– 8024) Dana-Farber Cancer Institute Can Computers Do It Better? 4:06 PM Panel Question and Answer Posters discussed in this session are on display in the Lung Cancer—Non-Small Cell Metastatic Poster Session. See page 237 for poster information. Networking with presenters and discussants will take place right outside of the session rooms after the discussion. 3:00 PM - 4:15 PM Education Session The Challenges of Pain Management Location: S102 Toby Christopher Campbell, MD University of Wisconsin Carbone Cancer Center Nonopioid Pain Medicines and Adjunctive Alternatives Eduardo Bruera, MD The University of Texas MD Anderson Cancer Center Opioid Pain Medicines and Regulatory Issues Judith A. Paice, PhD, RN—Chair Northwestern University Screening and Managing Misuse and Abuse MONDAY Panel Question and Answer 3:00 PM - 4:30 PM Clinical Science Symposium Chimeric Antigen Receptor T-Cell Therapy for B-Cell Malignancies Location: E Arie Crown Theater Ranjana H. Advani, MD—Co-Chair Stanford School of Medicine Alexander M. Lesokhin, MD—Co-Chair Memorial Sloan Kettering Cancer Center 3:00 PM 292 Stephen Maxted Ansell, MD Mayo Clinic Chimeric Antigen Receptor T-Cell Technology 101 Monday, June 1, 2015 3:12 PM Phase I trial of 19 –28z chimeric antigen receptor modified T cells (19 –28z CAR-T) post-high dose therapy and autologous stem cell transplant (HDTASCT) for relapsed and refractory (rel/ref) aggressive B-cell non-Hodgkin lymphoma (B-NHL). (Abstract 8515) C. S. Sauter, I. Riviere, Y. Bernal, X. Wang, T. Purdon, S. Yoo, C. H. Moskowitz, S. Giralt, M. J. Matasar, K. J. Curran, J. H. Park, M. Sadelain, R. J. Brentjens 3:24 PM Phase IIa trial of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed or refractory CD19ⴙ lymphomas. (Abstract 8516) S. J. Schuster, J. Svoboda, S. Nasta, D. L. Porter, A. Mato, G. D. Shah, D. J. Landsburg, E. A. Chong, S. F. Lacey, J. J. Melenhorst, A. Chew, J. Hasskarl, N. N. Shah, M. A. Wasik, K. Marcucci, Z. Zheng, B. Levine, C. H. June 3:36 PM Safety and efficacy of anti-CD19 chimeric antigen receptor (CAR)-modified autologous T cells (CTL019) in advanced multiple myeloma. (Abstract 8517) A. L. Garfall, M. V. Maus, S. F. Lacey, Y. D. Mahnke, J. J. Melenhorst, Z. Zheng, D. T. Vogl, A. D. Cohen, B. M. Weiss, K. Dengel, N. D. Kerr, W. Hwang, B. Levine, C. H. June, E. A. Stadtmauer 3:48 PM Madhav V. Dhodapkar, MBBS (Discussion of Abstract(s) 8515– 8517) Yale University A Clinical Perspective on Chimeric Antigen Receptor T-Cell Research 4:00 PM David Avigan, MD Beth Israel Deaconess Medical Center The Future of Chimeric Antigen Receptor T-Cell Research 4:12 PM Panel Question and Answer 3:00 PM - 4:30 PM Clinical Science Symposium Intersection of the Mutanome and the Immunome Location: E354b Kunle Odunsi, MD, PhD—Co-Chair Roswell Park Cancer Institute 3:00 PM Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with previously treated, recurrent or refractory ovarian cancer: A phase Ib, open-label expansion trial. (Abstract 5509) M. L. Disis, M. R. Patel, S. Pant, J. R. Infante, A. Lockhart, K. Kelly, J. T. Beck, M. S. Gordon, G. J. Weiss, S. Ejadi, M. H. Taylor, A. von Heydebreck, K. M. Chin, J. Cuillerot, J. L. Gulley 3:12 PM Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1 positive advanced ovarian cancer: Interim results from a phase Ib study. (Abstract 5510) A. Varga, S. A. Piha-Paul, P. A. Ott, J. M. Mehnert, D. BertonRigaud, E. A. Johnson, J. D. Cheng, S. Yuan, E. H. Rubin, D. E. Matei 3:24 PM Adil Daud, MD (Discussion of Abstract(s) 5509 –5510) University of California, San Francisco Paddling Along with PD-L1 Research 3:36 PM Association of POLE-mutated and MSI endometrial cancers with an elevated number of tumor-infiltrating and peritumoral lymphocytes and higher expression of PD-L1. (Abstract 5511) B. E. Howitt, L. M. Sholl, L. Ritterhouse, J. C. Watkins, S. J. Rodig, K. Strickland, A. D. D’Andrea, U. Matulonis, P. Konstantinopoulos 3:48 PM Tumor infiltrating and peritumoral T cells and expression of PD-L1 in BRCA1/2-mutated high grade serous ovarian cancers. (Abstract 5512) K. Strickland, B. E. Howitt, S. J. Rodig, L. Ritterhouse, A. D. D’Andrea, U. Matulonis, P. Konstantinopoulos 293 MONDAY David R. Spriggs, MD—Co-Chair Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College Monday, June 1, 2015 4:00 PM Alexandra Snyder Charen, MD (Discussion of Abstract(s) 5511–5512) Memorial Sloan Kettering Cancer Center Defining Neoantigens 4:12 PM Panel Question and Answer 3:00 PM - 6:00 PM Oral Abstract Session Breast Cancer—Triple-Negative/Cytotoxics/Local Therapy Location: N Hall B1 Steven J. Isakoff, MD, PhD—Co-Chair Massachusetts General Hospital Cancer Center Pamela N. Munster, MD—Co-Chair University of California, San Francisco MONDAY 3:00 PM TITAN: Phase III study of doxorubicin/cyclophosphamide (AC) followed by ixabepilone (Ixa) or paclitaxel (Pac) in early-stage, triple-negative breast cancer (TNBC). (Abstract 1000) D. A. Yardley, L. D. Bosserman, M. R. Keaton, M. A. Ackerman, S. A. Goble, D. Shipley, E. Salloum, W. N. Harwin, B. R. Daniel, J. D. Hainsworth, H. A. Burris III 3:12 PM Phase III trial of etirinotecan pegol (EP) versus treatment of physician’s choice (TPC) in patients (pts) with advanced breast cancer (aBC) whose disease has progressed following anthracycline (A), taxane (T) and capecitabine (C): The BEACON study. (Abstract 1001) E. A. Perez, A. Awada, J. O’Shaughnessy, H. S. Rugo, C. Twelves, S. Im, C. Zhao, U. Hoch, A. L. Hannah, J. Cortes 3:24 PM Low-dose oral cyclophosphamide-methotrexate maintenance (CMM) for receptor-negative early breast cancer (BC). (Abstract 1002) M. Colleoni, K. P. Gray, S. I. Gelber, I. Lang, B. J. Thurlimann, L. Gianni, E. A. Abdi, K. N. Price, R. D. Gelber, G. Viale, A. S. Coates, A. Goldhirsch, International Breast Cancer Study Group 3:36 PM Harold J. Burstein, MD, PhD (Discussion of Abstract(s) 1000 –1002) Dana-Farber Cancer Institute Chemotherapy for Breast Cancer: The Long and Winding Road 3:48 PM Panel Question and Answer 4:00 PM Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced ARⴙ triple-negative breast cancer (TNBC). (Abstract 1003) T. A. Traina, K. Miller, D. A. Yardley, J. O’Shaughnessy, J. Cortes, A. Awada, C. M. Kelly, M. E. Trudeau, P. Schmid, L. Gianni, L. Garcı́a-Estevez, R. Nanda, F. O. Ademuyiwa, S. Chan, J. L. Steinberg, M. E. Blaney, I. C. Tudor, H. Uppal, A. C. Peterson, C. A. Hudis 4:12 PM Prediction of pathological complete response (pCR) by Homologous Recombination Deficiency (HRD) after carboplatin-containing neoadjuvant chemotherapy in patients with TNBC: Results from GeparSixto. (Abstract 1004) G. Von Minckwitz, K. Timms, M. Untch, E. P. Elkin, P. A. Fasching, A. Schneeweiss, C. Salat, M. Rezai, J. Blohmer, D. Zahm, C. Jackisch, B. Gerber, P. Klare, S. Kümmel, H. Eidtmann, S. Paepke, J. E. Reid, V. Nekljudova, A. Hartman, S. Loibl 4:24 PM Prevalence and predictors of androgen receptor (AR) and programmed death-ligand 1 (PD-L1) expression in BRCA1-associated and sporadic triple negative breast cancer (TNBC). (Abstract 1005) N. M. Tung, J. E. Garber, V. Torous, M. R. Hacker, G. J. Freeman, S. J. Rodig, E. Poles, B. M. Alexander, L. J. Lee, L. C. Collins, S. J. Schnitt 294 Monday, June 1, 2015 4:36 PM Pamela N. Munster, MD (Discussion of Abstract(s) 1003–1005) University of California, San Francisco High Hopes for Exploitation of the Heterogeneity of Triple-Negative Breast Cancer 4:48 PM Panel Question and Answer 5:00 PM The survival benefit offered by the surgical management of low-grade ductal carcinoma in situ of the breast. (Abstract 1006) Y. Sagara, W. T. Barry, M. A. Mallory, S. M. Wong, F. Aydogan, S. DeSantis, M. Golshan 5:12 PM Impact of neoadjuvant therapy on breast conservation rates in triple-negative and HER2-positive breast cancer: Combined results of CALGB 40603 and 40601 (Alliance). (Abstract 1007) M. Golshan, C. T. Cirrincione, L. A. Carey, W. M. Sikov, D. A. Berry, H. J. Burstein, B. Overmoyer, N. L. Henry, G. Somlo, E. R. Port, E. P. Winer, C. A. Hudis, D. W. Ollila 5:24 PM Relationship of omission of adjuvant radiotherapy to outcomes of locoregional control and disease-free survival in patients with or without pCR after neoadjuvant chemotherapy for breast cancer: A meta-analysis on 3481 patients from the Gepar-trials. (Abstract 1008) D. Krug, B. Lederer, J. Debus, J. Blohmer, S. D. Costa, H. Eidtmann, C. Hanusch, J. Hilfrich, J. B. Huober, C. Jackisch, S. Kümmel, S. Paepke, A. Schneeweiss, M. Untch, G. Von Minckwitz, S. Loibl 5:36 PM Monica Morrow, MD (Discussion of Abstract(s) 1006 –1008) Memorial Sloan Kettering Cancer Center Tailoring Local Therapy: You Can’t Always Get What You What, But You Should Get What You Need 5:48 PM Panel Question and Answer 3:00 PM - 6:00 PM Oral Abstract Session Sarcoma Location: S504 Sebastian Bauer, MD—Co-Chair Universitaetsklinikum Essen-Innere Medizin-Essen 3:00 PM GeDDiS: A prospective randomised controlled phase III trial of gemcitabine and docetaxel compared with doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft tissue sarcomas (EudraCT 2009 – 014907-29). (Abstract 10500) B. M. Seddon, J. Whelan, S. J. Strauss, M. G. Leahy, P. J. Woll, F. Cowie, C. A. Rothermundt, Z. Wood, S. Forsyth, I. Khan, S. Nash, P. Patterson, S. Beare 3:12 PM A randomized phase Ib/II study evaluating the safety and efficacy of olaratumab (IMC-3G3), a human anti-platelet-derived growth factor ␣ (PDGFR␣) monoclonal antibody, with or without doxorubicin (Dox), in advanced soft tissue sarcoma (STS). (Abstract 10501) W. D. Tap, R. L. Jones, B. Chmielowski, A. D. Elias, D. Adkins, B. A. Van Tine, M. Agulnik, M. M. Cooney, M. B. Livingston, G. K. Pennock, A. Qin, A. Shahir, R. L. Ilaria Jr., I. Conti, J. Cosaert, G. K. Schwartz 3:24 PM Laurence H. Baker, DO (Discussion of Abstract(s) 10500 –10501) University of Michigan Front-Line Therapies for Soft-Tissue Sarcomas: Advancing the Standard of Care 3:36 PM Panel Question and Answer 295 MONDAY Vicki Leigh Keedy, MD, MSCI—Co-Chair Vanderbilt University Medical Center Monday, June 1, 2015 MONDAY 3:48 PM Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI). (Abstract LBA10502) P. Schöffski, R. G. Maki, A. Italiano, H. Gelderblom, G. Grignani, V. P. Camargo, S. Bauer, S. Y. Rha, S. P. Chawla, J. Blay, P. Hohenberger, D. R. D’Adamo, B. Wang, B. Chmielowski, A. Le Cesne, G. D. Demetri, S. Patel 4:00 PM A randomized phase III study of trabectedin (T) or dacarbazine (D) for the treatment of patients (pts) with advanced liposarcoma (LPS) or leiomyosarcoma (LMS). (Abstract 10503) G. D. Demetri, M. von Mehren, R. L. Jones, M. L. Hensley, S. Schuetze, A. P. Staddon, M. M. Milhem, A. D. Elias, K. N. Ganjoo, H. A. Tawbi, B. A. Van Tine, A. I. Spira, A. P. Dean, N. Z. Khokhar, Y. C. Park, R. E. Knoblauch, T. V. Parekh, R. G. Maki, S. Patel 4:12 PM Activity of regorafenib (RE) in leiomyosarcomas (LMS) and other types of soft-tissue sarcomas (OTS): Results of a double-blind, randomized placebo (PL) controlled phase II trial. (Abstract 10504) O. Mir, T. Brodowicz, J. Wallet, A. Italiano, A. Le Cesne, J. Blay, T. Ryckewaert, F. Bertucci, S. Piperno-Neumann, F. Ploner, M. Toulmonde, J. Domont, E. Saada, C. Delcambre, N. Isambert, S. C. Delaine, S. Taieb, E. Lindner, B. Lieg-Atzwanger, N. Penel 4:24 PM Ian Robert Judson, MD (Discussion of Abstract(s) LBA10502–10504) The Institute of Cancer Research Potential New Treatments for Patients with Soft-Tissue Sarcoma 4:36 PM Panel Question and Answer 4:48 PM Three vs. 1 year of adjuvant imatinib (IM) for operable high-risk GIST: The second planned analysis of the randomized SSGXVIII/AIO trial. (Abstract 10505) H. Joensuu, M. Eriksson, K. Sundby Hall, A. Reichardt, G. Ramadori, P. Hohenberger, S. Al-Batran, M. Schlemmer, S. Bauer, D. Pink, J. Duyster, B. E. Nilsson, O. R. Monge, R. Kallio, P. Bono, J. Junnila, E. Wardelmann, T. Alvegard, P. Reichardt 5:00 PM Final results of the multicenter randomized phase II PAZOGIST trial evaluating the efficacy of pazopanib (P) plus best supportive care (BSC) vs BSC alone in resistant unresectable metastatic and/or locally advanced gastrointestinal stromal tumors (GIST). (Abstract 10506) J. Blay, M. Molimard, C. Cropet, J. Domont, M. Toulmonde, E. Bompas, P. A. Cassier, I. L. Ray-Coquard, M. Rios, A. Adenis, A. Italiano, A. Le Cesne, O. Bouche Sr., O. Mir, F. Duffaud, F. Bertucci, N. Isambert, A. Belleville, J. Gautier, D. Pérol 5:12 PM A phase Ib/II study of MEK162 (binimetinib [BINI]) in combination with imatinib in patients with advanced gastrointestinal stromal tumor (GIST). (Abstract 10507) P. Chi, L. Qin, S. P. D’Angelo, M. A. Dickson, M. M. Gounder, M. Keohan, A. N. Shoushtari, M. M. Condy, T. Konen, A. Fruauff, R. P. DeMatteo, S. Singer, S. Hwang, C. R. Antonescu, W. D. Tap 5:24 PM Robert G. Maki, MD, PhD (Discussion of Abstract(s) 10505–10507) Icahn School of Medicine at Mount Sinai Gastrointestinal Stromal Tumor: Attempting to Improve the Adjuvant and Refractory Treatment Landscape 5:36 PM Panel Question and Answer 3:00 PM - 6:00 PM Oral Abstract Session Tumor Biology Location: E450 Michael J. Birrer, MD, PhD—Co-Chair Harvard Medical School Massachusetts General Hospital David Potter, MD, PhD—Co-Chair University of Minnesota 296 3:00 PM Identifying somatic oncogenic mutations in leukocytes that infiltrate primary breast cancers. (Abstract 11000) E. A. Comen, M. Kleppe, Y. H. Wen, F. Rapaport, Z. Granot, N. D. Socci, A. Viale, D. You, R. Benezra, B. Weigelt, E. Brogi, M. F. Berger, J. Reis-Filho, R. L. Levine, L. Norton, L. Bastian, M. Keller 3:12 PM White adipose tissue inflammation and breast cancer progression. (Abstract 11001) N. M. Iyengar, P. G. Morris, X. K. Zhou, H. Wang, A. Gucalp, D. D. Giri, M. D. Harbus, J. Park, S. S. Park, M. Morrow, C. A. Hudis, A. Dannenberg 3:24 PM Association of inactivation of STK11/LKB1 with a suppressive immune microenvironment in lung adenocarcinoma (LUAC). (Abstract 11002) F. Skoulidis, W. Denning, L. Diao, P. Tong, Y. H. Fan, V. Papadimitrakopoulou, J. Izzo, C. Behrens, H. Kadara, E. R. Parra Cuentas, J. Rodriguez, J. Wang, D. L. Gibbons, L. A. Byers, I. I. Wistuba, J. Heymach 3:36 PM Victoria Louise Seewaldt, MD (Discussion of Abstract(s) 11000 –11002) Duke University Medical Center The Role of the Microenvironment in Therapeutic Targeting 3:48 PM Panel Question and Answer 4:00 PM Discordance between HER2-phenotype on circulating tumor cells and primary tumor in women with advanced breast cancer. (Abstract 11003) A. Schramm, T. W. Friedl, F. Schochter, J. B. Huober, L. M. Wiesmueller, B. K. Rack, M. Alunni-Fabbroni, P. A. Fasching, F. Taran, A. D. Hartkopf, A. Schneeweiss, V. Mueller, B. Aktas, K. Pantel, N. Krawczyk, W. Janni, T. N. Fehm 4:12 PM Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor DNA assay. (Abstract 11004) R. Kurzrock, M. C. Schwaederle, H. Husain, R. B. Schwab, R. J. Nagy, R. B. Lanman, A. Talasaz 4:24 PM Protein expression by genetic mutations identified in gene panels (hotspots) and efficacy of targeted treatments. (Abstract 11005) S. C. Benz, S. Rabizadeh, J. Z. Sanborn, C. J. Vaske, G. A. Palmer, P. Soon-Shiong 4:36 PM To Be Determined (Discussion of Abstract(s) 11003–11005) Biomarkers and Circulating Tumor Cells: Promise and Controversies 4:48 PM Panel Question and Answer 5:00 PM Safety and activity of DCR-MYC, a first-in-class Dicer-substrate small interfering RNA (DsiRNA) targeting MYC, in a phase I study in patients with advanced solid tumors. (Abstract 11006) A. W. Tolcher, K. P. Papadopoulos, A. Patnaik, D. W. Rasco, D. Martinez, D. L. Wood, B. Fielman, M. Sharma, L. A. Janisch, B. D. Brown, P. Bhargava, M. J. Ratain 5:12 PM Comprehensive genomic profiling (CGP) of advanced cancers to identify MET exon 14 alterations that confer sensitivity to MET inhibitors. (Abstract 11007) G. M. Frampton, S. M. Ali, M. Rosenzweig, J. W. Goldman, C. B. Lee, J. Weiss, J. A. Bufill, R. Salgia, M. Jahanzeb, K. Konduri, P. M. Forde, D. Morosini, J. S. Ross, S. I. Ou, R. Yelensky, V. A. Miller, P. J. Stephens 5:24 PM Altering the tumor microenvironment: A phase II study of copper depletion using tetrathiomolybdate (TM) in patients (pts) with breast cancer (BC) at high risk for recurrence. (Abstract 11008) E. N. Nackos, N. Kornhauser, M. M. Ward, T. Cigler, A. Moore, E. Andreopoulou, N. Chan, V. Fitzpatrick, S. E. Schneider, A. Wiener, J. D. Warren, A. Rubinchik, A. Willis, S. Lee, M. E. Lane, V. Mittal, L. T. Vahdat 5:36 PM Mark M. Moasser, MD (Discussion of Abstract(s) 11006 –11008) University of California, San Francisco Myc, Met, and Metal: Linking Therapy to Biology 5:48 PM Panel Question and Answer 297 MONDAY Monday, June 1, 2015 Monday, June 1, 2015 4:45 PM - 6:00 PM Poster Discussion Session Cancer Prevention, Genetics, and Epidemiology Location: S102 James M. Foran, MD—Co-Chair Mayo Clinic Joshua David Schiffman, MD—Co-Chair University of Utah 4:45 PM Susan M. Domchek, MD (Discussion of Abstract(s) 1512–1515) University of Pennsylvania Perelman School of Medicine Putting Germline Mutations into Context 4:57 PM Panel Question and Answer 5:03 PM Matthew B. Yurgelun, MD (Discussion of Abstract(s) 1516 –1518) Dana-Farber Cancer Institute Identifying Lynch Syndrome 5:15 PM Panel Question and Answer 5:21 PM Jonathan Riess, MD, MS (Discussion of Abstract(s) 1519 –1520) UC Davis Comprehensive Cancer Center Emerging Risk Factors for Lung Cancer 5:33 PM Panel Question and Answer 5:39 PM Christopher Flowers, MD (Discussion of Abstract(s) 1521–1522) Winship Cancer Institute of Emory University Lymphoma Epidemiology and Survivorship 5:51 PM Panel Question and Answer Posters discussed in this session are on display in the Cancer Prevention, Genetics, and Epidemiology Poster Session. See page 260 for poster information. Networking with presenters and discussants will take place right outside of the session rooms after the discussion. 4:45 PM - 6:00 PM Poster Discussion Session MONDAY Central Nervous System Tumors Location: S100a Phioanh Leia Nghiemphu, MD—Co-Chair University of California, Los Angeles Christina L. Tsien, MD—Co-Chair Washington University School of Medicine 4:45 PM Erik P. Sulman, MD, PhD (Discussion of Abstract(s) 2012–2014) The University of Texas MD Anderson Cancer Center Key Phase II Trials for Glioblastoma 4:57 PM Panel Question and Answer 5:03 PM Ingo K. Mellinghoff, MD (Discussion of Abstract(s) 2015–2017) Memorial Sloan Kettering Cancer Center EGFR and MGMT: Present or Passé? 5:15 PM Panel Question and Answer 5:21 PM Tobias Walbert, MD, PhD (Discussion of Abstract(s) 2018 –2019) Henry Ford Hospital Improving Quality of Life for Patients with Central Nervous System Tumors 5:33 PM Panel Question and Answer 298 Monday, June 1, 2015 5:39 PM Manmeet Singh Ahluwalia, MD (Discussion of Abstract(s) 2020 –2021) Cleveland Clinic Novel Approaches to Brain Metastases 5:51 PM Panel Question and Answer Posters discussed in this session are on display in the Central Nervous System Tumors Poster Session. See page 265 for poster information. Networking with presenters and discussants will take place right outside of the session rooms after the discussion. 4:45 PM - 6:00 PM Poster Discussion Session Genitourinary (Nonprostate) Cancer Location: E Arie Crown Theater Peter H. O’Donnell, MD—Co-Chair The University of Chicago 4:45 PM Matthew I. Milowsky, MD (Discussion of Abstract(s) 4512– 4514) UNC Chapel Hill Lineberger Comprehensive Cancer Center Novel Research on Prediction of Chemotherapy Resistance 4:57 PM Panel Question and Answer 5:03 PM Lawrence Fong, MD (Discussion of Abstract(s) 4515, 4516, 4586) UCSF Helen Diller Family Comprehensive Cancer Center Combination Immunotherapy in Genitourinary Tumors 5:15 PM Panel Question and Answer 5:21 PM Bernard J. Escudier, MD (Discussion of Abstract(s) 4518 – 4519) Institut Gustave Roussy Targets and Targeted Therapy in Kidney Cancer 5:33 PM Panel Question and Answer 5:39 PM Daniel J. George, MD (Discussion of Abstract(s) 4520 – 4523) Duke Cancer Institute The Optimal Targets in Papillary Renal Cell Carcinoma 5:51 PM Panel Question and Answer Posters discussed in this session are on display in the Genitourinary (Nonprostate) Cancer Poster Session. See page 271 for poster information. Networking with presenters and discussants will take place right outside of the session rooms after the discussion. 4:45 PM - 6:00 PM Poster Discussion Session Health Services Research and Quality of Care Location: S404 George J. Chang, MD, MS—Co-Chair The University of Texas MD Anderson Cancer Center Monika K. Krzyzanowska, MD, MPH, FRCPC—Co-Chair Princess Margaret Cancer Centre 4:45 PM Christine Marie Veenstra, MD (Discussion of Abstract(s) 6512– 6514) University of Michigan Shaping Cancer Care through Policy 299 MONDAY Phillip Lee Palmbos, MD, PhD—Co-Chair University of Michigain Health System Monday, June 1, 2015 4:57 PM Panel Question and Answer 5:03 PM Jennifer Elston Lafata, PhD (Discussion of Abstract(s) 6515– 6517) Virginia Commonwealth University Talking to Those Who Know Best: Patient- and Family-Reported Outcomes 5:15 PM Panel Question and Answer 5:21 PM David L. Graham, MD (Discussion of Abstract(s) 6518 – 6520) Levine Cancer Institute-Cornelius Twitter, Social Media, and Email as Cancer Communication Tools 5:33 PM Panel Question and Answer 5:39 PM Rebecca A. Miksad, MD, MPH (Discussion of Abstract(s) 6521– 6523) Beth Israel Deaconess Medical Center Data-Driven Strategies for Change in Cancer Care 5:51 PM Panel Question and Answer Posters discussed in this session are on display in the Health Services Research and Quality of Care Poster Session. See page 277 for poster information. Networking with presenters and discussants will take place right outside of the session rooms after the discussion. 4:45 PM - 6:00 PM Poster Discussion Session Melanoma/Skin Cancers Location: S100bc Alain Patrick Algazi, MD—Co-Chair University of California, San Francisco Roxana Stefania Dronca, MD—Co-Chair Mayo Clinic MONDAY 4:45 PM Richard Kefford, MB, BS, PhD (Discussion of Abstract(s) 9009 –9011) Crown Princess Mary Cancer Centre Anti-PD-1 Therapy in Special Clinical Cohorts 4:57 PM Panel Question and Answer 5:03 PM Antoni Ribas, MD, PhD (Discussion of Abstract(s) 9012–9014) David Geffen School of Medicine at UCLA Biomarkers for PD1 Inhibition 5:15 PM Panel Question and Answer 5:21 PM Mohammed Kashani-Sabet, MD (Discussion of Abstract(s) 9015–9017) California Pacific Medical Center Research Institute Usefulness of Liquid Biopsies 5:33 PM Panel Question and Answer 5:39 PM Georgina V. Long, PhD, MBBS, FRACP (Discussion of Abstract(s) 9018 –9019) Melanoma Institute Australia and The University of Sydney Checkpoint Inhibitor-Associated Toxicity 5:51 PM Panel Question and Answer Posters discussed in this session are on display in the Melanoma/Skin Cancers Poster Session. See page 284 for poster information. Networking with presenters and discussants will take place right outside of the session rooms after the discussion. 300 Monday, June 1, 2015 4:45 PM - 6:00 PM Education Session Progress in Myeloproliferative Neoplasms: Biology to Bedside Location: E354b Alison Moliterno, MD—Chair Johns Hopkins University Risk Stratification in Ph-Negative Myeloproliferative Neoplasms Jean-Jacques Kiladjian, MD, PhD Hôpital Saint-Louis and Paris Diderot University Current Therapies and Their Indications for Ph-Negative Myeloproliferative Neoplasms Michael W. N. Deininger, MD, PhD University of Utah Huntsman Cancer Institute Identify and Manage Advanced or Progressive Chronic Myeloid Leukemia Panel Question and Answer 4:45 PM - 6:00 PM Education Session The ABCs of Cancer Immunotherapy Location: S406 F. Stephen Hodi, MD Dana-Farber Cancer Institute How to Interpret Antitumor Response in Immunotherapy Drew M. Pardoll, MD, PhD—Chair The Johns Hopkins University School of Medicine Immunotherapy Overview: Mechanisms and Modalities Michael Andrew Postow, MD Memorial Sloan Kettering Cancer Center Managing Immunotherapy-Related Side Effects MONDAY Panel Question and Answer 4:45 PM - 6:00 PM Education Session Treatment of Colorectal Cancer Peritoneal Carcinomatosis: The Role of Surgery, Systemic, and Heated Intraperitoneal Chemotherapy Location: E Hall D1 David P. Ryan, MD—Chair Massachusetts General Hospital Cancer Center The Role of Systemic Chemotherapy Andrea Cercek, MD Memorial Sloan Kettering Cancer Center The Role of Intraperitoneal Chemotherapy James C. Cusack, MD Massachusetts General Hospital The Role of Debulking Surgery Panel Question and Answer 301 Tuesday, June 2, 2015 7:30 AM - 9:15 AM Highlights of the Day Session Highlights of the Day Session III Location: E Hall D1 Apar Kishor Ganti, MD—Chair University of Nebraska Medical Center 7:30 AM Eric P. Winer, MD Dana-Farber Cancer Institute Breast Cancer 7:50 AM Ian D. Davis, MBBS, PhD, FRACP, FAChPM Monash University Eastern Health Clinical School Developmental Therapeutics—Immunotherapy 8:05 AM Peter Albers, MD Duesseldorf University Genitourinary (Nonprostate) Cancer 8:20 AM Kunle Odunsi, MD, PhD Roswell Park Cancer Institute Gynecologic Cancer 8:35 AM Quynh-Thu Le, MD Stanford University Medical Center Head and Neck Cancer 8:50 AM Jonathan C. Trent, MD, PhD Sylvester Comprehensive Cancer Center, University of Miami Sarcoma 9:05 AM Mark M. Moasser, MD University of California, San Francisco Tumor Biology 8:00 AM - 9:15 AM Education Session Adjuvant Treatment of Soft Tissue Sarcoma: What, When, and Why Location: S504 H. Thomas Temple, MD Nova Southeastern University Optimization of Surgical Resection for Soft Tissue Sarcoma Paolo Giovanni Casali, MD—Chair Fondazione IRCCS Istituto Nazionale dei Tumori Is There a Role for Adjuvant Chemotherapy for Resected Soft-Tissue Sarcoma? Brian O’Sullivan, MD Princess Margaret Hospital What Are the Indications for Adjuvant Radiation for Resected Soft-Tissue Sarcomas? TUESDAY Panel Question and Answer 8:00 AM - 9:15 AM Education Session Integrative Cancer Prevention: Nutrition, Supplements, and Lifestyle Location: S102 302 Tuesday, June 2, 2015 Michelle Harvie, PhD Nightingale and Genesis Prevention Centre, Wythenshawe Hospital Can Correct Diet and Exercise Choices Prevent Cancer? Heather Greenlee, ND, PhD Columbia University Medical Center Clinical Practice Guidelines on the Use of Integrative Therapies During Breast Cancer Treatment Donald I. Abrams, MD—Chair San Francisco General Hospital Lifestyle Modification and Dietary Supplements in Secondary Prevention Panel Question and Answer 8:00 AM - 9:15 AM Education Session New Targets and Therapies for Triple-Negative Breast Cancer Location: E450 Brian D. Lehmann, PhD Vanderbilt-Ingram Cancer Center Illuminating the Biology of Triple-Negative Breast Cancer Mary L. Disis, MD University of Washington Immunology and Triple-Negative Disease Antoinette R. Tan, MD—Chair Levine Cancer Institute/Carolinas Healthcare System Novel Therapies for Triple-Negative Breast Cancer Panel Question and Answer 8:00 AM - 9:15 AM Education Session Personalized Therapy for Multiple Myeloma in a Value-Oriented Environment Location: E354b Marı́a-Victoria Mateos, MD, PhD University Hospital of Salamanca-IBSAL Smoldering Multiple Myeloma: When to Observe and When to Treat? Saad Zafar Usmani, MD—Chair Levine Cancer Institute/Carolinas Healthcare System Multiple Myeloma: Is It Time for Biomarker-Driven Therapy? TUESDAY Philippe Moreau, MD CHU de Nantes, Hotel Dieu—HME Multiple Myeloma: How to Sequence Therapy? Panel Question and Answer 303 Tuesday, June 2, 2015 8:00 AM - 9:15 AM Education Session Targeting Cancer Metabolism Location: S100bc W. Marston Linehan, MD—Chair National Cancer Institute at the National Institutes of Health Lessons from IDH: Understanding Basic Metabolic Pathways and Translation to Clinical Trials Jeff Rathmell, PhD Duke University Metabolic Reprogramming of the Immune Response in the Tumor Microenvironment Robert Bachoo, MD, PhD The University of Texas Southwestern Medical Center Identification of New Metabolic Targets from Metabolic Tracer Studies in Patients Panel Question and Answer 8:00 AM - 11:00 AM Oral Abstract Session Central Nervous System Tumors Location: S404 Manmeet Singh Ahluwalia, MD—Co-Chair Cleveland Clinic Lakshmi Nayak, MD—Co-Chair Dana-Farber Cancer Institute TUESDAY 8:00 AM Tumor treating fields (TTFields): A novel treatment modality added to standard chemo- and radiotherapy in newly diagnosed glioblastoma—First report of the full dataset of the EF14 randomized phase III trial. (Abstract 2000) R. Stupp, S. Taillibert, A. Kanner, S. Kesari, S. A. Toms, G. H. Barnett, K. L. Fink, A. Silvani, F. S. Lieberman, J. Zhu, L. P. Taylor, J. Honnorat, A. Hottinger, T. Chen, D. D. Tran, C. Kim, H. W. Hirte, M. E. Hegi, Y. Palti, Z. Ram 8:12 AM Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. (Abstract 2001) W. Wick, P. Roth, B. Wiestler, C. Hartmann, P. Hau, M. Nakamura, F. Stockhammer, M. Sabel, S. Koeppen, R. Ketter, P. Vajkoczy, I. Eyupoglus, S. Kaendler, R. Kalff, N. Galldiks, F. Schmidt-Graf, A. von Deimling, M. Platten, G. Reifenberger, M. Weller 8:24 AM Results of NRG oncology/RTOG 9813: A phase III randomized study of radiation therapy (RT) and temozolomide (TMZ) versus RT and nitrosourea (NU) therapy for anaplastic astrocytoma (AA). (Abstract 2002) S. M. Chang, P. Zhang, J. G. Cairncross, M. R. Gilbert, J. Bahary, C. Dolinskas, K. D. Aldape, A. Chakravarti, D. Schiff, K. A. Jaeckle, P. D. Brown, G. Barger, M. Werner-Wasik, H. A. Shih, D. Brachman, M. Penas-Prado, H. Robins, K. Belanger, C. J. Schultz, M. P. Mehta 8:36 AM Martin J. Van Den Bent, MD (Discussion of Abstract(s) 2000 –2002) Daniel den Hoed Cancer Center Radiation, Chemotherapy, or More for Newly Diagnosed, High-Grade Gliomas 8:48 AM Panel Question and Answer 304 Tuesday, June 2, 2015 9:00 AM Continuing or ceasing bevacizumab at disease progression: Results from the CABARET study, a prospective randomized phase II trial in patients with recurrent glioblastoma. (Abstract 2003) E. J. Hovey, K. M. Field, M. Rosenthal, A. K. Nowak, L. Cher, H. Wheeler, E. Barnes, P. Phal, A. Livingstone, K. Sawkins, J. Simes, COGNO CABARET Investigators 9:12 AM NCCTG N0872 (Alliance): A randomized placebo-controlled phase II trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma (GBM). (Abstract 2004) E. Galanis, S. Anderson, P. Anastasiadis, D. D. Tran, S. A. Jeyapalan, D. M. Anderson, T. J. Kaufmann, C. Giannini, J. C. Buckner, D. Schiff 9:24 AM A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma. (Abstract 2005) S. S. Weathers, S. X. Han, D. D. Liu, C. A. Conrad, M. R. Gilbert, M. E. Loghin, B. J. O’Brien, M. Penas-Prado, V. K. Puduvalli, I. Tremont-Lukats, W. A. Yung, J. F. De Groot 9:36 AM Timothy F. Cloughesy, MD (Discussion of Abstract(s) 2003–2005) University of California, Los Angeles Bevacizumab for Glioblastoma: Selection, Dose, and Schedule 9:48 AM Panel Question and Answer 10:00 AM Radiotherapy in relation to temozolomide: Subgroup analysis of molecular markers of the randomized phase III study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033–26033) in patients with a high risk low-grade glioma. (Abstract 2006) B. G. Baumert, M. E. Hegi, W. P. Mason, G. Ryan, K. Hoang-Xuan, J. E. Bromberg, M. J. Van Den Bent, M. Ben Hassel, C. Marosi, A. A. Brandes, J. Rees, A. von Deimling, C. Hartmann, J. M. Kros, D. A. Lacombe, T. Gorlia, D. Capper, S. Kurscheid, R. Stupp 10:12 AM Molecular classification of diffuse cerebral gliomas using genome- and transcriptome-wide profiling. (Abstract 2007) M. Weller, R. Weber, E. Willscher, V. Riehmer, B. Hentschel, M. Kreuz, J. Felsberg, U. Beyer, H. Loeffler-Wirth, K. Kaulich, D. Gramatzki, M. Westphal, G. Schackert, M. Simon, J. Tonn, T. Pietsch, M. Loeffler, A. von Deimling, H. Binder, G. Reifenberger, German Glioma Network 10:24 AM The landscape and clonal architecture in lower grade glioma. (Abstract 2008) H. Suzuki, K. Aoki, K. Chiba, Y. Sato, Y. Shiozawa, Y. Shiraishi, T. Shimamura, A. Niida, K. Motomura, F. Ohka, H. Nakamura, M. Mizoguchi, T. Abe, Y. Muragaki, R. Watanabe, I. Ito, T. Wakabayashi, S. Ogawa, A. Natsume 10:36 AM Howard Alan Fine, MD (Discussion of Abstract(s) 2006 –2008) Weill Cornell Medical Center Molecular Determinants in the Management of Gliomas 10:48 AM Panel Question and Answer 8:00 AM - 11:00 AM Oral Abstract Session Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics Location: S100a TUESDAY Emiliano Calvo, MD, PhD—Co-Chair START Madrid, Centro Integral Oncológico Clara Campal Timothy Anthony Yap, MD, PhD—Co-Chair The Royal Marsden NHS Foundation Trust 305 Tuesday, June 2, 2015 TUESDAY 8:00 AM A pharmacokinetically (PK) and pharmacodynamically (PD) driven phase I trial of the pan-AKT inhibitor AZD5363 with expansion cohorts in PIK3CA mutant breast and gynecological cancers. (Abstract 2500) U. Banerji, E. J. Dean, J. A. Perez-Fidalgo, G. Batist, P. L. Bedard, B. You, S. N. Westin, P. Kabos, B. Davies, P. Elvin, P. Lawrence, J. W. Yates, H. Ambrose, P. Rugman, A. Foxley, S. Salim, E. Casson, J. P. Lindemann, J. H. Schellens 8:12 AM First-in-human, phase I, dose-escalation study of selective PI3K␣ isoform inhibitor MLN1117 in patients (pts) with advanced solid malignancies. (Abstract 2501) D. Juric, J. S. De Bono, P. LoRusso, J. J. Nemunaitis, E. I. Heath, E. L. Kwak, T. Macarulla, E. Geuna, M. de Miguel Luken, C. Patel, K. Kuida, S. Sankoh, F. Zohren, Y. Shou, J. Tabernero 8:24 AM Filip Janku, MD, PhD (Discussion of Abstract(s) 2500 –2501) The University of Texas MD Anderson Cancer Center PI3K Pathway as a Target: Early-Phase Data 8:36 AM Panel Question and Answer 8:48 AM Phase I studies of anti-ENPP3 antibody drug conjugates (ADCs) in advanced refractory renal cell carcinomas (RRCC). (Abstract 2503) J. A. Thompson, R. Motzer, A. M. Molina, T. K. Choueiri, E. I. Heath, C. K. Kollmannsberger, B. G. Redman, R. S. Sangha, D. S. Ernst, R. Pili, A. Butturini, A. Wiseman, F. Trave, B. Anand, Y. Huang, L. M. Reyno 9:00 AM Therapy of advanced metastatic lung cancer with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase I/II clinical experience. (Abstract 2504) M. J. Guarino, A. Starodub, G. A. Masters, R. S. Heist, W. A. Messersmith, A. Bardia, A. J. Ocean, S. S. Thomas, P. P. Maliakal, W. A. Wegener, R. M. Sharkey, F. Wilhelm, D. M. Goldenberg 9:12 AM A new anti-CEA-SN-38 antibody-drug conjugate (ADC), IMMU-130, is active in controlling metastatic colorectal cancer (mCRC) in patients (pts) refractory or relapsing after irinotecan-containing chemotherapies: Initial results of a phase I/II study. (Abstract 2505) E. Dotan, A. Starodub, J. Berlin, C. H. Lieu, M. J. Guarino, J. Marshall, J. R. Hecht, S. J. Cohen, W. A. Messersmith, P. P. Maliakal, W. A. Wegener, R. M. Sharkey, D. M. Goldenberg 9:24 AM Anthony W. Tolcher, MD (Discussion of Abstract(s) 2503–2505) START Antibody-Drug Conjugates: To Join or Not to Join? 9:36 AM Panel Question and Answer 9:48 AM Dose escalation stage of a first-in-class phase I study of the novel oral ERK 1/2 kinase inhibitor BVD-523 (ulixertinib) in patients with advanced solid tumors. (Abstract 2506) J. R. Infante, F. Janku, A. W. Tolcher, M. R. Patel, R. J. Sullivan, K. Flaherty, R. D. Carvajal, A. M. Varghese, D. J. Wong, M. Sznol, J. A. Sosman, A. Wang-Gillam, H. A. Burris III, A. Ribas, S. P. Patel, D. J. Welsch, S. Saha 10:00 AM Phase II study with Wee1 inhibitor AZD1775 plus carboplatin in patients with p53 mutated ovarian cancer refractory or resistant (<3 months) to standard first line therapy. (Abstract 2507) S. Leijen, R. van Geel, G. S. Sonke, D. de Jong, E. H. Rosenberg, S. Marchetti, D. Pluim, E. D. van Werkhoven, S. Rose, M. A. Lee, J. H. Beijnen, J. H. Schellens 10:12 AM Phase II multicenter proof of concept study of AZD4547 in FGFR amplified tumours. (Abstract 2508) E. C. Smyth, N. C. Turner, C. Peckitt, A. Pearson, G. Brown, S. Chua, A. Gillbanks, S. R. Johnston, N. Tarazona, R. Cutts, E. Kilgour, C. Rooney, N. R. Smith, K. A. Sumpter, M. A. Ajaz, A. L. Thomas, D. Watkins, I. Chau, S. Popat, D. Cunningham 10:24 AM Ryan Bruce Corcoran, MD, PhD (Discussion of Abstract(s) 2506 –2508) Massachusetts General Hospital Promising Novel Targets and Agents 10:36 AM Panel Question and Answer 306 Tuesday, June 2, 2015 9:45 AM - 11:00 AM Education Session Latest Advances in Systemic Therapy for Bone Sarcomas Location: S504 Robert S. Benjamin, MD The University of Texas MD Anderson Cancer Center Chemotherapy for Adults with Bone Sarcomas Paul A. Meyers, MD Memorial Sloan Kettering Cancer Center Chemotherapy for Children with Bone Sarcomas Jonathan C. Trent, MD, PhD—Chair Sylvester Comprehensive Cancer Center, University of Miami Novel Aproaches to the Treatment of Chondrosarcoma and Nonosteosarcoma of Bone Panel Question and Answer 9:45 AM - 11:00 AM Education Session Making Sense of Emerging Therapies in Pancreatic Cancer: Are We Finally on the Right Track? Location: E450 Andrew H. Ko, MD UCSF Helen Diller Family Comprehensive Cancer Center Current and Emerging Cytotoxic and Targeted Therapeutics: An Expanding Landscape Tanios S. Bekaii-Saab, MD—Chair The Ohio State University Comprehensive Cancer Center The Emerging Role of Immunotherapeutic Approaches in Pancreas Cancer: The Future Is Now Neal J. Meropol, MD University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University Of Nab-, Nano-, and Other Emerging Therapies in Pancreas Cancer: Do They Provide Good Value? Panel Question and Answer 9:45 AM - 11:00 AM Education Session Moving Survivorship Care Forward: Lessons from Quality Measures Location: S100bc TUESDAY Charles L. Shapiro, MD Mount Sinai School of Medicine Survivorship Quality Measures Deborah Mayer, RN, PhD The University of North Carolina at Chapel Hill Integration of Survivorship Care Plans into Electronic Health Records 307 Tuesday, June 2, 2015 Mary S. McCabe, RN, MA—Chair Memorial Sloan Kettering Cancer Center Using Quality Measures to Guide Improvements in Survivorship Care Panel Question and Answer 9:45 AM - 11:00 AM Education Session Optimizing Treatment of HER2-Positive Breast Cancer Location: E Hall D1 Stephen K. L. Chia, MD—Chair BC Cancer Agency Neoadjuvant and Adjuvant Therapy for HER2-Positive Disease Sunil Verma, MD, MSEd, FRCP(C) Sunnybrook Odette Cancer Centre Targeted Therapies for Metastatic HER2-Positive Disease Michelle E. Melisko, MD UCSF Helen Diller Family Comprehensive Cancer Center Management of Brain Metastases in HER2-Positive Breast Cancer Panel Question and Answer 9:45 AM - 11:00 AM Education Session Universal Screening for BRCA1/2 Mutations: Good Idea or Bad Idea? Location: S102 Allison W. Kurian, MD, MSc—Chair Stanford University Medical Center Moderator Elizabeth M. Swisher, MD University of Washington School of Medicine The Pros of Universal Genetic Testing Mark E. Robson, MD Memorial Sloan Kettering Cancer Center The Cons of Universal Genetic Testing Panel Question and Answer 9:45 AM - 11:15 AM Clinical Science Symposium TUESDAY Molecular Drivers and Genomic Biomarkers in Genitourinary Cancers Location: S406 Petros Grivas, MD, PhD—Co-Chair Cleveland Clinic Gopa Iyer, MD—Co-Chair Memorial Sloan Kettering Cancer Center 308 Tuesday, June 2, 2015 9:45 AM Identification of efficacy biomarkers in a large metastatic renal cell carcinoma (mRCC) cohort through next generation sequencing (NGS): Results from RECORD-3. (Abstract 4509) J. Hsieh, D. Chen, P. Wang, Y. Chen, A. Redzematovic, M. Marker, P. Patel, M. Chevinsky, U. Bhanot, P. Pinciroli, N. Bouvier, K. H. Huberman, M. F. Berger, N. D. Socci, E. Cheng, W. Lee, J. J. Knox, M. H. Voss, M. Voi, R. Motzer 9:57 AM Walter Michael Stadler, MD (Discussion of Abstract(s) 4509) The University of Chicago Molecular Predictors of Response in Renal Cell Cancer 10:09 AM Association of genomic alterations with cisplatin resistance (cisR) in advanced germ cell tumors (aGCT). (Abstract 4510) D. R. Feldman, A. Bagrodia, B. Lee, W. Lee, H. Al-Ahmadie, E. K. Cha, J. Sfakianos, G. Iyer, E. C. Zabor, I. Ostrovnaya, J. Eng, M. E. Arcila, R. S. Chaganti, N. Schultz, V. E. Reuter, M. S. Bains, J. Sheinfeld, B. S. Carver, G. J. Bosl, D. B. Solit 10:21 AM Carsten Bokemeyer, MD (Discussion of Abstract(s) 4510) University Medical Center Hamburg-Eppendorf Using Sequencing as a New Risk Stratifier for Germ Cell Tumors 10:33 AM Molecular drivers of the non-T cell-inflamed tumor microenvironment in urothelial bladder cancer. (Abstract 4511) R. F. Sweis, S. Spranger, T. Gajewski 10:45 AM William Y. Kim, MD (Discussion of Abstract(s) 4511) UNC Lineberger Comprehensive Cancer Center Genomics and Inflammation in Genitourinary Tumors 10:57 AM Panel Question and Answer 9:45 AM - 12:45 PM Oral Abstract Session Myeloma Location: E354b Thomas G. Martin III, MD—Co-Chair University of California, San Francisco Saad Zafar Usmani, MD—Co-Chair Levine Cancer Institute/Carolinas Healthcare System ELOQUENT-2: A phase III, randomized, open-label study of lenalidomide (Len)/dexamethasone (dex) with/without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM). (Abstract 8508) S. Lonial, M. A. Dimopoulos, A. Palumbo, D. White, S. Grosicki, I. Spicka, A. Walter-Croneck, P. Moreau, M. Mateos, H. Magen-Nativ, A. Belch, D. E. Reece, M. Beksac, M. Taniwaki, C. Röllig, A. K. Singhal, J. Katz, E. W. Bleickardt, V. Poulart, P. G. Richardson, ELOQUENT-2 Investigators 9:57 AM Carfilzomib and dexamethasone (Kd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed multiple myeloma (RMM): Results from the phase III study ENDEAVOR. (Abstract 8509) M. A. Dimopoulos, P. Moreau, A. Palumbo, D. E. Joshua, L. Pour, R. Hajek, T. Facon, H. Ludwig, A. Oriol, H. Goldschmidt, L. Rosinol, J. Straub, A. Suvorov, C. Araujo, T. Pika, G. Gaidano, K. Weisel, V. Goranova-Marinova, H. H. Gillenwater, W. J. Chng TUESDAY 9:45 AM 10:09 AM Jeffrey Lee Wolf, MD (Discussion of Abstract(s) 8508 – 8509) University of California, San Francisco Using Big Data to Guide Therapeutic Decisions for Early-Relapsed Multiple Myeloma 10:21 AM Panel Question and Answer 309 Tuesday, June 2, 2015 10:33 AM Phase II MMRC trial of extended treatment with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX) plus autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (NDMM). (Abstract 8510) T. M. Zimmerman, K. A. Griffith, J. Jasielec, C. A. Rosenbaum, K. McDonnell, J. Waite-Marin, J. G. Berdeja, N. S. Raje, D. E. Reece, R. Vij, M. Alonge, S. Rosebeck, S. Gurbuxani, M. Faham, K. A. Kong, J. Levy, A. J. Jakubowiak 10:45 AM Results from two phase III studies of bortezomib (BTZ) consolidation vs observation (OBS) post-transplant in patients (pts) with newly diagnosed multiple myeloma (NDMM). (Abstract 8511) C. Straka, M. Vogel, J. Müller, M. Kropff, B. Metzner, C. Langer, H. Sayer, W. Jung, H. A. Dürk, H. Wandt, F. Bassermann, M. Gramatzki, W. Rösler, S. Knop, H. Wolf, W. Brugger, M. M. Engelhardt, T. Fischer, H. Einsele 10:57 AM Saad Zafar Usmani, MD (Discussion of Abstract(s) 8510 – 8511) Levine Cancer Institute/Carolinas Healthcare System Optimal Management of Newly Diagnosed Transplant-Eligible Multiple Myeloma 11:09 AM Panel Question and Answer 11:21 AM Phase II study of daratumumab (DARA) monotherapy in patients with > 3 lines of prior therapy or double refractory multiple myeloma (MM): 54767414MMY2002 (Sirius). (Abstract LBA8512) S. Lonial, B. M. Weiss, S. Z. Usmani, S. Singhal, A. Chari, N. J. Bahlis, A. Belch, A. Y. Krishnan, R. A. Vescio, M. Mateos, A. Mazumder, R. Z. Orlowski, H. J. Sutherland, J. Blade, E. C. Scott, H. Feng, I. Khan, C. M. Uhlar, T. Ahmadi, P. M. Voorhees 11:33 AM A phase I/II study of the combination of panobinostat (PAN) and carfilzomib (CFZ) in patients (pts) with relapsed or relapsed/refractory multiple myeloma (MM). (Abstract 8513) J. G. Berdeja, T. K. Gregory, J. Matous, L. L. Hart, R. Owera, J. R. Mace, J. H. Essell, I. Flinn, E. A. Faber 11:45 AM Cardiac and renal biomarker responses in a phase 1/2 study of NEOD001 in patients with AL amyloidosis and persistent organ dysfunction. (Abstract 8514) M. A. Gertz, H. J. Landau, R. Comenzo, D. C. Seldin, B. M. Weiss, J. A. Zonder, J. Walling, G. Kinney, M. Koller, M. Liedtke 11:57 AM Suzanne Lentzsch, MD, PhD (Discussion of Abstract(s) LBA8512– 8514) Columbia University Medical Center New Drug Classes in Plasma Cell Disorders 12:09 PM Panel Question and Answer 11:30 AM - 12:45 PM Education Session Immunotherapy for Genitourinary Tumors: Are We Ready for Prime Time? Location: S406 Susan F. Slovin, MD, PhD, FACP—Chair Memorial Sloan Kettering Cancer Center Immunotherapeutic Approaches in Prostate Cancer, Combinations, and Clinical Integration TUESDAY Piyush K. Agarwal, MD National Cancer Institute at the National Institutes of Health Evolving Immunotherapy Strategies in Urothelial Carcinoma David F. McDermott, MD Beth Israel Deaconess Medical Center Emerging Role for Novel Immunotherapy Agents in Renal Cell Carcinoma: From Bench to Bedside Panel Question and Answer 310 Tuesday, June 2, 2015 11:30 AM - 12:45 PM Education Session Managing Side Effects of Endocrine Therapy in Men and Women Location: S100bc Catherine H. Van Poznak, MD University of Michigan Comprehensive Cancer Center Don’t Break the Bones Leslie R. Schover, PhD The University of Texas MD Anderson Cancer Center Sexual Healing in Men with Cancer Shari Beth Goldfarb, MD—Chair Memorial Sloan Kettering Cancer Center Don’t Lose That Loving Feeling: Sexual Health in Women with Cancer Panel Question and Answer 11:30 AM - 12:45 PM Education Session The Many Faces of Neuroendocrine Cancers Location: E450 David Klimstra, MD Memorial Sloan Kettering Cancer Center Pathologist Perspective Rogerio Lilenbaum, MD Yale University School of Medicine Lung Cancer Himisha Beltran, MD New York-Presbyterian Hospital Prostate Cancer Emily K. Bergsland, MD—Chair UCSF Helen Diller Family Comprehensive Cancer Center Pancreatic Cancer Panel Question and Answer 11:30 AM - 12:45 PM Education Session Well-Differentiated and Dedifferentiated Liposarcoma: New Challenges and New Directions TUESDAY Location: S504 Samuel Singer, MD—Chair Memorial Sloan Kettering Cancer Center Dissecting the Molecular Biology of Liposarcoma for Therapeutic Interventions and Novel Surgical Approaches Andrew Koff, PhD Memorial Sloan Kettering Cancer Center Understanding the Biology of CDK4 Targeting: A Biomarker-Driven Approach to Patient Selection 311 Tuesday, June 2, 2015 Gary K. Schwartz, MD Columbia University Medical Center MDM2 Targeting in Liposarcoma: Where Are We Going and Will Toxicites Impede Drug Development in Liposarcoma? Panel Question and Answer TUESDAY 312 Attendee Resource Center Streamline Your Meeting FIND A COLLEAGUE Connect with other attendees through the Message & Networking Center. Limited to professional attendees. ABSTRACTS AND EDUCATIONAL ARTICLES Download abstracts and articles from the Educational Book, a peer-reviewed and PubMed-indexed publication. ASCO DAILY NEWS Read expert perspectives on controversial topics and session highlights as well as live coverage of sessions. Accessible through your desktop and mobile device, the Attendee Resource Center is your single point of access to the planning and networking tools needed to optimize your Meeting experience. PLAN YOUR MEETING Browse and search sessions to create a customized schedule with the iPlanner. This publication is supported by Additional support has been provided by Support for this program is funded through
![“Basic and translational oncology” [Selezionare la data] Italian](http://s1.studyres.com/store/data/003369983_1-0c2f97f3754c36ff0d6a75a322ab9225-150x150.png)
![Genistein [446-72-0] - Università degli Studi di Roma "Tor Vergata"](http://s1.studyres.com/store/data/001069358_1-826841ed5b5b39775155b3058987503a-150x150.png)
